adenine has been researched along with Hepatitis B, Chronic in 1207 studies
Hepatitis B, Chronic: INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Entecavir (ETV) and tenofovir alafenamide fumarate (TAF) have been used widely to treat patients with chronic hepatitis B virus (HBV) infection, but it is still unclear how best to use these drugs." | 9.51 | Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study. ( Akahane, T; Inoue, J; Iwata, T; Kisara, N; Kobayashi, T; Masamune, A; Ninomiya, M; Onuki, M; Sano, A; Sato, K; Sato, S; Tsuruoka, M, 2022) |
| "The aim of this study was to demonstrate how tenofovir alafenamide (TAF) and other hepatitis B treatment drugs differentially impact lipid profiles in chronic hepatitis B patients." | 9.41 | Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. ( Hwang, EG; Jung, EA; Kim, SG; Kim, YS; Yoo, JJ, 2023) |
| "Treatment with tenofovir disoproxil fumarate has been associated with renal toxicity or reductions in bone mineral density, or both, in some patients with chronic hepatitis B virus (HBV) infection." | 9.34 | Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. ( Agarwal, K; Ahn, SH; Bae, H; Buti, M; Chan, HLY; Chen, CY; Chuang, WL; Flaherty, JF; Fung, S; Gaggar, A; Lampertico, P; Lau, A; Lim, YS; Liu, Y; Ma, X; Ramji, A; Subramanian, GM; Suri, V; Tak, WY; Tam, E; Tan, SK; Trinh, H; Wu, G; Yoon, SK, 2020) |
| "Tenofovir disoproxil fumarate (TDF) is a first-line treatment for chronic hepatitis B (CHB)." | 9.30 | Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. ( Buggisch, P; Buti, M; Cathcart, AL; Crans, G; Flaherty, J; Flisiak, R; Gaggar, A; Jump, B; Kaita, K; Krastev, Z; Lee, SS; Manns, M; Marcellin, P; Op den Brouw, M; Petersen, J; Sievert, W; Wong, DK, 2019) |
| " We divided 48 chronic hepatitis B patients who had taken entecavir (ETV) for ≥2 years into two groups: the ETV continuation (n = 24) and the TAF switching (n = 24) groups, and compared the antiviral effects and safety until 48 weeks after the start of the study." | 9.30 | Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B. ( Hagiwara, S; Ida, H; Komeda, Y; Kudo, M; Minami, Y; Nishida, N; Takita, M; Ueshima, K, 2019) |
| "The nucleos(t)ide analogues (NAs) entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are preferred treatment options for patients with chronic hepatitis B infection (CHB)." | 9.22 | Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data. ( Agarwal, K; Flaherty, JF; Fung, S; Gordon, SC; Hou, J; Kao, JH; Kurosaki, M; Lampertico, P; Lim, YS; Seto, WK; Yee, LJ; Zhao, Y, 2022) |
| "To explore clinical efficacy of Yiguanjian Decoction (YD) combined Adefovir Dipivoxil Tablet (ADT) in treating HBeAg negative chronic viral hepatitis B (CVHB) active compensated liver cirrhosis (LC) patients." | 9.22 | [Efficacy Observation of Yiguanjian Decoction Combined Adefovir Dipivoxil Tablet in Treating HBeAg Negative Chronic Viral Hepatitis B Active Compensated Liver Cirrhosis Patients]. ( Bao, ZY; Duan, SH; Liu, MS; Wang, L; Yuan, XD, 2016) |
| "Tenofovir disoproxil fumarate (TDF) has demonstrated long-term efficacy and a high barrier to resistance in multiple chronic hepatitis B (CHB) populations outside of China." | 9.20 | Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial. ( Chen, CW; Chen, SJ; Cheng, J; Dong, J; Gao, ZL; Hou, JL; Ji, Y; Jia, JD; Li, J; Mao, Q; Mao, YM; Ning, Q; Niu, JQ; Pan, C; Ren, H; Sheng, JF; Tan, DM; Tang, H; Wang, H; Wu, SM; Xie, Q; Xu, M; Zhang, JM; Zhang, XX; Zhao, W, 2015) |
| "We evaluated the antiviral response of Asian or Pacific Islander (API) patients with chronic hepatitis B (CHB) who had baseline high viral load (HVL), defined as pre-treatment hepatitis B virus (HBV) DNA ≥9 log10 copies/ml, following up to 288 weeks of tenofovir disoproxil fumarate (TDF) treatment." | 9.20 | Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml). ( Buti, M; Dinh, P; Dusheiko, G; Flaherty, JF; Flisiak, R; Fung, S; Gane, E; Gordon, SC; Horban, A; Jacobson, IM; Kitrinos, KM; Krastev, Z; Marcellin, P; Martins, EB; Petersen, J; Rustgi, VK; Sperl, J; Trinh, H; Yee, LJ, 2015) |
| "Non-cirrhotic, treatment-naïve subjects with chronic hepatitis B were randomized (1:1:1:1:1) to receive tenofovir alafenamide 8, 25, 40, or 120 mg, or tenofovir disoproxil fumarate 300 mg for 28 days and assessed for safety, antiviral response, and pharmacokinetics, followed-up by off-treatment for 4 weeks." | 9.20 | Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. ( Agarwal, K; Cheng, W; Flaherty, JF; Foster, GR; Fung, SK; Gane, EJ; Lawson, E; McHutchison, JG; Nguyen, TT; Ryder, SD; Sicard, E; Subramanian, GM; Zhao, S, 2015) |
| "The purpose of this study was to analyze the cost-effectiveness of lamivudine (LMV), telbivudine (LdT), and entecavir (ETV) in treatment of chronic hepatitis B with adefovir dipivoxil (ADV) resistance." | 9.20 | Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance. ( Liu, Y; Qiu, P; Wang, G; Wen, J; Wen, P; Xiao, X; Xu, L; Zhou, SF, 2015) |
| "This study aimed to research the efficiency of adefovir dipivoxil in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B treatment and in combination with α-2b interferon in the treatment of HBeAg-positive chronic hepatitis B." | 9.20 | The curative effect of adefovir dipivoxil treating HBeAg negative chronic hepatitis B and treating HBeAg positive chronic hepatitis B combining interferon α-2b. ( Gu, J; Shen, S; Sun, R; Yu, Z, 2015) |
| "To compare the efficacies ofentecavir and adefovir in patients with chronic hepatitis B (CHB) and cirrhosis when administered as monotherapies using a 240-week course." | 9.20 | [A randomized controlled trial on 240-week monotherapy with entecavir or adefovir in patients with chronic hepatitis B and cirrhosis]. ( Gao, Y; Han, T; Lian, J; Liu, F; Lyu, H; Wang, F; Xiang, H, 2015) |
| "To prospectively observe the long-term antiviral efficacy and safety of telbivudine (LDT) administered as a monotherapy and as a combination therapy with adefovir dipivoxil (ADV) in patients diagnosed with chronic hepatitis B (CHB) and positivity for hepatitis B e antigen (HBeAg)." | 9.19 | [Long-term efficacy and safety of telbivudine as monotherapy and as combination therapy with adefovir dipivoxil in HBeAg-positive chronic hepatitis B patients]. ( Chang, L; Du, Y; Jia, T; Li, H; Li, W; Liu, L; Liu, Y; Peng, D, 2014) |
| "A 48-week PegIFN therapy was added to HBeAg positive-HIV co-infected patients on TDF and emtricitabine, or lamivudine for at least 6 months." | 9.19 | Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study. ( Barthe, Y; Bouix, C; Cacoub, P; Carrat, F; Lascoux-Combe, C; Lebossé, F; Maynard-Muet, M; Miailhes, P; Piroth, L; Pol, S; Rey, D; Sogni, P; Zoulim, F, 2014) |
| "A recent study compared the efficacy of tenofovir disoproxil fumarate (TDF) vs the combination of emtricitabine and TDF (FTC/TDF) in patients with lamivudine-resistant chronic hepatitis B who were treated for as long as 96 weeks." | 9.19 | No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. ( Corsa, AC; Flaherty, JF; Fung, SK; Gane, E; Kitrinos, KM; Liu, Y; Miller, MD; Mitchell, B, 2014) |
| "In a study of 266 chronic hepatitis B e antigen (HBeAg)-positive patients, 23 experienced hepatitis B surface antigen (HBsAg) loss with up to 5 years of tenofovir disoproxil fumarate (TDF) treatment." | 9.19 | Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. ( Buti, M; de Man, RA; Dinh, P; Dusheiko, GM; Flaherty, JF; Flisiak, R; Gaggar, A; Gurel, S; Heathcote, EJ; Krastev, Z; Lin, L; Lou, L; Marcellin, P; Massetto, B; McHutchison, JG; Subramanian, GM; Zeuzem, S, 2014) |
| "The objective of this study was to compare the efficacy and safety of two rescue strategies for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients with resistance to adefovir dipivoxil (ADV)." | 9.17 | Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil. ( Chen, EQ; Liu, K; Lu, JJ; Ma, YJ; Tang, H; Wang, J, 2013) |
| "Telbivudine (LdT) has demonstrated potent antiviral activity in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B patients (CHB), but data on its efficacy in NA-experienced patients are limited." | 9.17 | Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil. ( Bai, XF; Li, Y; Lian, JQ; Wang, JP; Zhang, Y, 2013) |
| "In this study, we aimed to identify baseline predictors of response in chronic hepatitis B patients treated with a combination of pegylated interferon (PEG-IFN)-α2a and adefovir." | 9.17 | Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir. ( Beld, MG; de Niet, A; Dijkgraaf, MG; Jansen, L; Jansen, PL; Janssen, HL; Koot, M; Molenkamp, R; Reesink, HW; Rijckborst, V; Takkenberg, RB; Terpstra, V; Weegink, CJ; Zaaijer, HL, 2013) |
| "A 1-year trial with entecavir plus adefovir resulted in a rate of virological response (VR) higher than that seen with lamivudine plus adefovir in multiple-drug-refractory chronic hepatitis B (CHB) patients." | 9.17 | Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients. ( Lee, D; Lee, HC; Lee, JY; Lee, YS; Lim, YS; Shim, JH; Suh, DJ, 2013) |
| "To investigate the efficacy and safety of an extended course (96-week) of combination treatment with peginterferon alfa-2a (Peg-IFNa-2a; 40 kd] plus adefovir (ADV) for treating chronic hepatitis B (CHB) in Chinese patients with negativity for hepatitis B e antigen (HBeAg)." | 9.17 | [Efficacy and safety of peginterferon alfa-2a (40 kd) plus adefovir for 96 weeks in HBeAg-negative chronic hepatitis B patients]. ( Cao, ZH; Chen, XY; He, ZM; Jin, Y; Liu, YL; Lu, JF; Ma, LN; Zhang, YH, 2013) |
| "To compare the efficacy and safety of recombinant human interferon α-2b (INFα-2b) monotherapy and combined therapy with entecavir (ETV) plus adefovir dipivoxil (ADV) in chronic hepatitis B patients with poor response to combined therapy with lamivudine and ADV." | 9.17 | [Therapeutic effect of antiviral regimens for chronic hepatitis B refractory to lamivudine plus adefovir]. ( Chen, Z; Li, M; Liu, Z; Wu, J; Xu, G; Zhang, Q, 2013) |
| " At month 24, virological response rate [hepatitis B virus (HBV) DNA <60 IU/ml] was higher in the adefovir-lamivudine combination group compared with entecavir group (56." | 9.17 | Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial. ( Baik, SK; Chae, HB; Hong, SP; Kim, CW; Kim, JH; Kim, MY; Kim, YS; Lee, CD; Lee, JI; Lee, JW; Lee, MS; Park, CK; Park, SH; Seo, YS; Um, SH; Yim, HJ; Yoon, EL, 2013) |
| "Telbivudine therapy with tenofovir intensification at Week 24, where indicated by the Roadmap strategy, appears effective and well tolerated for the treatment of chronic hepatitis B." | 9.17 | 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. ( Bessone, F; Chan, HL; Cheinquer, H; Daruich, J; Dong, Y; Fassio, E; Komolmit, P; Ono, SK; Pathan, R; Pessôa, MG; Piratvisuth, T; Sukeepaisarnjaroen, W; Tanwandee, T; Trylesinski, A; Zeuzem, S, 2013) |
| "In this study, we aimed to devise a simple scoring system predicting the risk of genotypic resistance (GR) to current rescue therapies for patients with lamivudine (LAM)-resistant chronic hepatitis B." | 9.16 | Simple scoring system predicting genotypic resistance during rescue therapy for Lamivudine-resistant chronic hepatitis B. ( Cho, EJ; Hwang, SY; Jang, ES; Kim, CY; Kim, YJ; Kwak, MS; Lee, CH; Lee, HS; Lee, JH; Yang, HJ; Yoon, JH; Yu, SJ, 2012) |
| "Adefovir dipivoxil (ADV) is a nucleotide analogue with proven efficacy in chronic hepatitis B (CHB)." | 9.16 | Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B. ( Barker, K; Daozhen, X; Dixon, J; Guangbi, Y; Hao, W; Hong, R; JinLin, H; Junqi, N; Minde, Z; Xiaqiu, Z; Yagang, C; Yaozong, W; Yimin, M; Youming, C; Yuming, W, 2012) |
| "In a cohort of 95 chronic hepatitis B patients, who were treated with peg-interferon and adefovir for 1 year, and who had 15% HBsAg loss (overall), no association was found between IL28B polymorphisms and HBeAg seroconversion or HBsAg clearance." | 9.16 | Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir. ( Beld, MG; Benayed, R; de Niet, A; Jansen, PL; Koot, M; Lopatin, U; Reesink, HW; Riley-Gillis, B; Takkenberg, RB; Weegink, CJ; Zaaijer, HL, 2012) |
| "Patients with chronic hepatitis B with and without previous lamivudine therapy were randomised to receive adefovir alone (10 mg/daily) or adefovir and lamivudine (100 mg/daily) for up to 192 weeks." | 9.16 | Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B. ( Doo, E; Feld, JJ; Ghany, MG; Heller, T; Hoofnagle, JH; Kleiner, DE; Koh, C; Liang, TJ; Nagabhyru, P; Rotman, Y; Wright, EC; Zhao, X, 2012) |
| "To investigate the efficacy of 104 weeks of lamivudine (LAM) and adefovir (ADV) de novo combination therapy, as compared to optimized combination therapy administered after 48 weeks of treatment with lamivudine or adefovir mono-therapy, in chronic hepatitis B (CHB) patients." | 9.16 | [Efficacy of lamivudine and adefovir de novo combination therapy or after mono-therapy in chronic hepatitis B patients]. ( Chen, R; Chen, WL; Chen, XF; Chen, XP; Huang, J; Luo, XD; Ma, HY; Ma, XJ, 2012) |
| "The safety and efficacy of adefovir dipivoxil (ADV) for chronic hepatitis B infection in children was demonstrated in a randomized, placebo-controlled trial." | 9.16 | Efficacy and safety of long-term adefovir dipivoxil therapy in children with chronic hepatitis B infection. ( Frederick, D; Jonas, MM; Kelly, D; Mizerski, J; Mondou, E; Pollack, H; Rousseau, F; Sokal, E; Sorbel, J, 2012) |
| "Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are potent antiviral agents that might have additive or synergistic antiviral activity in treatment of patients with chronic hepatitis B (CHB)." | 9.16 | Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. ( Akarca, US; Carosi, G; Cohen, D; Gadano, A; Habersetzer, F; Llamoso, C; Lok, AS; Lovegren, M; Sievert, W; Trinh, H; Wong, D, 2012) |
| "The aim of the study was to compare the virologic response to adefovir (ADV) add-on therapy with switching to entecavir (ETV) monotherapy in children and adolescents with chronic hepatitis B (CHB) who have developed lamivudine (LAM) resistance during LAM treatment." | 9.16 | Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B. ( Cho, MH; Cho, SM; Choe, BH; Chu, M; Kwon, S; Lee, WK, 2012) |
| "To study the changes of experimental markers of hepatic fibrosis in patients with chronic hepatitis B treated by Dahuang Zhechong Wan combined with adefovir dipivoxil." | 9.16 | [Experimental study on effect of dahuang zhechong wan combined with adefovir dipivoxil in preventing hepatic fibrosis in patients with chronic hepatitis B]. ( Chang, Y; Zhang, L, 2012) |
| "To observe the efficacy of adefovir dipivoxil(ADV) in combination with Anluohuaxian capsule in the treatment of chronic hepatitis B (CHB) patients." | 9.16 | [The therapeutic effect of Anluohuaxian capsule combined with adefovir dipivoxil on patients with chronic hepatitis B and influence on hepatic histology]. ( Gong, GZ; He, B; Jiang, YF; Li, NP; Ma, J; Tang, W, 2012) |
| "To evaluate the efficacy and safety of tenofovir disoproxil fumarate (TDF) for chronic hepatitis B (CHB) patients after multiple failures." | 9.16 | Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. ( Choi, MS; Gwak, GY; Kim, YJ; Koh, KC; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC, 2012) |
| "To determine the efficacy of tenofovir disoproxil fumarate (TDF) in adults with chronic hepatitis B virus (HBV) infection who had previously failed lamivudine (LAM) and had significant viral replication (HBV DNA >10⁵ copies/ml if HBeAg positive, > 10⁴ copies/ml if HBeAg negative) despite at least 24 weeks of treatment with adefovir dipivoxil (ADV)." | 9.15 | Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. ( Angus, PW; Bowden, S; Desmond, PV; George, J; Lee, AU; Locarnini, S; Nicoll, AJ; Patterson, SJ; Roberts, SK; Sievert, W; Strasser, SI, 2011) |
| "This prospective randomized pilot study was conducted in Lok Nayak Hospital, New Delhi, involving 30 patients of chronic hepatitis B (both e antigen positive and negative); 15 were randomly selected to receive either adefovir or lamivudine for a period of 6 months." | 9.15 | Evaluation of adefovir & lamivudine in chronic hepatitis B: correlation with HBV viral kinetic, hepatic-necro inflammation & fibrosis. ( Asim, M; Das, BC; Gondal, R; Kar, P; Medhi, S; Pradeep Kumar, S, 2011) |
| " In two phase 3 studies (GS-US-174-0102 and GS-US-174-0103), 375 hepatitis B e antigen-negative (HBeAg(-) ) patients and 266 HBeAg(+) patients with chronic hepatitis B (some nucleoside-naive and some lamivudine-experienced) were randomized 2:1 to receive TDF (n = 426) or adefovir dipivoxil (ADV; n = 215) for 48 weeks." | 9.15 | No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. ( Borroto-Esoda, K; Chappell, B; Curtis, M; Heathcote, J; Kitrinos, K; Marcellin, P; Miller, MD; Myrick, F; Schawalder, J; Snow-Lampart, A; Sorbel, J; Svarovskaia, ES; Zhu, Y, 2011) |
| "A randomized, open-label comparative study of entecavir versus adefovir therapy was performed in subjects with chronic hepatitis B who had hepatic decompensation (Child-Turcotte-Pugh score ≥7)." | 9.15 | Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. ( Beebe, S; Bialkowska, J; Brown, RS; Cheinquer, H; Cooney, E; Jeffers, L; Leung, N; Liaw, YF; Myers, RP; Peng, CY; Raptopoulou-Gigi, M; Sarin, SK; Tang, S; Tanwandee, T; Tsai, N, 2011) |
| "We investigated whether intrahepatic markers could predict response in chronic hepatitis B virus (HBV) patients treated with peg-interferon and adefovir for 48 weeks." | 9.15 | Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir. ( Beld, M; Dijkgraaf, M; Jansen, P; Reesink, H; Takkenberg, B; Terpstra, V; Weegink, C; Zaaijer, H, 2011) |
| "To evaluate the safety and efficacy of the combined therapy with entecavir (ETV) and adefovir (ADV) in patients with chronic hepatitis B (CHB) who experienced failure of treatment with single or multiple nucleoside analogs, and analyze the factors that affect the patients response to the treatment." | 9.15 | [Safety and efficacy of Entecavir combined with Adefovir in patients with chronic hepatitis B who fail to respond to nucleoside analog treatment]. ( Guo, YB; Hou, JL; Peng, J; Sun, J; Wang, ZH; Yan, L; Yang, J; Zhou, B, 2011) |
| "In this randomised study, chronic hepatitis B patients with lamivudine resistance were treated with peginterferon alfa-2a for 48 weeks (n=155) or adefovir for 72 weeks (n=80)." | 9.15 | Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. ( Chan, HL; Chen, SJ; Hou, JL; Jia, JD; Jiang, M; Lai, JY; Li, MK; Li, XH; Popescu, M; Sheng, JF; Sun, J; Sung, JJ; Wang, H; Wang, JF; Wang, YM; Xie, Q; Zhang, JM, 2011) |
| "To investigate the levels of HBsAg in predicting the efficacy of peglated interferon-alpha 2a combined with adefovir dipivoxil (ADV), in HBeAg-positive chronic hepatitis B patients." | 9.15 | [The levels of HBsAg can predict the efficacy of peglated interferon-alpha 2a combined with adefovir dipivoxil, in HBeAg-positive chronic hepatitis B patients]. ( Cao, H; Li, G; Sun, HX; Xu, QH; Yang, XA; Zhang, K, 2011) |
| "A large clinic cohort of chronic hepatitis B cirrhotic patients were enrolled in a treatment program of lamivudine ± adefovir therapy." | 9.15 | Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis. ( Aung, MO; Dan, YY; Fernandes, M; Lai, V; Lee, GH; Lee, YM; Lim, SG; Low, HC; Mak, B; Sutedja, D, 2011) |
| "To explore relationship between HBeAg seroconversion with HBV genotypes and HBV specific CTL in patients with chronic hepatitis B (CHB) treated with Adefovir dipivoxil." | 9.15 | [Relationship between HBeAg seroconversion with genotypes and HBV specific CTL in patients with chronic hepatitis B treated with Adefovir dipivoxil]. ( Gu, XB; Pan, JQ; Tan, YF; Tang, JM; Wang, XC; Wu, YT; Yang, ZX; Zhao, YP; Zhou, YL, 2011) |
| "To observe the efficacy and safety on the efficacy of HBeAg-positive chronic Hepatitis B patients treated with adefovir dipivoxil for 4 years." | 9.15 | [A clinical study on the efficacy of HBeAg-positive chronic hepatitis B patients treated with adefovir dipivoxil for 4 years]. ( Chen, LB; Liang, JY; Shu, X; Xu, QH; Yang, XA; Zhang, K, 2011) |
| "0 mg/d or ETV plus adefovir dipivoxil (ADV) in adults with chronic hepatitis B virus (HBV) infection who had previously resisted lamivudine (LAM) and failed with rescue treatment of LAM + ADV." | 9.15 | [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil]. ( Han, T; Li, J; Li, Y; Liu, L; Xiao, SX; Xing, J, 2011) |
| "To investigate the clinical efficacy and safety of adefovir dipivoxil (ADV) in combination with bicyclol for the treatment of chronic hepatitis B (CHB) in seniors." | 9.15 | [The clinical efficacy and safety of adefovir dipivoxil in combination with bicyclol for the treatment of senior patients with chronic hepatitis B]. ( Cai, SP; Fan, ZP; He, WP; Ji, YJ; Zhang, WJ, 2011) |
| "This study was undertaken to compare the early antiviral activity and viral kinetic profiles of entecavir (ETV) versus adefovir (ADV) in hepatitis B e antigen positive nucleoside-naïve adults with chronic hepatitis B (CHB)." | 9.14 | Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. ( Cross, A; Diva, U; Hann, HW; Hsu, CW; Jeffers, L; Lao-Tan, J; Lesmana, L; Leung, N; Lopez-Talavera, J; Mencarini, K; Min, A; Peng, CY; Sherman, M; Sollano, J; Wilber, R; Yuen, MF, 2009) |
| "Lamivudine (3TC)-resistant chronic hepatitis B patients demonstrated a higher rate of adefovir dipivoxil (ADV) resistance compared with nucleoside-naive patients." | 9.14 | Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B. ( Barraud, L; Durantel, S; Fasano, M; Guastadisegni, A; Heichen, M; Pastore, G; Santantonio, T; Zoulim, F, 2009) |
| "Entecavir (ETV) is currently recommended as a rescue therapy purely for adefovir (ADV)-resistant chronic hepatitis B virus (HBV) infections." | 9.14 | Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. ( Chung, YH; Kim, KM; Lee, HC; Lee, YS; Lim, YS; Shim, JH; Suh, DJ, 2009) |
| "The efficacy of adefovir dipivoxil (ADV) or entecavir (ETV) rescue monotherapy has not been directly compared in hepatitis B e antigen (HBeAg)-positive patients with lamivudine (3TC)-resistant chronic hepatitis B (CHB)." | 9.14 | Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. ( Ahn, SH; Chon, CY; Han, KH; Hong, SP; Kim, DY; Kim, HJ; Kim, JK; Lee, CK; Lee, HW; Lee, JM; Lee, KS; Nguyen, T; Paik, YH; Park, JY, 2009) |
| "Adefovir dipivoxil (ADV) is effective in lamivudine (LAM)-resistant hepatitis B e antigen-negative (HBeAg(-)) chronic hepatitis B (CHB)." | 9.14 | Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study. ( Eugenidis, N; Giouleme, O; Gkisakis, D; Grammatikos, N; Katsinelos, P; Koumaras, H; Koumerkeridis, G; Mpoumponaris, A; Panderi, A; Patsiaoura, K; Theodoropoulos, K; Tziomalos, K; Vassiliadis, TG, 2010) |
| "Entecavir is a potent inhibitor of viral replication in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B patients, but data on the efficacy in NA-experienced subjects are limited." | 9.14 | Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. ( Buti, M; Deterding, K; Hansen, BE; Janssen, HL; Petersen, J; Reijnders, JG; Santantonio, T; van Bömmel, F; Wedemeyer, H; Zoulim, F, 2010) |
| "Large clinical studies assessing long-term adefovir dipivoxil salvage monotherapy in patients with lamivudine-resistant chronic hepatitis B (CHB) are lacking, particularly in patients positive for hepatitis B e antigen (HBeAg)." | 9.14 | Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. ( Ahn, SH; Chon, CY; Han, KH; Hong, SP; Kim, DY; Kim, SO; Lee, JM; Nguyen, T; Park, JY, 2010) |
| "To compare the efficacy of 48 week-Entecavir therapy with that of Adefovir therapy for chronic hepatitis B patients." | 9.14 | [Comparison of the efficacy of 48 week-Entecavir therapy with that of Adefovir therapy for chronic hepatitis B patients]. ( Hu, P; Lin, Q; Ren, H; Shi, XF; Wang, ZY; Zeng, WQ; Zhang, DZ; Zhou, Z, 2010) |
| "No study has reported on the comparative effect of adefovir (ADV) add-on lamivudine (LAM) versus switching to entecavir (ETV) in LAM-resistant patients with chronic hepatitis B." | 9.14 | Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. ( Ahn, SH; Chon, CY; Han, KH; Kim, DY; Lee, JM; Lee, MH; Park, JY; Ryu, HJ, 2010) |
| "To investigate the efficacy of the 96-week antiviral therapy with adefovir dipivoxil in patients with chronic hepatitis B." | 9.14 | [Efficacy of the 96-week adefovir dipivoxil therapy in patients with chronic hepatitis B]. ( Cao, H; Chen, LB; Li, G; Shu, X; Xie, QF; Xu, QH; Xu, Z, 2010) |
| "To observe the efficacy and safety of PEG-interferon alpha-2a (PEG-IFNalpha-2a) treatment on lamivudine (LAM)-resistant chronic hepatitis B (CHB) patients." | 9.14 | [Observation on effect of peg interferon lphaa-2a treating lamivudine resistant chronic hepatitis B]. ( Bai, HL; Long, H; Luo, HT; Ye, YN; Zhong, RX, 2010) |
| "To explore the influence of adefovir dipivoxil on HBV specific CTL in patients with chronic hepatitis B (CHB)." | 9.14 | [Influence of adefovir dipivoxil on HBV specific CTL in patients with chronic hepatitis B]. ( Pan, JQ; Tan, YF; Tang, JM; Wang, XC; Wu, YT; Zhao, YP; Zhou, YL, 2010) |
| "Treatment of 171 patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) with adefovir dipivoxil (ADV) 10 mg over 48 weeks resulted in significant histological, virological, serological, and biochemical improvement compared with placebo." | 9.13 | Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. ( Arterburn, S; Borroto-Esoda, K; Chang, TT; Frederick, D; Lim, SG; Marcellin, P; Rousseau, F; Sievert, W; Tong, M, 2008) |
| "Thai patients enrolled in STACCATO with HIV/hepatitis B virus (HBV) co-infection and tenofovir/emtricitabine-based antiretroviral therapy (ART) were randomly assigned to continuous treatment or CD4 cell count-guided interruptions." | 9.13 | Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. ( Ananworanich, J; Chetchotisakd, P; Hirschel, B; Jupimai, T; Klinbuayam, W; Mahanontharit, A; Nüesch, R; Prasithsirikul, W; Ruxrungtham, K; Srasuebkul, P, 2008) |
| "To evaluate the efficacy of short-term overlap lamivudine therapy with adefovir in patients with lamivudine-resistant and naive chronic hepatitis B, we compared patients receiving overlap therapy with those receiving adefovir alone." | 9.13 | Short-term overlap lamivudine treatment with adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B. ( Bae, SH; Cho, SH; Choi, JY; Han, JY; Kang, SB; Kim, YS; Lee, SW; Lee, YS; Nam, SW; Yang, JM; Yoon, SK, 2008) |
| "This study investigated the efficacy, safety, and pharmacokinetics of adefovir dipivoxil (ADV) in children and adolescents with chronic hepatitis B (CHB)." | 9.13 | Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. ( Frederick, D; Jonas, MM; Kelly, D; Mizerski, J; Mondou, E; Pollack, H; Rousseau, F; Sokal, E; Sorbel, J, 2008) |
| "Four hundred and eighty Chinese subjects with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) were enrolled in a multicenter, double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) 10 mg once daily." | 9.12 | A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. ( Barker, KF; Chang, CN; Hou, J; Ji, BN; Mao, Y; Wang, H; Wang, Y; Yao, G; Zeng, M, 2006) |
| "Treatment with adefovir dipivoxil for 48 weeks resulted in clinical improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B that was lost when treatment was discontinued." | 9.12 | Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. ( Arterburn, S; Borroto-Esoda, K; Brosgart, CL; Chang, TT; Chuck, SL; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Ma, J; Marcellin, P; Rizzetto, M; Tassopoulos, NC, 2006) |
| "In patients failing to respond to adefovir monotherapy or an adefovir-containing regimen for chronic hepatitis B virus, a combination of tenofovir and emtricitabine resulted in undetectable hepatitis B viral DNA levels without any renal toxicity." | 9.12 | Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen. ( Carriero, D; Dieterich, DT; Jaffe, D; Lucas, J; Park, JS; Santos, SA; Uriel, AJ, 2006) |
| "To investigate the efficacy and safety of adefovir dipivoxil (ADV, DAIDING) for Chinese chronic hepatitis B patients with lamivudine (LAM) resistance." | 9.12 | [A double-blind, randomized, lamivudine-controlled clinical trial of DAIDING (adefovir dipivoxil) for lamivudine-resistant patients with chronic hepatitis B]. ( Chen, YK; Lei, BJ; Lu, ZM; Wang, YM; Yin, YK; Yu, YS; Zhang, DZ, 2006) |
| "To evaluate the efficacy and safety of a China made adefovir dipivoxil (ADV) treatment for hepatitis B e antigen-positive patients with chronic hepatitis B." | 9.12 | [A clinical study of adefovir dipivoxil, made in China, for treatment of hepatitis B e antigen-positive patients with chronic hepatitis B]. ( Chen, XY; Kang, XP; Li, J; Lin, XH; Liu, P; Ren, XM; Si, CW; Yu, YY; Zhang, SL, 2006) |
| "We studied the long-term efficacy of adefovir dipivoxil (ADV) treatment in 42 HBeAg-negative patients with chronic hepatitis B (CHB) who had developed genotypical lamivudine (LAM) resistance with virological and clinical breakthroughs under long-term LAM treatment." | 9.12 | Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. ( Dimou, E; Hadziyannis, SJ; Mitsoula, P; Rapti, I, 2007) |
| "To evaluate the efficacy and safety of adefovir dipivoxil (ADV) treatment in patients with hepatitis B e antigen (HBeAg) positive chronic hepatitis B (CHB)." | 9.12 | [Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients]. ( Ling, N; Ren, H; Zhang, DZ; Zhou, Z, 2007) |
| "To evaluate the efficacy and safety of adefovir dipivoxil (ADV) in treating patients with lamivudine (LAM) refractory HBeAg-positive chronic hepatitis B." | 9.12 | [A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B]. ( Chen, XY; Si, CW; Tang, XP; Wang, L; Zhang, YX; Zhao, H, 2007) |
| "To evaluate the cost effectiveness of treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) with entecavir compared with lamivudine with adefovir salvage, based primarily on the results of a recent 2-year, randomised, multicentre, clinical trial (n = 709)." | 9.12 | Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. ( Clarke, L; Di Bisceglie, A; Gish, RG; Iloeje, UH; Kowdley, KV; Sullivan, SD; Tafesse, E; Veenstra, DL, 2007) |
| "To evaluate the effect of diammonium glycyrrhizinate on the antiviral therapy with adefovir dipivoxil (ADV) in patients with HBeAg-positive chronic hepatitis B." | 9.12 | [Diammonium glycyrrhizinate does not affect efficacy of adefovir dipivoxil therapy in patients with HBeAg-positive chronic hepatitis B]. ( Chen, XY; Lei, CL; Li, J; Si, CW; Tang, XP; Wang, L; Zhang, YX; Zhao, H, 2007) |
| "The safety and efficacy of 10 mg of adefovir dipivoxil was compared to placebo in 501 Asian (n = 259) or Caucasian (n = 242) HBeAg+ and HBeAg- chronic hepatitis B virus patients treated for 48 weeks in two randomized, double-blind, placebo-controlled studies." | 9.12 | Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B. ( Arterburn, S; Brosgart, CL; Chang, TT; Hadziyannis, S; Hu, P; Lim, SG; Marcellin, P; Sievert, W; Tassopoulos, N; Tong, M, 2007) |
| " We evaluated the efficacy and safety of adding adefovir dipivoxil to lamivudine in 135 patients with chronic hepatitis B (CHB) and YMDD mutant HBV." | 9.11 | Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. ( Bourne, E; Brosgart, CL; Gardner, S; Hann, HW; Lee, WM; Leung, N; Moorat, A; Mutimer, D; Perrillo, R; Schiff, E; Willems, B; Woessner, M, 2004) |
| " This study assessed the safety and efficacy of adefovir dipivoxil alone and in combination with lamivudine compared with ongoing lamivudine therapy in patients with chronic hepatitis B with compensated liver disease and lamivudine-resistant hepatitis B virus (HBV)." | 9.11 | Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. ( Bourliere, M; Brosgart, CL; Buggisch, P; Ebrahimi, R; Gray Df, Df; Hann Hw, Hw; Heathcote, EJ; Kleber, K; Kowdley, K; Martin, P; Peters, MG; Rubin, R; Sullivan, M; Trepo, C; Xiong, S, 2004) |
| "Lamivudine treatment in patients with chronic hepatitis B virus (HBV) infection may improve clinical state and suppress viral replication before liver transplantation." | 9.11 | Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. ( Chan, SC; Fan, ST; Lau, GK; Liu, CL; Lo, CM; Ng, IO, 2005) |
| "Treatment with adefovir dipivoxil for 48 weeks resulted in histologic, virologic, and biochemical improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B." | 9.11 | Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. ( Arterburn, S; Brosgart, CL; Chang, TT; Currie, G; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Ma, J; Marcellin, P; Rizzetto, M; Tassopoulos, NC; Xiong, S, 2005) |
| "Adefovir dipivoxil is safe for the treatment of chronic hepatitis B in patients with varying degrees of renal dysfunction and lamivudine-resistant HBV and results in biochemical and virological efficacy similar to that reported in the general population." | 9.11 | Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. ( Brosgart, C; Chaix, ML; Currie, G; Fontaine, H; Morales, E; Nalpas, B; Pol, S; Serpaggi, J; Vallet-Pichard, A; Varaut, A; Verkarre, V, 2005) |
| " Currently available treatments for chronic hepatitis B (interferon [IFN]-alpha and lamivudine [3TC]) have limited long-term utility because of side effects or of the development of resistance." | 9.10 | Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. ( Aberg, JA; Crippin, J; Kessels, L; Lisker-Melman, M; Powderly, WG; Ristig, MB; Tebas, P, 2002) |
| "We randomly assigned 515 patients with chronic hepatitis B who were positive for hepatitis B e antigen (HBeAg) to receive 10 mg of adefovir dipivoxil (172 patients), 30 mg of adefovir dipivoxil (173), or placebo (170) daily for 48 weeks." | 9.10 | Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. ( Brosgart, CL; Chang, TT; Fry, J; Goodman, Z; Jeffers, L; Lim, SG; Marcellin, P; Shiffman, ML; Sievert, W; Tong, MJ; Wulfsohn, MS; Xiong, S, 2003) |
| "Adefovir dipivoxil, a nucleotide analogue, demonstrated clinically significant antiviral activity in patients with chronic hepatitis B in phase 1 and 2 clinical trials." | 9.10 | Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. ( Brosgart, CL; Chang, TT; Fry, J; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Marcellin, P; Rizzetto, M; Tassopoulos, NC; Wulfsohn, MS; Xiong, S, 2003) |
| "Seven hundred nucleoside treatment-naive patients were enrolled in two phase 3 trials of adefovir dipivoxil (ADV) for the treatment of chronic hepatitis B." | 9.10 | Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. ( Brosgart, CL; Delaney, WE; Fry, J; Gibbs, CS; Miller, MD; Westland, CE; Wulfsohn, M; Xiong, S; Yang, H, 2003) |
| "In April 2017 tenofovir alafenamide (TAF) was added to the list of first-line therapies recommended for chronic hepatitis B (CHB)." | 8.95 | Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. ( Abdul Basit, S; Dawood, A; Gish, R; Ryan, J, 2017) |
| "Tenofovir alafenamide (TAF) has recently been approved for chronic hepatitis B (CHB)." | 8.95 | Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. ( Hsu, YC; Nguyen, MH; Wei, MT, 2017) |
| "Tenofovir alafenamide (TAF), a novel prodrug of tenofovir (TFV), has been approved for the treatment of chronic hepatitis B virus (HBV) infection." | 8.95 | Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy. ( Furusyo, N; Nguyen, MH; Ogawa, E, 2017) |
| "Long-term adefovir dipivoxil therapy is connected to renal dysfunction in chronic hepatitis B, necessitating the monitoring of kidney function." | 8.93 | Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis. ( Cheng, F; Deng, Y; Kang, J; Luo, Q; Zeng, W; Zhang, D; Zhong, S, 2016) |
| " He had been receiving low-dose adefovir dipivoxil (ADV) for the treatment of lamivudine-resistant chronic hepatitis B virus infection for eight years and subsequently developed severe hypophosphatemia and proximal renal tubule dysfunction." | 8.90 | Hypophosphatemic osteomalacia due to drug-induced Fanconi's syndrome associated with adefovir dipivoxil treatment for hepatitis B. ( Eguchi, H; Hiromatsu, Y; Kuwahara, R; Tani, J; Tsuruta, M, 2014) |
| "Tenofovir (TDF) and entecavir (ETV) are both potent antiviral agents for the treatment of chronic hepatitis B virus (HBV) infection." | 8.90 | Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. ( Gao, Y; Ke, W; Liu, L; Yang, Y; Ye, X; Zhang, C; Zhou, S, 2014) |
| " Currently, lamivudine plus adefovir combination therapy or entecavir monotherapy is usually used for the treatment of patients with lamivudine-resistant chronic hepatitis B (CHB)." | 8.89 | Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. ( Chen, RC; Dai, XH; Fan, XG; Huang, Y; Huang, ZB; Li, N; Li, WT; Yi, PP; Zhang, BX; Zhao, SS; Zhou, RR, 2013) |
| "The aim of the current study was to compare the effectiveness of adefovir dipivoxil (ADV) monotherapy with that of combination ADV and lamivudine (LAM) therapy in the treatment of LAM-resistant chronic hepatitis B (CHB)." | 8.88 | Comparative meta-analysis of adefovir dipivoxil monotherapy and combination therapy of adefovir dipivoxil and lamivudine for lamivudine-resistant chronic hepatitis B. ( Chen, Y; Ju, T, 2012) |
| "Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are potent nucleos(t)ide analogues (NUCs) recommended as first-line monotherapies for chronic hepatitis B." | 8.88 | First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. ( Lampertico, P; Pol, S, 2012) |
| "Although entacavir and adefovir were widely used in most Asian countries, there were few conclusions drawn from a meta-analysis for comparing the efficacy between entecavir and adefovir in nucleos(t)ide-naïve Asian patients with chronic hepatitis B (CHB)." | 8.87 | Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis. ( Guan, Q; Liu, W; Zhao, J; Zhao, P, 2011) |
| " Currently, several drugs, such as tenofovir and adefovir, are recommended for treatment of patients with chronic hepatitis B." | 8.87 | Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: a systematic review. ( Chen, LZ; Dai, XH; Fan, XG; Tang, LH; Wang, W; Zhao, SS; Zhou, RR, 2011) |
| "Chronic hepatitis B virus (HBV) infection represents a serious global health problem and resistance to lamivudine (LAM) has become a serious clinical challenge." | 8.87 | Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. ( Hu, HD; Hu, P; Liu, JY; Ren, H; Sheng, YJ; Tong, SW; Zhang, DZ, 2011) |
| " Lamivudine and adefovir dipivoxil are effective and tolerable for chronic hepatitis B by suppressing the viral load and to reduce fibrosis in the liver." | 8.87 | Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma. ( Li, le Q; Wu, LC; Zhong, JH, 2011) |
| "Since its approval for the treatment of chronic hepatitis B in 1998, lamivudine (LAM) has been used extensively throughout the world, because of its relatively low costs and favourable tolerability." | 8.86 | Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon. ( Marcellin, P; Piratvisuth, T; Sung, J, 2010) |
| "This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B, in accordance with the licensed indication, based upon the evidence submission from Gilead to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process." | 8.86 | Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection. ( Colquitt, J; Cooper, K; Harris, P; Jones, J; Shepherd, J, 2010) |
| "Tenofovir is a nucleotide analog reverse transcriptase inhibitor approved recently by the US FDA for the treatment of chronic hepatitis B (CHB) in adult patients based on the results of two double-blind randomized trials demonstrating superiority of tenofovir compared with adefovir." | 8.86 | Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. ( Jenh, AM; Pham, PA, 2010) |
| "To update and extend a 2006 report on the clinical effectiveness and cost-effectiveness of adefovir dipivoxil (ADV) and pegylated interferon alpha (PEG-alpha) for the treatment of chronic hepatitis B (CHB)." | 8.85 | Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation. ( Baxter, L; Gospodarevskaya, E; Harris, P; Hartwell, D; Jones, J; Price, A; Shepherd, J, 2009) |
| "Clinical trials demonstrated telbivudine to be a safe and potent antiviral agent for treatment of chronic hepatitis B." | 8.84 | A review of telbivudine for the management of chronic hepatitis B virus infection. ( Chan, HL; Lui, YY, 2008) |
| "Standard treatments for chronic hepatitis B (CHB) include interferon-alpha (IFN-alpha) and lamivudine (LAM), but these are associated with adverse effects and viral resistance, respectively." | 8.84 | A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B. ( Davidson, P; Jones, J; Price, A; Shepherd, J; Takeda, A, 2007) |
| "To evaluate properties of the new acyclic nucleotide analog adefovir dipivoxil in the treatment of chronic hepatitis B (CHB)." | 8.82 | Adefovir dipivoxil in the treatment of chronic hepatitis B. ( Rivkin, AM, 2004) |
| " To determine the effectiveness of adefovir, three populations of patients with chronic hepatitis B patients were studied: hepatitis B e antigen (HBeAg)-positive patients, HBeAg-negative patients, and patients with lamivudine-resistant tyrosine-methionine-asparate-aspartate (YMDD) mutants." | 8.82 | Treatment of patients with chronic hepatitis B with adefovir dipivoxil. ( Tong, MJ; Tu, SS, 2004) |
| "Adefovir dipivoxil, an acyclic nucleotide analogue, is effective for the treatment of chronic hepatitis B in both hepatitis B e antigen (HBeAg)-positive and -negative patients, with improvement in liver histology, hepatitis B virus (HBV) DNA levels, alanine aminotransferase levels, and HBeAg seroconversion (for HBeAg-positive patients)." | 8.82 | Adefovir dipivoxil in chronic hepatitis B infection. ( Lai, CL; Yuen, MF, 2004) |
| " Adefovir dipivoxil is indicated for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (alanine [ALT] or aspartate [AST]) or histologically active disease." | 8.82 | Adefovir dipivoxil: focus on its use in the treatment of chronic hepatitis B. ( Baker, DE, 2005) |
| "As tenofovir disoproxil fumarate (TDF) requires long-term use, a reduction in bone density should be considered a possibility when treating patients with chronic hepatitis B (CHB) with aging and systemic diseases." | 8.31 | Tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: A nationwide claims study in South Korea. ( Chang, JI; Cho, YY; Jang, ES; Kim, E; Kim, HJ; Kim, SS; Lee, HW; Seo, GH; Yoon, E, 2023) |
| "Switching to a tenofovir alafenamide (TAF)-containing regimen has been reported to be associated with body weight gain in human immunodeficiency virus-infected subjects." | 8.12 | Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide ( Chuang, WL; Dai, CY; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Nguyen, MH; Trinh, S; Yeh, ML; Yu, ML, 2022) |
| "Data on long-term tenofovir alafenamide (TAF) therapy for pregnant women with active chronic hepatitis B (CHB) (immune clearance and reactivation phases, currently and previously diagnosed) and their infants are lacking." | 8.12 | Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study. ( Chen, ZM; Cui, GL; Feng, YH; Huang, S; Li, GM; Li, GT; Li, J; Li, W; Li, WZ; Li, ZQ; Liang, HX; Lin, WB; Liu, N; Liu, YM; Lv, J; Pan, YJ; Song, N; Sun, CY; Wang, FS; Wang, M; Xu, GH; Xu, JH; Yu, ZJ; Zeng, QL; Zeng, YL; Zhang, DW; Zhang, GF; Zhang, GQ; Zhang, HX; Zhang, JY; Zhou, YH, 2022) |
| "We aimed to investigate the long-term effects of tenofovir disoproxil fumarate and entecavir treatment on bone mineral density and evaluated the fracture risk assessment tool score in patients with chronic hepatitis B." | 8.12 | Effects of Long-Term Tenofovir and Entecavir Treatment on Bone Mineral Density in Patients with Chronic Hepatitis B. ( Çalhan, T; Doğanay, L; Kahraman, R; Kanat, E; Özdil, K; Öztürk, O; Şahin, A; Sayar, S, 2022) |
| "HBV DNA was extracted from blood samples of two patients with HBeAg-positive chronic HBV infection and persistent viremia despite tenofovir treatment, and subsequently amplified by PCR before full-length HBV genomes were assembled by deep sequencing." | 8.12 | Novel hepatitis B virus reverse transcriptase mutations in patients with sustained viremia despite long-term tenofovir treatment. ( Bajpai, PS; Bukh, J; Dalegaard, MI; Fahnøe, U; Lundh, A; Ryom, L; Weis, N; Winckelmann, A, 2022) |
| "Antenatal antiviral therapy (AVT) is effective in preventing mother-to-child transmission (MTCT) in chronic hepatitis B (CHB); tenofovir disoproxil fumarate (TDF) is the preferred agent." | 8.12 | Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection. ( Cottrell, M; Crane, H; Di Girolamo, J; Dumond, J; Gane, E; Kashuba, A; Kayes, T; Levy, MT; Lim, TH; Manandhar, S; Symonds, A, 2022) |
| "Tenofovir alafenamide (TAF) may be preferable to other nucleos(t)ide analogues (NA) regarding outcomes against chronic hepatitis B virus (HBV) infection." | 8.12 | Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study. ( Amagase, H; Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Ichiki, Y; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Kuniyoshi, M; Morita, C; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Sugimoto, R; Takahashi, K; Yamashita, N, 2022) |
| "Non-inferior antiviral efficacy and better renal safety have been reported in chronic hepatitis B patients with tenofovir alafenamide (TAF) treatment." | 8.12 | One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study. ( Chen, YC; Chien, RN; Hsu, CW; Tai, DI, 2022) |
| "Although tenofovir alafenamide (TAF) and besifovir dipivoxil maleate (BSV) are potent antiviral agents in the treatment of chronic hepatitis B (CHB) infection, their renal safety profiles have not been previously compared." | 8.12 | Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B. ( Ahn, SH; Jung, CY; Kim, BS; Kim, HW; Kim, SU; Lee, HW; Lee, JI, 2022) |
| "Entecavir (ETV) or adefovir dipivoxil (ADV) are not recommended during pregnancy because of embryotoxicity or teratogenicity found in animal studies; however, information on the safety of ETV or ADV in humans is limited." | 8.12 | Pregnancy outcomes for pregnant women with chronic hepatitis B exposing to entecavir or adefovir dipivoxil therapy before or in early pregnancy. ( Cai, H; Duan, X; Fu, D; Gao, X; Hu, Y; Kang, K; Liu, M; Yi, W; Zhou, M, 2022) |
| " This study aimed to compare the efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) in relation to the adverse clinical outcomes among chronic hepatitis B (CHB) patients stratified according to adherence to medication and MVR." | 8.02 | Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir. ( Jeong, J; Jung, SW; Kim, MJ; Lee, SB; Park, BR; Park, EJ; Park, NH; Shin, JW, 2021) |
| "Tenofovir alafenamide (TAF) has been newly approved for the treatment of chronic hepatitis B (CHB)." | 7.96 | Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. ( Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Takahashi, K, 2020) |
| "Renal toxicity is a concern in patients with chronic hepatitis B taking nucleotide analogues, such as adefovir (ADV) and tenofovir disoproxil fumarate (TDF)." | 7.96 | Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B. ( Chang, Y; Cho, EJ; Cho, H; Cho, YY; Kim, YJ; Lee, JH; Nam, JY; Yoon, JH; Yu, SJ, 2020) |
| " He had been receiving adefovir dipivoxil (ADV) for the treatment of entecavir (ETV)-resistant chronic hepatitis B (CHB) for four years in his 8-year treatment of hepatocellular carcinoma (HCC), but was referred to our hospital after increased levels of bone pain in his ribs, knees, and ankles." | 7.91 | [Adefovir Dipivoxil-induced Fanconi's Syndrome and Osteomalacia Following Multiple Bone Fractures in a Patient with Chronic Hepatitis B]. ( Ikeda, A; Ikeda, F; Kanzaki, H; Kitamura, Y; Makita, T; Murakawa, K; Nishihara, S; Okada, H; Onishi, H; Sendo, T; Shiraha, H; Takaki, A; Takeuchi, Y; Tanaka, Y; Wada, N; Yasunaka, T, 2019) |
| "Adefovir dipivoxil (ADV) is one of the most important nucleostide analogues currently in use for the treatment of chronic hepatitis B virus (HBV) infection." | 7.91 | Low-dose adefovir dipivoxil-induced hypophosphatemia osteomalacia in five chronic hepatitis B virus-infected patients. Is low-dose adefovir dipivoxil-induced nephrotoxicity completely reversible? ( Dai, ZJ; Jin, J; Pan, YJ; Qian, YY; Ruan, LY; Shi, MT; Wu, CM; Zhu, YX, 2019) |
| "Renal toxicity of adefovir disoproxil (ADV) and tenofovir disoproxil fumarate (TDF) is a significant concern in chronic hepatitis B (CHB) patients." | 7.91 | In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue. ( Chan, TM; Fung, J; Lai, CL; Liu, SH; Mak, LY; Seto, WK; Wong, DK; Yap, DY; Yuen, MF, 2019) |
| "Adefovir dipivoxil (ADV)-induced renal tubular dysfunction and hypophosphatemic osteomalacia (HO) have been given great consideration in the past few years." | 7.88 | Adefovir dipivoxil induced hypophosphatemic osteomalacia in chronic hepatitis B: a comparative study of Chinese and foreign case series. ( Chen, N; Li, LY; Liu, LW; Peng, T; Tang, KX; Yu, F; Yu, X; Zhang, JB; Zhang, Q; Zhao, YP, 2018) |
| "Few studies have addressed the impact of adefovir dipivoxil (ADV)-based combination therapy on the renal function of patients with chronic hepatitis B (CHB)." | 7.88 | Telbivudine and adefovir dipivoxil combination therapy improves renal function in patients with chronic hepatitis B: A STROBE-compliant article. ( Nie, ZW; Xu, Y, 2018) |
| "Although high potent nucleos(t)ide analogues are strongly recommended as first-line therapy for chronic hepatitis B (CHB) in China, some patients are still being treated with adefovir disoproxil (ADV), especially those low-income patients whose health insurance could not reimburse the drug cost." | 7.85 | Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy. ( Chen, EQ; Du, LY; Lei, BJ; Lei, XZ; Liao, J; Lu, JJ; Tang, H; Wang, ML; Yan, LB; Zhang, DM; Zhou, TY, 2017) |
| "This study compared virologic response to entecavir monotherapy and de novo lamivudine plus adefovir (LAM + ADV) combination therapy in patients with chronic hepatitis B (CHB) with high viral load (HVL)." | 7.83 | Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result. ( Cai, S; Jiang, Y; Lv, F; Peng, J; Yu, T; Zhang, Y, 2016) |
| "We investigated the long-term efficacy of adefovir add-on lamivudine rescue therapy in lamivudine-resistant chronic hepatitis B and the optimal cutoff hepatitis B virus (HBV) DNA level that predicts complete virological response (CVR) among patients without CVR after 1 year of treatment." | 7.83 | Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B. ( Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, SB; Kim, SU; Park, JY, 2016) |
| "Lamivudine (LAM) plus adefovir (ADV) combination therapy is clinically efficacious for treating chronic hepatitis B (CHB) patients in China, but no pharmacoeconomic evaluations of this strategy are available." | 7.83 | Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients. ( Gao, Y; Ke, W; Liu, L; Yang, Y; Yao, Z; Ye, X; Zhang, C; Zhou, S, 2016) |
| " We aimed to establish if IP-10 expression in liver tissue and in plasma of chronic hepatitis B (CHB) patients correlated with each other and further to investigate if IP-10 levels before and during therapy with peginterferon and adefovir could predict treatment outcome in CHB patients." | 7.83 | Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir. ( de Niet, A; Jansen, L; Kootstra, NA; Reesink, HW; Sinnige, MJ; Takkenberg, RB; Verheij, J; Willemse, SB, 2016) |
| "Tenofovir disoproxil fumarate (TDF) is newly available for treatment of chronic hepatitis B patients in China." | 7.83 | Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China. ( Gao, Y; Ke, W; Liu, L; Yang, Y; Yao, Z; Ye, X; Zhang, C; Zhou, S, 2016) |
| "Adefovir dipivoxil (ADV) is effective for hepatitis B virus (HBV) infection; however, ADV may provoke renal injury resulting in osteomalacia, and this side effect is seldom recognized until bone fractures emerge." | 7.83 | Urinary β-2 Microglobulin Levels Sensitively Altered in an Osteomalacia Patient Receiving Add-on Adefovir Dipivoxil Therapy for Hepatitis B Virus Infection. ( Hirase, S; Ito, K; Ito, T; Morishima, T; Morita, H; Ohashi, T; Otake, K; Takagi, J; Yoneda, M, 2016) |
| "Entecavir (ETV) is a potent viral replication inhibitor for chronic hepatitis B (CHB) patients." | 7.83 | A five years study of antiviral effect of entecavir in Chinese chronic hepatitis B patients. ( Bao, R; Bao, S; Chen, R; Guo, Q; Liu, K; Liu, Y; Wang, H; Xiang, X; Xie, J; Xie, Q, 2016) |
| "The aim of this study was to evaluate serum kidney injury molecule-1 (KIM-1) as a new diagnostic marker of renal dysfunction in chronic hepatitis B (CHB) patients receiving long-term adefovir dipivoxil (ADV) treatment." | 7.83 | Circulating kidney injury molecule-1 is a novel diagnostic biomarker for renal dysfunction during long-term adefovir therapy in chronic hepatitis B. ( Li, Z; Liu, Z; Shen, C; Wang, W; Wang, Y; Zhao, C; Zhao, Q, 2016) |
| "Tenofovir disoproxil fumarate (TDF) is an established nucleotide analogue in the treatment of chronic hepatitis B." | 7.81 | Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? ( Al-Shamma, S; Barr, DA; Burke, K; Foster, GR; Gill, US; Kallis, YN; Kennedy, PT; Kooner, P; Marley, RT; McPhail, MJ; Zissimopoulos, A, 2015) |
| "The risk of hepatocellular carcinoma (HCC) in Caucasian patients with chronic hepatitis B (CHB), treated with entecavir (ETV) or tenofovir (TDF), is unclear." | 7.81 | Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. ( Arends, P; Buti, M; Colombo, M; Dalekos, GN; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HL; Keskın, O; Lampertico, P; Mangia, G; Manolakopoulos, S; Papaioannou, C; Papatheodoridis, GV; Savvidou, S; Sypsa, V; Yurdaydin, C, 2015) |
| "Increased risk of defective urinary phosphate reabsorption and osteoporosis has been reported in HIV and chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF)." | 7.81 | Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling. ( Bae, HS; Chan, LS; Chang, M; Fong, TL; Huh, B; Lee, S; Lim, C; Shinada, S; Tien, C; Xu, JJ, 2015) |
| "To investigate the association between the baseline profiles and dynamics of hepatitis B virus (HBV) DNA polymerase gene mutations and the long-term virological response of lamivudine (LAM)-adefovir (ADV) combination therapy in patients with LAM-resistant chronic hepatitis B." | 7.81 | Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B. ( Choi, K; Jang, JY; Jeong, SW; Kim, BS; Kim, HS; Kim, J; Kim, SG; Kim, YS; Lee, SH, 2015) |
| "Tenofovir disoproxil fumarate (TDF) monotherapy is a therapeutic option for chronic hepatitis B (CHB) patients infected with hepatitis B virus (HBV) variants resistant to lamivudine (LAM)." | 7.81 | Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B. ( Ahn, H; Cho, EJ; Cho, H; Cho, Y; Cho, YY; Choi, WM; Jung, EU; Kim, BH; Kim, CM; Kim, CY; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Lee, M; Lee, YB; Lee, YJ; Park, JW; Park, SJ; Yoo, JJ; Yoon, JH; Yu, SJ, 2015) |
| "Entecavir (ETV) plus adefovir (ADV) combination therapy is one of the useful treatment option for the patients with chronic hepatitis B (CHB) who had failed on prior nucleos(t) ide analogue (NA) treatments." | 7.81 | Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments. ( Cho, Y; Kim, YJ; Lee, HS; Lee, JH; Yoon, JH; Yu, SJ, 2015) |
| " These pregnant females developed lamivudine (LAM)- or telbivudine (LdT)-resistant chronic hepatitis B and received tenofovir (TDF) therapy (300 mg/d), and its curative effect, maternal and perinatal adverse events, fetal growth and development, and neonatal prognosis were evaluated." | 7.81 | Tenofovir rescue therapy in pregnant females with chronic hepatitis B. ( Cai, HD; Cao, YJ; Hu, YH; Liu, M; Yi, W, 2015) |
| "Patients with chronic hepatitis B (HBV DNA load, >17 000 IU/mL) were treated with pegylated interferon alfa-2a and adefovir for 48 weeks." | 7.81 | Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir. ( de Niet, A; Jansen, L; Kootstra, NA; Reesink, HW; Stelma, F; Takkenberg, RB; Tempelmans Plat-Sinnige, MJ; van Leeuwen, EM, 2015) |
| "Tenofovir disoproxil fumarate has been used in chronic hepatitis B patients with suboptimal virologic response to nucleos(t)ide analogues." | 7.81 | Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B. ( Chan, HL; Chan, HY; Lo, AO; Tse, YK; Wong, GL; Wong, VW, 2015) |
| "To evaluate urine β2-microglobulin (β2-M), retinol-binding protein (RBP) excretion, and renal impairment with adefovir dipivoxil (ADV) for chronic hepatitis B." | 7.81 | Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B. ( Cai, H; Chen, JY; Ding, F; Hu, JH; Jia, HY; Li, LJ; Lian, JS; Lu, YF; Xiang, DR; Yang, YD; Yu, GD; Yu, L; Zeng, LY; Zhang, YM; Zheng, L, 2015) |
| "We evaluated the efficacy of tenofovir (TDF)-based rescue therapy and compared the outcomes of TDF monotherapy and TDF-based nucleoside analog (NA) combination therapy in patients with suboptimal response (SOR) to adefovir (ADV) with or without NAs in lamivudine (LAM)-resistant chronic hepatitis B." | 7.81 | Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance. ( Cheong, JY; Cho, HJ; Cho, SW; Kim, SS; Shin, SJ; Yoo, BM, 2015) |
| "In chronic hepatitis B patients, lamivudine (LAM) and adefovir (ADV) combination therapy is commonly used as a rescue therapy for LAM resistance, but it often results in incomplete viral suppression." | 7.81 | Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination. ( Bang, SJ; Jeong, ID; Jung, SW; Kim, BG; Kim, CJ; Kim, MH; Lee, BU; Park, BR; Park, JH; Park, NH; Shin, JW, 2015) |
| "In the past decade, many chronic hepatitis B (CHB) patients have undergone sequential treatment with lamivudine (LAM), adefovir (ADV), and entecavir (ETV) to manage antiviral resistance or insufficient suppression of HBV-DNA." | 7.81 | Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir. ( Bang, SJ; Jeong, ID; Jung, SW; Kim, BG; Kim, CJ; Kim, EH; Kim, JH; Kim, MH; Lee, BU; Park, BR; Park, JH; Park, NH; Shin, JW; Sung, SJ, 2015) |
| "To compare the efficacy of telbivudine monotherapy and telbivudine combination therapy with adefovir in patients with nucleos(t)ide-naive chronic hepatitis B, high-level hepatitis B virus (HBV) load and hepatitis B e antigen (HBeAg)-positivity, and to explore the relationship between treatment regimen adherence and treatment outcomes." | 7.81 | [Efficacy and safety of telbivudine alone and combined with adefovir for the treatment of nucleos(t)ide-naive chronic hepatitis B in patients with high-level hepatitis B virus load]. ( Dang, B; Kang, W; Liu, Q; Sun, Y; Wang, C; Yao, N; Yu, Z; Zhao, K, 2015) |
| "To investigate the effects of adefovir dipivoxil (ADV) on blood phosphorus metabolism in patients with chronic hepatitis B (CHB)." | 7.81 | [Adefovir dipivoxil effects on and related factors of blood phosphorus metabolism in patients with chronic hepatitis B]. ( Ding, G; Kang, Y; Li, K; Li, W; Mao, Z; Ning, H; Shang, J; Xiao, E, 2015) |
| "To evaluate the long-term efficacy adefovir (ADV)-based combination therapies in entecavir (ETV)-resistant chronic hepatitis B (CHB) patients." | 7.81 | Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies. ( Hwang, SG; Jang, MK; Jeong, SH; Jung, YK; Kim, BH; Kim, HS; Kim, IH; Kim, JH; Kim, JW; Kim, SG; Kim, TY; Kim, YS; Lee, JI; Lee, JW; Lee, SH; Park, H; Park, JW; Park, SJ; Seo, YS; Suh, SJ; Yim, HJ, 2015) |
| "We compared the efficacies of entecavir (ETV) plus tenofovir (TDF) and ETV plus adefovir (ADV) in chronic hepatitis B (CHB) patients with genotypic resistance to lamivudine (LAM) who showed a suboptimal response to LAM and ADV combination therapy." | 7.81 | Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy. ( Park, JG; Park, SY, 2015) |
| "Renal dysfunction and Fanconi's syndrome associated with hypophosphatemia caused by long-term administration of low-dose adefovir dipivoxil (ADV) has been reported in recent years." | 7.80 | Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. ( Akuta, N; Arase, Y; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y; Tanaka, M, 2014) |
| "Few studies have investigated the emergence of multidrug resistance to adefovir dipivoxil (ADV) plus lamivudine (LAM) combination therapy for patients with LAM-refractory chronic hepatitis B (CHB)." | 7.80 | Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine. ( Akuta, N; Arase, Y; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Mineta, R; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Watahiki, S, 2014) |
| "We investigated the long-term efficacy of entecavir (ETV) + adefovir (ADV) combination therapy versus ETV monotherapy in lamivudine (LAM)-resistant chronic hepatitis B (CHB) patients who failed to respond to ADV rescue therapy." | 7.80 | Long-term efficacy of entecavir plus adefovir combination therapy versus entecavir monotherapy in adefovir refractory chronic hepatitis B patients with prior lamivudine resistance. ( Kim, DG; Kim, IH; Kim, SH; Kim, SW; Lee, S; Lee, SO; Lee, ST; Seo, SY; Sohn, JY, 2014) |
| "Previous studies have demonstrated that the treatment of chronic hepatitis B (CHB) infection with adefovir (ADV) can impair renal function." | 7.80 | Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy. ( Kim, HY; Kim, YJ; Lee, HJ; Lee, HS; Lee, JH; Lee, M; Oh, S; Yeum, TS; Yoon, JH; Yu, SJ, 2014) |
| "Entecavir (ETV) plus adefovir (ADV) combination therapy may be a promising option for chronic hepatitis B (CHB) patients who have failed on prior nucleos(t)ide analog (NA) treatment." | 7.80 | Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment. ( Wang, X; Wang, Y; Xiong, Y; Zhang, C; Zhu, Y, 2014) |
| "Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are the two first-line anti-viral therapies for chronic hepatitis B (CHB); however, there are limited studies directly comparing their effectiveness." | 7.80 | Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. ( Gao, L; Li, J; Nguyen, MH; Trinh, HN, 2014) |
| "We investigated the efficacy and safety of tenofovir disoproxil fumarate (TDF)-based treatment in chronic hepatitis B (CHB) patients who failed previous antiviral therapies." | 7.80 | Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure. ( Byun, KS; Choe, WH; Kim, JH; Kim, YS; Kwon, SY; Lee, CH; Lee, CI; Yeon, JE; Yoon, EL, 2014) |
| "Tenofovir (TDF) has similar antiviral efficacy in both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patients." | 7.80 | Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B. ( Akyüz, F; Badur, S; Baran, B; Bozdayi, AM; Idilman, R; Kabaçam, G; Karatayli, E; Karatayli, S; Kaymakoglu, S; Keskin, O; Onel, D; Ormeci, AC; Tüzün, A; Yurdaydin, C, 2014) |
| "The role of quantitative hepatitis B surface antigen (HBsAg) levels in patients receiving highly potent oral antiviral therapy is controversial, and here, we determined the HBsAg response in 121 chronic hepatitis B patients treated with tenofovir 300 mg daily." | 7.80 | Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment. ( Gupta, E; Hissar, SS; Sarin, SK; Sharma, MK; Singh, AK, 2014) |
| "The aim of the present study was to assess the long-term impact of entecavir (ETV) on T, B and natural killer (NK) cell immunity in patients with suboptimal responses to adefovir (SRA) chronic hepatitis B (CHB)." | 7.80 | Effects of entecavir on peripheral blood lymphocyte profiles in chronic hepatitis B patients with suboptimal responses to adefovir. ( Hu, X; Jiang, Y; Wang, Q; Zhang, L; Zhao, P, 2014) |
| "A 64-year-old woman was prescribed lamivudine and adefovir (ADV) for chronic hepatitis B." | 7.80 | [A case of chronic hepatitis B managed with continued adefovir despite treatment-related Fanconi syndrome and osteomalacia]. ( Asahina, Y; Iizuka, K; Iizuka, Y; Ito, E; Kobayashi, K; Mochizuki, N; Sakai, H; Watanabe, M, 2014) |
| "In chronic hepatitis B patients with kidney transplantation, sequential monotherapy with antiviral agents with low barriers to resistance should be avoided, and initial therapy with entecavir is a better option." | 7.80 | Efficacy and safety of tenofovir in a kidney transplant patient with chronic hepatitis B and nucleos(t)ide multidrug resistance: a case report. ( Shan, C; Wu, P; Yin, GQ, 2014) |
| "To investigate the treatment efficacy of adefovir dipivoxil combined with a corticosteroid on hepatitis B virus-associated glomerulonephritis (HBV-GN)." | 7.80 | Efficacy of adefovir dipivoxil combined with a corticosteroid in 38 cases of nephrotic syndrome induced by hepatitis B virus-associated glomerulonephritis. ( Li, H; Qiu, L; Xiao, P; Yuan, X; Zhou, Q, 2014) |
| "This study investigated the antiviral efficacy of adefovir (ADV) rescue therapy and the feasibility of lamivudine (LAM) discontinuation in LAM-resistant chronic hepatitis B (CH-B) patients who had attained a virological response (VR) with LAM + ADV combination therapy." | 7.80 | The feasibility of discontinuing lamivudine in lamivudine-resistant chronic hepatitis B patients on lamivudine and adefovir combination therapy. ( Byoun, YS; Chung, SM; Jang, ES; Jeong, SH; Kim, HS; Kim, JW, 2014) |
| "Adefovir (ADV) resistance is more frequent in lamivudine (LMV)-resistant chronic hepatitis B (CHB) patients than in nucleos(t)ide analogue-naïve patients." | 7.80 | Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B. ( Cho, YK; Cui, XJ; Jeong, SU; Song, BC, 2014) |
| "This study assessed the antiviral efficacy and safety of tenofovir disoproxil fumarate (TDF) for up to 12 months in Korean treatment-naïve chronic hepatitis B (CHB) patients." | 7.80 | Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. ( Ahn, SH; Ahn, SS; Chon, YE; Han, KH; Kim, BK; Kim, DY; Kim, SU; Park, JY, 2014) |
| "Adefovir (ADV) and lamivudine (LAM) combination therapy (ADV+LAM) has been a useful option for patients with LAM-resistant (LAM-r) chronic hepatitis B (CHB)." | 7.80 | Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir. ( Ahn, DG; Baek, EK; Cho, HJ; Chung, HW; Kim, HJ; Kwon, JC; Lee, H; Lee, JJ; Ze, E, 2014) |
| " Here, we describe two additional patients with chronic hepatitis B (CHB) who developed a TDF-induced Fanconi syndrome that reverted after TDF withdrawal and had viral replication fully suppressed upon switching to entecavir (ETV)." | 7.80 | Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal. ( Brocchieri, A; Castelli, F; Colombo, M; Facchetti, F; Fugazza, A; Lampertico, P; Mangia, G; Spinetti, A; Viganò, M; Zaltron, S, 2014) |
| "Tenofovir (300 mg/d) is an effective and safe rescue therapy in chronic hepatitis B patients who failed initial treatment with LAM and secondary treatment of LAM plus ADV." | 7.80 | [Tenofovir rescue therapy for chronic hepatitis B patients after suboptimal response to treatment with lamivudine plus adefovir dipivoxil]. ( Fan, H; Fan, Y; Ge, Y; Li, D; Liu, X; Liu, Z; Lyu, W; Yang, H; Zhou, B, 2014) |
| "There is very limited experience in the management of telbivudine (LdT)-associated virological breakthrough (VBT) and resistance in the treatment of chronic hepatitis B (CHB) patients, and the guideline recommendations are primitively based on the general principles of rescue therapy to nucleos(t)ide analog resistance." | 7.79 | Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine. ( Bai, XF; Huang, CX; Li, Y; Lian, JQ; Wang, JP; Zhang, Y, 2013) |
| "Chronic hepatitis B patients (CHB) treated with adefovir were followed up to evaluate nephrotoxicity and its outcome." | 7.79 | Resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B. ( Aung, MO; Chiu, LL; Dan, YY; Gowans, M; Hartono, JL; Khoo, MJ; Koay, E; Lee, GH; Lee, YM; Lim, K; Lim, SG; Low, HC; Soon, C; Tan, PS; Thwin, MA, 2013) |
| "In patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB) receiving adefovir (ADV) add-on LAM therapy, insufficient viral suppression or the appearance of additional ADV resistance has remained unresolved." | 7.79 | Partial virological response to adefovir add-on lamivudine rescue therapy in patients with lamivudine-resistant chronic hepatitis B. ( Ahn, SH; Choi, A; Chon, CY; Chon, YE; Han, KH; Kim, DY; Kim, SU; Park, JY, 2013) |
| "To evaluate the efficacy and safety of Entecavir (ETV) plus adefovir (ADV) for chronic hepatitis B (CHB) patients after multiple nucleos(t)ide analogue (NAs) failure treatment." | 7.79 | Entecavir plus adefovir rescue therapy for chronic hepatitis B patients after multiple treatment failures in real-life practice. ( Deng, JY; He, FQ; Li, GL; Li, JY; Li, Q; Pan, QR; Qin, Y; Xu, XH, 2013) |
| "Tenofovir disoproxil fumarate (TDF) is increasingly used in patients with chronic hepatitis B (CHB) infection." | 7.79 | Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection. ( Gracey, DM; McKenzie, P; Snelling, P; Strasser, SI, 2013) |
| "The aim of this study was to compare the effect of combination lamivudine (LAM) and adefovir dipivoxil (ADV) versus entecavir (ETV) monotherapy for naïve HBeAg-positive chronic hepatitis B (CHB) patients." | 7.79 | Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: a pilot study. ( Cai, FJ; Ding, JG; Du, QW; Fu, RQ; Hong, L; Sun, QF; Wu, YH; Zhou, QQ, 2013) |
| "The aim of our study was to validate the roadmap concept in the treatment of chronic hepatitis B, and to investigate the virologic efficacy and kinetics of quantitative hepatitis B surface antigen (qHBsAg) during telbivudine therapy in a real-world setting." | 7.79 | Real-world application of the roadmap model in chronic hepatitis B patients with telbivudine therapy. ( Hsu, PI; Lai, KH; Lin, KH; Tsai, TJ; Tsay, FW; Wang, HM; Yu, HC, 2013) |
| "Treatment strategies for entecavir (ETV)-resistant chronic hepatitis B (CHB) patients are not yet well established." | 7.79 | Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection. ( Cho, Y; Cho, YY; Choi, WM; Kim, CY; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Lee, M; Lee, YB; Yoo, JJ; Yoon, JH; Yu, SJ, 2013) |
| "Lamivudine (LAM) plus adefovir (ADV) combination therapy has been accepted as one of the best treatments for LAM-resistant chronic hepatitis B (CHB)." | 7.79 | Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients. ( Choe, WH; Kim, JH; Ko, SY; Kwon, SY; Lee, CH, 2013) |
| "To investigate the efficacy and safety ofTelbivudine +Tenofovir combination therapy in chronic hepatitis B patients, over a period of 52 weeks, in real life clinical settings." | 7.79 | Telbivudine plus tenofovir in combination therapy in patients with chronic hepatitis B infection--an Indian experience. ( Panda, C, 2013) |
| "The efficacy of adefovir (ADV) plus entecavir (ETV) combination in patients with chronic hepatitis B (CHB) who developed multidrug refractoriness had not been fully evaluated." | 7.79 | The efficacy of adefovir plus entecavir combination therapy in patients with chronic hepatitis B refractory to both lamivudine and adefovir. ( Cho, EJ; Cho, Y; Chung, KH; Jeong, SH; Jin, E; Kim, CY; Kim, JW; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Yoon, JH; Yu, SJ, 2013) |
| "Fifty-three patients with confirmed genotypic lamivudine-resistant chronic hepatitis B were treated with entecavir." | 7.79 | The short-term efficacy of entecavir in lamivudine-resistant chronic hepatitis B: influence of sequential adefovir-refractoriness. ( Choi, DJ; Jung, YK; Kim, JH; Kim, YS; Ku, YS; Kwon, OS, 2013) |
| "To compare the efficacy of rescue therapies in lamivudine (LAM)-resistant chronic hepatitis B (CHB) infections including: (1) adefovir dipivoxil (ADV) monotherapy, (2) ADV plus LAM combination therapy and (3) entecavir (ETV) 1." | 7.79 | Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study. ( Ahn, SH; Hong, SP; Hwang, SG; Kim, BH; Kim, HS; Kim, IH; Kim, JH; Lee, JI; Lee, JM; Lee, JW; Lee, SH; Lee, SJ; Park, SJ; Park, YM; Seo, YS; Yim, HJ; Yoon, EL, 2013) |
| "We evaluated the efficacy of tenofovir disoproxil fumarate (TDF) in patients with lamivudine failure (LAM-F) in comparison with that in nucleoside/nucleotide analogue (NA)-naïve patients with chronic hepatitis B (CHB)." | 7.79 | Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B. ( Akyuz, F; Badur, S; Baran, B; Besisik, F; Bozbey, HU; Demir, K; Evirgen, S; Gokturk, S; Gulluoglu, M; Karaca, C; Kaymakoglu, S; Onel, D; Ormeci, AC; Soyer, OM, 2013) |
| "The impact of adefovir dipivoxil (ADV) treatment on the immune system in patients with chronic hepatitis B (CHB) is unknown." | 7.78 | Adefovir dipivoxil modulates cytokine expression in Th1/Th2 cells in patients with chronic hepatitis B. ( Liu, YY; Ma, ZH; Niu, JQ; Piao, RL; Tian, D; Zhang, M; Zhao, C, 2012) |
| "A male 36 years old patient diagnosed with anti HBe-positive chronic hepatitis B (CHB) had received lamivudine treatment for 7 years following an initial unsuccessfull interferon treatment." | 7.78 | Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection. ( Bozdayi, AM; Cinar, K; Gokahmetoglu, S; Güven, K; Idilman, R; Karatayli, E; Karatayli, SC; Yurdaydin, C, 2012) |
| "Adefovir is usually applied for therapy of chronic hepatitis B (CHB), but its effectiveness after cessation is still unknown." | 7.78 | A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir. ( Diao, S; Ha, M; Huang, C; Huang, Z; Kuan, C; Lin, M; She, H; Shen, L; Shen, W; Sun, L; Zhang, G, 2012) |
| "The optimal treatment of patients with chronic hepatitis B (CHB) who develop resistance to both lamivudine (LMV) and entecavir (ETV) after sequential monotherapy of LMV and ETV remains little known." | 7.78 | Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B. ( Cha, JM; Jeon, JW; Joo, KR; Kim, S; Lee, JI; Lim, JU; Lim, K; Park, JJ; Shin, HP, 2012) |
| "The combination of entecavir, a nucleoside analogue, and adefovir, a nucleotide analogue, would be a promising salvage treatment for chronic hepatitis B (CHB) patients who fail nucleoside/nucleotide analogue (NA) regimens." | 7.78 | Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues. ( Heo, NY; Lee, HC; Lee, TH; Lim, YS; Shim, JH; Suh, DJ, 2012) |
| "Among 141 HIV-HBV-coinfected patients treated with tenofovir in our centre, 87% were good-responders to therapy." | 7.78 | Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir. ( Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Lada, O; Leclerc, L; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B, 2012) |
| " entecavir (ETV) monotherapy in HBeAg-positive hepatitis B patients who fail to respond to sequential treatment with LAM and ADV." | 7.78 | Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir. ( Ahn, SH; Chon, CY; Han, KH; Kim, DY; Lee, JM; Lee, MH; Park, JY; Ryu, HJ; Son, CY, 2012) |
| "Adefovir and tenofovir are nucleotide analogues used as long-term therapy of chronic hepatitis B." | 7.78 | Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. ( Chong, WH; Collins, MT; Gara, N; Ghany, MG; Hoofnagle, JH; Jake Liang, T; Kleiner, DE; Zhao, X, 2012) |
| "Tenofovir is a nucleotide reverse-transcriptase inhibitor approved for treatment of human immunodeficiency virus infection, as well as chronic hepatitis B (CHB)." | 7.78 | Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. ( Baqai, S; Clark, MD; Gish, RG; Kane, SD; Mangahas, MF; Shaw, RE, 2012) |
| "To evaluate the changes in the renal function of patients with chronic hepatitis B (CHB) receiving adefovir dipivoxil (ADV) or telbivudine (L-DT) monotherapy." | 7.78 | [Influence of adefovir dipivoxil or telbivudine monotherapy on renal function of patients with chronic hepatitis B]. ( Fan, R; Guo, Y; Hou, J; Li, X; Peng, J; Sun, J; Yang, S; Zhong, C, 2012) |
| "In the first year of treatment for chronic hepatitis B, virologic response and tolerability did not differ significantly between tenofovir and entecavir." | 7.78 | Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B. ( Akin, MS; Doğan, ÜB; Gümürdülü, Y; Kara, B; Soylu, A, 2012) |
| "We present a case of a 62-year-old man who underwent total hip arthroplasty for treatment of pathologic femoral neck fracture associated with adefovir dipivoxil-induced osteomalacia." | 7.78 | Pathological femoral fractures due to osteomalacia associated with adefovir dipivoxil treatment for hepatitis B: a case report. ( Arishima, Y; Hirotsu, M; Ishidou, Y; Kakoi, H; Kamizono, J; Komiya, S; Nagano, S; Nakamura, S; Saitoh, Y; Setoguchi, T; Tanaka, M; Yokouchi, M, 2012) |
| "There is a paucity of data on the long-term efficacy of combination lamivudine and adefovir therapy in patients with lamivudine-resistant chronic hepatitis B." | 7.78 | Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir. ( Fung, J; Hung, IF; Lai, CL; Liu, K; Seto, WK; Wong, DK; Yuen, JC; Yuen, MF, 2012) |
| "Lamivudine (LAM) resistance now poses a major problem in the management of patients with chronic hepatitis B virus (HBV) infection." | 7.78 | Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B. ( Huang, L; Li, T; Wang, C; Xu, D; Zhao, P, 2012) |
| " To evaluate the resistance to adefovir (ADV) therapy in patients with chronic hepatitis B infection, a study was conducted on 70 patients (63 males and 7 females), who had received in first line lamivudine and second line adefovir." | 7.78 | Use of ALLGIO probe assays for detection of HBV resistance to adefovir in patients with chronic hepatitis B, Kerman, Iran. ( Afshar, RM; Mollaie, HR, 2012) |
| "To investigate retrospectively the long-term efficacy of various treatment strategies using adefovir dipivoxil (adefovir) in patients with lamivudine-resistant chronic hepatitis B." | 7.78 | Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B. ( An, H; Chun, HJ; Jeen, YT; Jung, JY; Keum, B; Kim, CD; Kim, CH; Kim, JD; Kim, YS; Lee, HS; Ryu, HS; Seo, YS; Um, SH; Yim, HJ; Yun, TJ, 2012) |
| "Although adefovir dipivoxil (ADV) has been used for antiviral treatment of lamivudine (LAM)-resistant chronic hepatitis B (CHB) patients, the long-term efficacy of this treatment is not well understood." | 7.77 | Initial virological response and viral mutation with adefovir dipivoxil added to ongoing Lamivudine therapy in Lamivudine-resistant chronic hepatitis B. ( Arai, M; Fukai, K; Imazeki, F; Kanda, T; Wu, S; Yokosuka, O; Yonemitsu, Y, 2011) |
| "Tenofovir disoproxil fumarate (TDF), a nucleotide analogue and potent inhibitor of hepatitis B virus (HBV) polymerase, showed superior efficacy to adefovir dipivoxil in treatment of chronic hepatitis B through 48 weeks." | 7.77 | Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. ( Anderson, J; Borroto-Esoda, K; Buggisch, P; Buti, M; De Man, RA; Flisiak, R; Gane, E; Germanidis, G; Gurel, S; Heathcote, EJ; Kaita, K; Kotzev, I; Krastev, Z; Kurdas, OO; Lee, SS; Manns, M; Marcellin, P; Mondou, E; Rousseau, F; Shiffman, ML; Snow-Lampart, A; Sorbel, J; Tchernev, K; Trinh, H; Weilert, F, 2011) |
| "The study evaluated whether a liquid suspension of adefovir dipivoxil (ADV) is effective and safe when dose adjusted based on varying degrees of renal impairment in patients with chronic hepatitis B." | 7.77 | Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment. ( Frederick, D; Pol, S; Rostaing, L; Rousseau, F; Schiff, E; Shiffman, ML; Thabut, D; Zeuzem, S; Zong, J, 2011) |
| "The aim of this study was to determine the optimal time and HBV DNA levels during the treatment period for prediction of virological breakthrough (VBT) 3 years after adefovir monotherapy in chronic hepatitis B (CHB) patients with lamivudine resistance." | 7.77 | The level of HBV DNA at month 12 is an important predictor of virological breakthrough during adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance. ( Jung, SW; Kim, MC; Park, NH; Shin, JW, 2011) |
| "This study included 82 patients with HBeAg-negative chronic hepatitis B (CHB) who received adefovir dipivoxil therapy." | 7.77 | [Virological response to adefovir dipivoxil predicts the long-term development of resistance in previously untreated patients with HBeAg-negative chronic hepatitis B]. ( Andrade, RJ; Chueca, N; Figueruela, B; Fraga, E; García, F; Gila, A; Martín, JM; Muñoz Rueda, P; Nogales, C; Puche, B; Romero-Gómez, M; Salmerón, J; Suárez, E, 2011) |
| "An increasing number of patients with chronic hepatitis B infection are being treated with the newly licensed drug, adefovir." | 7.77 | Adefovir-induced Stevens-Johnson syndrome and toxic epidermal necrolysis overlap syndrome. ( Chattopadhyay, P; Sarma, N, 2011) |
| "To assess the long-term effectiveness and safety of adefovir (ADV) plus lamivudine (LMV) in LMV-resistant (R) kidney transplants with chronic hepatitis B, 11 such patients were treated with add-on ADV." | 7.77 | Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B. ( Aroldi, A; Colombo, M; Facchetti, F; Invernizzi, F; Lampertico, P; Lunghi, G; Messa, PG; Viganò, M, 2011) |
| "The aims of this study were to assess the long-term efficacy of lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy in patients with chronic hepatitis B resistant to LAM, to identify predictive factors of complete viral response (HBV-DNA <2." | 7.77 | Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients. ( Aizawa, M; Fujise, K; Hoshina, S; Kono, M; Tajiri, H; Tatsuzawa, K; Tsubota, A, 2011) |
| "We report a case of an immunocompromised patient affected by chronic hepatitis B virus (HBV) with high basal HBV viremia (>8 log(10) IU/ml) who failed an entecavir regimen, despite the absence of primary or secondary drug resistance mutations." | 7.77 | Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. ( Andreoni, M; Bertoli, A; Ceccarelli, L; Perno, CF; Salpini, R; Sarrecchia, C; Sordillo, P; Svicher, V; Volpi, A, 2011) |
| "An increasing number of patients with chronic hepatitis B (CHB) have experienced treatment failure to adefovir (ADV) and their management poses a growing challenge." | 7.77 | The efficacy of entecavir therapy in chronic hepatitis B patients with suboptimal response to adevofir. ( Do, ST; Garcia, RT; Nguyen, HA; Nguyen, KK; Nguyen, MH; Nguyen, TT; Sheen, E; Tran, P; Trinh, HN, 2011) |
| "In chronic hepatitis B (CHB) patients, adefovir is commonly used as a rescue therapy for lamivudine resistance, but often results in incomplete virological suppression." | 7.77 | Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. ( Chan, HL; Chan, HY; Ong, A; Tse, CH; Wong, GL; Wong, VW, 2011) |
| "This study aimed to evaluate the long-term efficacy of entecavir (ETV) in adefovir (ADV)-refractory chronic hepatitis B (CHB) patients with prior lamivudine (LMV) resistance." | 7.77 | Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance. ( Jang, JS; Jang, MK; Kim, DJ; Kim, HS; Kim, HY; Kim, KH; Lee, JH; Lee, MS; Park, CK; Park, JW; Seo, DD; Shin, WG, 2011) |
| "To study the factors influencing the long-term usage of lamivudine (LAM) in chronic hepatitis B (CHB) patients and the management after drug-resistance." | 7.77 | [Lamivudine-resistant analysis and management for chronic hepatitis B patients with initial lamivudine therapy]. ( Chen, Y; He, LL; Lei, BJ; Lei, XZ; Xu, H, 2011) |
| "Previous research has demonstrated that tenofovir disoproxil fumarate (DF) is the most cost-effective nucleos(t)ide treatment for chronic hepatitis B (CHB) in the UK, Spain, Italy and France." | 7.77 | Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective. ( Bentley, A; Dakin, H; Fidler, C; Fung, S; Sherman, M, 2011) |
| "Adefovir dipivoxil is commonly used for treatment of chronic hepatitis B." | 7.77 | [Adefovir dipivoxil-induced Fanconi syndrome and hypophosphatemic osteomalacia associated with muscular weakness in a patient with chronic hepatitis B]. ( Dong, GF; Li, L; Xie, YS; Zhang, X, 2011) |
| "We investigated the durability of the biochemical and virologic responses after adefovir (ADV) discontinuation in lamivudine-resistant (LMV-R) chronic hepatitis B (CHB) patients, and the outcomes of ADV discontinuation compared to that of ADV maintenance." | 7.77 | Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients. ( Byun, KS; Jung, ES; Jung, YK; Kim, JH; Lee, KG; Ryu, HS; Seo, YS; Um, SH; Yeon, JE; Yim, HJ, 2011) |
| " The use of lamivudine and tenofovir resulted in arrest of proteinuria and stabilisation of renal function." | 7.77 | Hepatitis B virus related membranous glomerulonephritis and proteinuria treated with lamivudine and tenofovir. ( Das, P; Ford, M; Holt, S; Kingdon, E; Vivek, V, 2011) |
| " The purpose of this study was to evaluate the effect of a new therapeutic strategy combining Lamivudine (LAM) and ADV in patients with HBeAg-positive chronic hepatitis B (CHB) and poor response to ADV monotherapy." | 7.76 | Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy. ( Cao, J; Chen, EQ; Lei, BJ; Liu, L; Tang, H; Wang, JR; Wang, LC, 2010) |
| "Long-term lamivudine (LAM) and adefovir (ADV) treatment has been found to induce the emergence of drug-resistant hepatitis B virus (HBV) in a significant number of patients with chronic hepatitis B (CHB) infection." | 7.76 | Lamivudine and adefovir resistance in children and young adults with chronic hepatitis B. ( Akman, SA; Halicioglu, O; Kose, S, 2010) |
| " In adefovir (ADV) treated chronic hepatitis B patients carrying rtA181T/rtA181V mutations, overlap with surface gene mutations such as sW172stop/sL173F has been reported." | 7.76 | Hepatitis B viral surface mutations in patients with adefovir resistant chronic hepatitis B with A181T/V polymerase mutations. ( Bak, YT; Byun, KS; Joo, MK; Jung, YK; Kim, JH; Kim, JS; Park, JJ; Yeon, JE; Yim, HJ, 2010) |
| "The aim of this study was to determine the evolution of full-length hepatitis B virus (HBV) sequences in chronic hepatitis B (CHB) patients with sequential lamivudine (LAM) and adefovir (ADV) resistance." | 7.76 | Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance. ( Changchien, CS; Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Tung, WC; Wang, JC; Wang, JH, 2010) |
| " The aim of this study was to clarify the effect of molecular characteristics on the antiviral response to adefovir in patients with lamivudine-resistant chronic hepatitis B (CHB)." | 7.76 | Response to adefovir depends on mutation patterns in precore region, basal core promoter and reverse transcriptase, and on-treatment responses in Lamivudine-resistant chronic hepatitis B patients. ( Cho, YK; Choi, EK; Cui, XJ; Hyun, S; Jeong, SU; Kim, HU; Park, NH; Shin, JW; Song, BC; Song, HJ, 2010) |
| "There have been no reports comparing the therapeutic results of adefovir (ADV) and entecavir (ETV) rescue therapy for patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB)." | 7.76 | Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. ( Cho, YK; Jeon, WK; Kim, BI; Kim, HJ; Park, DI; Park, JH; Sohn, CI, 2010) |
| "The aim of this study was to assess the cost-effectiveness of tenofovir disoproxil fumarate (TDF) in the treatment of chronic hepatitis B (CHB) versus alternative nucleos(t)ides from a UK National Health Service (NHS) perspective." | 7.76 | Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. ( Bentley, A; Dakin, H; Dusheiko, G, 2010) |
| "Adefovir dipivoxil treatment has significantly improved the outcome of chronic hepatitis B virus (HBV) infection." | 7.76 | Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. ( Hao, C; Jiang, Y; Li, W; Ma, Z; Niu, J; Xin, G; Xu, H; Yan, H; Zhao, P, 2010) |
| " The aim was to evaluate the long-term outcome of lamivudine monoprophylaxis with adefovir salvage for liver transplantation in chronic hepatitis B." | 7.75 | Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study. ( Chan, HL; Chan, HY; Kwan, KY; Lai, PB; Limquiaco, JL; Tse, CH; Wong, GL; Wong, J; Wong, VW, 2009) |
| "Patients with chronic hepatitis B (CHB) who will and those who will not respond to adefovir (ADV) monotherapy need to be identified at an early stage in order to adjust treatment and prevent future development of antiviral resistance." | 7.75 | On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks. ( de Man, RA; Hansen, BE; Janssen, HL; Leemans, WF; Pas, SD; Reijnders, JG; Schutten, M, 2009) |
| "The aims of the study were to investigate the efficacy of rescue therapy with lamivudine (LAM) and adefovir (ADV) combination for 6 months followed by ADV monotherapy in lamivudine-resistant chronic hepatitis B (LAM-R CHB) patients, and to analyze the frequency of ADV resistance mutant development in such patients." | 7.75 | A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients. ( Ahishali, E; Badur, S; Bektas, M; Bozkaya, H; Cakaloglu, Y; Cinar, K; Idilman, R; Karayalcin, S; Kaymakoglu, S; Mithat Bozdayi, A; Oguz Onder, F; Okten, A; Pinarbasi, B; Yurdaydin, C, 2009) |
| "It has been shown that adefovir dipivoxil is an effective antiviral agent in the treatment of chronic hepatitis B (CHB), not only in wild-type hepatitis B virus (HBV) infection, but also in lamivudine-resistant (LAMV-R) cases." | 7.75 | [Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, lamivudine-resistant chronic hepatitis B patients]. ( Choi, MS; Jung, HW; Kim, KH; Koh, KC; Lee, JH; Paik, SW; Park, SH; Yeon, KK; Yoo, BC, 2009) |
| "The antiviral effect of adefovir dipivoxil (ADV) added to ongoing lamivudine (LAM) treatment for LAM-resistant chronic hepatitis B (CHB) differs among patients." | 7.75 | Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B. ( Doi, Y; Hagiwara, H; Hayashi, E; Hayashi, N; Hiramatsu, N; Imai, Y; Kanto, T; Kasahara, A; Kashihara, T; Kato, M; Kiso, S; Kurashige, N; Mita, E; Nagase, T; Ohkawa, K; Oshita, M; Takehara, T; Yakushijin, T; Yamada, A; Yoshihara, H, 2009) |
| "The aim of this study was to elucidate the antiviral efficacy of lamivudine (LMV)-adefovir (ADV) combination therapy in chronic hepatitis B patients who showed resistance to LMV and ADV consecutively." | 7.75 | [Antiviral efficacy of lamivudine/adefovir combination therapy in chronic hepatitis b patients with resistance to lamivudine and adefovir consecutively]. ( Gwak, GY; Koh, KC; Lee, HIe; Lee, JH; Paik, SW; Park, MK; Suh, HJ; Yoo, BC, 2009) |
| "The aim of the study was to estimate the effect of viral factors (HBV genotype, viral load and kinetics) to treatment response in chronic hepatitis B (CHB) and first-line therapy with adefovir dipivoxil (ADV)." | 7.75 | Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B. ( Bock, T; Hass, HG; Kaiser, S; Nehls, O, 2009) |
| "Data concerning the outcome of lamivudine-resistant (LAM-R) chronic hepatitis B (CHB) patients with compensated cirrhosis under adefovir (ADV) treatment are limited." | 7.75 | Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance. ( Buti, M; Elefsiniotis, I; Esteban, R; Jardi, R; Vezali, E, 2009) |
| "Clinical data of 233 chronic hepatitis B patients treated with lamivudine 100mg daily (91 patients were switched to Adefovir 10mg daily or Adefovir 10mg in combination with lamivudine 100mg daily) were retrospective." | 7.75 | [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B]. ( Fu, J; Li, SG; Tan, B; Wen, FY; Wu, JL; Yang, XY; Zhou, HJ, 2009) |
| "To explore the mechanism for adefovir dipivoxil (ADV) resistance occurred in chronic hepatitis B patients of a series of phase III clinical trails." | 7.75 | [Dissection of mechanism for the adefovir dipivoxil resistance in chronic hepatitis B patients]. ( Cai, SF; Deng, H; Deng, XH; Guo, JJ; Huang, AL; Li, QL; Lu, P; Xin, XJ; Yang, C; Zeng, AZ, 2009) |
| "To study the predictive value of ALT, HBeAg and HBV DNA levels at baseline and HBV DNA levels at week 12 adefovir dipivoxil (ADV) treatment to the efficacy of it at week 52 in patients with HBeAg-positive chronic hepatitis B (CHB)." | 7.74 | [The predictive value of ALT, HBeAg and HBV DNA levels at baseline and the degree of HBV suppression at week 12 adefovir dipivoxil treatment to the efficacy of it at week 52 in patients with HBeAg-positive chronic hepatitis B]. ( Chen, YM; Gao, ZL; Li, JG; Lin, BL; Lu, WL; Xie, DY; Xu, QH, 2008) |
| "A 43-year-old man was treated with lamivudine for hepatitis B e antigen-positive chronic hepatitis B." | 7.74 | Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir. ( de Man, RA; Janssen, HL; Leemans, WF; Niesters, HG; Schalm, SW; van der Eijk, AA, 2008) |
| "This longitudinal study included 41 patients with chronic hepatitis B virus (HBV) infection receiving ADV monotherapy or ADV plus lamivudine (3TC)." | 7.74 | Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response. ( Buti, M; Esteban, R; Ferrer-Costa, C; Homs, M; Jardi, R; Rodriguez-Frias, F; Schaper, M; Tabernero, D, 2008) |
| "To study the resistant rate of hepatitis B virus (HBV) to ADV and the dynamic evolution of HBV in lamivudine (Lam)-resistant chronic hepatitis B (CHB) patients." | 7.74 | [The rate of hepatitis B virus resistance to adefovir dipivoxil (ADV) and the evolution of hepatitis B virus in lamivudine-resistant chronic hepatitis B patients with ADV monotherapy]. ( Huang, YX; Mao, RC; Qin, YL; Weng, XH; Wu, XH; Yin, YK; Zhang, JM; Zhang, QB; Zhang, WQ, 2007) |
| "To determine the factors affecting the virological response to adefovir dipivoxil (ADV) among patients with lamivudine resistant chronic hepatitis B." | 7.74 | Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. ( Chan, HL; Chan, HY; Chim, AM; Sung, JJ; Tse, CH; Wong, GL; Wong, VW, 2007) |
| "To determine the factors associated with virological response (VR), HBeAg loss or the emergence of adefovir (ADV)-related mutations in ADV-treated chronic hepatitis B (CHB) patients with lamivudine (LAM) resistance." | 7.74 | Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. ( Bonovas, S; Buti, M; Elefsiniotis, I; Esteban, R; Jardi, R; Rodriguez-Frias, F; Schapper, M; Vargas, V, 2007) |
| "Adefovir dipivoxil (ADV) resistance in patients with lamivudine-resistant chronic hepatitis B is not well understood." | 7.74 | [Effect of initial virologic response to adefovir on the development of resistance to adefovir in lamivudine-resistant chronic hepatitis B]. ( Kim, DG; Kim, HC; Kim, IH; Kim, SH; Kim, SW; Lee, SO; Lee, ST; Shin, KD, 2007) |
| "We summarize the clinical history and laboratory results following the introduction of tenofovir among 6 patients coinfected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) who presented with severe liver disease while receiving lamivudine-based highly active antiretroviral therapy." | 7.74 | Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine. ( Guillemi, S; Gutiérrez, S; Harrigan, PR; Jahnke, N; Montaner, JS; Montessori, V, 2008) |
| " In our department, tenofovir was prescribed in addition to lamivudine for the treatment of lamivudine resistant chronic hepatitis B." | 7.74 | Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression. ( de Man, RA; Janssen, HL; Leemans, WF; Niesters, HG, 2008) |
| "The aims of the present study were to assess initial virological response (IVR) to adefovir (ADV) treatment for chronic hepatitis B, to identify patients with suboptimal response and to determine the incidence of ADV-resistant mutants." | 7.74 | Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. ( Enrĺquez, J; Gallego, A; García-Samaniego, J; Hornillos, P; Margall, N; Romero, M; Sheldon, J; Soriano, V, 2008) |
| "In lamivudine-resistant patients with chronic hepatitis B (CHB), we compared efficacy, predictive response factors and changes in viral mutants in two antiviral approaches with adefovir." | 7.74 | Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. ( Alessandria, C; Barbon, V; Carenzi, S; Gaia, S; Lagget, M; Marzano, A; Olivero, A; Rizzetto, M; Smedile, A, 2008) |
| "The aim of this study was to assess the therapeutic effectiveness of adefovir dipivoxil (ADV), administered in combination with lamivudine (LAM) or as monotherapy, and the rate of resistance to ADV, in hepatitis B e antigen (HBeAg)-negative adult patients with chronic hepatitis B virus (HBV) infection and clinical or virologic resistance to LAM." | 7.74 | Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study. ( Armignacco, O; Barbarini, G; Barbaro, G; Barlattani, A; Camporiondo, MP; Ferri, F; Francavilla, R; Mazzoni, E; Mecenate, F; Nauri, L; Nosotti, L; Paffetti, A; Pellicelli, AM; Romano, M; Soccorsi, F; Struglia, C; Villani, R, 2008) |
| "Long-term treatment with lamivudine is required to control viral replication in patients with hepatitis B e antigen-negative chronic hepatitis B, but is associated with a high rate of viral resistance." | 7.73 | Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. ( Eugenidis, N; Giouleme, O; Gkisakis, D; Grammatikos, N; Katsinelos, P; Nikolaidis, N; Orfanou-Koumerkeridou, E; Patsiaoura, K; Theodoropoulos, K; Tziomalos, K; Vassiliadis, T; Zezos, P, 2005) |
| "We determined the clinical outcome of hepatitis e antigen (HBeAg)-negative chronic hepatitis B patients treated with long-term nucleos(t)ide analog therapy starting with lamivudine." | 7.73 | Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. ( Dimakopoulos, K; Dimou, E; Hadziyannis, SJ; Kitis, G; Manesis, E; Manolakopoulos, S; Papatheodoridis, GV; Rapti, I; Tzourmakliotis, D, 2005) |
| "Fifty chronic hepatitis B (CHB) patients with lamivudine resistant HBV mutants who had received lamivudine for more than 12 months were included in the study." | 7.73 | [Clinical outcomes after discontinuation of Lamivudine in chronic hepatitis B patients with Lamivudine resistant HBV mutant]. ( Cho, HJ; Choi, HY; Hong, SP; Hwang, SG; Kim, JK; Kim, NK; Ko, KH; Park, H; Park, PW; Rim, KS, 2005) |
| "To evaluate the efficacy and safety of adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD motif mutation during lamivudine therapy." | 7.73 | [Adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD mutation]. ( Su, GG; Ying, MF; Zhao, NF; Zhou, Y, 2005) |
| "Seven antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir for longer than 6 months were assessed." | 7.73 | Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. ( Berger, F; Corral, A; Mauss, S; Rockstroh, J; Rodés, B; Schwarze-Zander, C; Sheldon, JA; Soriano, V, 2005) |
| "We studied the impact of tenofovir disoproxil fumarate, given as an antiretroviral medication, on patients with chronic hepatitis B virus (HBV) co-infection." | 7.73 | Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. ( Berger, A; Bickel, M; Carlebach, A; Klauke, S; Lutz, T; Staszewski, S; Stephan, C; Stuermer, M, 2005) |
| "Currently, adefovir is an effective rescue therapy that broadens the existing range of options for patients with lamivudine-resistant chronic hepatitis B infection, particularly those with decompensated cirrhosis awaiting a liver graft, and those with recurrent posttransplantation HBV." | 7.73 | Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection. ( Baliellas, C; Cañas, C; Casanovas, A; Casanovas, T; Chahri, N; Figueras, J; Gil-Vernet, S; Gornals, JB; Sabidó, M; Serrano, T; Verdura, B, 2005) |
| "To estimate the cost-effectiveness over a 4-year duration of lamivudine and adefovir dipivoxil for patients with hepatitis B 'e' antigen-negative chronic hepatitis B." | 7.73 | Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. ( Aguilar, J; Buti, M; Calleja, JL; Casado, MA; Esteban, R; Rueda, M; Salmerón, J, 2006) |
| "We have studied a 49-year-old patient with a HBeAg-negative chronic hepatitis B in whom, after 34 months of treatment with lamivudine and associated with an increase in the serum hepatitis B virus (HBV) DNA, the lamivudine resistance mutations M204I and L180V were detected." | 7.73 | [Lamivudine and adefovir resistance in a patient with HBeAg negative chronic hepatitis B]. ( Mateos, ML; Moreira, V; Tato, M, 2006) |
| "A 56-year-old male patient received adefovir dipivoxil (10 mg/day) for chronic hepatitis B resistant to lamivudine." | 7.73 | Adefovir dipivoxil-associated thrombocytopenia in a patient with chronic hepatitis B. ( Amato, A; Gaeta, GB; Stornaiuolo, G, 2006) |
| "Although adefovir dipivoxil (ADV) has a unique profile of delayed and infrequent resistance in treatment-naïve chronic hepatitis B patients, the association of ADV resistance with previous lamivudine (LAM) resistance is not well understood." | 7.73 | Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. ( Chung, YH; Jung, SW; Kim, KM; Kim, SO; Lee, HC; Lee, YS; Lim, YS; Suh, DJ; Yoo, W, 2006) |
| "The nucleotide analog adefovir dipivoxil (ADV) is an effective antiviral treatment for chronic hepatitis B virus (HBV) infection, with resistance to ADV estimated to occur less frequently than resistance to lamivudine treatment." | 7.73 | Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). ( Borlang, J; Giles, E; Heathcote, EJ; Osiowy, C; Villeneuve, JP, 2006) |
| "Continuation of lamivudine therapy is controversial for patients with chronic hepatitis B when viral breakthrough occurs." | 7.73 | [Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy in acute exacerbation after viral breakthrough during lamivudine therapy in chronic hepatitis B]. ( Eun, JR, 2006) |
| "Lamivudine is widely used for the treatment of chronic hepatitis B infection because of it's remarkable antiviral efficacy and safety." | 7.73 | [A case of severe skin eruption caused by lamivudine in a patient with chronic hepatitis B]. ( Baik, du S; Kim, BH; Kim, HJ; Kim, SB; Seo, PJ; Shin, JE; Song, IH; Yun, SY, 2006) |
| "Lamivudine is a treatment option for the therapy of chronic hepatitis B with an excellent safety profile." | 7.72 | Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated. ( Flemming, P; Klempnauer, J; Manns, MP; Nashan, B; Niemann, P; Rohde, P; Tillmann, HL; Tischendorf, JJ; Trautwein, C; Wiegand, J, 2004) |
| " Ninety-eight liver biopsy samples from patients in the major phases of the natural history of chronic hepatitis B and 32 pairs of samples from patients receiving adefovir dipivoxil (ADV) therapy were assessed." | 7.72 | Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. ( Bowden, S; Brosgart, CL; Chen, SS; Delaney, WE; Gibbs, CS; Goodman, Z; Lau, G; Locarnini, S; Marcellin, P; Petersen, J; Trepo, C; Werle-Lapostolle, B; Wursthorn, K; Xiong, S; Zoulim, F, 2004) |
| "Among 3656 highly viremic mothers treated with TDF, hepatitis B virus DNA suppression to the levels <200,000 IU/mL at delivery was achieved in 34% to 100% of mothers." | 7.01 | The Use of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide for Preventing Vertical Transmission of Hepatitis B. ( Deng, Y; Pan, CQ; Park, J; Zhu, L, 2023) |
| " However, greater adverse effects on renal function were observed for TDF than ETV at 60 months compared to 12 months." | 7.01 | Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis. ( Liu, S; Liu, Z; Ma, X; Xin, Y; Zhao, Z, 2023) |
| " The treatment using NAs was well-tolerated and there was no serious drug-related adverse event reported." | 7.01 | Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. ( Chen, T; Chen, Y; Fu, M; Fu, S; Gao, Z; He, Y; Hu, C; Li, J; Liu, J; Yan, T; Yang, Y; Zhang, R; Zhao, Y; Zhou, M, 2021) |
| "Pradefovir is a liver targeted novel prodrug of adefovir (PMEA) developed to provide higher antiviral activity with reduced systemic toxicities." | 6.94 | Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection. ( Chen, H; Ding, Y; Jin, W; Li, C; Li, X; Liu, C; Liu, J; Niu, J; Wu, M; Zhang, D; Zhang, H; Zhu, X, 2020) |
| "In lamivudine-treated patients with suboptimal virological response at week 24, promptly adding on ADV is necessary to prevent resistance development." | 6.80 | Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients. ( Chen, C; Chen, S; Chen, X; Cheng, J; Dou, X; Hou, J; Jia, J; Jiang, J; Li, T; Liang, X; Long, H; Ma, H; Ning, Q; Niu, J; Ren, H; Sheng, J; Shi, G; Shi, J; Sun, J; Sun, Y; Tan, D; Tang, H; Wan, M; Wang, H; Xie, Q; Yu, Y; Zhuang, H, 2015) |
| " Most adverse events were mild in severity and considered unrelated to study drug." | 6.79 | Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings. ( Bae, H; Chan, S; Lou, L; Pan, CQ; Trinh, H; Yao, A, 2014) |
| "Sixty-one HBeAg-positive chronic hepatitis B patients were randomized to receive Peg-IFN alpha-2b alone (1." | 6.79 | Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study. ( Dai, YR; Liu, YH; Sun, N; Wang, GL; Wu, T; Yuan, JZ; Zhou, XH, 2014) |
| " Tenofovir gel, when used intermittently, was safe to use in women with HBV infection." | 6.78 | Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: results from the CAPRISA 004 trial. ( Abdool Karim, Q; Abdool Karim, SS; Baxter, C; Tshabalala, P; Yende-Zuma, N, 2013) |
| "There is no standard management of chronic hepatitis B (CHB) patients with suboptimal response to nucleoside/nucleotide analogues (NAs)." | 6.77 | Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir. ( Bai, L; Chen, EQ; Liang, LB; Tang, H; Wang, JR; Yan, LB; Zhou, TY, 2012) |
| "Adefovir dipivoxil (ADV) has demonstrated activity against wild-type and lamivudine-resistant hepatitis B virus (HBV)." | 6.73 | Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants. ( Carrouée-Durantel, S; Durantel, D; Naesens, L; Neyts, J; Pichoud, C; Trépo, C; Werle-Lapostolle, B; Zoulim, F, 2008) |
| "Adefovir dipivoxil (ADV) is a licensed treatment for chronic hepatitis B in adults." | 6.73 | The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection. ( Dhawan, A; Frederick, D; Kelly, D; Mizerski, J; Sokal, EM; Wirth, S, 2008) |
| "Lamivudine was combined for | 6.72 | Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants. ( Chen, DS; Chen, PJ; Chen, TC; Kao, JH; Lai, MY; Lin, FY; Liu, CJ, 2006) |
| "To investigate the efficacy, safety, and the tolerability of two dosing regimens of ADV (10 mg daily or 30 mg daily), two double-blind, placebo-controlled studies were performed in patients with chronic hepatitis B and compensated liver disease who were not undergoing current treatment and who had evidence of hepatitis B virus (HBV) replication." | 6.71 | Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. ( Arterbrun, S; Brosgart, CL; Currie, G; Deray, G; Hadziyannis, SJ; Hulot, JS; Izzedine, H; Launay-Vacher, V; Marcellini, P; Westland, C, 2004) |
| "Adefovir dipivoxil (ADV) has demonstrated clinical activity against wild-type and lamivudine-resistant HBV, but it is unclear whether resistance mutations will emerge after long-term therapy with this drug." | 6.70 | Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. ( Brosgart, C; Delaney, WE; Fry, J; Gibbs, CS; Heathcote, EJ; Ho, V; Miller, MD; Westland, CE; Xiong, S; Yang, H, 2002) |
| "Treatment for chronic hepatitis B as a once-daily oral dose was well tolerated and associated with significant and sustained reductions in serum HBV DNA levels during treatment." | 6.69 | A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. ( Chopra, KB; Gilson, RJ; Jaffe, HS; Murray-Lyon, IM; Nelson, MR; Newell, AM; Rice, SJ; Tedder, RS; Toole, J; Weller, IV, 1999) |
| "The specific drugs available for chronic hepatitis B infection include standard and pegylated IFN-α, and nucleoside/nucleotide analogs that directly inhibit the reverse transcriptase." | 6.48 | Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. ( Buti, M; Homs, M, 2012) |
| "Adefovir dipivoxil (Hepsera) is an oral prodrug of the nucleotide analogue adefovir." | 6.42 | Adefovir dipivoxil: a review of its use in chronic hepatitis B. ( Dando, T; Plosker, G, 2003) |
| "Adefovir dipivoxil is an oral prodrug of adefovir, a nucleotide analogue of adenosine monophosphate." | 6.42 | [Application and efficacy of adefovir dipivoxil in hepatitis B virus-associated chronic liver diseases]. ( Cho, YK; Kim, BI, 2003) |
| "Treatment with Adefovir dipivoxil is a long term treatment (48 weeks), it is well tolerated, and side effects are moderate and reversible." | 6.42 | [Adefovir dipivoxil is a new drug for treatment of chronic hepatitis B]. ( Stránský, J, 2004) |
| "In hepatitis B e antigen-negative chronic hepatitis B, adefovir dipivoxil was recently found to maintain its efficacy even after 3 years of therapy." | 6.42 | Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. ( Hadziyannis, SJ; Papatheodoridis, GV, 2004) |
| " The aim was to investigate the expression of IL-1β in CHB patients treated with Peg-IFN-α combination with TDF and TDF/Peg-IFN-α monotherapy." | 5.91 | The expression of interleukin-1β in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy. ( Hu, X; Li, Y; Luo, H; Qin, B; Tan, G, 2023) |
| "Fanconi syndrome with osteomalacia can develop in patients with chronic hepatitis B infection being treated with adefovir at a conventional low dosage of 10 mg/day." | 5.56 | Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report. ( Cen, X; Cui, Y; Liu, Z; Mu, G; Xiang, Q; Xie, Q; Yu, Y; Zhang, H; Zhang, J, 2020) |
| "Entecavir (ETV) and tenofovir alafenamide fumarate (TAF) have been used widely to treat patients with chronic hepatitis B virus (HBV) infection, but it is still unclear how best to use these drugs." | 5.51 | Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study. ( Akahane, T; Inoue, J; Iwata, T; Kisara, N; Kobayashi, T; Masamune, A; Ninomiya, M; Onuki, M; Sano, A; Sato, K; Sato, S; Tsuruoka, M, 2022) |
| "A major hurdle in the long-term treatment of chronic hepatitis B (CHB) patients is to maintain viral suppression in the absence of drug resistance." | 5.46 | No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment. ( Buti, M; Cathcart, AL; Corsa, AC; Flaherty, JF; Gane, EJ; Kitrinos, KM; Liu, Y; Marcellin, P; Miller, MD, 2017) |
| "Long-term TDF treatment appears to be safe and effective in patients with prior failure of LAM and a suboptimal response to ADV therapy." | 5.46 | Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy. ( Angus, P; Bowden, S; Desmond, P; George, J; Lee, A; Lim, L; Locarnini, S; Marion, K; Nicoll, A; Patterson, S; Roberts, S; Sievert, W; Strasser, S; Thompson, A, 2017) |
| "Eighty-one chronic hepatitis B patients with a viral load above 4 log 10 copies/ml and high levels of serum alanine aminotransferase were treated with ETV 0." | 5.43 | Profile of HBV polymerase gene mutations during entecavir treatment in patients with chronic hepatitis B. ( Song, J; Sun, M; Tan, G; Wang, J; Wu, X, 2016) |
| "This case indicates that Fanconi's syndrome with osteomalacia can be acquired by a chronic hepatitis B patient taking ADV at a conventional dosage of 10 mg/day." | 5.42 | Osteomalacia and Fanconi's syndrome caused by long-term low-dose adefovir dipivoxil. ( Chen, YS; Sun, FR; Wang, BF; Wang, BY; Wang, Y; Zhang, D, 2015) |
| "Charts were reviewed for LAM-resistant chronic hepatitis B (CHB) patients who visited the Zhejiang Province People's Hospital and The First Affiliated Hospital, College of Medicine, Zhejiang University, from June 2009 to May 2013." | 5.42 | Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients. ( Huang, HJ; Li, MW; Pan, HY; Xie, YJ; Yang, DH; Zhao, NF, 2015) |
| "The aim of this study was to demonstrate how tenofovir alafenamide (TAF) and other hepatitis B treatment drugs differentially impact lipid profiles in chronic hepatitis B patients." | 5.41 | Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. ( Hwang, EG; Jung, EA; Kim, SG; Kim, YS; Yoo, JJ, 2023) |
| "Tenofovir disoproxil fumarate (TDF) is a novel nucleotide reverse transcriptase inhibitor that is mainly used to treat human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections." | 5.41 | [Research progress on the effect of tenofovir disoproxil fumarate on blood lipid profile]. ( Duan, YQ; Hu, P, 2023) |
| "Twenty chronic hepatitis B (CHB) patients who had been receiving ETV for more than 6 months and developed virologic breakthrough due to ETV resistance were consecutively enrolled." | 5.40 | Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations. ( Baik, SK; Chae, HB; Hong, SP; Kim, CW; Kim, JH; Kim, MY; Kim, YS; Lee, CD; Lee, HJ; Lee, JI; Lee, JW; Lee, MS; Park, CK; Park, SH; Seo, YS; Suh, SJ; Um, SH; Yim, HJ, 2014) |
| "The prevalence of chronic hepatitis B in Bangladesh is reported to be 7." | 5.40 | Efficacy of adefovir dipivoxil therapy in patients with chronic hepatitis B viral infection. ( Chowdhury, MS; Khan, MR; Mahmuduzzaman, M; Miah, AR; Rahman, KM; Raihan, MA; Roknuzzaman, SM; Roy, PK; Saha, M, 2014) |
| "HIV worsens the natural history of chronic hepatitis B virus (HBV) infection." | 5.39 | Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B. ( Aguilera, A; Barreiro, P; del Romero, J; Mena, A; Pedreira, J; Plaza, Z; Poveda, E; Rodriguez, C; Sierra-Enguita, R; Soriano, V; Tomé, S; Vispo, E, 2013) |
| "To investigate 3-year antiviral efficacy and side effect of adefovir dipivoxil (ADV) on the old patients with hepatitis B chronic infection." | 5.38 | [Three-year efficacy and side effect of adefovir dipivoxil for the treatment of the old patients with chronic hepatitis B virus infection]. ( Lou, GQ; Lu, L; Qian, JC; Shi, JP; Yan, FL; Zhu, MF, 2012) |
| " Modification of the dosing interval or discontinuation of ADV was required in seven and three patients, respectively, and none of them showed a further decline in the eGFR." | 5.38 | Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. ( Cho, HC; Choi, MS; Gwak, GY; Kim, YJ; Koh, KC; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC, 2012) |
| "The effectiveness of antiviral treatments of chronic hepatitis B has been poorly studied in Brazil." | 5.38 | Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes. ( Fernandes, CA; Gomes, Sde A; Mello, FC, 2012) |
| "Lamivudine (LAM) has been extensively used to treat hepatitis B, but high incidence of drug resistance has required rescue studies." | 5.37 | Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B. ( Chung, GE; Hwang, SY; Jeong, JB; Jung, YJ; Kim, BG; Kim, D; Kim, HY; Kim, W; Kim, YJ; Lee, HS; Lee, JH; Lee, KL; Yoon, JH, 2011) |
| "In total, 33 patients with chronic hepatitis B virus (HBV) infection with evidence of active viral replication (HBV DNA levels ≥ 10(5) copies/mL) or a history of treatment failure to lamivudine/adefovir sequential therapy between April 2007 and July 2009 were treated with entecavir (1." | 5.37 | Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir. ( Cho, YS; Choi, JW; Kim, KA; Kwak, MS; Lee, CK; Lee, JS; Park, BK; Suh, JH; Won, SY, 2011) |
| "Lamivudine resistance is a result of mutations in YMDD motif in which rt203-206th codons (Y: tyrosine; M: methionin; D: aspartic acid; D: aspartic acid) of reverse trancriptase; the catalytic part of hepatitis B polymerase enzyme, takes place." | 5.35 | [YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy]. ( Arslan, U; Findik, D; Ural, O, 2008) |
| "Adefovir dipivoxil (ADV) is a nucleotide analogue that inhibits wild-type hepatitis B virus (HBV) and lamivudine (LMV)-resistant HBV mutants." | 5.35 | [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection]. ( Bae, JH; Cho, M; Heo, J; Kang, DH; Kim, GH; Moon, JH; Song, GA; Yoon, KT, 2008) |
| "Adefovir has a potent antiviral activity as a rescue treatment against lamivudine-resistant strains." | 5.35 | Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B. ( Cha, CK; Cheong, JY; Cho, SW; Hong, SP; Kim, SO; Kwon, HC; Yoo, WD, 2009) |
| "We performed a cohort study of 290 chronic hepatitis B patients: 145 patients treated with 10 mg ADV and 145 patients unexposed to ADV at two community clinics, who were matched for age (+/-10 years), sex, and baseline eGFR." | 5.35 | Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. ( Garcia, RT; Ha, NB; Levitt, BS; Nguyen, HA; Nguyen, KK; Nguyen, MH; Trinh, HN; Vu, AA, 2009) |
| "Treatment with tenofovir disoproxil fumarate has been associated with renal toxicity or reductions in bone mineral density, or both, in some patients with chronic hepatitis B virus (HBV) infection." | 5.34 | Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. ( Agarwal, K; Ahn, SH; Bae, H; Buti, M; Chan, HLY; Chen, CY; Chuang, WL; Flaherty, JF; Fung, S; Gaggar, A; Lampertico, P; Lau, A; Lim, YS; Liu, Y; Ma, X; Ramji, A; Subramanian, GM; Suri, V; Tak, WY; Tam, E; Tan, SK; Trinh, H; Wu, G; Yoon, SK, 2020) |
| "Adefovir dipivoxil is a nucleotide prodrug indicated for the treatment of patients with hepatitis B e antigen positive or hepatitis B e antigen negative chronic hepatitis B, lamivudine-resistant HBV infection, HBV infection pre- or post-liver transplantation, or HlV co-infection." | 5.34 | Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil. ( Delaney, WE, 2007) |
| "In this report, a chronic hepatitis B case who had never received adefovir dipivoxil but had primary adefovir resistance, was presented." | 5.34 | [A case of chronic hepatitis B with primary adefovir resistance]. ( Erensoy, S; Pullukçu, H; Sertöz, R; Taşbakan, M; Ulusoy, S; Yamazhan, T, 2007) |
| "Forty-four patients with chronic hepatitis B (CHB) were included." | 5.34 | Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance. ( Bak, YT; Byun, KS; Kim, JH; Kim, JS; Lee, CH; Park, JJ; Seo, YS; Yeon, JE, 2007) |
| "Adefovir dipivoxil (ADV) is a potent nucleotide analogue against both the wild-type and lamivudine (LMV) resistant hepatitis B virus (HBV)." | 5.33 | Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. ( Byun, KS; Chang, YJ; Chung, HJ; Hong, SP; Kim, JH; Kim, SO; Lee, CH; Moon, MS; Seo, YS; Yeon, JE; Yoo, W; Yu, SK, 2006) |
| "Current therapies for the treatment of chronic hepatitis B virus (HBV) infection do not eliminate viral replication once therapy is stopped, resulting in a rapid rebound of viremia in a majority of patients." | 5.32 | Use of adefovir in the treatment of the chronic hepatitis B virus infection with resistance to lamivudine. ( Barcena Marugan, R; Cid Gomez, L; Lopez Serrano, P, 2003) |
| "Adefovir dipivoxil is a clinically approved drug that can block the action of an anthrax toxin." | 5.32 | Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. ( Bergson, P; Gibbs, CS; Shen, Y; Soelaiman, S; Tang, WJ; Wang, CR; Zhukovskaya, NL; Zimmer, MI, 2004) |
| "Tenofovir disoproxil fumarate (TDF) is a first-line treatment for chronic hepatitis B (CHB)." | 5.30 | Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. ( Buggisch, P; Buti, M; Cathcart, AL; Crans, G; Flaherty, J; Flisiak, R; Gaggar, A; Jump, B; Kaita, K; Krastev, Z; Lee, SS; Manns, M; Marcellin, P; Op den Brouw, M; Petersen, J; Sievert, W; Wong, DK, 2019) |
| " We divided 48 chronic hepatitis B patients who had taken entecavir (ETV) for ≥2 years into two groups: the ETV continuation (n = 24) and the TAF switching (n = 24) groups, and compared the antiviral effects and safety until 48 weeks after the start of the study." | 5.30 | Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B. ( Hagiwara, S; Ida, H; Komeda, Y; Kudo, M; Minami, Y; Nishida, N; Takita, M; Ueshima, K, 2019) |
| "The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear." | 5.27 | Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients. ( Chung, WJ; Heo, J; Hwang, JS; Jang, BK; Kim, BS; Kim, SJ; Kweon, YO; Lee, CH; Lee, HJ; Park, SY; Suh, JI; Tak, WY; Woo, HY, 2018) |
| "In patients with chronic hepatitis B with a low viral load, combination treatment (peg-IFN plus adefovir and peg-IFN plus tenofovir) did not result in significant HBsAg loss compared with no treatment, which does not support the use of combination treatment in this population of patients." | 5.24 | Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial. ( Beuers, U; de Niet, A; Jansen, L; Koot, M; Kuiken, SD; Molenkamp, R; Reesink, HW; Stelma, F; Takkenberg, RB; van Nieuwkerk, CMJ; Verheij, J; Weijer, S; Willemse, SB; Zaaijer, HL, 2017) |
| "In the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores." | 5.24 | Effects of the combined administration of entecavir and adefovir dipivoxil to improve hepatic fibrosis in hepatitis B patients with interferon resistance. ( Chang, S; Chen, B; Qiu, L; Shen, F; Sun, Y; Wu, K; Yu, L, 2017) |
| "The nucleos(t)ide analogues (NAs) entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are preferred treatment options for patients with chronic hepatitis B infection (CHB)." | 5.22 | Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data. ( Agarwal, K; Flaherty, JF; Fung, S; Gordon, SC; Hou, J; Kao, JH; Kurosaki, M; Lampertico, P; Lim, YS; Seto, WK; Yee, LJ; Zhao, Y, 2022) |
| "To explore clinical efficacy of Yiguanjian Decoction (YD) combined Adefovir Dipivoxil Tablet (ADT) in treating HBeAg negative chronic viral hepatitis B (CVHB) active compensated liver cirrhosis (LC) patients." | 5.22 | [Efficacy Observation of Yiguanjian Decoction Combined Adefovir Dipivoxil Tablet in Treating HBeAg Negative Chronic Viral Hepatitis B Active Compensated Liver Cirrhosis Patients]. ( Bao, ZY; Duan, SH; Liu, MS; Wang, L; Yuan, XD, 2016) |
| "Here, we evaluated the safety and immunogenicity of hepatitis B virus (HBV) DNA vaccine, HB-110, in mice and Korean patients with chronic hepatitis B (CHB) undergoing adefovir dipivoxil (ADV) treatment." | 5.20 | Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice. ( Bae, SH; Im, SJ; Jang, JW; Jeong, SH; Kim, BM; Kim, CY; Seo, YB; Song, JS; Song, MJ; Suh, YS; Sung, YC; Yang, SH; Yoon, SK; You, CR, 2015) |
| "In patients with hepatitis B-related HCC, adefovir antiviral therapy reduced late HCC recurrence and significantly improved overall survival after R0 hepatic resection." | 5.20 | Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. ( Huang, G; Lau, WY; Pan, ZY; Shen, F; Wang, ZG; Wu, MC; Yuan, SX; Zhou, WP, 2015) |
| "Tenofovir disoproxil fumarate (TDF) has demonstrated long-term efficacy and a high barrier to resistance in multiple chronic hepatitis B (CHB) populations outside of China." | 5.20 | Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial. ( Chen, CW; Chen, SJ; Cheng, J; Dong, J; Gao, ZL; Hou, JL; Ji, Y; Jia, JD; Li, J; Mao, Q; Mao, YM; Ning, Q; Niu, JQ; Pan, C; Ren, H; Sheng, JF; Tan, DM; Tang, H; Wang, H; Wu, SM; Xie, Q; Xu, M; Zhang, JM; Zhang, XX; Zhao, W, 2015) |
| "We evaluated the antiviral response of Asian or Pacific Islander (API) patients with chronic hepatitis B (CHB) who had baseline high viral load (HVL), defined as pre-treatment hepatitis B virus (HBV) DNA ≥9 log10 copies/ml, following up to 288 weeks of tenofovir disoproxil fumarate (TDF) treatment." | 5.20 | Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml). ( Buti, M; Dinh, P; Dusheiko, G; Flaherty, JF; Flisiak, R; Fung, S; Gane, E; Gordon, SC; Horban, A; Jacobson, IM; Kitrinos, KM; Krastev, Z; Marcellin, P; Martins, EB; Petersen, J; Rustgi, VK; Sperl, J; Trinh, H; Yee, LJ, 2015) |
| "Non-cirrhotic, treatment-naïve subjects with chronic hepatitis B were randomized (1:1:1:1:1) to receive tenofovir alafenamide 8, 25, 40, or 120 mg, or tenofovir disoproxil fumarate 300 mg for 28 days and assessed for safety, antiviral response, and pharmacokinetics, followed-up by off-treatment for 4 weeks." | 5.20 | Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. ( Agarwal, K; Cheng, W; Flaherty, JF; Foster, GR; Fung, SK; Gane, EJ; Lawson, E; McHutchison, JG; Nguyen, TT; Ryder, SD; Sicard, E; Subramanian, GM; Zhao, S, 2015) |
| "The purpose of this study was to analyze the cost-effectiveness of lamivudine (LMV), telbivudine (LdT), and entecavir (ETV) in treatment of chronic hepatitis B with adefovir dipivoxil (ADV) resistance." | 5.20 | Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance. ( Liu, Y; Qiu, P; Wang, G; Wen, J; Wen, P; Xiao, X; Xu, L; Zhou, SF, 2015) |
| "This study aimed to research the efficiency of adefovir dipivoxil in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B treatment and in combination with α-2b interferon in the treatment of HBeAg-positive chronic hepatitis B." | 5.20 | The curative effect of adefovir dipivoxil treating HBeAg negative chronic hepatitis B and treating HBeAg positive chronic hepatitis B combining interferon α-2b. ( Gu, J; Shen, S; Sun, R; Yu, Z, 2015) |
| "To compare the efficacies ofentecavir and adefovir in patients with chronic hepatitis B (CHB) and cirrhosis when administered as monotherapies using a 240-week course." | 5.20 | [A randomized controlled trial on 240-week monotherapy with entecavir or adefovir in patients with chronic hepatitis B and cirrhosis]. ( Gao, Y; Han, T; Lian, J; Liu, F; Lyu, H; Wang, F; Xiang, H, 2015) |
| "We examined the durability of the virological response after discontinuing lamivudine (LVD) in chronic hepatitis B (CHB) patients with LVD-resistant hepatitis B virus (HBV), who responded to LVD plus adefovir (ADV) combination therapy, and the outcome of switching to ADV monotherapy compared to maintaining combination therapy." | 5.19 | Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy. ( Ahn, SH; Chon, CY; Han, KH; Kim, DY; Kim, HS; Kim, MN; Kim, SU; Lee, CK; Lee, S; Park, JY, 2014) |
| "To prospectively observe the long-term antiviral efficacy and safety of telbivudine (LDT) administered as a monotherapy and as a combination therapy with adefovir dipivoxil (ADV) in patients diagnosed with chronic hepatitis B (CHB) and positivity for hepatitis B e antigen (HBeAg)." | 5.19 | [Long-term efficacy and safety of telbivudine as monotherapy and as combination therapy with adefovir dipivoxil in HBeAg-positive chronic hepatitis B patients]. ( Chang, L; Du, Y; Jia, T; Li, H; Li, W; Liu, L; Liu, Y; Peng, D, 2014) |
| "A 48-week PegIFN therapy was added to HBeAg positive-HIV co-infected patients on TDF and emtricitabine, or lamivudine for at least 6 months." | 5.19 | Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study. ( Barthe, Y; Bouix, C; Cacoub, P; Carrat, F; Lascoux-Combe, C; Lebossé, F; Maynard-Muet, M; Miailhes, P; Piroth, L; Pol, S; Rey, D; Sogni, P; Zoulim, F, 2014) |
| "A recent study compared the efficacy of tenofovir disoproxil fumarate (TDF) vs the combination of emtricitabine and TDF (FTC/TDF) in patients with lamivudine-resistant chronic hepatitis B who were treated for as long as 96 weeks." | 5.19 | No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. ( Corsa, AC; Flaherty, JF; Fung, SK; Gane, E; Kitrinos, KM; Liu, Y; Miller, MD; Mitchell, B, 2014) |
| "In a study of 266 chronic hepatitis B e antigen (HBeAg)-positive patients, 23 experienced hepatitis B surface antigen (HBsAg) loss with up to 5 years of tenofovir disoproxil fumarate (TDF) treatment." | 5.19 | Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. ( Buti, M; de Man, RA; Dinh, P; Dusheiko, GM; Flaherty, JF; Flisiak, R; Gaggar, A; Gurel, S; Heathcote, EJ; Krastev, Z; Lin, L; Lou, L; Marcellin, P; Massetto, B; McHutchison, JG; Subramanian, GM; Zeuzem, S, 2014) |
| "The objective of this study was to compare the efficacy and safety of two rescue strategies for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients with resistance to adefovir dipivoxil (ADV)." | 5.17 | Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil. ( Chen, EQ; Liu, K; Lu, JJ; Ma, YJ; Tang, H; Wang, J, 2013) |
| "Telbivudine (LdT) has demonstrated potent antiviral activity in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B patients (CHB), but data on its efficacy in NA-experienced patients are limited." | 5.17 | Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil. ( Bai, XF; Li, Y; Lian, JQ; Wang, JP; Zhang, Y, 2013) |
| "The incidence of multidrug-resistant (MDR) chronic hepatitis B (CHB) during sequential lamivudine (LAM) and adefovir dipivoxil (ADV) treatment is increasing." | 5.17 | Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B. ( Ahn, SH; Baartarkhuu, O; Chon, CY; Han, KH; Kim, BK; Kim, DY; Kim, JK; Kim, KS; Kim, SU; Park, JY; Park, MS, 2013) |
| "The study aimed to investigate the efficacy and safety of peginterferon α-2a (PEG IFNα-2a) in combination with lamivudine or adefovir in the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB)." | 5.17 | Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion. ( Cao, ZH; Chen, XY; Liu, YL; Ma, LN; Zhang, HW, 2013) |
| "In this study, we aimed to identify baseline predictors of response in chronic hepatitis B patients treated with a combination of pegylated interferon (PEG-IFN)-α2a and adefovir." | 5.17 | Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir. ( Beld, MG; de Niet, A; Dijkgraaf, MG; Jansen, L; Jansen, PL; Janssen, HL; Koot, M; Molenkamp, R; Reesink, HW; Rijckborst, V; Takkenberg, RB; Terpstra, V; Weegink, CJ; Zaaijer, HL, 2013) |
| "A 1-year trial with entecavir plus adefovir resulted in a rate of virological response (VR) higher than that seen with lamivudine plus adefovir in multiple-drug-refractory chronic hepatitis B (CHB) patients." | 5.17 | Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients. ( Lee, D; Lee, HC; Lee, JY; Lee, YS; Lim, YS; Shim, JH; Suh, DJ, 2013) |
| "To compare the efficacy and safety of the common antivirals, including adefovir dipivoxil (ADV), pegylated-interferon alpha-2a (peg-IFN) and lamivudine (LAM), used as combination therapies to treat chronic hepatitis B (CHB) patients with positivity for the hepatitis B e antigen (HBeAg) and hepatitis B virus (HBV) harboring the ADV-resistance mutation, rtN236T, and to explore the factors associated with curative outcome." | 5.17 | [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation]. ( Chen, L; Deng, YD; Mao, XR; Yuan, H; Yue, W, 2013) |
| "To investigate the efficacy and safety of an extended course (96-week) of combination treatment with peginterferon alfa-2a (Peg-IFNa-2a; 40 kd] plus adefovir (ADV) for treating chronic hepatitis B (CHB) in Chinese patients with negativity for hepatitis B e antigen (HBeAg)." | 5.17 | [Efficacy and safety of peginterferon alfa-2a (40 kd) plus adefovir for 96 weeks in HBeAg-negative chronic hepatitis B patients]. ( Cao, ZH; Chen, XY; He, ZM; Jin, Y; Liu, YL; Lu, JF; Ma, LN; Zhang, YH, 2013) |
| "To compare the efficacy and safety of recombinant human interferon α-2b (INFα-2b) monotherapy and combined therapy with entecavir (ETV) plus adefovir dipivoxil (ADV) in chronic hepatitis B patients with poor response to combined therapy with lamivudine and ADV." | 5.17 | [Therapeutic effect of antiviral regimens for chronic hepatitis B refractory to lamivudine plus adefovir]. ( Chen, Z; Li, M; Liu, Z; Wu, J; Xu, G; Zhang, Q, 2013) |
| "To examine the efficacy of telbivudine (LdT) + adefovir (ADV) vs continuation of lamivudine (LAM) + ADV in patients with LAM-resistant chronic hepatitis B (CHB) who show a suboptimal response to LAM + ADV." | 5.17 | Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir. ( Ahn, SH; Chon, CY; Han, KH; Kim, DY; Kim, SU; Park, H; Park, JY, 2013) |
| " At month 24, virological response rate [hepatitis B virus (HBV) DNA <60 IU/ml] was higher in the adefovir-lamivudine combination group compared with entecavir group (56." | 5.17 | Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial. ( Baik, SK; Chae, HB; Hong, SP; Kim, CW; Kim, JH; Kim, MY; Kim, YS; Lee, CD; Lee, JI; Lee, JW; Lee, MS; Park, CK; Park, SH; Seo, YS; Um, SH; Yim, HJ; Yoon, EL, 2013) |
| "Telbivudine therapy with tenofovir intensification at Week 24, where indicated by the Roadmap strategy, appears effective and well tolerated for the treatment of chronic hepatitis B." | 5.17 | 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. ( Bessone, F; Chan, HL; Cheinquer, H; Daruich, J; Dong, Y; Fassio, E; Komolmit, P; Ono, SK; Pathan, R; Pessôa, MG; Piratvisuth, T; Sukeepaisarnjaroen, W; Tanwandee, T; Trylesinski, A; Zeuzem, S, 2013) |
| "In this study, we aimed to devise a simple scoring system predicting the risk of genotypic resistance (GR) to current rescue therapies for patients with lamivudine (LAM)-resistant chronic hepatitis B." | 5.16 | Simple scoring system predicting genotypic resistance during rescue therapy for Lamivudine-resistant chronic hepatitis B. ( Cho, EJ; Hwang, SY; Jang, ES; Kim, CY; Kim, YJ; Kwak, MS; Lee, CH; Lee, HS; Lee, JH; Yang, HJ; Yoon, JH; Yu, SJ, 2012) |
| "Adefovir dipivoxil (ADV) is a nucleotide analogue with proven efficacy in chronic hepatitis B (CHB)." | 5.16 | Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B. ( Barker, K; Daozhen, X; Dixon, J; Guangbi, Y; Hao, W; Hong, R; JinLin, H; Junqi, N; Minde, Z; Xiaqiu, Z; Yagang, C; Yaozong, W; Yimin, M; Youming, C; Yuming, W, 2012) |
| "In a cohort of 95 chronic hepatitis B patients, who were treated with peg-interferon and adefovir for 1 year, and who had 15% HBsAg loss (overall), no association was found between IL28B polymorphisms and HBeAg seroconversion or HBsAg clearance." | 5.16 | Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir. ( Beld, MG; Benayed, R; de Niet, A; Jansen, PL; Koot, M; Lopatin, U; Reesink, HW; Riley-Gillis, B; Takkenberg, RB; Weegink, CJ; Zaaijer, HL, 2012) |
| "Monotherapy with pegylated interferon alpha (Peg-IFNa) or adefovir dipivoxil (ADV) to HBeAg-positive chronic hepatitis B (CHB) patients has limited effects." | 5.16 | Improved efficacy by individualized combination therapy with Peg IFN-a 2a and ADV in HBeAg positive chronic hepatitis B patients. ( Lu, HZ; Shen, C; Wang, W; Wang, YD; Yan, WZ; Yu, WY; Zhang, L; Zhao, CY; Zhou, JY, 2012) |
| "Patients with chronic hepatitis B with and without previous lamivudine therapy were randomised to receive adefovir alone (10 mg/daily) or adefovir and lamivudine (100 mg/daily) for up to 192 weeks." | 5.16 | Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B. ( Doo, E; Feld, JJ; Ghany, MG; Heller, T; Hoofnagle, JH; Kleiner, DE; Koh, C; Liang, TJ; Nagabhyru, P; Rotman, Y; Wright, EC; Zhao, X, 2012) |
| "To investigate the efficacy of 104 weeks of lamivudine (LAM) and adefovir (ADV) de novo combination therapy, as compared to optimized combination therapy administered after 48 weeks of treatment with lamivudine or adefovir mono-therapy, in chronic hepatitis B (CHB) patients." | 5.16 | [Efficacy of lamivudine and adefovir de novo combination therapy or after mono-therapy in chronic hepatitis B patients]. ( Chen, R; Chen, WL; Chen, XF; Chen, XP; Huang, J; Luo, XD; Ma, HY; Ma, XJ, 2012) |
| "The safety and efficacy of adefovir dipivoxil (ADV) for chronic hepatitis B infection in children was demonstrated in a randomized, placebo-controlled trial." | 5.16 | Efficacy and safety of long-term adefovir dipivoxil therapy in children with chronic hepatitis B infection. ( Frederick, D; Jonas, MM; Kelly, D; Mizerski, J; Mondou, E; Pollack, H; Rousseau, F; Sokal, E; Sorbel, J, 2012) |
| "To observe the effects on patients with HBeAg positive chronic hepatitis B by Baihua Xianglian Detoxification Recipe (BXDR) combined adefovir dipivoxil (AD), and to assess its clinical efficacy." | 5.16 | [Clinical study on Baihua Xianglian detoxification recipe combined with adefovir dipivoxil in treating HBeAg positive chronic hepatitis]. ( Mao, DW; Qiu, H; Wei, AL, 2012) |
| "Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are potent antiviral agents that might have additive or synergistic antiviral activity in treatment of patients with chronic hepatitis B (CHB)." | 5.16 | Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. ( Akarca, US; Carosi, G; Cohen, D; Gadano, A; Habersetzer, F; Llamoso, C; Lok, AS; Lovegren, M; Sievert, W; Trinh, H; Wong, D, 2012) |
| "The aim of the study was to compare the virologic response to adefovir (ADV) add-on therapy with switching to entecavir (ETV) monotherapy in children and adolescents with chronic hepatitis B (CHB) who have developed lamivudine (LAM) resistance during LAM treatment." | 5.16 | Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B. ( Cho, MH; Cho, SM; Choe, BH; Chu, M; Kwon, S; Lee, WK, 2012) |
| "To study the changes of experimental markers of hepatic fibrosis in patients with chronic hepatitis B treated by Dahuang Zhechong Wan combined with adefovir dipivoxil." | 5.16 | [Experimental study on effect of dahuang zhechong wan combined with adefovir dipivoxil in preventing hepatic fibrosis in patients with chronic hepatitis B]. ( Chang, Y; Zhang, L, 2012) |
| "To observe the efficacy of adefovir dipivoxil(ADV) in combination with Anluohuaxian capsule in the treatment of chronic hepatitis B (CHB) patients." | 5.16 | [The therapeutic effect of Anluohuaxian capsule combined with adefovir dipivoxil on patients with chronic hepatitis B and influence on hepatic histology]. ( Gong, GZ; He, B; Jiang, YF; Li, NP; Ma, J; Tang, W, 2012) |
| "To evaluate the efficacy and safety of tenofovir disoproxil fumarate (TDF) for chronic hepatitis B (CHB) patients after multiple failures." | 5.16 | Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. ( Choi, MS; Gwak, GY; Kim, YJ; Koh, KC; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC, 2012) |
| "To determine the efficacy of tenofovir disoproxil fumarate (TDF) in adults with chronic hepatitis B virus (HBV) infection who had previously failed lamivudine (LAM) and had significant viral replication (HBV DNA >10⁵ copies/ml if HBeAg positive, > 10⁴ copies/ml if HBeAg negative) despite at least 24 weeks of treatment with adefovir dipivoxil (ADV)." | 5.15 | Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. ( Angus, PW; Bowden, S; Desmond, PV; George, J; Lee, AU; Locarnini, S; Nicoll, AJ; Patterson, SJ; Roberts, SK; Sievert, W; Strasser, SI, 2011) |
| "This prospective randomized pilot study was conducted in Lok Nayak Hospital, New Delhi, involving 30 patients of chronic hepatitis B (both e antigen positive and negative); 15 were randomly selected to receive either adefovir or lamivudine for a period of 6 months." | 5.15 | Evaluation of adefovir & lamivudine in chronic hepatitis B: correlation with HBV viral kinetic, hepatic-necro inflammation & fibrosis. ( Asim, M; Das, BC; Gondal, R; Kar, P; Medhi, S; Pradeep Kumar, S, 2011) |
| " This study compares cccDNA reduction with relation to liver histology in nucleoside/nucleotide-naïve chronic hepatitis B patients receiving oral antiviral monotherapy (n=35), including entecavir (ETV, n=13), adefovir dipivoxil (ADV, n=22) or placebo (n=14)." | 5.15 | Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents. ( Chang, TT; Cheng, PN; Liu, WC; Tsai, HW; Wu, IC; Young, KC, 2011) |
| " In two phase 3 studies (GS-US-174-0102 and GS-US-174-0103), 375 hepatitis B e antigen-negative (HBeAg(-) ) patients and 266 HBeAg(+) patients with chronic hepatitis B (some nucleoside-naive and some lamivudine-experienced) were randomized 2:1 to receive TDF (n = 426) or adefovir dipivoxil (ADV; n = 215) for 48 weeks." | 5.15 | No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. ( Borroto-Esoda, K; Chappell, B; Curtis, M; Heathcote, J; Kitrinos, K; Marcellin, P; Miller, MD; Myrick, F; Schawalder, J; Snow-Lampart, A; Sorbel, J; Svarovskaia, ES; Zhu, Y, 2011) |
| "A randomized, open-label comparative study of entecavir versus adefovir therapy was performed in subjects with chronic hepatitis B who had hepatic decompensation (Child-Turcotte-Pugh score ≥7)." | 5.15 | Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. ( Beebe, S; Bialkowska, J; Brown, RS; Cheinquer, H; Cooney, E; Jeffers, L; Leung, N; Liaw, YF; Myers, RP; Peng, CY; Raptopoulou-Gigi, M; Sarin, SK; Tang, S; Tanwandee, T; Tsai, N, 2011) |
| "We investigated whether intrahepatic markers could predict response in chronic hepatitis B virus (HBV) patients treated with peg-interferon and adefovir for 48 weeks." | 5.15 | Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir. ( Beld, M; Dijkgraaf, M; Jansen, P; Reesink, H; Takkenberg, B; Terpstra, V; Weegink, C; Zaaijer, H, 2011) |
| "To evaluate the safety and efficacy of the combined therapy with entecavir (ETV) and adefovir (ADV) in patients with chronic hepatitis B (CHB) who experienced failure of treatment with single or multiple nucleoside analogs, and analyze the factors that affect the patients response to the treatment." | 5.15 | [Safety and efficacy of Entecavir combined with Adefovir in patients with chronic hepatitis B who fail to respond to nucleoside analog treatment]. ( Guo, YB; Hou, JL; Peng, J; Sun, J; Wang, ZH; Yan, L; Yang, J; Zhou, B, 2011) |
| "In this randomised study, chronic hepatitis B patients with lamivudine resistance were treated with peginterferon alfa-2a for 48 weeks (n=155) or adefovir for 72 weeks (n=80)." | 5.15 | Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. ( Chan, HL; Chen, SJ; Hou, JL; Jia, JD; Jiang, M; Lai, JY; Li, MK; Li, XH; Popescu, M; Sheng, JF; Sun, J; Sung, JJ; Wang, H; Wang, JF; Wang, YM; Xie, Q; Zhang, JM, 2011) |
| "To investigate the levels of HBsAg in predicting the efficacy of peglated interferon-alpha 2a combined with adefovir dipivoxil (ADV), in HBeAg-positive chronic hepatitis B patients." | 5.15 | [The levels of HBsAg can predict the efficacy of peglated interferon-alpha 2a combined with adefovir dipivoxil, in HBeAg-positive chronic hepatitis B patients]. ( Cao, H; Li, G; Sun, HX; Xu, QH; Yang, XA; Zhang, K, 2011) |
| "A large clinic cohort of chronic hepatitis B cirrhotic patients were enrolled in a treatment program of lamivudine ± adefovir therapy." | 5.15 | Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis. ( Aung, MO; Dan, YY; Fernandes, M; Lai, V; Lee, GH; Lee, YM; Lim, SG; Low, HC; Mak, B; Sutedja, D, 2011) |
| "To explore relationship between HBeAg seroconversion with HBV genotypes and HBV specific CTL in patients with chronic hepatitis B (CHB) treated with Adefovir dipivoxil." | 5.15 | [Relationship between HBeAg seroconversion with genotypes and HBV specific CTL in patients with chronic hepatitis B treated with Adefovir dipivoxil]. ( Gu, XB; Pan, JQ; Tan, YF; Tang, JM; Wang, XC; Wu, YT; Yang, ZX; Zhao, YP; Zhou, YL, 2011) |
| "To observe the therapeutic effect and safety of entecavir and adefovir in the treatment of lamivudine-resistant HBeAg-negative chronic hepatitis B." | 5.15 | [Efficacy of two nucleoside analogs to treat resistant HBeAg-negative chronic hepatitis B]. ( Li, XJ; Shu, X; Xu, QH; Zhu, JY, 2011) |
| "To observe the efficacy and safety on the efficacy of HBeAg-positive chronic Hepatitis B patients treated with adefovir dipivoxil for 4 years." | 5.15 | [A clinical study on the efficacy of HBeAg-positive chronic hepatitis B patients treated with adefovir dipivoxil for 4 years]. ( Chen, LB; Liang, JY; Shu, X; Xu, QH; Yang, XA; Zhang, K, 2011) |
| "0 mg/d or ETV plus adefovir dipivoxil (ADV) in adults with chronic hepatitis B virus (HBV) infection who had previously resisted lamivudine (LAM) and failed with rescue treatment of LAM + ADV." | 5.15 | [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil]. ( Han, T; Li, J; Li, Y; Liu, L; Xiao, SX; Xing, J, 2011) |
| "To investigate the clinical efficacy and safety of adefovir dipivoxil (ADV) in combination with bicyclol for the treatment of chronic hepatitis B (CHB) in seniors." | 5.15 | [The clinical efficacy and safety of adefovir dipivoxil in combination with bicyclol for the treatment of senior patients with chronic hepatitis B]. ( Cai, SP; Fan, ZP; He, WP; Ji, YJ; Zhang, WJ, 2011) |
| "This study was undertaken to compare the early antiviral activity and viral kinetic profiles of entecavir (ETV) versus adefovir (ADV) in hepatitis B e antigen positive nucleoside-naïve adults with chronic hepatitis B (CHB)." | 5.14 | Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. ( Cross, A; Diva, U; Hann, HW; Hsu, CW; Jeffers, L; Lao-Tan, J; Lesmana, L; Leung, N; Lopez-Talavera, J; Mencarini, K; Min, A; Peng, CY; Sherman, M; Sollano, J; Wilber, R; Yuen, MF, 2009) |
| "In patients with hepatitis B e antigen-negative chronic hepatitis B, adefovir dipivoxil administration selects variants bearing reverse transcriptase rtN236T and/or rtA181V/T substitutions in 29% of cases after 5 years." | 5.14 | Complex dynamics of hepatitis B virus resistance to adefovir. ( Brillet, R; Hézode, C; Nordmann, P; Pallier, C; Pawlotsky, JM; Rodriguez, C, 2009) |
| "Adefovir dipivoxil in combination with lamivudine or entecavir are safe and effective therapies for chronic hepatitis B patients with YMDD mutation." | 5.14 | [A study on the treatment of chronic hepatitis B with YMDD mutation]. ( Dai, YX; Ding, H; Hu, TH; Huang, LH; Jiang, XH; Jiang, YM; Qiu, YW; Zhou, M, 2009) |
| "Lamivudine (3TC)-resistant chronic hepatitis B patients demonstrated a higher rate of adefovir dipivoxil (ADV) resistance compared with nucleoside-naive patients." | 5.14 | Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B. ( Barraud, L; Durantel, S; Fasano, M; Guastadisegni, A; Heichen, M; Pastore, G; Santantonio, T; Zoulim, F, 2009) |
| "Entecavir (ETV) is currently recommended as a rescue therapy purely for adefovir (ADV)-resistant chronic hepatitis B virus (HBV) infections." | 5.14 | Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. ( Chung, YH; Kim, KM; Lee, HC; Lee, YS; Lim, YS; Shim, JH; Suh, DJ, 2009) |
| "The efficacy of adefovir dipivoxil (ADV) or entecavir (ETV) rescue monotherapy has not been directly compared in hepatitis B e antigen (HBeAg)-positive patients with lamivudine (3TC)-resistant chronic hepatitis B (CHB)." | 5.14 | Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. ( Ahn, SH; Chon, CY; Han, KH; Hong, SP; Kim, DY; Kim, HJ; Kim, JK; Lee, CK; Lee, HW; Lee, JM; Lee, KS; Nguyen, T; Paik, YH; Park, JY, 2009) |
| "Adefovir dipivoxil (ADV) is effective in lamivudine (LAM)-resistant hepatitis B e antigen-negative (HBeAg(-)) chronic hepatitis B (CHB)." | 5.14 | Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study. ( Eugenidis, N; Giouleme, O; Gkisakis, D; Grammatikos, N; Katsinelos, P; Koumaras, H; Koumerkeridis, G; Mpoumponaris, A; Panderi, A; Patsiaoura, K; Theodoropoulos, K; Tziomalos, K; Vassiliadis, TG, 2010) |
| "Adefovir dipivoxil combined with bicyclol is efective in the treatment of chronic hepatitis B." | 5.14 | [The analyse of effectiveness in HBeAg-positive chronic viral hepatitis B treated by adefovir dipivoxil combined with bicyclol]. ( Sheng, JF; Xiang, DR, 2009) |
| "Entecavir is a potent inhibitor of viral replication in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B patients, but data on the efficacy in NA-experienced subjects are limited." | 5.14 | Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. ( Buti, M; Deterding, K; Hansen, BE; Janssen, HL; Petersen, J; Reijnders, JG; Santantonio, T; van Bömmel, F; Wedemeyer, H; Zoulim, F, 2010) |
| "Large clinical studies assessing long-term adefovir dipivoxil salvage monotherapy in patients with lamivudine-resistant chronic hepatitis B (CHB) are lacking, particularly in patients positive for hepatitis B e antigen (HBeAg)." | 5.14 | Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. ( Ahn, SH; Chon, CY; Han, KH; Hong, SP; Kim, DY; Kim, SO; Lee, JM; Nguyen, T; Park, JY, 2010) |
| "To compare the efficacy of 48 week-Entecavir therapy with that of Adefovir therapy for chronic hepatitis B patients." | 5.14 | [Comparison of the efficacy of 48 week-Entecavir therapy with that of Adefovir therapy for chronic hepatitis B patients]. ( Hu, P; Lin, Q; Ren, H; Shi, XF; Wang, ZY; Zeng, WQ; Zhang, DZ; Zhou, Z, 2010) |
| "The aim of this study was to investigate the outcome of overlap/switch to adefovir dipivoxil (ADV) monotherapy for chronic hepatitis B (CHB) patients with lamivudine (LAM)-resistant HBV, who responded to LAM plus ADV combination therapy." | 5.14 | Overlap/switch to adefovir monotherapy for lamivudine-resistant patients who responded to combination therapy: a pilot controlled study. ( Aizawa, M; Baba, M; Fujise, K; Namiki, Y; Ohkusa, T; Sato, K; Tajiri, H; Takamatsu, M; Tsubota, A, 2010) |
| "We compared treatments for patients with chronic hepatitis B virus (HBV) infection who had an incomplete response to adefovir dipivoxil (ADV)." | 5.14 | Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. ( Berg, T; Borroto-Esoda, K; Chan, S; Frederick, D; Lavocat, F; Marcellin, P; Moller, B; Oldach, D; Rousseau, F; Snow-Lampart, A; Sorbel, J; Suarez, E; Trinh, H; Zoulim, F, 2010) |
| "Earlier clinical studies have reported an ALT flare greater than 10 times the upper limit of normal in some patients with chronic hepatitis B when their lamivudine (LAM) treatment was switched to adefovir (ADV) therapy." | 5.14 | Question of ALT flare during switch to adefovir from lamivudine: A single center open-label, randomized, safety study (June 17, 2005 to February 5, 2009). ( Ahn, M; Dunn, SR; Hann, HW; Park, SY, 2010) |
| "Therapy for chronic hepatitis B with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC) or emtricitabine (FTC) is currently recommended for HIV-HBV coinfection." | 5.14 | Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand. ( Avihingsanon, A; Bowden, S; Chang, JJ; Dore, GJ; Kerr, S; Lange, J; Lewin, SR; Matthews, GV; Napissanant, N; Piyawat, K; Ruxrungtham, K, 2010) |
| "No study has reported on the comparative effect of adefovir (ADV) add-on lamivudine (LAM) versus switching to entecavir (ETV) in LAM-resistant patients with chronic hepatitis B." | 5.14 | Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. ( Ahn, SH; Chon, CY; Han, KH; Kim, DY; Lee, JM; Lee, MH; Park, JY; Ryu, HJ, 2010) |
| "To investigate the efficacy of the 96-week antiviral therapy with adefovir dipivoxil in patients with chronic hepatitis B." | 5.14 | [Efficacy of the 96-week adefovir dipivoxil therapy in patients with chronic hepatitis B]. ( Cao, H; Chen, LB; Li, G; Shu, X; Xie, QF; Xu, QH; Xu, Z, 2010) |
| "To observe the efficacy and safety of PEG-interferon alpha-2a (PEG-IFNalpha-2a) treatment on lamivudine (LAM)-resistant chronic hepatitis B (CHB) patients." | 5.14 | [Observation on effect of peg interferon lphaa-2a treating lamivudine resistant chronic hepatitis B]. ( Bai, HL; Long, H; Luo, HT; Ye, YN; Zhong, RX, 2010) |
| "To explore the influence of adefovir dipivoxil on HBV specific CTL in patients with chronic hepatitis B (CHB)." | 5.14 | [Influence of adefovir dipivoxil on HBV specific CTL in patients with chronic hepatitis B]. ( Pan, JQ; Tan, YF; Tang, JM; Wang, XC; Wu, YT; Zhao, YP; Zhou, YL, 2010) |
| "Treatment of 171 patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) with adefovir dipivoxil (ADV) 10 mg over 48 weeks resulted in significant histological, virological, serological, and biochemical improvement compared with placebo." | 5.13 | Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. ( Arterburn, S; Borroto-Esoda, K; Chang, TT; Frederick, D; Lim, SG; Marcellin, P; Rousseau, F; Sievert, W; Tong, M, 2008) |
| "Nine patients with lamivudine-resistant chronic hepatitis B infection who had been treated with adefovir 10 mg/day and had had a suboptimal response but did not have genotypic resistance to adefovir were treated with high-dose adefovir (20 mg/day)." | 5.13 | Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and lamivudine. ( Colombo, M; Facchetti, F; Lampertico, P; Lunghi, G; Viganò, M, 2008) |
| "Thai patients enrolled in STACCATO with HIV/hepatitis B virus (HBV) co-infection and tenofovir/emtricitabine-based antiretroviral therapy (ART) were randomly assigned to continuous treatment or CD4 cell count-guided interruptions." | 5.13 | Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. ( Ananworanich, J; Chetchotisakd, P; Hirschel, B; Jupimai, T; Klinbuayam, W; Mahanontharit, A; Nüesch, R; Prasithsirikul, W; Ruxrungtham, K; Srasuebkul, P, 2008) |
| "To evaluate the efficacy of short-term overlap lamivudine therapy with adefovir in patients with lamivudine-resistant and naive chronic hepatitis B, we compared patients receiving overlap therapy with those receiving adefovir alone." | 5.13 | Short-term overlap lamivudine treatment with adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B. ( Bae, SH; Cho, SH; Choi, JY; Han, JY; Kang, SB; Kim, YS; Lee, SW; Lee, YS; Nam, SW; Yang, JM; Yoon, SK, 2008) |
| "This study investigated the efficacy, safety, and pharmacokinetics of adefovir dipivoxil (ADV) in children and adolescents with chronic hepatitis B (CHB)." | 5.13 | Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. ( Frederick, D; Jonas, MM; Kelly, D; Mizerski, J; Mondou, E; Pollack, H; Rousseau, F; Sokal, E; Sorbel, J, 2008) |
| "Four hundred and eighty Chinese subjects with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) were enrolled in a multicenter, double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) 10 mg once daily." | 5.12 | A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. ( Barker, KF; Chang, CN; Hou, J; Ji, BN; Mao, Y; Wang, H; Wang, Y; Yao, G; Zeng, M, 2006) |
| "We conducted a multicenter, 1: 2 matched pair analysis comparing patients with HBV/HIV-coinfection starting an antiretroviral regimen including tenofovir plus lamivudine with patients who had highly replicative, lamivudine resistant HBe-antigen positive chronic hepatitis B and started with tenofovir as the only active HBV polymerase inhibitor subsequent to lamivudine." | 5.12 | Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. ( Berg, T; Berger, F; Bruno, R; Carlebach, A; Hoffmann, C; Jaeger, H; Lutz, T; Mauss, S; Nelson, M; Rockstroh, J; Schmutz, G; Schürmann, D; Schwarze-Zander, C; Sheldon, J; Soriano, V; Stoehr, A; von Boemmel, F; Wolf, E, 2006) |
| "Treatment with adefovir dipivoxil for 48 weeks resulted in clinical improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B that was lost when treatment was discontinued." | 5.12 | Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. ( Arterburn, S; Borroto-Esoda, K; Brosgart, CL; Chang, TT; Chuck, SL; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Ma, J; Marcellin, P; Rizzetto, M; Tassopoulos, NC, 2006) |
| "In patients failing to respond to adefovir monotherapy or an adefovir-containing regimen for chronic hepatitis B virus, a combination of tenofovir and emtricitabine resulted in undetectable hepatitis B viral DNA levels without any renal toxicity." | 5.12 | Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen. ( Carriero, D; Dieterich, DT; Jaffe, D; Lucas, J; Park, JS; Santos, SA; Uriel, AJ, 2006) |
| "To investigate the efficacy and safety of adefovir dipivoxil (ADV, DAIDING) for Chinese chronic hepatitis B patients with lamivudine (LAM) resistance." | 5.12 | [A double-blind, randomized, lamivudine-controlled clinical trial of DAIDING (adefovir dipivoxil) for lamivudine-resistant patients with chronic hepatitis B]. ( Chen, YK; Lei, BJ; Lu, ZM; Wang, YM; Yin, YK; Yu, YS; Zhang, DZ, 2006) |
| "To evaluate the efficacy and safety of a China made adefovir dipivoxil (ADV) treatment for hepatitis B e antigen-positive patients with chronic hepatitis B." | 5.12 | [A clinical study of adefovir dipivoxil, made in China, for treatment of hepatitis B e antigen-positive patients with chronic hepatitis B]. ( Chen, XY; Kang, XP; Li, J; Lin, XH; Liu, P; Ren, XM; Si, CW; Yu, YY; Zhang, SL, 2006) |
| "We studied the long-term efficacy of adefovir dipivoxil (ADV) treatment in 42 HBeAg-negative patients with chronic hepatitis B (CHB) who had developed genotypical lamivudine (LAM) resistance with virological and clinical breakthroughs under long-term LAM treatment." | 5.12 | Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. ( Dimou, E; Hadziyannis, SJ; Mitsoula, P; Rapti, I, 2007) |
| "Forty-six consecutive lamivudine-resistant chronic hepatitis B patients treated with ADV for more than 12 months with or without 3TC overlapping were prospectively examined for virological response and adefovir resistance." | 5.12 | Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. ( Changchien, CS; Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JC; Wang, JH, 2006) |
| "We assessed the efficacy and safety of adefovir 20 mg daily in patients with hepatitis B e antigen-positive chronic hepatitis B resistant to lamivudine and a suboptimal virological response to adefovir 10 mg daily add-on." | 5.12 | Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. ( Bouvier-Alias, M; Brillet, R; Chevaliez, S; Dhumeaux, D; Hézode, C; Pawlotsky, JM; Roudot-Thoraval, F; Zafrani, ES, 2007) |
| "To evaluate the efficacy and safety of adefovir dipivoxil (ADV) treatment in patients with hepatitis B e antigen (HBeAg) positive chronic hepatitis B (CHB)." | 5.12 | [Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients]. ( Ling, N; Ren, H; Zhang, DZ; Zhou, Z, 2007) |
| "To evaluate the efficacy and safety of adefovir dipivoxil (ADV) in treating patients with lamivudine (LAM) refractory HBeAg-positive chronic hepatitis B." | 5.12 | [A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B]. ( Chen, XY; Si, CW; Tang, XP; Wang, L; Zhang, YX; Zhao, H, 2007) |
| "We investigated the impact of early viral load decline on virus-specific T-cell reactivity in 30 hepatitis B e antigen (HBeAg)-positive patients with chronic hepatitis B randomized to monotherapy with adefovir dipivoxil (ADV) or in combination with emtricitabine (ADV/FTC)." | 5.12 | Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B. ( Anderson, J; Bowden, S; Cooksley, H; Hui, CK; Lau, GK; Lewin, S; Locornini, S; Mondou, E; Naoumov, NV; Perelson, AS; Powers, KA; Ribeiro, RM; Rousseau, F; Shudo, E; Sorbel, J, 2007) |
| "To compare the antiviral efficacy of telbivudine and adefovir dipivoxil, and the effects of switching from adefovir to telbivudine, in hepatitis B e antigen (HBeAg)-positive patients with chronic hepatitis B." | 5.12 | Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. ( Brown, NA; Bzowej, N; Chan, HL; Chao, YC; Cho, M; Harb, G; Heathcote, EJ; Jeffers, L; Kaiser, R; Lai, CL; Marcellin, P; Minuk, GY; Moon, YM; Myers, RP; Qiao, XJ; Sievert, W, 2007) |
| "To evaluate the cost effectiveness of treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) with entecavir compared with lamivudine with adefovir salvage, based primarily on the results of a recent 2-year, randomised, multicentre, clinical trial (n = 709)." | 5.12 | Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. ( Clarke, L; Di Bisceglie, A; Gish, RG; Iloeje, UH; Kowdley, KV; Sullivan, SD; Tafesse, E; Veenstra, DL, 2007) |
| "To evaluate the effect of diammonium glycyrrhizinate on the antiviral therapy with adefovir dipivoxil (ADV) in patients with HBeAg-positive chronic hepatitis B." | 5.12 | [Diammonium glycyrrhizinate does not affect efficacy of adefovir dipivoxil therapy in patients with HBeAg-positive chronic hepatitis B]. ( Chen, XY; Lei, CL; Li, J; Si, CW; Tang, XP; Wang, L; Zhang, YX; Zhao, H, 2007) |
| "To determine the relationship between the response to adefovir dipivoxil (ADV) treatment in patients with HBV genotypes B and C of HBeAg positive chronic hepatitis B." | 5.12 | [Efficacy of adefovir dipivoxil was not related to genotypes B and C of hepatitis B virus: a randomized, double-blind, multicenter clinical study]. ( Chen, XY; Lei, CL; Li, J; Si, CW; Tang, XP; Wang, L; Zhang, YX; Zhao, H, 2007) |
| "The safety and efficacy of 10 mg of adefovir dipivoxil was compared to placebo in 501 Asian (n = 259) or Caucasian (n = 242) HBeAg+ and HBeAg- chronic hepatitis B virus patients treated for 48 weeks in two randomized, double-blind, placebo-controlled studies." | 5.12 | Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B. ( Arterburn, S; Brosgart, CL; Chang, TT; Hadziyannis, S; Hu, P; Lim, SG; Marcellin, P; Sievert, W; Tassopoulos, N; Tong, M, 2007) |
| "The extended treatment with lamivudine in patients with chronic hepatitis B is associated with the emergence of resistances." | 5.12 | [Adefovir dipivoxil compassionate use program in Spain: efficacy and resistance analysis]. ( Buti, M; Calleja, JL; Carnicer, F; Casanovas, T; Crespo, J; Enríquez, J; Esteban, R; García Bengoechea, M; García Samaniego, J; Jardí, R; Miras, M; Pérez Roldán, F; Pons, F; Prieto, M; Rodríguez Frías, F; Romero, M; Rueda, M, 2007) |
| " We evaluated the efficacy and safety of adding adefovir dipivoxil to lamivudine in 135 patients with chronic hepatitis B (CHB) and YMDD mutant HBV." | 5.11 | Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. ( Bourne, E; Brosgart, CL; Gardner, S; Hann, HW; Lee, WM; Leung, N; Moorat, A; Mutimer, D; Perrillo, R; Schiff, E; Willems, B; Woessner, M, 2004) |
| " This study assessed the safety and efficacy of adefovir dipivoxil alone and in combination with lamivudine compared with ongoing lamivudine therapy in patients with chronic hepatitis B with compensated liver disease and lamivudine-resistant hepatitis B virus (HBV)." | 5.11 | Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. ( Bourliere, M; Brosgart, CL; Buggisch, P; Ebrahimi, R; Gray Df, Df; Hann Hw, Hw; Heathcote, EJ; Kleber, K; Kowdley, K; Martin, P; Peters, MG; Rubin, R; Sullivan, M; Trepo, C; Xiong, S, 2004) |
| "Lamivudine treatment in patients with chronic hepatitis B virus (HBV) infection may improve clinical state and suppress viral replication before liver transplantation." | 5.11 | Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. ( Chan, SC; Fan, ST; Lau, GK; Liu, CL; Lo, CM; Ng, IO, 2005) |
| "Treatment with adefovir dipivoxil for 48 weeks resulted in histologic, virologic, and biochemical improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B." | 5.11 | Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. ( Arterburn, S; Brosgart, CL; Chang, TT; Currie, G; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Ma, J; Marcellin, P; Rizzetto, M; Tassopoulos, NC; Xiong, S, 2005) |
| "Adefovir dipivoxil is safe for the treatment of chronic hepatitis B in patients with varying degrees of renal dysfunction and lamivudine-resistant HBV and results in biochemical and virological efficacy similar to that reported in the general population." | 5.11 | Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. ( Brosgart, C; Chaix, ML; Currie, G; Fontaine, H; Morales, E; Nalpas, B; Pol, S; Serpaggi, J; Vallet-Pichard, A; Varaut, A; Verkarre, V, 2005) |
| " Currently available treatments for chronic hepatitis B (interferon [IFN]-alpha and lamivudine [3TC]) have limited long-term utility because of side effects or of the development of resistance." | 5.10 | Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. ( Aberg, JA; Crippin, J; Kessels, L; Lisker-Melman, M; Powderly, WG; Ristig, MB; Tebas, P, 2002) |
| "We randomly assigned 515 patients with chronic hepatitis B who were positive for hepatitis B e antigen (HBeAg) to receive 10 mg of adefovir dipivoxil (172 patients), 30 mg of adefovir dipivoxil (173), or placebo (170) daily for 48 weeks." | 5.10 | Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. ( Brosgart, CL; Chang, TT; Fry, J; Goodman, Z; Jeffers, L; Lim, SG; Marcellin, P; Shiffman, ML; Sievert, W; Tong, MJ; Wulfsohn, MS; Xiong, S, 2003) |
| "Adefovir dipivoxil, a nucleotide analogue, demonstrated clinically significant antiviral activity in patients with chronic hepatitis B in phase 1 and 2 clinical trials." | 5.10 | Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. ( Brosgart, CL; Chang, TT; Fry, J; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Marcellin, P; Rizzetto, M; Tassopoulos, NC; Wulfsohn, MS; Xiong, S, 2003) |
| "Seven hundred nucleoside treatment-naive patients were enrolled in two phase 3 trials of adefovir dipivoxil (ADV) for the treatment of chronic hepatitis B." | 5.10 | Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. ( Brosgart, CL; Delaney, WE; Fry, J; Gibbs, CS; Miller, MD; Westland, CE; Wulfsohn, M; Xiong, S; Yang, H, 2003) |
| "In a recent phase II clinical study, 13 chronic hepatitis B-infected patients treated daily with 30 mg adefovir dipivoxil for 12 weeks displayed a median 4." | 5.09 | Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. ( Gibbs, CS; Rooney, JF; Toole, JJ; Tsiang, M, 1999) |
| "Tenofovir disoproxil fumarate (TDF), an ester prodrug of tenofovir (TFV), is one of the recommended drugs for chronic hepatitis B (CHB) patients." | 4.98 | Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? ( Grossi, G; Lampertico, P; Loglio, A; Viganò, M, 2018) |
| "We aimed to evaluate the efficacy of five oral nucleos(t)ide analogues (NAs), including lamivudine, entecavir, adefovir, telbivudine and tenofovir, for the prevention of hepatitis B virus (HBV) reactivation and HBV-related complications in chronic hepatitis B virus (CHB) infected patients with hematological malignancies receiving chemotherapy or hematopoietic stem cell transplantation (HSCT) by network meta-analysis." | 4.95 | Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis. ( Chen, FY; Cheng, Z; Huang, HH; Shi, KQ; Van Poucke, S; Zhang, MY; Zheng, JN; Zheng, MH; Zhu, GQ, 2017) |
| "In April 2017 tenofovir alafenamide (TAF) was added to the list of first-line therapies recommended for chronic hepatitis B (CHB)." | 4.95 | Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. ( Abdul Basit, S; Dawood, A; Gish, R; Ryan, J, 2017) |
| "Tenofovir alafenamide (TAF) has recently been approved for chronic hepatitis B (CHB)." | 4.95 | Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. ( Hsu, YC; Nguyen, MH; Wei, MT, 2017) |
| "Tenofovir alafenamide (TAF), a novel prodrug of tenofovir (TFV), has been approved for the treatment of chronic hepatitis B virus (HBV) infection." | 4.95 | Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy. ( Furusyo, N; Nguyen, MH; Ogawa, E, 2017) |
| "Conventional interferon alfa and nucleos(t)ide analogues, such as lamivudine, are frequently used for chronic hepatitis B (CHB) treatment, but are associated with adverse effects and viral resistance." | 4.93 | Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis. ( Abreu, RM; Baldassare, RM; Carrilho, FJ; Kim, V; Nakagawa, DM; Ono, SK, 2016) |
| "Long-term adefovir dipivoxil therapy is connected to renal dysfunction in chronic hepatitis B, necessitating the monitoring of kidney function." | 4.93 | Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis. ( Cheng, F; Deng, Y; Kang, J; Luo, Q; Zeng, W; Zhang, D; Zhong, S, 2016) |
| "The treatment of chronic hepatitis B (CHB) in patients with chronic kidney disease (CKD) is based on nucleoside (lamivudine, telbivudine, entecavir) or nucleotide (adefovir, tenofovir) analogues (NAs), but it may be complex and the information is scarce." | 4.90 | Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. ( Cholongitas, E; Papatheodoridis, G; Pipili, C, 2014) |
| " He had been receiving low-dose adefovir dipivoxil (ADV) for the treatment of lamivudine-resistant chronic hepatitis B virus infection for eight years and subsequently developed severe hypophosphatemia and proximal renal tubule dysfunction." | 4.90 | Hypophosphatemic osteomalacia due to drug-induced Fanconi's syndrome associated with adefovir dipivoxil treatment for hepatitis B. ( Eguchi, H; Hiromatsu, Y; Kuwahara, R; Tani, J; Tsuruta, M, 2014) |
| "Tenofovir (TDF) and entecavir (ETV) are both potent antiviral agents for the treatment of chronic hepatitis B virus (HBV) infection." | 4.90 | Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. ( Gao, Y; Ke, W; Liu, L; Yang, Y; Ye, X; Zhang, C; Zhou, S, 2014) |
| " Currently, lamivudine plus adefovir combination therapy or entecavir monotherapy is usually used for the treatment of patients with lamivudine-resistant chronic hepatitis B (CHB)." | 4.89 | Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. ( Chen, RC; Dai, XH; Fan, XG; Huang, Y; Huang, ZB; Li, N; Li, WT; Yi, PP; Zhang, BX; Zhao, SS; Zhou, RR, 2013) |
| "To conduct a meta-analysis to determine the efficacy of peginterferon alpha (PEG-IFN α) therapy versus IFN α, adefovir dipivoxil (ADV) and entecavir (ETV) for HBeAg-positive chronic hepatitis B patients in China." | 4.89 | Peginterferon alpha versus other antiviral regimes for Chinese HBeAg-positive chronic hepatitis B patients. ( Deng, Z; Li, B; Li, Z; Liu, S; Wang, C, 2013) |
| "The aim of this study was to systematically review the quality of cost-effectiveness evidence on first-line treatment with entecavir (ETV) or tenofovir difumarate (TDF) for patients with chronic hepatitis B." | 4.89 | Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B : a systematic review. ( Buti, M; Casado, MA; Lozano, V; Oyagüez, I, 2013) |
| "The aim of the current study was to compare the effectiveness of adefovir dipivoxil (ADV) monotherapy with that of combination ADV and lamivudine (LAM) therapy in the treatment of LAM-resistant chronic hepatitis B (CHB)." | 4.88 | Comparative meta-analysis of adefovir dipivoxil monotherapy and combination therapy of adefovir dipivoxil and lamivudine for lamivudine-resistant chronic hepatitis B. ( Chen, Y; Ju, T, 2012) |
| "Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are potent nucleos(t)ide analogues (NUCs) recommended as first-line monotherapies for chronic hepatitis B." | 4.88 | First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. ( Lampertico, P; Pol, S, 2012) |
| "First-line treatment options for chronic hepatitis B (CHB) consist of nucleos(t)ide analogues with a high barrier to resistance (entecavir and tenofovir) or the immunomodulatory agent peginterferon (PEG-IFN)." | 4.87 | Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy? ( Janssen, HL; Rijckborst, V; Sonneveld, MJ, 2011) |
| "Although entacavir and adefovir were widely used in most Asian countries, there were few conclusions drawn from a meta-analysis for comparing the efficacy between entecavir and adefovir in nucleos(t)ide-naïve Asian patients with chronic hepatitis B (CHB)." | 4.87 | Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis. ( Guan, Q; Liu, W; Zhao, J; Zhao, P, 2011) |
| " Currently, several drugs, such as tenofovir and adefovir, are recommended for treatment of patients with chronic hepatitis B." | 4.87 | Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: a systematic review. ( Chen, LZ; Dai, XH; Fan, XG; Tang, LH; Wang, W; Zhao, SS; Zhou, RR, 2011) |
| "Chronic hepatitis B virus (HBV) infection represents a serious global health problem and resistance to lamivudine (LAM) has become a serious clinical challenge." | 4.87 | Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. ( Hu, HD; Hu, P; Liu, JY; Ren, H; Sheng, YJ; Tong, SW; Zhang, DZ, 2011) |
| " Combination therapy with Interferon-α and ribavirin remains the backbone treatment for chronic hepatitis C; the addition of serine protease inhibitors improves the treatment outcome of patients infected with hepatitis C virus genotype 1." | 4.87 | Antiviral drugs for viruses other than human immunodeficiency virus. ( Razonable, RR, 2011) |
| " Lamivudine and adefovir dipivoxil are effective and tolerable for chronic hepatitis B by suppressing the viral load and to reduce fibrosis in the liver." | 4.87 | Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma. ( Li, le Q; Wu, LC; Zhong, JH, 2011) |
| "Since its approval for the treatment of chronic hepatitis B in 1998, lamivudine (LAM) has been used extensively throughout the world, because of its relatively low costs and favourable tolerability." | 4.86 | Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon. ( Marcellin, P; Piratvisuth, T; Sung, J, 2010) |
| "This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B, in accordance with the licensed indication, based upon the evidence submission from Gilead to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process." | 4.86 | Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection. ( Colquitt, J; Cooper, K; Harris, P; Jones, J; Shepherd, J, 2010) |
| "Tenofovir is a nucleotide analog reverse transcriptase inhibitor approved recently by the US FDA for the treatment of chronic hepatitis B (CHB) in adult patients based on the results of two double-blind randomized trials demonstrating superiority of tenofovir compared with adefovir." | 4.86 | Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. ( Jenh, AM; Pham, PA, 2010) |
| "To update and extend a 2006 report on the clinical effectiveness and cost-effectiveness of adefovir dipivoxil (ADV) and pegylated interferon alpha (PEG-alpha) for the treatment of chronic hepatitis B (CHB)." | 4.85 | Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation. ( Baxter, L; Gospodarevskaya, E; Harris, P; Hartwell, D; Jones, J; Price, A; Shepherd, J, 2009) |
| "Tenofovir disoproxil fumarate is a nucleotide analog reverse transcriptase inhibitor recently approved by the United States Food and Drug Administration (FDA) for the treatment of chronic hepatitis B virus (HBV) infection in adults." | 4.85 | Tenofovir for the treatment of hepatitis B virus. ( Jenh, AM; Pham, PA; Thio, CL, 2009) |
| "Currently, there are no conclusive results on the efficacy of adefovir dipivoxil (ADV) plus lamivudine (LAM) in LAM-resistant patients with chronic hepatitis B (CHB)." | 4.85 | Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. ( Chen, EQ; Lei, J; Tang, H; Wang, LC; Xu, L, 2009) |
| "Clinical trials demonstrated telbivudine to be a safe and potent antiviral agent for treatment of chronic hepatitis B." | 4.84 | A review of telbivudine for the management of chronic hepatitis B virus infection. ( Chan, HL; Lui, YY, 2008) |
| " Interferon alfa-2b, lamivudine, adefovir, entecavir, peginterferon alfa-2a, telbivudine, and tenofovir are approved as initial therapy for chronic hepatitis B and have certain advantages and disadvantages." | 4.84 | A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. ( Dieterich, DT; Han, SH; Jacobson, IM; Keeffe, EB; Martin, P; Schiff, ER; Tobias, H, 2008) |
| " In the last few years the therapeutic options in chronic hepatitis B have increased and currently six treatments are authorized: standard interferon (IFN)-alpha, pegylated interferon-alpha (PEG-IFNalpha), lamivudine, adefovir, entecavir, and telbivudine." | 4.84 | [Interferon in hepatitis B]. ( García Buey, L; González Mateos, F; Moreno Otero, R, 2008) |
| "At least 4 nucleos(t)ide analogs have been approved for the treatment of chronic hepatitis B: lamivudine, adefovir dipivoxil, entecavir, and telbivudine." | 4.84 | [Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B]. ( Buti, M, 2008) |
| "The practising clinician is currently faced with a number of effective treatment options for chronic hepatitis B, including two formulations of interferon (standard IFN and pegylated IFN) and five nucleos(t)ide analogues (lamivudine, adefovir, entecavir, telbivudine and tenofovir)." | 4.84 | Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues. ( Buster, EH; Janssen, HL; Schalm, SW, 2008) |
| " Treatment options for chronic hepatitis B include pegylated interferon and 4 licensed oral nucleosides/nucleotides (lamivudine, adefovir entecavir and tenofovir)." | 4.84 | [Chronic hepatitis B: current therapy]. ( Buffet, C, 2008) |
| "Lamivudine and adefovir were approved for treatment of chronic hepatitis B virus (HBV) infection based on placebo-controlled trials, and entecavir was recently approved on the basis of its superiority over lamivudine in phase II/III trials; however, to date, these three therapies have not been compared head to head." | 4.84 | Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients. ( Dienstag, JL; Kreter, B; Wei, LJ; Xu, D, 2007) |
| "Standard treatments for chronic hepatitis B (CHB) include interferon-alpha (IFN-alpha) and lamivudine (LAM), but these are associated with adverse effects and viral resistance, respectively." | 4.84 | A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B. ( Davidson, P; Jones, J; Price, A; Shepherd, J; Takeda, A, 2007) |
| "Among the six drugs licensed for the treatment of chronic hepatitis B in the US, the preferred agents in 2008 will include entecavir, peginterferon alfa-2a, possibly telbivudine, and tenofovir following licensure." | 4.84 | Review article: current antiviral therapy of chronic hepatitis B. ( Ayoub, WS; Keeffe, EB, 2008) |
| "Five agents are currently approved for the treatment of chronic hepatitis B: standard interferon-alpha (IFN-alpha), pegylated interferon-alpha 2a (PEG-IFN-alpha 2a), lamivudine, adefovir and entecavir." | 4.83 | Medical therapy of patients affected by HBeAg-negative chronic hepatitis B. ( Asselah, T; Boyer, N; Marcellin, P, 2006) |
| "There are two new nucleoside analogues available for the management of chronic hepatitis B, adefovir and entecavir, and several more in development." | 4.83 | Personal view: the management of chronic hepatitis B infection. ( Sherman, M, 2006) |
| " The treatment of choice in chronic hepatitis C currently is pegylated interferon plus ribavirin." | 4.83 | Chronic Hepatitis B and C--current treatment and future therapeutic prospects. ( Müller, C, 2006) |
| " Chronic hepatitis C can be treated preferably with a combination therapy (pegylated interferons + Ribavirin)." | 4.82 | [Hepatitis: associated diseases. Risk groups -- prevention -- treatment]. ( Maier, KP, 2003) |
| "To evaluate properties of the new acyclic nucleotide analog adefovir dipivoxil in the treatment of chronic hepatitis B (CHB)." | 4.82 | Adefovir dipivoxil in the treatment of chronic hepatitis B. ( Rivkin, AM, 2004) |
| " To determine the effectiveness of adefovir, three populations of patients with chronic hepatitis B patients were studied: hepatitis B e antigen (HBeAg)-positive patients, HBeAg-negative patients, and patients with lamivudine-resistant tyrosine-methionine-asparate-aspartate (YMDD) mutants." | 4.82 | Treatment of patients with chronic hepatitis B with adefovir dipivoxil. ( Tong, MJ; Tu, SS, 2004) |
| "Adefovir dipivoxil, an acyclic nucleotide analogue, is effective for the treatment of chronic hepatitis B in both hepatitis B e antigen (HBeAg)-positive and -negative patients, with improvement in liver histology, hepatitis B virus (HBV) DNA levels, alanine aminotransferase levels, and HBeAg seroconversion (for HBeAg-positive patients)." | 4.82 | Adefovir dipivoxil in chronic hepatitis B infection. ( Lai, CL; Yuen, MF, 2004) |
| "Adefovir dipivoxil (ADF) is a novel acyclic nucleoside analogue that has recently been approved for the treatment of chronic hepatitis B virus (HBV)." | 4.82 | Adefovir dipivoxil: review of a novel acyclic nucleoside analogue. ( Danta, M; Dusheiko, G, 2004) |
| "Although the management of chronic hepatitis B has improved over the last decade, none of the available therapeutic agents, IFN-alpha, lamivudine and adefovir dipivoxil, can achieve sustained off-therapy responses in most cases." | 4.82 | Emerging treatments in chronic hepatitis B. ( Hadziyannis, SJ; Papatheodoridis, GV, 2004) |
| " The conference issued recommendations on the investigation and management of chronic hepatitis B, including the use of lamivudine, adefovir and interferon." | 4.82 | The management of chronic viral hepatitis: a Canadian consensus conference 2004. ( Bain, V; Cooper, C; Lowe, C; Martin, S; Myers, RP; Sherman, M; Villeneuve, JP, 2004) |
| " Adefovir dipivoxil is indicated for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (alanine [ALT] or aspartate [AST]) or histologically active disease." | 4.82 | Adefovir dipivoxil: focus on its use in the treatment of chronic hepatitis B. ( Baker, DE, 2005) |
| "Two agents are currently approved for the treatment of chronic hepatitis B: interferon alfa and lamivudine." | 4.81 | Advances in therapy for chronic hepatitis B. ( Marcellin, P, 2002) |
| "There are two licensed drugs for chronic hepatitis B virus (HBV), interferon alfa and lamivudine, with similar efficacy rates." | 4.81 | How will we use the new antiviral agents for hepatitis B? ( Perrillo, RP, 2002) |
| "This retrospective study included 289 chronic hepatitis B (CHB) patients without cirrhosis who received entecavir (n = 93), TDF (n = 103), or TAF (n = 86) retreatment for at least 12 months after entecavir or TDF cessation." | 4.31 | Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation. ( Chang, KC; Chen, CH; Chiu, SM; Hu, TH; Hung, CH; Lu, SN; Wang, JH, 2023) |
| "As tenofovir disoproxil fumarate (TDF) requires long-term use, a reduction in bone density should be considered a possibility when treating patients with chronic hepatitis B (CHB) with aging and systemic diseases." | 4.31 | Tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: A nationwide claims study in South Korea. ( Chang, JI; Cho, YY; Jang, ES; Kim, E; Kim, HJ; Kim, SS; Lee, HW; Seo, GH; Yoon, E, 2023) |
| "Switching to a tenofovir alafenamide (TAF)-containing regimen has been reported to be associated with body weight gain in human immunodeficiency virus-infected subjects." | 4.12 | Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide ( Chuang, WL; Dai, CY; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Nguyen, MH; Trinh, S; Yeh, ML; Yu, ML, 2022) |
| "Data on long-term tenofovir alafenamide (TAF) therapy for pregnant women with active chronic hepatitis B (CHB) (immune clearance and reactivation phases, currently and previously diagnosed) and their infants are lacking." | 4.12 | Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study. ( Chen, ZM; Cui, GL; Feng, YH; Huang, S; Li, GM; Li, GT; Li, J; Li, W; Li, WZ; Li, ZQ; Liang, HX; Lin, WB; Liu, N; Liu, YM; Lv, J; Pan, YJ; Song, N; Sun, CY; Wang, FS; Wang, M; Xu, GH; Xu, JH; Yu, ZJ; Zeng, QL; Zeng, YL; Zhang, DW; Zhang, GF; Zhang, GQ; Zhang, HX; Zhang, JY; Zhou, YH, 2022) |
| "We aimed to investigate the long-term effects of tenofovir disoproxil fumarate and entecavir treatment on bone mineral density and evaluated the fracture risk assessment tool score in patients with chronic hepatitis B." | 4.12 | Effects of Long-Term Tenofovir and Entecavir Treatment on Bone Mineral Density in Patients with Chronic Hepatitis B. ( Çalhan, T; Doğanay, L; Kahraman, R; Kanat, E; Özdil, K; Öztürk, O; Şahin, A; Sayar, S, 2022) |
| "HBV DNA was extracted from blood samples of two patients with HBeAg-positive chronic HBV infection and persistent viremia despite tenofovir treatment, and subsequently amplified by PCR before full-length HBV genomes were assembled by deep sequencing." | 4.12 | Novel hepatitis B virus reverse transcriptase mutations in patients with sustained viremia despite long-term tenofovir treatment. ( Bajpai, PS; Bukh, J; Dalegaard, MI; Fahnøe, U; Lundh, A; Ryom, L; Weis, N; Winckelmann, A, 2022) |
| "Antenatal antiviral therapy (AVT) is effective in preventing mother-to-child transmission (MTCT) in chronic hepatitis B (CHB); tenofovir disoproxil fumarate (TDF) is the preferred agent." | 4.12 | Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection. ( Cottrell, M; Crane, H; Di Girolamo, J; Dumond, J; Gane, E; Kashuba, A; Kayes, T; Levy, MT; Lim, TH; Manandhar, S; Symonds, A, 2022) |
| "Tenofovir alafenamide (TAF) may be preferable to other nucleos(t)ide analogues (NA) regarding outcomes against chronic hepatitis B virus (HBV) infection." | 4.12 | Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study. ( Amagase, H; Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Ichiki, Y; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Kuniyoshi, M; Morita, C; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Sugimoto, R; Takahashi, K; Yamashita, N, 2022) |
| "Non-inferior antiviral efficacy and better renal safety have been reported in chronic hepatitis B patients with tenofovir alafenamide (TAF) treatment." | 4.12 | One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study. ( Chen, YC; Chien, RN; Hsu, CW; Tai, DI, 2022) |
| "Tenofovir is a nucleotidic analog inhibitor used in monotherapy as first line treatment of chronic Hepatitis B virus (HBV) infection." | 4.12 | Treatment of chronic hepatitis B: virological and pharmacological aspects ( Foucault, T; Gaudy-Graffin, C; Handala, L; Marlet, J; Paintaud, G, 2022) |
| "Although tenofovir alafenamide (TAF) and besifovir dipivoxil maleate (BSV) are potent antiviral agents in the treatment of chronic hepatitis B (CHB) infection, their renal safety profiles have not been previously compared." | 4.12 | Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B. ( Ahn, SH; Jung, CY; Kim, BS; Kim, HW; Kim, SU; Lee, HW; Lee, JI, 2022) |
| "Entecavir (ETV) or adefovir dipivoxil (ADV) are not recommended during pregnancy because of embryotoxicity or teratogenicity found in animal studies; however, information on the safety of ETV or ADV in humans is limited." | 4.12 | Pregnancy outcomes for pregnant women with chronic hepatitis B exposing to entecavir or adefovir dipivoxil therapy before or in early pregnancy. ( Cai, H; Duan, X; Fu, D; Gao, X; Hu, Y; Kang, K; Liu, M; Yi, W; Zhou, M, 2022) |
| " This study aimed to compare the efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) in relation to the adverse clinical outcomes among chronic hepatitis B (CHB) patients stratified according to adherence to medication and MVR." | 4.02 | Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir. ( Jeong, J; Jung, SW; Kim, MJ; Lee, SB; Park, BR; Park, EJ; Park, NH; Shin, JW, 2021) |
| "Adefovir plus entecavir (ADV+ETV) rescue therapy in ETV-resistant patients with chronic hepatitis B virus (HBV) infection is suboptimal in some patients." | 4.02 | Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients. ( Chen, R; Li, J; Li, L; Li, X; Liu, LM; Liu, Y; Shao, J; Xu, D; Zhao, L; Zhou, Y, 2021) |
| "Tenofovir alafenamide (TAF) has been newly approved for the treatment of chronic hepatitis B (CHB)." | 3.96 | Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. ( Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Takahashi, K, 2020) |
| "We amplified a full-length hepatitis B virus (HBV) genome from the serum of a chronic hepatitis B patient who experienced virological breakthrough with high HBV DNA titer following adefovir (ADV) therapy." | 3.96 | An antiviral drug-resistant mutant of hepatitis B virus with high replication capacity in association with a large in-frame deletion in the preS1 region of viral surface gene. ( Li, X; Qin, Y; Tong, S; Wang, T; Zhang, J; Zhao, W, 2020) |
| "Renal toxicity is a concern in patients with chronic hepatitis B taking nucleotide analogues, such as adefovir (ADV) and tenofovir disoproxil fumarate (TDF)." | 3.96 | Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B. ( Chang, Y; Cho, EJ; Cho, H; Cho, YY; Kim, YJ; Lee, JH; Nam, JY; Yoon, JH; Yu, SJ, 2020) |
| "Tenofovir alafenamide (TAF) is the latest agent approved for chronic hepatitis B virus (HBV) treatment." | 3.96 | Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis. ( Kim, WR; Kwo, PY; Mannalithara, A; Sripongpun, P, 2020) |
| " A 68-year-old woman, who underwent long-term treatment with lamivudine and adefovir for chronic hepatitis B, developed proximal muscle weakness in the four extremities." | 3.91 | Toxic myopathy with multiple deletions in mitochondrial DNA associated with long-term use of oral anti-viral drugs for hepatitis B: A case study. ( Fujii, T; Honda, H; Iwaki, T; Kawamura, N; Kira, JI; Takase, KI; Uchiumi, T; Urata, M; Yamasaki, R, 2019) |
| " He had been receiving adefovir dipivoxil (ADV) for the treatment of entecavir (ETV)-resistant chronic hepatitis B (CHB) for four years in his 8-year treatment of hepatocellular carcinoma (HCC), but was referred to our hospital after increased levels of bone pain in his ribs, knees, and ankles." | 3.91 | [Adefovir Dipivoxil-induced Fanconi's Syndrome and Osteomalacia Following Multiple Bone Fractures in a Patient with Chronic Hepatitis B]. ( Ikeda, A; Ikeda, F; Kanzaki, H; Kitamura, Y; Makita, T; Murakawa, K; Nishihara, S; Okada, H; Onishi, H; Sendo, T; Shiraha, H; Takaki, A; Takeuchi, Y; Tanaka, Y; Wada, N; Yasunaka, T, 2019) |
| " The patient had been treated with lamivudine (LAM) in 2005, LAM+adefovir (ADV) in 2009, and ADV+entecavir in 2015 for chronic hepatitis B (CH-B)." | 3.91 | [Marked improvement in renal tubular markers after switching from adefovir to tenofovir alafenamide in a case of Fanconi syndrome diagnosed through high ALP levels]. ( Hiraoka, A; Izumoto, H; Kitahata, S; Kondoh, K; Michitaka, K; Ninomiya, T; Tsubouchi, E; Ueki, H; Yamago, H, 2019) |
| " 61 HBeAg-positive chronic hepatitis B (CHB) patients treated with pegylated interferon alfa-2a alone or in combination with adefovir (10 mg/day) for 48 weeks were included in this retrospective analysis." | 3.91 | Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a. ( Chen, PD; Fan, QQ; Jia, W; Qi, X; Wang, T; Wen, X; Zhang, JM; Zhang, WH; Zhu, MQ, 2019) |
| "Adefovir dipivoxil (ADV) is one of the most important nucleostide analogues currently in use for the treatment of chronic hepatitis B virus (HBV) infection." | 3.91 | Low-dose adefovir dipivoxil-induced hypophosphatemia osteomalacia in five chronic hepatitis B virus-infected patients. Is low-dose adefovir dipivoxil-induced nephrotoxicity completely reversible? ( Dai, ZJ; Jin, J; Pan, YJ; Qian, YY; Ruan, LY; Shi, MT; Wu, CM; Zhu, YX, 2019) |
| "Renal toxicity of adefovir disoproxil (ADV) and tenofovir disoproxil fumarate (TDF) is a significant concern in chronic hepatitis B (CHB) patients." | 3.91 | In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue. ( Chan, TM; Fung, J; Lai, CL; Liu, SH; Mak, LY; Seto, WK; Wong, DK; Yap, DY; Yuen, MF, 2019) |
| " Drugs currently used against HBV include IFN-α that decreases viremia, inflammation and the growth of liver fibrosis, and adefovir that decreases the viral load." | 3.88 | Chronic hepatitis B virus and liver fibrosis: A mathematical model. ( Friedman, A; Siewe, N, 2018) |
| "Adefovir dipivoxil (ADV)-induced renal tubular dysfunction and hypophosphatemic osteomalacia (HO) have been given great consideration in the past few years." | 3.88 | Adefovir dipivoxil induced hypophosphatemic osteomalacia in chronic hepatitis B: a comparative study of Chinese and foreign case series. ( Chen, N; Li, LY; Liu, LW; Peng, T; Tang, KX; Yu, F; Yu, X; Zhang, JB; Zhang, Q; Zhao, YP, 2018) |
| "Few studies have addressed the impact of adefovir dipivoxil (ADV)-based combination therapy on the renal function of patients with chronic hepatitis B (CHB)." | 3.88 | Telbivudine and adefovir dipivoxil combination therapy improves renal function in patients with chronic hepatitis B: A STROBE-compliant article. ( Nie, ZW; Xu, Y, 2018) |
| "None of the patients developed lactic acidosis during follow-up [median: 58 (6-155) months]." | 3.85 | Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis. ( Aggeletopoulou, I; Anastassiou, ED; Assimakopoulos, S; Gogos, C; Kalafateli, M; Labropoulou-Karatza, C; Mandellou, M; Taprantzi, D; Thomopoulos, K; Triantos, C; Tselekouni, P; Tsiaoussis, G; Vourli, G, 2017) |
| "Although high potent nucleos(t)ide analogues are strongly recommended as first-line therapy for chronic hepatitis B (CHB) in China, some patients are still being treated with adefovir disoproxil (ADV), especially those low-income patients whose health insurance could not reimburse the drug cost." | 3.85 | Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy. ( Chen, EQ; Du, LY; Lei, BJ; Lei, XZ; Liao, J; Lu, JJ; Tang, H; Wang, ML; Yan, LB; Zhang, DM; Zhou, TY, 2017) |
| "We investigated the durability of virological response after lamivudine (LAM) discontinuation in LAM-resistant chronic hepatitis B (CHB) patients with complete virological response after LAM-adefovir (ADV) combination therapy." | 3.85 | Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy. ( Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, MN; Kim, SU; Park, JY, 2017) |
| "Tenofovir disoproxil fumarate (TDF) is recommended as first-line monotherapy for nucleos(t)ide (NA)-naïve chronic hepatitis B (CHB) patients and as a second-line rescue therapy for NA-experienced patients with a previous treatment failure." | 3.85 | Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients. ( Angarano, G; Fasano, M; Fiore, JR; Leone, A; Maggi, P; Santantonio, TA; Volpe, A, 2017) |
| "This study compared virologic response to entecavir monotherapy and de novo lamivudine plus adefovir (LAM + ADV) combination therapy in patients with chronic hepatitis B (CHB) with high viral load (HVL)." | 3.83 | Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result. ( Cai, S; Jiang, Y; Lv, F; Peng, J; Yu, T; Zhang, Y, 2016) |
| "We investigated the long-term efficacy of adefovir add-on lamivudine rescue therapy in lamivudine-resistant chronic hepatitis B and the optimal cutoff hepatitis B virus (HBV) DNA level that predicts complete virological response (CVR) among patients without CVR after 1 year of treatment." | 3.83 | Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B. ( Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, SB; Kim, SU; Park, JY, 2016) |
| "Lamivudine, telbivudine, and entecavir are the first-line drugs covered by the Taiwan National Health Insurance as 3-year treatments for patients with chronic hepatitis B virus (HBV), but the optimal treatment duration of each remains unclear." | 3.83 | Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients. ( Bair, MJ; Chang, CW; Chen, CJ; Chen, MJ; Chu, CH; Hu, KC; Lee, KH; Lin, CC; Lin, SC; Liou, TC; Liu, CY; Shih, SC; Wang, HY; Wang, TE, 2016) |
| "Lamivudine (LAM) plus adefovir (ADV) combination therapy is clinically efficacious for treating chronic hepatitis B (CHB) patients in China, but no pharmacoeconomic evaluations of this strategy are available." | 3.83 | Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients. ( Gao, Y; Ke, W; Liu, L; Yang, Y; Yao, Z; Ye, X; Zhang, C; Zhou, S, 2016) |
| "Entecavir-resistance mutations are commonly induced by entecavir treatment in chronic hepatitis B patients." | 3.83 | De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine. ( Cheng, J; Liu, S; Wang, Q; Wang, X; Xing, H; Yang, S, 2016) |
| " We aimed to establish if IP-10 expression in liver tissue and in plasma of chronic hepatitis B (CHB) patients correlated with each other and further to investigate if IP-10 levels before and during therapy with peginterferon and adefovir could predict treatment outcome in CHB patients." | 3.83 | Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir. ( de Niet, A; Jansen, L; Kootstra, NA; Reesink, HW; Sinnige, MJ; Takkenberg, RB; Verheij, J; Willemse, SB, 2016) |
| " He had been receiving low-dose adefovir dipivoxil (ADV, 10 mg/day) for the treatment of chronic hepatitis B virus infection for 7 years and he subsequently developed severe hypophosphatemia and proximal renal tubule dysfunction." | 3.83 | Pathologic Femoral Neck Fracture Due to Fanconi Syndrome Induced by Adefovir Dipivoxil Therapy for Hepatitis B. ( Dan, J; Kim, BK; Lee, HJ; Lee, YS, 2016) |
| "Tenofovir disoproxil fumarate (TDF) is newly available for treatment of chronic hepatitis B patients in China." | 3.83 | Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China. ( Gao, Y; Ke, W; Liu, L; Yang, Y; Yao, Z; Ye, X; Zhang, C; Zhou, S, 2016) |
| "Adefovir dipivoxil (ADV) is effective for hepatitis B virus (HBV) infection; however, ADV may provoke renal injury resulting in osteomalacia, and this side effect is seldom recognized until bone fractures emerge." | 3.83 | Urinary β-2 Microglobulin Levels Sensitively Altered in an Osteomalacia Patient Receiving Add-on Adefovir Dipivoxil Therapy for Hepatitis B Virus Infection. ( Hirase, S; Ito, K; Ito, T; Morishima, T; Morita, H; Ohashi, T; Otake, K; Takagi, J; Yoneda, M, 2016) |
| "Before tenofovir (TDF) become available in South Korea, combination therapy with entecavir (ETV) and adefovir (ADV) was the most potent regimen for chronic hepatitis B (CHB) patients who fail to respond to rescue therapy for drug resistance." | 3.83 | The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy. ( Ahn, SH; Choe, WH; Kim, JH; Kim, KH; Ko, SY; Kwon, SY, 2016) |
| "Entecavir (ETV) is a potent viral replication inhibitor for chronic hepatitis B (CHB) patients." | 3.83 | A five years study of antiviral effect of entecavir in Chinese chronic hepatitis B patients. ( Bao, R; Bao, S; Chen, R; Guo, Q; Liu, K; Liu, Y; Wang, H; Xiang, X; Xie, J; Xie, Q, 2016) |
| "To analyze the effects of preexisting lamivudine (LAM) resistance and applying antiviral treatment (adefovir [ADV] add-on LAM combination treatment) on long-term treatment outcomes, and comparing the clinical outcomes of antiviral-naïve chronic hepatitis B patients receiving entecavir (ETV) monotherapy." | 3.83 | Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment. ( Cho, YK; Choi, KY; Jeon, WK; Jung, YS; Kim, BI; Kim, HJ; Park, DI; Park, JH; Park, SK; Sohn, CI; Yang, HJ, 2016) |
| "The aim of this study was to evaluate serum kidney injury molecule-1 (KIM-1) as a new diagnostic marker of renal dysfunction in chronic hepatitis B (CHB) patients receiving long-term adefovir dipivoxil (ADV) treatment." | 3.83 | Circulating kidney injury molecule-1 is a novel diagnostic biomarker for renal dysfunction during long-term adefovir therapy in chronic hepatitis B. ( Li, Z; Liu, Z; Shen, C; Wang, W; Wang, Y; Zhao, C; Zhao, Q, 2016) |
| "Tenofovir disoproxil fumarate (TDF) is an established nucleotide analogue in the treatment of chronic hepatitis B." | 3.81 | Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? ( Al-Shamma, S; Barr, DA; Burke, K; Foster, GR; Gill, US; Kallis, YN; Kennedy, PT; Kooner, P; Marley, RT; McPhail, MJ; Zissimopoulos, A, 2015) |
| "Suboptimal viral suppression with adefovir (ADV) poses a challenge in managing chronic hepatitis B." | 3.81 | Safety and efficacy of entecavir in adefovir-experienced patients. ( Do, ST; Garcia, RT; Lutchman, GA; Nguyen, HA; Nguyen, KK; Nguyen, MH; Nguyen, NH; Nguyen, TT; Tran, P; Trinh, HN, 2015) |
| "The risk of hepatocellular carcinoma (HCC) in Caucasian patients with chronic hepatitis B (CHB), treated with entecavir (ETV) or tenofovir (TDF), is unclear." | 3.81 | Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. ( Arends, P; Buti, M; Colombo, M; Dalekos, GN; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HL; Keskın, O; Lampertico, P; Mangia, G; Manolakopoulos, S; Papaioannou, C; Papatheodoridis, GV; Savvidou, S; Sypsa, V; Yurdaydin, C, 2015) |
| "Increased risk of defective urinary phosphate reabsorption and osteoporosis has been reported in HIV and chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF)." | 3.81 | Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling. ( Bae, HS; Chan, LS; Chang, M; Fong, TL; Huh, B; Lee, S; Lim, C; Shinada, S; Tien, C; Xu, JJ, 2015) |
| "To investigate the association between the baseline profiles and dynamics of hepatitis B virus (HBV) DNA polymerase gene mutations and the long-term virological response of lamivudine (LAM)-adefovir (ADV) combination therapy in patients with LAM-resistant chronic hepatitis B." | 3.81 | Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B. ( Choi, K; Jang, JY; Jeong, SW; Kim, BS; Kim, HS; Kim, J; Kim, SG; Kim, YS; Lee, SH, 2015) |
| "Tenofovir disoproxil fumarate (TDF) monotherapy is a therapeutic option for chronic hepatitis B (CHB) patients infected with hepatitis B virus (HBV) variants resistant to lamivudine (LAM)." | 3.81 | Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B. ( Ahn, H; Cho, EJ; Cho, H; Cho, Y; Cho, YY; Choi, WM; Jung, EU; Kim, BH; Kim, CM; Kim, CY; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Lee, M; Lee, YB; Lee, YJ; Park, JW; Park, SJ; Yoo, JJ; Yoon, JH; Yu, SJ, 2015) |
| "Chronic hepatitis B pregnant women with normal levels of ALT and high levels of HBV DNA were treated with Telbivudine during the third trimester of their pregnancy." | 3.81 | Effect of Peg-interferon α-2a combined with Adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA. ( Chen, X; Chen, Y; Du, X; Liu, Y; Lu, J; Ma, L; Ren, S; Shen, C; Zhang, H; Zhang, S, 2015) |
| "Entecavir (ETV) plus adefovir (ADV) combination therapy is one of the useful treatment option for the patients with chronic hepatitis B (CHB) who had failed on prior nucleos(t) ide analogue (NA) treatments." | 3.81 | Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments. ( Cho, Y; Kim, YJ; Lee, HS; Lee, JH; Yoon, JH; Yu, SJ, 2015) |
| "To investigate the predictors of proximal kidney tubular dysfunction (PKTD) induced by adefovir dipivoxil (ADV) treatment for chronic hepatitis B." | 3.81 | Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B. ( Furusyo, N; Harada, Y; Hayashi, J; Hayashi, T; Ihara, T; Ikezaki, H; Murata, M; Ogawa, E; Shimizu, M; Toyoda, K, 2015) |
| " These pregnant females developed lamivudine (LAM)- or telbivudine (LdT)-resistant chronic hepatitis B and received tenofovir (TDF) therapy (300 mg/d), and its curative effect, maternal and perinatal adverse events, fetal growth and development, and neonatal prognosis were evaluated." | 3.81 | Tenofovir rescue therapy in pregnant females with chronic hepatitis B. ( Cai, HD; Cao, YJ; Hu, YH; Liu, M; Yi, W, 2015) |
| "Patients with chronic hepatitis B (HBV DNA load, >17 000 IU/mL) were treated with pegylated interferon alfa-2a and adefovir for 48 weeks." | 3.81 | Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir. ( de Niet, A; Jansen, L; Kootstra, NA; Reesink, HW; Stelma, F; Takkenberg, RB; Tempelmans Plat-Sinnige, MJ; van Leeuwen, EM, 2015) |
| "Tenofovir disoproxil fumarate has been used in chronic hepatitis B patients with suboptimal virologic response to nucleos(t)ide analogues." | 3.81 | Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B. ( Chan, HL; Chan, HY; Lo, AO; Tse, YK; Wong, GL; Wong, VW, 2015) |
| "To evaluate urine β2-microglobulin (β2-M), retinol-binding protein (RBP) excretion, and renal impairment with adefovir dipivoxil (ADV) for chronic hepatitis B." | 3.81 | Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B. ( Cai, H; Chen, JY; Ding, F; Hu, JH; Jia, HY; Li, LJ; Lian, JS; Lu, YF; Xiang, DR; Yang, YD; Yu, GD; Yu, L; Zeng, LY; Zhang, YM; Zheng, L, 2015) |
| "We evaluated the efficacy of tenofovir (TDF)-based rescue therapy and compared the outcomes of TDF monotherapy and TDF-based nucleoside analog (NA) combination therapy in patients with suboptimal response (SOR) to adefovir (ADV) with or without NAs in lamivudine (LAM)-resistant chronic hepatitis B." | 3.81 | Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance. ( Cheong, JY; Cho, HJ; Cho, SW; Kim, SS; Shin, SJ; Yoo, BM, 2015) |
| "In chronic hepatitis B patients, lamivudine (LAM) and adefovir (ADV) combination therapy is commonly used as a rescue therapy for LAM resistance, but it often results in incomplete viral suppression." | 3.81 | Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination. ( Bang, SJ; Jeong, ID; Jung, SW; Kim, BG; Kim, CJ; Kim, MH; Lee, BU; Park, BR; Park, JH; Park, NH; Shin, JW, 2015) |
| "In the past decade, many chronic hepatitis B (CHB) patients have undergone sequential treatment with lamivudine (LAM), adefovir (ADV), and entecavir (ETV) to manage antiviral resistance or insufficient suppression of HBV-DNA." | 3.81 | Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir. ( Bang, SJ; Jeong, ID; Jung, SW; Kim, BG; Kim, CJ; Kim, EH; Kim, JH; Kim, MH; Lee, BU; Park, BR; Park, JH; Park, NH; Shin, JW; Sung, SJ, 2015) |
| "To compare the efficacy of telbivudine monotherapy and telbivudine combination therapy with adefovir in patients with nucleos(t)ide-naive chronic hepatitis B, high-level hepatitis B virus (HBV) load and hepatitis B e antigen (HBeAg)-positivity, and to explore the relationship between treatment regimen adherence and treatment outcomes." | 3.81 | [Efficacy and safety of telbivudine alone and combined with adefovir for the treatment of nucleos(t)ide-naive chronic hepatitis B in patients with high-level hepatitis B virus load]. ( Dang, B; Kang, W; Liu, Q; Sun, Y; Wang, C; Yao, N; Yu, Z; Zhao, K, 2015) |
| "To investigate the effects of adefovir dipivoxil (ADV) on blood phosphorus metabolism in patients with chronic hepatitis B (CHB)." | 3.81 | [Adefovir dipivoxil effects on and related factors of blood phosphorus metabolism in patients with chronic hepatitis B]. ( Ding, G; Kang, Y; Li, K; Li, W; Mao, Z; Ning, H; Shang, J; Xiao, E, 2015) |
| "To evaluate the long-term efficacy adefovir (ADV)-based combination therapies in entecavir (ETV)-resistant chronic hepatitis B (CHB) patients." | 3.81 | Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies. ( Hwang, SG; Jang, MK; Jeong, SH; Jung, YK; Kim, BH; Kim, HS; Kim, IH; Kim, JH; Kim, JW; Kim, SG; Kim, TY; Kim, YS; Lee, JI; Lee, JW; Lee, SH; Park, H; Park, JW; Park, SJ; Seo, YS; Suh, SJ; Yim, HJ, 2015) |
| "We compared the efficacies of entecavir (ETV) plus tenofovir (TDF) and ETV plus adefovir (ADV) in chronic hepatitis B (CHB) patients with genotypic resistance to lamivudine (LAM) who showed a suboptimal response to LAM and ADV combination therapy." | 3.81 | Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy. ( Park, JG; Park, SY, 2015) |
| "To observe the clinical efficacy of combination therapy with peg-IFNalpha and adefovir (CPIA) in women who were hepatfis B virus (HBV) carriers and had just given birth and received telbivudine (LdT) during pregnancy for prevention of mother-to-child transmission." | 3.81 | [Efficacy of combination antiviral therapy following childbirth in pregnant HBV carriers receiving telbivudine for prevention of mother-to-child transmission]. ( Cao, ZH; Chen, XY; He, ZM; Jin, Y; Liu, YL; Lu, JF; Ma, LN; Zhang, SB, 2015) |
| "Renal dysfunction and Fanconi's syndrome associated with hypophosphatemia caused by long-term administration of low-dose adefovir dipivoxil (ADV) has been reported in recent years." | 3.80 | Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. ( Akuta, N; Arase, Y; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y; Tanaka, M, 2014) |
| "Few studies have investigated the emergence of multidrug resistance to adefovir dipivoxil (ADV) plus lamivudine (LAM) combination therapy for patients with LAM-refractory chronic hepatitis B (CHB)." | 3.80 | Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine. ( Akuta, N; Arase, Y; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Mineta, R; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Watahiki, S, 2014) |
| "We investigated the long-term efficacy of entecavir (ETV) + adefovir (ADV) combination therapy versus ETV monotherapy in lamivudine (LAM)-resistant chronic hepatitis B (CHB) patients who failed to respond to ADV rescue therapy." | 3.80 | Long-term efficacy of entecavir plus adefovir combination therapy versus entecavir monotherapy in adefovir refractory chronic hepatitis B patients with prior lamivudine resistance. ( Kim, DG; Kim, IH; Kim, SH; Kim, SW; Lee, S; Lee, SO; Lee, ST; Seo, SY; Sohn, JY, 2014) |
| "Previous studies have demonstrated that the treatment of chronic hepatitis B (CHB) infection with adefovir (ADV) can impair renal function." | 3.80 | Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy. ( Kim, HY; Kim, YJ; Lee, HJ; Lee, HS; Lee, JH; Lee, M; Oh, S; Yeum, TS; Yoon, JH; Yu, SJ, 2014) |
| "Entecavir (ETV) plus adefovir (ADV) combination therapy may be a promising option for chronic hepatitis B (CHB) patients who have failed on prior nucleos(t)ide analog (NA) treatment." | 3.80 | Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment. ( Wang, X; Wang, Y; Xiong, Y; Zhang, C; Zhu, Y, 2014) |
| "Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are the two first-line anti-viral therapies for chronic hepatitis B (CHB); however, there are limited studies directly comparing their effectiveness." | 3.80 | Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. ( Gao, L; Li, J; Nguyen, MH; Trinh, HN, 2014) |
| "We investigated the efficacy and safety of tenofovir disoproxil fumarate (TDF)-based treatment in chronic hepatitis B (CHB) patients who failed previous antiviral therapies." | 3.80 | Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure. ( Byun, KS; Choe, WH; Kim, JH; Kim, YS; Kwon, SY; Lee, CH; Lee, CI; Yeon, JE; Yoon, EL, 2014) |
| "Tenofovir (TDF) has similar antiviral efficacy in both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patients." | 3.80 | Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B. ( Akyüz, F; Badur, S; Baran, B; Bozdayi, AM; Idilman, R; Kabaçam, G; Karatayli, E; Karatayli, S; Kaymakoglu, S; Keskin, O; Onel, D; Ormeci, AC; Tüzün, A; Yurdaydin, C, 2014) |
| " The first choice of therapy in chronic hepatitis B infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy." | 3.80 | [Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline]. ( Gervain, J; Horváth, G; Hunyady, B; Lengyel, G; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I, 2014) |
| "Only lamivudine has been included for patients with chronic hepatitis B (CHB) in the National List of Essential Drugs (NLED), a pharmaceutical reimbursement list in Thailand." | 3.80 | A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand. ( Chaikledkaew, U; Tantai, N; Tanwandee, T; Teerawattananon, Y; Werayingyong, P, 2014) |
| "The role of quantitative hepatitis B surface antigen (HBsAg) levels in patients receiving highly potent oral antiviral therapy is controversial, and here, we determined the HBsAg response in 121 chronic hepatitis B patients treated with tenofovir 300 mg daily." | 3.80 | Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment. ( Gupta, E; Hissar, SS; Sarin, SK; Sharma, MK; Singh, AK, 2014) |
| "The aim of the present study was to assess the long-term impact of entecavir (ETV) on T, B and natural killer (NK) cell immunity in patients with suboptimal responses to adefovir (SRA) chronic hepatitis B (CHB)." | 3.80 | Effects of entecavir on peripheral blood lymphocyte profiles in chronic hepatitis B patients with suboptimal responses to adefovir. ( Hu, X; Jiang, Y; Wang, Q; Zhang, L; Zhao, P, 2014) |
| "In chronic hepatitis B patients treated with peginterferon and adefovir, we identified strong associations of SLC16A9 gene variation and carnitine levels with HBsAg loss." | 3.80 | HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels. ( Chin, DJ; de Niet, A; Jansen, L; Kootstra, NA; Lopatin, U; Plat-Sinnige, MJ; Reesink, HW; Stelma, F; Takkenberg, RB; van Dort, KA; van Iperen, EP; Zwinderman, AH, 2014) |
| "Tenofovir disoproxil fumarate (TDF) is recommended as treatment for chronic hepatitis B patients harboring lamivudine-associated resistance mutations (LAM-R, rtM204V/I ± rtL180M)." | 3.80 | Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF. ( Dinh, P; Flaherty, JF; Fung, S; Gane, EJ; Kitrinos, KM; Liu, Y; Miller, MD; Svarovskaia, ES, 2014) |
| " Fifteen HBeAg-positive chronic hepatitis B (CHB) patients were treated with adefovir dipivoxil." | 3.80 | Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBeAg loss. ( Chen, J; Chen, LH; Dong, J; Gao, LY; Jiang, JJ; Liu, YR; You, J; Zeng, DW; Zheng, Q; Zhu, YY, 2014) |
| "Knowledge on Hepatitis B surface antigen (HBsAg) kinetics in chronic hepatitis B (CHB) patients with long-term adefovir dipivoxil (ADV) treatment is limited." | 3.80 | Kinetics of serum HBsAg in Chinese patients with chronic HBV infection with long-term adefovir dipivoxil treatment. ( Hou, F; Huo, N; Li, F; Li, M; Wang, Q; Xi, H; Xu, X; Zhang, X, 2014) |
| "Since the licensing of lamivudine in 1999, the treatment of chronic hepatitis B has been revolutionized by the introduction of oral nucleoside and nucleotide analogues (NAs), which act as inhibitors of the HBV polymerase." | 3.80 | Antiviral therapy of chronic hepatitis B. ( Berg, T; van Bömmel, F, 2014) |
| "A 64-year-old woman was prescribed lamivudine and adefovir (ADV) for chronic hepatitis B." | 3.80 | [A case of chronic hepatitis B managed with continued adefovir despite treatment-related Fanconi syndrome and osteomalacia]. ( Asahina, Y; Iizuka, K; Iizuka, Y; Ito, E; Kobayashi, K; Mochizuki, N; Sakai, H; Watanabe, M, 2014) |
| "In chronic hepatitis B patients with kidney transplantation, sequential monotherapy with antiviral agents with low barriers to resistance should be avoided, and initial therapy with entecavir is a better option." | 3.80 | Efficacy and safety of tenofovir in a kidney transplant patient with chronic hepatitis B and nucleos(t)ide multidrug resistance: a case report. ( Shan, C; Wu, P; Yin, GQ, 2014) |
| "To evaluate the efficacy and safety of tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (CHB) after failure of nucleoside-analogues (NAs)." | 3.80 | [Efficacy of 48-week tenofovir disoproxil fumarate therapy in patients who were unresponsive to nucleoside-analogue treatments]. ( Ao, Y; Chong, Y; Huang, M; Jie, Y; Li, X; Lin, G; Pang, Y; Shi, H; Tao, L; Wu, Y; Yang, F; Zhang, M, 2014) |
| "To investigate the treatment efficacy of adefovir dipivoxil combined with a corticosteroid on hepatitis B virus-associated glomerulonephritis (HBV-GN)." | 3.80 | Efficacy of adefovir dipivoxil combined with a corticosteroid in 38 cases of nephrotic syndrome induced by hepatitis B virus-associated glomerulonephritis. ( Li, H; Qiu, L; Xiao, P; Yuan, X; Zhou, Q, 2014) |
| "This study investigated the antiviral efficacy of adefovir (ADV) rescue therapy and the feasibility of lamivudine (LAM) discontinuation in LAM-resistant chronic hepatitis B (CH-B) patients who had attained a virological response (VR) with LAM + ADV combination therapy." | 3.80 | The feasibility of discontinuing lamivudine in lamivudine-resistant chronic hepatitis B patients on lamivudine and adefovir combination therapy. ( Byoun, YS; Chung, SM; Jang, ES; Jeong, SH; Kim, HS; Kim, JW, 2014) |
| "Adefovir (ADV) resistance is more frequent in lamivudine (LMV)-resistant chronic hepatitis B (CHB) patients than in nucleos(t)ide analogue-naïve patients." | 3.80 | Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B. ( Cho, YK; Cui, XJ; Jeong, SU; Song, BC, 2014) |
| "This study assessed the antiviral efficacy and safety of tenofovir disoproxil fumarate (TDF) for up to 12 months in Korean treatment-naïve chronic hepatitis B (CHB) patients." | 3.80 | Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. ( Ahn, SH; Ahn, SS; Chon, YE; Han, KH; Kim, BK; Kim, DY; Kim, SU; Park, JY, 2014) |
| "Adefovir (ADV) and lamivudine (LAM) combination therapy (ADV+LAM) has been a useful option for patients with LAM-resistant (LAM-r) chronic hepatitis B (CHB)." | 3.80 | Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir. ( Ahn, DG; Baek, EK; Cho, HJ; Chung, HW; Kim, HJ; Kwon, JC; Lee, H; Lee, JJ; Ze, E, 2014) |
| " Here, we describe two additional patients with chronic hepatitis B (CHB) who developed a TDF-induced Fanconi syndrome that reverted after TDF withdrawal and had viral replication fully suppressed upon switching to entecavir (ETV)." | 3.80 | Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal. ( Brocchieri, A; Castelli, F; Colombo, M; Facchetti, F; Fugazza, A; Lampertico, P; Mangia, G; Spinetti, A; Viganò, M; Zaltron, S, 2014) |
| "Tenofovir (300 mg/d) is an effective and safe rescue therapy in chronic hepatitis B patients who failed initial treatment with LAM and secondary treatment of LAM plus ADV." | 3.80 | [Tenofovir rescue therapy for chronic hepatitis B patients after suboptimal response to treatment with lamivudine plus adefovir dipivoxil]. ( Fan, H; Fan, Y; Ge, Y; Li, D; Liu, X; Liu, Z; Lyu, W; Yang, H; Zhou, B, 2014) |
| "There is very limited experience in the management of telbivudine (LdT)-associated virological breakthrough (VBT) and resistance in the treatment of chronic hepatitis B (CHB) patients, and the guideline recommendations are primitively based on the general principles of rescue therapy to nucleos(t)ide analog resistance." | 3.79 | Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine. ( Bai, XF; Huang, CX; Li, Y; Lian, JQ; Wang, JP; Zhang, Y, 2013) |
| "Chronic hepatitis B patients (CHB) treated with adefovir were followed up to evaluate nephrotoxicity and its outcome." | 3.79 | Resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B. ( Aung, MO; Chiu, LL; Dan, YY; Gowans, M; Hartono, JL; Khoo, MJ; Koay, E; Lee, GH; Lee, YM; Lim, K; Lim, SG; Low, HC; Soon, C; Tan, PS; Thwin, MA, 2013) |
| "A 55-year-old male patient with chronic hepatitis B was started on tenofovir." | 3.79 | Geographic tongue and tenofovir. ( Costa, JB; Ferreira, AO; Marinho, RT; Velosa, J, 2013) |
| "In patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB) receiving adefovir (ADV) add-on LAM therapy, insufficient viral suppression or the appearance of additional ADV resistance has remained unresolved." | 3.79 | Partial virological response to adefovir add-on lamivudine rescue therapy in patients with lamivudine-resistant chronic hepatitis B. ( Ahn, SH; Choi, A; Chon, CY; Chon, YE; Han, KH; Kim, DY; Kim, SU; Park, JY, 2013) |
| "To evaluate the efficacy and safety of Entecavir (ETV) plus adefovir (ADV) for chronic hepatitis B (CHB) patients after multiple nucleos(t)ide analogue (NAs) failure treatment." | 3.79 | Entecavir plus adefovir rescue therapy for chronic hepatitis B patients after multiple treatment failures in real-life practice. ( Deng, JY; He, FQ; Li, GL; Li, JY; Li, Q; Pan, QR; Qin, Y; Xu, XH, 2013) |
| "Tenofovir disoproxil fumarate (TDF) is increasingly used in patients with chronic hepatitis B (CHB) infection." | 3.79 | Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection. ( Gracey, DM; McKenzie, P; Snelling, P; Strasser, SI, 2013) |
| " A total of 71 subjects under follow-up for chronic hepatitis B and receiving lamivudine (LVD) therapy for one year or longer at the Hacettepe University Faculty of Medicine, Department of Internal Medicine, Gastroenterology Unit were included in the study with informed consent." | 3.79 | [Detection of resistance mutations in chronic hepatitis B patients receiving antiviral therapy for over one year]. ( Alp, A; Aydoğan, S; Balaban, Y; Ergünay, K; Hasçelik, G; Simşek, H; Tatar, G; Us, D, 2013) |
| "The aim of this study was to compare the effect of combination lamivudine (LAM) and adefovir dipivoxil (ADV) versus entecavir (ETV) monotherapy for naïve HBeAg-positive chronic hepatitis B (CHB) patients." | 3.79 | Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: a pilot study. ( Cai, FJ; Ding, JG; Du, QW; Fu, RQ; Hong, L; Sun, QF; Wu, YH; Zhou, QQ, 2013) |
| "The aim of our study was to validate the roadmap concept in the treatment of chronic hepatitis B, and to investigate the virologic efficacy and kinetics of quantitative hepatitis B surface antigen (qHBsAg) during telbivudine therapy in a real-world setting." | 3.79 | Real-world application of the roadmap model in chronic hepatitis B patients with telbivudine therapy. ( Hsu, PI; Lai, KH; Lin, KH; Tsai, TJ; Tsay, FW; Wang, HM; Yu, HC, 2013) |
| "Patients with chronic hepatitis B treated with tenofovir or entecavir were included in this retrospective study." | 3.79 | Comparison of tenofovir and entecavir in patients with chronic HBV infection. ( Akkoyunlu, Y; Ceylan, B; Eren, G; Fincanci, M; Muderrisoglu, C; Tozalgan, U; Yardimci, C, 2013) |
| "Treatment strategies for entecavir (ETV)-resistant chronic hepatitis B (CHB) patients are not yet well established." | 3.79 | Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection. ( Cho, Y; Cho, YY; Choi, WM; Kim, CY; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Lee, M; Lee, YB; Yoo, JJ; Yoon, JH; Yu, SJ, 2013) |
| "Lamivudine (LAM) plus adefovir (ADV) combination therapy has been accepted as one of the best treatments for LAM-resistant chronic hepatitis B (CHB)." | 3.79 | Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients. ( Choe, WH; Kim, JH; Ko, SY; Kwon, SY; Lee, CH, 2013) |
| "In the current study we aimed to show the common YMDD motif mutations in viral polymerase gene in chronic hepatitis B patients during lamivudine and adefovir therapy." | 3.79 | Prevelance of common YMDD motif mutations in long term treated chronic HBV infections in a Turkish population. ( Alagozlu, H; Coskun, M; Koksal, B; Ozdemir, O; Yilmaz, A, 2013) |
| " Adefovir, entecavir, tenofovir and lamivudine (with rescue therapy in cases of viral resistance) were compared for treating adult patients with chronic hepatitis B undergoing treatment for the first time, with high levels of alanine aminotransferase, no evidence of cirrhosis and without HIV co-infection." | 3.79 | Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis. ( Acurcio, Fde A; Almeida, AM; Andrade, EI; Brandão, CM; Cherchiglia, ML; Oliveira, GL; Silva, AL, 2013) |
| "To investigate the efficacy and safety ofTelbivudine +Tenofovir combination therapy in chronic hepatitis B patients, over a period of 52 weeks, in real life clinical settings." | 3.79 | Telbivudine plus tenofovir in combination therapy in patients with chronic hepatitis B infection--an Indian experience. ( Panda, C, 2013) |
| " We investigated the long-term safety and efficacy of these antiviral drugs in patients with chronic hepatitis B virus (HBV) infection, with compensated or decompensated cirrhosis, and compared results with those from lamivudine." | 3.79 | Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. ( Akbal, E; Akin, E; Alkan, E; Ataseven, H; Aygün, C; Başar, O; Baykal, O; Coban, S; Demir, M; Gülşen, MT; Ibiş, M; Koçkar, MC; Köklü, S; Köksal, AŞ; Küçükazman, M; Nadir, I; Ozdil, K; Pürnak, T; Tuna, Y; Yildirim, B; Yüksel, I; Yüksel, O, 2013) |
| "The efficacy of adefovir (ADV) plus entecavir (ETV) combination in patients with chronic hepatitis B (CHB) who developed multidrug refractoriness had not been fully evaluated." | 3.79 | The efficacy of adefovir plus entecavir combination therapy in patients with chronic hepatitis B refractory to both lamivudine and adefovir. ( Cho, EJ; Cho, Y; Chung, KH; Jeong, SH; Jin, E; Kim, CY; Kim, JW; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Yoon, JH; Yu, SJ, 2013) |
| "Fifty-three patients with confirmed genotypic lamivudine-resistant chronic hepatitis B were treated with entecavir." | 3.79 | The short-term efficacy of entecavir in lamivudine-resistant chronic hepatitis B: influence of sequential adefovir-refractoriness. ( Choi, DJ; Jung, YK; Kim, JH; Kim, YS; Ku, YS; Kwon, OS, 2013) |
| "To compare the efficacy of rescue therapies in lamivudine (LAM)-resistant chronic hepatitis B (CHB) infections including: (1) adefovir dipivoxil (ADV) monotherapy, (2) ADV plus LAM combination therapy and (3) entecavir (ETV) 1." | 3.79 | Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study. ( Ahn, SH; Hong, SP; Hwang, SG; Kim, BH; Kim, HS; Kim, IH; Kim, JH; Lee, JI; Lee, JM; Lee, JW; Lee, SH; Lee, SJ; Park, SJ; Park, YM; Seo, YS; Yim, HJ; Yoon, EL, 2013) |
| "We studied the cost-effectiveness of tenofovir and entecavir in e antigen positive (CHBe+) and negative (CHBe-) chronic hepatitis B." | 3.79 | Should chronic hepatitis B be treated as early as possible? ( Colle, I; Gamil, M; Horsmans, Y; Hulstaert, F; Nevens, F; Schwierz, C; Thiry, N; Van de Sande, S, 2013) |
| "We evaluated the efficacy of tenofovir disoproxil fumarate (TDF) in patients with lamivudine failure (LAM-F) in comparison with that in nucleoside/nucleotide analogue (NA)-naïve patients with chronic hepatitis B (CHB)." | 3.79 | Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B. ( Akyuz, F; Badur, S; Baran, B; Besisik, F; Bozbey, HU; Demir, K; Evirgen, S; Gokturk, S; Gulluoglu, M; Karaca, C; Kaymakoglu, S; Onel, D; Ormeci, AC; Soyer, OM, 2013) |
| "The availability of entecavir is economically attractive as part of early treatment for patients with chronic hepatitis B without HIV co-infection." | 3.78 | [Cost-effectiveness of nucleoside/nucleotide analogues in chronic hepatitis B]. ( Acurcio, Fde A; Almeida, AM; Andrade, EI; Araújo de Oliveira, GL; Brandão, CM; Carmo, RA; Cherchiglia, ML; Silva, AL, 2012) |
| "To understand the genotype characteristics and its evolution of patients with poor response to initial combined treatment of Lamivudine and Adefovir dipivoxil for chronic hepatitis B." | 3.78 | [Genotypes and evolution characteristics of three patients with poor response to initial treatment of Lamivudine and Adefovir dipivoxil for hepatitis]. ( Huang, XX; Lou, GQ; Shi, JP; Wang, J; Wu, J; Zhu, MF, 2012) |
| "We intended to investigate the effects of pre-existing mutations at reverse transcriptase region of hepatitis B virus (HBV) on the occurrence of virological breakthrough (VB) to adefovir dipivoxil (ADV) in patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB)." | 3.78 | rtL180M mutation of hepatitis B virus is closely associated with frequent virological resistance to adefovir dipivoxil therapy. ( Chung, YH; Jin, YJ; Kim, JA; Kim, KM; Kim, SE; Lee, D; Lee, HC; Lee, YS; Lim, YS; Park, WH; Shim, JH; Suh, DJ, 2012) |
| "Before tenofovir approval for chronic hepatitis B therapy, the clinical management of patients with suboptimal response or virological breakthrough during combination treatment with lamivudine and adefovir dipivoxil was a difficult clinical challenge." | 3.78 | High dose lamivudine in HBV-related cirrhotic patients with unsatisfactory response after adefovir add-on. ( Aldini, R; Azzaroli, F; Buonfiglioli, F; Galli, S; Giandinoto, M; Lisotti, A; Mazzella, G; Montagnani, M; Turco, L, 2012) |
| "The impact of adefovir dipivoxil (ADV) treatment on the immune system in patients with chronic hepatitis B (CHB) is unknown." | 3.78 | Adefovir dipivoxil modulates cytokine expression in Th1/Th2 cells in patients with chronic hepatitis B. ( Liu, YY; Ma, ZH; Niu, JQ; Piao, RL; Tian, D; Zhang, M; Zhao, C, 2012) |
| "A male 36 years old patient diagnosed with anti HBe-positive chronic hepatitis B (CHB) had received lamivudine treatment for 7 years following an initial unsuccessfull interferon treatment." | 3.78 | Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection. ( Bozdayi, AM; Cinar, K; Gokahmetoglu, S; Güven, K; Idilman, R; Karatayli, E; Karatayli, SC; Yurdaydin, C, 2012) |
| "Adefovir is usually applied for therapy of chronic hepatitis B (CHB), but its effectiveness after cessation is still unknown." | 3.78 | A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir. ( Diao, S; Ha, M; Huang, C; Huang, Z; Kuan, C; Lin, M; She, H; Shen, L; Shen, W; Sun, L; Zhang, G, 2012) |
| "The optimal treatment of patients with chronic hepatitis B (CHB) who develop resistance to both lamivudine (LMV) and entecavir (ETV) after sequential monotherapy of LMV and ETV remains little known." | 3.78 | Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B. ( Cha, JM; Jeon, JW; Joo, KR; Kim, S; Lee, JI; Lim, JU; Lim, K; Park, JJ; Shin, HP, 2012) |
| "A total of 559 chronic hepatitis B (CHB) patients who had been treated for at least 12 months with adefovir add-on therapy due to resistance to lamivudine were retrospectively included." | 3.78 | Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance. ( Choi, MS; Gwak, GY; Kim, YJ; Koh, KC; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC, 2012) |
| "We investigated serum viral kinetics and peripheral blood lymphocyte dynamics in chronic hepatitis B patients during the first year of tenofovir therapy." | 3.78 | Peripheral blood lymphocyte dynamics and viral kinetics in patients with chronic active hepatitis B virus infection treated by tenofovir. ( Arasli, M; Buyukuysal, C; Delikanli, B; Harmandar, F; Ustundag, Y, 2012) |
| "The combination of entecavir, a nucleoside analogue, and adefovir, a nucleotide analogue, would be a promising salvage treatment for chronic hepatitis B (CHB) patients who fail nucleoside/nucleotide analogue (NA) regimens." | 3.78 | Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues. ( Heo, NY; Lee, HC; Lee, TH; Lim, YS; Shim, JH; Suh, DJ, 2012) |
| "Among 141 HIV-HBV-coinfected patients treated with tenofovir in our centre, 87% were good-responders to therapy." | 3.78 | Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir. ( Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Lada, O; Leclerc, L; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B, 2012) |
| "The aim of this study was to investigate the relationship between HBV DNA levels at baseline and on-treatment and the virological response at 96 weeks after adefovir add-on therapy in chronic hepatitis B (CHB) patients with lamivudine resistance." | 3.78 | HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine resistance. ( Bang, SJ; Du Jeong, I; Eum, JB; Jung, SW; Kim, BG; Kim, CJ; Park, BR; Park, NH; Shin, JW, 2012) |
| " entecavir (ETV) monotherapy in HBeAg-positive hepatitis B patients who fail to respond to sequential treatment with LAM and ADV." | 3.78 | Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir. ( Ahn, SH; Chon, CY; Han, KH; Kim, DY; Lee, JM; Lee, MH; Park, JY; Ryu, HJ; Son, CY, 2012) |
| "Adefovir and tenofovir are nucleotide analogues used as long-term therapy of chronic hepatitis B." | 3.78 | Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. ( Chong, WH; Collins, MT; Gara, N; Ghany, MG; Hoofnagle, JH; Jake Liang, T; Kleiner, DE; Zhao, X, 2012) |
| "Tenofovir is a nucleotide reverse-transcriptase inhibitor approved for treatment of human immunodeficiency virus infection, as well as chronic hepatitis B (CHB)." | 3.78 | Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. ( Baqai, S; Clark, MD; Gish, RG; Kane, SD; Mangahas, MF; Shaw, RE, 2012) |
| "To evaluate the changes in the renal function of patients with chronic hepatitis B (CHB) receiving adefovir dipivoxil (ADV) or telbivudine (L-DT) monotherapy." | 3.78 | [Influence of adefovir dipivoxil or telbivudine monotherapy on renal function of patients with chronic hepatitis B]. ( Fan, R; Guo, Y; Hou, J; Li, X; Peng, J; Sun, J; Yang, S; Zhong, C, 2012) |
| "In the first year of treatment for chronic hepatitis B, virologic response and tolerability did not differ significantly between tenofovir and entecavir." | 3.78 | Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B. ( Akin, MS; Doğan, ÜB; Gümürdülü, Y; Kara, B; Soylu, A, 2012) |
| "We present a case of a 62-year-old man who underwent total hip arthroplasty for treatment of pathologic femoral neck fracture associated with adefovir dipivoxil-induced osteomalacia." | 3.78 | Pathological femoral fractures due to osteomalacia associated with adefovir dipivoxil treatment for hepatitis B: a case report. ( Arishima, Y; Hirotsu, M; Ishidou, Y; Kakoi, H; Kamizono, J; Komiya, S; Nagano, S; Nakamura, S; Saitoh, Y; Setoguchi, T; Tanaka, M; Yokouchi, M, 2012) |
| "There is a paucity of data on the long-term efficacy of combination lamivudine and adefovir therapy in patients with lamivudine-resistant chronic hepatitis B." | 3.78 | Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir. ( Fung, J; Hung, IF; Lai, CL; Liu, K; Seto, WK; Wong, DK; Yuen, JC; Yuen, MF, 2012) |
| "Lamivudine (LAM) resistance now poses a major problem in the management of patients with chronic hepatitis B virus (HBV) infection." | 3.78 | Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B. ( Huang, L; Li, T; Wang, C; Xu, D; Zhao, P, 2012) |
| "The patient cohort included four adult chronic hepatitis B patients who had undergone sequential monotherapy, first with lamivudine (LMV) and then, after developing viral breakthrough, with adefovir (ADV) therapy." | 3.78 | Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment. ( Choe, WH; Kim, BK; Kim, JH; Kim, KH; Ko, SY; Kwon, SY; Lee, CH, 2012) |
| " To evaluate the resistance to adefovir (ADV) therapy in patients with chronic hepatitis B infection, a study was conducted on 70 patients (63 males and 7 females), who had received in first line lamivudine and second line adefovir." | 3.78 | Use of ALLGIO probe assays for detection of HBV resistance to adefovir in patients with chronic hepatitis B, Kerman, Iran. ( Afshar, RM; Mollaie, HR, 2012) |
| "To investigate retrospectively the long-term efficacy of various treatment strategies using adefovir dipivoxil (adefovir) in patients with lamivudine-resistant chronic hepatitis B." | 3.78 | Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B. ( An, H; Chun, HJ; Jeen, YT; Jung, JY; Keum, B; Kim, CD; Kim, CH; Kim, JD; Kim, YS; Lee, HS; Ryu, HS; Seo, YS; Um, SH; Yim, HJ; Yun, TJ, 2012) |
| "To investigate the efficacy of long-term lamivudine (3TC) and adefovir dipivoxil (ADV) combination therapy in 3TC-resistant chronic hepatitis B virus (HBV) infected patients, we analysed 28 3TC-resistant patients treated with the combination therapy during 47 months (range, 9-75)." | 3.77 | Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern. ( Fukushima, K; Inoue, J; Iwasaki, T; Kakazu, E; Kondo, Y; Niitsuma, H; Obara, N; Shiina, M; Shimosegawa, T; Tamai, K; Ueno, Y; Wakui, Y; Yamagiwa, Y, 2011) |
| "Although adefovir dipivoxil (ADV) has been used for antiviral treatment of lamivudine (LAM)-resistant chronic hepatitis B (CHB) patients, the long-term efficacy of this treatment is not well understood." | 3.77 | Initial virological response and viral mutation with adefovir dipivoxil added to ongoing Lamivudine therapy in Lamivudine-resistant chronic hepatitis B. ( Arai, M; Fukai, K; Imazeki, F; Kanda, T; Wu, S; Yokosuka, O; Yonemitsu, Y, 2011) |
| "Tenofovir disoproxil fumarate (TDF), a nucleotide analogue and potent inhibitor of hepatitis B virus (HBV) polymerase, showed superior efficacy to adefovir dipivoxil in treatment of chronic hepatitis B through 48 weeks." | 3.77 | Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. ( Anderson, J; Borroto-Esoda, K; Buggisch, P; Buti, M; De Man, RA; Flisiak, R; Gane, E; Germanidis, G; Gurel, S; Heathcote, EJ; Kaita, K; Kotzev, I; Krastev, Z; Kurdas, OO; Lee, SS; Manns, M; Marcellin, P; Mondou, E; Rousseau, F; Shiffman, ML; Snow-Lampart, A; Sorbel, J; Tchernev, K; Trinh, H; Weilert, F, 2011) |
| "The study evaluated whether a liquid suspension of adefovir dipivoxil (ADV) is effective and safe when dose adjusted based on varying degrees of renal impairment in patients with chronic hepatitis B." | 3.77 | Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment. ( Frederick, D; Pol, S; Rostaing, L; Rousseau, F; Schiff, E; Shiffman, ML; Thabut, D; Zeuzem, S; Zong, J, 2011) |
| "We investigated the 4-year incidence and predictors of adefovir resistance in chronic hepatitis B patients with or without lamivudine (LAM)-resistance treated with adefovir dipivoxil with or without short-term LAM overlapping." | 3.77 | Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience. ( Chang, MH; Changchien, CS; Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JH, 2011) |
| "The aim of this study was to determine the optimal time and HBV DNA levels during the treatment period for prediction of virological breakthrough (VBT) 3 years after adefovir monotherapy in chronic hepatitis B (CHB) patients with lamivudine resistance." | 3.77 | The level of HBV DNA at month 12 is an important predictor of virological breakthrough during adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance. ( Jung, SW; Kim, MC; Park, NH; Shin, JW, 2011) |
| " We analyzed the frequency and effect of Tregs on cellular immune responses against HBV in 35 chronic hepatitis B eAg-ve and eAg+ve patients treated with tenofovir 300 mg/day." | 3.77 | Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate. ( Hissar, SS; Khanam, A; Kotillil, S; Mishra, SK; Sarin, SK; Shrivastava, S; Sukriti, S; TrehanPati, N, 2011) |
| "Amino acid (AA) changes in specific hepatitis B core antigen (HBcAg) regions were assessed in patients infected with chronic hepatitis B (CHB) after a 12-month untreated period and after receiving antiviral therapy (interferon, lamivudine or adefovir dipivoxil), and in inactive hepatitis B surface antigen-positive carriers." | 3.77 | HBV core region variability: effect of antiviral treatments on main epitopic regions. ( Buti, M; Esteban, R; Fernandez-Fernandez, P; Homs, M; Jardi, R; Quer, J; Rodriguez-Frias, F; Schaper, M; Tabernero, D, 2011) |
| "This study included 82 patients with HBeAg-negative chronic hepatitis B (CHB) who received adefovir dipivoxil therapy." | 3.77 | [Virological response to adefovir dipivoxil predicts the long-term development of resistance in previously untreated patients with HBeAg-negative chronic hepatitis B]. ( Andrade, RJ; Chueca, N; Figueruela, B; Fraga, E; García, F; Gila, A; Martín, JM; Muñoz Rueda, P; Nogales, C; Puche, B; Romero-Gómez, M; Salmerón, J; Suárez, E, 2011) |
| "Combination emtricitabine (FTC) or lamivudine (LAM) with tenofovir disoproxil (TDF) is the recommended first-line regime for treatment in chronic hepatitis B virus (HBV)/HIV co-infection." | 3.77 | Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients. ( Beadsworth, MB; Pennell, A; Phillips, M; Ratcliffe, L; Vilar, FJ, 2011) |
| "An increasing number of patients with chronic hepatitis B infection are being treated with the newly licensed drug, adefovir." | 3.77 | Adefovir-induced Stevens-Johnson syndrome and toxic epidermal necrolysis overlap syndrome. ( Chattopadhyay, P; Sarma, N, 2011) |
| "To assess the long-term effectiveness and safety of adefovir (ADV) plus lamivudine (LMV) in LMV-resistant (R) kidney transplants with chronic hepatitis B, 11 such patients were treated with add-on ADV." | 3.77 | Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B. ( Aroldi, A; Colombo, M; Facchetti, F; Invernizzi, F; Lampertico, P; Lunghi, G; Messa, PG; Viganò, M, 2011) |
| "The aims of this study were to assess the long-term efficacy of lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy in patients with chronic hepatitis B resistant to LAM, to identify predictive factors of complete viral response (HBV-DNA <2." | 3.77 | Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients. ( Aizawa, M; Fujise, K; Hoshina, S; Kono, M; Tajiri, H; Tatsuzawa, K; Tsubota, A, 2011) |
| " A 46-year-old female patient with chronic hepatitis B had persistent detectable HBV DNA and positive serum hepatitis B e antigen (HBeAg), even while on long-term lamivudine and adefovir therapy." | 3.77 | Development of immunity against hepatitis B virus after donor lymphocyte infusion in a peripheral blood stem cell transplantation recipient with chronic hepatitis B. ( Chen, CH; Chiang, LT; Ko, BS; Yao, M, 2011) |
| "To assess the peripheral T lymphocyte subsets in chronic hepatitis B virus (HBV) infection, and their dynamics in response to adefovir dipivoxil monotherapy." | 3.77 | Parallel decline of CD8+CD38+ lymphocytes and viremia in treated hepatitis B patients. ( Cao, W; Li, TS; Qiu, ZF, 2011) |
| "Chronic hepatitis B patients who were treated with anti-viral agents (lamivudine, adefovir, entecavir) and have stopped the treatment were recruited." | 3.77 | Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. ( Chan, HL; Ge, S; Guo, W; Hu, J; Huang, X; Jiang, J; Jiang, Z; Liang, Y; Liu, Z; Su, M; Wong, VW; Xie, R; Zhu, M, 2011) |
| "We report a case of an immunocompromised patient affected by chronic hepatitis B virus (HBV) with high basal HBV viremia (>8 log(10) IU/ml) who failed an entecavir regimen, despite the absence of primary or secondary drug resistance mutations." | 3.77 | Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. ( Andreoni, M; Bertoli, A; Ceccarelli, L; Perno, CF; Salpini, R; Sarrecchia, C; Sordillo, P; Svicher, V; Volpi, A, 2011) |
| "Primary or secondary failure of adefovir dipivoxil (ADV) therapy of chronic hepatitis B is not infrequent." | 3.77 | Adefovir serum levels do not differ between responders and nonresponders. ( Buti, M; Deterding, K; Guerrero, A; Janssen, H; Kirschner, J; Naesens, L; Neyts, J; Reijnders, J; Wedemeyer, H; Zoulim, F, 2011) |
| "Therapy of chronic hepatitis B with HBV-polymerase inhibitors, in particular tenofovir or adefovir, may affect renal function." | 3.77 | Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. ( Athmann, C; Berger, F; Filmann, N; Hegener, P; Henke, J; Herrmann, E; Hueppe, D; Mauss, S; Schmutz, G, 2011) |
| "An increasing number of patients with chronic hepatitis B (CHB) have experienced treatment failure to adefovir (ADV) and their management poses a growing challenge." | 3.77 | The efficacy of entecavir therapy in chronic hepatitis B patients with suboptimal response to adevofir. ( Do, ST; Garcia, RT; Nguyen, HA; Nguyen, KK; Nguyen, MH; Nguyen, TT; Sheen, E; Tran, P; Trinh, HN, 2011) |
| "In chronic hepatitis B (CHB) patients, adefovir is commonly used as a rescue therapy for lamivudine resistance, but often results in incomplete virological suppression." | 3.77 | Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. ( Chan, HL; Chan, HY; Ong, A; Tse, CH; Wong, GL; Wong, VW, 2011) |
| "This study aimed to evaluate the long-term efficacy of entecavir (ETV) in adefovir (ADV)-refractory chronic hepatitis B (CHB) patients with prior lamivudine (LMV) resistance." | 3.77 | Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance. ( Jang, JS; Jang, MK; Kim, DJ; Kim, HS; Kim, HY; Kim, KH; Lee, JH; Lee, MS; Park, CK; Park, JW; Seo, DD; Shin, WG, 2011) |
| "To evaluate virological response to adefovir (ADV) monotherapy and emergence of ADV-resistant mutations in lamivudine (LAM)-resistant chronic hepatitis B patients." | 3.77 | Virological response to adefovir monotherapy and the risk of adefovir resistance. ( Choi, MS; Gwak, GY; Koh, KC; Lee, HIe; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC, 2011) |
| "To study the factors influencing the long-term usage of lamivudine (LAM) in chronic hepatitis B (CHB) patients and the management after drug-resistance." | 3.77 | [Lamivudine-resistant analysis and management for chronic hepatitis B patients with initial lamivudine therapy]. ( Chen, Y; He, LL; Lei, BJ; Lei, XZ; Xu, H, 2011) |
| "Previous research has demonstrated that tenofovir disoproxil fumarate (DF) is the most cost-effective nucleos(t)ide treatment for chronic hepatitis B (CHB) in the UK, Spain, Italy and France." | 3.77 | Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective. ( Bentley, A; Dakin, H; Fidler, C; Fung, S; Sherman, M, 2011) |
| "Adefovir dipivoxil is commonly used for treatment of chronic hepatitis B." | 3.77 | [Adefovir dipivoxil-induced Fanconi syndrome and hypophosphatemic osteomalacia associated with muscular weakness in a patient with chronic hepatitis B]. ( Dong, GF; Li, L; Xie, YS; Zhang, X, 2011) |
| "We investigated the durability of the biochemical and virologic responses after adefovir (ADV) discontinuation in lamivudine-resistant (LMV-R) chronic hepatitis B (CHB) patients, and the outcomes of ADV discontinuation compared to that of ADV maintenance." | 3.77 | Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients. ( Byun, KS; Jung, ES; Jung, YK; Kim, JH; Lee, KG; Ryu, HS; Seo, YS; Um, SH; Yeon, JE; Yim, HJ, 2011) |
| " The use of lamivudine and tenofovir resulted in arrest of proteinuria and stabilisation of renal function." | 3.77 | Hepatitis B virus related membranous glomerulonephritis and proteinuria treated with lamivudine and tenofovir. ( Das, P; Ford, M; Holt, S; Kingdon, E; Vivek, V, 2011) |
| "The aims of this study were to evaluate therapy with lamivudine (LAM) and adefovir dipivoxil (ADV) monotherapy in chronic hepatitis B virus (HBV)-infected patients with frequent measurements of DNA levels, to characterize HBV genotypes, and to determine the emergence of nucleos(t)ide analogue mutants before and during the therapy by direct-sequencing the reverse transcriptase region and by INNO-LiPA HBV DR v3." | 3.76 | Monitoring of therapy in patients with chronic hepatitis B virus. ( Arrese, E; Basaras, M; Blanco, S; Cisterna, R; Ruiz, P, 2010) |
| " The purpose of this study was to evaluate the effect of a new therapeutic strategy combining Lamivudine (LAM) and ADV in patients with HBeAg-positive chronic hepatitis B (CHB) and poor response to ADV monotherapy." | 3.76 | Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy. ( Cao, J; Chen, EQ; Lei, BJ; Liu, L; Tang, H; Wang, JR; Wang, LC, 2010) |
| "Long-term lamivudine (LAM) and adefovir (ADV) treatment has been found to induce the emergence of drug-resistant hepatitis B virus (HBV) in a significant number of patients with chronic hepatitis B (CHB) infection." | 3.76 | Lamivudine and adefovir resistance in children and young adults with chronic hepatitis B. ( Akman, SA; Halicioglu, O; Kose, S, 2010) |
| "Recently, we reported on three patients with chronic hepatitis B virus (HBV) infection for whom adefovir (ADF) therapy virologically failed, most likely due to a preexisting rtI233V HBV polymerase mutation." | 3.76 | Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy. ( Funk, A; Helm, M; Olotu, C; Rockstroh, JK; Schildgen, O; Sirma, H; Zöllner, B, 2010) |
| " In adefovir (ADV) treated chronic hepatitis B patients carrying rtA181T/rtA181V mutations, overlap with surface gene mutations such as sW172stop/sL173F has been reported." | 3.76 | Hepatitis B viral surface mutations in patients with adefovir resistant chronic hepatitis B with A181T/V polymerase mutations. ( Bak, YT; Byun, KS; Joo, MK; Jung, YK; Kim, JH; Kim, JS; Park, JJ; Yeon, JE; Yim, HJ, 2010) |
| "The aim of this study was to determine the evolution of full-length hepatitis B virus (HBV) sequences in chronic hepatitis B (CHB) patients with sequential lamivudine (LAM) and adefovir (ADV) resistance." | 3.76 | Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance. ( Changchien, CS; Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Tung, WC; Wang, JC; Wang, JH, 2010) |
| " The aim of this study was to clarify the effect of molecular characteristics on the antiviral response to adefovir in patients with lamivudine-resistant chronic hepatitis B (CHB)." | 3.76 | Response to adefovir depends on mutation patterns in precore region, basal core promoter and reverse transcriptase, and on-treatment responses in Lamivudine-resistant chronic hepatitis B patients. ( Cho, YK; Choi, EK; Cui, XJ; Hyun, S; Jeong, SU; Kim, HU; Park, NH; Shin, JW; Song, BC; Song, HJ, 2010) |
| "There have been no reports comparing the therapeutic results of adefovir (ADV) and entecavir (ETV) rescue therapy for patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB)." | 3.76 | Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. ( Cho, YK; Jeon, WK; Kim, BI; Kim, HJ; Park, DI; Park, JH; Sohn, CI, 2010) |
| "Adefovir dipivoxil, an acyclic nucleoside analogue, has been approved for the treatment of patients with chronic hepatitis B." | 3.76 | [A case of osteomalacia related to adefovir in a patient with chronic hepatitis B]. ( Ahn, SY; Choe, WH; Choi, YH; Jang, YM; Kim, BK; Ko, SY; Kwon, SY; Lee, CH, 2010) |
| "The aim of this study was to assess the cost-effectiveness of tenofovir disoproxil fumarate (TDF) in the treatment of chronic hepatitis B (CHB) versus alternative nucleos(t)ides from a UK National Health Service (NHS) perspective." | 3.76 | Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. ( Bentley, A; Dakin, H; Dusheiko, G, 2010) |
| "Adefovir dipivoxil treatment has significantly improved the outcome of chronic hepatitis B virus (HBV) infection." | 3.76 | Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. ( Hao, C; Jiang, Y; Li, W; Ma, Z; Niu, J; Xin, G; Xu, H; Yan, H; Zhao, P, 2010) |
| "Data on the efficacy of adefovir dipivoxil (ADV) in elderly and cirrhotic patients with lamivudine-resistant (LAM-R) chronic hepatitis B are scarce." | 3.75 | Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure. ( Bailly, F; Beaugrand, M; Benhamou, Y; Marcellin, P; Maynard, M; Monchecourt, F; Parvaz, P; Trepo, C; Trylesinski, A; Zarski, JP; Zoulim, F, 2009) |
| " The aim was to evaluate the long-term outcome of lamivudine monoprophylaxis with adefovir salvage for liver transplantation in chronic hepatitis B." | 3.75 | Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study. ( Chan, HL; Chan, HY; Kwan, KY; Lai, PB; Limquiaco, JL; Tse, CH; Wong, GL; Wong, J; Wong, VW, 2009) |
| "Patients with chronic hepatitis B (CHB) who will and those who will not respond to adefovir (ADV) monotherapy need to be identified at an early stage in order to adjust treatment and prevent future development of antiviral resistance." | 3.75 | On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks. ( de Man, RA; Hansen, BE; Janssen, HL; Leemans, WF; Pas, SD; Reijnders, JG; Schutten, M, 2009) |
| "The purpose of this study was to evaluate the renal side-effects of adefovir therapy in kidney-transplant (KT) recipients with chronic hepatitis B virus (HBV) infection, who have become resistant to lamivudine therapy." | 3.75 | Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients. ( Alric, L; Huart, A; Izopet, J; Kamar, N; Rostaing, L; Tack, I, 2009) |
| "The aims of the study were to investigate the efficacy of rescue therapy with lamivudine (LAM) and adefovir (ADV) combination for 6 months followed by ADV monotherapy in lamivudine-resistant chronic hepatitis B (LAM-R CHB) patients, and to analyze the frequency of ADV resistance mutant development in such patients." | 3.75 | A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients. ( Ahishali, E; Badur, S; Bektas, M; Bozkaya, H; Cakaloglu, Y; Cinar, K; Idilman, R; Karayalcin, S; Kaymakoglu, S; Mithat Bozdayi, A; Oguz Onder, F; Okten, A; Pinarbasi, B; Yurdaydin, C, 2009) |
| "Fourteen chronic hepatitis B patients (57% lamivudine-experienced) with a viral load above 5log(10)copies/mL after 12months of adefovir therapy and thereafter were treated with entecavir 1mg daily." | 3.75 | Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. ( de Man, RA; Janssen, HL; Pas, SD; Reijnders, JG; Schutten, M, 2009) |
| "It has been shown that adefovir dipivoxil is an effective antiviral agent in the treatment of chronic hepatitis B (CHB), not only in wild-type hepatitis B virus (HBV) infection, but also in lamivudine-resistant (LAMV-R) cases." | 3.75 | [Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, lamivudine-resistant chronic hepatitis B patients]. ( Choi, MS; Jung, HW; Kim, KH; Koh, KC; Lee, JH; Paik, SW; Park, SH; Yeon, KK; Yoo, BC, 2009) |
| "The antiviral effect of adefovir dipivoxil (ADV) added to ongoing lamivudine (LAM) treatment for LAM-resistant chronic hepatitis B (CHB) differs among patients." | 3.75 | Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B. ( Doi, Y; Hagiwara, H; Hayashi, E; Hayashi, N; Hiramatsu, N; Imai, Y; Kanto, T; Kasahara, A; Kashihara, T; Kato, M; Kiso, S; Kurashige, N; Mita, E; Nagase, T; Ohkawa, K; Oshita, M; Takehara, T; Yakushijin, T; Yamada, A; Yoshihara, H, 2009) |
| "The aim of this study was to elucidate the antiviral efficacy of lamivudine (LMV)-adefovir (ADV) combination therapy in chronic hepatitis B patients who showed resistance to LMV and ADV consecutively." | 3.75 | [Antiviral efficacy of lamivudine/adefovir combination therapy in chronic hepatitis b patients with resistance to lamivudine and adefovir consecutively]. ( Gwak, GY; Koh, KC; Lee, HIe; Lee, JH; Paik, SW; Park, MK; Suh, HJ; Yoo, BC, 2009) |
| "The aim of the study was to estimate the effect of viral factors (HBV genotype, viral load and kinetics) to treatment response in chronic hepatitis B (CHB) and first-line therapy with adefovir dipivoxil (ADV)." | 3.75 | Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B. ( Bock, T; Hass, HG; Kaiser, S; Nehls, O, 2009) |
| "Data concerning the outcome of lamivudine-resistant (LAM-R) chronic hepatitis B (CHB) patients with compensated cirrhosis under adefovir (ADV) treatment are limited." | 3.75 | Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance. ( Buti, M; Elefsiniotis, I; Esteban, R; Jardi, R; Vezali, E, 2009) |
| "Clinical data of 233 chronic hepatitis B patients treated with lamivudine 100mg daily (91 patients were switched to Adefovir 10mg daily or Adefovir 10mg in combination with lamivudine 100mg daily) were retrospective." | 3.75 | [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B]. ( Fu, J; Li, SG; Tan, B; Wen, FY; Wu, JL; Yang, XY; Zhou, HJ, 2009) |
| "To explore the mechanism for adefovir dipivoxil (ADV) resistance occurred in chronic hepatitis B patients of a series of phase III clinical trails." | 3.75 | [Dissection of mechanism for the adefovir dipivoxil resistance in chronic hepatitis B patients]. ( Cai, SF; Deng, H; Deng, XH; Guo, JJ; Huang, AL; Li, QL; Lu, P; Xin, XJ; Yang, C; Zeng, AZ, 2009) |
| "The efficacy of entecavir (ETV) monotherapy in treatment-experienced patients with chronic hepatitis B (CHB) is debatable." | 3.75 | Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. ( Byun, KS; Choe, WH; Hong, SP; Ji, SI; Jung, YK; Kim, BK; Kim, JH; Kim, KH; Kim, SO; Ko, SY; Kwon, SY; Lee, CH; Yeon, JE, 2009) |
| "To study the predictive value of ALT, HBeAg and HBV DNA levels at baseline and HBV DNA levels at week 12 adefovir dipivoxil (ADV) treatment to the efficacy of it at week 52 in patients with HBeAg-positive chronic hepatitis B (CHB)." | 3.74 | [The predictive value of ALT, HBeAg and HBV DNA levels at baseline and the degree of HBV suppression at week 12 adefovir dipivoxil treatment to the efficacy of it at week 52 in patients with HBeAg-positive chronic hepatitis B]. ( Chen, YM; Gao, ZL; Li, JG; Lin, BL; Lu, WL; Xie, DY; Xu, QH, 2008) |
| "A 43-year-old man was treated with lamivudine for hepatitis B e antigen-positive chronic hepatitis B." | 3.74 | Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir. ( de Man, RA; Janssen, HL; Leemans, WF; Niesters, HG; Schalm, SW; van der Eijk, AA, 2008) |
| "This longitudinal study included 41 patients with chronic hepatitis B virus (HBV) infection receiving ADV monotherapy or ADV plus lamivudine (3TC)." | 3.74 | Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response. ( Buti, M; Esteban, R; Ferrer-Costa, C; Homs, M; Jardi, R; Rodriguez-Frias, F; Schaper, M; Tabernero, D, 2008) |
| "The long-term efficacy of adefovir dipivoxil in combination with lamivudine to chronic hepatitis B virus (HBV) infection is still unclear." | 3.74 | Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil. ( Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H, 2008) |
| "To study the resistant rate of hepatitis B virus (HBV) to ADV and the dynamic evolution of HBV in lamivudine (Lam)-resistant chronic hepatitis B (CHB) patients." | 3.74 | [The rate of hepatitis B virus resistance to adefovir dipivoxil (ADV) and the evolution of hepatitis B virus in lamivudine-resistant chronic hepatitis B patients with ADV monotherapy]. ( Huang, YX; Mao, RC; Qin, YL; Weng, XH; Wu, XH; Yin, YK; Zhang, JM; Zhang, QB; Zhang, WQ, 2007) |
| "To determine the factors affecting the virological response to adefovir dipivoxil (ADV) among patients with lamivudine resistant chronic hepatitis B." | 3.74 | Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. ( Chan, HL; Chan, HY; Chim, AM; Sung, JJ; Tse, CH; Wong, GL; Wong, VW, 2007) |
| "To determine the factors associated with virological response (VR), HBeAg loss or the emergence of adefovir (ADV)-related mutations in ADV-treated chronic hepatitis B (CHB) patients with lamivudine (LAM) resistance." | 3.74 | Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. ( Bonovas, S; Buti, M; Elefsiniotis, I; Esteban, R; Jardi, R; Rodriguez-Frias, F; Schapper, M; Vargas, V, 2007) |
| "The outcomes of lamivudine-resistant chronic hepatitis B patients treated with long-term adefovir dipivoxil have not been well described." | 3.74 | Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B. ( Khoo, TL; Lee, AU; McCaughan, GW; Ngu, MC; Prakoso, E; Strasser, SI; van der Poorten, D, 2007) |
| "This study was conducted to clarify the resistance profile of a novel mutation pattern emerging during lamivudine (3TC) therapy and showing cross-resistance to adefovir dipivoxil (ADV) in a patient with chronic hepatitis B." | 3.74 | A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. ( Bozdayi, AM; Karaaslan, H; Karatayli, E; Karayalçin, S; Kayhan, H; Sahin, F; Türkyilmaz, AR; Yurdaydin, C, 2007) |
| "Adefovir dipivoxil (ADV) resistance in patients with lamivudine-resistant chronic hepatitis B is not well understood." | 3.74 | [Effect of initial virologic response to adefovir on the development of resistance to adefovir in lamivudine-resistant chronic hepatitis B]. ( Kim, DG; Kim, HC; Kim, IH; Kim, SH; Kim, SW; Lee, SO; Lee, ST; Shin, KD, 2007) |
| "The efficacy of long-term adefovir dipivoxil monotherapy or combination of adefovir and lamivudine in hepatitis B e antigen (HBe-Ag)-negative lamivudine-resistant chronic hepatitis B (CHB) patients is still under investigation." | 3.74 | Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. ( Bethanis, S; Christias, E; Christidou, A; Goulis, J; Karamanolis, D; Koutsounas, S; Manolakopoulos, S; Papatheodoridis, G; Pavlidis, C; Saveriadis, A; Triantos, C; Tzourmakliotis, D; Vlachogiannakos, J, 2008) |
| "We summarize the clinical history and laboratory results following the introduction of tenofovir among 6 patients coinfected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) who presented with severe liver disease while receiving lamivudine-based highly active antiretroviral therapy." | 3.74 | Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine. ( Guillemi, S; Gutiérrez, S; Harrigan, PR; Jahnke, N; Montaner, JS; Montessori, V, 2008) |
| " In our department, tenofovir was prescribed in addition to lamivudine for the treatment of lamivudine resistant chronic hepatitis B." | 3.74 | Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression. ( de Man, RA; Janssen, HL; Leemans, WF; Niesters, HG, 2008) |
| "The aims of the present study were to assess initial virological response (IVR) to adefovir (ADV) treatment for chronic hepatitis B, to identify patients with suboptimal response and to determine the incidence of ADV-resistant mutants." | 3.74 | Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. ( Enrĺquez, J; Gallego, A; García-Samaniego, J; Hornillos, P; Margall, N; Romero, M; Sheldon, J; Soriano, V, 2008) |
| "In lamivudine-resistant patients with chronic hepatitis B (CHB), we compared efficacy, predictive response factors and changes in viral mutants in two antiviral approaches with adefovir." | 3.74 | Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. ( Alessandria, C; Barbon, V; Carenzi, S; Gaia, S; Lagget, M; Marzano, A; Olivero, A; Rizzetto, M; Smedile, A, 2008) |
| "The aim of this study was to assess the therapeutic effectiveness of adefovir dipivoxil (ADV), administered in combination with lamivudine (LAM) or as monotherapy, and the rate of resistance to ADV, in hepatitis B e antigen (HBeAg)-negative adult patients with chronic hepatitis B virus (HBV) infection and clinical or virologic resistance to LAM." | 3.74 | Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study. ( Armignacco, O; Barbarini, G; Barbaro, G; Barlattani, A; Camporiondo, MP; Ferri, F; Francavilla, R; Mazzoni, E; Mecenate, F; Nauri, L; Nosotti, L; Paffetti, A; Pellicelli, AM; Romano, M; Soccorsi, F; Struglia, C; Villani, R, 2008) |
| "One hundred and thirty-one post-liver transplantation patients with chronic hepatitis B and failing lamivudine therapy with detectable serum hepatitis B virus (HBV) deoxyribonucleic acid by hybridization assays or > or =1 x 10(6) copies/mL by polymerase chain reaction, and elevated alanine transaminase levels despite continuous lamivudine, were enrolled in an open-label study of adefovir dipivoxil." | 3.73 | Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. ( Brosgart, CL; Delaney, WE; Fry, J; Gibbs, CS; Lama, N; Miller, MD; Schiff, ER; Westland, CE; Wulfsohn, M; Xiong, S; Yang, H, 2005) |
| "We describe the case of a patient with chronic hepatitis B who became resistant to lamivudine and was treated successfully with adefovir dipivoxil in addition to lamivudine." | 3.73 | Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. ( Chevallier, M; Chevallier, P; Durantel, S; Lot, M; Maynard, M; Parvaz, P; Trepo, C; Zoulim, F, 2005) |
| "Long-term treatment with lamivudine is required to control viral replication in patients with hepatitis B e antigen-negative chronic hepatitis B, but is associated with a high rate of viral resistance." | 3.73 | Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. ( Eugenidis, N; Giouleme, O; Gkisakis, D; Grammatikos, N; Katsinelos, P; Nikolaidis, N; Orfanou-Koumerkeridou, E; Patsiaoura, K; Theodoropoulos, K; Tziomalos, K; Vassiliadis, T; Zezos, P, 2005) |
| "We determined the clinical outcome of hepatitis e antigen (HBeAg)-negative chronic hepatitis B patients treated with long-term nucleos(t)ide analog therapy starting with lamivudine." | 3.73 | Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. ( Dimakopoulos, K; Dimou, E; Hadziyannis, SJ; Kitis, G; Manesis, E; Manolakopoulos, S; Papatheodoridis, GV; Rapti, I; Tzourmakliotis, D, 2005) |
| "Although a recent study did not show any differences in the reduction of HBV DNA comparing monotherapy with adefovir dipivoxil to adefovir-lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B, mathematical analysis of early viral kinetics suggests an additional effect of lamivudine on the infected cell loss during adefovir-lamivudine combination therapy." | 3.73 | Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy. ( Faust, D; Gärtner, BC; Herrmann, E; Hofmann, WP; Mihm, U; Sarrazin, C; Zeuzem, S, 2005) |
| "Fifty chronic hepatitis B (CHB) patients with lamivudine resistant HBV mutants who had received lamivudine for more than 12 months were included in the study." | 3.73 | [Clinical outcomes after discontinuation of Lamivudine in chronic hepatitis B patients with Lamivudine resistant HBV mutant]. ( Cho, HJ; Choi, HY; Hong, SP; Hwang, SG; Kim, JK; Kim, NK; Ko, KH; Park, H; Park, PW; Rim, KS, 2005) |
| "To evaluate the efficacy and safety of adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD motif mutation during lamivudine therapy." | 3.73 | [Adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD mutation]. ( Su, GG; Ying, MF; Zhao, NF; Zhou, Y, 2005) |
| "Seven antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir for longer than 6 months were assessed." | 3.73 | Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. ( Berger, F; Corral, A; Mauss, S; Rockstroh, J; Rodés, B; Schwarze-Zander, C; Sheldon, JA; Soriano, V, 2005) |
| "We studied the impact of tenofovir disoproxil fumarate, given as an antiretroviral medication, on patients with chronic hepatitis B virus (HBV) co-infection." | 3.73 | Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. ( Berger, A; Bickel, M; Carlebach, A; Klauke, S; Lutz, T; Staszewski, S; Stephan, C; Stuermer, M, 2005) |
| "Currently, adefovir is an effective rescue therapy that broadens the existing range of options for patients with lamivudine-resistant chronic hepatitis B infection, particularly those with decompensated cirrhosis awaiting a liver graft, and those with recurrent posttransplantation HBV." | 3.73 | Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection. ( Baliellas, C; Cañas, C; Casanovas, A; Casanovas, T; Chahri, N; Figueras, J; Gil-Vernet, S; Gornals, JB; Sabidó, M; Serrano, T; Verdura, B, 2005) |
| "To estimate the cost-effectiveness over a 4-year duration of lamivudine and adefovir dipivoxil for patients with hepatitis B 'e' antigen-negative chronic hepatitis B." | 3.73 | Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. ( Aguilar, J; Buti, M; Calleja, JL; Casado, MA; Esteban, R; Rueda, M; Salmerón, J, 2006) |
| "We have studied a 49-year-old patient with a HBeAg-negative chronic hepatitis B in whom, after 34 months of treatment with lamivudine and associated with an increase in the serum hepatitis B virus (HBV) DNA, the lamivudine resistance mutations M204I and L180V were detected." | 3.73 | [Lamivudine and adefovir resistance in a patient with HBeAg negative chronic hepatitis B]. ( Mateos, ML; Moreira, V; Tato, M, 2006) |
| "A 56-year-old male patient received adefovir dipivoxil (10 mg/day) for chronic hepatitis B resistant to lamivudine." | 3.73 | Adefovir dipivoxil-associated thrombocytopenia in a patient with chronic hepatitis B. ( Amato, A; Gaeta, GB; Stornaiuolo, G, 2006) |
| "One patient with chronic hepatitis B virus (HBV) infection developed resistance to lamivudine after 15 months of treatment." | 3.73 | Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. ( Lai, V; Mirza, D; Mutimer, D; Zhang, WX, 2006) |
| "Although adefovir dipivoxil (ADV) has a unique profile of delayed and infrequent resistance in treatment-naïve chronic hepatitis B patients, the association of ADV resistance with previous lamivudine (LAM) resistance is not well understood." | 3.73 | Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. ( Chung, YH; Jung, SW; Kim, KM; Kim, SO; Lee, HC; Lee, YS; Lim, YS; Suh, DJ; Yoo, W, 2006) |
| "The nucleotide analog adefovir dipivoxil (ADV) is an effective antiviral treatment for chronic hepatitis B virus (HBV) infection, with resistance to ADV estimated to occur less frequently than resistance to lamivudine treatment." | 3.73 | Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). ( Borlang, J; Giles, E; Heathcote, EJ; Osiowy, C; Villeneuve, JP, 2006) |
| "Continuation of lamivudine therapy is controversial for patients with chronic hepatitis B when viral breakthrough occurs." | 3.73 | [Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy in acute exacerbation after viral breakthrough during lamivudine therapy in chronic hepatitis B]. ( Eun, JR, 2006) |
| "Lamivudine is widely used for the treatment of chronic hepatitis B infection because of it's remarkable antiviral efficacy and safety." | 3.73 | [A case of severe skin eruption caused by lamivudine in a patient with chronic hepatitis B]. ( Baik, du S; Kim, BH; Kim, HJ; Kim, SB; Seo, PJ; Shin, JE; Song, IH; Yun, SY, 2006) |
| "Adefovir dipivoxil effectively inhibits both hepatitis B virus (HBV) replication and disease activity in patients with chronic hepatitis B." | 3.72 | Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. ( Angus, P; Ayres, A; Bartholomeusz, A; Brosgart, C; Colledge, D; Delaney, W; Edwards, R; Gibbs, C; Locarnini, S; Vaughan, R; Xiong, S; Yang, H, 2003) |
| "3%) patients developed hepatitis B virus DNA breakthrough 47 and 53 months, respectively, after transplantation, but they remained well after treatment with adefovir." | 3.72 | Live-donor liver transplantation for acute-on-chronic hepatitis B liver failure. ( Fan, ST; Lai, CL; Liu, CL; Lo, CM; Wei, WI; Wong, J; Yong, BH, 2003) |
| "Three-hundred and twenty-four patients were enrolled in an open-label, multicenter, international study in which pre- and post-liver transplantation (LT) patients with recurrent chronic hepatitis B (CHB) and evidence of lamivudine-resistant HBV were treated with adefovir dipivoxil 10 mg once daily." | 3.72 | Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. ( Brosgart, CL; Choy, GS; Colombo, M; Fry, J; Hadziyannis, S; James, C; Lai, CL; Lama, N; Lilly, L; Namini, H; Neuhaus, P; Rendina, M; Samuel, D; Schiff, ER; Terrault, N; Tillmann, HL; Van Doren, S; Villeneuve, JP; Westland, C; Wulfsohn, MS; Xiong, S; Zeuzem, S, 2003) |
| " This article reviews recently published clinical data on the two currently available antivirals for the treatment of chronic hepatitis B infection, lamivudine and adefovir dipivoxil." | 3.72 | Antivirals for the treatment of chronic hepatitis B: current and future options. ( Dixon, JS; Humphries, JC, 2003) |
| "Lamivudine is a treatment option for the therapy of chronic hepatitis B with an excellent safety profile." | 3.72 | Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated. ( Flemming, P; Klempnauer, J; Manns, MP; Nashan, B; Niemann, P; Rohde, P; Tillmann, HL; Tischendorf, JJ; Trautwein, C; Wiegand, J, 2004) |
| "Lamivudine resistance occurs in patients with chronic hepatitis B at rates of 16%-32% after 1 year and 49% after 3 years." | 3.72 | Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. ( Chung, RT; Dienstag, JL; Kuo, A, 2004) |
| " Ninety-eight liver biopsy samples from patients in the major phases of the natural history of chronic hepatitis B and 32 pairs of samples from patients receiving adefovir dipivoxil (ADV) therapy were assessed." | 3.72 | Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. ( Bowden, S; Brosgart, CL; Chen, SS; Delaney, WE; Gibbs, CS; Goodman, Z; Lau, G; Locarnini, S; Marcellin, P; Petersen, J; Trepo, C; Werle-Lapostolle, B; Wursthorn, K; Xiong, S; Zoulim, F, 2004) |
| "Resistant hepatitis B virus (HBV) strains develop in 30% of liver transplant recipients treated with lamivudine within 2 years from the time of transplantation." | 3.72 | Tenofovir therapy for lamivudine resistance following liver transplantation. ( Duncan, R; Lau, DT; Madariaga, JR; Montalbano, M; Muslu, H; Neff, GW; Nery, C; Nery, J; O'Brien, CB; Ruiz, P; Safdar, K; Schiff, ER; Shire, NJ; Tzakis, AG, 2004) |
| "Adefovir dipivoxil (Hepsera), a first-line therapy for chronic hepatitis B, is an esterase-activated prodrug of PMEA." | 3.72 | Remofovir mesylate: a prodrug of PMEA with improved liver-targeting and safety in rats and monkeys. ( Erion, MD; Hong, Z; Lin, CC; Vitarella, D; Yeh, LT, 2004) |
| "Lamivudine has been shown to be an effective therapy for chronic hepatitis B, but resistance to this nucleoside agent is common after prolonged use." | 3.70 | Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. ( Gutfreund, K; Hirsch, K; Lamy, P; Murray, A; Perrillo, R; Schiff, E; Statler, A; Wright, T; Yoshida, E, 2000) |
| "Among 3656 highly viremic mothers treated with TDF, hepatitis B virus DNA suppression to the levels <200,000 IU/mL at delivery was achieved in 34% to 100% of mothers." | 3.01 | The Use of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide for Preventing Vertical Transmission of Hepatitis B. ( Deng, Y; Pan, CQ; Park, J; Zhu, L, 2023) |
| " However, greater adverse effects on renal function were observed for TDF than ETV at 60 months compared to 12 months." | 3.01 | Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis. ( Liu, S; Liu, Z; Ma, X; Xin, Y; Zhao, Z, 2023) |
| " The treatment using NAs was well-tolerated and there was no serious drug-related adverse event reported." | 3.01 | Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. ( Chen, T; Chen, Y; Fu, M; Fu, S; Gao, Z; He, Y; Hu, C; Li, J; Liu, J; Yan, T; Yang, Y; Zhang, R; Zhao, Y; Zhou, M, 2021) |
| "Pradefovir is a liver targeted novel prodrug of adefovir (PMEA) developed to provide higher antiviral activity with reduced systemic toxicities." | 2.94 | Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection. ( Chen, H; Ding, Y; Jin, W; Li, C; Li, X; Liu, C; Liu, J; Niu, J; Wu, M; Zhang, D; Zhang, H; Zhu, X, 2020) |
| "Functional cure is the major goal of chronic hepatitis B (CHB) therapy though few biomarkers predict this outcome." | 2.90 | Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure. ( Cloherty, G; Deerain, J; Gaggar, A; Hammond, R; Kitrinos, K; Leary, T; Locarnini, S; O'Donnell, T; Subramanian, M; Walsh, R; Wong, D; Yuen, L, 2019) |
| "A total of 95 patients with chronic hepatitis B being treated with NUCs were enrolled." | 2.87 | Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy. ( Chayama, K; Enomoto, H; Enomoto, M; Hino, K; Hiramatsu, N; Ikeda, F; Kagawa, T; Kanda, T; Kang, JH; Kurosaki, M; Matsumoto, A; Mine, T; Miyase, S; Morihara, D; Murata, K; Nagaoka, S; Nishiguchi, S; Okuse, C; Saito, S; Sakisaka, S; Shinkai, N; Suzuki, Y; Takaguchi, K; Tanaka, E; Tanaka, Y; Tsuge, M; Yatsuhashi, H; Yokosuka, O, 2018) |
| "Current treatments for chronic hepatitis B (CHB) include pegylated interferon alpha (PEG-IFN-α) which is an immune modulator, and nucleos(t)ide analogs (NAs) which directly inhibit HBV DNA polymerase." | 2.84 | Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial. ( Guo, H; Jiao, J; Liu, Z; Qi, W; Wang, J; Wang, X; Xu, Y; Yu, F; Zhao, P; Zhou, C, 2017) |
| "Treatment of patients with chronic hepatitis B (CHB) with nucleos(t)ide analogues (NAs) suppresses hepatitis B virus (HBV) DNA production but does not affect the synthesis of the RNA pregenome or HBV messenger RNA." | 2.82 | Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues. ( Jansen, L; Kootstra, NA; Reesink, HW; Takkenberg, RB; van Dort, KA; Zaaijer, HL, 2016) |
| "In lamivudine-treated patients with suboptimal virological response at week 24, promptly adding on ADV is necessary to prevent resistance development." | 2.80 | Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients. ( Chen, C; Chen, S; Chen, X; Cheng, J; Dou, X; Hou, J; Jia, J; Jiang, J; Li, T; Liang, X; Long, H; Ma, H; Ning, Q; Niu, J; Ren, H; Sheng, J; Shi, G; Shi, J; Sun, J; Sun, Y; Tan, D; Tang, H; Wan, M; Wang, H; Xie, Q; Yu, Y; Zhuang, H, 2015) |
| " During the open-label phase, grade 3/4 drug-related adverse events were uncommon (1." | 2.80 | Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. ( Aguilar Schall, R; Buti, M; Charuworn, P; Flaherty, JF; Flisiak, R; Gane, E; Gurel, S; Kitrinos, KM; Krastev, Z; Marcellin, P; Martins, EB; Petersen, J; Subramanian, GM; Tsai, N, 2015) |
| "Adefovir + telbivudine treatment resulted in a significant reduction in HBV DNA levels." | 2.79 | Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections. ( Chang, KC; Chiu, KW; Chou, YP; Hsu, YC; Hu, TH; Lin, MT; Tsai, MC; Tseng, PL; Yen, YH; Yu, HC, 2014) |
| "One major challenge in the treatment of chronic hepatitis B is to maintain long-term viral suppression without promoting the selection of drug-resistant mutations." | 2.79 | No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. ( Borroto-Esoda, K; Corsa, A; Flaherty, J; Kitrinos, KM; Liu, Y; Marcellin, P; Miller, MD; Snow-Lampart, A, 2014) |
| " Most adverse events were mild in severity and considered unrelated to study drug." | 2.79 | Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings. ( Bae, H; Chan, S; Lou, L; Pan, CQ; Trinh, H; Yao, A, 2014) |
| "Current treatment options for chronic hepatitis B (CHB) are nucleoside or nucleotide analogues and pegylated interferons." | 2.79 | First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment. ( Cagatay, A; Ceylan, B; Erdem, L; Gokturk, K; Gunduz, A; Karaosmanoglu, H; Kocak, F; Mete, B; Ozaras, R; Ozgunes, N; Senates, E; Tabak, F, 2014) |
| "Sixty-one HBeAg-positive chronic hepatitis B patients were randomized to receive Peg-IFN alpha-2b alone (1." | 2.79 | Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study. ( Dai, YR; Liu, YH; Sun, N; Wang, GL; Wu, T; Yuan, JZ; Zhou, XH, 2014) |
| "No patient experienced HBV recurrence through 72 weeks of the study while he or she was receiving the randomized treatment." | 2.78 | Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. ( Bzowej, N; Dinh, P; Flaherty, J; Martin, P; Poordad, F; Pungpapong, S; Rossi, S; Schiano, T; Spivey, J; Subramanian, GM; Teperman, LW, 2013) |
| "Patients with chronic hepatitis B and incomplete response to ADV were randomized in a double-blind trial of TDF vs." | 2.78 | Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy. ( Al Hawajri, N; Borroto-Esoda, K; Dény, P; Kitrinos, K; Lavocat, F; Pichoud, C; Zoulim, F, 2013) |
| " Tenofovir gel, when used intermittently, was safe to use in women with HBV infection." | 2.78 | Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: results from the CAPRISA 004 trial. ( Abdool Karim, Q; Abdool Karim, SS; Baxter, C; Tshabalala, P; Yende-Zuma, N, 2013) |
| "There is no standard management of chronic hepatitis B (CHB) patients with suboptimal response to nucleoside/nucleotide analogues (NAs)." | 2.77 | Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir. ( Bai, L; Chen, EQ; Liang, LB; Tang, H; Wang, JR; Yan, LB; Zhou, TY, 2012) |
| "Spontaneous reactivation of chronic hepatitis B (CHB) is an important cause of acute-on-chronic liver failure (ACLF)." | 2.76 | Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. ( Garg, H; Garg, V; Kumar, A; Kumar, M; Sarin, SK; Sharma, BC, 2011) |
| "Patients with chronic hepatitis B (HBeAg+ and HBeAg-) randomized in two trials of adefovir (ADV) vs placebo, with available paired liver biopsies and FT-AT at baseline and after 48 weeks of treatment were included." | 2.74 | Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. ( Benhamou, Y; Hadziyannis, S; Marcellin, P; Ngo, Y; Poynard, T; Ratziu, V, 2009) |
| "Treatment of chronic hepatitis B with generic ADV was effective and well tolerated, but relapse may develop when treatment was discontinued." | 2.74 | [Efficacy and durability of generic adefovir dipivoxil in patients with HBeAg positive chronic hepatitis]. ( Chen, XY; Ding, HG; Dong, PL; Min, J; Wang, DM; Zhang, B; Zhang, XM, 2009) |
| "Adefovir dipivoxil (ADV) has demonstrated activity against wild-type and lamivudine-resistant hepatitis B virus (HBV)." | 2.73 | Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants. ( Carrouée-Durantel, S; Durantel, D; Naesens, L; Neyts, J; Pichoud, C; Trépo, C; Werle-Lapostolle, B; Zoulim, F, 2008) |
| "Treatment with adefovir dipivoxil (ADV) increases the rate of HBV e antigen (HBeAg) loss; however, the immune mechanisms associated with this treatment response are not understood." | 2.73 | Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity. ( Andreone, P; Brosgart, CL; Chokshi, S; Cooksley, H; Frederick, D; Gilson, R; Maayan, Y; Naoumov, NV; Neumann, AU; Paganin, S; Warnes, T; Wedemeyer, H; Zoulim, F, 2008) |
| "Adefovir dipivoxil (ADV) is a licensed treatment for chronic hepatitis B in adults." | 2.73 | The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection. ( Dhawan, A; Frederick, D; Kelly, D; Mizerski, J; Sokal, EM; Wirth, S, 2008) |
| "Adefovir/lamivudine treatment resulted in greater viraemia reduction than adefovir monotherapy." | 2.73 | Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. ( Arnold, C; Dervisevic, S; Ijaz, S; Mechurova, J; Naoumov, NV; Tatman, N; Tedder, RS, 2008) |
| "Lamivudine was combined for | 2.72 | Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants. ( Chen, DS; Chen, PJ; Chen, TC; Kao, JH; Lai, MY; Lin, FY; Liu, CJ, 2006) |
| "To investigate the efficacy, safety, and the tolerability of two dosing regimens of ADV (10 mg daily or 30 mg daily), two double-blind, placebo-controlled studies were performed in patients with chronic hepatitis B and compensated liver disease who were not undergoing current treatment and who had evidence of hepatitis B virus (HBV) replication." | 2.71 | Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. ( Arterbrun, S; Brosgart, CL; Currie, G; Deray, G; Hadziyannis, SJ; Hulot, JS; Izzedine, H; Launay-Vacher, V; Marcellini, P; Westland, C, 2004) |
| "Adefovir dipivoxil was recently approved for the treatment of wild-type and lamivudine-resistant hepatitis B virus (HBV) infection." | 2.71 | Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. ( Berg, T; Bergk, A; Mauss, S; Reinke, P; Schürmann, D; van Bömmel, F; Wiedenmann, B; Wünsche, T, 2004) |
| "Adefovir dipivoxil (ADV) has demonstrated clinical activity against wild-type and lamivudine-resistant HBV, but it is unclear whether resistance mutations will emerge after long-term therapy with this drug." | 2.70 | Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. ( Brosgart, C; Delaney, WE; Fry, J; Gibbs, CS; Heathcote, EJ; Ho, V; Miller, MD; Westland, CE; Xiong, S; Yang, H, 2002) |
| "Treatment for chronic hepatitis B as a once-daily oral dose was well tolerated and associated with significant and sustained reductions in serum HBV DNA levels during treatment." | 2.69 | A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. ( Chopra, KB; Gilson, RJ; Jaffe, HS; Murray-Lyon, IM; Nelson, MR; Newell, AM; Rice, SJ; Tedder, RS; Toole, J; Weller, IV, 1999) |
| " However, less attention has been put on their adverse events." | 2.61 | Bayesian Network Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B Drugs. ( Ji, J; Jia, Y; Shen, Y; Xun, P; Zhou, J, 2019) |
| "Long-term treatment of chronic hepatitis B (CHB) with nucleos(t)ide analogues is often necessary to achieve durable viral suppression." | 2.58 | Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. ( Buti, M; Esteban, R; Riveiro-Barciela, M, 2018) |
| "The primary goal of therapy for chronic hepatitis B (CHB) is to prevent liver disease progression." | 2.55 | Management of Antiviral Resistance in Chronic Hepatitis B. ( Lim, YS, 2017) |
| "Current agents for the treatment of chronic hepatitis B (CHB) can be classified into interferon-α (standard or pegylated) (IFN) and nucleos(t)ide analogues (NAs)." | 2.52 | Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients? ( Papatheodoridis, GV; Vlachogiannakos, J, 2015) |
| "HBeAg negative chronic hepatitis B (CHB) is a frequent, progressive and difficult-to-cure phase of CHB." | 2.52 | Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients? ( Invernizzi, F; Lampertico, P; Viganò, M, 2015) |
| "For chronic HBV carrier liver cirrhosis patients, a successful vaccine response can only be achieved in selected patients, such as those treated with experimentally reduced immunosuppression protocols." | 2.52 | Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence. ( Takaki, A; Yagi, T; Yasunaka, T, 2015) |
| " Long-term use of NUCs with maintained viral suppression results in a decrease in liver-related complications." | 2.52 | Monotherapy for hepatitis B infection: a review of treatment options. ( Demirhan, YE; Gultekin, G; Isal, B; Khodor, H; Ozaras, R; Unal, UK; Yetim, N, 2015) |
| "Increased risk of lactic acidosis has also been described for those with impaired liver and renal function taking entecavir." | 2.50 | Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. ( Fung, J; Lai, CL; Seto, WK; Yuen, MF, 2014) |
| "NAs are used in most HBeAg-positive chronic hepatitis B patients for several reasons." | 2.50 | HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs? ( Buti, M, 2014) |
| " Long-term administration of ETV or TDF suppresses HBV replication in >95% of patients after 5 years of treatment with high rates of biochemical normalization, regression of fibrosis and cirrhosis at histology as well as preventing clinical decompensation but not HCC, in compensated cirrhosis and improving survival." | 2.50 | HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues? ( Lampertico, P; Mangia, G; Viganò, M, 2014) |
| "Although a rather benign course of chronic hepatitis B virus (HBV) infection during childhood has been described, 3-5% and 0." | 2.50 | Management of chronic hepatitis B in children: an unresolved issue. ( Cainelli, F; Comparcola, D; Della Corte, C; Nobili, V; Vento, S, 2014) |
| "Should treatment of chronic hepatitis B virus infection be necessary during pregnancy, tenofovir, listed by the FDA as pregnancy category B drug, is to be preferred." | 2.49 | [Interdisciplinary aspects of and new drugs for chronic hepatitis B]. ( Horváth, G, 2013) |
| "We expect future eradication of chronic hepatitis B virus infection by proper prevention and optimal management of antiviral resistance." | 2.49 | Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade. ( Hwang, SG; Yim, HJ, 2013) |
| "In children, the natural history of chronic hepatitis B and C is different from that in adults." | 2.49 | [Treatment of viral hepatitis in children]. ( Kekez, AJ, 2013) |
| "Specialized treatment of CHB in pregnancy, coinfection, decompensated cirrhosis, and posttransplant is safe and effective." | 2.48 | New advances in chronic hepatitis B. ( Lee, WM; Tujios, SR, 2012) |
| "There are five approved drugs for the treatment of chronic hepatitis B(lamivudine, adefovir dipivoxil [ADV], entecavir [ETV], as well as pegylated and standard interferon) in Japan." | 2.48 | [New drugs of treatment of patients with chronic hepatitis B]. ( Suzuki, F, 2012) |
| "The specific drugs available for chronic hepatitis B infection include standard and pegylated IFN-α, and nucleoside/nucleotide analogs that directly inhibit the reverse transcriptase." | 2.48 | Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. ( Buti, M; Homs, M, 2012) |
| "Treatment of chronic hepatitis B (CHB) with nucleos(t)ide analogs is often required over a prolonged period to achieve durable virologic suppression." | 2.48 | Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs. ( Buti, M; Petersen, J, 2012) |
| " However, drug resistance caused by their long-term use becomes a practical problem, which influences the long-term outcomes in patients." | 2.48 | Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues. ( Cui, YJ; Song, ZL; Teng, DH; Zheng, H; Zheng, WP, 2012) |
| "In the natural history of chronic hepatitis B infection, HBeAg marks the first two of the four phases, namely the immune tolerant phase and the immune clearance phase, and is associated with highly replicative activity of the hepatitis B virus (HBV)." | 2.47 | Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues. ( Leung, N, 2011) |
| "Major progress in the treatment of chronic hepatitis B (CHB) has been made during the last decade with the development of antivirals that inhibit viral polymerase activity." | 2.47 | Hepatitis B virus resistance to antiviral drugs: where are we going? ( Zoulim, F, 2011) |
| "Treatment of chronic hepatitis B is still challenging." | 2.47 | [Interferon-based versus direct antiviral therapy in patients with chronic hepatitis B]. ( Tornai, I, 2011) |
| " In most patients, NUC need to be administered on a long-term basis, thus increasing the risk of adverse effects." | 2.47 | Drug safety evaluation of adefovir in HBV infection. ( Colombo, M; Lampertico, P; Viganò, M, 2011) |
| "Antiviral therapy is aimed to persistently suppress hepatitis B virus (HBV) to prevent liver complications and improve survival and long-term administration of nucleos(t)ide analogues represents an attractive treatment strategy." | 2.45 | HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues. ( Colombo, M; Lampertico, P, 2009) |
| "The main goal for treatment of chronic hepatitis B is to prevent complications such as liver cirrhosis or hepatocellular carcinoma." | 2.44 | Treatment of chronic hepatitis B infection: an update of Swedish recommendations. ( Bläckberg, J; Duberg, AS; Fischler, B; Friman, S; Karlström, O; Lindh, M; Norkrans, G; Reichard, O; Sangfeldt, P; Söderström, A; Sönnerborg, A; Uhnoo, I; Weiland, O; Wejstål, R; Wiström, J, 2008) |
| "Chronic hepatitis B is still a major public health problem, aggravated by the growing phenomenon of immigration from areas with a high prevalence of infection with this virus." | 2.44 | [Clinical management of patients with chronic hepatitis B virus infection]. ( González-Diéguez, ML; Rodríguez, M, 2008) |
| "adefovir/pegIFN-alpha) were not available." | 2.44 | Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: a systematic review of economic evidence. ( Jiang, XH; Li, YP; Qin, WX; Sun, X, 2007) |
| "However, recurrence rates are high after cessation of treatment." | 2.43 | [Management of chronic hepatitis B]. ( von Weizsäcker, F, 2005) |
| "Appropriate management of chronic hepatitis B must rely not only on the standard serologic markers but also on tests that quantify viral load and on the study of viral genome variability according to clinical situation." | 2.43 | [New virologic tests and their application in management of chronic hepatitis B]. ( Zoulim, F, 2006) |
| "Regardless of prophylaxis, the risk of recurrence is associated with pre-graft viral load." | 2.43 | [Liver transplantation for complications of hepatitis B]. ( Roche, B; Samuel, D, 2006) |
| "To address the clinical management of chronic hepatitis B virus (HBV) infection." | 2.43 | Management of chronic hepatitis B virus infection: current perspectives for the nurse practitioner. ( Perrillo, R, 2006) |
| "Registered treatment for chronic hepatitis B currently consists of (pegylated) interferon, lamivudine and adefovir, while entecavir is expected to be licensed in the short term." | 2.43 | Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression? ( Buster, EH; Janssen, HL, 2006) |
| " Physicochemical properties, cellular permeation, renal toxicity, and bioavailability all had to be addressed during the development of these compounds." | 2.43 | Perspectives on the development of acyclic nucleotide analogs as antiviral drugs. ( Lee, WA; Martin, JC, 2006) |
| "In patients with liver cirrhosis (Child B and C) only nucleos(t)ides should be used." | 2.43 | [Therapy of hepatitis B virus infection]. ( Trautwein, C, 2006) |
| "About 350 million people worldwide have chronic hepatitis B virus (HBV) infection." | 2.42 | Slowing the progression of chronic hepatitis B. Early antiviral therapy can help minimize complications. ( Jacobson, IM; Purow, DB, 2003) |
| "Adefovir dipivoxil (Hepsera) is an oral prodrug of the nucleotide analogue adefovir." | 2.42 | Adefovir dipivoxil: a review of its use in chronic hepatitis B. ( Dando, T; Plosker, G, 2003) |
| "Furthermore, chronic hepatitis B was historically a controversial indication for liver transplantation because of a low post-transplant survival, with graft infection being the major contributor to adverse outcomes." | 2.42 | Nucleoside analogues and other antivirals for treatment of hepatitis B in the peritransplant period. ( Keeffe, EB; Yu, AS, 2003) |
| "Adefovir dipivoxil is an oral prodrug of adefovir, a nucleotide analogue of adenosine monophosphate." | 2.42 | [Application and efficacy of adefovir dipivoxil in hepatitis B virus-associated chronic liver diseases]. ( Cho, YK; Kim, BI, 2003) |
| "Adefovir dipivoxil is an acyclic nucleotide analogue that was developed in part to improve on the limitations of earlier therapies." | 2.42 | Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection. ( Mattes, KA; Qaqish, RB; Ritchie, DJ, 2003) |
| "The treatment plan for chronic hepatitis B needs to be individualized based on the stage of both viral infections and the available options." | 2.42 | Management of chronic hepatitis B in the HIV-infected patient. ( Thio, CL, 2004) |
| "Treatment with Adefovir dipivoxil is a long term treatment (48 weeks), it is well tolerated, and side effects are moderate and reversible." | 2.42 | [Adefovir dipivoxil is a new drug for treatment of chronic hepatitis B]. ( Stránský, J, 2004) |
| "Currently approved treatments for chronic hepatitis B are limited by low rates of sustained response, side effects, or drug resistance." | 2.42 | New treatment of chronic hepatitis B. ( Lok, AS, 2004) |
| "The prevalence of chronic hepatitis B infection varies greatly in different regions of the world." | 2.42 | Antiviral therapy for treatment-naïve hepatitis B virus patients. ( Lau, DT; Membreno, FE, 2004) |
| "The treatment of the patient with chronic hepatitis B virus infection (HBV) must be carried out with the knowledge that the percentage of patients infected with the B virus that develop chronic hepatitis remains between 5-10%." | 2.42 | [Treatment of chronic hepatitis B virus infection]. ( Carreño, N; Moreno, D; Sangro, B, 2004) |
| "Treatment of chronic hepatitis B needs to consider two aspects." | 2.42 | [Management of hepatitis B]. ( de Gottardi, A; Negro, F, 2004) |
| "For HBeAG-positive chronic hepatitis B and HBeAG-negative chronic hepatitis B, the duration of interferon therapy is 4-6 months and 12 months, respectively." | 2.42 | Treatment of chronic hepatitis B: who to treat, what to use, and for how long? ( Fung, SK; Lok, AS, 2004) |
| "In hepatitis B e antigen-negative chronic hepatitis B, adefovir dipivoxil was recently found to maintain its efficacy even after 3 years of therapy." | 2.42 | Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. ( Hadziyannis, SJ; Papatheodoridis, GV, 2004) |
| "Chronic hepatitis B virus infection is common and may cause significant disease morbidity, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma." | 2.41 | Update on the management of chronic hepatitis B. ( Davis, GL, 2002) |
| "In IFN-naive patients with chronic hepatitis B (and compensated liver disease) alpha-interferon is still the first-line therapy." | 2.41 | [New developments in therapy of chronic hepatitis B. When are nucleoside analogs indicated?]. ( Erhardt, A; Häussinger, D; Heintges, T; Petry, W, 2000) |
| "Lamivudine has been demonstrated to have consistent efficacy and safety in large-scale, phase III clinical trials." | 2.41 | Nucleoside analogues in the treatment of chronic hepatitis B. ( Leung, N, 2000) |
| "Lamivudine has been introduced as an alternative to IFN, showing at least similar efficacy, but with a wider spectrum of indications and without the adverse effects." | 2.41 | Drug therapy for hepatitis B. ( Regev, A; Schiff, ER, 2001) |
| " The aim was to investigate the expression of IL-1β in CHB patients treated with Peg-IFN-α combination with TDF and TDF/Peg-IFN-α monotherapy." | 1.91 | The expression of interleukin-1β in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy. ( Hu, X; Li, Y; Luo, H; Qin, B; Tan, G, 2023) |
| "We retrospectively enrolled 70 unresectable HCC patients who were seropositive for HBsAg and accepted tenofovir alafenamide fumarate (TAF) therapy before anti-PD-1 in combination with an antiangiogenic treatment." | 1.72 | Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis. ( Chen, J; Hu, X; Li, Q; Li, R; Yuan, G; Zang, M, 2022) |
| " TAF was well tolerated and only 4 patients discontinued therapy due to adverse event during a median duration of TAF dosing of 74 weeks." | 1.72 | Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV. ( Bernstein, DE; Fried, MW; Lok, AS; Mospan, AR; Schiff, ER; Smith, CI; Trinh, HN; Zink, RC, 2022) |
| "The prediction of hepatocellular carcinoma (HCC) development during nucleotide/nucleoside analog (NA) therapy is clinically important in patients with chronic hepatitis B." | 1.56 | Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog. ( Hayakawa, Y; Higuchi, M; Inada, K; Itakura, J; Izumi, N; Kaneko, S; Kirino, S; Kurosaki, M; Maeyashiki, C; Nakanishi, H; Okada, M; Osawa, L; Sekiguchi, S; Shimizu, T; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Wang, W; Watakabe, K; Yamashita, K; Yasui, Y, 2020) |
| "Fanconi syndrome with osteomalacia can develop in patients with chronic hepatitis B infection being treated with adefovir at a conventional low dosage of 10 mg/day." | 1.56 | Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report. ( Cen, X; Cui, Y; Liu, Z; Mu, G; Xiang, Q; Xie, Q; Yu, Y; Zhang, H; Zhang, J, 2020) |
| " Secondary assessments included maternal HBV DNA reduction at delivery, and maternal or infant adverse events during follow up." | 1.56 | Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study. ( Cao, L; Chen, B; Chen, R; Ding, Y; Fan, J; Gan, W; Huang, Y; Lin, C; Liu, Y; Pan, CQ; Sheng, Q; Wang, S; Wang, Y; Zhu, L, 2020) |
| "A 68-year-old man with type 2 diabetes mellitus and chronic hepatitis B infection was referred to the nephrology department before planned surgery for hepatocellular carcinoma." | 1.51 | Hypophosphatemic Osteomalacia Associated with Adefovir-induced Fanconi Syndrome Initially Diagnosed as Diabetic Kidney Disease and Vitamin D Deficiency. ( Iino, N; Koda, R; Narita, I; Tsuchida, M, 2019) |
| "The optimal management of chronic hepatitis B (CHB) patients with partial virologic response (PVR) to tenofovir disoproxil fumarate (TDF) remains unclear." | 1.51 | Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice. ( Kim, BS; Lee, CH; Song, JE, 2019) |
| "Acquired Fanconi syndrome has been associated with the long-term ingestion of several nucleoside analogs used to treat chronic hepatitis B virus infection." | 1.51 | A case of entecavir-induced Fanconi syndrome. ( Fujii, T; Kawasoe, K; Nitta, K; Ohta, A, 2019) |
| "In areas where chronic hepatitis B virus infection is prevalent, acute hepatitis E virus superinfection on chronic hepatitis B virus infection occurs sporadically." | 1.48 | Seroclearance of hepatitis B surface antigen following hepatitis E exacerbation on chronic hepatitis E and B dual infection in a renal transplant recipient: a case report. ( Chiang, YJ; Chu, YD; Yeh, CS; Yeh, CT, 2018) |
| "Fanconi syndrome is a rare adverse effect of tenofovir disoproxil fumarate (TDF)." | 1.46 | Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient. ( Karris, MY, 2017) |
| "A major hurdle in the long-term treatment of chronic hepatitis B (CHB) patients is to maintain viral suppression in the absence of drug resistance." | 1.46 | No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment. ( Buti, M; Cathcart, AL; Corsa, AC; Flaherty, JF; Gane, EJ; Kitrinos, KM; Liu, Y; Marcellin, P; Miller, MD, 2017) |
| "Long-term TDF treatment appears to be safe and effective in patients with prior failure of LAM and a suboptimal response to ADV therapy." | 1.46 | Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy. ( Angus, P; Bowden, S; Desmond, P; George, J; Lee, A; Lim, L; Locarnini, S; Marion, K; Nicoll, A; Patterson, S; Roberts, S; Sievert, W; Strasser, S; Thompson, A, 2017) |
| "Mortality and complications including hepatocellular carcinoma are associated primarily with cirrhosis and age, but not with HBeAg status or viral load probably because modern therapies considerably reduce viral replication in almost all patients." | 1.43 | Long-term follow-up of HBsAg-positive patients in Germany. ( Amani, A; Niederau, C; Thiel, A, 2016) |
| "Multidrug resistance protein 4 is a critical protein associated with the antiviral efficacy of NAs, and combination therapy of NA and MRP inhibitors could reduce the dosage for long-term NA use." | 1.43 | Multidrug resistance protein 4 is a critical protein associated with the antiviral efficacy of nucleos(t)ide analogues. ( Chen, Q; Liu, W; Liu, Y; Lu, M; Song, H; Wang, B; Xu, C; Xu, D; Yang, D; Zhang, W; Zheng, X, 2016) |
| "Eighty-one chronic hepatitis B patients with a viral load above 4 log 10 copies/ml and high levels of serum alanine aminotransferase were treated with ETV 0." | 1.43 | Profile of HBV polymerase gene mutations during entecavir treatment in patients with chronic hepatitis B. ( Song, J; Sun, M; Tan, G; Wang, J; Wu, X, 2016) |
| "The cumulative probability of HBV recurrence at 1, 3, 5, and 7 years was 1%, 3%, 3%, and 4%, respectively." | 1.43 | The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence. ( Akyildiz, M; Balci, D; Cinar, K; Dayangac, M; Gungor, G; Hazinedaroglu, S; Idilman, R; Kalkan, C; Keskin, O; Tokat, Y; Yilmaz, TU, 2016) |
| "Reduction of viraemia in patients with chronic hepatitis B virus (HBV) infection using nucleoside/nucleotide analogues reduces fatal liver disease-related events, but development of resistance in virus presents serious clinical challenge." | 1.43 | Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study. ( Dixit, VK; Jain, AK; Nath, G; Singh, N; Srivastava, M, 2016) |
| "The treatments for chronic hepatitis B (CHB) are interferon and nucleoside analogues reverse transcriptase (RT) inhibitors." | 1.42 | Discovering novel direct acting antiviral agents for HBV using in silico screening. ( Enomoto, M; Hayakawa, M; Iwadate, M; Kawada, N; Murakami, Y; Tamori, A; Tanahashi, T; Umeyama, H; Yano, Y, 2015) |
| "This case indicates that Fanconi's syndrome with osteomalacia can be acquired by a chronic hepatitis B patient taking ADV at a conventional dosage of 10 mg/day." | 1.42 | Osteomalacia and Fanconi's syndrome caused by long-term low-dose adefovir dipivoxil. ( Chen, YS; Sun, FR; Wang, BF; Wang, BY; Wang, Y; Zhang, D, 2015) |
| "Charts were reviewed for LAM-resistant chronic hepatitis B (CHB) patients who visited the Zhejiang Province People's Hospital and The First Affiliated Hospital, College of Medicine, Zhejiang University, from June 2009 to May 2013." | 1.42 | Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients. ( Huang, HJ; Li, MW; Pan, HY; Xie, YJ; Yang, DH; Zhao, NF, 2015) |
| "Splenomegaly is a common finding in chronic hepatitis B infection." | 1.42 | Remission of splenic marginal zone lymphoma in a patient treated for hepatitis B: a case of HBV-associated lymphoma. ( Huits, RM; Koot, AW; Visscher, AP, 2015) |
| "Viral genotype shift in chronic hepatitis B (CHB) patients during antiviral therapy has been reported, but the underlying mechanism remains elusive." | 1.42 | Deep sequencing analysis of HBV genotype shift and correlation with antiviral efficiency during adefovir dipivoxil therapy. ( Chen, J; Gong, X; Huang, A; Huang, W; Liang, Z; Shan, X; Shan, Y; Wang, Y; Xu, G; Zen, A; Zhang, D; Zhang, X; Zhao, Y; Zhou, X, 2015) |
| "Lamivudine resistance was common in all populations, especially in Hans with prevalence of 42." | 1.42 | Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China. ( Cai, B; Chen, J; Liao, Y; Lu, X; Su, Z; Tao, C; Wang, L; Ying, B; Zhang, Q, 2015) |
| " No significant adverse event was observed due to TDF administration; renal function pre- and post-LT were also acceptably preserved." | 1.40 | One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation. ( Lilly, LB; Renner, EL; Selzner, N; Tanaka, T; Therapondos, G, 2014) |
| "Chronic hepatitis B is an important health problem worldwide." | 1.40 | Lamivudine and Adefovir Motif Variants Detected in chronic Hepatıtıs B patients. ( Atmaca, S; Mese, S; Ozbek, E; Ozekinci, T, 2014) |
| "Adefovir has a good inhibitory effect against the latent or hidden HBV in neutrophils." | 1.40 | [Detection and analysis of HBV in polymorphonuclear neutrophils of patients with hepatitis B]. ( Han, Z; Wang, J, 2014) |
| " Antiviral treatments were withdrawn in patients who met all of the following 7 criteria: (i) no clinical and histologic evidence of cirrhosis, (ii) normal liver biochemistry, (iii) negative for both HBV DNA and hepatitis B envelope antigen (HBeAg), (iv) no resistance to antiviral agent, (v) antiviral therapy > 9 months, (vi) maintenance dosage of immunosuppressant for > 3 months, and (vii) no history of acute rejection during recent 6 months." | 1.40 | Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection. ( Cho, JH; Choi, JY; Huh, S; Kang, YJ; Kim, CD; Kim, HK; Kim, JS; Kim, YL; Kwon, O; Lim, JH; Park, GY; Park, SH, 2014) |
| "Twenty chronic hepatitis B (CHB) patients who had been receiving ETV for more than 6 months and developed virologic breakthrough due to ETV resistance were consecutively enrolled." | 1.40 | Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations. ( Baik, SK; Chae, HB; Hong, SP; Kim, CW; Kim, JH; Kim, MY; Kim, YS; Lee, CD; Lee, HJ; Lee, JI; Lee, JW; Lee, MS; Park, CK; Park, SH; Seo, YS; Suh, SJ; Um, SH; Yim, HJ, 2014) |
| "The treatment of HBeAg-negative chronic hepatitis B (CHB) is considered to be open-ended, with no guidelines for treatment cessation." | 1.40 | Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides. ( Afdhal, NH; Bonder, A; Lau, D; Patwardhan, VR; Sengupta, N, 2014) |
| "The prevalence of chronic hepatitis B in Bangladesh is reported to be 7." | 1.40 | Efficacy of adefovir dipivoxil therapy in patients with chronic hepatitis B viral infection. ( Chowdhury, MS; Khan, MR; Mahmuduzzaman, M; Miah, AR; Rahman, KM; Raihan, MA; Roknuzzaman, SM; Roy, PK; Saha, M, 2014) |
| "Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) is the most frequent and difficult-to-treat viral hepatitis worldwide." | 1.39 | Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis. ( Bonino, F; Brunetto, MR; Caputo, A; Coco, B; Espinos, B; Iannazzo, S; Latour, A; Rossetti, F, 2013) |
| "HIV worsens the natural history of chronic hepatitis B virus (HBV) infection." | 1.39 | Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B. ( Aguilera, A; Barreiro, P; del Romero, J; Mena, A; Pedreira, J; Plaza, Z; Poveda, E; Rodriguez, C; Sierra-Enguita, R; Soriano, V; Tomé, S; Vispo, E, 2013) |
| "Combined prophylaxis with TDF/ETV nucleoside plus nucleotide analogs and cessation of immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective." | 1.39 | Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective. ( Braat, AE; Claas, EC; Coenraad, MJ; Knoester, M; van Hoek, B; Vossen, AC; Wesdorp, DJ, 2013) |
| "Treated with adefovir dipivoxil antiviral therapy, and mesured the setologic indicators after 12 weeks, 24 weeks,36 weeks and 48 weeks." | 1.39 | [The clinical significance of hepatitis B virus large surface protein in the diagnosis and treatment of patients with hepatitis B]. ( Chen, W; Sun, Q; Xie, FY, 2013) |
| "Some patients with chronic hepatitis B virus (HBV) infection progress to hepatocellular carcinoma (HCC)." | 1.39 | Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. ( Andou, Y; Hisanaga, Y; Kanamori, A; Kiriyama, S; Kumada, T; Niinomi, T; Tada, T; Tanaka, J; Tanikawa, M; Toyoda, H; Yamamoto, K; Yasuda, S, 2013) |
| "Patients with chronic hepatitis B receiving different schedules of nucleoside/nucleotide analogues were followed for a median duration of 102 months, i." | 1.39 | Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. ( Bahrami, S; Chevaliez, S; Grare, M; Hézode, C; Pawlotsky, JM, 2013) |
| "In patients affected by chronic hepatitis because of HBV infection, long-term suppressive therapy with nucleos(t)ides analogues in the HBeAg- patients has shown low effects on HBsAg titre (qHBsAg) decrease, and HBsAg loss is difficult to achieve." | 1.39 | Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D. ( Baietto, L; Boglione, L; Burdino, E; Cariti, G; Cusato, J; D'Avolio, A; De Rosa, FG; Di Perri, G; Ghisetti, V; Gregori, G, 2013) |
| "TDF/emtricitabine was less likely to be associated with detectable HBV than other regimens, including TDF monotherapy (odds ratio, 2." | 1.39 | Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. ( Avihingsanon, A; Bowden, S; Dore, GJ; Finlayson, R; Hoy, JF; Lewin, SR; Littlejohn, M; Locarnini, S; Matthews, GV; Revill, PA; Ruxrungtham, K; Sasadeusz, J; Saulynas, M; Seaberg, EC; Thio, CL, 2013) |
| "Patients with HBV recurrence were divided into four groups according to their treatment: group L (lamivudine-based therapy n = 21) and group N [new nucleos(t)ide analogue (NA)-based therapy, n = 38]." | 1.39 | Outcome of various treatments for posttransplant hepatitis B virus recurrence. ( Han, SS; Hong, G; Kong, SY; Lee, KB; Lee, KW; Park, KU; Park, SJ; Suh, KS; Yi, NJ, 2013) |
| "To investigate 3-year antiviral efficacy and side effect of adefovir dipivoxil (ADV) on the old patients with hepatitis B chronic infection." | 1.38 | [Three-year efficacy and side effect of adefovir dipivoxil for the treatment of the old patients with chronic hepatitis B virus infection]. ( Lou, GQ; Lu, L; Qian, JC; Shi, JP; Yan, FL; Zhu, MF, 2012) |
| "Adefovir dipivoxil (ADV) is an oral bioavailable prodrug of adefovir that possesses potent in vitro activity against hepadnaviruses, retroviruses and herpes viruses." | 1.38 | Nephrotoxicity, including acquired Fanconi's syndrome, caused by adefovir dipivoxil - is there a safe dose? ( Ho, YY; Law, ST; Li, KK, 2012) |
| " Modification of the dosing interval or discontinuation of ADV was required in seven and three patients, respectively, and none of them showed a further decline in the eGFR." | 1.38 | Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. ( Cho, HC; Choi, MS; Gwak, GY; Kim, YJ; Koh, KC; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC, 2012) |
| "This retrospective study enrolled 38 chronic hepatitis B patients treated with IFN-α plus a nucleos(t)ide analog who achieved HBsAg seroconversion during the period from June 2001 to May 2009." | 1.38 | Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog. ( Cao, Z; Chen, X; Jin, Y; Liu, Y; Ma, B; Ma, L; Wu, H; Yu, H; Zhang, H; Zhang, Y; Zheng, Y, 2012) |
| " Several studies suggest that NAs long-term administration have been associated with low rates of serious adverse events (AEs), including lactic acidosis, renal function impairment, osteopenia and osteoporosis." | 1.38 | Safety of long-term nucleos(t)ide treatment in chronic hepatitis B. ( Ridruejo, E; Silva, MO, 2012) |
| "The effectiveness of antiviral treatments of chronic hepatitis B has been poorly studied in Brazil." | 1.38 | Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes. ( Fernandes, CA; Gomes, Sde A; Mello, FC, 2012) |
| "In patients with chronic hepatitis B virus (HBV) infection, persistent exposure to high concentrations of antigen can disrupt T-cell functions." | 1.38 | Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. ( Alfieri, A; Boni, C; Brancaccio, G; Colombo, M; Ferrari, C; Gaeta, GB; Giuberti, T; Laccabue, D; Lampertico, P; Missale, G; Pesci, M; Schivazappa, S; Viganò, M, 2012) |
| "We report on how adefovir-induced membranous nephropathy related to hepatitis B was caused by lamivudine-resistant virus after a liver transplant due to Byler's disease." | 1.38 | A case of adefovir-induced membranous nephropathy related to hepatitis B caused by lamivudine-resistant virus after liver transplant due to Byler's disease. ( Ebata, S; Hashimoto, S; Ishikawa, Y; Ito, M; Koike, T; Maoka, T; Mochizuki, T; Suzuki, A, 2012) |
| "New insights into the treatment of chronic hepatitis B with relevance for clinical practice have been adopted in these concise, revised guidelines." | 1.38 | The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection. ( Baak, BC; Bakker, CM; Beuers, UH; Brouwer, JT; Buster, EH; Drenth, JP; Honkoop, P; Janssen, HL; Kerbert-Dreteler, MJ; Koek, GH; Tan, AC; van der Spek, BW; van Erpecum, KJ; van Hoek, B; van Nieuwkerk, KM; van Soest, H; Vrolijk, JM, 2012) |
| "Lamivudine treatment improves renal outcome in patients with hepatitis B virus-associated MN (HBV-MN), but prolonged use leads to the emergence of lamivudine-resistant variants." | 1.38 | Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains. ( Choi, BS; Choi, SR; Chung, BH; Hong, YA; Kim, YS; Park, CW; Park, HS; Sun, IO; Yang, CW, 2012) |
| "Current agents used in the treatment of chronic hepatitis B (CHB) can be classified into interferons-α (IFN-α: standard or pegylated) and nucleos(t)ide analogues (NUCs)." | 1.37 | Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues. ( Papatheodoridis, GV, 2011) |
| "Lamivudine (LAM) has been extensively used to treat hepatitis B, but high incidence of drug resistance has required rescue studies." | 1.37 | Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B. ( Chung, GE; Hwang, SY; Jeong, JB; Jung, YJ; Kim, BG; Kim, D; Kim, HY; Kim, W; Kim, YJ; Lee, HS; Lee, JH; Lee, KL; Yoon, JH, 2011) |
| "Forty-five HBeAg-positive chronic hepatitis B patients with a virologic response [negative PCR (<12 IU/ml)] who had discontinued therapy were analyzed retrospectively for VR, HBeAg reversion and biochemical flare." | 1.37 | Defining virologic relapse in chronic hepatitis B. ( Cho, HC; Choi, MS; Gwak, GY; Kim, KH; Koh, KC; Lee, JH; Lee, YY; Paik, SW; Sinn, DH; Yoo, BC; Yun, WK, 2011) |
| " IFN therapy requires dosage reduction and close monitoring in patients with a GFR <50 ml/min/1." | 1.37 | Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects? ( Bob, F; Bozdog, G; Cioca, D; Curescu, M; Gadalean, F; Gluhovschi, C; Gluhovschi, G; Kaycsa, A; Petrica, L; Sporea, I; Velciov, S; Vernic, C, 2011) |
| "The effect of chronic hepatitis B (CHB) treatment on hepatocyte apoptosis has not been evaluated." | 1.37 | Changes of serum levels of keratin-18 fragments in hepatitis B e antigen-negative chronic hepatitis B patients under oral antiviral therapy. ( Georgiou, A; Giannousis, IP; Hadziyannis, E; Manolakopoulos, SG; Papatheodoridis, GV, 2011) |
| "Treatment with adefovir dipivoxil reduced the frequency of CD4(+)CXCR5(+) TFH, PD-1(+)CD4(+)CXCR5(+) TFH cells and the concentrations of HBsAg and HBeAg, but increased the concentrations of HBsAb, HBeAb, IL-2 and IFN-γ in IA patients." | 1.37 | High frequency of CD4+ CXCR5+ TFH cells in patients with immune-active chronic hepatitis B. ( Feng, J; Hua, C; Jiang, Y; Li, W; Lu, L; Qin, L; Shi, X; Wang, J; Wang, Y; Zhao, P, 2011) |
| "In total, 33 patients with chronic hepatitis B virus (HBV) infection with evidence of active viral replication (HBV DNA levels ≥ 10(5) copies/mL) or a history of treatment failure to lamivudine/adefovir sequential therapy between April 2007 and July 2009 were treated with entecavir (1." | 1.37 | Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir. ( Cho, YS; Choi, JW; Kim, KA; Kwak, MS; Lee, CK; Lee, JS; Park, BK; Suh, JH; Won, SY, 2011) |
| "Adefovir Dipivoxil (ADV) is an important agent to suppress hepatitis B virus (HBV) replication with suboptimal effect on virological and serological response." | 1.37 | Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective study. ( Geng, da Y; Lu, B; Lu, H; Ma, LX; Shen, F; Zhang, JY, 2011) |
| "Forty adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance who had received entecavir for > or = 6 months were included and monitored for virologic response and entecavir resistance." | 1.36 | Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance. ( Cheong, JY; Cho, SW; Hong, SP; Kim, SO; Koh, KH; Lee, MH; Yoo, WD, 2010) |
| "A total of 44 chronic hepatitis B (CHB) patients (mean age: 42 +/- 13." | 1.36 | [Genotype distribution of chronic hepatitis B and hepatitis C patients and investigation of the resistance patterns in hepatitis B cases]. ( Akcan, Y; Altindiş, M; Demirdal, T; Demirtürk, N; Gülamber, G; Kalayci, R, 2010) |
| "With lamivudine as initial treatment, 62% of patients developed drug resistance after 4 years." | 1.36 | Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments. ( Chan, TM; Choy, BY; Tang, CS; Yap, DY; Yuen, MF; Yung, S, 2010) |
| "In treatment-naive patients with chronic hepatitis B the first line therapy should be PeglFN-alpha2a monotherapy, and the first-line should be entecavir or tenofovir (highest potential for HBV replication suppression and high genetic barrier to resistance)." | 1.36 | [Antiviral treatment of chronic B hepatitis; 2010 - therapeutic recommendations]. ( Boroń-Kaczmarska, A; Cianciara, J; Flisiak, R; Gładysz, A; Halota, W; Juszczyk, J; Kryczka, W; Malkowski, P; Pawlowska, M; Simon, K, 2010) |
| "Data on liver fibrosis evolution in HIV-HBV-coinfected patients treated with tenofovir disoproxil fumarate (TDF) are scarce." | 1.36 | Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. ( Bonnard, P; Boyd, A; Girard, PM; Lacombe, K; Lascoux-Combe, C; Lasnier, E; Meynard, JL; Miailhes, P; Molina, JM; Wendum, D, 2010) |
| "Overall, 63 (13%) patients had chronic hepatitis B (HBsAg-positive), 115 (23%) had never been exposed to HBV (HBsAg-negative, anti-HBc-negative and anti-HBs-negative), 108 (22%) had signs of cured infection (anti-HBc-positive and anti-HBs-positive) and 209 (42%) had isolated anti-HBc (HBsAg-negative, anti-HBc-positive and anti-HBs-negative)." | 1.36 | Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire. ( Anglaret, X; Attia, A; Chenal, H; Danel, C; Eholié, S; Gabillard, D; Messou, E; N'Dri-Yoman, T; Polneau, S; Seyler, C; Toni, T; Wakasugi, N, 2010) |
| "Serum samples of 199 chronic hepatitis B patients undergoing NA treatment from five hospitals in four northern cities of China were obtained between January 2007 and July 2009." | 1.36 | Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients. ( Abuduheilili, X; Dong, JP; Hou, CS; Jiao, XJ; Li, T; Li, XG; Liu, BM; Sun, XW; Wang, YH; Xu, J; Yan, CH; Yan, L; Yang, JX; Zhuang, H, 2010) |
| "HBV genotypes from 177 HBeAg-positive chronic hepatitis B (CHB) patients were identified and the patients were treated with ADV 10 mg per day for 48 weeks." | 1.35 | [Comparison of antiviral responses to adefovir dipivoxil therapy of genotype B and genotype C HBV infected patients]. ( Deng, H; Guo, JJ; Hao, MJ; Huang, AL; Huang, WX; Li, QL; Peng, FY; Xin, XJ; Yang, C; Yuan, Z; Zeng, AZ; Zhang, ZZ, 2008) |
| "Lamivudine has a high rate of antiviral resistance." | 1.35 | Rapid re-emergence of YMDD mutation of hepatitis B virus with hepatic decompensation after lamivudine retreatment. ( Byun, KS; Choe, WH; Kwon, SY; Lee, CH; Yeon, JE, 2008) |
| "Lamivudine resistance is a result of mutations in YMDD motif in which rt203-206th codons (Y: tyrosine; M: methionin; D: aspartic acid; D: aspartic acid) of reverse trancriptase; the catalytic part of hepatitis B polymerase enzyme, takes place." | 1.35 | [YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy]. ( Arslan, U; Findik, D; Ural, O, 2008) |
| "Adefovir dipivoxil (ADV) is a nucleotide analogue that inhibits wild-type hepatitis B virus (HBV) and lamivudine (LMV)-resistant HBV mutants." | 1.35 | [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection]. ( Bae, JH; Cho, M; Heo, J; Kang, DH; Kim, GH; Moon, JH; Song, GA; Yoon, KT, 2008) |
| "Adefovir has a potent antiviral activity as a rescue treatment against lamivudine-resistant strains." | 1.35 | Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B. ( Cha, CK; Cheong, JY; Cho, SW; Hong, SP; Kim, SO; Kwon, HC; Yoo, WD, 2009) |
| "A total of 97 chronic hepatitis B (CHB) patients with YMDD mutants who had been treated with ADV for >12 months were analysed." | 1.35 | Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy. ( Chung, YH; Kim, JA; Kim, KM; Kim, SE; Lee, HC; Lee, YS; Lim, YS; Park, NH; Shin, JW; Suh, DJ, 2009) |
| "Lamivudine was started at the same time as the TNF antagonist in the other 2 patients, whose viral loads remained undetectable." | 1.35 | Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy. ( Di Martino, V; Herbein, G; Prati, C; Toussirot, E; Wendling, D, 2009) |
| "Long-term management of some chronic hepatitis B patients might require combination therapy using drugs with distinct resistance profiles to sustain viral suppression and to reduce the resistance-associated failure." | 1.35 | Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues. ( Borroto-Esoda, K; Curtis, M; Miller, MD; Qi, X; Zhu, Y, 2009) |
| "Diagnosis and treatment of chronic hepatitis B (CHB) have improved in recent years with introduction of new oral antiviral drugs." | 1.35 | Current trends in chronic hepatitis B management: results of a questionnaire. ( Buti, M; Córdoba, J; Esteban, R; García-Martínez, R; Les, I; Quintana, M, 2009) |
| "We performed a cohort study of 290 chronic hepatitis B patients: 145 patients treated with 10 mg ADV and 145 patients unexposed to ADV at two community clinics, who were matched for age (+/-10 years), sex, and baseline eGFR." | 1.35 | Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. ( Garcia, RT; Ha, NB; Levitt, BS; Nguyen, HA; Nguyen, KK; Nguyen, MH; Trinh, HN; Vu, AA, 2009) |
| "A 36 year old man with chronic hepatitis B and cirrhosis was admitted in our Department for the onset of jaundice, ascites and ALT flare (x 35 u." | 1.35 | Salvage therapy with tenofovir followed by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare. ( Brancaccio, G; Gaeta, GB; Nardiello, S; Precone, V; Sgrò, G; Stornaiuolo, G, 2009) |
| "In lamivudine-treated samples, wild-type strains (57." | 1.35 | Dynamic changes of HBV quasispecies and deletion patterns in a chronic hepatitis B patient. ( Ding, H; Ji, F; Li, F; Ma, S; Zeng, C; Zhou, L, 2009) |
| "A total of 170 naïve HBeAg-positive chronic hepatitis B patients were treated with a nucleoside/nucleotide analogues (NA), either lamivudine, adefovir, entecavir, or telbivudine, for at least 2 years and followed up for 1 more year." | 1.35 | Different models of HBeAg seroconversion predicated by on-treatment ALT and HBV DNA profiles. ( Cong, M; Jia, J; Li, H; Liu, T; Ma, H; Ou, X; Ren, J; Wang, B; Wang, P; Wang, X; You, H, 2009) |
| "Chronic hepatitis B affects 5-10% of HIV patients in Western countries." | 1.35 | Hepatitis B in HIV patients: what is the current treatment and what are the challenges? ( Barreiro, P; Fernández, JV; Labarga, P; Medrano, J; Soriano, V; Tuma, P; Vispo, E, 2009) |
| "Individuals with chronic hepatitis B infection carry a significantly increased risk of life-threatening liver sequelae including cirrhosis, hepatic decompensation and hepatocellular carcinoma." | 1.35 | Tenofovir disoproxil fumarate for the treatment of hepatitis B infection. ( Adusumilli, S, 2009) |
| "Success in antiviral therapy for chronic hepatitis B is supported by highly sensitive PCR-based assays for hepatitis B virus (HBV) DNA." | 1.34 | COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma. ( Allice, T; Cerutti, F; Colucci, G; Franchello, A; Gabella, S; Ghisetti, V; Marzano, A; Pittaluga, F; Varetto, S, 2007) |
| "Adefovir dipivoxil is a nucleotide prodrug indicated for the treatment of patients with hepatitis B e antigen positive or hepatitis B e antigen negative chronic hepatitis B, lamivudine-resistant HBV infection, HBV infection pre- or post-liver transplantation, or HlV co-infection." | 1.34 | Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil. ( Delaney, WE, 2007) |
| "Adefovir dipivoxil (ADV) has demonstrated clinical activity against both wild-type and lamivudine-resistant hepatitis B virus (HBV)." | 1.34 | Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy. ( Bae, SH; Chang, UI; Choi, JY; Jang, JW; Lee, YC; Sun, HS; Wie, SH; Yang, JM; Yoon, SK, 2007) |
| "Adefovir dipivoxil is an analogue nucleotide recently approved for the treatment of chronic hepatitis HBV-related." | 1.34 | [Recent advances in the treatment of the hepatitis HBV-related. Effectiveness and tolerability of adefovir dipivoxil]. ( Palumbo, E, 2007) |
| "In this report, a chronic hepatitis B case who had never received adefovir dipivoxil but had primary adefovir resistance, was presented." | 1.34 | [A case of chronic hepatitis B with primary adefovir resistance]. ( Erensoy, S; Pullukçu, H; Sertöz, R; Taşbakan, M; Ulusoy, S; Yamazhan, T, 2007) |
| "Forty-four patients with chronic hepatitis B (CHB) were included." | 1.34 | Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance. ( Bak, YT; Byun, KS; Kim, JH; Kim, JS; Lee, CH; Park, JJ; Seo, YS; Yeon, JE, 2007) |
| "Treatment with lamivudine for 1-year is highly cost-effective compared with no treatment of CHB but has limited effect on reducing the rate of disease progression." | 1.34 | The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore. ( Gane, E; Lacey, LF, 2007) |
| "Adefovir dipivoxil is a acyclic nucleotide phosphate analogue and known to have potent anti-HBV effect." | 1.33 | [Therapeutic effect of adefovir dipivoxil on recurrent or de novo infection of hepatitis B virus after liver transplantation: a preliminary report]. ( Ahn, CS; Ha, TY; Hwang, S; Kim, KH; Kim, KK; Lee, SG; Moon, DB, 2005) |
| "Treatment options for chronic hepatitis B virus (HBV) infection have disparate risks and benefits." | 1.33 | Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. ( Dulai, GS; Farid, M; Gralnek, IM; Kanwal, F; Martin, P; Spiegel, BM, 2005) |
| "Adefovir dipivoxil is an oral prodrug of adefovir." | 1.33 | Chronic hepatitis B--treatment with nucleoside analogues. ( Leung, N, 2005) |
| "Treatment with adefovir dipivoxil for 144 weeks was well tolerated and resulted in significant and sustained reductions in HBV DNA and ALT in HIV/HBV co-infected patients." | 1.33 | Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. ( Benhamou, Y; Biao, L; Brosgart, C; Calvez, V; Chang, CG; Currie, G; Fievet, MH; Marcelin, AG; Poynard, T; Thibault, V; Vig, P; Xiong, S, 2006) |
| "Lamivudine treatment was initially effective in all patients; three patients during the second year of treatment developed lamivudine resistance-associated mutations (rt-L180M, rt-M204V) with severe disease reactivation, remitted after switch to adefovir treatment." | 1.33 | Heart transplantation in patients with chronic hepatitis B: clinical evolution, molecular analysis, and effect of treatment. ( Cirillo, G; Costagliola, L; Karayiannis, P; Marrone, A; Ragone, E; Ruggiero, G; Utili, R; Zampino, R, 2005) |
| "Adefovir dipivoxil (ADV) is a potent nucleotide analogue against both the wild-type and lamivudine (LMV) resistant hepatitis B virus (HBV)." | 1.33 | Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. ( Byun, KS; Chang, YJ; Chung, HJ; Hong, SP; Kim, JH; Kim, SO; Lee, CH; Moon, MS; Seo, YS; Yeon, JE; Yoo, W; Yu, SK, 2006) |
| "Treatment of chronic hepatitis B (CHB) involves a number of complex and controversial issues." | 1.33 | Chronic hepatitis B: a critical appraisal of current approaches to therapy. ( Alberti, A; Buti, M; Cooksley, WG; Fried, MW; Gish, RG; Hadziyannis, SJ; Keeffe, EB; Liaw, YF; Naoumov, NV; Perrillo, RP; Peters, M; Schalm, S; Schiff, ER; Thio, CL; Tsai, N, 2006) |
| "In patients with chronic hepatitis B virus (HBV), 2 predominant precursor dendritic cell (DC) subtypes, the myeloid dendritic cell (mDC) and the plasmacytoid dendritic cell (pDC), were recently found to be functionally impaired." | 1.33 | Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. ( Biesta, PJ; Janssen, HL; Kusters, JG; Sprengers, D; van der Molen, RG, 2006) |
| "Patients with chronic hepatitis B virus (HBV) infection were tested for HBeAg, anti-HBe, liver profile and HBV-DNA by a branched DNA (bDNA) assay." | 1.32 | Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea. ( Cha, YJ; Kim, HJ; Lee, DH; Park, JW; Park, SM; Yoo, BC, 2003) |
| "Hepatitis B e antigen (HBeAg) negative chronic hepatitis B (CHB) is frequently caused by a mutation (G1896A) in the hepatitis B virus (HBV) precore (PC) reading frame that creates a stop codon, causing premature termination of the PC protein." | 1.32 | Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. ( Bowden, S; Chen, RY; Colledge, D; Delaney, WE; Desmond, P; Edwards, R; Isom, H; Locarnini, SA; Shaw, T, 2003) |
| "Adefovir is a potent nucleotide analog inhibitor of hepatitis B virus (HBV) DNA polymerase." | 1.32 | Comparative effects of adefovir and selected nucleoside inhibitors of hepatitis B virus DNA polymerase on mitochondrial DNA in liver and skeletal muscle cells. ( Birkus, G; Cihlar, T; Gibbs, CS, 2003) |
| "Current therapies for the treatment of chronic hepatitis B virus (HBV) infection do not eliminate viral replication once therapy is stopped, resulting in a rapid rebound of viremia in a majority of patients." | 1.32 | Use of adefovir in the treatment of the chronic hepatitis B virus infection with resistance to lamivudine. ( Barcena Marugan, R; Cid Gomez, L; Lopez Serrano, P, 2003) |
| "Lamivudine was then reintroduced together with ADV, and serum HBV DNA became undetectable by polymerase chain reaction." | 1.32 | Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. ( Brosgart, CL; Durantel, D; Durantel, S; Gibbs, CS; Parvaz, P; Trépo, C; Villeneuve, JP; Werle, B; Westland, C; Xiong, S; Zoulim, F, 2003) |
| "The management of chronic hepatitis B poses specific problems in the presence of human immunodeficiency virus (HIV) coinfection, because therapeutic approaches have to address both hepatitis B virus (HBV) and HIV infections." | 1.32 | Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. ( Camino, N; Núñez, M; Puoti, M; Soriano, V, 2003) |
| "Our study shows that ADV dosed at 10 mg/day for the treatment of LAM-resistant chronic hepatitis B in patients co-infected with HIV is not associated with renal tubular dysfunction or a significant change in renal function." | 1.32 | The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV. ( Bagnis, CI; Beaufils, H; Benhamou, Y; Brosgart, C; Deray, G; Hannon, H; Izzedine, H; Poynard, T; Sullivan, M, 2004) |
| "Adefovir dipivoxil is a clinically approved drug that can block the action of an anthrax toxin." | 1.32 | Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. ( Bergson, P; Gibbs, CS; Shen, Y; Soelaiman, S; Tang, WJ; Wang, CR; Zhukovskaya, NL; Zimmer, MI, 2004) |
| "Lamivudine was administered in 2 patients, lamivudine+hepatitis B immunoglobulin (HBIG) in 63, and adefovir+HBIG in 3." | 1.32 | Prevention of hepatitis B virus reinfection after orthotopic liver transplantation. ( Chen, XS; Ding, GS; Fu, H; Fu, ZR; Guo, WY; Shi, XM; Wang, ZX; Zhang, JJ, 2004) |
| "Worldwide, hepatocellular carcinoma (HCC) is more prevalent in men than in women, suggesting that sex hormones and/or X-chromosome-linked genes may be involved in hepatocarcinogenesis." | 1.31 | Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. ( Chang, HC; Chen, CJ; Chen, PJ; Cheng, SW; Hsiao, TJ; Lee, SD; Liaw, YF; Lin, MW; Lin, SM; Liu, CJ; Yang, SY; Yu, MW, 2000) |
| "Adefovir dipivoxil has recently been reported to be a potent and highly effective inhibitor of HBV replication in both wild-type and lamivudine resistant HBV infection." | 1.31 | Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. ( Alexander, GJ; Bloor, S; Lamy, P; Walsh, KM; Wight, DG; Woodall, T, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (0.25) | 18.2507 |
| 2000's | 428 (35.46) | 29.6817 |
| 2010's | 702 (58.16) | 24.3611 |
| 2020's | 74 (6.13) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, Y | 7 |
| Kong, F | 2 |
| Song, X | 1 |
| Shang, J | 2 |
| Yao, L | 3 |
| Xia, J | 2 |
| Peng, Y | 1 |
| Liu, W | 6 |
| Gong, H | 1 |
| Mu, M | 1 |
| Cui, H | 1 |
| Han, T | 4 |
| Chen, W | 6 |
| Wu, X | 8 |
| Yang, Y | 11 |
| Yan, X | 4 |
| Jin, Z | 1 |
| Wang, P | 4 |
| Zhu, Q | 1 |
| Chen, L | 10 |
| Zhao, C | 3 |
| Zhang, D | 6 |
| Jin, W | 2 |
| Wang, D | 2 |
| Wen, X | 2 |
| Liu, C | 4 |
| Jia, J | 8 |
| Mao, Q | 3 |
| Ding, Y | 3 |
| Jin, X | 2 |
| Zhang, Z | 4 |
| Li, G | 7 |
| Niu, J | 9 |
| Yeh, ML | 2 |
| Liang, PC | 1 |
| Trinh, S | 1 |
| Huang, CI | 1 |
| Huang, CF | 2 |
| Hsieh, MY | 3 |
| Huang, JF | 3 |
| Dai, CY | 4 |
| Chuang, WL | 8 |
| Nguyen, MH | 15 |
| Yu, ML | 3 |
| Zeng, QL | 1 |
| Zhang, HX | 1 |
| Zhang, JY | 2 |
| Huang, S | 1 |
| Li, WZ | 1 |
| Li, GM | 1 |
| Pan, YJ | 2 |
| Feng, YH | 1 |
| Li, ZQ | 2 |
| Zhang, GF | 1 |
| Xu, JH | 1 |
| Lin, WB | 1 |
| Xu, GH | 1 |
| Liu, N | 1 |
| Zhang, GQ | 1 |
| Li, GT | 1 |
| Li, W | 9 |
| Zeng, YL | 1 |
| Song, N | 1 |
| Wang, M | 5 |
| Zhang, DW | 1 |
| Chen, ZM | 1 |
| Cui, GL | 1 |
| Li, J | 29 |
| Lv, J | 4 |
| Liu, YM | 1 |
| Liang, HX | 1 |
| Sun, CY | 1 |
| Zhou, YH | 2 |
| Yu, ZJ | 2 |
| Wang, FS | 1 |
| Jeong, J | 2 |
| Shin, JW | 9 |
| Jung, SW | 8 |
| Park, EJ | 2 |
| Park, NH | 10 |
| Kahraman, R | 1 |
| Şahin, A | 1 |
| Öztürk, O | 2 |
| Çalhan, T | 1 |
| Sayar, S | 1 |
| Kanat, E | 1 |
| Doğanay, L | 2 |
| Özdil, K | 2 |
| Han, N | 1 |
| Yan, LL | 1 |
| Tang, H | 13 |
| Kumada, T | 5 |
| Toyoda, H | 5 |
| Yasuda, S | 3 |
| Ito, T | 2 |
| Tanaka, J | 4 |
| Ogawa, E | 7 |
| Nakamuta, M | 3 |
| Koyanagi, T | 3 |
| Ooho, A | 3 |
| Furusyo, N | 6 |
| Kajiwara, E | 3 |
| Dohmen, K | 3 |
| Kawano, A | 3 |
| Satoh, T | 3 |
| Takahashi, K | 3 |
| Azuma, K | 3 |
| Yamashita, N | 4 |
| Sugimoto, R | 2 |
| Amagase, H | 2 |
| Kuniyoshi, M | 2 |
| Ichiki, Y | 2 |
| Morita, C | 2 |
| Kato, M | 5 |
| Shimoda, S | 3 |
| Nomura, H | 3 |
| Hayashi, J | 5 |
| Liu, JK | 1 |
| Vutien, P | 1 |
| Huang, DQ | 1 |
| Ishigami, M | 1 |
| Landis, CS | 1 |
| Dilokthornsakul, P | 1 |
| Sawangjit, R | 1 |
| Tangkijvanich, P | 2 |
| Chayanupatkul, M | 1 |
| Tanwandee, T | 4 |
| Sukeepaisarnjaroen, W | 2 |
| Sriuttha, P | 1 |
| Permsuwan, U | 1 |
| Lim, YS | 18 |
| Seto, WK | 9 |
| Kurosaki, M | 3 |
| Fung, S | 8 |
| Kao, JH | 5 |
| Hou, J | 7 |
| Gordon, SC | 4 |
| Flaherty, JF | 17 |
| Yee, LJ | 3 |
| Zhao, Y | 10 |
| Agarwal, K | 5 |
| Lampertico, P | 20 |
| Lin, HY | 1 |
| Tseng, TC | 2 |
| Innocenti, I | 1 |
| Reda, G | 1 |
| Visentin, A | 1 |
| Coscia, M | 1 |
| Motta, M | 1 |
| Murru, R | 1 |
| Moia, R | 1 |
| Gentile, M | 1 |
| Pennese, E | 1 |
| Quaglia, FM | 1 |
| Albano, F | 1 |
| Cassin, R | 1 |
| Deodato, M | 1 |
| Ielo, C | 1 |
| Frustaci, AM | 1 |
| Piciocchi, A | 1 |
| Rughini, A | 1 |
| Arena, V | 1 |
| Di Sevo, D | 1 |
| Tomasso, A | 1 |
| Autore, F | 1 |
| Del Poeta, G | 1 |
| Scarfò, L | 1 |
| Mauro, FR | 1 |
| Tedeschi, A | 1 |
| Trentin, L | 1 |
| Pompili, M | 1 |
| Foà, R | 1 |
| Ghia, P | 1 |
| Cuneo, A | 1 |
| Laurenti, L | 1 |
| Lim, J | 1 |
| Choi, WM | 4 |
| Shim, JH | 6 |
| Lee, D | 5 |
| Kim, KM | 5 |
| Lee, HC | 10 |
| Choi, J | 3 |
| Kudose, S | 1 |
| Lunenfeld, E | 1 |
| Markowitz, GS | 1 |
| Winckelmann, A | 1 |
| Fahnøe, U | 1 |
| Bajpai, PS | 1 |
| Dalegaard, MI | 1 |
| Lundh, A | 1 |
| Ryom, L | 1 |
| Bukh, J | 1 |
| Weis, N | 1 |
| Kayes, T | 1 |
| Crane, H | 1 |
| Symonds, A | 1 |
| Dumond, J | 1 |
| Cottrell, M | 1 |
| Di Girolamo, J | 1 |
| Manandhar, S | 1 |
| Lim, TH | 1 |
| Gane, E | 14 |
| Kashuba, A | 2 |
| Levy, MT | 3 |
| Papatheodoridis, GV | 14 |
| Mimidis, K | 1 |
| Manolakopoulos, S | 5 |
| Gatselis, N | 2 |
| Goulis, J | 3 |
| Kapatais, A | 1 |
| Manesis, E | 2 |
| Vasiliadis, T | 2 |
| Triantos, C | 3 |
| Samonakis, D | 1 |
| Sevastianos, V | 2 |
| Karatapanis, S | 1 |
| Elefsiniotis, I | 4 |
| Deutsch, M | 1 |
| Mylopoulou, T | 1 |
| Papatheodoridi, M | 1 |
| Kranidioti, H | 1 |
| Agorastou, P | 1 |
| Karaoulani, T | 1 |
| Kyriazidou, A | 1 |
| Zisimopoulos, K | 1 |
| Dalekos, GN | 2 |
| Chen, YC | 1 |
| Hsu, CW | 3 |
| Chien, RN | 6 |
| Tai, DI | 1 |
| Foucault, T | 1 |
| Handala, L | 1 |
| Paintaud, G | 1 |
| Gaudy-Graffin, C | 1 |
| Marlet, J | 1 |
| Kumar, M | 2 |
| Lee, MH | 7 |
| Hu, X | 5 |
| Li, R | 1 |
| Li, Q | 6 |
| Zang, M | 1 |
| Yuan, G | 3 |
| Chen, J | 9 |
| Tseng, TN | 1 |
| Chen, CH | 6 |
| Jung, CY | 1 |
| Kim, HW | 1 |
| Lee, JI | 7 |
| Lee, HW | 4 |
| Ahn, SH | 23 |
| Kim, SU | 9 |
| Kim, BS | 4 |
| Chiu, SM | 1 |
| Chang, KC | 3 |
| Hu, TH | 7 |
| Hung, CH | 4 |
| Wang, JH | 6 |
| Lu, SN | 5 |
| Wang, ML | 3 |
| Chen, EQ | 8 |
| Yim, HJ | 12 |
| Kim, JH | 26 |
| Cho, YK | 6 |
| Kweon, YO | 3 |
| Cho, HC | 3 |
| Hwang, JS | 2 |
| Lee, C | 2 |
| Koh, MS | 1 |
| Baek, YH | 1 |
| Park, YM | 2 |
| Lee, JH | 25 |
| Kang, MK | 1 |
| Lee, JS | 4 |
| Chon, YE | 4 |
| Cheon, GJ | 1 |
| Chae, HB | 5 |
| Sohn, JH | 1 |
| Sato, K | 4 |
| Inoue, J | 4 |
| Akahane, T | 2 |
| Kobayashi, T | 3 |
| Sato, S | 1 |
| Kisara, N | 1 |
| Ninomiya, M | 2 |
| Iwata, T | 2 |
| Sano, A | 2 |
| Tsuruoka, M | 2 |
| Onuki, M | 2 |
| Masamune, A | 2 |
| Takai, S | 1 |
| Nakamura, T | 1 |
| Sato, T | 3 |
| Kimura, O | 1 |
| Sawahashi, S | 1 |
| Niitsuma, H | 2 |
| Chen, JW | 1 |
| Cao, XY | 1 |
| Qi, X | 4 |
| Zhang, JM | 6 |
| Suda, G | 1 |
| Baba, M | 2 |
| Yamamoto, Y | 1 |
| Sho, T | 1 |
| Ogawa, K | 1 |
| Kimura, M | 3 |
| Hosoda, S | 1 |
| Yoshida, S | 1 |
| Kubo, A | 1 |
| Fu, Q | 1 |
| Yang, Z | 5 |
| Tokuchi, Y | 1 |
| Kitagataya, T | 1 |
| Maehara, O | 1 |
| Ohnishi, S | 1 |
| Yamada, R | 1 |
| Ohara, M | 1 |
| Kawagishi, N | 1 |
| Natsuizaka, M | 1 |
| Nakai, M | 1 |
| Morikawa, K | 1 |
| Furuya, K | 1 |
| Suzuki, K | 1 |
| Izumi, T | 1 |
| Meguro, T | 1 |
| Terashita, K | 1 |
| Ito, J | 1 |
| Tsunematsu, I | 1 |
| Sakamoto, N | 1 |
| Zhu, L | 3 |
| Park, J | 1 |
| Deng, Y | 2 |
| Pan, CQ | 6 |
| Byun, KS | 10 |
| Yoo, BC | 11 |
| Cheng, CH | 1 |
| Hung, HC | 1 |
| Lee, JC | 1 |
| Wang, YC | 1 |
| Wu, TH | 1 |
| Lee, CF | 1 |
| Wu, TJ | 1 |
| Chou, HS | 1 |
| Chan, KM | 1 |
| Lee, WC | 1 |
| Hwang, EG | 1 |
| Jung, EA | 1 |
| Yoo, JJ | 5 |
| Kim, SG | 3 |
| Kim, YS | 12 |
| Luo, H | 1 |
| Tan, G | 2 |
| Li, Y | 19 |
| Qin, B | 1 |
| Kim, E | 1 |
| Kim, SS | 4 |
| Yoon, E | 1 |
| Jang, ES | 3 |
| Chang, JI | 1 |
| Cho, YY | 5 |
| Seo, GH | 1 |
| Kim, HJ | 10 |
| Liu, Z | 11 |
| Zhao, Z | 3 |
| Ma, X | 3 |
| Liu, S | 5 |
| Xin, Y | 1 |
| Duan, YQ | 1 |
| Hu, P | 6 |
| Murata, K | 3 |
| Tsukuda, S | 1 |
| Suizu, F | 1 |
| Kimura, A | 1 |
| Sugiyama, M | 2 |
| Watashi, K | 1 |
| Noguchi, M | 1 |
| Mizokami, M | 4 |
| Blackard, JT | 1 |
| Kwara, A | 1 |
| Sherman, KE | 2 |
| Kim, KH | 12 |
| Deng, HH | 1 |
| Xu, M | 4 |
| Lou, Y | 1 |
| Gao, HB | 1 |
| Uchida, Y | 1 |
| Nakao, M | 1 |
| Tsuji, S | 1 |
| Uemura, H | 1 |
| Kouyama, JI | 1 |
| Naiki, K | 1 |
| Motoya, D | 1 |
| Sugawara, K | 1 |
| Nakayama, N | 1 |
| Imai, Y | 2 |
| Tomiya, T | 1 |
| Mochida, S | 1 |
| Zhang, H | 9 |
| Wu, M | 1 |
| Zhu, X | 5 |
| Li, C | 6 |
| Li, X | 23 |
| Chen, H | 3 |
| Liu, J | 10 |
| Zheng, Z | 1 |
| Liao, W | 1 |
| Liu, L | 11 |
| Cai, S | 3 |
| Zhu, H | 2 |
| Yin, S | 1 |
| Li, XK | 1 |
| Zhang, MX | 1 |
| Shao, FZ | 1 |
| Zhou, DQ | 1 |
| Xue, JD | 1 |
| Liu, TJ | 1 |
| Chi, XL | 1 |
| Lu, BJ | 1 |
| Wang, XB | 1 |
| Mao, DW | 2 |
| Yang, HS | 1 |
| Yang, HZ | 1 |
| Zhao, WX | 1 |
| Zhang, GL | 1 |
| Zhao, YM | 1 |
| Zou, JD | 1 |
| Liu, MY | 2 |
| Zhang, KK | 1 |
| Yang, XZ | 1 |
| Gan, DN | 1 |
| Zhang, P | 1 |
| Li, ZG | 1 |
| Li, S | 3 |
| Ye, YA | 1 |
| Kirino, S | 1 |
| Tamaki, N | 1 |
| Kaneko, S | 2 |
| Inada, K | 1 |
| Yamashita, K | 1 |
| Osawa, L | 1 |
| Hayakawa, Y | 1 |
| Sekiguchi, S | 1 |
| Watakabe, K | 1 |
| Okada, M | 1 |
| Wang, W | 8 |
| Shimizu, T | 1 |
| Higuchi, M | 1 |
| Takaura, K | 1 |
| Maeyashiki, C | 1 |
| Yasui, Y | 1 |
| Nakanishi, H | 1 |
| Tsuchiya, K | 1 |
| Itakura, J | 1 |
| Takahashi, Y | 1 |
| Izumi, N | 2 |
| Gao, X | 1 |
| Duan, X | 1 |
| Cai, H | 2 |
| Hu, Y | 4 |
| Liu, M | 5 |
| Kang, K | 1 |
| Zhou, M | 3 |
| Fu, D | 1 |
| Yi, W | 2 |
| Madeddu, G | 2 |
| Fiore, V | 1 |
| Melis, M | 2 |
| Ortu, S | 2 |
| Mannu, F | 1 |
| Muredda, AA | 2 |
| Garrucciu, G | 2 |
| Bandiera, F | 2 |
| Zaru, S | 1 |
| Bagella, P | 1 |
| Calvisi, DF | 1 |
| Babudieri, S | 2 |
| Mak, LY | 2 |
| Buti, M | 37 |
| Tak, WY | 3 |
| Ramji, A | 1 |
| Chen, CY | 3 |
| Tam, E | 1 |
| Bae, H | 2 |
| Gaggar, A | 8 |
| Lau, A | 1 |
| Liu, Y | 35 |
| Wu, G | 3 |
| Suri, V | 1 |
| Tan, SK | 1 |
| Subramanian, GM | 11 |
| Trinh, H | 9 |
| Yoon, SK | 5 |
| Chan, HLY | 2 |
| Halim, AA | 1 |
| Alsayed, B | 1 |
| Embarak, S | 1 |
| Yaseen, T | 1 |
| Dabbous, S | 1 |
| Fontaine, O | 1 |
| Dueluzeau, R | 1 |
| Raibaud, P | 1 |
| Chabanet, C | 1 |
| Popoff, MR | 1 |
| Badoual, J | 1 |
| Gabilan, JC | 1 |
| Andremont, A | 1 |
| Gómez, L | 1 |
| Andrés, S | 1 |
| Sánchez, J | 1 |
| Alonso, JM | 1 |
| Rey, J | 1 |
| López, F | 1 |
| Jiménez, A | 1 |
| Yan, Z | 1 |
| Zhou, L | 3 |
| Wang, J | 24 |
| Huang, L | 4 |
| Hu, K | 1 |
| Liu, H | 6 |
| Wang, H | 14 |
| Guo, Z | 1 |
| Song, Y | 1 |
| Huang, H | 7 |
| Yang, R | 1 |
| Owen, TW | 1 |
| Al-Kaysi, RO | 1 |
| Bardeen, CJ | 1 |
| Cheng, Q | 1 |
| Wu, S | 2 |
| Cheng, T | 1 |
| Zhou, X | 6 |
| Wang, B | 8 |
| Zhang, Q | 9 |
| Yao, Y | 3 |
| Ochiai, T | 1 |
| Ishiguro, H | 2 |
| Nakano, R | 2 |
| Kubota, Y | 2 |
| Hara, M | 1 |
| Sunada, K | 1 |
| Hashimoto, K | 1 |
| Kajioka, J | 1 |
| Fujishima, A | 1 |
| Jiao, J | 5 |
| Gai, QY | 3 |
| Zang, YP | 2 |
| Niu, LL | 2 |
| Fu, YJ | 3 |
| Wang, X | 14 |
| Yao, LP | 2 |
| Qin, QP | 1 |
| Wang, ZY | 2 |
| Aleksic Sabo, V | 1 |
| Knezevic, P | 1 |
| Borges-Argáez, R | 1 |
| Chan-Balan, R | 1 |
| Cetina-Montejo, L | 1 |
| Ayora-Talavera, G | 1 |
| Sansores-Peraza, P | 1 |
| Gómez-Carballo, J | 1 |
| Cáceres-Farfán, M | 1 |
| Jang, J | 1 |
| Akin, D | 1 |
| Bashir, R | 1 |
| Yu, Z | 3 |
| Zhu, J | 2 |
| Jiang, H | 1 |
| He, C | 2 |
| Xiao, Z | 1 |
| Xu, J | 7 |
| Sun, Q | 2 |
| Han, D | 1 |
| Lei, H | 1 |
| Zhao, K | 3 |
| Fu, H | 3 |
| Wilson, BK | 1 |
| Step, DL | 1 |
| Maxwell, CL | 1 |
| Gifford, CA | 1 |
| Richards, CJ | 1 |
| Krehbiel, CR | 1 |
| Warner, JM | 1 |
| Doerr, AJ | 1 |
| Erickson, GE | 1 |
| Guretzky, JA | 1 |
| Rasby, RJ | 1 |
| Watson, AK | 1 |
| Klopfenstein, TJ | 1 |
| Sun, Y | 7 |
| Pham, TD | 1 |
| Lee, BK | 1 |
| Yang, FC | 1 |
| Wu, KH | 1 |
| Lin, WP | 1 |
| Hu, MK | 1 |
| Lin, L | 6 |
| Shao, J | 3 |
| Sun, M | 2 |
| Xu, G | 3 |
| Zhang, X | 12 |
| Xu, N | 1 |
| Wang, R | 1 |
| He, H | 1 |
| Dong, X | 3 |
| Yang, M | 3 |
| Yang, Q | 2 |
| Duan, S | 1 |
| Yu, Y | 5 |
| Han, J | 2 |
| Zhang, C | 11 |
| Yang, X | 2 |
| Wang, T | 4 |
| Campbell, DA | 1 |
| Gao, K | 1 |
| Zager, RA | 1 |
| Johnson, ACM | 1 |
| Guillem, A | 1 |
| Keyser, J | 1 |
| Singh, B | 1 |
| Steubl, D | 1 |
| Schneider, MP | 1 |
| Meiselbach, H | 1 |
| Nadal, J | 1 |
| Schmid, MC | 1 |
| Saritas, T | 1 |
| Krane, V | 1 |
| Sommerer, C | 1 |
| Baid-Agrawal, S | 1 |
| Voelkl, J | 1 |
| Kotsis, F | 1 |
| Köttgen, A | 1 |
| Eckardt, KU | 1 |
| Scherberich, JE | 1 |
| Li, H | 8 |
| Sun, L | 5 |
| Zhu, Z | 1 |
| Naren, N | 1 |
| Zhang, XX | 7 |
| Gentile, GL | 1 |
| Rupert, AS | 1 |
| Carrasco, LI | 1 |
| Garcia, EM | 1 |
| Kumar, NG | 1 |
| Walsh, SW | 1 |
| Jefferson, KK | 1 |
| Guest, RL | 1 |
| Samé Guerra, D | 1 |
| Wissler, M | 1 |
| Grimm, J | 1 |
| Silhavy, TJ | 1 |
| Yoo, JS | 1 |
| Kim, Y | 1 |
| Kim, JS | 5 |
| Lee, EJ | 1 |
| Roe, JH | 1 |
| Delorme, M | 1 |
| Bouchard, PA | 1 |
| Simon, M | 1 |
| Simard, S | 1 |
| Lellouche, F | 1 |
| D'Urzo, KA | 1 |
| Mok, F | 1 |
| D'Urzo, AD | 1 |
| Koneru, B | 1 |
| Lopez, G | 1 |
| Farooqi, A | 1 |
| Conkrite, KL | 1 |
| Nguyen, TH | 1 |
| Macha, SJ | 1 |
| Modi, A | 1 |
| Rokita, JL | 1 |
| Urias, E | 1 |
| Hindle, A | 1 |
| Davidson, H | 1 |
| Mccoy, K | 1 |
| Nance, J | 1 |
| Yazdani, V | 1 |
| Irwin, MS | 1 |
| Yang, S | 6 |
| Wheeler, DA | 1 |
| Maris, JM | 1 |
| Diskin, SJ | 1 |
| Reynolds, CP | 1 |
| Abhilash, L | 1 |
| Kalliyil, A | 1 |
| Sheeba, V | 1 |
| Hartley, AM | 2 |
| Meunier, B | 2 |
| Pinotsis, N | 1 |
| Maréchal, A | 2 |
| Xu, JY | 1 |
| Genko, N | 1 |
| Haraux, F | 1 |
| Rich, PR | 1 |
| Kamalanathan, M | 1 |
| Doyle, SM | 1 |
| Xu, C | 2 |
| Achberger, AM | 1 |
| Wade, TL | 1 |
| Schwehr, K | 1 |
| Santschi, PH | 1 |
| Sylvan, JB | 1 |
| Quigg, A | 1 |
| Leong, W | 1 |
| Xu, W | 2 |
| Gao, S | 1 |
| Zhai, X | 1 |
| Wang, C | 8 |
| Gilson, E | 1 |
| Ye, J | 1 |
| Lu, Y | 1 |
| Yan, R | 1 |
| Zhang, Y | 16 |
| Hu, Z | 2 |
| You, Q | 1 |
| Cai, Q | 1 |
| Yang, D | 5 |
| Gu, S | 1 |
| Dai, H | 1 |
| Zhao, X | 4 |
| Gui, C | 1 |
| Gui, J | 1 |
| Wu, PK | 1 |
| Hong, SK | 1 |
| Starenki, D | 1 |
| Oshima, K | 1 |
| Shao, H | 1 |
| Gestwicki, JE | 1 |
| Tsai, S | 1 |
| Park, JI | 1 |
| Wang, Y | 24 |
| Zhao, R | 1 |
| Gu, Z | 1 |
| Dong, C | 2 |
| Guo, G | 1 |
| Li, L | 11 |
| Barrett, HE | 1 |
| Meester, EJ | 1 |
| van Gaalen, K | 1 |
| van der Heiden, K | 1 |
| Krenning, BJ | 1 |
| Beekman, FJ | 1 |
| de Blois, E | 1 |
| de Swart, J | 1 |
| Verhagen, HJ | 1 |
| Maina, T | 1 |
| Nock, BA | 1 |
| Norenberg, JP | 1 |
| de Jong, M | 1 |
| Gijsen, FJH | 1 |
| Bernsen, MR | 1 |
| Martínez-Milla, J | 1 |
| Galán-Arriola, C | 1 |
| Carnero, M | 1 |
| Cobiella, J | 1 |
| Pérez-Camargo, D | 1 |
| Bautista-Hernández, V | 1 |
| Rigol, M | 1 |
| Solanes, N | 1 |
| Villena-Gutierrez, R | 1 |
| Lobo, M | 1 |
| Mateo, J | 1 |
| Vilchez-Tschischke, JP | 1 |
| Salinas, B | 1 |
| Cussó, L | 1 |
| López, GJ | 1 |
| Fuster, V | 1 |
| Desco, M | 1 |
| Sanchez-González, J | 1 |
| Ibanez, B | 1 |
| van den Berg, P | 1 |
| Schweitzer, DH | 1 |
| van Haard, PMM | 1 |
| Geusens, PP | 1 |
| van den Bergh, JP | 1 |
| Huang, X | 3 |
| Xu, H | 6 |
| Yang, G | 3 |
| Lin, Z | 2 |
| Salem, HF | 1 |
| Nafady, MM | 1 |
| Kharshoum, RM | 1 |
| Abd El-Ghafar, OA | 1 |
| Farouk, HO | 1 |
| Domiciano, D | 1 |
| Nery, FC | 1 |
| de Carvalho, PA | 1 |
| Prudente, DO | 1 |
| de Souza, LB | 1 |
| Chalfun-Júnior, A | 1 |
| Paiva, R | 1 |
| Marchiori, PER | 1 |
| Lu, M | 3 |
| An, Z | 1 |
| Jiang, J | 5 |
| Du, S | 1 |
| Zhou, H | 1 |
| Cui, J | 1 |
| Wu, W | 2 |
| Song, J | 2 |
| Lian, Q | 1 |
| Uddin Ahmad, Z | 1 |
| Gang, DD | 1 |
| Konggidinata, MI | 1 |
| Gallo, AA | 1 |
| Zappi, ME | 1 |
| Yang, TWW | 1 |
| Johari, Y | 1 |
| Burton, PR | 1 |
| Earnest, A | 1 |
| Shaw, K | 1 |
| Hare, JL | 1 |
| Brown, WA | 1 |
| Kim, GA | 1 |
| Han, S | 1 |
| Choi, GH | 1 |
| Gallo, A | 1 |
| Cancelli, C | 1 |
| Ceron, E | 1 |
| Covino, M | 1 |
| Capoluongo, E | 1 |
| Pocino, K | 1 |
| Ianiro, G | 1 |
| Cammarota, G | 1 |
| Gasbarrini, A | 1 |
| Montalto, M | 1 |
| Somasundar, Y | 1 |
| Lu, IC | 1 |
| Mills, MR | 1 |
| Qian, LY | 1 |
| Olivares, X | 1 |
| Ryabov, AD | 1 |
| Collins, TJ | 1 |
| Zhao, L | 3 |
| Doddipatla, S | 1 |
| Thomas, AM | 1 |
| Nikolayev, AA | 1 |
| Galimova, GR | 1 |
| Azyazov, VN | 1 |
| Mebel, AM | 1 |
| Kaiser, RI | 1 |
| Guo, S | 1 |
| Yang, P | 1 |
| Yu, X | 3 |
| Wu, Y | 5 |
| Yu, B | 2 |
| Han, B | 1 |
| George, MW | 1 |
| Moor, MB | 1 |
| Bonny, O | 1 |
| Langenberg, E | 1 |
| Paik, H | 1 |
| Smith, EH | 1 |
| Nair, HP | 1 |
| Hanke, I | 1 |
| Ganschow, S | 1 |
| Catalan, G | 1 |
| Domingo, N | 1 |
| Schlom, DG | 1 |
| Assefa, MK | 1 |
| Hayton, TW | 1 |
| Becker, B | 1 |
| Enikeev, D | 1 |
| Netsch, C | 1 |
| Gross, AJ | 1 |
| Laukhtina, E | 1 |
| Glybochko, P | 1 |
| Rapoport, L | 1 |
| Herrmann, TRW | 1 |
| Taratkin, M | 1 |
| Dai, W | 1 |
| Shi, J | 4 |
| Carreno, J | 1 |
| Kloner, RA | 1 |
| Pickersgill, NA | 1 |
| Vetter, JM | 1 |
| Kim, EH | 2 |
| Cope, SJ | 1 |
| Du, K | 1 |
| Venkatesh, R | 1 |
| Giardina, JD | 1 |
| Saad, NES | 1 |
| Bhayani, SB | 1 |
| Figenshau, RS | 1 |
| Eriksson, J | 1 |
| Landfeldt, E | 1 |
| Ireland, S | 1 |
| Jackson, C | 1 |
| Wyatt, E | 1 |
| Gaudig, M | 1 |
| Stancill, JS | 1 |
| Happ, JT | 1 |
| Broniowska, KA | 1 |
| Hogg, N | 1 |
| Corbett, JA | 1 |
| Tang, LF | 1 |
| Bi, YL | 1 |
| Fan, Y | 3 |
| Sun, YB | 1 |
| Wang, AL | 1 |
| Xiao, BH | 1 |
| Wang, LF | 2 |
| Qiu, SW | 1 |
| Guo, SW | 1 |
| Wáng, YXJ | 1 |
| Sun, J | 9 |
| Chu, S | 1 |
| Pan, Q | 1 |
| Li, D | 4 |
| Zheng, S | 3 |
| Ma, L | 4 |
| Wang, L | 11 |
| Hu, T | 1 |
| Wang, F | 3 |
| Han, Z | 2 |
| Yin, Z | 1 |
| Ge, X | 1 |
| Xie, K | 1 |
| Lei, P | 1 |
| Dias-Santagata, D | 1 |
| Lennerz, JK | 1 |
| Sadow, PM | 1 |
| Frazier, RP | 1 |
| Govinda Raju, S | 1 |
| Henry, D | 1 |
| Chung, T | 1 |
| Kherani, J | 1 |
| Rothenberg, SM | 1 |
| Wirth, LJ | 1 |
| Marti, CN | 1 |
| Choi, NG | 1 |
| Bae, SJ | 1 |
| Ni, L | 1 |
| Luo, X | 1 |
| Dai, T | 1 |
| Lee, R | 1 |
| Fleischer, AS | 1 |
| Wemhoff, AP | 1 |
| Ford, CR | 1 |
| Kleppinger, EL | 1 |
| Helms, K | 1 |
| Bush, AA | 1 |
| Luna-Abanto, J | 1 |
| García Ruiz, L | 1 |
| Laura Martinez, J | 1 |
| Álvarez Larraondo, M | 1 |
| Villoslada Terrones, V | 1 |
| Dukic, L | 1 |
| Maric, N | 1 |
| Simundic, AM | 1 |
| Chogtu, B | 1 |
| Ommurugan, B | 1 |
| Thomson, SR | 1 |
| Kalthur, SG | 1 |
| Benidir, M | 1 |
| El Massoudi, S | 1 |
| El Ghadraoui, L | 1 |
| Lazraq, A | 1 |
| Benjelloun, M | 1 |
| Errachidi, F | 1 |
| Cassar, M | 1 |
| Law, AD | 1 |
| Chow, ES | 1 |
| Giebultowicz, JM | 1 |
| Kretzschmar, D | 1 |
| Salonurmi, T | 1 |
| Nabil, H | 1 |
| Ronkainen, J | 1 |
| Hyötyläinen, T | 1 |
| Hautajärvi, H | 1 |
| Savolainen, MJ | 1 |
| Tolonen, A | 1 |
| Orešič, M | 1 |
| Känsäkoski, P | 1 |
| Rysä, J | 1 |
| Hakkola, J | 1 |
| Hukkanen, J | 1 |
| Zhu, N | 1 |
| Du, Q | 1 |
| Hao, P | 1 |
| Cao, X | 1 |
| Li, CX | 1 |
| Zhao, S | 2 |
| Luo, XM | 1 |
| Feng, JX | 1 |
| Gonzalez-Cotto, M | 1 |
| Guo, L | 1 |
| Karwan, M | 1 |
| Sen, SK | 1 |
| Barb, J | 1 |
| Collado, CJ | 1 |
| Elloumi, F | 1 |
| Palmieri, EM | 1 |
| Boelte, K | 1 |
| Kolodgie, FD | 1 |
| Finn, AV | 1 |
| Biesecker, LG | 1 |
| McVicar, DW | 1 |
| Qu, F | 1 |
| Deng, Z | 2 |
| Xie, Y | 2 |
| Tang, J | 3 |
| Chen, Z | 4 |
| Luo, W | 1 |
| Xiong, D | 1 |
| Zhao, D | 1 |
| Fang, J | 1 |
| Zhou, Z | 4 |
| Niu, PP | 1 |
| Song, B | 1 |
| Xu, YM | 1 |
| Qiu, N | 1 |
| Yin, J | 1 |
| Zhang, J | 9 |
| Guo, W | 2 |
| Liu, T | 6 |
| Chen, D | 6 |
| Luo, K | 1 |
| He, Z | 3 |
| Zheng, G | 1 |
| Xu, F | 2 |
| Sun, W | 1 |
| Yin, F | 1 |
| van Hest, JCM | 1 |
| Du, L | 2 |
| Shi, X | 2 |
| Kang, S | 1 |
| Duan, W | 2 |
| Zhang, S | 4 |
| Feng, J | 4 |
| Qi, N | 1 |
| Shen, G | 1 |
| Ren, H | 10 |
| Shang, Q | 1 |
| Zhao, W | 4 |
| Jiang, X | 3 |
| Alame, M | 1 |
| Cornillot, E | 1 |
| Cacheux, V | 1 |
| Tosato, G | 1 |
| Four, M | 1 |
| De Oliveira, L | 1 |
| Gofflot, S | 1 |
| Delvenne, P | 1 |
| Turtoi, E | 1 |
| Cabello-Aguilar, S | 1 |
| Nishiyama, M | 1 |
| Turtoi, A | 1 |
| Costes-Martineau, V | 1 |
| Colinge, J | 1 |
| Guo, Q | 2 |
| Quan, M | 1 |
| Dong, J | 3 |
| Bai, J | 1 |
| Han, R | 1 |
| Cai, Y | 2 |
| Lv, YQ | 1 |
| Chen, Q | 3 |
| Lyu, HD | 1 |
| Deng, L | 1 |
| Zhou, D | 1 |
| Xiao, X | 2 |
| De Langhe, S | 1 |
| Billadeau, DD | 1 |
| Lou, Z | 1 |
| Zhang, JS | 1 |
| Xue, Z | 1 |
| Shen, XD | 1 |
| Gao, F | 1 |
| Busuttil, RW | 1 |
| Kupiec-Weglinski, JW | 1 |
| Ji, H | 2 |
| Otano, I | 1 |
| Alvarez, M | 1 |
| Minute, L | 1 |
| Ochoa, MC | 1 |
| Migueliz, I | 1 |
| Molina, C | 1 |
| Azpilikueta, A | 1 |
| de Andrea, CE | 1 |
| Etxeberria, I | 1 |
| Sanmamed, MF | 1 |
| Teijeira, Á | 1 |
| Berraondo, P | 1 |
| Melero, I | 1 |
| Zhong, Z | 1 |
| Xie, X | 1 |
| Yu, Q | 1 |
| Zhou, C | 3 |
| Yin, Y | 1 |
| Li, CW | 1 |
| Hsu, JL | 1 |
| Zhou, Q | 2 |
| Hu, B | 1 |
| Fu, P | 1 |
| Atyah, M | 1 |
| Ma, Q | 2 |
| Xu, Y | 4 |
| Dong, Q | 1 |
| Hung, MC | 1 |
| Ren, N | 1 |
| Huang, P | 1 |
| Liao, R | 1 |
| Chen, X | 12 |
| Cao, Q | 1 |
| Yuan, X | 2 |
| Nie, W | 1 |
| Yang, J | 6 |
| Shao, B | 1 |
| Bi, Z | 1 |
| Liang, X | 2 |
| Tie, Y | 1 |
| Mo, F | 1 |
| Xie, D | 1 |
| Wei, Y | 1 |
| Wei, X | 2 |
| Dokla, EME | 1 |
| Fang, CS | 1 |
| Chu, PC | 1 |
| Chang, CS | 1 |
| Abouzid, KAM | 1 |
| Chen, CS | 1 |
| Blaszczyk, R | 1 |
| Brzezinska, J | 1 |
| Dymek, B | 1 |
| Stanczak, PS | 1 |
| Mazurkiewicz, M | 1 |
| Olczak, J | 1 |
| Nowicka, J | 1 |
| Dzwonek, K | 1 |
| Zagozdzon, A | 1 |
| Golab, J | 1 |
| Golebiowski, A | 1 |
| Xin, Z | 1 |
| Himmelbauer, MK | 1 |
| Jones, JH | 1 |
| Enyedy, I | 1 |
| Gilfillan, R | 1 |
| Hesson, T | 1 |
| King, K | 1 |
| Marcotte, DJ | 1 |
| Murugan, P | 1 |
| Santoro, JC | 1 |
| Gonzalez-Lopez de Turiso, F | 1 |
| Pedron, J | 1 |
| Boudot, C | 1 |
| Brossas, JY | 1 |
| Pinault, E | 1 |
| Bourgeade-Delmas, S | 1 |
| Sournia-Saquet, A | 1 |
| Boutet-Robinet, E | 1 |
| Destere, A | 1 |
| Tronnet, A | 1 |
| Bergé, J | 1 |
| Bonduelle, C | 1 |
| Deraeve, C | 1 |
| Pratviel, G | 1 |
| Stigliani, JL | 1 |
| Paris, L | 1 |
| Mazier, D | 1 |
| Corvaisier, S | 1 |
| Since, M | 1 |
| Malzert-Fréon, A | 1 |
| Wyllie, S | 1 |
| Milne, R | 1 |
| Fairlamb, AH | 1 |
| Valentin, A | 1 |
| Courtioux, B | 1 |
| Verhaeghe, P | 1 |
| Fang, X | 1 |
| Gao, M | 1 |
| Gao, H | 2 |
| Bi, W | 1 |
| Cui, Y | 2 |
| Zhang, L | 8 |
| Fan, H | 2 |
| Yu, H | 2 |
| Mathison, CJN | 1 |
| Chianelli, D | 1 |
| Rucker, PV | 1 |
| Nelson, J | 1 |
| Roland, J | 1 |
| Huang, Z | 4 |
| Xie, YF | 1 |
| Epple, R | 1 |
| Bursulaya, B | 1 |
| Gao, MY | 1 |
| Shaffer, J | 1 |
| Briones, S | 1 |
| Sarkisova, Y | 1 |
| Galkin, A | 1 |
| Li, N | 2 |
| Hua, S | 1 |
| Kasibhatla, S | 1 |
| Kinyamu-Akunda, J | 1 |
| Kikkawa, R | 1 |
| Molteni, V | 1 |
| Tellew, JE | 1 |
| Pang, B | 1 |
| Liu, Q | 3 |
| Liu, X | 5 |
| Huang, Y | 7 |
| Josephine Fauci, A | 1 |
| Ma, Y | 1 |
| Soo Lee, M | 1 |
| Yuan, W | 1 |
| Gao, R | 1 |
| Qi, H | 1 |
| Zheng, W | 1 |
| Yang, F | 5 |
| Chua, H | 1 |
| Wang, K | 4 |
| Ou, Y | 1 |
| Huang, M | 4 |
| Zhu, Y | 8 |
| Yu, J | 2 |
| Tian, J | 1 |
| Zhao, M | 1 |
| Hu, J | 5 |
| Yao, C | 1 |
| Zhang, B | 2 |
| Usawachintachit, M | 1 |
| Tzou, DT | 1 |
| Washington, SL | 1 |
| Hu, W | 1 |
| Chi, T | 1 |
| Sorensen, MD | 1 |
| Bailey, MR | 1 |
| Hsi, RS | 1 |
| Cunitz, BW | 1 |
| Simon, J | 1 |
| Wang, YN | 1 |
| Dunmire, BL | 1 |
| Paun, M | 1 |
| Starr, F | 1 |
| Lu, W | 3 |
| Evan, AP | 1 |
| Harper, JD | 1 |
| Han, G | 1 |
| Rodrigues, AE | 1 |
| Fouladvand, F | 1 |
| Falahi, E | 1 |
| Asbaghi, O | 1 |
| Abbasnezhad, A | 1 |
| Anigboro, AA | 1 |
| Avwioroko, OJ | 1 |
| Cholu, CO | 1 |
| Sonei, A | 1 |
| Fazelipour, S | 1 |
| Kanaani, L | 1 |
| Jahromy, MH | 1 |
| Jo, K | 1 |
| Hong, KB | 1 |
| Suh, HJ | 2 |
| Park, JH | 7 |
| Shin, E | 1 |
| Park, E | 1 |
| Kouakou-Kouamé, CA | 1 |
| N'guessan, FK | 1 |
| Montet, D | 1 |
| Djè, MK | 1 |
| Kim, GD | 1 |
| González-Fernández, D | 1 |
| Pons, EDC | 1 |
| Rueda, D | 1 |
| Sinisterra, OT | 1 |
| Murillo, E | 1 |
| Scott, ME | 1 |
| Koski, KG | 1 |
| Shete, PB | 1 |
| Gonzales, R | 1 |
| Ackerman, S | 1 |
| Cattamanchi, A | 1 |
| Handley, MA | 1 |
| Li, XX | 1 |
| Xiao, SZ | 1 |
| Gu, FF | 1 |
| He, WP | 2 |
| Ni, YX | 1 |
| Han, LZ | 1 |
| Heffernan, JK | 1 |
| Valgepea, K | 1 |
| de Souza Pinto Lemgruber, R | 1 |
| Casini, I | 1 |
| Plan, M | 1 |
| Tappel, R | 1 |
| Simpson, SD | 1 |
| Köpke, M | 1 |
| Nielsen, LK | 1 |
| Marcellin, E | 1 |
| Cen, YK | 1 |
| Lin, JG | 1 |
| Wang, YL | 1 |
| Wang, JY | 1 |
| Liu, ZQ | 1 |
| Zheng, YG | 1 |
| Spirk, D | 1 |
| Noll, S | 1 |
| Burnier, M | 1 |
| Rimoldi, S | 1 |
| Noll, G | 1 |
| Sudano, I | 1 |
| Penzhorn, BL | 1 |
| Oosthuizen, MC | 1 |
| Kobos, LM | 1 |
| Alqatani, S | 1 |
| Ferreira, CR | 1 |
| Aryal, UK | 1 |
| Hedrick, V | 1 |
| Sobreira, TJP | 1 |
| Shannahan, JH | 1 |
| Gale, P | 1 |
| Singhroy, DN | 1 |
| MacLean, E | 1 |
| Kohli, M | 1 |
| Lessem, E | 1 |
| Branigan, D | 1 |
| England, K | 1 |
| Suleiman, K | 1 |
| Drain, PK | 1 |
| Ruhwald, M | 1 |
| Schumacher, S | 1 |
| Denkinger, CM | 1 |
| Waning, B | 1 |
| Van Gemert, W | 1 |
| Pai, M | 1 |
| Myers, RK | 1 |
| Bonsu, JM | 1 |
| Carey, ME | 1 |
| Yerys, BE | 1 |
| Mollen, CJ | 1 |
| Curry, AE | 1 |
| Douglas, TA | 1 |
| Alinezhadbalalami, N | 1 |
| Balani, N | 1 |
| Schmelz, EM | 1 |
| Davalos, RV | 1 |
| Kamaldinov, T | 1 |
| Erndt-Marino, J | 1 |
| Levin, M | 1 |
| Kaplan, DL | 1 |
| Hahn, MS | 1 |
| Heidarimoghadam, R | 1 |
| Farmany, A | 1 |
| Lee, JJ | 2 |
| Kang, J | 2 |
| Park, S | 3 |
| Cho, JH | 3 |
| Oh, S | 2 |
| Park, DJ | 1 |
| Perez-Maldonado, R | 1 |
| Cho, JY | 2 |
| Park, IH | 1 |
| Kim, HB | 1 |
| Song, M | 1 |
| Mfarrej, B | 1 |
| Jofra, T | 1 |
| Morsiani, C | 1 |
| Gagliani, N | 1 |
| Fousteri, G | 1 |
| Battaglia, M | 1 |
| Giuliano, C | 1 |
| Levinger, I | 1 |
| Vogrin, S | 1 |
| Neil, CJ | 1 |
| Allen, JD | 1 |
| Lv, Y | 2 |
| Yuan, R | 1 |
| Cai, B | 2 |
| Bahrami, B | 1 |
| Chowdhury, AH | 1 |
| Yang, C | 5 |
| Qiao, Q | 1 |
| Liu, SF | 1 |
| Zhang, WH | 3 |
| Kolano, L | 1 |
| Knappe, D | 1 |
| Volke, D | 1 |
| Sträter, N | 1 |
| Hoffmann, R | 1 |
| Coussens, M | 1 |
| Calders, P | 1 |
| Lapauw, B | 1 |
| Celie, B | 1 |
| Banica, T | 1 |
| De Wandele, I | 1 |
| Pacey, V | 1 |
| Malfait, F | 1 |
| Rombaut, L | 1 |
| Vieira, D | 1 |
| Angel, S | 1 |
| Honjol, Y | 1 |
| Gruenheid, S | 1 |
| Gbureck, U | 1 |
| Harvey, E | 1 |
| Merle, G | 1 |
| Seo, G | 1 |
| Lee, G | 1 |
| Kim, MJ | 4 |
| Baek, SH | 1 |
| Choi, M | 1 |
| Ku, KB | 1 |
| Lee, CS | 1 |
| Jun, S | 1 |
| Park, D | 1 |
| Kim, HG | 1 |
| Kim, SJ | 2 |
| Lee, JO | 1 |
| Kim, BT | 1 |
| Park, EC | 1 |
| Kim, SI | 1 |
| Ende, M | 1 |
| Kirkkala, T | 1 |
| Loitzenbauer, M | 1 |
| Talla, D | 1 |
| Wildner, M | 1 |
| Miletich, R | 1 |
| Criado, A | 1 |
| Lavela, P | 1 |
| Tirado, JL | 1 |
| Pérez-Vicente, C | 1 |
| Kang, D | 1 |
| Feng, D | 2 |
| Fang, Z | 1 |
| Wei, F | 3 |
| De Clercq, E | 1 |
| Pannecouque, C | 1 |
| Zhan, P | 1 |
| Guo, Y | 4 |
| Shen, Y | 3 |
| Wang, Q | 7 |
| Kawazoe, Y | 1 |
| Jena, P | 1 |
| Sun, Z | 1 |
| Li, Z | 5 |
| Liang, H | 1 |
| Xu, X | 3 |
| Ma, G | 1 |
| Huo, X | 1 |
| Church, JS | 1 |
| Chace-Donahue, F | 1 |
| Blum, JL | 1 |
| Ratner, JR | 1 |
| Zelikoff, JT | 1 |
| Schwartzer, JJ | 1 |
| Fiseha, T | 1 |
| Tamir, Z | 1 |
| Yao, W | 1 |
| Mi, K | 1 |
| Cheng, J | 6 |
| Gu, C | 1 |
| Huang, J | 3 |
| Sun, HB | 1 |
| Xing, WQ | 1 |
| Liu, XB | 1 |
| Zheng, Y | 3 |
| Yang, SJ | 1 |
| Wang, ZF | 1 |
| Liu, SL | 1 |
| Ba, YF | 1 |
| Zhang, RX | 1 |
| Liu, BX | 1 |
| Fan, CC | 1 |
| Chen, PN | 1 |
| Liang, GH | 1 |
| Yu, YK | 1 |
| Wang, HR | 1 |
| Li, HM | 1 |
| Li, ZX | 1 |
| Lalani, SS | 1 |
| Anasir, MI | 1 |
| Poh, CL | 1 |
| Khan, IT | 1 |
| Nadeem, M | 1 |
| Imran, M | 1 |
| Khalique, A | 1 |
| Raspini, B | 1 |
| Porri, D | 1 |
| De Giuseppe, R | 1 |
| Chieppa, M | 1 |
| Liso, M | 1 |
| Cerbo, RM | 1 |
| Civardi, E | 1 |
| Garofoli, F | 1 |
| Monti, MC | 1 |
| Vacca, M | 1 |
| De Angelis, M | 1 |
| Cena, H | 1 |
| Kong, D | 1 |
| Han, X | 1 |
| Zhou, Y | 10 |
| Xue, H | 1 |
| Zhang, W | 4 |
| Ruan, Z | 1 |
| Noer, PR | 1 |
| Kjaer-Sorensen, K | 1 |
| Juhl, AK | 1 |
| Goldstein, A | 1 |
| Ke, C | 1 |
| Oxvig, C | 1 |
| Duan, C | 2 |
| Lin, S | 1 |
| Wang, Z | 4 |
| Bhattacharya, R | 1 |
| Mazumder, D | 1 |
| Ma, C | 1 |
| Tang, Y | 1 |
| Kong, X | 1 |
| Lu, J | 2 |
| Zhang, M | 5 |
| Vital-Jacome, M | 1 |
| Cazares-Granillo, M | 1 |
| Carrillo-Reyes, J | 1 |
| Buitron, G | 1 |
| Jacob, SI | 1 |
| Douair, I | 1 |
| Maron, L | 1 |
| Ménard, G | 1 |
| Rusjan, P | 1 |
| Sabioni, P | 1 |
| Di Ciano, P | 1 |
| Mansouri, E | 1 |
| Boileau, I | 1 |
| Laveillé, A | 1 |
| Capet, M | 1 |
| Duvauchelle, T | 1 |
| Schwartz, JC | 1 |
| Robert, P | 1 |
| Le Foll, B | 1 |
| Xia, Y | 1 |
| Chen, S | 4 |
| Luo, M | 1 |
| Wu, J | 6 |
| He, Y | 3 |
| Garbacz, P | 1 |
| Misiak, M | 1 |
| Jackowski, K | 1 |
| Yuan, Q | 1 |
| Sherrell, PC | 1 |
| Bi, X | 1 |
| Nutho, B | 1 |
| Mahalapbutr, P | 1 |
| Hengphasatporn, K | 1 |
| Pattaranggoon, NC | 1 |
| Simanon, N | 1 |
| Shigeta, Y | 1 |
| Hannongbua, S | 1 |
| Rungrotmongkol, T | 1 |
| Caffrey, PJ | 1 |
| Kher, R | 1 |
| Bian, K | 1 |
| Delaney, S | 1 |
| Xue, J | 1 |
| Wu, P | 2 |
| Xu, L | 4 |
| Yuan, Y | 1 |
| Luo, J | 1 |
| Ye, S | 1 |
| Ustriyana, P | 1 |
| Wei, B | 1 |
| Raee, E | 1 |
| Wesdemiotis, C | 1 |
| Sahai, N | 1 |
| Kaur, A | 1 |
| Nigam, K | 1 |
| Srivastava, S | 1 |
| Tyagi, A | 1 |
| Dang, S | 1 |
| Millar, JE | 1 |
| Bartnikowski, N | 1 |
| Passmore, MR | 1 |
| Obonyo, NG | 1 |
| Malfertheiner, MV | 1 |
| von Bahr, V | 1 |
| Redd, MA | 1 |
| See Hoe, L | 1 |
| Ki, KK | 1 |
| Pedersen, S | 1 |
| Boyle, AJ | 1 |
| Baillie, JK | 1 |
| Shekar, K | 1 |
| Palpant, N | 1 |
| Suen, JY | 1 |
| Matthay, MA | 1 |
| McAuley, DF | 1 |
| Fraser, JF | 1 |
| Settles, JA | 1 |
| Gerety, GF | 1 |
| Spaepen, E | 1 |
| Suico, JG | 1 |
| Child, CJ | 1 |
| Oh, BL | 1 |
| Lee, EY | 1 |
| Lee, HY | 1 |
| Yu, HG | 1 |
| Leslie, I | 1 |
| Boos, LA | 1 |
| Larkin, J | 1 |
| Pickering, L | 1 |
| Lima, HK | 1 |
| Vogel, K | 1 |
| Hampel, D | 1 |
| Wagner-Gillespie, M | 1 |
| Fogleman, AD | 1 |
| Ferraz, SL | 1 |
| O'Connor, M | 1 |
| Mazzucchelli, TG | 1 |
| Kajiyama, H | 1 |
| Suzuki, S | 1 |
| Shimbo, A | 1 |
| Utsumi, F | 1 |
| Yoshikawa, N | 1 |
| Kikkawa, F | 1 |
| Javvaji, PK | 1 |
| Dhali, A | 1 |
| Francis, JR | 1 |
| Kolte, AP | 1 |
| Roy, SC | 1 |
| Selvaraju, S | 1 |
| Mech, A | 1 |
| Sejian, V | 1 |
| DeSilva, S | 1 |
| Vaidya, SS | 1 |
| Mao, C | 1 |
| Akhatayeva, Z | 1 |
| Cheng, H | 1 |
| Zhang, G | 3 |
| Jiang, F | 1 |
| Meng, X | 1 |
| Elnour, IE | 1 |
| Lan, X | 1 |
| Song, E | 1 |
| Rohde, S | 1 |
| Antonides, CFJ | 1 |
| Muslem, R | 1 |
| de Woestijne, PCV | 1 |
| der Meulen, MHV | 1 |
| Kraemer, US | 1 |
| Dalinghaus, M | 1 |
| Bogers, AJJC | 1 |
| Pourmand, A | 1 |
| Ghassemi, M | 1 |
| Sumon, K | 1 |
| Amini, SB | 1 |
| Hood, C | 1 |
| Sikka, N | 1 |
| Duan, H | 1 |
| Chen, WP | 1 |
| Fan, M | 1 |
| Wang, WP | 1 |
| Yu, L | 5 |
| Tan, SJ | 1 |
| Xin, S | 6 |
| Wan, LJ | 1 |
| Guo, YG | 1 |
| Tanda, S | 1 |
| Gingl, K | 1 |
| Ličbinský, R | 1 |
| Hegrová, J | 1 |
| Goessler, W | 1 |
| Li, ZL | 1 |
| Zhou, YL | 3 |
| Yan, W | 1 |
| Luo, L | 1 |
| Su, ZZ | 1 |
| Fan, MZ | 1 |
| Wang, SR | 1 |
| Zhao, WG | 1 |
| Xu, D | 17 |
| Hassan, HM | 1 |
| Jiang, Z | 2 |
| Bachmann, KF | 1 |
| Haenggi, M | 1 |
| Jakob, SM | 1 |
| Takala, J | 1 |
| Gattinoni, L | 1 |
| Berger, D | 1 |
| Bentley, RF | 1 |
| Vecchiarelli, E | 1 |
| Banks, L | 1 |
| Gonçalves, PEO | 1 |
| Thomas, SG | 1 |
| Goodman, JM | 1 |
| Mather, K | 1 |
| Boachie, R | 1 |
| Anini, Y | 1 |
| Panahi, S | 1 |
| Anderson, GH | 1 |
| Luhovyy, BL | 1 |
| Nafie, MS | 1 |
| Arafa, K | 1 |
| Sedky, NK | 1 |
| Alakhdar, AA | 1 |
| Arafa, RK | 1 |
| Fan, S | 1 |
| Hu, H | 3 |
| Liang, J | 2 |
| Hu, BC | 1 |
| Wen, Z | 1 |
| Hu, D | 1 |
| Liu, YY | 2 |
| Chu, Q | 1 |
| Wu, MC | 3 |
| Lu, X | 2 |
| Hu, M | 1 |
| Shen, H | 1 |
| Yao, M | 2 |
| Dahlgren, RA | 1 |
| Vysloužil, J | 1 |
| Kulich, P | 1 |
| Zeman, T | 1 |
| Vaculovič, T | 1 |
| Tvrdoňová, M | 1 |
| Mikuška, P | 1 |
| Večeřa, Z | 1 |
| Stráská, J | 1 |
| Moravec, P | 1 |
| Balcar, VJ | 1 |
| Šerý, O | 1 |
| Qiao, L | 1 |
| Xiong, X | 1 |
| Peng, X | 1 |
| Zheng, J | 1 |
| Duan, J | 1 |
| Xiao, W | 2 |
| Zhou, HY | 1 |
| Sui, ZY | 1 |
| Zhao, FL | 1 |
| Sun, YN | 1 |
| Wang, HY | 2 |
| Han, BH | 1 |
| Jintao, X | 1 |
| Shasha, Y | 1 |
| Jincai, W | 1 |
| Chunyan, L | 1 |
| Mengya, Y | 1 |
| Yongli, S | 1 |
| Rasoanirina, BNV | 1 |
| Lassoued, MA | 1 |
| Miladi, K | 1 |
| Razafindrakoto, Z | 1 |
| Chaâbane-Banaoues, R | 1 |
| Ramanitrahasimbola, D | 1 |
| Cornet, M | 1 |
| Sfar, S | 1 |
| Liang, C | 1 |
| Xing, Q | 1 |
| Yi, JL | 1 |
| Zhang, YQ | 1 |
| Li, CY | 1 |
| Tang, SJ | 1 |
| Gao, C | 1 |
| Sun, X | 2 |
| Peng, M | 1 |
| Sun, XF | 1 |
| Zhang, T | 1 |
| Shi, JH | 1 |
| Liao, CX | 1 |
| Gao, WJ | 1 |
| Sun, LL | 1 |
| Cao, WH | 1 |
| Lyu, J | 1 |
| Yu, CQ | 1 |
| Wang, SF | 1 |
| Pang, ZC | 1 |
| Cong, LM | 1 |
| Dong, Z | 1 |
| Wu, F | 1 |
| Wu, XP | 1 |
| Jiang, GH | 1 |
| Wang, XJ | 1 |
| Wang, BY | 2 |
| Li, LM | 1 |
| Pan, L | 1 |
| Wan, SP | 1 |
| Yi, HWL | 1 |
| He, HJ | 1 |
| Yong, ZP | 1 |
| Shan, GL | 1 |
| Weng, TT | 1 |
| Yan, SQ | 1 |
| Gao, GP | 1 |
| Wei, C | 1 |
| Tao, FB | 1 |
| Shao, ZH | 1 |
| Yao, T | 1 |
| Dong, S | 1 |
| Shi, S | 1 |
| Feng, YL | 1 |
| Zhang, YW | 1 |
| Wang, SP | 1 |
| Shi, AX | 1 |
| Operario, D | 1 |
| Zhang, ZH | 1 |
| Zhu, XF | 1 |
| Zaller, N | 1 |
| Gao, P | 1 |
| Sun, YH | 1 |
| Zhang, HB | 2 |
| Woo, HY | 2 |
| Park, JY | 13 |
| Bae, SH | 5 |
| Kim, CW | 4 |
| Jang, JY | 2 |
| Kim, DJ | 2 |
| Kim, IH | 7 |
| Heo, J | 4 |
| Xiang, Q | 1 |
| Xie, Q | 9 |
| Mu, G | 1 |
| Cen, X | 1 |
| Lee, SB | 1 |
| Park, BR | 5 |
| Chen, R | 8 |
| Luo, D | 1 |
| Si, L | 2 |
| Huang, B | 1 |
| Cheng, F | 2 |
| Jang, BK | 2 |
| Qin, Y | 3 |
| Tong, S | 2 |
| Cao, L | 1 |
| Lin, C | 2 |
| Sheng, Q | 1 |
| Wang, S | 2 |
| Fan, J | 3 |
| Gan, W | 2 |
| Chen, B | 3 |
| Yip, TC | 1 |
| Wong, GL | 8 |
| Song, K | 1 |
| Yan, Q | 1 |
| Lv, M | 1 |
| Chen, Y | 7 |
| Dai, Y | 2 |
| Gao, Z | 4 |
| Li, ZB | 1 |
| Niu, XX | 1 |
| Chen, SH | 1 |
| Fu, YM | 1 |
| Wang, CY | 1 |
| Shao, Q | 1 |
| Chen, G | 2 |
| Ji, D | 4 |
| Liu, LM | 1 |
| Tian, Y | 1 |
| Yao, Z | 4 |
| Liao, H | 3 |
| Zhao, J | 3 |
| Bernstein, DE | 1 |
| Trinh, HN | 9 |
| Schiff, ER | 8 |
| Smith, CI | 1 |
| Mospan, AR | 1 |
| Zink, RC | 1 |
| Fried, MW | 2 |
| Lok, AS | 12 |
| Hu, C | 2 |
| Zhang, R | 2 |
| Fu, S | 1 |
| Fu, M | 1 |
| Yan, T | 1 |
| Chen, T | 1 |
| Marcos-Fosch, C | 1 |
| Esteban, R | 16 |
| Zhang, MY | 1 |
| Zhu, GQ | 1 |
| Zheng, JN | 1 |
| Cheng, Z | 2 |
| Van Poucke, S | 1 |
| Shi, KQ | 1 |
| Huang, HH | 1 |
| Chen, FY | 1 |
| Zheng, MH | 1 |
| Vincenti, D | 2 |
| Piselli, P | 1 |
| Solmone, M | 1 |
| D'Offizi, G | 1 |
| Capobianchi, MR | 1 |
| Menzo, S | 1 |
| He, L | 2 |
| Jiang, Y | 8 |
| Karris, MY | 1 |
| Chan, HL | 17 |
| Hui, AJ | 3 |
| Janssen, HL | 25 |
| Chowdhury, A | 1 |
| Tsang, TY | 1 |
| Mehta, R | 2 |
| Massetto, B | 4 |
| Kitrinos, KM | 12 |
| McHutchison, JG | 8 |
| Acharya, SK | 2 |
| Stepanova, T | 1 |
| Cathcart, AL | 3 |
| Kim, K | 1 |
| Brunetto, M | 2 |
| Marcellin, P | 42 |
| Abdul Basit, S | 1 |
| Dawood, A | 1 |
| Ryan, J | 1 |
| Gish, R | 2 |
| Scott, LJ | 1 |
| Su, TH | 1 |
| Liu, CJ | 3 |
| Zhou, F | 1 |
| Zhang, YY | 1 |
| de Niet, A | 8 |
| Jansen, L | 11 |
| Stelma, F | 4 |
| Willemse, SB | 2 |
| Kuiken, SD | 1 |
| Weijer, S | 1 |
| van Nieuwkerk, CMJ | 1 |
| Zaaijer, HL | 9 |
| Molenkamp, R | 3 |
| Takkenberg, RB | 10 |
| Koot, M | 3 |
| Verheij, J | 2 |
| Beuers, U | 1 |
| Reesink, HW | 13 |
| van der Ree, MH | 2 |
| Peters, MW | 1 |
| Janssen, HLA | 1 |
| Matsumoto, A | 2 |
| Nishiguchi, S | 1 |
| Enomoto, H | 1 |
| Kang, JH | 1 |
| Tanaka, Y | 4 |
| Shinkai, N | 1 |
| Enomoto, M | 2 |
| Kanda, T | 2 |
| Yokosuka, O | 2 |
| Yatsuhashi, H | 1 |
| Nagaoka, S | 1 |
| Okuse, C | 1 |
| Kagawa, T | 1 |
| Mine, T | 1 |
| Takaguchi, K | 2 |
| Saito, S | 1 |
| Hino, K | 1 |
| Ikeda, F | 4 |
| Sakisaka, S | 1 |
| Morihara, D | 1 |
| Miyase, S | 1 |
| Tsuge, M | 2 |
| Chayama, K | 2 |
| Hiramatsu, N | 2 |
| Suzuki, Y | 8 |
| Tanaka, E | 3 |
| Gong, GZ | 3 |
| Xu, DZ | 1 |
| Guo, LM | 1 |
| Pan, C | 3 |
| Geng, S | 1 |
| Mi, H | 1 |
| Zhao, G | 1 |
| Yu, W | 2 |
| Wen, YM | 1 |
| Wang, XY | 2 |
| Kalafateli, M | 1 |
| Aggeletopoulou, I | 1 |
| Mandellou, M | 1 |
| Assimakopoulos, S | 1 |
| Tselekouni, P | 1 |
| Taprantzi, D | 1 |
| Tsiaoussis, G | 1 |
| Vourli, G | 1 |
| Anastassiou, ED | 1 |
| Gogos, C | 1 |
| Labropoulou-Karatza, C | 1 |
| Thomopoulos, K | 1 |
| Welkers, MRA | 2 |
| van Dort, KA | 4 |
| Lopatin, U | 4 |
| de Jong, MD | 1 |
| Kootstra, NA | 7 |
| Qi, W | 1 |
| Yu, F | 2 |
| Guo, H | 1 |
| Zhao, P | 8 |
| Wu, K | 1 |
| Shen, F | 4 |
| Qiu, L | 2 |
| Chang, S | 1 |
| Shaheen, AA | 1 |
| Al-Mattooq, M | 1 |
| Yazdanfar, S | 1 |
| Burak, KW | 2 |
| Swain, MG | 1 |
| Congly, SE | 1 |
| Borman, MA | 1 |
| Lee, SS | 7 |
| Myers, RP | 5 |
| Coffin, CS | 3 |
| Huang, R | 1 |
| Wu, C | 1 |
| Hsu, YC | 2 |
| Wei, MT | 1 |
| Tartaglia, A | 2 |
| Ferrara, SM | 1 |
| Sica, S | 1 |
| Santantonio, T | 5 |
| Zhang, DM | 1 |
| Du, LY | 1 |
| Yan, LB | 2 |
| Zhou, TY | 3 |
| Lei, XZ | 2 |
| Lei, BJ | 4 |
| Lu, JJ | 2 |
| Liao, J | 2 |
| Kong, Y | 2 |
| Ma, H | 5 |
| You, H | 4 |
| Ou, X | 3 |
| Rodríguez, M | 2 |
| Pascasio, JM | 1 |
| Fraga, E | 2 |
| Fuentes, J | 1 |
| Prieto, M | 3 |
| Sánchez-Antolín, G | 1 |
| Calleja, JL | 5 |
| Molina, E | 1 |
| García-Buey, ML | 1 |
| Blanco, MÁ | 1 |
| Salmerón, J | 3 |
| Bonet, ML | 1 |
| Pons, JA | 1 |
| González, JM | 1 |
| Casado, MÁ | 4 |
| Jorquera, F | 1 |
| Kim, DH | 4 |
| Kang, HS | 2 |
| Hur, SS | 1 |
| Sim, S | 1 |
| Park, YK | 3 |
| Park, ES | 3 |
| Lee, AR | 2 |
| Kwon, SY | 12 |
| Lee, HJ | 5 |
| Park, SY | 3 |
| Chung, WJ | 1 |
| Lee, CH | 15 |
| Suh, JI | 1 |
| Viganò, M | 10 |
| Loglio, A | 2 |
| Grossi, G | 1 |
| Wong, D | 4 |
| Littlejohn, M | 2 |
| Edwards, R | 3 |
| Jackson, K | 2 |
| Revill, P | 1 |
| Kitrinos, K | 5 |
| Subramanian, M | 2 |
| Buti-Ferret, M | 1 |
| Janssen, H | 2 |
| Locarnini, S | 11 |
| Thompson, A | 2 |
| Riveiro-Barciela, M | 1 |
| Su, WW | 1 |
| Lee, CM | 7 |
| Peng, CY | 3 |
| Chu, HC | 1 |
| Huang, YH | 1 |
| Liaw, YF | 11 |
| Yeh, CT | 2 |
| Yeh, CS | 1 |
| Chu, YD | 1 |
| Chiang, YJ | 1 |
| Ayoub, MM | 1 |
| Elantouny, NG | 1 |
| El-Nahas, HM | 1 |
| Ghazy, FES | 1 |
| Cheng, Y | 1 |
| Su, H | 2 |
| Friedman, A | 1 |
| Siewe, N | 1 |
| Guo, X | 3 |
| Ouyang, Y | 1 |
| Liu, K | 6 |
| Lin, CL | 1 |
| Chen, N | 1 |
| Zhang, JB | 1 |
| Zhao, YP | 3 |
| Li, LY | 1 |
| Liu, LW | 1 |
| Peng, T | 1 |
| Tang, KX | 1 |
| Huang, C | 3 |
| Yang, XH | 1 |
| Yang, YL | 1 |
| Huang, AL | 5 |
| Shi, XF | 2 |
| Xu, WX | 1 |
| Lin, CS | 1 |
| Chen, YM | 2 |
| Deng, H | 4 |
| Mei, YY | 1 |
| Zhao, ZX | 1 |
| Xie, DY | 4 |
| Gao, ZL | 4 |
| Xie, C | 1 |
| Peng, L | 1 |
| Bao, L | 1 |
| Yang, L | 1 |
| Li, WT | 2 |
| Zhao, ZH | 1 |
| Caviglia, GP | 1 |
| Olivero, A | 2 |
| Ngatchou, D | 1 |
| Saracco, GM | 1 |
| Smedile, A | 3 |
| Feenstra, KA | 1 |
| Su, Q | 1 |
| Watanabe, K | 1 |
| Hashimoto, S | 2 |
| Maoka, T | 2 |
| Yamamoto, R | 1 |
| Okamoto, N | 1 |
| Koike, T | 2 |
| Koda, R | 1 |
| Tsuchida, M | 1 |
| Iino, N | 1 |
| Narita, I | 1 |
| Yan, JY | 1 |
| Kan, QC | 1 |
| Udompap, P | 1 |
| Kim, D | 2 |
| Ahmed, A | 2 |
| Kim, WR | 2 |
| Min, IS | 1 |
| Shin, IS | 1 |
| Lee, NE | 1 |
| Son, HS | 1 |
| Kim, SB | 3 |
| Seo, SY | 2 |
| Kim, SH | 3 |
| Kim, SW | 3 |
| Lee, SO | 3 |
| Lee, ST | 3 |
| Deng, R | 1 |
| Tao, CM | 1 |
| Nie, ZW | 1 |
| Chen, K | 1 |
| Liang, L | 1 |
| Cai, X | 1 |
| Huang, A | 2 |
| Tang, N | 1 |
| Fong, TL | 2 |
| Lee, BT | 1 |
| Tien, A | 1 |
| Chang, M | 2 |
| Lim, C | 2 |
| Ahn, A | 1 |
| Bae, HS | 2 |
| Wu, CS | 1 |
| Zhao, Q | 2 |
| Wang, JW | 1 |
| Qian, Y | 1 |
| Fan, YC | 2 |
| Liang, S | 1 |
| Liang, D | 1 |
| Zeng, C | 2 |
| Xia, Z | 1 |
| Shen, J | 2 |
| Peng, W | 1 |
| Wen, T | 1 |
| Fujii, T | 2 |
| Takase, KI | 1 |
| Honda, H | 1 |
| Kawamura, N | 1 |
| Yamasaki, R | 1 |
| Urata, M | 1 |
| Uchiumi, T | 1 |
| Iwaki, T | 1 |
| Kira, JI | 1 |
| Makita, T | 1 |
| Kanzaki, H | 1 |
| Onishi, H | 1 |
| Ikeda, A | 1 |
| Takaki, A | 3 |
| Wada, N | 1 |
| Takeuchi, Y | 2 |
| Yasunaka, T | 3 |
| Shiraha, H | 1 |
| Nishihara, S | 1 |
| Murakawa, K | 1 |
| Kitamura, Y | 1 |
| Okada, H | 1 |
| Sendo, T | 1 |
| Song, JE | 1 |
| Kondoh, K | 1 |
| Michitaka, K | 1 |
| Hiraoka, A | 2 |
| Izumoto, H | 1 |
| Ueki, H | 1 |
| Kitahata, S | 1 |
| Yamago, H | 1 |
| Tsubouchi, E | 1 |
| Ninomiya, T | 1 |
| He, F | 1 |
| Xiang, C | 1 |
| Feng, X | 2 |
| Bai, X | 2 |
| Takeda, S | 1 |
| Qing, Y | 1 |
| Chang, Y | 2 |
| Nam, JY | 1 |
| Cho, H | 3 |
| Cho, EJ | 6 |
| Yu, SJ | 9 |
| Yoon, JH | 11 |
| Kim, YJ | 16 |
| Jia, W | 1 |
| Zhu, MQ | 1 |
| Chen, PD | 1 |
| Fan, QQ | 1 |
| Sutherland, N | 1 |
| Li Wai Suen, CFD | 1 |
| Mills, C | 1 |
| Lokan, J | 1 |
| Sinclair, M | 1 |
| Tada, T | 4 |
| Miyake, N | 1 |
| Kurisu, A | 1 |
| Ohisa, M | 1 |
| Akita, T | 1 |
| Qian, YY | 1 |
| Dai, ZJ | 1 |
| Ruan, LY | 1 |
| Jin, J | 1 |
| Shi, MT | 1 |
| Zhu, YX | 1 |
| Wu, CM | 1 |
| Wong, DK | 6 |
| Sievert, W | 9 |
| Buggisch, P | 6 |
| Petersen, J | 11 |
| Flisiak, R | 9 |
| Manns, M | 4 |
| Kaita, K | 3 |
| Krastev, Z | 7 |
| Crans, G | 1 |
| Op den Brouw, M | 1 |
| Jump, B | 1 |
| Flaherty, J | 3 |
| Kawasoe, K | 1 |
| Ohta, A | 1 |
| Nitta, K | 1 |
| Hagiwara, S | 1 |
| Nishida, N | 2 |
| Ida, H | 1 |
| Ueshima, K | 1 |
| Minami, Y | 1 |
| Takita, M | 1 |
| Komeda, Y | 1 |
| Kudo, M | 1 |
| Jia, Y | 1 |
| Zhou, J | 2 |
| Ji, J | 1 |
| Xun, P | 1 |
| Sripongpun, P | 1 |
| Mannalithara, A | 1 |
| Kwo, PY | 1 |
| Liu, SH | 1 |
| Yap, DY | 2 |
| Fung, J | 8 |
| Chan, TM | 2 |
| Lai, CL | 16 |
| Yuen, MF | 14 |
| Walsh, R | 1 |
| Hammond, R | 1 |
| Yuen, L | 1 |
| Deerain, J | 1 |
| O'Donnell, T | 1 |
| Leary, T | 1 |
| Cloherty, G | 1 |
| Sheng, HP | 1 |
| Zhang, XY | 1 |
| Wang, GN | 1 |
| Shi, WB | 1 |
| Zhao, F | 1 |
| Lian, JQ | 2 |
| Wang, JP | 3 |
| Huang, CX | 1 |
| Bai, XF | 2 |
| Hartono, JL | 1 |
| Aung, MO | 2 |
| Dan, YY | 2 |
| Gowans, M | 1 |
| Lim, K | 2 |
| Lee, YM | 2 |
| Lee, GH | 2 |
| Low, HC | 2 |
| Tan, PS | 1 |
| Thwin, MA | 1 |
| Soon, C | 1 |
| Chiu, LL | 1 |
| Khoo, MJ | 1 |
| Koay, E | 1 |
| Lim, SG | 9 |
| Childs, K | 1 |
| Joshi, D | 1 |
| Byrne, R | 1 |
| Bruce, M | 1 |
| Carey, I | 1 |
| Taylor, C | 1 |
| Teperman, LW | 1 |
| Poordad, F | 2 |
| Bzowej, N | 2 |
| Martin, P | 4 |
| Pungpapong, S | 1 |
| Schiano, T | 1 |
| Dinh, P | 9 |
| Rossi, S | 2 |
| Spivey, J | 1 |
| Ma, YJ | 1 |
| Iannazzo, S | 1 |
| Coco, B | 1 |
| Brunetto, MR | 3 |
| Rossetti, F | 1 |
| Caputo, A | 1 |
| Latour, A | 1 |
| Espinos, B | 1 |
| Bonino, F | 1 |
| Almeida, AM | 2 |
| Silva, AL | 2 |
| Brandão, CM | 2 |
| Cherchiglia, ML | 2 |
| Andrade, EI | 2 |
| Araújo de Oliveira, GL | 1 |
| Carmo, RA | 1 |
| Acurcio, Fde A | 2 |
| Rodriguez, C | 4 |
| Chevaliez, S | 4 |
| Bensadoun, P | 1 |
| Pawlotsky, JM | 5 |
| Amarapurkar, DN | 1 |
| Patel, N | 1 |
| Tujios, SR | 2 |
| Lee, WM | 3 |
| Tanaka, M | 2 |
| Suzuki, F | 10 |
| Seko, Y | 1 |
| Hara, T | 2 |
| Kawamura, Y | 6 |
| Sezaki, H | 6 |
| Hosaka, T | 7 |
| Akuta, N | 6 |
| Kobayashi, M | 13 |
| Saitoh, S | 5 |
| Arase, Y | 6 |
| Ikeda, K | 6 |
| Kumada, H | 7 |
| Ji, YY | 2 |
| Yao, GB | 2 |
| Ma, XY | 3 |
| Pang, HY | 1 |
| Wu, SM | 3 |
| Chen, CW | 3 |
| Xu, XW | 2 |
| Gu, EL | 2 |
| Zhu, MF | 3 |
| Qian, JC | 1 |
| Lu, L | 2 |
| Yan, FL | 1 |
| Shi, JP | 2 |
| Lou, GQ | 2 |
| Arama, V | 2 |
| Leblebicioglu, H | 2 |
| Zarski, JP | 6 |
| Zeuzem, S | 8 |
| Mauss, S | 6 |
| Sieklucki, J | 2 |
| Acalovschi, M | 1 |
| Usluer, G | 1 |
| Klauck, I | 2 |
| Morais, E | 2 |
| Bjork, S | 2 |
| Lescrauwaet, B | 3 |
| Kamar, D | 2 |
| Simon, K | 4 |
| Ichchou, L | 1 |
| Rist, S | 1 |
| Lespessailles, E | 1 |
| Prié, D | 1 |
| Benhamou, CL | 1 |
| Salpini, R | 3 |
| Alteri, C | 2 |
| Cento, V | 1 |
| Pollicita, M | 1 |
| Micheli, V | 2 |
| Gubertini, G | 2 |
| De Sanctis, GM | 2 |
| Visca, M | 2 |
| Romano, S | 2 |
| Sarrecchia, C | 2 |
| Andreoni, M | 2 |
| Angelico, M | 3 |
| Parruti, G | 2 |
| Svicher, V | 3 |
| Perno, CF | 3 |
| Park, MS | 1 |
| Kim, BK | 11 |
| Kim, KS | 1 |
| Kim, JK | 3 |
| Kim, DY | 12 |
| Baartarkhuu, O | 1 |
| Han, KH | 14 |
| Chon, CY | 8 |
| Ferreira, AO | 1 |
| Marinho, RT | 1 |
| Velosa, J | 1 |
| Costa, JB | 1 |
| Cao, ZH | 3 |
| Ma, LN | 4 |
| Zhang, HW | 1 |
| Liu, YL | 3 |
| Chen, XY | 8 |
| Huang, XX | 1 |
| Gunsar, F | 2 |
| Chan, SC | 2 |
| Cheung, C | 1 |
| Chok, KS | 1 |
| Sharr, W | 1 |
| Chan, AC | 1 |
| Cheung, TT | 1 |
| Fan, ST | 3 |
| Lo, CM | 3 |
| Weegink, CJ | 3 |
| Terpstra, V | 3 |
| Dijkgraaf, MG | 1 |
| Jansen, PL | 2 |
| Rijckborst, V | 2 |
| Beld, MG | 2 |
| Lee, JY | 2 |
| Lee, YS | 13 |
| Suh, DJ | 8 |
| Plaza, Z | 1 |
| Aguilera, A | 1 |
| Mena, A | 1 |
| Vispo, E | 3 |
| Sierra-Enguita, R | 1 |
| Tomé, S | 1 |
| Pedreira, J | 1 |
| Barreiro, P | 4 |
| del Romero, J | 1 |
| Soriano, V | 12 |
| Poveda, E | 2 |
| Choi, A | 1 |
| Wang, JC | 3 |
| He, LL | 2 |
| Xu, XH | 1 |
| Li, GL | 1 |
| He, FQ | 1 |
| Li, JY | 1 |
| Pan, QR | 1 |
| Deng, JY | 1 |
| Singal, AK | 2 |
| Salameh, H | 1 |
| Kuo, YF | 1 |
| Fontana, RJ | 3 |
| Terrault, N | 2 |
| Lavocat, F | 5 |
| Dény, P | 1 |
| Pichoud, C | 3 |
| Al Hawajri, N | 1 |
| Borroto-Esoda, K | 11 |
| Zoulim, F | 34 |
| Wong, VW | 11 |
| Chan, FK | 2 |
| Huang, FY | 2 |
| Hung, IF | 2 |
| Baxter, C | 1 |
| Yende-Zuma, N | 1 |
| Tshabalala, P | 1 |
| Abdool Karim, Q | 1 |
| Abdool Karim, SS | 1 |
| Gracey, DM | 1 |
| Snelling, P | 1 |
| McKenzie, P | 1 |
| Strasser, SI | 5 |
| Goel, V | 1 |
| Bose, PD | 1 |
| Sarma, MP | 1 |
| Hazam, RK | 1 |
| Das, BC | 2 |
| Gondal, R | 2 |
| Kar, P | 3 |
| Horváth, G | 3 |
| Lin, MT | 2 |
| Chou, YP | 1 |
| Yu, HC | 2 |
| Tsai, MC | 3 |
| Tseng, PL | 3 |
| Yen, YH | 2 |
| Chiu, KW | 1 |
| Wesdorp, DJ | 1 |
| Knoester, M | 1 |
| Braat, AE | 1 |
| Coenraad, MJ | 1 |
| Vossen, AC | 1 |
| Claas, EC | 1 |
| van Hoek, B | 2 |
| Asselah, T | 5 |
| Rodriguez-Frias, F | 5 |
| Frias, FR | 1 |
| Tabernero, D | 4 |
| Šperl, J | 3 |
| Pradat, P | 2 |
| Le Pogam, MA | 1 |
| Okon, JB | 1 |
| Trolliet, P | 1 |
| Miailhes, P | 5 |
| Brochier, C | 1 |
| Maynard, M | 3 |
| Bailly, F | 3 |
| Cotte, L | 1 |
| Watahiki, S | 3 |
| Mineta, R | 2 |
| Corsa, A | 3 |
| Snow-Lampart, A | 6 |
| Miller, MD | 11 |
| Yue, W | 1 |
| Yuan, H | 1 |
| Mao, XR | 1 |
| Deng, YD | 1 |
| Tian, JH | 2 |
| He, YQ | 1 |
| Li, RH | 1 |
| Zhang, SF | 1 |
| Wan, G | 1 |
| Cai, HD | 2 |
| Aydoğan, S | 1 |
| Ergünay, K | 1 |
| Balaban, Y | 2 |
| Alp, A | 1 |
| Simşek, H | 2 |
| Tatar, G | 2 |
| Hasçelik, G | 1 |
| Us, D | 1 |
| Sayan, M | 2 |
| Buğdacı, MS | 1 |
| Sohn, JY | 1 |
| Lee, S | 4 |
| Kim, DG | 2 |
| Srivastava, M | 2 |
| Rungta, S | 1 |
| Dixit, VK | 2 |
| Shukla, SK | 1 |
| Singh, TB | 1 |
| Jain, AK | 2 |
| Du, QW | 1 |
| Ding, JG | 2 |
| Sun, QF | 2 |
| Hong, L | 2 |
| Cai, FJ | 1 |
| Zhou, QQ | 1 |
| Wu, YH | 2 |
| Fu, RQ | 2 |
| Lin, KH | 1 |
| Hsu, PI | 1 |
| Tsay, FW | 1 |
| Wang, HM | 1 |
| Tsai, TJ | 1 |
| Lai, KH | 1 |
| Jin, Y | 3 |
| He, ZM | 2 |
| Lu, JF | 2 |
| Zhang, YH | 2 |
| Sun, H | 3 |
| Tu, Z | 2 |
| Yan, H | 4 |
| Pan, Y | 2 |
| Lian, Z | 1 |
| Chi, X | 2 |
| Ceylan, B | 2 |
| Yardimci, C | 1 |
| Fincanci, M | 1 |
| Eren, G | 1 |
| Tozalgan, U | 1 |
| Muderrisoglu, C | 1 |
| Akkoyunlu, Y | 1 |
| González-Artacho, C | 1 |
| Rodríguez Sicilia, MJ | 1 |
| Alegría-Motte, C | 1 |
| Gómez García, M | 1 |
| Lee, YB | 3 |
| Lee, M | 5 |
| Lee, DH | 6 |
| Cho, Y | 6 |
| Kim, CY | 6 |
| Lee, HS | 11 |
| Peng, H | 1 |
| Yin, W | 2 |
| Hwang, SG | 5 |
| Ko, SY | 7 |
| Choe, WH | 10 |
| Ding, XC | 1 |
| Liu, XY | 1 |
| Xu, CQ | 1 |
| Liu, SW | 1 |
| Alagozlu, H | 1 |
| Ozdemir, O | 1 |
| Koksal, B | 1 |
| Yilmaz, A | 1 |
| Coskun, M | 1 |
| Ouzan, D | 1 |
| Pénaranda, G | 1 |
| Joly, H | 1 |
| Khiri, H | 1 |
| Pironti, A | 1 |
| Halfon, P | 1 |
| Yuan, L | 1 |
| Qiao, B | 1 |
| Tanaka, T | 1 |
| Renner, EL | 1 |
| Selzner, N | 1 |
| Therapondos, G | 1 |
| Lilly, LB | 1 |
| Huang, ZB | 1 |
| Zhao, SS | 2 |
| Dai, XH | 2 |
| Zhou, RR | 2 |
| Yi, PP | 1 |
| Chen, RC | 2 |
| Zhang, BX | 1 |
| Fan, XG | 2 |
| Klause, U | 1 |
| Takkenberg, B | 2 |
| Chu, T | 1 |
| Petric, R | 1 |
| Berg, T | 8 |
| Moeller, B | 1 |
| Chan, S | 5 |
| Pipili, C | 1 |
| Cholongitas, E | 4 |
| Papatheodoridis, G | 2 |
| Kim, MN | 2 |
| Lee, CK | 3 |
| Kim, HS | 9 |
| Niederau, C | 2 |
| Habersetzer, F | 2 |
| Vermehren, J | 1 |
| Bludzin, W | 1 |
| Jinga, M | 1 |
| Ulusoy, S | 2 |
| Oliveira, GL | 1 |
| Yeum, TS | 1 |
| Kim, HY | 4 |
| Kwan, P | 2 |
| Fabri, M | 1 |
| Horban, A | 5 |
| Pelemis, M | 1 |
| Hann, HW | 4 |
| Gurel, S | 4 |
| Caruntu, FA | 1 |
| Husa, P | 2 |
| Li, M | 5 |
| Mangia, G | 4 |
| Triolo, M | 1 |
| Della Corte, C | 2 |
| Colombo, M | 12 |
| Pérez-Cameo, C | 1 |
| Pons, M | 1 |
| Tan, D | 2 |
| Ning, Q | 3 |
| Fan, R | 2 |
| Shi, G | 2 |
| Wan, M | 2 |
| Sheng, J | 2 |
| Dou, X | 2 |
| Chen, C | 2 |
| Li, B | 1 |
| Park, H | 3 |
| Chan, CK | 1 |
| Chang, TT | 12 |
| Mathurin, P | 1 |
| Lau, G | 2 |
| Gane, EJ | 4 |
| Xiong, Y | 1 |
| Gao, L | 3 |
| Jia, S | 1 |
| Li, F | 5 |
| Chang, K | 1 |
| Zhang, K | 5 |
| Jiang, W | 1 |
| Shang, Y | 1 |
| Deng, S | 1 |
| Chen, M | 1 |
| Eguchi, H | 1 |
| Tsuruta, M | 1 |
| Tani, J | 1 |
| Kuwahara, R | 1 |
| Hiromatsu, Y | 1 |
| Kim, HN | 1 |
| Rodriguez, CV | 1 |
| Van Rompaey, S | 1 |
| Eron, JJ | 1 |
| Thio, CL | 6 |
| Crane, HM | 1 |
| Overton, ET | 1 |
| Saag, MS | 1 |
| Martin, J | 1 |
| Geng, E | 1 |
| Mugavero, M | 1 |
| Rodriguez, B | 1 |
| Mathews, WC | 1 |
| Boswell, S | 1 |
| Moore, R | 1 |
| Kitahata, MM | 1 |
| Lee, CI | 1 |
| Yoon, EL | 3 |
| Yeon, JE | 8 |
| Keskin, O | 3 |
| Ormeci, AC | 2 |
| Baran, B | 2 |
| Kabaçam, G | 2 |
| Tüzün, A | 1 |
| Karatayli, E | 4 |
| Akyüz, F | 2 |
| Karatayli, S | 1 |
| Bozdayi, AM | 4 |
| Onel, D | 2 |
| Badur, S | 3 |
| Idilman, R | 6 |
| Kaymakoglu, S | 3 |
| Yurdaydin, C | 6 |
| Hamnvik, OP | 1 |
| Vaidya, A | 1 |
| Becker, C | 1 |
| Cai, SH | 1 |
| Lv, FF | 1 |
| Jiang, YG | 1 |
| Peng, J | 5 |
| Price, J | 1 |
| Stalke, P | 1 |
| Rybicka, M | 1 |
| Wróblewska, A | 1 |
| Dreczewski, M | 1 |
| Stracewska, E | 1 |
| Smiatacz, T | 1 |
| Bielawski, KP | 1 |
| Xie, FY | 1 |
| Zeng, Y | 1 |
| Su, M | 2 |
| Lin, J | 1 |
| Jiang, L | 1 |
| Yang, B | 1 |
| Ou, Q | 1 |
| Ozekinci, T | 1 |
| Mese, S | 1 |
| Ozbek, E | 1 |
| Atmaca, S | 1 |
| Yao, A | 1 |
| Lou, L | 2 |
| Boyd, A | 5 |
| Maylin, S | 4 |
| Gozlan, J | 5 |
| Delaugerre, C | 5 |
| Simon, F | 2 |
| Girard, PM | 7 |
| Lacombe, K | 8 |
| Seo, YB | 1 |
| Im, SJ | 1 |
| Song, MJ | 1 |
| You, CR | 1 |
| Jang, JW | 3 |
| Yang, SH | 1 |
| Suh, YS | 1 |
| Song, JS | 1 |
| Kim, BM | 1 |
| Jeong, SH | 5 |
| Sung, YC | 1 |
| Lim, JH | 1 |
| Park, GY | 1 |
| Kang, YJ | 1 |
| Kwon, O | 1 |
| Choi, JY | 4 |
| Park, SH | 4 |
| Kim, YL | 1 |
| Kim, HK | 1 |
| Huh, S | 1 |
| Kim, CD | 2 |
| Maklad, S | 1 |
| Doss, W | 1 |
| El Din, SS | 1 |
| Hassan, K | 1 |
| Zeid, AA | 1 |
| Hunyady, B | 2 |
| Gervain, J | 2 |
| Lengyel, G | 1 |
| Makara, M | 2 |
| Pár, A | 2 |
| Szalay, F | 2 |
| Telegdy, L | 2 |
| Tornai, I | 3 |
| Zhou, P | 1 |
| Li, XJ | 2 |
| Nguyen, V | 1 |
| Tan, PK | 1 |
| Greenup, AJ | 1 |
| Glass, A | 1 |
| Davison, S | 1 |
| Samarasinghe, D | 1 |
| Holdaway, S | 1 |
| Chatterjee, U | 1 |
| Locarnini, SA | 3 |
| Liu, F | 2 |
| Bradshaw, D | 1 |
| Danta, M | 2 |
| Xu, Z | 4 |
| Tantai, N | 1 |
| Chaikledkaew, U | 1 |
| Werayingyong, P | 1 |
| Teerawattananon, Y | 1 |
| Błudzin, W | 1 |
| Dziambor, A | 1 |
| Goryszewski, D | 1 |
| Postawa-Kłosińska, B | 1 |
| Kolasa, K | 1 |
| Singh, AK | 1 |
| Sharma, MK | 1 |
| Hissar, SS | 2 |
| Gupta, E | 1 |
| Sarin, SK | 5 |
| Peytavin, G | 4 |
| Geipel, A | 2 |
| Glebe, D | 2 |
| Will, H | 2 |
| Gerlich, WH | 6 |
| Lee, AJ | 1 |
| Jeon, CH | 1 |
| Sadler, MD | 1 |
| Peng, D | 1 |
| Du, Y | 2 |
| Jia, T | 1 |
| Chang, L | 1 |
| van Iperen, EP | 1 |
| Plat-Sinnige, MJ | 1 |
| Chin, DJ | 1 |
| Zwinderman, AH | 1 |
| Chang, HY | 1 |
| Yang, SY | 2 |
| Svarovskaia, ES | 3 |
| Nobili, V | 1 |
| Comparcola, D | 1 |
| Cainelli, F | 1 |
| Vento, S | 1 |
| Tang, CM | 1 |
| Yau, TO | 1 |
| Maynard-Muet, M | 1 |
| Lebossé, F | 1 |
| Carrat, F | 2 |
| Bouix, C | 1 |
| Lascoux-Combe, C | 3 |
| Sogni, P | 1 |
| Rey, D | 2 |
| Barthe, Y | 1 |
| Pol, S | 7 |
| Cacoub, P | 2 |
| Piroth, L | 2 |
| Galati, G | 1 |
| De Vincentis, A | 1 |
| Vespasiani-Gentilucci, U | 1 |
| Gallo, P | 1 |
| Solmone, MC | 1 |
| Dell'Unto, C | 1 |
| Picardi, A | 1 |
| Zheng, Q | 1 |
| Zhu, YY | 1 |
| Liu, YR | 1 |
| You, J | 1 |
| Zeng, DW | 1 |
| Gao, LY | 1 |
| Chen, LH | 1 |
| Jiang, JJ | 1 |
| Xi, H | 2 |
| Hou, F | 1 |
| Huo, N | 2 |
| Ozaras, R | 2 |
| Mete, B | 1 |
| Ozgunes, N | 1 |
| Gunduz, A | 1 |
| Karaosmanoglu, H | 1 |
| Cagatay, A | 1 |
| Gokturk, K | 1 |
| Erdem, L | 1 |
| Kocak, F | 1 |
| Senates, E | 1 |
| Tabak, F | 1 |
| Ke, W | 3 |
| Ye, X | 4 |
| Zhou, S | 3 |
| Li, MR | 1 |
| Xi, HL | 1 |
| Wang, QH | 1 |
| Hou, FQ | 1 |
| Xu, XY | 2 |
| Goulis, I | 2 |
| Antoniadis, N | 2 |
| Fouzas, I | 2 |
| Imvrios, G | 2 |
| Papanikolaou, V | 2 |
| Akriviadis, E | 2 |
| Lo, GH | 2 |
| Corsa, AC | 3 |
| Mitchell, B | 1 |
| Fung, SK | 5 |
| Zeng, T | 1 |
| Liu, JY | 2 |
| Lei, Y | 1 |
| Zhong, S | 2 |
| Ridruejo, E | 2 |
| Panda, C | 1 |
| Kekez, AJ | 1 |
| Suh, SJ | 3 |
| Seo, YS | 9 |
| Lee, CD | 2 |
| Lee, MS | 3 |
| Park, CK | 3 |
| Kim, MY | 2 |
| Baik, SK | 2 |
| Lee, JW | 5 |
| Hong, SP | 15 |
| Um, SH | 4 |
| Ruhi, Ç | 1 |
| Süleymanlar, İ | 1 |
| Koçak, H | 1 |
| Dinçkan, A | 1 |
| Ersoy, F | 1 |
| Süleymanlar, G | 1 |
| Xiong, H | 3 |
| Cheng, YC | 1 |
| van Bömmel, F | 3 |
| Warner, N | 2 |
| Gürtler, LG | 1 |
| Neumann-Fraune, M | 1 |
| Beggel, B | 2 |
| Kaiser, R | 3 |
| Obermeier, M | 1 |
| de Man, RA | 11 |
| Dusheiko, GM | 1 |
| Heathcote, EJ | 14 |
| Huang, G | 2 |
| Lau, WY | 2 |
| Wang, ZG | 1 |
| Pan, ZY | 2 |
| Yuan, SX | 1 |
| Zhou, WP | 2 |
| Sirma, H | 4 |
| Schildgen, O | 6 |
| Iizuka, Y | 1 |
| Sakai, H | 1 |
| Kobayashi, K | 1 |
| Iizuka, K | 1 |
| Ito, E | 1 |
| Mochizuki, N | 1 |
| Asahina, Y | 1 |
| Watanabe, M | 1 |
| Patwardhan, VR | 1 |
| Sengupta, N | 1 |
| Bonder, A | 1 |
| Lau, D | 1 |
| Afdhal, NH | 1 |
| Liu, YH | 1 |
| Wu, T | 1 |
| Sun, N | 1 |
| Wang, GL | 2 |
| Yuan, JZ | 1 |
| Dai, YR | 1 |
| Zhou, XH | 1 |
| Shan, C | 1 |
| Yin, GQ | 1 |
| Ahn, H | 2 |
| Gill, US | 1 |
| Zissimopoulos, A | 1 |
| Al-Shamma, S | 1 |
| Burke, K | 1 |
| McPhail, MJ | 1 |
| Barr, DA | 1 |
| Kallis, YN | 1 |
| Marley, RT | 1 |
| Kooner, P | 1 |
| Foster, GR | 2 |
| Kennedy, PT | 1 |
| Nguyen, NH | 1 |
| Nguyen, TT | 3 |
| Do, ST | 2 |
| Tran, P | 2 |
| Nguyen, HA | 5 |
| Nguyen, KK | 4 |
| Garcia, RT | 4 |
| Lutchman, GA | 1 |
| Tao, L | 1 |
| Jie, Y | 2 |
| Shi, H | 2 |
| Lin, G | 2 |
| Ao, Y | 2 |
| Pang, Y | 1 |
| Chong, Y | 3 |
| Tsai, NC | 2 |
| Washington, MK | 3 |
| Charuworn, P | 2 |
| Arends, P | 1 |
| Sypsa, V | 1 |
| Savvidou, S | 1 |
| Hansen, BE | 6 |
| Papaioannou, C | 1 |
| Galanis, K | 1 |
| Mweemba, A | 1 |
| Zanolini, A | 1 |
| Mulenga, L | 1 |
| Emge, D | 1 |
| Chi, BH | 1 |
| Wandeler, G | 1 |
| Vinikoor, MJ | 1 |
| Tien, C | 1 |
| Xu, JJ | 1 |
| Chan, LS | 1 |
| Huh, B | 1 |
| Shinada, S | 1 |
| Hou, JL | 6 |
| Sheng, JF | 3 |
| Tan, DM | 1 |
| Niu, JQ | 2 |
| Chen, SJ | 3 |
| Mao, YM | 1 |
| Jia, JD | 2 |
| Ji, Y | 1 |
| Xiao, P | 1 |
| Chung, SM | 1 |
| Byoun, YS | 1 |
| Kim, JW | 5 |
| Samarkos, M | 1 |
| Theofanis, V | 1 |
| Eliadi, I | 1 |
| Vlachogiannakos, J | 3 |
| Polyzos, A | 1 |
| Jacobson, IM | 5 |
| Martins, EB | 3 |
| Dusheiko, G | 4 |
| Rustgi, VK | 2 |
| Kim, J | 1 |
| Lee, SH | 4 |
| Choi, K | 1 |
| Jeong, SW | 1 |
| Grizzi, F | 1 |
| Desmet, VJ | 1 |
| Cui, XJ | 2 |
| Jeong, SU | 2 |
| Song, BC | 3 |
| Rezaeeaval, M | 1 |
| Pang, JX | 1 |
| Alcantara, L | 1 |
| Klein, P | 1 |
| Ahn, SS | 1 |
| Ze, E | 1 |
| Baek, EK | 1 |
| Chung, HW | 1 |
| Ahn, DG | 1 |
| Cho, HJ | 3 |
| Kwon, JC | 1 |
| Lee, H | 1 |
| Moon, HW | 1 |
| Li, T | 4 |
| Long, H | 2 |
| Zhuang, H | 4 |
| Jung, EU | 1 |
| Kim, BH | 5 |
| Park, SJ | 5 |
| Park, JW | 4 |
| Lee, YJ | 1 |
| Kim, CM | 1 |
| Du, X | 1 |
| Ren, S | 1 |
| Shen, C | 3 |
| Murakami, Y | 1 |
| Hayakawa, M | 1 |
| Yano, Y | 1 |
| Tanahashi, T | 1 |
| Tamori, A | 1 |
| Kawada, N | 1 |
| Iwadate, M | 1 |
| Umeyama, H | 1 |
| Cheng, W | 1 |
| Sicard, E | 1 |
| Ryder, SD | 1 |
| Lawson, E | 1 |
| Brocchieri, A | 1 |
| Spinetti, A | 2 |
| Zaltron, S | 2 |
| Facchetti, F | 4 |
| Fugazza, A | 1 |
| Castelli, F | 2 |
| Khan, MR | 1 |
| Chowdhury, MS | 1 |
| Saha, M | 1 |
| Roknuzzaman, SM | 1 |
| Mahmuduzzaman, M | 1 |
| Miah, AR | 1 |
| Roy, PK | 1 |
| Raihan, MA | 1 |
| Rahman, KM | 1 |
| Jiang, SW | 2 |
| Hu, AR | 2 |
| Hu, YR | 2 |
| Chen, SX | 1 |
| Xiong, T | 1 |
| Gao, GS | 1 |
| Liang, XY | 2 |
| Ding, SX | 2 |
| Weng, PJ | 1 |
| Ge, Y | 1 |
| Yang, H | 7 |
| Lyu, W | 1 |
| Zhou, B | 2 |
| Maggi, P | 2 |
| Montinaro, V | 1 |
| Leone, A | 2 |
| Fasano, M | 3 |
| Volpe, A | 2 |
| Bellacosa, C | 1 |
| Grattagliano, V | 1 |
| Coladonato, L | 1 |
| Lapadula, G | 1 |
| Angarano, G | 3 |
| Invernizzi, F | 3 |
| Tsai, N | 4 |
| Aguilar Schall, R | 2 |
| Makowska, Z | 1 |
| Dill, MT | 1 |
| Bart Takkenberg, R | 1 |
| Heim, MH | 1 |
| Cui, S | 1 |
| Gong, Y | 1 |
| Lin, Q | 3 |
| Pan, F | 1 |
| Hong, F | 1 |
| Wongcharatrawee, S | 1 |
| Llamoso, C | 2 |
| Lee, KS | 2 |
| Gwak, GY | 7 |
| Paik, YH | 2 |
| Choi, MS | 7 |
| Koh, KC | 8 |
| Paik, SW | 8 |
| Yu, YQ | 1 |
| Wang, JL | 1 |
| Pan, HY | 2 |
| Wang, YE | 1 |
| Gomes-Gouvêa, MS | 2 |
| Ferreira, AC | 1 |
| Teixeira, R | 1 |
| Andrade, JR | 1 |
| Ferreira, AS | 1 |
| Barros, LM | 1 |
| Rezende, RE | 1 |
| Nastri, AC | 1 |
| Leite, AG | 2 |
| Piccoli, LZ | 1 |
| Galvan, J | 1 |
| Conde, SR | 1 |
| Soares, MC | 1 |
| Kliemann, DA | 1 |
| Bertolini, DA | 1 |
| Kunyoshi, AS | 1 |
| Lyra, AC | 1 |
| Oikawa, MK | 1 |
| de Araújo, LV | 1 |
| Carrilho, FJ | 2 |
| Mendes-Corrêa, MC | 2 |
| Pinho, JR | 2 |
| Nie, CY | 1 |
| Ha, FS | 1 |
| Shimizu, M | 3 |
| Ikezaki, H | 1 |
| Hayashi, T | 1 |
| Ihara, T | 1 |
| Harada, Y | 1 |
| Toyoda, K | 1 |
| Murata, M | 2 |
| Wang, BF | 1 |
| Sun, FR | 1 |
| Chen, YS | 1 |
| Hu, YH | 1 |
| Cao, YJ | 1 |
| De Francesco, MA | 1 |
| Gargiulo, F | 1 |
| Giagulli, C | 1 |
| Caccuri, F | 1 |
| Caruso, A | 1 |
| Ouyang, R | 1 |
| Yang, DH | 1 |
| Xie, YJ | 1 |
| Zhao, NF | 2 |
| Li, MW | 1 |
| Huang, HJ | 1 |
| Ho, EY | 1 |
| Yau, T | 1 |
| Rousseau, F | 12 |
| Lau, GK | 6 |
| Tempelmans Plat-Sinnige, MJ | 1 |
| van Leeuwen, EM | 1 |
| An, J | 1 |
| Xu, LJ | 1 |
| Liao, RX | 1 |
| Mao, JF | 1 |
| Chi, Y | 1 |
| Wang, O | 1 |
| Liu, XQ | 1 |
| Liu, ZY | 1 |
| Xing, XP | 1 |
| Xia, WB | 1 |
| Lo, AO | 1 |
| Tse, YK | 1 |
| Chan, HY | 5 |
| Zhao, N | 1 |
| Pan, H | 1 |
| Jia, HY | 1 |
| Ding, F | 1 |
| Chen, JY | 1 |
| Lian, JS | 1 |
| Zhang, YM | 1 |
| Zeng, LY | 1 |
| Xiang, DR | 2 |
| Hu, JH | 1 |
| Yu, GD | 1 |
| Lu, YF | 1 |
| Zheng, L | 1 |
| Li, LJ | 1 |
| Yang, YD | 1 |
| Chen, HL | 1 |
| Lee, CN | 1 |
| Chang, CH | 1 |
| Ni, YH | 1 |
| Shyu, MK | 1 |
| Chen, SM | 1 |
| Hu, JJ | 1 |
| Lin, HH | 1 |
| Zhao, LL | 1 |
| Mu, SC | 1 |
| Lai, MW | 1 |
| Lee, CL | 1 |
| Lin, HM | 1 |
| Tsai, MS | 1 |
| Hsu, JJ | 1 |
| Chen, DS | 2 |
| Chan, KA | 1 |
| Chang, MH | 2 |
| Jin, B | 1 |
| Kim, S | 2 |
| Kim, ND | 1 |
| Nam, CM | 1 |
| Choi, SH | 2 |
| Mao, R | 1 |
| Zhao, PW | 1 |
| Ji, HF | 1 |
| Feng, JY | 1 |
| Jiang, YF | 3 |
| Doğan, ÜB | 2 |
| Öztürk, AB | 1 |
| Akın, MS | 2 |
| Yalaki, S | 1 |
| Singla, B | 1 |
| Bhattacharyya, R | 1 |
| Chakraborti, A | 1 |
| Sharma, BK | 1 |
| Kapil, S | 1 |
| Chawla, YK | 1 |
| Arora, SK | 1 |
| Das, A | 1 |
| Dhiman, RK | 1 |
| Duseja, A | 1 |
| Li, XY | 1 |
| You, X | 1 |
| Jie, YS | 2 |
| Lin, GL | 1 |
| Wu, YK | 1 |
| Huang, MX | 1 |
| Li, ZY | 1 |
| Chong, YT | 1 |
| Shin, SJ | 1 |
| Yoo, BM | 1 |
| Cho, SW | 9 |
| Cheong, JY | 9 |
| Kim, MH | 2 |
| Kim, CJ | 4 |
| Lee, BU | 2 |
| Jeong, ID | 3 |
| Kim, BG | 4 |
| Bang, SJ | 4 |
| Kim, V | 1 |
| Abreu, RM | 1 |
| Nakagawa, DM | 1 |
| Baldassare, RM | 1 |
| Ono, SK | 2 |
| Sung, SJ | 1 |
| Koot, AW | 1 |
| Visscher, AP | 1 |
| Huits, RM | 1 |
| Lu, F | 1 |
| Duan, Z | 1 |
| Su, F | 1 |
| Dai, J | 2 |
| Cui, X | 1 |
| Ning, H | 2 |
| Wang, G | 1 |
| Qiu, P | 2 |
| Zhou, SF | 2 |
| Wen, P | 2 |
| Wen, J | 1 |
| Primignani, M | 1 |
| Jovani, M | 1 |
| Iavarone, M | 1 |
| Fraquelli, M | 1 |
| Casazza, G | 1 |
| de Franchis, R | 1 |
| Jiang, D | 1 |
| Shan, X | 1 |
| Liang, Z | 1 |
| Shan, Y | 1 |
| Huang, W | 2 |
| Zen, A | 1 |
| Gong, X | 1 |
| Lai, J | 1 |
| Yang, N | 1 |
| Yao, N | 1 |
| Kang, W | 1 |
| Dang, B | 1 |
| Yu, T | 1 |
| Lv, F | 1 |
| Yagi, T | 1 |
| Shin, GC | 1 |
| Rhee, JK | 1 |
| Yang, SI | 1 |
| Khodor, H | 1 |
| Yetim, N | 1 |
| Unal, UK | 1 |
| Demirhan, YE | 1 |
| Gultekin, G | 1 |
| Isal, B | 1 |
| Gu, J | 1 |
| Sun, R | 2 |
| Shen, S | 1 |
| Amani, A | 1 |
| Thiel, A | 1 |
| Li, K | 1 |
| Ding, G | 1 |
| Xiao, E | 1 |
| Mao, Z | 1 |
| Kang, Y | 1 |
| Jang, MK | 2 |
| Kim, TY | 1 |
| Jung, YK | 6 |
| Park, JG | 1 |
| Lian, J | 1 |
| Xiang, H | 1 |
| Lyu, H | 1 |
| Liao, Y | 1 |
| Su, Z | 1 |
| Ying, B | 1 |
| Tao, C | 1 |
| Thu, AM | 1 |
| Poovorawan, K | 1 |
| Kittitrakul, C | 1 |
| Nontprasert, A | 1 |
| Sriboonvorakul, N | 1 |
| Phumratanaprapin, W | 1 |
| Leowattana, W | 1 |
| Wilairatana, P | 1 |
| Kim, SK | 1 |
| Kim, SR | 1 |
| Imoto, S | 1 |
| Tohyama, M | 1 |
| Otono, Y | 1 |
| Tamura, T | 1 |
| Zhang, SB | 1 |
| Lin, CC | 3 |
| Bair, MJ | 1 |
| Chen, CJ | 2 |
| Lee, KH | 1 |
| Chen, MJ | 1 |
| Liu, CY | 1 |
| Chang, CW | 1 |
| Hu, KC | 1 |
| Liou, TC | 1 |
| Lin, SC | 1 |
| Chu, CH | 1 |
| Shih, SC | 1 |
| Wang, TE | 1 |
| Bai, L | 2 |
| Feng, Y | 1 |
| Yuan, Z | 2 |
| Song, H | 1 |
| Zheng, X | 1 |
| Jiang, B | 1 |
| Li, XM | 1 |
| Su, R | 1 |
| Cao, Y | 1 |
| Hou, W | 1 |
| Xu, LF | 1 |
| Wen, JB | 1 |
| Xiao, XZ | 1 |
| Chi, J | 1 |
| Song, S | 1 |
| Tsai, HW | 2 |
| Lin, YJ | 1 |
| Wu, HC | 1 |
| Wu, IC | 3 |
| Cheng, PN | 2 |
| Yen, CJ | 1 |
| Chan, SH | 1 |
| Su, IJ | 1 |
| Xing, H | 1 |
| Sinnige, MJ | 1 |
| Goyal, A | 1 |
| Murray, JM | 1 |
| Garcia, M | 1 |
| Le Moal, G | 1 |
| Godet, C | 1 |
| Beraud, G | 1 |
| Chagneau-Derrode, C | 1 |
| Roblot, F | 1 |
| Dan, J | 1 |
| Defresne, F | 1 |
| Sokal, E | 3 |
| Tsuji, K | 1 |
| Takagi, J | 1 |
| Morita, H | 1 |
| Ito, K | 1 |
| Ohashi, T | 1 |
| Hirase, S | 1 |
| Morishima, T | 1 |
| Otake, K | 1 |
| Yoneda, M | 1 |
| Xiang, X | 1 |
| Bao, R | 1 |
| Xie, J | 1 |
| Bao, S | 1 |
| Duan, SH | 1 |
| Bao, ZY | 1 |
| Yuan, XD | 1 |
| Liu, MS | 1 |
| Akyildiz, M | 2 |
| Gungor, G | 1 |
| Yilmaz, TU | 1 |
| Kalkan, C | 1 |
| Dayangac, M | 1 |
| Cinar, K | 3 |
| Balci, D | 1 |
| Hazinedaroglu, S | 1 |
| Tokat, Y | 1 |
| Giakoustidis, D | 1 |
| Giouleme, O | 3 |
| Wei, W | 1 |
| Cheng, KL | 1 |
| Xu, MM | 1 |
| Qiu, Q | 1 |
| Yang, LK | 1 |
| Duan, XW | 1 |
| Duan, ZP | 1 |
| Cao, H | 3 |
| Shu, X | 5 |
| Xu, Q | 1 |
| Cho, EY | 1 |
| Lee, JM | 6 |
| Ip, P | 1 |
| Kopaniszen, M | 1 |
| Lee, B | 1 |
| Cullaro, G | 1 |
| Chong, CK | 1 |
| Wu, R | 1 |
| Cheng, C | 1 |
| Yuen, J | 1 |
| Ngai, V | 1 |
| Pereira-Gómez, M | 1 |
| Bou, JV | 1 |
| Andreu, I | 1 |
| Sanjuán, R | 1 |
| Park, SK | 1 |
| Yang, HJ | 3 |
| Jung, YS | 1 |
| Park, DI | 2 |
| Sohn, CI | 2 |
| Jeon, WK | 2 |
| Kim, BI | 3 |
| Choi, KY | 1 |
| Santana, LC | 1 |
| Mantovani, NP | 1 |
| Ferreira, MC | 1 |
| Arnold, R | 1 |
| Duro, RL | 1 |
| Ferreira, PR | 1 |
| Hunter, JR | 1 |
| Leal, É | 1 |
| Diaz, RS | 1 |
| Komninakis, SV | 1 |
| Asano, M | 1 |
| Inoue, T | 1 |
| Sakamoto, M | 1 |
| Enomoto, N | 1 |
| Shirasaki, T | 1 |
| Honda, M | 1 |
| Gatanaga, H | 1 |
| Oka, S | 1 |
| Kawamura, YI | 1 |
| Dohi, T | 1 |
| Shuno, Y | 1 |
| Yano, H | 1 |
| You, S | 1 |
| Naftel, J | 1 |
| Khakoo, SI | 1 |
| Buchanan, R | 1 |
| Wu, CK | 1 |
| Wang, LP | 1 |
| Han, FZ | 1 |
| Yan, XB | 2 |
| Lim, L | 1 |
| Patterson, S | 1 |
| George, J | 2 |
| Strasser, S | 1 |
| Lee, A | 1 |
| Nicoll, A | 1 |
| Desmond, P | 2 |
| Roberts, S | 1 |
| Marion, K | 1 |
| Bowden, S | 9 |
| Angus, P | 2 |
| Maida, I | 1 |
| Mura, MS | 1 |
| Luo, Q | 1 |
| Zeng, W | 1 |
| Ruggiero, G | 2 |
| Marrone, A | 2 |
| Rainone, I | 1 |
| Boemio, A | 1 |
| Adinolfi, LE | 1 |
| Pasquale, G | 1 |
| Rinaldi, L | 1 |
| Guerrera, B | 1 |
| Andreana, L | 1 |
| Zampino, R | 2 |
| Singh, N | 1 |
| Nath, G | 1 |
| Ying, H | 1 |
| Wei, L | 3 |
| Hong, LJ | 1 |
| Fiore, JR | 1 |
| Santantonio, TA | 1 |
| Chung, GE | 2 |
| Lin, BL | 1 |
| Xu, QH | 7 |
| Lu, WL | 1 |
| Li, JG | 1 |
| Jaroszewicz, J | 1 |
| Lu, YP | 1 |
| Guo, T | 1 |
| Wang, BJ | 1 |
| Dong, JH | 1 |
| Zhu, JF | 1 |
| Lu, MJ | 1 |
| Yang, DL | 1 |
| Carrouée-Durantel, S | 1 |
| Durantel, D | 2 |
| Werle-Lapostolle, B | 2 |
| Naesens, L | 2 |
| Neyts, J | 3 |
| Trépo, C | 9 |
| Zeng, AZ | 3 |
| Peng, FY | 1 |
| Xin, XJ | 3 |
| Li, QL | 3 |
| Guo, JJ | 3 |
| Zhang, ZZ | 1 |
| Hao, MJ | 1 |
| Huang, WX | 1 |
| Lindh, M | 1 |
| Uhnoo, I | 1 |
| Bläckberg, J | 1 |
| Duberg, AS | 1 |
| Friman, S | 1 |
| Fischler, B | 1 |
| Karlström, O | 1 |
| Norkrans, G | 1 |
| Reichard, O | 1 |
| Sangfeldt, P | 1 |
| Söderström, A | 1 |
| Sönnerborg, A | 1 |
| Weiland, O | 1 |
| Wejstål, R | 1 |
| Wiström, J | 1 |
| Leemans, WF | 4 |
| Niesters, HG | 4 |
| van der Eijk, AA | 2 |
| Schalm, SW | 4 |
| Shorbagi, A | 1 |
| Fournier, C | 1 |
| Bronowicki, JP | 1 |
| Nani, A | 1 |
| Barraud, H | 1 |
| Cadranel, JF | 2 |
| Menne, S | 2 |
| Butler, SD | 2 |
| George, AL | 2 |
| Tochkov, IA | 2 |
| Xiong, S | 16 |
| Gerin, JL | 2 |
| Cote, PJ | 2 |
| Tennant, BC | 2 |
| Tong, M | 3 |
| Arterburn, S | 4 |
| Frederick, D | 9 |
| Parvaz, P | 3 |
| Beaugrand, M | 1 |
| Benhamou, Y | 12 |
| Trylesinski, A | 2 |
| Monchecourt, F | 1 |
| Lui, YY | 2 |
| Deterding, K | 4 |
| Manns, MP | 2 |
| Wedemeyer, H | 6 |
| Choi, JW | 2 |
| Kim, TN | 1 |
| Eun, JR | 2 |
| Arslan, U | 1 |
| Ural, O | 1 |
| Findik, D | 1 |
| Keeffe, EB | 8 |
| Shiffman, ML | 5 |
| Tong, MJ | 3 |
| Mondou, E | 7 |
| Sorbel, J | 8 |
| Dieterich, DT | 3 |
| Han, SH | 1 |
| Tobias, H | 1 |
| Ahmed, CS | 1 |
| Lu, P | 2 |
| Katsounas, A | 1 |
| Jochum, C | 1 |
| Canbay, A | 1 |
| Schlaak, J | 1 |
| Gerken, G | 2 |
| Germanidis, G | 3 |
| Kotzev, I | 2 |
| Tchernev, K | 2 |
| Weilert, F | 2 |
| Kurdas, OO | 2 |
| Anderson, J | 3 |
| Quinn, J | 1 |
| Leung, N | 6 |
| Sollano, J | 1 |
| Lao-Tan, J | 1 |
| Lesmana, L | 1 |
| Jeffers, L | 4 |
| Sherman, M | 7 |
| Min, A | 1 |
| Mencarini, K | 1 |
| Diva, U | 1 |
| Cross, A | 1 |
| Wilber, R | 1 |
| Lopez-Talavera, J | 1 |
| Pallier, C | 1 |
| Brillet, R | 2 |
| Nordmann, P | 1 |
| Hézode, C | 3 |
| Koh, KH | 2 |
| Kang, CJ | 2 |
| Choi, YW | 1 |
| Lunghi, G | 2 |
| Amini-Bavil-Olyaee, S | 3 |
| Sheldon, J | 5 |
| Lutz, T | 4 |
| Trautwein, C | 5 |
| Tacke, F | 3 |
| García Buey, L | 1 |
| González Mateos, F | 1 |
| Moreno Otero, R | 1 |
| Peñas, B | 2 |
| Sarmento E Castro, R | 1 |
| González-Diéguez, ML | 1 |
| Limquiaco, JL | 1 |
| Wong, J | 2 |
| Tse, CH | 4 |
| Kwan, KY | 1 |
| Lai, PB | 1 |
| Moon, JH | 1 |
| Cho, M | 2 |
| Yoon, KT | 1 |
| Bae, JH | 1 |
| Kim, GH | 3 |
| Kang, DH | 1 |
| Song, GA | 1 |
| Rebers, SP | 1 |
| Menting, S | 1 |
| Schinkel, J | 1 |
| Cha, CK | 1 |
| Kwon, HC | 1 |
| Kim, SO | 10 |
| Yoo, WD | 3 |
| Izzedine, H | 4 |
| Kheder-Elfekih, R | 1 |
| Housset, P | 1 |
| Sarkozy, C | 1 |
| Brocheriou, I | 1 |
| Deray, G | 3 |
| Scott, JD | 1 |
| McMahon, B | 1 |
| Poynard, T | 7 |
| Ngo, Y | 1 |
| Hadziyannis, S | 4 |
| Ratziu, V | 4 |
| Reijnders, JG | 5 |
| Pas, SD | 3 |
| Schutten, M | 3 |
| Buster, EH | 3 |
| Hwang, YJ | 1 |
| Kwon, OS | 2 |
| Choi, DJ | 2 |
| Jardi, R | 6 |
| Schaper, M | 3 |
| Ferrer-Costa, C | 1 |
| Homs, M | 3 |
| Kamar, N | 2 |
| Huart, A | 1 |
| Tack, I | 1 |
| Alric, L | 2 |
| Izopet, J | 2 |
| Rostaing, L | 3 |
| Oguz Onder, F | 1 |
| Ahishali, E | 1 |
| Bektas, M | 1 |
| Pinarbasi, B | 1 |
| Karayalcin, S | 2 |
| Cakaloglu, Y | 1 |
| Mithat Bozdayi, A | 1 |
| Bozkaya, H | 1 |
| Okten, A | 1 |
| Yatsuji, H | 3 |
| Valencia, ME | 1 |
| Moreno, V | 1 |
| Ohkawa, K | 2 |
| Takehara, T | 2 |
| Kanada, A | 1 |
| Deguchi, M | 1 |
| Kagita, M | 1 |
| Hikita, H | 1 |
| Sasakawa, A | 1 |
| Kohga, K | 1 |
| Uemura, A | 1 |
| Sakamori, R | 1 |
| Yamaguchi, S | 1 |
| Miyagi, T | 1 |
| Ishida, H | 1 |
| Tatsumi, T | 1 |
| Hayashi, N | 2 |
| Chung, YH | 6 |
| Kim, JA | 2 |
| Kim, SE | 2 |
| Saab, S | 1 |
| Ham, MY | 1 |
| Stone, MA | 1 |
| Holt, C | 1 |
| Qiu, YW | 1 |
| Jiang, XH | 2 |
| Huang, LH | 2 |
| Ding, H | 2 |
| Jiang, YM | 1 |
| Dai, YX | 1 |
| Wendling, D | 1 |
| Di Martino, V | 1 |
| Prati, C | 1 |
| Toussirot, E | 1 |
| Herbein, G | 1 |
| Choi, HM | 1 |
| Koo, HW | 1 |
| Jung, HW | 1 |
| Yeon, KK | 1 |
| Curtis, M | 5 |
| Kurashige, N | 1 |
| Yakushijin, T | 1 |
| Kiso, S | 1 |
| Kanto, T | 1 |
| Kasahara, A | 1 |
| Doi, Y | 1 |
| Yamada, A | 1 |
| Oshita, M | 1 |
| Mita, E | 1 |
| Hagiwara, H | 1 |
| Nagase, T | 1 |
| Yoshihara, H | 1 |
| Hayashi, E | 1 |
| Kashihara, T | 1 |
| Les, I | 1 |
| García-Martínez, R | 1 |
| Córdoba, J | 1 |
| Quintana, M | 1 |
| Buffet, C | 1 |
| Park, MK | 1 |
| Lee, HIe | 2 |
| Hass, HG | 1 |
| Bock, T | 1 |
| Nehls, O | 1 |
| Kaiser, S | 1 |
| Han, Y | 1 |
| Liu, CM | 1 |
| Lin, ZM | 1 |
| Kong, XF | 1 |
| Yu, DM | 1 |
| Zhang, DH | 1 |
| Jin, GD | 1 |
| Lu, ZM | 2 |
| Gong, QM | 1 |
| Ha, NB | 4 |
| Vu, AA | 1 |
| Levitt, BS | 2 |
| Arrese, E | 1 |
| Basaras, M | 1 |
| Blanco, S | 1 |
| Ruiz, P | 2 |
| Cisterna, R | 1 |
| Brosa, M | 1 |
| Rueda, M | 3 |
| Durantel, S | 4 |
| Barraud, L | 1 |
| Heichen, M | 1 |
| Guastadisegni, A | 1 |
| Pastore, G | 2 |
| Herbers, U | 2 |
| Mohebbi, SR | 1 |
| Sabahi, F | 1 |
| Zali, MR | 1 |
| Luedde, T | 2 |
| Stornaiuolo, G | 2 |
| Brancaccio, G | 2 |
| Precone, V | 1 |
| Sgrò, G | 1 |
| Nardiello, S | 1 |
| Gaeta, GB | 4 |
| Jones, J | 4 |
| Shepherd, J | 4 |
| Baxter, L | 1 |
| Gospodarevskaya, E | 1 |
| Hartwell, D | 1 |
| Harris, P | 2 |
| Price, A | 3 |
| Ji, F | 1 |
| Ma, S | 1 |
| Cong, M | 2 |
| Ren, J | 1 |
| Wang, LC | 2 |
| Cao, J | 1 |
| Wang, JR | 2 |
| Akman, SA | 1 |
| Kose, S | 1 |
| Halicioglu, O | 1 |
| Nguyen, T | 2 |
| Vezali, E | 1 |
| McMahon, BJ | 2 |
| Zhou, HJ | 1 |
| Li, SG | 1 |
| Wen, FY | 1 |
| Yang, XY | 1 |
| Wu, JL | 1 |
| Tan, B | 1 |
| Fu, J | 1 |
| Wang, CM | 1 |
| Liang, ZL | 1 |
| Zhong, YW | 1 |
| Ren, XQ | 1 |
| Xu, ZH | 1 |
| Xu, DP | 1 |
| Tuma, P | 1 |
| Labarga, P | 1 |
| Fernández, JV | 1 |
| Medrano, J | 1 |
| Vassiliadis, TG | 1 |
| Koumerkeridis, G | 1 |
| Koumaras, H | 1 |
| Tziomalos, K | 2 |
| Patsiaoura, K | 2 |
| Grammatikos, N | 2 |
| Mpoumponaris, A | 1 |
| Gkisakis, D | 2 |
| Theodoropoulos, K | 2 |
| Panderi, A | 1 |
| Katsinelos, P | 2 |
| Eugenidis, N | 2 |
| Wu, MS | 1 |
| Chen, WL | 2 |
| Xiao, L | 1 |
| Zhao, LZ | 1 |
| Wei, SJ | 1 |
| Jenh, AM | 2 |
| Pham, PA | 2 |
| Lei, J | 1 |
| Perry, CM | 1 |
| Simpson, D | 1 |
| Zhang, DZ | 6 |
| Cai, SF | 1 |
| Deng, XH | 1 |
| Gong, ZJ | 1 |
| Hu, DF | 1 |
| Ji, SI | 1 |
| Adusumilli, S | 1 |
| Llop, E | 1 |
| de la Revilla, J | 1 |
| Pons, F | 2 |
| Martínez, JL | 1 |
| Abreu, L | 1 |
| Olotu, C | 2 |
| Funk, A | 3 |
| Zöllner, B | 2 |
| Helm, M | 2 |
| Rockstroh, JK | 2 |
| Jain, P | 1 |
| Zhu, M | 2 |
| Fan, X | 1 |
| Fang, D | 1 |
| Bin, D | 1 |
| Xueyong, L | 1 |
| Jun, C | 1 |
| Hongshan, W | 1 |
| Piccolo, P | 1 |
| Lenci, I | 1 |
| Demelia, L | 1 |
| Piras, MR | 1 |
| Antonucci, G | 1 |
| Nosotti, L | 2 |
| Mari, T | 1 |
| De Santis, A | 1 |
| Ponti, ML | 1 |
| Sorbello, O | 1 |
| Iacomi, F | 1 |
| Joo, MK | 1 |
| Park, JJ | 3 |
| Bak, YT | 2 |
| Wu, XF | 1 |
| Wei, N | 1 |
| Wong, T | 1 |
| Girgis, CM | 1 |
| Ngu, MC | 2 |
| Emmett, L | 1 |
| Archer, KA | 1 |
| Seibel, MJ | 1 |
| Sung, J | 1 |
| Piratvisuth, T | 3 |
| Perrillo, RP | 5 |
| Tung, WC | 1 |
| Changchien, CS | 4 |
| Zhao, WF | 2 |
| Shao, YL | 1 |
| Chen, LY | 1 |
| Wu, JH | 1 |
| Zhu, YL | 1 |
| Gan, JH | 2 |
| Scotto, G | 3 |
| Fazio, V | 3 |
| Song, HJ | 1 |
| Hyun, S | 1 |
| Choi, EK | 1 |
| Kim, HU | 1 |
| Muñoz Bertrán, E | 1 |
| Pérez Ceballos, E | 1 |
| Gómez Espín, R | 1 |
| Ortega González, I | 1 |
| Ueno, Y | 2 |
| Wakui, Y | 1 |
| Fukushima, K | 1 |
| Yamagiwa, Y | 1 |
| Shiina, M | 1 |
| Kondo, Y | 1 |
| Kakazu, E | 1 |
| Tamai, K | 1 |
| Obara, N | 1 |
| Iwasaki, T | 1 |
| Shimosegawa, T | 2 |
| Tsoi, KK | 1 |
| Teo, EK | 1 |
| Mohamed, R | 1 |
| Mihm, U | 2 |
| Thibault, V | 5 |
| Valantin, MA | 2 |
| Schneider, L | 1 |
| Cuestas, ML | 1 |
| Rivero, CW | 1 |
| Minassian, ML | 1 |
| Castillo, AI | 1 |
| Gentile, EA | 1 |
| Trinks, J | 1 |
| León, L | 1 |
| Daleoso, G | 1 |
| Frider, B | 1 |
| Lezama, C | 1 |
| Galoppo, M | 1 |
| Giacove, G | 1 |
| Mathet, VL | 1 |
| Oubiña, JR | 1 |
| Wörmann, T | 1 |
| Prüfer-Krämer, L | 1 |
| Krämer, A | 1 |
| Moucari, R | 2 |
| Boyer, N | 2 |
| Ripault, MP | 2 |
| Castelnau, C | 2 |
| Mackiewicz, V | 1 |
| Dauvergne, A | 1 |
| Valla, D | 1 |
| Vidaud, M | 1 |
| Chanoine, MH | 1 |
| Mitsui, F | 1 |
| Kimura, T | 1 |
| Kitamura, S | 1 |
| Abe, H | 1 |
| Saneto, H | 1 |
| Kawaoka, T | 1 |
| Miki, D | 1 |
| Hatakeyama, T | 1 |
| Hiraga, N | 1 |
| Imamura, M | 1 |
| Kawakami, Y | 1 |
| Aikata, H | 1 |
| Takahashi, S | 1 |
| Hayes, CN | 1 |
| Igarashi, H | 1 |
| Morimoto, K | 1 |
| Colquitt, J | 1 |
| Cooper, K | 1 |
| Zeng, WQ | 1 |
| Kalayci, R | 1 |
| Altindiş, M | 1 |
| Gülamber, G | 1 |
| Demirtürk, N | 1 |
| Akcan, Y | 1 |
| Demirdal, T | 1 |
| Aizawa, M | 2 |
| Tsubota, A | 2 |
| Fujise, K | 2 |
| Takamatsu, M | 1 |
| Namiki, Y | 1 |
| Ohkusa, T | 1 |
| Tajiri, H | 2 |
| Wu, B | 1 |
| Tang, CS | 1 |
| Yung, S | 1 |
| Choy, BY | 1 |
| Liu, LJ | 1 |
| Du, SC | 1 |
| Yang, RF | 1 |
| Moller, B | 1 |
| Suarez, E | 2 |
| Oldach, D | 1 |
| Woo, G | 1 |
| Tomlinson, G | 1 |
| Nishikawa, Y | 1 |
| Kowgier, M | 1 |
| Pham, B | 1 |
| Ungar, WJ | 1 |
| Einarson, TR | 1 |
| Krahn, M | 1 |
| Gori, C | 1 |
| Marcuccilli, F | 1 |
| Bertoli, A | 2 |
| Longo, R | 1 |
| Bernassola, M | 1 |
| Gallinaro, V | 1 |
| Ursitti, A | 1 |
| Feasi, M | 1 |
| Cassola, G | 1 |
| Ceccherini-Silberstein, F | 1 |
| Cappiello, G | 1 |
| Spanò, A | 1 |
| Schildgen, V | 1 |
| Ziegler, S | 1 |
| Tillmann, RL | 1 |
| Heo, NY | 2 |
| Dunn, SR | 1 |
| Ahn, M | 1 |
| Xu, QJ | 1 |
| Liang, ZG | 1 |
| He, ZK | 1 |
| Dong, PL | 1 |
| Wang, DM | 1 |
| Zhang, XM | 1 |
| Ding, HG | 1 |
| Min, J | 1 |
| Cho, YJ | 1 |
| Jeon, SJ | 1 |
| Lee, YC | 2 |
| Ahn, SY | 1 |
| Jang, YM | 1 |
| Choi, YH | 2 |
| Rami, A | 1 |
| Loustau-Ratti, V | 1 |
| Morlat, P | 1 |
| Goderel, I | 1 |
| Sene, D | 1 |
| Rosenthal, E | 1 |
| de Vries-Sluijs, TE | 1 |
| Prins, JM | 1 |
| Hoepelman, AI | 1 |
| Richter, C | 1 |
| Mulder, JW | 1 |
| van der Ende, ME | 1 |
| Dakin, H | 3 |
| Bentley, A | 2 |
| Fidler, C | 2 |
| Harper, C | 1 |
| Rago, A | 1 |
| Lichtner, M | 1 |
| Mecarocci, S | 1 |
| Marocco, R | 1 |
| Cenfra, N | 1 |
| Belvisi, V | 1 |
| Del Borgo, C | 1 |
| Cimino, G | 1 |
| Mastroianni, CM | 1 |
| Avihingsanon, A | 2 |
| Lewin, SR | 2 |
| Kerr, S | 1 |
| Chang, JJ | 1 |
| Piyawat, K | 1 |
| Napissanant, N | 1 |
| Matthews, GV | 2 |
| Dore, GJ | 3 |
| Lange, J | 1 |
| Ruxrungtham, K | 3 |
| Hirakawa, M | 1 |
| Juszczyk, J | 2 |
| Boroń-Kaczmarska, A | 2 |
| Cianciara, J | 1 |
| Gładysz, A | 1 |
| Halota, W | 1 |
| Kryczka, W | 1 |
| Malkowski, P | 1 |
| Pawlowska, M | 2 |
| Chen, LB | 3 |
| Yang, XA | 3 |
| Einecke, D | 1 |
| Ryu, HJ | 2 |
| Rhee, SY | 1 |
| Margeridon-Thermet, S | 1 |
| Liu, TF | 1 |
| Kagan, RM | 1 |
| Verheyen, J | 1 |
| Shafer, RW | 1 |
| Chotiyaputta, W | 1 |
| Peterson, C | 1 |
| Ditah, FA | 1 |
| Goodwin, D | 1 |
| Jonas, MM | 3 |
| Block, JM | 1 |
| Haber, BA | 1 |
| Karpen, SJ | 1 |
| London, WT | 1 |
| Murray, KF | 2 |
| Narkewicz, MR | 1 |
| Rosenthal, P | 2 |
| Schwarz, KB | 1 |
| Xin, G | 2 |
| Sun, P | 1 |
| Fukai, K | 1 |
| Imazeki, F | 1 |
| Arai, M | 1 |
| Yonemitsu, Y | 1 |
| Fontanges, T | 1 |
| Blin, P | 1 |
| Bregman, B | 1 |
| Schmidely, N | 1 |
| Roudot-Thoraval, F | 2 |
| Bonacini, M | 2 |
| Schiff, E | 3 |
| Thabut, D | 2 |
| Zong, J | 1 |
| Patterson, SJ | 1 |
| Lee, AU | 2 |
| Nicoll, AJ | 1 |
| Desmond, PV | 1 |
| Roberts, SK | 1 |
| Angus, PW | 1 |
| Lasnier, E | 1 |
| Molina, JM | 1 |
| Bonnard, P | 1 |
| Wendum, D | 1 |
| Meynard, JL | 1 |
| N'Dri-Yoman, T | 1 |
| Anglaret, X | 1 |
| Messou, E | 1 |
| Attia, A | 1 |
| Polneau, S | 1 |
| Toni, T | 1 |
| Chenal, H | 1 |
| Seyler, C | 1 |
| Gabillard, D | 1 |
| Wakasugi, N | 1 |
| Eholié, S | 1 |
| Danel, C | 1 |
| Kahloun, A | 1 |
| Bourlière, M | 2 |
| Pais, R | 1 |
| Ma, Z | 1 |
| Hao, C | 1 |
| Yang, JX | 1 |
| Liu, BM | 1 |
| Li, XG | 1 |
| Yan, CH | 1 |
| Sun, XW | 1 |
| Wang, YH | 1 |
| Jiao, XJ | 1 |
| Yan, L | 2 |
| Dong, JP | 1 |
| Hou, CS | 1 |
| Abuduheilili, X | 1 |
| Zhong, Y | 3 |
| Hilgendorf, I | 1 |
| Loebermann, M | 1 |
| Borchert, K | 1 |
| Junghanss, C | 1 |
| Freund, M | 1 |
| Schmitt, M | 1 |
| Xie, QF | 1 |
| Bai, HL | 1 |
| Luo, HT | 1 |
| Ye, YN | 1 |
| Zhong, RX | 1 |
| Sonneveld, MJ | 3 |
| Shamliyan, TA | 1 |
| Johnson, JR | 1 |
| MacDonald, R | 1 |
| Shaukat, A | 1 |
| Yuan, JM | 1 |
| Kane, RL | 1 |
| Wilt, TJ | 1 |
| Tu, XL | 1 |
| Cheng, QH | 1 |
| Mutimer, D | 3 |
| Kim, MC | 1 |
| Durval, A | 1 |
| Zamidei, L | 1 |
| Bettocchi, D | 1 |
| Luzzio, MG | 1 |
| Consales, G | 1 |
| Kim, W | 1 |
| Lee, KL | 1 |
| Hwang, SY | 2 |
| Jung, YJ | 1 |
| Jeong, JB | 1 |
| Sheen, IS | 1 |
| Akarca, US | 2 |
| Suet-Hing Wong, F | 1 |
| Peschell, K | 1 |
| Carosi, G | 2 |
| Rizzetto, M | 8 |
| Alberti, A | 4 |
| Cariti, G | 2 |
| Craxì, A | 2 |
| Filice, G | 2 |
| Levrero, M | 1 |
| Mazzotta, F | 1 |
| Piccinino, F | 1 |
| Prati, D | 1 |
| Raimondo, G | 1 |
| Sagnelli, E | 1 |
| Toti, M | 1 |
| Bruno, R | 3 |
| Di Marco, V | 3 |
| Ferrari, C | 2 |
| Marzano, A | 5 |
| Pollicino, T | 1 |
| Puoti, M | 4 |
| Wang, XC | 2 |
| Wu, YT | 2 |
| Tan, YF | 2 |
| Tang, JM | 2 |
| Pan, JQ | 2 |
| Garg, H | 1 |
| Garg, V | 1 |
| Sharma, BC | 1 |
| Kumar, A | 1 |
| TrehanPati, N | 2 |
| Kotillil, S | 1 |
| Shrivastava, S | 1 |
| Khanam, A | 1 |
| Sukriti, S | 1 |
| Mishra, SK | 1 |
| Kobashi, H | 2 |
| Yamamoto, K | 3 |
| Ozeki, I | 2 |
| Arakawa, T | 2 |
| Nakajima, T | 2 |
| Kuwata, Y | 2 |
| Akaike, J | 1 |
| Ohmura, T | 2 |
| Karino, Y | 2 |
| Toyota, J | 2 |
| Fernandez-Fernandez, P | 1 |
| Quer, J | 1 |
| Shin, SK | 1 |
| Hahn, JS | 1 |
| Sinn, DH | 5 |
| Yun, WK | 1 |
| Lee, YY | 1 |
| Gluhovschi, C | 1 |
| Gadalean, F | 1 |
| Kaycsa, A | 1 |
| Curescu, M | 1 |
| Sporea, I | 1 |
| Gluhovschi, G | 1 |
| Petrica, L | 1 |
| Velciov, S | 1 |
| Bozdog, G | 1 |
| Bob, F | 1 |
| Vernic, C | 1 |
| Cioca, D | 1 |
| Pradeep Kumar, S | 1 |
| Medhi, S | 2 |
| Asim, M | 1 |
| Daudé, M | 1 |
| Sauné, K | 1 |
| Lavayssière, L | 1 |
| Basse, G | 1 |
| Esposito, L | 1 |
| Guitard, J | 1 |
| Chaung, KT | 1 |
| Liu, WC | 1 |
| Young, KC | 1 |
| Gila, A | 1 |
| Figueruela, B | 1 |
| Chueca, N | 1 |
| Muñoz Rueda, P | 1 |
| Puche, B | 1 |
| García, F | 1 |
| Martín, JM | 1 |
| Andrade, RJ | 1 |
| Nogales, C | 1 |
| Romero-Gómez, M | 1 |
| Guan, Q | 1 |
| Ratcliffe, L | 1 |
| Beadsworth, MB | 1 |
| Pennell, A | 1 |
| Phillips, M | 1 |
| Vilar, FJ | 1 |
| Chattopadhyay, P | 1 |
| Sarma, N | 1 |
| Chappell, B | 1 |
| Myrick, F | 1 |
| Schawalder, J | 1 |
| Heathcote, J | 1 |
| Tang, LH | 1 |
| Chen, LZ | 1 |
| Ren, X | 1 |
| Choi, PC | 1 |
| Chan, AW | 1 |
| Chim, AM | 2 |
| Yiu, KK | 1 |
| Chu, SH | 1 |
| Sung, JJ | 4 |
| Stitou, H | 1 |
| Desire, N | 1 |
| Tubiana, R | 1 |
| Katlama, C | 2 |
| Aroldi, A | 1 |
| Messa, PG | 1 |
| Tatsuzawa, K | 1 |
| Kono, M | 1 |
| Hoshina, S | 1 |
| Raptopoulou-Gigi, M | 1 |
| Cheinquer, H | 2 |
| Brown, RS | 1 |
| Bialkowska, J | 1 |
| Tang, S | 1 |
| Beebe, S | 1 |
| Cooney, E | 1 |
| Chiang, LT | 1 |
| Ko, BS | 1 |
| Zaaijer, H | 1 |
| Weegink, C | 1 |
| Dijkgraaf, M | 1 |
| Jansen, P | 1 |
| Beld, M | 1 |
| Reesink, H | 1 |
| Manesis, EK | 1 |
| Petraki, K | 1 |
| Tiniakos, D | 1 |
| Hadziyannis, SJ | 16 |
| Minami, M | 4 |
| Okanoue, T | 5 |
| Cao, W | 1 |
| Qiu, ZF | 1 |
| Li, TS | 1 |
| Ciancio, A | 1 |
| Liang, Y | 1 |
| Xie, R | 1 |
| Ge, S | 1 |
| Volpi, A | 1 |
| Ceccarelli, L | 1 |
| Sordillo, P | 1 |
| Giannousis, IP | 1 |
| Manolakopoulos, SG | 1 |
| Hadziyannis, E | 2 |
| Georgiou, A | 1 |
| Wang, ZH | 1 |
| Guo, YB | 1 |
| Li, XH | 1 |
| Wang, YM | 2 |
| Lai, JY | 2 |
| Wang, JF | 1 |
| Li, MK | 1 |
| Jiang, M | 1 |
| Popescu, M | 1 |
| Kirschner, J | 1 |
| Guerrero, A | 1 |
| Reijnders, J | 1 |
| Mirandola, S | 2 |
| Campagnolo, D | 2 |
| Bortoletto, G | 1 |
| Franceschini, L | 1 |
| Marcolongo, M | 1 |
| Cassino, L | 1 |
| Benetti, S | 1 |
| Fay, F | 1 |
| Tanno, H | 1 |
| Quarleri, J | 1 |
| Berger, F | 3 |
| Filmann, N | 1 |
| Hueppe, D | 1 |
| Henke, J | 1 |
| Hegener, P | 1 |
| Athmann, C | 1 |
| Schmutz, G | 2 |
| Herrmann, E | 2 |
| Law, ST | 1 |
| Li, KK | 1 |
| Ho, YY | 1 |
| Kwak, MS | 2 |
| Zoutendijk, R | 2 |
| van Vuuren, AJ | 1 |
| Boucher, CA | 1 |
| Yuen, LK | 1 |
| Hua, C | 1 |
| Qin, L | 1 |
| Si-Ahmed, SN | 1 |
| Mallet, V | 1 |
| Cruiziat, C | 1 |
| Dumortier, J | 1 |
| Jin, YJ | 1 |
| Park, WH | 1 |
| Yu, JH | 1 |
| Fan, WB | 1 |
| Xie, SS | 1 |
| Li, WW | 1 |
| Sheen, E | 1 |
| Wu, XL | 1 |
| Zeng, WZ | 1 |
| Qin, JP | 2 |
| Jiang, MD | 2 |
| Giles, M | 1 |
| Visvanathan, K | 1 |
| Sasadeusz, J | 2 |
| Sheng, YJ | 1 |
| Tong, SW | 1 |
| Hu, HD | 1 |
| Sun, HX | 1 |
| Montagnani, M | 1 |
| Giandinoto, M | 1 |
| Lisotti, A | 1 |
| Galli, S | 1 |
| Azzaroli, F | 1 |
| Buonfiglioli, F | 1 |
| Turco, L | 1 |
| Aldini, R | 1 |
| Mazzella, G | 1 |
| Ong, A | 1 |
| Kim, KA | 1 |
| Suh, JH | 1 |
| Cho, YS | 1 |
| Won, SY | 1 |
| Park, BK | 1 |
| Seo, DD | 1 |
| Jang, JS | 1 |
| Shin, WG | 1 |
| Mak, B | 1 |
| Sutedja, D | 1 |
| Fernandes, M | 1 |
| Lai, V | 2 |
| da Silva, AC | 1 |
| Guastini, CF | 1 |
| Martins, LG | 1 |
| Silva, MH | 1 |
| Gianini, RJ | 1 |
| Uip, DE | 1 |
| Lu, H | 1 |
| Geng, da Y | 1 |
| Lu, B | 2 |
| Ma, LX | 1 |
| Razonable, RR | 1 |
| Zhou, PP | 1 |
| Hao, JG | 1 |
| Li, SK | 1 |
| Hou, XC | 1 |
| Yang, ZX | 1 |
| Gu, XB | 1 |
| Piao, RL | 1 |
| Tian, D | 1 |
| Ma, ZH | 1 |
| Brown, A | 1 |
| Schollmeyer, J | 1 |
| Sterneck, M | 1 |
| Sarrazin, C | 2 |
| Lutgehetmann, M | 2 |
| Wang, QY | 1 |
| Dou, YQ | 1 |
| Zhang, LR | 1 |
| Zhao, LF | 1 |
| Karatayli, SC | 2 |
| Gokahmetoglu, S | 1 |
| Güven, K | 1 |
| Ha, M | 2 |
| Diao, S | 2 |
| Lin, M | 2 |
| She, H | 2 |
| Kuan, C | 1 |
| Shen, L | 2 |
| Shen, W | 2 |
| Miyajima, I | 1 |
| Sata, M | 1 |
| Ebinuma, H | 1 |
| Saito, H | 1 |
| Zhu, JY | 1 |
| Minde, Z | 1 |
| Yimin, M | 1 |
| Guangbi, Y | 1 |
| JinLin, H | 1 |
| Hao, W | 1 |
| Hong, R | 1 |
| Yuming, W | 1 |
| Xiaqiu, Z | 1 |
| Daozhen, X | 1 |
| Yagang, C | 1 |
| Junqi, N | 1 |
| Youming, C | 1 |
| Yaozong, W | 1 |
| Dixon, J | 1 |
| Barker, K | 1 |
| D'Addiego, G | 1 |
| Giammario, A | 1 |
| Campanale, F | 1 |
| Cao, Z | 1 |
| Ma, B | 1 |
| Wu, H | 1 |
| Dong, GF | 1 |
| Xie, YS | 1 |
| Jeon, JW | 1 |
| Shin, HP | 1 |
| Joo, KR | 1 |
| Cha, JM | 1 |
| Lim, JU | 1 |
| Xing, X | 1 |
| Fan, XH | 1 |
| Geng, JZ | 1 |
| Zheng, YY | 1 |
| Lu, HY | 1 |
| Si, QT | 1 |
| Zhang, MH | 1 |
| Zhang, YG | 1 |
| Ji, SW | 1 |
| Guo, HH | 1 |
| Zhou, CY | 1 |
| Wang, JB | 1 |
| Zhong, JH | 1 |
| Li, le Q | 1 |
| Wu, LC | 1 |
| Arasli, M | 1 |
| Ustundag, Y | 1 |
| Delikanli, B | 1 |
| Harmandar, F | 1 |
| Buyukuysal, C | 1 |
| Cox, N | 1 |
| Tillmann, H | 1 |
| Ju, T | 1 |
| Segovia, MC | 1 |
| Chacra, W | 1 |
| Benayed, R | 1 |
| Riley-Gillis, B | 1 |
| Sone, Y | 1 |
| Fujimori, M | 1 |
| Lee, TH | 1 |
| Lada, O | 1 |
| Gervais, A | 1 |
| Branger, M | 1 |
| Roquebert, B | 1 |
| Collin, G | 1 |
| Fraqueiro, G | 1 |
| Leclerc, L | 1 |
| Martinot-Peignoux, M | 2 |
| Matheron, S | 1 |
| Zhang, WL | 1 |
| Xie, SL | 1 |
| Hu, JL | 1 |
| Cai, XF | 1 |
| Lai, GQ | 1 |
| Eum, JB | 1 |
| Du Jeong, I | 1 |
| Hsiao, CC | 1 |
| Chang, J | 1 |
| Wu, JY | 1 |
| Liu, WH | 1 |
| Han, SY | 1 |
| Chen, PJ | 3 |
| Yeh, SH | 1 |
| Ayana, DA | 1 |
| Lee, KG | 1 |
| Jung, ES | 1 |
| Ryu, HS | 2 |
| Hu, KQ | 2 |
| Yu, AS | 2 |
| Bunchorntavakul, C | 1 |
| Reddy, KR | 1 |
| Lassel, L | 1 |
| Liang, JY | 1 |
| Krygier, R | 1 |
| Bacia, V | 1 |
| Baka-Cwierz, B | 1 |
| Bluszcz-Roznowska, A | 1 |
| Brzostek, T | 1 |
| Deroń, Z | 1 |
| Durlik, M | 1 |
| Janczewska-Kazek, E | 1 |
| Kalinowska, A | 1 |
| Mach, T | 1 |
| Olszok, I | 1 |
| Pisula, A | 1 |
| Wawrzynowicz-Syczewska, M | 1 |
| Silva, MO | 1 |
| Xing, J | 1 |
| Xiao, SX | 1 |
| Wang, YD | 1 |
| Zhao, CY | 1 |
| Lu, HZ | 1 |
| Yu, WY | 1 |
| Zhou, JY | 1 |
| Yan, WZ | 1 |
| Ghany, MG | 2 |
| Feld, JJ | 1 |
| Heller, T | 1 |
| Doo, E | 1 |
| Rotman, Y | 1 |
| Nagabhyru, P | 1 |
| Koh, C | 1 |
| Kleiner, DE | 2 |
| Wright, EC | 1 |
| Liang, TJ | 1 |
| Hoofnagle, JH | 3 |
| Son, CY | 1 |
| Ma, XJ | 1 |
| Chen, XP | 1 |
| Chen, XF | 1 |
| Luo, XD | 1 |
| Ma, HY | 1 |
| Kelly, D | 3 |
| Pollack, H | 2 |
| Mizerski, J | 4 |
| Dai, WW | 1 |
| Li, DK | 1 |
| Gara, N | 1 |
| Collins, MT | 1 |
| Chong, WH | 1 |
| Jake Liang, T | 1 |
| Gish, RG | 5 |
| Clark, MD | 1 |
| Kane, SD | 1 |
| Shaw, RE | 1 |
| Mangahas, MF | 1 |
| Baqai, S | 1 |
| Mello, FC | 1 |
| Fernandes, CA | 1 |
| Gomes, Sde A | 1 |
| Seo, EG | 1 |
| Han, JH | 1 |
| Yoon, SM | 1 |
| Park, SM | 2 |
| Youn, SJ | 1 |
| Szenborn, L | 1 |
| Wysocki, J | 1 |
| McHutchison, J | 1 |
| Pang, PS | 1 |
| Luminos, LM | 1 |
| Qiu, H | 1 |
| Wei, AL | 1 |
| Kuang, X | 1 |
| Fan, K | 1 |
| Deng, G | 1 |
| Gadano, A | 1 |
| Lovegren, M | 1 |
| Cohen, D | 1 |
| Rapti, I | 3 |
| Vassilopoulos, D | 2 |
| Das, P | 1 |
| Vivek, V | 1 |
| Ford, M | 1 |
| Kingdon, E | 1 |
| Holt, S | 1 |
| Chu, M | 1 |
| Cho, SM | 1 |
| Choe, BH | 1 |
| Cho, MH | 1 |
| Kwon, S | 1 |
| Lee, WK | 1 |
| Zhong, C | 1 |
| Stroffolini, T | 1 |
| Spadaro, A | 1 |
| Scifo, G | 1 |
| Russello, M | 1 |
| Montalto, G | 1 |
| Bertino, G | 1 |
| Surace, L | 1 |
| Caroleo, B | 1 |
| Foti, G | 1 |
| Portelli, V | 1 |
| Madonia, S | 1 |
| Sapienza, M | 1 |
| Cosco, L | 1 |
| Frugiuele, P | 1 |
| Galdieri, A | 1 |
| Brandolino, N | 1 |
| Siciliano, R | 1 |
| Bruno, S | 1 |
| Almasio, PL | 1 |
| Liang, LB | 1 |
| Zhang, WJ | 1 |
| Cai, SP | 1 |
| Fan, ZP | 1 |
| Ji, YJ | 1 |
| Tuaillon, E | 1 |
| Lozano, C | 1 |
| Kuster, N | 1 |
| Poinso, A | 1 |
| Kania, D | 1 |
| Nagot, N | 1 |
| Mondain, AM | 1 |
| Pageaux, GP | 1 |
| Ducos, J | 1 |
| Van de Perre, P | 1 |
| Reynes, J | 1 |
| Boni, C | 1 |
| Laccabue, D | 1 |
| Giuberti, T | 1 |
| Schivazappa, S | 1 |
| Alfieri, A | 1 |
| Pesci, M | 1 |
| Missale, G | 1 |
| Kara, B | 1 |
| Gümürdülü, Y | 1 |
| Soylu, A | 1 |
| Mikulska, M | 1 |
| Taramasso, L | 1 |
| Giacobbe, DR | 1 |
| Caligiuri, P | 1 |
| Bruzzone, B | 1 |
| Di Biagio, A | 1 |
| Viscoli, C | 1 |
| Cevik, E | 1 |
| Yakut, M | 1 |
| Seven, G | 1 |
| Setoguchi, T | 1 |
| Ishidou, Y | 1 |
| Arishima, Y | 1 |
| Hirotsu, M | 1 |
| Saitoh, Y | 1 |
| Nakamura, S | 1 |
| Kakoi, H | 1 |
| Nagano, S | 1 |
| Yokouchi, M | 1 |
| Kamizono, J | 1 |
| Komiya, S | 1 |
| Ebata, S | 1 |
| Suzuki, A | 1 |
| Ito, M | 1 |
| Ishikawa, Y | 1 |
| Mochizuki, T | 1 |
| Baba, N | 1 |
| Kubota, J | 1 |
| Miyoshi, K | 1 |
| Fujioka, S | 1 |
| Moritou, Y | 1 |
| Miyake, Y | 1 |
| Iwasaki, Y | 1 |
| Lai, HW | 1 |
| Chang, CC | 1 |
| Chen, TH | 1 |
| Chen, TY | 1 |
| Yuen, JC | 2 |
| Ma, J | 4 |
| He, B | 2 |
| Li, NP | 2 |
| Tang, W | 1 |
| Yip, B | 1 |
| Chaung, K | 1 |
| Wong, CR | 1 |
| Cheung, R | 1 |
| Sebastiani, G | 1 |
| Rossi, C | 1 |
| Velo, E | 1 |
| Erne, EM | 1 |
| Vario, A | 1 |
| Tempesta, D | 1 |
| Romualdi, C | 1 |
| Li, MY | 1 |
| Yuan, XL | 1 |
| Köklü, S | 1 |
| Tuna, Y | 1 |
| Gülşen, MT | 1 |
| Demir, M | 1 |
| Köksal, AŞ | 1 |
| Koçkar, MC | 1 |
| Aygün, C | 1 |
| Coban, S | 1 |
| Ataseven, H | 2 |
| Akin, E | 1 |
| Pürnak, T | 1 |
| Yüksel, I | 1 |
| Ibiş, M | 1 |
| Yildirim, B | 1 |
| Nadir, I | 1 |
| Küçükazman, M | 1 |
| Akbal, E | 1 |
| Yüksel, O | 1 |
| Başar, O | 1 |
| Alkan, E | 1 |
| Baykal, O | 1 |
| Baak, BC | 1 |
| Bakker, CM | 1 |
| Beuers, UH | 1 |
| Brouwer, JT | 1 |
| Drenth, JP | 1 |
| van Erpecum, KJ | 1 |
| Honkoop, P | 1 |
| Kerbert-Dreteler, MJ | 1 |
| Koek, GH | 1 |
| van Nieuwkerk, KM | 1 |
| van Soest, H | 1 |
| van der Spek, BW | 1 |
| Tan, AC | 1 |
| Vrolijk, JM | 1 |
| Cai, M | 1 |
| Striki, A | 1 |
| Cheng, D | 1 |
| Wei, H | 2 |
| Tian, Z | 2 |
| Kiriyama, S | 1 |
| Tanikawa, M | 1 |
| Hisanaga, Y | 1 |
| Kanamori, A | 1 |
| Niinomi, T | 1 |
| Andou, Y | 1 |
| Chung, KH | 1 |
| Jin, E | 1 |
| Ku, YS | 1 |
| Lee, SJ | 1 |
| Bahrami, S | 1 |
| Grare, M | 1 |
| Zhao, KK | 1 |
| Miao, QL | 1 |
| Wang, YX | 1 |
| Zheng, SM | 1 |
| Lin, H | 1 |
| Liu, XC | 1 |
| Shen, CF | 1 |
| Afdhal, N | 1 |
| Bornstein, JD | 1 |
| Tana, MM | 1 |
| Fu, SY | 1 |
| Ma, MM | 1 |
| Sherman, AC | 1 |
| Daucher, M | 1 |
| Davey, RT | 1 |
| Masur, H | 1 |
| Kottilil, S | 1 |
| Kohli, A | 1 |
| Shimohata, H | 1 |
| Sakai, S | 1 |
| Ogawa, Y | 1 |
| Hirayama, K | 1 |
| Sun, IO | 1 |
| Hong, YA | 1 |
| Park, HS | 1 |
| Choi, SR | 1 |
| Chung, BH | 1 |
| Park, CW | 1 |
| Yang, CW | 1 |
| Choi, BS | 1 |
| Tuncer, I | 1 |
| Katrinli, S | 1 |
| Enc, FY | 1 |
| Colak, Y | 1 |
| Ulasoglu, C | 1 |
| Dinler, G | 1 |
| Hulstaert, F | 1 |
| Schwierz, C | 1 |
| Nevens, F | 1 |
| Thiry, N | 1 |
| Gamil, M | 1 |
| Colle, I | 1 |
| Van de Sande, S | 1 |
| Horsmans, Y | 1 |
| Hige, S | 1 |
| Jin, Q | 1 |
| Boglione, L | 1 |
| D'Avolio, A | 1 |
| Gregori, G | 1 |
| Burdino, E | 1 |
| Baietto, L | 1 |
| Cusato, J | 1 |
| Ghisetti, V | 3 |
| De Rosa, FG | 1 |
| Di Perri, G | 1 |
| Seaberg, EC | 1 |
| Revill, PA | 1 |
| Hoy, JF | 1 |
| Finlayson, R | 1 |
| Saulynas, M | 1 |
| Afshar, RM | 1 |
| Mollaie, HR | 1 |
| Yun, TJ | 1 |
| Jung, JY | 1 |
| Kim, CH | 1 |
| An, H | 1 |
| Kim, JD | 1 |
| Keum, B | 1 |
| Jeen, YT | 1 |
| Chun, HJ | 1 |
| Song, ZL | 1 |
| Cui, YJ | 1 |
| Zheng, WP | 1 |
| Teng, DH | 1 |
| Zheng, H | 1 |
| Oyagüez, I | 1 |
| Lozano, V | 1 |
| Yi, NJ | 1 |
| Lee, KW | 1 |
| Kong, SY | 1 |
| Park, KU | 1 |
| Lee, KB | 1 |
| Hong, G | 1 |
| Han, SS | 1 |
| Suh, KS | 1 |
| Maratea, D | 1 |
| Fadda, V | 1 |
| Trippoli, S | 1 |
| Messori, A | 1 |
| Bagnard, G | 1 |
| Lapalus, M | 1 |
| Soyer, OM | 1 |
| Gokturk, S | 1 |
| Evirgen, S | 1 |
| Bozbey, HU | 1 |
| Karaca, C | 1 |
| Demir, K | 1 |
| Besisik, F | 1 |
| Gulluoglu, M | 1 |
| Komolmit, P | 1 |
| Pessôa, MG | 1 |
| Fassio, E | 1 |
| Bessone, F | 1 |
| Daruich, J | 1 |
| Pathan, R | 1 |
| Dong, Y | 1 |
| Chen, ZT | 1 |
| Wu, JC | 1 |
| Chen, JJ | 1 |
| Luo, EP | 1 |
| Westland, CE | 3 |
| Delaney, WE | 8 |
| Ho, V | 1 |
| Fry, J | 7 |
| Brosgart, C | 7 |
| Gibbs, CS | 8 |
| Davis, GL | 1 |
| McClellan, MB | 1 |
| Núñez, M | 3 |
| Pérez-Olmeda, M | 1 |
| Díaz, B | 1 |
| Ríos, P | 1 |
| González-Lahoz, J | 2 |
| Ristig, MB | 1 |
| Crippin, J | 2 |
| Aberg, JA | 1 |
| Powderly, WG | 1 |
| Lisker-Melman, M | 2 |
| Kessels, L | 1 |
| Tebas, P | 2 |
| Nelson, M | 2 |
| Portsmouth, S | 1 |
| Stebbing, J | 1 |
| Atkins, M | 1 |
| Barr, A | 1 |
| Matthews, G | 1 |
| Pillay, D | 1 |
| Fisher, M | 1 |
| Bower, M | 1 |
| Gazzard, B | 1 |
| Cha, YJ | 1 |
| Chen, RY | 1 |
| Shaw, T | 2 |
| Colledge, D | 2 |
| Isom, H | 1 |
| Fisher, DA | 1 |
| Huffam, SE | 1 |
| Birkus, G | 1 |
| Cihlar, T | 1 |
| Goodman, Z | 5 |
| Wulfsohn, MS | 3 |
| Brosgart, CL | 16 |
| Tassopoulos, NC | 3 |
| Kitis, G | 4 |
| Mailliard, ME | 1 |
| Gollan, JL | 1 |
| Bernard-Chabert, B | 1 |
| Sacchi, P | 1 |
| Zocchetti, C | 1 |
| Ciappina, V | 1 |
| Iino, S | 1 |
| Mukherjee, S | 1 |
| Wulfsohn, M | 2 |
| Westland, C | 5 |
| Delaney, W | 2 |
| Chen, SS | 2 |
| Gibbs, C | 2 |
| Miller, M | 1 |
| Purow, DB | 1 |
| Vaughan, R | 1 |
| Ayres, A | 1 |
| Bartholomeusz, A | 1 |
| Ortleb, J | 1 |
| Barcena Marugan, R | 1 |
| Cid Gomez, L | 1 |
| Lopez Serrano, P | 1 |
| Dando, T | 1 |
| Plosker, G | 1 |
| Maier, KP | 2 |
| Lagget, M | 2 |
| Liu, CL | 2 |
| Wei, WI | 1 |
| Yong, BH | 1 |
| Ristig, M | 1 |
| Drechsler, H | 1 |
| Villeneuve, JP | 5 |
| Werle, B | 2 |
| Hochman, JA | 1 |
| Balistreri, WF | 1 |
| Neuhaus, P | 1 |
| Tillmann, HL | 3 |
| Samuel, D | 4 |
| Lilly, L | 1 |
| Rendina, M | 1 |
| Lama, N | 3 |
| James, C | 1 |
| Namini, H | 1 |
| Choy, GS | 1 |
| Van Doren, S | 1 |
| Aloman, C | 1 |
| Wands, JR | 1 |
| Humphries, JC | 1 |
| Dixon, JS | 1 |
| Camino, N | 2 |
| Perrillo, R | 3 |
| Willems, B | 1 |
| Moorat, A | 1 |
| Gardner, S | 1 |
| Woessner, M | 1 |
| Bourne, E | 1 |
| Peters, MG | 2 |
| Hann Hw, Hw | 1 |
| Rubin, R | 1 |
| Kowdley, K | 1 |
| Gray Df, Df | 1 |
| Sullivan, M | 2 |
| Kleber, K | 1 |
| Ebrahimi, R | 1 |
| Taéron, C | 1 |
| Daftary, MN | 1 |
| Hannon, H | 1 |
| Bagnis, CI | 1 |
| Beaufils, H | 1 |
| Qaqish, RB | 1 |
| Mattes, KA | 1 |
| Ritchie, DJ | 1 |
| Beckebaum, S | 1 |
| Malagó, M | 1 |
| Dirsch, O | 1 |
| Cicinnati, VR | 1 |
| Trippler, M | 1 |
| Treichel, U | 1 |
| Broelsch, CE | 1 |
| Zhukovskaya, NL | 1 |
| Zimmer, MI | 1 |
| Soelaiman, S | 1 |
| Bergson, P | 1 |
| Wang, CR | 1 |
| Tang, WJ | 1 |
| Rivkin, AM | 1 |
| Wiegand, J | 1 |
| Tischendorf, JJ | 1 |
| Nashan, B | 1 |
| Klempnauer, J | 1 |
| Flemming, P | 1 |
| Niemann, P | 1 |
| Rohde, P | 1 |
| Kuo, A | 1 |
| Dienstag, JL | 2 |
| Chung, RT | 1 |
| Cooper, DA | 1 |
| Pozniak, AL | 1 |
| DeJesus, E | 1 |
| Zhong, L | 1 |
| Cheng, AK | 1 |
| Ala, A | 1 |
| Stránský, J | 1 |
| Sagir, A | 1 |
| Avci, A | 1 |
| Erhardt, A | 2 |
| Lörke, J | 1 |
| Heintges, T | 2 |
| Häussinger, D | 2 |
| Sumida, Y | 1 |
| Kanemasa, K | 1 |
| Tachibana, S | 1 |
| Maekawa, K | 1 |
| Mori, K | 1 |
| Wursthorn, K | 3 |
| Tu, SS | 1 |
| Cooksley, WG | 2 |
| Stephan, C | 2 |
| Brodt, HR | 1 |
| Berger, A | 3 |
| Mösch, M | 1 |
| Lennemann, TS | 1 |
| Stürmer, M | 1 |
| Staszewski, S | 2 |
| Wang, ZX | 1 |
| Ding, GS | 1 |
| Zhang, JJ | 1 |
| Chen, XS | 1 |
| Guo, WY | 1 |
| Shi, XM | 1 |
| Fu, ZR | 1 |
| Woolley, IJ | 1 |
| Veitch, AJ | 1 |
| Harangozo, CS | 1 |
| Moyle, M | 1 |
| Korman, TM | 1 |
| Lau, DT | 2 |
| Membreno, FE | 1 |
| Bonyhay, L | 1 |
| Lai, CJ | 1 |
| Terrault, NA | 1 |
| Hulot, JS | 1 |
| Launay-Vacher, V | 1 |
| Marcellini, P | 1 |
| Currie, G | 5 |
| Arterbrun, S | 1 |
| Carreño, N | 1 |
| Moreno, D | 1 |
| Sangro, B | 1 |
| Kolyvanos Naumann, U | 1 |
| Käser, L | 1 |
| Vetter, W | 1 |
| de Gottardi, A | 1 |
| Negro, F | 1 |
| Karayiannis, P | 2 |
| Zhang, DF | 1 |
| Neff, GW | 1 |
| Nery, J | 1 |
| O'Brien, CB | 1 |
| Duncan, R | 1 |
| Shire, NJ | 1 |
| Nery, C | 1 |
| Montalbano, M | 1 |
| Muslu, H | 1 |
| Safdar, K | 1 |
| Tzakis, AG | 1 |
| Madariaga, JR | 1 |
| Wünsche, T | 1 |
| Reinke, P | 1 |
| Bergk, A | 1 |
| Schürmann, D | 2 |
| Wiedenmann, B | 1 |
| Ferenci, P | 1 |
| Bain, V | 1 |
| Cooper, C | 1 |
| Martin, S | 1 |
| Lowe, C | 1 |
| Vilde, JL | 1 |
| Dandri, M | 2 |
| Burda, MR | 1 |
| Zuckerman, DM | 1 |
| Matschl, U | 1 |
| Pollok, JM | 1 |
| Rogiers, X | 1 |
| Gocht, A | 1 |
| Köck, J | 1 |
| Blum, HE | 2 |
| von Weizsäcker, F | 2 |
| Yeh, LT | 1 |
| Vitarella, D | 1 |
| Hong, Z | 1 |
| Erion, MD | 1 |
| Chevallier, M | 1 |
| Chevallier, P | 1 |
| Lot, M | 1 |
| Brook, G | 1 |
| Cargnel, A | 1 |
| Rockstroh, J | 3 |
| Thio, C | 1 |
| Vassiliadis, T | 1 |
| Nikolaidis, N | 1 |
| Zezos, P | 1 |
| Orfanou-Koumerkeridou, E | 1 |
| Kim, KK | 1 |
| Hwang, S | 1 |
| Ahn, CS | 1 |
| Moon, DB | 1 |
| Ha, TY | 1 |
| Lee, SG | 1 |
| Mazzaferro, V | 1 |
| Carenzi, S | 2 |
| Romito, R | 1 |
| Pulvirenti, A | 1 |
| Franchello, A | 3 |
| Salizzoni, M | 1 |
| Del Poggio, P | 1 |
| Jamoletti, C | 1 |
| Zaccanelli, M | 1 |
| Kanwal, F | 1 |
| Gralnek, IM | 1 |
| Dulai, GS | 1 |
| Farid, M | 1 |
| Spiegel, BM | 1 |
| Owens, DK | 1 |
| Black, M | 1 |
| Boelle, PY | 1 |
| Serfaty, L | 1 |
| Valleron, AJ | 1 |
| Dimou, E | 2 |
| Dimakopoulos, K | 1 |
| Tzourmakliotis, D | 2 |
| Gärtner, BC | 1 |
| Faust, D | 2 |
| Hofmann, WP | 1 |
| Ng, IO | 1 |
| Baker, DE | 1 |
| Korba, BE | 1 |
| Orito, E | 2 |
| van de Ende, M | 1 |
| Tung, HD | 1 |
| Li, HQ | 1 |
| Li, JH | 1 |
| Dong, JQ | 1 |
| Gao, JR | 1 |
| Gou, CY | 1 |
| Choi, HY | 1 |
| Ko, KH | 1 |
| Park, PW | 1 |
| Kim, NK | 1 |
| Rim, KS | 1 |
| Su, GG | 1 |
| Ying, MF | 1 |
| Palumbo, E | 2 |
| Saracino, A | 1 |
| Sheldon, JA | 1 |
| Corral, A | 1 |
| Rodés, B | 1 |
| Schwarze-Zander, C | 2 |
| Carlebach, A | 2 |
| Bickel, M | 1 |
| Klauke, S | 1 |
| Stuermer, M | 2 |
| Vig, P | 1 |
| Calvez, V | 2 |
| Marcelin, AG | 2 |
| Fievet, MH | 1 |
| Chang, CG | 1 |
| Biao, L | 1 |
| Fontaine, H | 1 |
| Vallet-Pichard, A | 1 |
| Chaix, ML | 2 |
| Serpaggi, J | 1 |
| Verkarre, V | 2 |
| Varaut, A | 1 |
| Morales, E | 1 |
| Nalpas, B | 1 |
| Weitzman, G | 1 |
| Jacobson, I | 1 |
| Ragone, E | 1 |
| Costagliola, L | 1 |
| Cirillo, G | 1 |
| Utili, R | 1 |
| Conjeevaram, H | 1 |
| Marrero, J | 1 |
| Oberhelman, K | 2 |
| Hussain, M | 2 |
| Gornals, JB | 1 |
| Casanovas, T | 2 |
| Sabidó, M | 1 |
| Baliellas, C | 1 |
| Casanovas, A | 1 |
| Cañas, C | 1 |
| Serrano, T | 1 |
| Verdura, B | 1 |
| Chahri, N | 1 |
| Gil-Vernet, S | 1 |
| Figueras, J | 1 |
| Aguilar, J | 1 |
| Mateos, ML | 1 |
| Tato, M | 1 |
| Moreira, V | 1 |
| Yoo, W | 2 |
| Chang, YJ | 1 |
| Yu, SK | 1 |
| Chung, HJ | 1 |
| Moon, MS | 1 |
| Amato, A | 1 |
| Peters, M | 1 |
| Naoumov, NV | 4 |
| Schalm, S | 1 |
| Chun, S | 1 |
| Zucker, SD | 1 |
| Zhang, WX | 1 |
| Mirza, D | 1 |
| Hartmann, H | 2 |
| Roche, B | 1 |
| Libbrecht, E | 2 |
| Sablon, E | 2 |
| Cursaro, C | 1 |
| Andreone, P | 2 |
| Laoi, BN | 2 |
| Herra, C | 2 |
| Norris, S | 2 |
| Crowley, B | 2 |
| Osborn, MK | 1 |
| Butt, AA | 1 |
| Wend, UC | 1 |
| Willems, WR | 1 |
| Montazeri, G | 1 |
| Mohamadnejad, M | 1 |
| Takagi, H | 1 |
| Kakizaki, S | 1 |
| Sohara, N | 1 |
| Mori, M | 1 |
| Lu, JX | 1 |
| Feng, B | 1 |
| Zeng, GB | 1 |
| Osiowy, C | 1 |
| Giles, E | 1 |
| Borlang, J | 1 |
| Zeng, M | 1 |
| Mao, Y | 1 |
| Yao, G | 1 |
| Ji, BN | 1 |
| Chang, CN | 1 |
| Barker, KF | 1 |
| Lee, WA | 1 |
| Martin, JC | 1 |
| Chen, TC | 1 |
| Lin, FY | 1 |
| Lai, MY | 1 |
| Takeda, A | 2 |
| Davidson, P | 2 |
| Müller, C | 1 |
| Volz, T | 1 |
| Longerich, T | 1 |
| Schirmacher, P | 1 |
| Metzler, F | 1 |
| Zankel, M | 1 |
| Fischer, C | 1 |
| von Boemmel, F | 1 |
| Hoffmann, C | 1 |
| Stoehr, A | 1 |
| Wolf, E | 1 |
| Jaeger, H | 1 |
| Thimme, R | 1 |
| Ramos, B | 1 |
| Díaz-Pollán, B | 1 |
| Martín-Carbonero, L | 1 |
| van der Molen, RG | 2 |
| Sprengers, D | 1 |
| Biesta, PJ | 1 |
| Kusters, JG | 2 |
| Villet, S | 2 |
| Andersen, J | 1 |
| Lynch, P | 1 |
| Alston-Smith, B | 1 |
| Jacobson, JM | 1 |
| Johnson, VA | 1 |
| Pollard, RB | 1 |
| Rooney, JF | 2 |
| Swindells, S | 1 |
| Polsky, B | 1 |
| Seo, PJ | 1 |
| Baik, du S | 1 |
| Yun, SY | 1 |
| Shin, JE | 1 |
| Song, IH | 1 |
| Ollivet, A | 1 |
| Tran, N | 1 |
| Chuck, SL | 1 |
| Santos, SA | 1 |
| Uriel, AJ | 1 |
| Park, JS | 2 |
| Lucas, J | 1 |
| Carriero, D | 1 |
| Jaffe, D | 1 |
| Chen, YK | 1 |
| Yin, YK | 2 |
| Yu, YS | 1 |
| Wei, LJ | 1 |
| Kreter, B | 1 |
| Stoop, JN | 1 |
| Kuipers, EJ | 1 |
| Lin, XH | 1 |
| Si, CW | 4 |
| Yu, YY | 1 |
| Ren, XM | 1 |
| Liu, P | 1 |
| Zhang, SL | 1 |
| Kang, XP | 1 |
| Polipalli, SK | 1 |
| Chattopadhyay, S | 1 |
| Hussain, Z | 1 |
| Malik, A | 1 |
| Husain, SA | 1 |
| Begum, N | 1 |
| Allice, T | 2 |
| Cerutti, F | 2 |
| Pittaluga, F | 2 |
| Varetto, S | 2 |
| Gabella, S | 2 |
| Colucci, G | 1 |
| Ryu, SH | 1 |
| Qin, YL | 1 |
| Huang, YX | 1 |
| Mao, RC | 1 |
| Zhang, WQ | 1 |
| Zhang, QB | 1 |
| Wu, XH | 1 |
| Weng, XH | 1 |
| Mitsoula, P | 1 |
| Sasadeusz, JJ | 1 |
| Locarnini, SL | 1 |
| Macdonald, G | 1 |
| Bouvier-Alias, M | 1 |
| Zafrani, ES | 1 |
| Dhumeaux, D | 1 |
| Trojan, J | 1 |
| Teuber, G | 1 |
| Brunelle, MN | 1 |
| Lucifora, J | 1 |
| Holy, A | 1 |
| Lee, LP | 1 |
| Hou, NJ | 1 |
| Lin, ZY | 1 |
| Chen, SC | 1 |
| Wang, LY | 1 |
| Tsai, JF | 1 |
| Chang, WY | 1 |
| Takamura, M | 1 |
| Ichida, T | 1 |
| Ohkoshi, S | 1 |
| Tsubata, S | 1 |
| Osaki, A | 1 |
| Aoyagi, T | 1 |
| Nomoto, M | 1 |
| Uehara, K | 1 |
| Terada, H | 1 |
| Aoyagi, Y | 1 |
| Ersoz, G | 1 |
| Karasu, Z | 1 |
| Ilter, T | 1 |
| Batur, Y | 1 |
| Akarca, U | 1 |
| Widjaja, D | 1 |
| Yarlagadda, S | 1 |
| Singu, BS | 1 |
| Loganathan, RS | 1 |
| Blum, S | 1 |
| Bloom, A | 1 |
| Remy, P | 1 |
| Lim, CY | 1 |
| Kowdley, KV | 3 |
| Shah, U | 1 |
| Memon, I | 1 |
| Cheema, HA | 1 |
| Ali, S | 1 |
| Thobani, S | 1 |
| Mirza, R | 1 |
| Mallet, VO | 1 |
| Dhalluin-Venier, V | 1 |
| Correas, JM | 1 |
| Viard, JP | 1 |
| Chang, UI | 1 |
| Wie, SH | 1 |
| Yang, JM | 2 |
| Sun, HS | 1 |
| Ling, N | 1 |
| Vargas, V | 1 |
| Schapper, M | 1 |
| Bonovas, S | 1 |
| Gerlich, W | 1 |
| Garcia-Gasco, P | 1 |
| Larry, L | 1 |
| Lu, XZ | 1 |
| Alison, T | 1 |
| Arora, G | 1 |
| Kim, MS | 1 |
| Lee, SY | 1 |
| Cha, SB | 1 |
| Zhao, H | 3 |
| Zhang, YX | 3 |
| Tang, XP | 3 |
| Yamazhan, T | 1 |
| Sertöz, R | 1 |
| Pullukçu, H | 1 |
| Taşbakan, M | 1 |
| Erensoy, S | 1 |
| Gaglio, PJ | 1 |
| Sterling, R | 1 |
| Daniels, E | 1 |
| Tedaldi, E | 1 |
| van der Poorten, D | 1 |
| Prakoso, E | 1 |
| Khoo, TL | 1 |
| McCaughan, GW | 2 |
| Cooksley, H | 2 |
| Ribeiro, RM | 1 |
| Powers, KA | 1 |
| Shudo, E | 1 |
| Hui, CK | 2 |
| Lewin, S | 1 |
| Perelson, AS | 1 |
| Locornini, S | 1 |
| Karaaslan, H | 1 |
| Kayhan, H | 1 |
| Türkyilmaz, AR | 1 |
| Sahin, F | 1 |
| Qin, WX | 1 |
| Li, YP | 1 |
| Gimferrer, M | 1 |
| Kim, HC | 1 |
| Shin, KD | 1 |
| Moon, YM | 1 |
| Chao, YC | 1 |
| Minuk, GY | 1 |
| Harb, G | 1 |
| Qiao, XJ | 1 |
| Brown, NA | 1 |
| Doutreloigne, J | 1 |
| Van De Velde, H | 1 |
| Shapiro, F | 1 |
| Shiryu, H | 1 |
| Lacey, LF | 1 |
| Veenstra, DL | 2 |
| Sullivan, SD | 1 |
| Clarke, L | 1 |
| Iloeje, UH | 1 |
| Tafesse, E | 1 |
| Di Bisceglie, A | 2 |
| Lei, CL | 2 |
| Castelló Miralles, I | 1 |
| Del Val Antoñana, A | 1 |
| Muñoz Vicente, M | 1 |
| Moreno-Osset, E | 1 |
| Tassopoulos, N | 1 |
| Chokshi, S | 1 |
| Maayan, Y | 1 |
| Gilson, R | 1 |
| Warnes, T | 1 |
| Paganin, S | 1 |
| Neumann, AU | 1 |
| Bethanis, S | 1 |
| Koutsounas, S | 1 |
| Christias, E | 1 |
| Saveriadis, A | 1 |
| Pavlidis, C | 1 |
| Christidou, A | 1 |
| Karamanolis, D | 1 |
| Rodríguez Frías, F | 1 |
| Crespo, J | 1 |
| Enríquez, J | 1 |
| Carnicer, F | 1 |
| Romero, M | 2 |
| García Bengoechea, M | 1 |
| García Samaniego, J | 1 |
| Miras, M | 1 |
| Pérez Roldán, F | 1 |
| Ter Borg, MJ | 1 |
| Nüesch, R | 1 |
| Ananworanich, J | 1 |
| Srasuebkul, P | 1 |
| Chetchotisakd, P | 1 |
| Prasithsirikul, W | 1 |
| Klinbuayam, W | 1 |
| Mahanontharit, A | 1 |
| Jupimai, T | 1 |
| Hirschel, B | 1 |
| Gutiérrez, S | 1 |
| Guillemi, S | 1 |
| Jahnke, N | 1 |
| Montessori, V | 1 |
| Harrigan, PR | 1 |
| Montaner, JS | 1 |
| Dalmi, L | 1 |
| Ibrányi, E | 1 |
| Tan, J | 1 |
| Degertekin, B | 1 |
| Wong, SN | 1 |
| Husain, M | 1 |
| Zhang, HY | 1 |
| Luk, JM | 1 |
| Leung, KW | 1 |
| Yueng, YH | 1 |
| Wong, A | 1 |
| Yuen, KY | 1 |
| Naoumov, NN | 1 |
| Gallego, A | 1 |
| García-Samaniego, J | 1 |
| Margall, N | 1 |
| Hornillos, P | 1 |
| Enrĺquez, J | 1 |
| Sokal, EM | 1 |
| Wirth, S | 1 |
| Dhawan, A | 1 |
| Gaia, S | 1 |
| Barbon, V | 1 |
| Alessandria, C | 1 |
| Chow, WC | 1 |
| Woessner, MA | 1 |
| Scott, SA | 1 |
| Gray, DF | 1 |
| Gardner, SD | 1 |
| Sánchez-Tapias, JM | 1 |
| Pellicelli, AM | 1 |
| Barbaro, G | 1 |
| Francavilla, R | 1 |
| Romano, M | 1 |
| Barbarini, G | 1 |
| Mazzoni, E | 1 |
| Mecenate, F | 1 |
| Paffetti, A | 1 |
| Barlattani, A | 1 |
| Struglia, C | 1 |
| Villani, R | 1 |
| Nauri, L | 1 |
| Armignacco, O | 1 |
| Ferri, F | 1 |
| Camporiondo, MP | 1 |
| Soccorsi, F | 1 |
| Nam, SW | 1 |
| Lee, SW | 1 |
| Kang, SB | 1 |
| Cho, SH | 1 |
| Han, JY | 1 |
| Kato, N | 1 |
| Goto, T | 1 |
| Omata, M | 1 |
| Kang, JK | 1 |
| Lim, NK | 1 |
| Spackman, DE | 1 |
| Bisceglie, A | 1 |
| Lacey, L | 1 |
| Pwu, RF | 1 |
| Iwasaki, S | 1 |
| Ijaz, S | 1 |
| Arnold, C | 1 |
| Dervisevic, S | 1 |
| Mechurova, J | 1 |
| Tatman, N | 1 |
| Tedder, RS | 2 |
| Ayoub, WS | 1 |
| Tsiang, M | 1 |
| Toole, JJ | 1 |
| Gilson, RJ | 1 |
| Chopra, KB | 1 |
| Newell, AM | 1 |
| Murray-Lyon, IM | 1 |
| Nelson, MR | 1 |
| Rice, SJ | 1 |
| Toole, J | 1 |
| Jaffe, HS | 1 |
| Weller, IV | 1 |
| Petry, W | 1 |
| Freiman, JS | 1 |
| Yoshida, E | 1 |
| Statler, A | 1 |
| Hirsch, K | 1 |
| Wright, T | 1 |
| Gutfreund, K | 1 |
| Lamy, P | 2 |
| Murray, A | 1 |
| Yu, MW | 1 |
| Cheng, SW | 1 |
| Lin, MW | 1 |
| Chang, HC | 1 |
| Hsiao, TJ | 1 |
| Lin, SM | 1 |
| Lee, SD | 1 |
| Regev, A | 1 |
| Suárez García, E | 1 |
| Romero Gómez, M | 1 |
| Grande Santamaría, L | 1 |
| Walsh, KM | 1 |
| Woodall, T | 1 |
| Wight, DG | 1 |
| Bloor, S | 1 |
| Alexander, GJ | 1 |
| Wolters, LM | 1 |
| Bombled, T | 1 |
| Bochet, MV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B[NCT00230503] | Phase 2 | 220 participants | Interventional | 2004-06-30 | Completed | ||
| A Prospective Cohort Study of Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B Patients Who Are Unsatisfied to Entecavir Therapy[NCT05583006] | 60 participants (Anticipated) | Observational | 2023-11-06 | Recruiting | |||
| A Prospective Cohort Study of Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic Hepatitis B Virus Infection[NCT05410496] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-06-22 | Recruiting | ||
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25 mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed[NCT02979613] | Phase 3 | 490 participants (Actual) | Interventional | 2016-12-29 | Completed | ||
| Real World Study on the Effect of HBV-DNA High-precision Detection Based Anti-viral Regimen Adjustment on Achieving Complete Virologic Response in Patients With Chronic Hepatitis B.(REACH)[NCT04724785] | 10,000 participants (Anticipated) | Observational | 2020-12-01 | Recruiting | |||
| To Evaluate the Efficacy and Safety of Tenofovir Amibufenamide in Chronic Hepatitis B (CHB) Patients With Low-level Viraemia (LLV) After Entecavir Treatment[NCT05755776] | 204 participants (Anticipated) | Observational | 2023-03-01 | Recruiting | |||
| A Randomized, Multicenter, Prospective Study to Compare Antiviral Efficacy and Safety of Switching to ETV Plus TDF Versus Maintaining LAM/LDT Plus ADF Combination in CHC With PVR to LAM/LDF Plus ADF Combination Rescue Therapy for YMDD Mutation[NCT01597934] | Phase 4 | 104 participants (Anticipated) | Interventional | 2012-08-31 | Active, not recruiting | ||
| A Two-year, Open-label, Virological Response Adaptive Design, Multicenter Study to Evaluate Efficacy of Telbivudine in HBeAg Negative Adult CHB Patients With Roadmap Strategy[NCT01521975] | Phase 4 | 360 participants (Actual) | Interventional | 2011-01-01 | Completed | ||
| An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection[NCT03692897] | 5,000 participants (Anticipated) | Observational | 2018-10-11 | Recruiting | |||
| A Multicenter Controlled Open-label Trial of Evaluating Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate and Entecavir in Acute-on-chronic Liver Failure of Chronic Hepatitis B Patients[NCT03640728] | 200 participants (Anticipated) | Observational | 2019-01-25 | Recruiting | |||
| Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF) in Treatment-Naive CHB Related Fibrosis/Cirrhosis: a 96w Open-label Multicenter Study[NCT04939441] | Phase 4 | 100 participants (Anticipated) | Interventional | 2021-04-20 | Active, not recruiting | ||
| Switching From Tenofovir Disoproxil Fumarate(TDF) to Tenofovir AlaFenamide(TAF) vs. Maintaining TDF Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir or Entecavir[NCT03241641] | Phase 4 | 174 participants (Actual) | Interventional | 2017-10-26 | Completed | ||
| Chronic HBV Infection in Pregnant Women Taking TAF to Prevent Mother-to-child Transmission in the Third Trimester: a Multicenter, Prospective Study[NCT04237376] | 600 participants (Anticipated) | Observational | 2019-04-09 | Recruiting | |||
| Safety and Efficacy of Tenofovir Alafenamide for Chronic Hepatitis B Patients With Decompensated Liver Disease[NCT04683341] | Phase 4 | 100 participants (Anticipated) | Interventional | 2020-09-01 | Recruiting | ||
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B[NCT01940471] | Phase 3 | 875 participants (Actual) | Interventional | 2013-09-11 | Completed | ||
| Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) as Maintenance Treatment of HIV-1/Hepatitis B Virus (HBV)-Coinfected Patients: an Observational Study[NCT03425994] | 275 participants (Actual) | Observational [Patient Registry] | 2018-02-06 | Active, not recruiting | |||
| Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B: An Open Label, Randomized Controlled Trial[NCT03933384] | Phase 4 | 420 participants (Anticipated) | Interventional | 2019-08-19 | Recruiting | ||
| Efficacy and Safety of Tenofovir Alafenamide in Chronic Hepatitis B Patients With Suboptimal Response Following Nucleos(t)Ide Therapy[NCT04201808] | Phase 4 | 100 participants (Anticipated) | Interventional | 2021-05-01 | Recruiting | ||
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B[NCT01940341] | Phase 3 | 426 participants (Actual) | Interventional | 2013-09-12 | Completed | ||
| A Randomized Prospective Open-label Trial for Comparing Combination Therapy Peg-Interferon Alfa-2a/Adefovir Dipivoxil and Peg-Interferon Alfa-2a/Tenofovir Disoproxil Fumarate Versus no Treatment in HBeAg Negative Chronic Hepatitis B Patients With Low Vira[NCT00973219] | 151 participants (Actual) | Interventional | 2009-09-30 | Completed | |||
| Randomized Trial of Tenofovir Versus Lamivudine Plus Adefovir in Lamivudine Plus Adefovir Treated Lamivudine-resistant Chronic Hepatitis B Patients With Undetectable Hepatitis B Virus DNA.[NCT01732367] | Phase 4 | 171 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| Clinical Investigation About Therapeutic Effects and Long-term Follow-up After Ending Anti-hepatitis B Virus Therapy With Nucleos(t)Ide Analogs in Patients With Chronic Hepatitis b[NCT02883647] | 100 participants (Anticipated) | Observational | 2014-01-31 | Recruiting | |||
| "Analysis of Proximal Renal Tubular Function of Real World Chronic Hepatitis B (CHB) Patients Who Are Suppressed on TDF and Switched to TAF"[NCT02957994] | Phase 4 | 82 participants (Actual) | Interventional | 2016-12-22 | Active, not recruiting | ||
| The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With Tenofovir Disoproxil Fumarate[NCT05313477] | Phase 4 | 64 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | ||
| A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of Presumed Pre-Core Mutant Chronic Hepatitis B[NCT00117676] | Phase 3 | 382 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of HBeAg Positive Chronic Hepatitis B[NCT00116805] | Phase 3 | 266 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| The Effect of Telbivudine on Renal Function in Chronic Hepatitis B Patients With Mild to Moderate Renal Impairment[NCT03778567] | Phase 4 | 31 participants (Actual) | Interventional | 2013-08-01 | Completed | ||
| Continuation of Lamivudine Plus Adefovir Versus Switching to Entecavir Plus Adefovir in Adults With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus Adefovir[NCT01023217] | Phase 4 | 90 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Mechanisms Associated With Favorable Response to Peginterferon-Alpha Add-on Therapy Following Long-term Nucleos(t)Ide Analogue Treatment in Patients With Chronic Hepatitis B[NCT02364336] | Phase 2 | 14 participants (Actual) | Interventional | 2015-02-14 | Completed | ||
| A Prospective, Randomized, Controlled Clinical Trial to Evaluate the Role of Peg-IFN Alfa-2a in Reducing RelapSe Rate in Patients With Hepatitis B e Antigen(HBeAg)-nEgative Chronic Hepatitis B After Discontinuation of NUC Therapy[NCT02594293] | Phase 4 | 180 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| A Phase 3b, Randomized, Double-Blind, Double-Dummy Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine Plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects With C[NCT00737568] | Phase 3 | 280 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Antiviral Efficacy of Continuing Lamivudine Plus Adefovir or Switching to Telbivudine Plus Adefovir in HBeAg-positive Lamivudine-refractory Chronic Hepatitis B Patients Who Have Suboptimal Response to Lamivudine Plus Adefovir for at Least 12 Months[NCT01270165] | Phase 3 | 110 participants (Anticipated) | Interventional | 2010-06-30 | Recruiting | ||
| Exploratory Study on Antiviral Therapy for Patients With Chronic Hepatitis B Virus Infection (Immune Tolerance Period)[NCT05382351] | Phase 2 | 238 participants (Anticipated) | Interventional | 2022-05-10 | Recruiting | ||
| A Phase IV Study to Evaluate the Efficacy, Safety and Tolerability of Tenofovir DF in Asian-American Adults With Chronic Hepatitis B Infection[NCT00736190] | Phase 4 | 90 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Comparative Study of the Effect of Entecavir Versus Tenofovir on the Presence of HBV DNA in the Peripheral Blood Mononuclear Cells in Chronic Hepatitis B Patients[NCT05168293] | 100 participants (Anticipated) | Observational | 2022-02-01 | Not yet recruiting | |||
| Prevention of Mother-to-child Transmission of Hepatitis B Virus: a One Arm, Open Label Intervention Study to Estimate the Optimal Timing of Tenofovir (TDF) in Pregnancy[NCT02995005] | Phase 1/Phase 2 | 98 participants (Actual) | Interventional | 2018-05-24 | Completed | ||
| Multi-center Study Evaluating Persistence of Hepatitis B Virus Replication, Long-term Prognostic Indicators and Their Clinical Relevance in Patients Co-infected With the Human Immunodeficiency Virus and Chronic Hepatitis B[NCT02889094] | 152 participants (Actual) | Observational | 2016-10-31 | Active, not recruiting | |||
| HBV Viral Suppression by Entecavir in Adefovir Partial Responders[NCT00704106] | 60 participants (Actual) | Observational | 2008-05-31 | Completed | |||
| Combination Treatment of Nucleoside （Acid）Analogue (NAs) and Pegylated Interferon α-2b for NAs Treated, Hepatitis B Related, Compensatory Cirrhosis Patients With Low Level Hepatitis b Virus Surface Antigen (HBsAg)[NCT03969017] | Phase 2 | 84 participants (Anticipated) | Interventional | 2019-06-17 | Recruiting | ||
| A Multi-centre, Double Blind, Double Dummy, Randomised, Controlled Study to Evaluate the Efficacy and Safety of TDF 300mg Once Daily (QD) Versus Adefovir Dipivoxil (ADV) 10mg QD in Chinese Subjects With CHB[NCT01300234] | Phase 3 | 512 participants (Actual) | Interventional | 2011-03-30 | Completed | ||
| A Multinational, Multicenter, Open-label, Randomized Controlled Trial to Investigate the Effectiveness of Tenofovir Alafenamide in Reducing Clinical Events in Chronic Hepatitis B Patients Beyond Treatment Indications by Current Guidelines[NCT03753074] | Phase 4 | 780 participants (Anticipated) | Interventional | 2019-02-18 | Recruiting | ||
| A Multicenter Randomized Controlled Open-label Trial of Tenofovir Plus Entecavir Combination vs. Tenofovir Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir and Partial Virologic Response to Ongoing Treatment[NCT01639066] | Phase 4 | 102 participants (Actual) | Interventional | 2012-09-25 | Completed | ||
| Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy[NCT05965388] | 5,000 participants (Anticipated) | Observational | 2023-12-01 | Not yet recruiting | |||
| Clinical Efficacy and Safety of Tenofovir Disoproxil Fumarate and Entcavir in Treatment of Chronic Hepatitis B Patients in Upper Egypt[NCT05874440] | 100 participants (Anticipated) | Observational | 2023-04-15 | Recruiting | |||
| A Multinational, Multi-center, Open, Comparative, Paralleled, Roll-over Study to Assess the Safety and Antiviral Activity of LB80380 Tablet Compared to Entecavir 0.5 mg After Additional 48 Weeks of Treatment in Chronic Hepatitis B Patients Who Have Comple[NCT01242787] | Phase 2 | 115 participants (Anticipated) | Interventional | 2010-08-31 | Active, not recruiting | ||
| A Phase IIb, Open, Multinational, Multi-center, Randomised, Comparative, Parallel Study to Assess the Safety and Antiviral Activity of LB80380 Compared to Entecavir 0.5 mg in Chronic Hepatitis B Patients for 48 Weeks With a Planned Analysis of Efficacy an[NCT01026610] | Phase 2 | 115 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa: a Collaborative Multi-country Prospective Cohort Analysis for International Epidemiologic Databases to Evaluate AIDS- Southern Africa (HIV/HBV-coinfection in IeDEA-SA)[NCT02060162] | 897 participants (Actual) | Observational | 2013-10-31 | Completed | |||
| A Randomized, Open-label, Multi-center Clinical Trial to Evaluate Addition of Peginterferon Alfa-2a to CHB Patients Treated With NAs and Achieved HBV DNA<15 IU/ml、HBeAg<100 PEIU/ml、HBsAg Positive and HBsAg<1500 IU/ml.[NCT02894918] | Phase 4 | 114 participants (Anticipated) | Interventional | 2016-09-30 | Active, not recruiting | ||
| A Phase 2, Randomized, Double-Blind Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine Plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects Currently Being Treated With Adef[NCT00307489] | Phase 2 | 106 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Randomized, Open-Label, Comparative Study to Evaluate Early Viral Load Reductions and Exploratory Viral Kinetics Following Administration of Entecavir or Adefovir in Nucleoside-Naive Adults With Chronic Hepatitis B Infection[NCT00096785] | Phase 3 | 69 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Efficacy of HBV Therapeutic Vaccine in Consolidation of Nucleos(t)Ide Analogues Therapy: a Pilot Study[NCT02505009] | Phase 4 | 116 participants (Actual) | Interventional | 2015-05-01 | Completed | ||
| [NCT01918631] | 36 participants (Actual) | Interventional | 2013-08-31 | Completed | |||
| The Natural History of Liver Disease in a Cohort of Participants With Hepatitis B and/or Hepatitis C With or Without HIV Infection[NCT01350648] | 569 participants (Actual) | Observational | 2011-08-23 | Completed | |||
| A Phase 1b/2a Randomized, Open-label Clinical Trial of Daily Myrcludex B Versus Entecavir in Patients With HBeAg Negative Chronic Hepatitis B[NCT02881008] | Phase 1/Phase 2 | 48 participants (Actual) | Interventional | 2012-11-14 | Completed | ||
| Efficacy of Adefovir and Lamivudine Combination Therapy in Patients With Entecavir Resistance[NCT01546116] | Phase 4 | 20 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| [NCT02019966] | 1,020 participants (Actual) | Observational | 2014-05-12 | Completed | |||
| Maâthermes a Randomised Controlled Trial of Spa Treatment of Overweight and Obesity[NCT01258114] | Phase 3 | 400 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Phase 2, Double-Blind, Multi-center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatment of Chronic Hepatitis B Subjects With Decompensated Liver Disease and in the P[NCT00298363] | Phase 2 | 112 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Tenofovir Reduces Morbidity and Mortality in Patients With Spontaneous Reactivation of Hepatitis B Presenting as Acute-on-chronic Liver Failure (ACLF): A Randomized Placebo Controlled Trial[NCT01074645] | Phase 4 | 27 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy[NCT02068365] | Phase 4 | 41 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Combination of Lamivudine and Adefovir Dipivoxil for Treatment of Chronic Hepatitis B[NCT00023309] | Phase 2 | 41 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Open Label Study of Nucleus(t)Ide Treated Patients Randomised to Tenofovir, or Tenofovir + Telbivudine[NCT02774837] | Phase 4 | 146 participants (Actual) | Interventional | 2016-04-30 | Active, not recruiting | ||
| A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents With Chronic Hepatitis B Infection[NCT00734162] | Phase 3 | 106 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| A Comparative Study of Chronic Hepatitis B Subjects Treated With Entecavir Plus Tenofovir Combination Therapy vs. Entecavir Monotherapy in Adults Who Are Treatment-Naive to Nucleosides and Nucleotides: The BE-LOW Study[NCT00410072] | Phase 3 | 669 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Changes in Dynamic Liver Function Tests in Patients With Chronic Viral Hepatitis Undergoing Antiviral Therapy[NCT02782247] | 52 participants (Actual) | Observational | 2016-05-31 | Completed | |||
| Prognostic Relevance of Fatty Liver Disease for Patients With Chronic Hepatitis B[NCT05317260] | 408 participants (Actual) | Observational | 2002-01-01 | Completed | |||
| Liver Fibrosis in Zambian HIV-HBV Co-infected Patients: a Long-term Prospective Cohort Study[NCT02344680] | 303 participants (Actual) | Observational | 2015-10-31 | Active, not recruiting | |||
| A Single-arm, Multinational, Two Year Study Evaluating the Efficacy and Safety of lead-in Telbivudine for 24 Weeks With or Without Tenofovir Treatment Intensification in Adult Patients With HBeAg-positive Chronic Hepatitis B.[NCT00651209] | Phase 4 | 105 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Multi-Center Phase 3, Open-Label, Parallel-Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B and Varying Degrees of Renal Impairment[NCT00071201] | Phase 3 | 48 participants | Interventional | 2003-06-30 | Completed | ||
| Treatment With Peginterferon Alfa-2a (40 KD) (PEGASYS®) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment. A Pilot Study.[NCT00226382] | Phase 4 | 50 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| A Prospective, Randomized, Multicenter, Open-label Study Evaluating HBeAg Seroconversion in HBeAg Positive CHB Patients on Treatment With NA Switched to Combined Therapy With Peginterferon Alfa-2a and NA for 48 Weeks[NCT02474316] | Phase 4 | 366 participants (Anticipated) | Interventional | 2014-08-31 | Recruiting | ||
| Tenofovir Disoproxil Fumarate Alone Versus Its Combination With Emtricitabine for Treatment of Chronic Hepatitis B[NCT00524173] | Phase 2 | 35 participants (Actual) | Interventional | 2007-08-29 | Terminated | ||
| Prospective Randomized Study for the Comparison of Adding Adefovir Dipivoxil and Switching to Entecavir in Patients With Lamivudine-resistant Chronic Hepatitis B[NCT00531167] | Phase 4 | 219 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial[NCT00663182] | Phase 4 | 200 participants (Anticipated) | Interventional | 2008-01-31 | Enrolling by invitation | ||
| Entecavir Intensification for Persistent Hepatitis B Virus (HBV) Viremia in HIV-HBV Infection[NCT00662545] | Phase 4 | 10 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| A Randomized, Phase II, Controlled Trial Comparing the Efficacy of Adefovir Dipivoxil and Tenofovir Disoproxil Fumarate for the Treatment of Lamivudine-Resistant Hepatitis B Virus in Subjects Who Are Co-Infected With HIV[NCT00033163] | Phase 2 | 90 participants | Interventional | Completed | |||
| A Randomized, Open-Label Trial of Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B[NCT00115245] | Phase 3 | 0 participants | Interventional | 2004-11-30 | Completed | ||
| A Study on the Viral Kinetics of Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in HBeAg Positive Chronic Hepatitis B[NCT00226447] | Phase 2 | 30 participants | Interventional | 2002-12-31 | Completed | ||
| A Phase 3b, Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B Who Have Limited Treatment Options[NCT00042393] | 0 participants | Expanded Access | Approved for marketing | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Cockcroft-Gault formula is as follows:~For men: Glomerular filtration rate (GFR) = (140 - age in years) * body weight in kg / 72 * serum creatinine (mg/dL)~For women: GFR = 0.85 * (140 - age in years) * body weight in kg / 72 * serum creatinine (mg/dL).~Change from baseline was calculated as the value at Week 96 minus the value at Baseline." (NCT02979613)
Timeframe: Baseline; Week 96
| Intervention | mL/min (Median) |
|---|---|
| TAF 25 mg | 1.626 |
| TDF 300 mg | 0.544 |
"Cockcroft-Gault formula is as follows:~For men: Glomerular filtration rate (GFR) = (140 - age in years) * body weight in kg / 72 * serum creatinine (mg/dL)~For women: GFR = 0.85 * (140 - age in years) * body weight in kg / 72 * serum creatinine (mg/dL).~Change from baseline was calculated as the value at Week 48 minus the value at Baseline." (NCT02979613)
Timeframe: Baseline; Week 48
| Intervention | mL/min (Median) |
|---|---|
| TAF 25 mg | 2.240 |
| TDF 300 mg | -1.722 |
The FibroTest score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 48 minus the value at Baseline. (NCT02979613)
Timeframe: Baseline; Week 48
| Intervention | scores on a scale (Mean) |
|---|---|
| TAF 25 mg | -0.02 |
| TDF 300 mg | -0.01 |
The FibroTest score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 96 minus the value at Baseline. (NCT02979613)
Timeframe: Baseline; Week 96
| Intervention | scores on a scale (Mean) |
|---|---|
| TAF 25 mg | -0.03 |
| TDF 300 mg | -0.03 |
Percent Change = Change from baseline at a postbaseline visit/baseline * 100%. (NCT02979613)
Timeframe: Baseline; Week 96
| Intervention | percent change (Mean) |
|---|---|
| TAF 25 mg | 1.157 |
| TDF 300 mg | 0.180 |
Percent Change = Change from baseline at a postbaseline visit/baseline * 100%. (NCT02979613)
Timeframe: Baseline; Week 48
| Intervention | percent change (Mean) |
|---|---|
| TAF 25 mg | 0.659 |
| TDF 300 mg | -0.507 |
Percent Change = Change from baseline at a postbaseline visit/baseline * 100%. (NCT02979613)
Timeframe: Baseline; Week 48
| Intervention | percent change (Mean) |
|---|---|
| TAF 25 mg | 1.743 |
| TDF 300 mg | -0.138 |
Percent Change = Change from baseline at a postbaseline visit/baseline * 100%. (NCT02979613)
Timeframe: Baseline; Week 96
| Intervention | percent change (Mean) |
|---|---|
| TAF 25 mg | 2.330 |
| TDF 300 mg | 1.726 |
HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline visit with baseline HBeAb negative or missing. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 17.9 |
| TDF 300 mg | 9.0 |
HBeAg seroconversion was defined as HBeAg loss and HBeAb changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 2.6 |
| TDF 300 mg | 0.0 |
HBeAg seroconversion was defined as HBeAg loss and HBeAb changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 5.1 |
| TDF 300 mg | 2.6 |
HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline visit with baseline HBsAb negative or missing. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 1.6 |
| TDF 300 mg | 2.4 |
HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 0.0 |
| TDF 300 mg | 0.0 |
HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 0.8 |
| TDF 300 mg | 0.4 |
The percentage of participants with HBV DNA < 20 IU/mL at Week 48 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 48 analysis window. Missing=Failure (M = F) approach was used for analysis. (NCT02979613)
Timeframe: Weeks 48
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 96.3 |
| TDF 300 mg | 96.3 |
The percentage of participants with HBV DNA < 20 IU/mL at Week 96 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 96 analysis window. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 94.7 |
| TDF 300 mg | 93.9 |
"The percentage of participants with HBV DNA ≥ 20 IU/mL at Week 96 was analyzed using the modified US FDA-defined snapshot algorithm, which included participants who:~Had the last available on-treatment HBV DNA ≥ 20 IU/mL in the Week 96 analysis window (from Day 589 to Day 840, inclusive), or~Did not have on-treatment HBV DNA data available in the Week 96 analysis window and~Discontinued study drug prior to or in the Week 96 analysis window due to lack of efficacy, or~Discontinued study drug prior to or in the Week 96 analysis window due to reason other than lack of efficacy and had the last available on-treatment HBV DNA ≥ 20 IU/mL" (NCT02979613)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 0.4 |
| TDF 300 mg | 0.4 |
HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline visit with baseline HBeAb negative or missing. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 7.7 |
| TDF 300 mg | 6.4 |
HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline visit with baseline HBsAb negative or missing. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 0.0 |
| TDF 300 mg | 2.0 |
"The percentage of participants with HBV DNA ≥ 20 IU/mL at Week 48 was analyzed using the modified US FDA-defined snapshot algorithm, which included participants who:~Had the last available on-treatment HBV DNA ≥ 20 IU/mL in the Week 48 analysis window (from Day 295 to Day 378, inclusive), or~Did not have on-treatment HBV DNA data available in the Week 48 analysis window and~Discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or~Discontinued study drug prior to or in the Week 48 analysis window due to reason other than lack of efficacy and had the last available on-treatment HBV DNA ≥ 20 IU/mL" (NCT02979613)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 0.4 |
| TDF 300 mg | 0.4 |
The percentage of participants with HBV DNA < 20 IU/mL at Week 48 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 48 analysis window. The method of determining percentage of participants with HBV DNA levels <20 IU/mL (target detected/not detected i.e., lower limit of detection) at Week 48, was handled by M = F, and Missing=Excluded (M = E) approaches. (NCT02979613)
Timeframe: Week 48
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| M = F Approach: < 20 IU/mL Target Not Detected | M = F Approach: < 20 IU/mL Target Detected | M = E Approach: < 20 IU/mL Target Not Detected | M = E Approach: < 20 IU/mL Target Detected | |
| TAF 25 mg | 63.4 | 32.9 | 65.5 | 34.0 |
| TDF 300 mg | 62.0 | 34.3 | 64.1 | 35.4 |
The percentage of participants with HBV DNA < 20 IU/mL at Week 96 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 96 analysis window. The method of determining percentage of participants with HBV DNA levels <20 IU/mL (target detected/not detected i.e., lower limit of detection) at Week 96, was handled by Missing=Failure (M = F), and Missing=Excluded (M = E) approaches. (NCT02979613)
Timeframe: Week 96
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| M = F Approach: < 20 IU/mL Target Not Detected | M = F Approach: < 20 IU/mL Target Detected | M = E Approach: < 20 IU/mL Target Not Detected | M = E Approach: < 20 IU/mL Target Detected | |
| TAF 25 mg | 65.8 | 28.8 | 69.3 | 30.3 |
| TDF 300 mg | 66.1 | 27.8 | 70.1 | 29.4 |
Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 48
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Central Laboratory Criteria | AASLD Criteria | |
| TAF 25 mg | 89.3 | 79.0 |
| TDF 300 mg | 84.9 | 75.1 |
Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 96
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Central Laboratory Criteria | AASLD Criteria | |
| TAF 25 mg | 88.5 | 80.7 |
| TDF 300 mg | 91.4 | 86.5 |
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 48
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Central Laboratory Criteria | AASLD Criteria | |
| TAF 25 mg | 50.0 | 50.0 |
| TDF 300 mg | 36.8 | 26.4 |
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 96
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Central Laboratory Criteria | AASLD Criteria | |
| TAF 25 mg | 56.3 | 55.8 |
| TDF 300 mg | 78.9 | 73.6 |
(NCT01940471)
Timeframe: Baseline, Week 48
| Intervention | mg/dL (Mean) |
|---|---|
| TAF 25 mg | 0.009 |
| TDF 300 mg | 0.026 |
(NCT01940471)
Timeframe: Baseline, Week 48
| Intervention | percentage change (Mean) |
|---|---|
| TAF 25 mg | -0.100 |
| TDF 300 mg | -1.715 |
(NCT01940471)
Timeframe: Baseline, Week 48
| Intervention | percentage change (Mean) |
|---|---|
| TAF 25 mg | -0.417 |
| TDF 300 mg | -2.294 |
(NCT01940471)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 10.3 |
| TDF 300 mg | 8.1 |
(NCT01940471)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 63.9 |
| TDF 300 mg | 66.8 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. (NCT01940471)
Timeframe: Up to 48 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | |
| TAF 25 mg | 23.9 | 3.5 | 0 |
| TDF 300 mg | 17.8 | 4.5 | 0.3 |
(NCT01940341)
Timeframe: Baseline, Week 48
| Intervention | mg/dL (Mean) |
|---|---|
| TAF 25 mg | 0.01 |
| TDF 300 mg | 0.02 |
(NCT01940341)
Timeframe: Baseline, Week 48
| Intervention | percentage change (Mean) |
|---|---|
| TAF 25 mg | -0.288 |
| TDF 300 mg | -2.156 |
(NCT01940341)
Timeframe: Baseline, Week 48
| Intervention | percentage change (Mean) |
|---|---|
| TAF 25 mg | -0.876 |
| TDF 300 mg | -2.514 |
The primary efficacy endpoint was determined by the achievement of HBV DNA < 29 IU/mL at Week 48. (NCT01940341)
Timeframe: Week 48
| Intervention | Percentage of participants (Number) |
|---|---|
| TAF 25 mg | 94.0 |
| TDF 300 mg | 92.9 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. (NCT01940341)
Timeframe: Up to 48 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | |
| TAF 25 mg | 18.1 | 1.1 | 0 |
| TDF 300 mg | 16.4 | 2.1 | 0 |
ALT normalization was defined as ALT > upper limit of normal (ULN) at baseline and within the normal range at the end of blinded treatment. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00117676)
Timeframe: Baseline; Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TDF-TDF | 76.3 |
| ADV-TDF | 77.1 |
ALT normalization was defined as ALT > ULN at baseline and within the normal range at Week 96. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00117676)
Timeframe: Baseline; Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| TDF-TDF | 72.4 |
| ADV-TDF | 68.5 |
(NCT00117676)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TDF-TDF | 93.2 |
| ADV-TDF | 63.2 |
(NCT00117676)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| TDF-TDF | 90.6 |
| ADV-TDF | 89.3 |
(NCT00117676)
Timeframe: Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480
| Intervention | units per liter (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 48 | Week 96 | Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | Week 432 | Week 480 | |
| ADV-TDF | -124.4 | -138.5 | -140.0 | -140.3 | -139.5 | -134.7 | -143.1 | -132.6 | -131.9 | -129.2 |
| TDF-TDF | -95.0 | -93.7 | -99.1 | -99.6 | -97.7 | -98.9 | -98.9 | -96.1 | -97.0 | -94.9 |
(NCT00117676)
Timeframe: Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480
| Intervention | log10 copies/mL (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 48 | Week 96 | Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | Week 432 | Week 480 | |
| ADV-TDF | -4.07 | -4.74 | -4.77 | -4.75 | -4.77 | -4.81 | -4.81 | -4.79 | -4.69 | -4.75 |
| TDF-TDF | -4.57 | -4.54 | -4.61 | -4.56 | -4.59 | -4.61 | -4.61 | -4.56 | -4.60 | -4.57 |
The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, and ranges from 0 (best) to 14 (worst). The Ishak score measures the degree of liver fibrosis (scarring) caused by chronic necroinflammation (inflammation leading to cell death) and ranges from 0 (best) to 6 (worst). (NCT00117676)
Timeframe: Baseline; Week 240
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Knodell Score | Ishak Score | |
| ADV-TDF | -4.9 | -4.2 |
| TDF-TDF | -4.6 | -4.0 |
The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, and ranges from 0 (best) to 14 (worst). The Ishak score measures the degree of liver fibrosis (scarring) caused by chronic necroinflammation (inflammation leading to cell death) and ranges from 0 (best) to 6 (worst). (NCT00117676)
Timeframe: Baseline; Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Knodell Necroinflammatory Score | Ishak Necroinflammatory Score | |
| ADV-TDF | -3.4 | -2.6 |
| TDF-TDF | -3.5 | -2.6 |
(NCT00117676)
Timeframe: Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480
| Intervention | units per liter (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Week 96 | Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | Week 432 | Week 480 | |
| ADV-TDF | -0.6 | -0.3 | -3.6 | -3.9 | -4.1 | -2.0 | -3.9 | -8.9 | -5.9 |
| TDF-TDF | 2.4 | -0.6 | 0.7 | -2.5 | -3.9 | -2.6 | -2.9 | -4.6 | -2.8 |
(NCT00117676)
Timeframe: Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480
| Intervention | log10 copies/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Week 96 | Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | Week 432 | Week 480 | |
| ADV-TDF | -0.60 | -0.63 | -0.61 | -0.61 | -0.64 | -0.65 | -0.66 | -0.67 | -0.72 |
| TDF-TDF | 0.02 | -0.03 | 0.01 | -0.04 | -0.04 | -0.05 | -0.02 | -0.04 | -0.05 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 144 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 96 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 96 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 97 to 144
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites within HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to genotype | |
| ADV-TDF | 0 | 0 | 0 | 0 | 0 |
| TDF-TDF | 4 | 0 | 1 | 2 | 1 |
| TDF-TDF With Addition of FTC | 0 | 0 | 0 | 0 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 192 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 144 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 144 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 145 to 192
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites within HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to genotype | |
| ADV-TDF | 0 | 0 | 0 | 0 | 0 |
| TDF-TDF | 3 | 0 | 1 | 1 | 1 |
| TDF-TDF With Addition of FTC | 1 | 0 | 0 | 1 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 240 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 192 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 192 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 193 to 240
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites within HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to genotype | |
| ADV-TDF | 2 | 0 | 0 | 0 | 2 |
| TDF-TDF | 1 | 1 | 0 | 0 | 0 |
| TDF-TDF With Addition of FTC | 2 | 0 | 2 | 0 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 288 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 240 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 240 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 241 to 288
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites within HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to genotype | |
| ADV-TDF | 1 | 0 | 1 | 0 | 0 |
| TDF-TDF | 3 | 0 | 2 | 1 | 0 |
| TDF-TDF With Addition of FTC | 1 | 0 | 1 | 0 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 336 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 288 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 288 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 289 to 336
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites within HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to genotype | |
| ADV-TDF | 1 | 0 | 0 | 0 | 1 |
| TDF-TDF | 0 | 0 | 0 | 0 | 0 |
| TDF-TDF With Addition of FTC | 1 | 0 | 0 | 1 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 384 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 336 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 336 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 337 to 384
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites within HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to genotype | |
| ADV-TDF | 0 | 0 | 0 | 0 | 0 |
| TDF-TDF | 1 | 0 | 0 | 0 | 1 |
| TDF-TDF With Addition of FTC | 0 | 0 | 0 | 0 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 432 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 384 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 384 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 385 to 432
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites within HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to genotype | |
| ADV-TDF | 1 | 0 | 1 | 0 | 0 |
| TDF-TDF | 2 | 0 | 0 | 2 | 0 |
| TDF-TDF With Addition of FTC | 0 | 0 | 0 | 0 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 48, those with viral breakthrough, and those who discontinued after Week 24 with HBV DNA ≥ 400 copies/mL. (NCT00117676)
Timeframe: Baseline; Week 48
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites in HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 42 | 7 | 14 | 20 | 1 |
| TDF-TDF | 8 | 0 | 3 | 4 | 1 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 480 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 432 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 432 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 433 to 480
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites within HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to genotype | |
| ADV-TDF | 0 | 0 | 0 | 0 | 0 |
| TDF-TDF | 0 | 0 | 0 | 0 | 0 |
| TDF-TDF With Addition of FTC | 0 | 0 | 0 | 0 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 96 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 48 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 49 to 96
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites within HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 0 | 0 | 0 | 0 | 0 |
| TDF-TDF | 6 | 0 | 2 | 4 | 0 |
| TDF-TDF With Addition of FTC | 1 | 0 | 1 | 0 | 0 |
ALT normalization was defined as ALT > ULN at baseline and within the normal range at the subsequent time point. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00117676)
Timeframe: Baseline; Weeks 144, 192, 240, 288, 336, and 384
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | |
| ADV-TDF | 70.0 | 76.4 | 75.7 | 72.9 | 65.4 | 69.2 |
| TDF-TDF | 74.3 | 68.2 | 70.3 | 69.9 | 65.9 | 65.3 |
ALT normalization was defined as ALT > ULN at baseline and within the normal range at the subsequent time point. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00117676)
Timeframe: Baseline; Weeks 432 and 480
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 432 | Week 480 | |
| ADV-TDF | 87.2 | 88.9 |
| TDF-TDF | 86.5 | 80.0 |
HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at Week 96. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at Week 96. (NCT00117676)
Timeframe: Baseline; Week 96
| Intervention | percentage of participants (Number) | |
|---|---|---|
| HBsAg Loss | Anti-HBs Seroconversion | |
| ADV-TDF | 0 | 0 |
| TDF-TDF | 0 | 0 |
HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at the subsequent time point. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at the subsequent time point. (NCT00117676)
Timeframe: Baseline; Weeks 144, 192, 240, 288, 336, 384, 432, and 480
| Intervention | percentage of participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HBsAg Loss - Week 144 | Anti-HBs Seroconversion - Week 144 | HBsAg Loss - Week 192 | Anti-HBs Seroconversion - Week 192 | HBsAg Loss - Week 240 | Anti-HBs Seroconversion - Week 240 | HBsAg Loss - Week 288 | Anti-HBs Seroconversion - Week 288 | HBsAg Loss - Week 336 | Anti-HBs Seroconversion - Week 336 | HBsAg Loss - Week 384 | Anti-HBs Seroconversion - Week 384 | HBsAg Loss - Week 432 | Anti-HBs Seroconversion - Week 432 | HBsAg Loss - Week 480 | Anti-HBs Seroconversion - Week 480 | |
| ADV-TDF | 0 | 0 | 0 | 0 | 0.8 | 0 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 1.6 | 0.8 | 2.4 | 0.8 |
| TDF-TDF | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.8 | 0.4 | 1.2 | 0.4 | 1.2 | 0.8 |
"Complete response was a composite endpoint defined as histological response and HBV DNA < 400 copies/mL. Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4.~A participant was a nonresponder for the primary endpoint if either biopsy (baseline or end-of-treatment) was missing or if there was not an HBV DNA value available at or beyond Week 40." (NCT00117676)
Timeframe: Baseline; Week 48
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Yes | No | |
| ADV-TDF | 48.8 | 51.2 |
| TDF-TDF | 70.8 | 29.2 |
(NCT00117676)
Timeframe: Weeks 144, 192, 240, 288, 336, and 384
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | |
| ADV-TDF | 88.4 | 86.8 | 83.9 | 82.9 | 78.0 | 76.3 |
| TDF-TDF | 86.7 | 84.0 | 82.8 | 80.5 | 77.0 | 74.3 |
(NCT00117676)
Timeframe: Weeks 432 and 480
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 432 | Week 480 | |
| ADV-TDF | 97.7 | 100.0 |
| TDF-TDF | 97.6 | 100.0 |
HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at Week 48. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at Week 48. (NCT00117676)
Timeframe: Baseline; Week 48
| Intervention | percentage of participants (Number) | |
|---|---|---|
| HBsAg Loss | Seroconversion to anti-HBs | |
| ADV-TDF | 0 | 0 |
| TDF-TDF | 0 | 0 |
Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4. (NCT00117676)
Timeframe: Baseline; Week 240
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Yes | No | |
| ADV-TDF | 85.1 | 14.9 |
| TDF-TDF | 87.3 | 12.7 |
Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4. (NCT00117676)
Timeframe: Baseline; Week 48
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Yes | No | |
| ADV-TDF | 68.8 | 31.2 |
| TDF-TDF | 72.4 | 27.6 |
Participants were ranked as having improvement, no change, worsening, or missing data (compared to Baseline) based on the Knodell scoring system, and results are presented as the percentage of participants in each category. The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, which ranges from 0 (best) to 14 (worst). The Knodell fibrosis domain score ranges from 0 (best) to 4 (worst). A decrease of 1 point or more indicated improvement, and an increase of 1 point or more indicated worsening. (NCT00117676)
Timeframe: Baseline; Week 240
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Improvement - Necroinflammation | No Change - Necroinflammation | Worsening - Necroinflammation | Improvement - Fibrosis | No Change - Fibrosis | Worsening - Fibrosis | |
| ADV-TDF | 94.6 | 1.4 | 4.1 | 59.5 | 33.8 | 6.8 |
| TDF-TDF | 96.7 | 2.7 | 0.7 | 62.0 | 34.0 | 4.0 |
Participants were ranked as having improvement, no change, worsening, or missing data (compared to Baseline) based on the Knodell scoring system, and results are presented as the percentage of participants in each category. The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, which ranges from 0 (best) to 14 (worst). The Knodell fibrosis domain score ranges from 0 (best) to 4 (worst). A decrease of 1 point or more indicated improvement, and an increase of 1 point or more indicated worsening. (NCT00117676)
Timeframe: Baseline; Week 48
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Improvement - Necroinflammation | No Change - Necroinflammation | Worsening - Necroinflammation | Missing Data - Necroinflammation | Improvement - Fibrosis | No Change - Fibrosis | Worsening - Fibrosis | Missing Data - Fibrosis | |
| ADV-TDF | 81.6 | 8.0 | 0.8 | 9.6 | 25.6 | 54.4 | 10.4 | 9.6 |
| TDF-TDF | 82.0 | 6.8 | 4.8 | 6.4 | 22.0 | 63.2 | 8.4 | 6.4 |
ALT normalization was defined as ALT > upper limit of normal (ULN) at baseline and within the normal range at the end of blinded treatment. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00116805)
Timeframe: Baseline; Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TDF-TDF | 68.0 |
| ADV-TDF | 54.4 |
ALT normalization was defined as ALT > ULN at baseline and within the normal range at Week 96. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00116805)
Timeframe: Baseline; Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| TDF-TDF | 65.2 |
| ADV-TDF | 74.4 |
"Complete response was a composite endpoint defined as histological response and HBV DNA < 400 copies/mL. Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4.~A participant was a nonresponder for the primary endpoint if either biopsy (baseline or end-of-treatment) was missing or if there was not an HBV DNA value available at or beyond Week 40." (NCT00116805)
Timeframe: Baseline; Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TDF-TDF | 66.5 |
| ADV 10 mg | 12.2 |
(NCT00116805)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TDF-TDF | 76.1 |
| ADV-TDF | 13.3 |
(NCT00116805)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| TDF-TDF | 77.6 |
| ADV-TDF | 77.9 |
(NCT00116805)
Timeframe: Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480
| Intervention | U/L (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 48 | Week 96 | Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | Week 432 | Week 480 | |
| ADV-TDF | -106.1 | -120.4 | -126.2 | -139.6 | -134.8 | -130.9 | -132.3 | -133.7 | -162.1 | -157.5 |
| TDF-TDF | -107.2 | -107.8 | -100.7 | -101.4 | -95.9 | -102.3 | -101.9 | -108.1 | -105.0 | -92.3 |
(NCT00116805)
Timeframe: Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480
| Intervention | log10 IU/mL (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 48 | Week 96 | Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | Week 432 | Week 480 | |
| ADV-TDF | -3.93 | -6.38 | -6.31 | -6.49 | -6.45 | -6.49 | -6.46 | -6.28 | -6.45 | -6.37 |
| TDF-TDF | -6.17 | -6.26 | -6.32 | -6.30 | -6.22 | -6.27 | -6.35 | -6.38 | -6.13 | -6.18 |
The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, and ranges from 0 (best) to 14 (worst). The Ishak score measures the degree of liver fibrosis (scarring) caused by chronic necroinflammation (inflammation leading to cell death) and ranges from 0 (best) to 6 (worst). (NCT00116805)
Timeframe: Baseline; Week 240
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Knodell Necroinflammatory Score | Ishak Necroinflammatory Score | |
| ADV-TDF | -5.1 | -4.5 |
| TDF-TDF | -4.8 | -4.1 |
The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, and ranges from 0 (best) to 14 (worst). The Ishak score measures the degree of liver fibrosis (scarring) caused by chronic necroinflammation (inflammation leading to cell death) and ranges from 0 (best) to 6 (worst). (NCT00116805)
Timeframe: Baseline; Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Knodell Necroinflammatory Score | Ishak Necroinflammatory Score | |
| ADV-TDF | -3.2 | -2.6 |
| TDF-TDF | -3.6 | -2.7 |
(NCT00116805)
Timeframe: Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480
| Intervention | U/L (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Week 96 | Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | Week 432 | Week 480 | |
| ADV-TDF | -6.9 | -0.7 | -7.8 | -8.1 | -10.3 | -9.3 | -6.9 | -11.6 | -7.1 |
| TDF-TDF | -2.0 | -0.4 | -1.3 | 3.7 | -1.6 | -1.2 | -4.4 | -4.3 | -5.5 |
(NCT00116805)
Timeframe: Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480
| Intervention | log10 IU/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Week 96 | Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | Week 432 | Week 480 | |
| ADV-TDF | -2.43 | -2.27 | -2.41 | -2.49 | -2.62 | -2.59 | -2.34 | -2.32 | -2.16 |
| TDF-TDF | -0.10 | -0.19 | -0.20 | -0.14 | -0.18 | -0.25 | -0.29 | -0.13 | -0.24 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 144 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 96 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 96 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 97 to 144
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites in HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 5 | 2 | 3 | 0 | 0 |
| ADV-TDF With Addition of FTC | 5 | 0 | 0 | 3 | 1 |
| TDF-TDF | 2 | 1 | 0 | 1 | 0 |
| TDF-TDF With Addition of FTC | 7 | 2 | 3 | 2 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 192 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 144 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 144 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 145 to 192
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites in HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 1 | 0 | 1 | 0 | 0 |
| ADV-TDF With Addition of FTC | 1 | 0 | 1 | 0 | 0 |
| TDF-TDF | 2 | 0 | 1 | 0 | 1 |
| TDF-TDF With Addition of FTC | 5 | 0 | 0 | 1 | 3 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 240 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 192 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 192 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 193 to 240
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites in HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 0 | 0 | 0 | 0 | 0 |
| ADV-TDF With Addition of FTC | 1 | 1 | 0 | 0 | 0 |
| TDF-TDF | 3 | 0 | 2 | 1 | 0 |
| TDF-TDF With Addition of FTC | 3 | 0 | 0 | 2 | 1 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 288 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 240 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 240 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 241 to 288
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites in HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 0 | 0 | 0 | 0 | 0 |
| ADV-TDF With Addition of FTC | 0 | 0 | 0 | 0 | 0 |
| TDF-TDF | 3 | 0 | 0 | 2 | 1 |
| TDF-TDF With Addition of FTC | 0 | 0 | 0 | 0 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 336 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 288 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 288 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 289 to 336
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites in HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 1 | 0 | 0 | 1 | 0 |
| ADV-TDF With Addition of FTC | 0 | 0 | 0 | 0 | 0 |
| TDF-TDF | 1 | 0 | 0 | 0 | 1 |
| TDF-TDF With Addition of FTC | 0 | 0 | 0 | 0 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 384 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 336 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 336 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 337 to 384
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites in HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 2 | 1 | 1 | 0 | 0 |
| ADV-TDF With Addition of FTC | 2 | 0 | 1 | 1 | 0 |
| TDF-TDF | 1 | 0 | 0 | 0 | 1 |
| TDF-TDF With Addition of FTC | 0 | 0 | 0 | 0 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 432 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 384 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 384 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 385 to 432
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites in HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 0 | 0 | 0 | 0 | 0 |
| ADV-TDF With Addition of FTC | 1 | 0 | 0 | 1 | 0 |
| TDF-TDF | 1 | 0 | 1 | 0 | 0 |
| TDF-TDF With Addition of FTC | 3 | 0 | 0 | 3 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL, those with viral breakthrough, and those who discontinued after Week 24 with HBV DNA ≥ 400 copies/mL. (NCT00116805)
Timeframe: Baseline; Week 48
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites in HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 75 | 8 | 17 | 43 | 7 |
| TDF-TDF | 31 | 2 | 13 | 7 | 9 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 480 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 432 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 432 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 433 to 480
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites in HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 1 | 0 | 0 | 1 | 0 |
| ADV-TDF With Addition of FTC | 0 | 0 | 0 | 0 | 0 |
| TDF-TDF | 0 | 0 | 0 | 0 | 0 |
| TDF-TDF With Addition of FTC | 3 | 0 | 1 | 2 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 96 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 48 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 49 to 96
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites in HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 16 | 2 | 1 | 12 | 1 |
| ADV-TDF With Addition of FTC | 10 | 3 | 2 | 3 | 2 |
| TDF-TDF | 18 | 2 | 3 | 10 | 3 |
| TDF-TDF With Addition of FTC | 13 | 0 | 1 | 5 | 7 |
ALT normalization was defined as ALT > ULN at baseline and within the normal range at the subsequent time point. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00116805)
Timeframe: Baseline; Weeks 144, 192, 240, 288, 336, and 384
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | |
| ADV-TDF | 67.8 | 69.4 | 65.9 | 70.1 | 67.9 | 67.1 |
| TDF-TDF | 60.2 | 59.6 | 50.0 | 51.3 | 46.2 | 52.6 |
ALT normalization was defined as ALT > ULN at baseline and within the normal range at the subsequent time point. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00116805)
Timeframe: Baseline; Weeks 432 and 480
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 432 | Week 480 | |
| ADV-TDF | 78.6 | 82.8 |
| TDF-TDF | 79.6 | 75.0 |
HBeAg loss was defined as HBeAg positive at baseline and HBeAg negative at Week 96. Seroconversion to anti-HBe was defined as change of detectable antibody to HBeAg from negative at baseline to positive at Week 96. (NCT00116805)
Timeframe: Baseline; Week 96
| Intervention | percentage of participants (Number) | |
|---|---|---|
| HBeAg Loss | Seroconversion to Anti-HBe | |
| ADV-TDF | 25.6 | 22.0 |
| TDF-TDF | 25.9 | 22.8 |
HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at the subsequent time point. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at the subsequent time point. (NCT00116805)
Timeframe: Baseline; Week 96
| Intervention | percentage of participants (Number) | |
|---|---|---|
| HBsAg Loss | Anti-HBs Seroconversion | |
| ADV-TDF | 5.8 | 4.7 |
| TDF-TDF | 5.3 | 4.1 |
HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at the subsequent time point. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at the subsequent time point. (NCT00116805)
Timeframe: Baseline; Weeks 144, 192, 240, 288, 336, 384, 432, and 480
| Intervention | percentage of participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HBsAg Loss - Week 144 | Anti-HBs Seroconversion - Week 144 | HBsAg Loss - Week 192 | Anti-HBs Seroconversion - Week 192 | HBsAg Loss - Week 240 | Anti-HBs Seroconversion - Week 240 | HBsAg Loss - Week 288 | Anti-HBs Seroconversion - Week 288 | HBsAg Loss - Week 336 | Anti-HBs Seroconversion - Week 336 | HBsAg Loss - Week 384 | Anti-HBs Seroconversion - Week 384 | HBsAg Loss - Week 432 | Anti-HBs Seroconversion - Week 432 | HBsAg Loss - Week 480 | Anti-HBs Seroconversion - Week 480 | |
| ADV-TDF | 8.0 | 6.8 | 7.9 | 6.7 | 8.0 | 8.0 | 8.0 | 8.0 | 7.9 | 7.9 | 9.0 | 7.9 | 10.2 | 8.0 | 10.1 | 7.9 |
| TDF-TDF | 7.5 | 5.2 | 9.4 | 6.4 | 9.2 | 6.3 | 9.2 | 6.4 | 10.3 | 7.5 | 11.0 | 8.1 | 10.9 | 7.6 | 10.9 | 8.0 |
(NCT00116805)
Timeframe: Weeks 144, 192, 240, 288, 336, and 384
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | |
| ADV-TDF | 70.5 | 71.6 | 66.3 | 64.8 | 62.1 | 60.5 |
| TDF-TDF | 71.7 | 67.9 | 63.4 | 61.3 | 59.4 | 56.1 |
(NCT00116805)
Timeframe: Weeks 432 and 480
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 432 | Week 480 | |
| ADV-TDF | 100.0 | 96.6 |
| TDF-TDF | 93.0 | 98.0 |
HBeAg loss was defined as HBeAg positive at baseline and HBeAg negative at Week 48. Seroconversion to anti-HBe was defined as change of detectable antibody to HBeAg from negative at baseline to positive at Week 48. (NCT00116805)
Timeframe: Baseline; Week 48
| Intervention | percentage of participants (Number) | |
|---|---|---|
| HBeAg Loss | HBeAg Seroconversion | |
| ADV-TDF | 17.5 | 17.5 |
| TDF-TDF | 22.2 | 20.9 |
HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at Week 48. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at Week 48. (NCT00116805)
Timeframe: Baseline; Week 48
| Intervention | percentage of participants (Number) | |
|---|---|---|
| HBsAg Loss | HBsAg Seroconversion | |
| ADV-TDF | 0 | 0 |
| TDF-TDF | 3.2 | 1.3 |
Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4. (NCT00116805)
Timeframe: Baseline; Week 240
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Yes | No | |
| ADV-TDF | 89.6 | 10.4 |
| TDF-TDF | 88.2 | 11.8 |
Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4. (NCT00116805)
Timeframe: Baseline; Week 48
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Yes | No | |
| ADV-TDF | 67.8 | 32.2 |
| TDF-TDF | 74.4 | 25.6 |
Participants were ranked as having improvement, no change, worsening, or missing data (compared to Baseline) based on the Knodell scoring system, and results are presented as the percentage of participants in each category. The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, which ranges from 0 (best) to 14 (worst). The Knodell fibrosis domain score ranges from 0 (best) to 4 (worst). A decrease of 1 point or more indicated improvement, and an increase of 1 point or more indicated worsening. (NCT00116805)
Timeframe: Baseline; Week 240
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Improvement - Necroinflammation | No Change - Necroinflammation | Worsening - Necroinflammation | Improvement - Fibrosis | No Change - Fibrosis | Worsening - Fibrosis | |
| ADV-TDF | 97.9 | 2.1 | 0 | 58.3 | 39.6 | 2.1 |
| TDF-TDF | 96.1 | 3.9 | 0 | 56.6 | 39.5 | 3.9 |
Participants were ranked as having improvement, no change, worsening, or missing data (compared to Baseline) based on the Knodell scoring system, and results are presented as the percentage of participants in each category. The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, which ranges from 0 (best) to 14 (worst). The Knodell fibrosis domain score ranges from 0 (best) to 4 (worst). A decrease of 1 point or more indicated improvement, and an increase of 1 point or more indicated worsening. (NCT00116805)
Timeframe: Baseline; Week 48
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Improvement - Necroinflammation | No Change - Necroinflammation | Worsening - Necroinflammation | Missing Data - Necroinflammation | Improvement - Fibrosis | No Change - Fibrosis | Worsening - Fibrosis | Missing Data - Fibrosis | |
| ADV-TDF | 78.9 | 3.3 | 5.6 | 12.2 | 20.0 | 61.1 | 6.7 | 12.2 |
| TDF-TDF | 81.3 | 4.5 | 3.4 | 10.8 | 19.9 | 63.6 | 5.1 | 11.4 |
(NCT01023217)
Timeframe: at week 52 from randomization
| Intervention | participants (Number) |
|---|---|
| Adefovir Plus Entecavir | 13 |
| Adefovir Plus Lamivudine | 2 |
Change in level of ISG expression before and after 1st peginterferon injection (NCT02364336)
Timeframe: 6 hours after first injection of peginterferon
| Intervention | log 2 fold change (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PPP1R3G | ALAS1 | INHBB | MMRN1 | LYVE1 | SLC8A1 | PPARGC1A | NOTUM | IGFBP3 | LTBP1 | STARD5 | RTN4RL1 | ZPR1 | |
| HBeAg Negative | -2.716 | 1.670 | -2.20 | -1.597 | -1.184 | -1.382 | -1.573 | 0.870 | -0.723 | -0.548 | 1.798 | 1.808 | -0.972 |
NK cell degranulation is calculated as 100*(degranulated NK cells)/(NK cells). Changes are calculated by subtracting baseline from 6 hours after first peginterferon injection. (NCT02364336)
Timeframe: 6 hours after first injection of peginterferon and baseline
| Intervention | % of NK cells (Mean) | ||
|---|---|---|---|
| Blood baseline | Blood 6 hours | Blood change | |
| HBeAg Positive | 0.08 | 0.06 | -0.02 |
NK cell degranulation is calculated as 100*(degranulated NK cells)/(NK cells). Changes are calculated by subtracting baseline from 6 hours after first peginterferon injection. (NCT02364336)
Timeframe: 6 hours after first injection of peginterferon and baseline
| Intervention | % of NK cells (Mean) | |||||
|---|---|---|---|---|---|---|
| Blood baseline | Blood 6 hours | Blood change | Liver baseline | Liver 6 hours | Liver change | |
| HBeAg Negative | 0.64 | 0.52 | -0.12 | 3.37 | 4.87 | 1.51 |
NK cell frequency is calculated as 100*(NK cells)/(mononuclear cells). Changes are calculated by subtracting baseline from 6 hours after first peginterferon injection. (NCT02364336)
Timeframe: 6 hours after first injection of peginterferon and baseline
| Intervention | percentage of mononuclear cells (Mean) | ||
|---|---|---|---|
| Blood baseline | Blood 6 hours | Blood change | |
| HBeAg Positive | 15.60 | 10.30 | -5.3 |
NK cell frequency is calculated as 100*(NK cells)/(mononuclear cells). Changes are calculated by subtracting baseline from 6 hours after first peginterferon injection. (NCT02364336)
Timeframe: 6 hours after first injection of peginterferon and baseline
| Intervention | percentage of mononuclear cells (Mean) | |||||
|---|---|---|---|---|---|---|
| Blood baseline | Blood 6 hours | Blood change | Liver baseline | Liver 6 hours | Liver change | |
| HBeAg Negative | 11.82 | 13.74 | 1.92 | 24.69 | 24.78 | 0.09 |
Proportion of HBeAg positive patients showing eAg loss at end of treatment, and 24 and 48 weeks off peginterferon treatment. (NCT02364336)
Timeframe: End of treatment, 24 weeks, and 48 weeks
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| End of treatment | Week 24 post treatment | Week 48 post treatment | |
| HBeAg Positive | 0 | 0 | 0 |
Proportion of HBsAg positive patients showing sAG loss at end of treatment and 24 and 48 weeks off peginterferon treatment (NCT02364336)
Timeframe: End of treatment, 24 weeks, and 48 weeks
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| End of treatment | Week 24 post treatment | Week 48 post treatment | |
| HBeAg Negative | 1 | 0 | 0 |
| HBeAg Positive | 0 | 0 | 0 |
(NCT00737568)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 89.4 |
| FTC/Tenofovir DF | 86.3 |
The development of DRMs was summarized, either as development of new DRMs or enrichment of existing DRMs. (NCT00737568)
Timeframe: Baseline to Week 240
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| New tenofovir DF DRMs | Enrichment of tenofovir DF DRMs | New FTC DRMs | Enrichment of FTC DRMs | |
| FTC/Tenofovir DF | 0 | 0 | 0 | 1 |
| Tenofovir DF | 0 | 0 | 0 | 0 |
(NCT00737568)
Timeframe: Weeks 48, 96, 144, 192, and 240
| Intervention | log10 copies/mL (Mean) | ||||
|---|---|---|---|---|---|
| Week 48 (TDF: n=130; FTC/TDF: n=133) | Week 96 (TDF: n=132; FTC/TDF: n=127) | Week 144 (TDF: n=128; FTC/TDF: n=123) | Week 192 (TDF: n=126; FTC/TDF: n=119) | Week 240 (TDF: n=118; FTC/TDF: n=116) | |
| FTC/Tenofovir DF | 2.48 | 2.28 | 2.29 | 2.23 | 2.26 |
| Tenofovir DF | 2.42 | 2.29 | 2.26 | 2.25 | 2.23 |
BMD is calculated as g/cm^2; the mean (SD) percentage change is presented. (NCT00737568)
Timeframe: Baseline; Weeks 24, 48, 72, 96, 144, 192, and 240
| Intervention | percentage change (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| % Change at Week 24 (TDF: n=130; FTC/TDF: n=127) | % Change at Week 48 (TDF: n=126; FTC/TDF: n=118) | % Change at Week 72 (TDF: n=121; FTC/TDF: n=115) | % Change at Week 96 (TDF: n=125; FTC/TDF: n=112) | % Change at Week 144 (TDF: n=120; FTC/TDF: n=107) | % Change at Week 192 (TDF: n=116; FTC/TDF: n=105) | % Change at Week 240 (TDF: n=111; FTC/TDF: n=100) | |
| FTC/Tenofovir DF | -0.59 | -1.00 | -1.61 | -1.77 | -1.91 | -2.41 | -2.63 |
| Tenofovir DF | -0.71 | -1.15 | -1.59 | -1.70 | -2.02 | -2.33 | -2.46 |
BMD is calculated as grams per cubic centimeter (g/cm^2); the mean (SD) percentage change is presented. (NCT00737568)
Timeframe: Baseline; Weeks 24, 48, 72, 96, 144, 192, and 240
| Intervention | percentage change (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| % Change at Week 24 (TDF: n=132; FTC/TDF: n=127) | % Change at Week 48 (TDF: n=126; FTC/TDF: n=121) | % Change at Week 72 (TDF: n=123; FTC/TDF: n=119) | % Change at Week 96 (TDF: n=126; FTC/TDF: n=114) | % Change at Week 144 (TDF: n=123; FTC/TDF: n=110) | % Change at Week 192 (TDF: n=120; FTC/TDF: n=106) | % Change at Week 240 (TDF: n=115; FTC/TDF: n=102) | |
| FTC/Tenofovir DF | -1.83 | -1.73 | -1.95 | -1.72 | -1.63 | -1.60 | -1.15 |
| Tenofovir DF | -1.74 | -1.68 | -1.35 | -1.24 | -1.36 | -1.32 | -0.83 |
The percentage of participants who were HBeAg positive at baseline and who had HBeAg Loss at the given time point was summarized. Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. (NCT00737568)
Timeframe: Baseline; Weeks 48, 96, 144, 192, and 240
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 48 | Week 96 | Week 144 | Week 192 | Week 240 | |
| FTC/Tenofovir DF | 5.9 | 13.2 | 17.6 | 14.7 | 19.1 |
| Tenofovir DF | 9.2 | 15.4 | 23.1 | 21.5 | 24.6 |
(NCT00737568)
Timeframe: Weeks 48, 96, 144, 192, and 240
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 48 | Week 96 | Week 144 | Week 192 | Week 240 | |
| FTC/Tenofovir DF | 77.7 | 83.5 | 84.9 | 84.2 | 82.0 |
| Tenofovir DF | 76.6 | 85.8 | 86.5 | 85.1 | 81.6 |
(NCT00737568)
Timeframe: Weeks 48, 144, 192, and 240
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Week 48 | Week 144 | Week 192 | Week 240 | |
| FTC/Tenofovir DF | 84.2 | 84.9 | 85.6 | 82.7 |
| Tenofovir DF | 81.6 | 87.2 | 86.5 | 83.0 |
The percentage of participants with HBsAg Loss at the given time point was summarized. Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. (NCT00737568)
Timeframe: Baseline; Weeks 48, 96, 144, 192, and 240
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 48 | Week 96 | Week 144 | Week 192 | Week 240 | |
| FTC/Tenofovir DF | 0.7 | 0.7 | 1.4 | 2.9 | 2.9 |
| Tenofovir DF | 0.0 | 0.0 | 0.7 | 0.7 | 1.4 |
Normal ALT was defined as having a value less than or equal to the ULN. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00737568)
Timeframe: Weeks 48, 96, 144, 192, and 240
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 48 | Week 96 | Week 144 | Week 192 | Week 240 | |
| FTC/Tenofovir DF | 69.8 | 69.8 | 75.5 | 76.3 | 71.9 |
| Tenofovir DF | 67.4 | 70.2 | 70.2 | 75.9 | 71.6 |
The percentage of participants who were HBeAg positive at baseline and who had seroconversion to anti-HBe at the given time point was summarized. Seroconversion to anti-HBe was defined as change of detectable antibody to HBeAg from negative to positive. (NCT00737568)
Timeframe: Baseline; Weeks 48, 96, 144, 192, and 240
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 48 | Week 96 | Week 144 | Week 192 | Week 240 | |
| FTC/Tenofovir DF | 4.4 | 10.3 | 11.8 | 10.3 | 10.3 |
| Tenofovir DF | 6.2 | 10.8 | 12.3 | 10.8 | 12.3 |
The percentage of participants with seroconversion to anti-HBs at the given time point was summarized. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative to positive. (NCT00737568)
Timeframe: Baseline; Weeks 48, 96, 144, 192, and 240
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 48 | Week 96 | Week 144 | Week 192 | Week 240 | |
| FTC/Tenofovir DF | 0.0 | 0.0 | 0.7 | 0.7 | 0.7 |
| Tenofovir DF | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
The percentage of participants with virologic breakthrough at the given time point was summarized. Virologic breakthrough was defined as having two consecutive 1.0 log10 or greater increases in serum HBV DNA from on-treatment nadir, or two consecutive HBV DNA values ≥ 400 copies/mL after being < 400 copies/mL. (NCT00737568)
Timeframe: Baseline; Weeks 48, 96, 144, 192, and 240
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 48 (TDF: n=130; FTC/TDF: n=133) | Week 96 (TDF: n=132; FTC/TDF: n=127) | Week 144 (TDF: n=128; FTC/TDF: n=123) | Week 192 (TDF: n=126; FTC/TDF: n=119) | Week 240 (TDF: n=118; FTC/TDF: n=116) | |
| FTC/Tenofovir DF | 0.8 | 0.0 | 0.8 | 0.0 | 0.0 |
| Tenofovir DF | 0.0 | 0.0 | 0.8 | 0.8 | 0.0 |
The FibroTest score is used to assess liver fibrosis and is calculated based on a formula including the participant's age and sex and 5 laboratory parameters: alpha 2 macroglobulin, haptoglobin, gamma-glutamyl transferase (GGT), bilirubin, and apolipoprotein A1. Scores can range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. (NCT00736190)
Timeframe: Baseline and Week 48
| Intervention | Scores on a scale (Mean) |
|---|---|
| Tenofovir DF | -0.006 |
Number of participants with normal ALT (at or below the upper limit of normal [ULN] for the central laboratory [34 U/L])at Week 48 (NCT00736190)
Timeframe: Week 48
| Intervention | Participants (Number) |
|---|---|
| Tenofovir DF | 59 |
A normal value at Week 48 after having elevated ALT at baseline; normal ALT is defined as being at or below the ULN for the central laboratory (34 U/L) (NCT00736190)
Timeframe: Week 48
| Intervention | participants (Number) |
|---|---|
| Tenofovir DF | 40 |
Blood samples were collected for evaluating serum chemistry, including determination of ALT, and for measuring HBV DNA via PCR method. Composite endpoints proposed in the protocol included the percentage of participants with HBV DNA < 400 copies/mL (<69 IU/mL) and normal ALT (ALT <= ULN [34 U/L]); and with HBV DNA < 400 copies/mL, normal ALT, and HBeAg loss/seroconversion. Because so few participants lost hepatitis B e antigen (HBeAg) or developed antibody to hepatitis B e antigen (anti-HBe), only the composite endpoint of HBV DNA < 400 copies/mL and normal ALT was analyzed. (NCT00736190)
Timeframe: Week 48
| Intervention | Participants (Number) |
|---|---|
| Tenofovir DF | 55 |
Blood samples from study participants were collected for measuring HBV DNA via PCR method. (NCT00736190)
Timeframe: Week 48
| Intervention | Participants (Number) |
|---|---|
| Tenofovir DF | 73 |
Blood samples were collected from study participants for measuring HBV DNA via polymerase chain reaction (PCR) method. (NCT00736190)
Timeframe: Week 48
| Intervention | Participants (Number) |
|---|---|
| Tenofovir DF | 74 |
HBeAg/HBsAg loss is defined for an individual participant as HBeAg+/HBsAg+ at baseline and HBeAg-/HBsAg- at Week 48. HBeAg/HBsAg serocoversion is defined for an individual participant as HBeAg+/HBsAg+ at baseline and HBeAg-/HBsAg- and anti-HBe+/antibody to hepatitis B surface antigen+ (anti-HBs+) at Week 48. (NCT00736190)
Timeframe: Week 48
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| HBsAg+ at baseline | HBsAg- at baseline | HBsAg+ at Week 48 | HBsAg data missing at Week 48 | HBeAg+ at baseline | HBeAg- at baseline | HBeAg loss by Week 48 | Anti-HBe+ seroconversion by Week 48 | |
| Tenofovir DF | 90 | 0 | 88 | 2 | 53 | 37 | 6 | 6 |
Serum was collected for HBV resistance surveillance, and sequence analysis of the HBV polymerase was assessed through di-deoxy sequencing of baseline and postbaseline samples. (NCT00736190)
Timeframe: Week 48
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| No changes in HBV pol/RT | Changes at polymorphic sites | Changes at conserved sites | Unable to genotype | |
| Tenofovir DF | 1 | 0 | 0 | 1 |
Serum was collected for HBV resistance surveillance, and sequence analysis of the HBV polymerase was assessed through di-deoxy sequencing of baseline and postbaseline samples. (NCT00736190)
Timeframe: Week 48
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| No changes in HBV pol/RT | Changes at polymorphic sites | Changes at conserved sites | Unable to genotype | |
| Tenofovir DF | 2 | 0 | 0 | 0 |
Serum was collected for HBV resistance surveillance, and sequence analysis of the HBV polymerase was assessed through di-deoxy sequencing of baseline and postbaseline samples. (NCT00736190)
Timeframe: Week 48
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| No changes in HBV pol/RT | Changes at polymorphic sites | Changes at conserved sites | Unable to genotype | |
| Tenofovir DF | 6 | 1 | 2 | 1 |
"Change from Baseline of log 10 copies/mL HBV DNA at Weeks 48, 96, 144, 192 and 240 in the HBeAg-positive and HBeAg-negative population was assessed. HBeAg is a viral protein that is secreted by hepatitis B-infected cells. It is associated with chronic hepatitis B infections and is used as a marker of active viral disease and a participant's degree of infectiousness. A positive result indicates that the participant has high levels of virus in the blood and greater infectiousness. Usually a negative result indicates that the participant has lower levels of virus in the blood and less infectious. Values at Day 0 were considered as Baseline values. Change from Baseline was calculated as post Baseline values minus Baseline values. A non-completers equal failures approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed." (NCT01300234)
Timeframe: Baseline, Weeks 48, 96, 144, 192 and 240
| Intervention | log10 copies/mL (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 48,HBeAg-positive, n=102, 97 | Week 48,HBeAg-negative, n=151, 148 | Week 96, HBeAg-positive, n=101, 97 | Week 96, HBeAg-negative, n=147,148 | Week 144, HBeAg-postive, n=100, 96 | Week 144, HBeAg-negative, n=145, 146 | Week 192, HBeAg-positive, n=97,93 | Week 192, HBeAg-negative, n=145,145 | Week 240, HBeAg-positive, n=91,90 | Week 240, HBeAg-negative, n=138,138 | |
| ADV-TDF | -4.4 | -4.3 | -6.5 | -4.8 | -6.5 | -4.9 | -6.6 | -4.8 | -6.5 | -4.9 |
| TDF-TDF | -6.4 | -4.9 | -6.5 | -4.9 | -6.6 | -4.9 | -6.6 | -4.9 | -6.6 | -4.9 |
HBsAg loss is defined as a negative HBsAg result for those participants with who were HBsAg positive at Baseline. Seroconversion to anti-HBs is defined as HBsAg loss and a positive anti-HBs result. This report includes data up to and including Week 240. (NCT01300234)
Timeframe: Weeks 24, 48, 96, 144, 192 and 240
| Intervention | Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 24, HBsAg loss | Week 24, HBsAg seroconversion | Week 48, HBsAg loss | Week 48, HBsAg seroconversion | Week 96, HBsAg loss | Week 96, HBsAg seroconversion | Week 144, HBsAg loss | Week 144, HBsAg seroconversion | Week 192, HBsAg loss | Week 192, HBsAg seroconversion | Week 240, HBsAg loss | Week 240, HBsAg seroconversion | |
| ADV-TDF | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| TDF-TDF | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HBeAg loss is defined as a negative HBeAg result for those participants who were HBeAg positive at Baseline. Seroconversion to anti-HBe is defined as HBeAg loss and a positive anti-HBe result. This report includes data up to and including Weeks 24, 48, 96, 144, 192 and 240. (NCT01300234)
Timeframe: Weeks 24, 48, 96, 144, 192 and 240
| Intervention | Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 24, HBeAg loss | Week 24, HBeAg seroconversion | Week 48, HBeAg loss | Week 48, HBeAg seroconversion | Week 96, HBeAg loss | Week 96, HBeAg seroconversion | Week 144, HBeAg loss | Week 144, HBeAg seroconversion | Week 192, HBeAg loss | Week 192, HBeAg seroconversion | Week 240, HBeAg loss | Week 240, HBeAg seroconversion | |
| ADV-TDF | 4 | 4 | 10 | 9 | 21 | 18 | 24 | 20 | 31 | 24 | 36 | 28 |
| TDF-TDF | 15 | 14 | 18 | 16 | 37 | 32 | 37 | 33 | 43 | 33 | 43 | 33 |
HBsAg loss is defined as negative HBsAg results for those participants with who were HBsAg positive at Baseline. Seroconversion to anti-HBs is defined as HBsAg loss and a positive anti-HBs result. This report includes data up to and including Week 240. (NCT01300234)
Timeframe: Weeks 24, 48, 96, 144, 192 and 240
| Intervention | Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 24, HBsAg loss | Week 24, HBsAg seroconversion | Week 48, HBsAg loss | Week 48, HBsAg seroconversion | Week 96, HBsAg loss | Week 96, HBsAg seroconversion | Week 144, HBsAg loss | Week 144, HBaAg seroconversion | Week 192, HBsAg, loss | Week 192, HBsAg, seroconversion | Week 240, HBsAg loss | Week 240 HBsAg seroconversion | |
| ADV-TDF | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| TDF-TDF | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
"Durable HBsAg loss is defined as the loss of HBsAg and no detectable HBV DNA and ALT normalization at any three consecutive visits at least 12 Weeks apart. This report includes data up to and including Week 48. A non-completers equal failures approach was used for the analysis in ITT population." (NCT01300234)
Timeframe: Week 24 to Week 48
| Intervention | Participants (Number) | |
|---|---|---|
| HBeAg-positive, n =100, 97 | HBeAg-negative, n=150, 147 | |
| ADV 10 mg | 0 | 0 |
| TDF 300 mg | 0 | 0 |
"Durable HBsAg loss is defined as the loss of HBsAg and no detectable HBV DNA and ALT normalization at any three consecutive visits at least 12 Weeks apart from Week 96 to 240. This report includes data up to and including Week 240. A non-completers equal failures approach was used for the analysis in ITT population." (NCT01300234)
Timeframe: Week 96 to Week 240
| Intervention | Participants (Number) | |
|---|---|---|
| HBeAg-positive, n= 88, 90 | HBeAg-negative, n = 132, 137 | |
| ADV-TDF | 0 | 1 |
| TDF-TDF | 1 | 0 |
"The Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, version 21, September 2011 was used for grading. Confirmed is defined as two consecutive visits. mg=milligrams. dL=deciliter, G= Grade." (NCT01300234)
Timeframe: Up to Week 240
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Creatinine increase of 0.5 mg/dL above Baseline | Confirmed creatinine >=2.0 mg/dL | Confirmed clearance <50 milliliters/minute | Confirmed phosphorus G 3/4 abnormality, <2.0 mg/dL | |
| ADV-TDF | 0 | 0 | 0 | 0 |
| TDF-TDF | 1 | 0 | 0 | 3 |
"Participants who had abnormal ALT at Baseline and had normalized ALT at Weeks 48, 96, 144, 192 and 240 were assessed. This report includes data up to and including Weeks 48, 96, 144, 192 and 240. An increased level of ALT is referred to as abnormal ALT (the normal range is 0 to 48 units per liter [U/L]). Values at Day 0 were considered as Baseline values. A non-completers equal failures approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed." (NCT01300234)
Timeframe: Baseline; Weeks 48, 96, 144, 192 and 240
| Intervention | Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 48, HBeAg-positive, n=102, 97 | Week 48, HBeAg-negative, n=136, 132 | Week 96, HBeAg-positive, n=102, 97 | Week 96, HBeAg-negative, n=136,132 | Week 144, HBeAg-positive, n=102, 97 | Week 144, HBeAg-negative, n=136, 132 | Week 192, HBeAg-positive, n=102, 97 | Week 192, HBeAg-negative, n=136,132 | Week 240, HBeAg-positive, n=102, 97 | Week 240, HBeAg-negative, n=136,132 | |
| ADV-TDF | 83 | 116 | 88 | 118 | 87 | 119 | 79 | 118 | 80 | 111 |
| TDF-TDF | 88 | 120 | 93 | 126 | 92 | 123 | 89 | 125 | 82 | 119 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is Grade 4 (life threatening or disabling). Participants with any non-serious AEs and SAEs has been reported. (NCT01300234)
Timeframe: Up to Week 240 treatment period and 24 weeks follow-up visit off treatment
| Intervention | Participants (Number) | |
|---|---|---|
| Non-serious AE | SAE | |
| ADV-TDF | 121 | 20 |
| TDF-TDF | 140 | 12 |
Histological improvement is defined as a reduction of >=2 points in the KNS with no increase in fibrosis at Week 48 and Week 240 in participants with Baseline KNS >=2 which was derived from the American Association for the Study of Liver Diseases Practice Guidelines for Management of Chronic Hepatitis B (2009) and the European Association for the Study of the Liver Clinical Practice Guidelines Management of chronic hepatitis B virus infection (2012). The Knodell scale consists of 5 domains: periportal +/- bridging necrosis (scored from best to worst: 0, 1, 3, 4, 5, 6, or 10); intralobular degeneration and focal necrosis (0 to 4); portal inflammation (0 to 4); and fibrosis (0 to 4). The necroinflammatory score (ranging from 0 [best] to 14 [worst]) is the combined score for necrosis (0 to 10) plus inflammation (0 to 4; the participant is scored for only one inflammatory condition). Liver biopsy slides within 6 months prior to randomization could be accepted as Baseline evaluation. (NCT01300234)
Timeframe: Baseline; Week 48 and Week 240
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Week 48, HBeAg-positive, n=38, 49 | Week 48, HBeAg-negative, n=45, 50 | Week 240, HBeAg-positive, n=38, 49 | Week 240, HBeAg-negative, n=45, 50 | |
| ADV-TDF | 39 | 34 | 2 | 4 |
| TDF-TDF | 31 | 32 | 5 | 8 |
TE grade 3 or grade 4 LAs are defined as values that increase by >=1 grade from Baseline (Day 0) to Grade 3 (severe) or 4 (potentially life threatening) at any post-Baseline value. The Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, version 21, September 2011 was referred for grading. Laboratory parameters assessed included Sodium for hyponatremia and hypernatremia; Potassium for hypokalemia and hyperkalemia; glucose for hypoglycemia and hyperglycemia non-fasting; Phosphate for hypophosphatemia; alanine aminotransferase/aspartate aminotransferase, bilirubin, creatinine kinase, hemoglobin, platelets, neutrophils, lymphocytes, prothrombin time and amylase. (NCT01300234)
Timeframe: Up to Week 240
| Intervention | participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sodium | Phosphate | Alanine aminotransferase | Aspartate aminotransferase | Bilirubin | Creatine kinase | Hemoglobin | Platelets | Neutrophils | Prothrombin time | Potassium | Glucose | Lymphocytes | Amylase | |
| ADV-TDF | 0 | 3 | 14 | 6 | 1 | 4 | 5 | 3 | 4 | 17 | 0 | 2 | 3 | 2 |
| TDF-TDF | 2 | 2 | 19 | 10 | 1 | 6 | 4 | 4 | 6 | 10 | 1 | 1 | 2 | 1 |
The Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, version 21, September 2011 was referred for grading. Serum creatinine: Grade 1, > 133 to 177 micromoles per Liter (µmoles/Liter), Grade 2, >177 to 265 µmoles/Liter, Grade 3, >265 to 530 µmoles/Liter, Grade 4, >530 µmoles/Liter. Serum phosphorus: Grade 2, 0.63 to <0.80 millimoles per Liter (mmoles/L), Grade 3, 0.31 to <0.63 mmoles/L, Grade 4, <0.31 mmoles/L. The normal range for serum phosphorus was 0.8 to 1.45 mmoles/L; the upper limit for a Grade 2 abnormality is 0.80 mmoles/L. Therefore, no Grade 1 abnormalities could be attributed, as values were contained within the normal range. NA indicates the value was not available for the indicated time point. (NCT01300234)
Timeframe: Up to Week 240
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Serum creatinine, Grade 1 | Serum creatinine, Grade 2 | Serum creatinine, Grade 3 | Serum creatinine, Grade 4 | Serum phosphorus, Grade 1 | Serum phosphorus, Grade 2 | Serum phosphorus, Grade 3 | Serum phosphorus, Grade 4 | |
| ADV-TDF | 1 | 0 | 0 | 0 | NA | 55 | 3 | 0 |
| TDF-TDF | 0 | 0 | 0 | 0 | NA | 42 | 2 | 0 |
"The number of HBeAg-positive and HBeAg-negative participants who had virological breakthrough at Weeks 48, 96, 144, 192 and 240 were assessed. Virological breakthrough is defined by >= one log increase in HBV DNA from NADIR (as determined by two sequential HBV DNA measurements at least one month apart or last on treatment measurement). A non-completers equal failures approach was used for the analysis in ITT population." (NCT01300234)
Timeframe: Weeks 48, 96, 144, 192 and 240
| Intervention | Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 48,HBeAg-Positive, n=103, 99 | Week 48, HBeAg-Negative, n=154, 153 | Week 96, HBeAg-positive, n=103, 99 | Week 96, HBeAg-negative, n=154, 153 | Week 144, HBeAg-positive, n=103, 99 | Week 144, HBeAg-negative, n=154, 153 | Week 192, HBeAg-positive, n=103, 99 | Week 192, HBeAg-negative, n=154, 153 | Week 240, HBeAg-positive, n=103, 99 | Week 240, HBeAg-negative, n=154, 153 | |
| ADV-TDF | 4 | 2 | 4 | 3 | 7 | 4 | 7 | 5 | 11 | 8 |
| TDF-TDF | 0 | 0 | 0 | 2 | 0 | 3 | 0 | 3 | 4 | 3 |
"The number of participants with HBV DNA <400 copies/mL in the hepatitis B e antigen (HBeAg)-positive and HBeAg-negative population was assessed. HBeAg is a viral protein that is secreted by hepatitis B-infected cells. It is associated with chronic hepatitis B infections and is used as a marker of active viral disease and a participant's degree of infectiousness. A positive result indicates that the participant has high levels of virus in the blood and greater infectiousness. Usually, a negative result indicates that the participant has lower levels of virus in the blood and is less infectious. Week 96, 144, 192, and 240 data are not yet available, as this report includes data up to and including Week 48. A non-completers equal failures approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed." (NCT01300234)
Timeframe: Weeks 96, 144, 192, and 240
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 96, HBeAg-positive, n=103, 99 | Week 96, HBeAg-negative, n=154, 153 | Week 144, HBeAg-positive, n=103, 99 | Week 144, HBeAg-negative, n=154,153 | Week 192, HBeAg-positive, n=103,99 | Week 192,HBeAg-negative, n=154,153 | Week 240, HBeAg-positive, n=103,99 | Week 240, HBeAg-negative, n=154,153 | |
| ADV-TDF | 92 | 143 | 95 | 145 | 93 | 141 | 87 | 137 |
| TDF-TDF | 95 | 144 | 97 | 144 | 94 | 144 | 87 | 138 |
"The number of participants with Hepatitis B Virus (HBV) deoxyribonucleic acid (DNA) <400 copies/milliliter (mL) at Week 48 in the hepatitis B e antigen (HBeAg)-positive and HBeAg-negative population was assessed. HBeAg is a viral protein that is secreted by hepatitis B-infected cells. It is associated with chronic hepatitis B infections and is used as a marker of active viral disease and a participant's degree of infectiousness. A positive result indicates that the participant has high levels of virus in the blood and greater infectiousness. Usually, a negative result indicates that the participant has lower levels of virus in the blood and is less infectious. A non-completers equal failures approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed." (NCT01300234)
Timeframe: Week 48
| Intervention | Participants (Number) | |
|---|---|---|
| HBeAg-positive, n=103, 99 | HBeAg-negative, n=154, 153 | |
| ADV 10 mg | 18 | 109 |
| TDF 300 mg | 79 | 149 |
(NCT00307489)
Timeframe: 168 weeks
| Intervention | U/mL (Mean) |
|---|---|
| Tenofovir DF | -26.8 |
| Emtricitibine/Tenofovir DF | -54.5 |
(NCT00307489)
Timeframe: 48 Weeks
| Intervention | U/mL (Mean) |
|---|---|
| Tenofovir DF | -21.6 |
| Emtricitibine/Tenofovir DF | -41.4 |
(NCT00307489)
Timeframe: 168 weeks
| Intervention | log10 copies/mL (Mean) |
|---|---|
| Tenofovir DF | -3.79 |
| Emtricitibine/Tenofovir DF | -3.48 |
(NCT00307489)
Timeframe: 48 Weeks
| Intervention | log10 copies/mL (Mean) |
|---|---|
| Tenofovir DF | -3.58 |
| Emtricitibine/Tenofovir DF | -3.34 |
Defined as having negative serum HBeAg and positive serum antibody to HBeAg [anti-HBe] for subjects with positive serum HBeAg at baseline. (NCT00307489)
Timeframe: 48 Weeks
| Intervention | participants (Number) |
|---|---|
| Tenofovir DF | 2 |
| Emtricitibine/Tenofovir DF | 3 |
Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline. (NCT00307489)
Timeframe: 168 weeks
| Intervention | Participants (Number) |
|---|---|
| Tenofovir DF | 1 |
| Emtricitibine/Tenofovir DF | 0 |
Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline. (NCT00307489)
Timeframe: 48 Weeks
| Intervention | participants (Number) |
|---|---|
| Tenofovir DF | 1 |
| Emtricitibine/Tenofovir DF | 0 |
Defined as having negative serum HBeAg for subjecst with positive HBeAg at baseline. (NCT00307489)
Timeframe: 168 weeks
| Intervention | Percent of Participants (Number) |
|---|---|
| Tenofovir DF | 21.6 |
| Emtricitibine/Tenofovir DF | 24.3 |
Defined as having negative serum HBeAg for subjects with positive HBeAg at baseline. (NCT00307489)
Timeframe: 48 Weeks
| Intervention | participants (Number) |
|---|---|
| Tenofovir DF | 3 |
| Emtricitibine/Tenofovir DF | 3 |
Defined as having negative serum BHsAg and positive serum antibody to HBsAg (anti-HBs) for subject with positive serum BHsAg at baseline. (NCT00307489)
Timeframe: 168 weeks
| Intervention | Participants (Number) |
|---|---|
| Tenofovir DF | 1 |
| Emtricitibine/Tenofovir DF | 0 |
Defined as having negative serum HBsAg and positive serum antibody to HBsAg [anti-HBs] for subject with positive serum HBsAg at baseline. (NCT00307489)
Timeframe: 48 Weeks
| Intervention | participants (Number) |
|---|---|
| Tenofovir DF | 1 |
| Emtricitibine/Tenofovir DF | 0 |
ULN for males = 43 U/L; ULN for females = 34 U/L (NCT00307489)
Timeframe: 168 weeks
| Intervention | Percent of Participants (Number) |
|---|---|
| Tenofovir DF | 74.0 |
| Emtricitibine/Tenofovir DF | 74.0 |
ULN for males = 43 U/L; 34 U/L for females (NCT00307489)
Timeframe: 48 Weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 66.7 |
| Emtricitibine/Tenofovir DF | 73.1 |
Subjects with elevated ALT at baseline that return to normal by Week 48. (NCT00307489)
Timeframe: 168 weeks
| Intervention | Percent of Participants (Number) |
|---|---|
| Tenofovir DF | 68.0 |
| Emtricitibine/Tenofovir DF | 70.8 |
Subjects with elevated ALT at baseline that return to normal by Week 48. (NCT00307489)
Timeframe: 48 Weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 40.7 |
| Emtricitibine/Tenofovir DF | 61.5 |
P-values were from a Cochran-Mantel-Haenszel test, controlling for baseline HBeAg status and prior lamivudine use. (NCT00307489)
Timeframe: 168 weeks
| Intervention | Percent of Participants (Number) |
|---|---|
| Tenofovir DF | 80.4 |
| Emtricitibine/Tenofovir DF | 78.0 |
(NCT00307489)
Timeframe: 48 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 75.5 |
| Emtricitibine/Tenofovir DF | 69.2 |
(NCT00307489)
Timeframe: 168 weeks
| Intervention | Percent of Participants (Number) |
|---|---|
| Tenofovir DF | 82.4 |
| Emtricitibine/Tenofovir DF | 84.0 |
(NCT00307489)
Timeframe: 48 Weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 81.1 |
| Emtricitibine/Tenofovir DF | 80.8 |
Number of participants with ALT ≤ 1 x upper limit of normal (ULN) (NCT00096785)
Timeframe: Week 48
| Intervention | participants (Number) |
|---|---|
| Entecavir | 25 |
| Adefovir | 20 |
Antiviral efficacy, as measured by the mean reduction in serum HBV DNA levels by PCR (log10 copies/mL) at Week 48, adjusted for baseline (Week 48 - Baseline). A negative value = improvement. (NCT00096785)
Timeframe: Baseline, Week 48
| Intervention | log10 c/mL (Mean) |
|---|---|
| Entecavir | -7.28 |
| Adefovir | -5.08 |
Antiviral efficacy, as measured by the mean reduction in serum HBV DNA levels by PCR (log10 copies/mL) at Week 12, adjusted for baseline (Week 12 - baseline). A negative value = improvement. (NCT00096785)
Timeframe: Baseline, Week 12
| Intervention | log10 copies/mL (Mean) |
|---|---|
| Entecavir | -6.23 |
| Adefovir | -4.52 |
The biphasic decline of HBV DNA is characterized via a 4-parameter exponential decay model previously published for HBV compounds. An important derived parameter is the half-life of free virus (ie, the average amount of time for HBV particles in plasma to be reduced to half the initial level), calculated as 24*ln(2)/c. The model parameters reflect the biphasic pattern that is typically observed after initiation of antiviral therapy. Parameters were estimated for each subject separately and then averaged within each treatment group. (NCT00096785)
Timeframe: Week 12
| Intervention | hours (Number) |
|---|---|
| Entecavir | 14.52 |
| Adefovir | 32.46 |
Number of Subjects with HBV DNA <300 copies/mL by Roche COBAS® Amplicor (limit of quantitation 300 copies/mL) (NCT00096785)
Timeframe: Week 48
| Intervention | Participants (Number) |
|---|---|
| Entecavir | 19 |
| Adefovir | 6 |
This analysis uses a 3-parameter piece-wise linear model and describes the biphasic decline in HBV DNA (measured by PCR assay) through Week 12. The 3 parameters are the values for the 2 slopes, describing the first and second phase declines, respectively, and the estimated HBV DNA at the knot (at day 10; the time point where the 2 phases join). The biphasic viral decay kinetics for each treatment were obtained using a spline fitting procedure to estimate the 3 parameters for each subject; these estimates were then averaged within each treatment group. (NCT00096785)
Timeframe: Week 12
| Intervention | log10 copies/mL (Number) | |
|---|---|---|
| First slope (first phase of viral decay) | Second slope (second phase of viral decay) | |
| Adefovir | -0.329 | -0.024 |
| Entecavir | -0.391 | -0.034 |
The biphasic decline of HBV DNA is characterized via a 4-parameter exponential decay model previously published for HBV compounds. The model parameters of interest are the effectiveness of the drug in blocking virus production from infected cells (efficacy, ε) and effectiveness of the study treatment in blocking de novo infection of susceptible cells (η). The model parameters reflect the biphasic pattern that is typically observed after initiation of antiviral therapy. Parameters were estimated for each subject separately and then averaged within each treatment group. (NCT00096785)
Timeframe: Week 12
| Intervention | percent effective (Number) | |
|---|---|---|
| Efficacy in blocking virus production - ε | Effectiveness in blocking de novo infections - η | |
| Adefovir | 99.46 | 5.87 |
| Entecavir | 99.87 | 6.07 |
The biphasic decline of HBV DNA is characterized via a 4-parameter exponential decay model previously published for HBV compounds. The model parameters of interest are the clearance rate of the free virus (c), the death rate of productively infected cells (δ), The model parameters reflect the biphasic pattern that is typically observed after initiation of antiviral therapy. Parameters were estimated for each subject separately and then averaged within each treatment group. (NCT00096785)
Timeframe: Week 12
| Intervention | per day (Number) | |
|---|---|---|
| Viral Clearance - c | Infected cell death - δ | |
| Adefovir | 0.91 | 0.04 |
| Entecavir | 1.70 | 0.08 |
Laboratory abnormalities reported as clinical AEs (NCT00096785)
Timeframe: Week 48
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| ALT increased | Lipase increased | Blood phosphorus decreased | Liver function test abnormal | Platelet count decreased | Protein urine present | |
| Adefovir | 2 | 2 | 1 | 1 | 1 | 1 |
| Entecavir | 1 | 1 | 0 | 0 | 0 | 0 |
AE=new untoward medical occurrence or worsening of pre-existing medical condition regardless of causal relationship to treatment. SAE=untoward medical occurrence that is life-threatening, a congenital anomaly/birth defect, or an important medical event, or results in death, inpatient hospitalization/prolongation of hospitalization, or persistent/significant disability. AE grades: mild (1), moderate (2), severe (3), life-threatening (4), death (5). ALT flare= >2x baseline & >10x ULN up to end of therapy + 5 days. Hepatic SAE=SAEs consistent with worsening of hepatitis or hepatic decompensation. (NCT00096785)
Timeframe: cumulative through the end of on-treatment observation as available at the time of the Week 48 dataset
| Intervention | Participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Death | Serious AE | Discontinuation due to AE | Malignant neoplasm | On Treatment: Any AE | On Treatment: Headache | On Treatment: Upper Respiratory Infection | On Treatment: Influenza | On Treatment: Nasopharyngitis | On Treatment: Pyrexia | On Treatment: Back Pain | On Treatment: Grade 3-4 AEs | ALT Flare | Hepatic SAE | |
| Adefovir | 0 | 3 | 1 | 0 | 27 | 6 | 8 | 4 | 6 | 6 | 5 | 5 | 1 | 2 |
| Entecavir | 0 | 1 | 0 | 0 | 28 | 9 | 8 | 6 | 4 | 4 | 0 | 2 | 0 | 1 |
Biochemical response is defined as normalization of ALT level at week 12 compared to baseline. (NCT02881008)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A | 3 |
| Arm B | 4 |
| Arm C | 4 |
| Arm D | 4 |
| Arm E | 2 |
| Arm F | 4 |
Biochemical response is defined as normalization of ALT level at week 24 compared to baseline. (NCT02881008)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm D | 5 |
| Arm F | 3 |
Virological cccDNA response is defined as reduction of intrahepatic cccDNA by 0.5 logs in comparison to baseline at week 24. (NCT02881008)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm F | 0 |
HBsAg response is defined as serum HBsAg decline of at least 0.5 logs IU/ml (or HBsAg negativation) at week 12 compared to baseline. (NCT02881008)
Timeframe: 12 week
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A | 0 |
| Arm B | 0 |
| Arm C | 1 |
| Arm D | 0 |
| Arm E | 0 |
| Arm F | 0 |
HBsAg response is defined as serum HBsAg decline of at least 0.5 logs IU/ml (or HBsAg negativation) at week 24 compared to baseline. (NCT02881008)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm D | 0 |
| Arm F | 0 |
HBV DNA response is defined as persistent reduction of HBV DNA by >1 log IU/ml or negativation at week 12 compared to baseline. (NCT02881008)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A | 2 |
| Arm B | 0 |
| Arm C | 2 |
| Arm D | 8 |
| Arm E | 1 |
| Arm F | 6 |
HBV DNA response is defined as persistent reduction of HBV DNA by >1 log IU/ml or negativation at week 24 compared to baseline. (NCT02881008)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm D | 7 |
| Arm F | 6 |
(NCT00298363)
Timeframe: Baseline to Week 168
| Intervention | Days (Number) |
|---|---|
| Tenofovir DF | NA |
| FTC/TDF | NA |
| Entecavir | NA |
| Overall | NA |
MELD scores, used to assess prognosis and suitability for transplant, are calculated based on laboratory values only and can range from 6 to 40, with higher scores indicating greater disease severity. (NCT00298363)
Timeframe: Baseline to Week 144
| Intervention | units on a scale (Median) |
|---|---|
| Tenofovir DF | -2.0 |
| FTC/TDF | -1.5 |
| Entecavir | -2.0 |
| Overall | -2.0 |
MELD scores, used to assess prognosis and suitability for transplant, are calculated based on laboratory values only and can range from 6 to 40, with higher scores indicating greater disease severity. (NCT00298363)
Timeframe: Baseline to Week 168
| Intervention | units on a scale (Median) |
|---|---|
| Tenofovir DF | -2.0 |
| FTC/TDF | -2.0 |
| Entecavir | -2.0 |
| Overall | -2.0 |
MELD scores, used to assess prognosis and suitability for transplant, are calculated based on laboratory values only and can range from 6 to 40, with higher scores indicating greater disease severity. (NCT00298363)
Timeframe: Baseline to Week 96
| Intervention | units on a scale (Median) |
|---|---|
| Tenofovir DF | -2.0 |
| FTC/TDF | -3.0 |
| Entecavir | -3.0 |
| Overall | -2.0 |
MELD scores, used to assess prognosis and suitability for transplant, are calculated based on laboratory values only and can range from 6 to 40, with higher scores indicating greater disease severity. (NCT00298363)
Timeframe: Baseline to Week 48
| Intervention | units on a scale (Median) |
|---|---|
| Tenofovir DF | -2.0 |
| FTC/TDF | -2.0 |
| Entecavir | -2.0 |
| Overall | -2.0 |
Change from baseline was evaluated by subtracting baseline HBV DNA log_10 copies/mL from Week 144 HBV DNA log_10 copies/mL. DAVG is defined as the area of the trapezoid under the response-time curve divided by time to the last available evaluation of the patient minus the baseline value. (NCT00298363)
Timeframe: Baseline to 144 weeks
| Intervention | log _10 copies/mL (Median) |
|---|---|
| Tenofovir DF | -3.07 |
| FTC/TDF | -3.82 |
| Entecavir | -3.76 |
| Overall | -3.49 |
Change from baseline was evaluated by subtracting baseline HBV DNA log_10 copies/mL from Week 168 HBV DNA log_10 copies/mL. DAVG is defined as the area of the trapezoid under the response-time curve divided by time to the last available evaluation of the patient minus the baseline value. (NCT00298363)
Timeframe: Baseline to 168 weeks
| Intervention | log_10 copies/mL (Median) |
|---|---|
| Tenofovir DF | -3.16 |
| FTC/TDF | -4.06 |
| Entecavir | -3.77 |
| Overall | -3.66 |
Change from baseline was evaluated by subtracting baseline HBV DNA log_10 copies/mL from Week 96 HBV DNA log_10 copies/mL. DAVG is defined as the area of the trapezoid under the response-time curve divided by time to the last available evaluation of the patient minus the baseline value. (NCT00298363)
Timeframe: Baseline to 96 weeks
| Intervention | log_10 copies/mL (Median) |
|---|---|
| Tenofovir DF | -3.06 |
| FTC/TDF | -4.06 |
| Entecavir | -3.32 |
| Overall | -3.40 |
Change from baseline was evaluated by subtracting baseline HBV DNA log_10 copies/mL from Week 48 HBV DNA log_10 copies/mL. DAVG is defined as the area of the trapezoid under the response-time curve divided by time to the last available evaluation of the patient minus the baseline value. (NCT00298363)
Timeframe: Baseline to 48 weeks
| Intervention | log_10 copies/mL (Median) |
|---|---|
| Tenofovir DF | -2.93 |
| FTC/TDF | -3.45 |
| Entecavir | -3.61 |
| Overall | -3.19 |
Results are expressed as proportions of participants who experience a confirmed increase in serum creatinine of ≥ 0.5 mg/dL from baseline or a confirmed serum phosphorus level < 2.0 mg/dL using the KM method of estimation. (NCT00298363)
Timeframe: Baseline to Week 168
| Intervention | percent probability (KM estimate) (Number) |
|---|---|
| Tenofovir DF | 15 |
| FTC/TDF | 14 |
| TDF or FTC/TDF | 14 |
| Entecavir | 10 |
Tolerability failure was defined as permanent discontinuation of study drug due to a treatment-emergent adverse event (AE), including any subject who temporarily discontinued study drug due to an AE and did not restart. Results are expressed as proportions of participants who experience tolerability failure using the Kaplan-Meier (KM) method of estimation. (NCT00298363)
Timeframe: Baseline to Week 168
| Intervention | percent probability (KM estimate) (Number) |
|---|---|
| Tenofovir DF | 18 |
| FTC/TDF | 4 |
| TDF or FTC/TDF | 11 |
| Entecavir | 14 |
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease. (NCT00298363)
Timeframe: Baseline to Week 144
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 25.9 |
| FTC/TDF | 51.9 |
| Entecavir | 45.5 |
| Overall | 40.0 |
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease. (NCT00298363)
Timeframe: Baseline to Week 168
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 24.0 |
| FTC/TDF | 45.8 |
| Entecavir | 45.5 |
| Overall | 36.7 |
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease. (NCT00298363)
Timeframe: Baseline to Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 25.9 |
| FTC/TDF | 48.0 |
| Entecavir | 41.7 |
| Overall | 37.5 |
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease. (NCT00298363)
Timeframe: Baseline to Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 23.1 |
| FTC/TDF | 52.0 |
| Entecavir | 50.0 |
| Overall | 39.3 |
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease. (NCT00298363)
Timeframe: Baseline to Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 0.0 |
| FTC/TDF | 2.6 |
| Entecavir | 0.0 |
| Overall | 1.0 |
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease. (NCT00298363)
Timeframe: Baseline to Week 144
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 0.0 |
| FTC/TDF | 2.5 |
| Entecavir | 0.0 |
| Overall | 1.0 |
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease. (NCT00298363)
Timeframe: Baseline to Week 168
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 2.4 |
| FTC/TDF | 0.0 |
| Entecavir | 0.0 |
| Overall | 1.0 |
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease. (NCT00298363)
Timeframe: Baseline to Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 0.0 |
| FTC/TDF | 0.0 |
| Entecavir | 0.0 |
| Overall | 0.0 |
ADV resistance mutation + LAM resistance mutations are defined as the presence of the rtA181T/V HBV gene mutation and/or the rtN236T HBV gene mutation, and the rtM204V/I HBV gene mutation with or without the rtL180M HBV gene mutation. (NCT00298363)
Timeframe: Baseline to Week 168
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 50 |
Normalized ALT is defined as having a baseline ALT value > the upper limit of the normal range (ULN), and a decrease in ALT value to ≤ ULN at the given time point. (NCT00298363)
Timeframe: Baseline to Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 46.2 |
| FTC/TDF | 64.0 |
| Entecavir | 41.2 |
| Overall | 51.5 |
Normalized ALT is defined as having a baseline ALT value > ULN, and a decrease in ALT value to ≤ ULN at the given time point. (NCT00298363)
Timeframe: Baseline to Week 144
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 34.6 |
| FTC/TDF | 64.0 |
| Entecavir | 37.5 |
| Overall | 46.3 |
Normalized ALT is defined as having a baseline ALT value > ULN, and a decrease in ALT value to ≤ ULN at the given time point. (NCT00298363)
Timeframe: Baseline to Week 168
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 29.2 |
| FTC/TDF | 60.0 |
| Entecavir | 37.5 |
| Overall | 43.1 |
Normalized ALT is defined as having a baseline ALT value > ULN, and a decrease in ALT value to ≤ ULN at the given time point. (NCT00298363)
Timeframe: Baseline to Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 50.0 |
| FTC/TDF | 58.3 |
| Entecavir | 31.3 |
| Overall | 48.5 |
ADV resistance mutations are defined as the presence of the rtA181T/V HBV gene mutation and/or the rtN236T HBV gene mutation. (NCT00298363)
Timeframe: Baseline to Week 168
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 100 |
| FTC/TDF | 100 |
LAM resistance mutations are defined as the presence of the rtM204V/I HBV gene mutation with or without the rtL180M HBV gene mutation. (NCT00298363)
Timeframe: Baseline to Week 168
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 100 |
| FTC/TDF | 100 |
| Entecavir | 100 |
The percentage of participants with plasma HBV DNA < 400 copies/mL at Week 144 was summarized. (NCT00298363)
Timeframe: Week 144
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 50.0 |
| FTC/TDF | 77.5 |
| Entecavir | 52.4 |
| Overall | 61.0 |
The percentage of participants with plasma HBV DNA < 400 copies/mL at Week 168 was summarized. (NCT00298363)
Timeframe: Week 168
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 50.0 |
| FTC/TDF | 75.7 |
| Entecavir | 52.4 |
| Overall | 60.0 |
The percentage of participants with plasma HBV DNA < 400 copies/mL at Week 48 was summarized. (NCT00298363)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 70.5 |
| FTC/TDF | 87.8 |
| Entecavir | 72.7 |
| Overall | 77.6 |
The percentage of participants with plasma HBV DNA < 400 copies/mL at Week 96 was summarized. (NCT00298363)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 59.1 |
| FTC/TDF | 79.5 |
| Entecavir | 57.1 |
| Overall | 66.3 |
Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. (NCT00298363)
Timeframe: Baseline to Week 144
| Intervention | percentage of participants (Number) | |
|---|---|---|
| HBeAg Loss | HBeAg Seroconversion | |
| Entecavir | 16.7 | 0.0 |
| FTC/TDF | 33.3 | 13.3 |
| Overall | 22.9 | 11.4 |
| Tenofovir DF | 14.3 | 14.3 |
Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. (NCT00298363)
Timeframe: Baseline to Week 168
| Intervention | percentage of participants (Number) | |
|---|---|---|
| HBeAg Loss | HBeAg Seroconversion | |
| Entecavir | 16.7 | 0.0 |
| FTC/TDF | 35.7 | 21.4 |
| Overall | 27.3 | 18.2 |
| Tenofovir DF | 23.1 | 23.1 |
Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. (NCT00298363)
Timeframe: Baseline to Week 96
| Intervention | percentage of participants (Number) | |
|---|---|---|
| HBeAg Loss | HBeAg Seroconversion | |
| Entecavir | 0.0 | 0.0 |
| FTC/TDF | 33.3 | 13.3 |
| Overall | 20.0 | 11.4 |
| Tenofovir DF | 14.3 | 14.3 |
Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. (NCT00298363)
Timeframe: Baseline to Week 144
| Intervention | percentage of participants (Number) | |
|---|---|---|
| HBsAg Loss | HBsAg Seroconversion | |
| Entecavir | 0.0 | 0.0 |
| FTC/TDF | 0.0 | 0.0 |
| Overall | 0.0 | 0.0 |
| Tenofovir DF | 0.0 | 0.0 |
Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. (NCT00298363)
Timeframe: Baseline to Week 168
| Intervention | percentage of participants (Number) | |
|---|---|---|
| HBsAg Loss | HBsAg Seroconversion | |
| Entecavir | 0.0 | 0.0 |
| FTC/TDF | 0.0 | 0.0 |
| Overall | 0.0 | 0.0 |
| Tenofovir DF | 0.0 | 0.0 |
Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. (NCT00298363)
Timeframe: Baseline to Week 96
| Intervention | percentage of participants (Number) | |
|---|---|---|
| HBsAg Loss | HBsAg Seroconversion | |
| Entecavir | 0.0 | 0.0 |
| FTC/TDF | 0.0 | 0.0 |
| Overall | 0.0 | 0.0 |
| Tenofovir DF | 0.0 | 0.0 |
Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. (NCT00298363)
Timeframe: Baseline to Week 48
| Intervention | percentage of participants (Number) | |
|---|---|---|
| HBeAg Loss | HBeAg Seroconversion | |
| Entecavir | 0.0 | 0.0 |
| FTC/TDF | 26.7 | 13.3 |
| Overall | 19.4 | 13.9 |
| Tenofovir DF | 21.4 | 21.4 |
Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. (NCT00298363)
Timeframe: Baseline to Week 48
| Intervention | percentage of participants (Number) | |
|---|---|---|
| HBsAg Loss | HBsAg Seroconversion | |
| Entecavir | 0.0 | 0.0 |
| FTC/TDF | 0.0 | 0.0 |
| Overall | 0.0 | 0.0 |
| Tenofovir DF | 0.0 | 0.0 |
A biochemical response was defined as a decrease in serum ALT levels into the normal range (<41 U/L). (NCT00023309)
Timeframe: week 196 from randomization
| Intervention | participants (Number) | |
|---|---|---|
| Yes | No | |
| Adefovir | 12 | 7 |
| Lamivudine and Adefovir | 21 | 1 |
Loss of hepatitis B surface antigen (HBsAg) at week 196 (NCT00023309)
Timeframe: Week 196 from randomization
| Intervention | participants (Number) | |
|---|---|---|
| Yes | No | |
| Adefovir | 5 | 9 |
| Lamivudine and Adefovir | 13 | 4 |
A histological response was defined as a decrease in the HAI score by at least three points with no worsening of the Ishak fibrosis score. (NCT00023309)
Timeframe: week 196 from randomization
| Intervention | participants (Number) | |
|---|---|---|
| Yes | No | |
| Adefovir | 5 | 5 |
| Lamivudine and Adefovir | 15 | 3 |
A maintained combined response was defined as a combination of a virological, biochemical and histological responses at weeks 48 and 192. A virological response was defined as a decrease in HBV DNA levels to undetectable by the Amplicor assay (<500 copies/mL). A biochemical response was defined as a decrease in serum ALT levels into the normal range (<41 U/L). A histological response was defined as a decrease in the HAI score by at least three points with no worsening of the Ishak fibrosis score. (NCT00023309)
Timeframe: 196 weeks from randomization
| Intervention | participants (Number) | |
|---|---|---|
| Yes | No | |
| Adefovir | 6 | 13 |
| Lamivudine and Adefovir | 15 | 7 |
A virological response was defined as a decrease in HBV DNA levels to undetectable by the Amplicor assay (<500 copies/mL). (NCT00023309)
Timeframe: Week 196 from randomization
| Intervention | participants (Number) | |
|---|---|---|
| Yes | No | |
| Adefovir | 6 | 13 |
| Lamivudine and Adefovir | 17 | 5 |
Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 144
| Intervention | z-score (Mean) |
|---|---|
| TDF 12-14 Years | -0.20 |
| TDF 15-17 Years | -0.05 |
| Placebo 12-14 Years | -0.16 |
| Placebo 15-17 Years | -0.04 |
| Total TDF 12-17 Years | -0.08 |
| Total Placebo 12-17 Years | -0.06 |
Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 192
| Intervention | z-score (Mean) |
|---|---|
| TDF 12-14 Years | -0.24 |
| TDF 15-17 Years | 0.08 |
| Placebo 12-14 Years | -0.26 |
| Placebo 15-17 Years | -0.05 |
| Total TDF 12-17 Years | 0.02 |
| Total Placebo 12-17 Years | -0.10 |
To assess any effect of treatment on growth, Z-scores were used to express the deviation from a reference population for lumbar spine BMD. A Z-score of 0 indicated that a subject was typical of the population for their age, ethnicity, and gender. A negative Z-score indicated that the subject's recorded value was lower than typical for their age, ethnicity, and gender. A positive Z-score indicates that the subject's recorded value was higher than typical for their age, ethnicity, and gender. Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 48
| Intervention | z-score (Mean) |
|---|---|
| TDF 12-14 Years | 0.02 |
| TDF 15-17 Years | -0.10 |
| Placebo 12-14 Years | 0.04 |
| Placebo 15-17 Years | 0.05 |
| Total TDF 12-17 Years | -0.08 |
| Total Placebo 12-17 Years | 0.05 |
Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 72
| Intervention | z-score (Mean) |
|---|---|
| TDF 12-14 Years | -0.10 |
| TDF 15-17 Years | -0.05 |
| Placebo 12-14 Years | 0.09 |
| Placebo 15-17 Years | 0.10 |
| Total TDF 12-17 Years | -0.06 |
| Total Placebo 12-17 Years | 0.10 |
Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 96
| Intervention | z-score (Mean) |
|---|---|
| TDF 12-14 Years | -0.19 |
| TDF 15-17 Years | -0.07 |
| Placebo 12-14 Years | -0.02 |
| Placebo 15-17 Years | -0.13 |
| Total TDF 12-17 Years | -0.10 |
| Total Placebo 12-17 Years | -0.11 |
Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 144
| Intervention | z-score (Mean) |
|---|---|
| TDF 12-14 Years | -0.27 |
| TDF 15-17 Years | -0.21 |
| Placebo 12-14 Years | -0.06 |
| Placebo 15-17 Years | -0.16 |
| Total TDF 12-17 Years | -0.22 |
| Total Placebo 12-17 Years | -0.14 |
Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 192
| Intervention | z-score (Mean) |
|---|---|
| TDF 12-14 Years | -0.34 |
| TDF 15-17 Years | -0.11 |
| Placebo 12-14 Years | -0.21 |
| Placebo 15-17 Years | -0.19 |
| Total TDF 12-17 Years | -0.16 |
| Total Placebo 12-17 Years | -0.19 |
Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 48
| Intervention | z-score (Mean) |
|---|---|
| TDF 12-14 Years | 0.02 |
| TDF 15-17 Years | -0.15 |
| Placebo 12-14 Years | 0.10 |
| Placebo 15-17 Years | 0.04 |
| Total TDF 12-17 Years | -0.12 |
| Total Placebo 12-17 Years | 0.05 |
Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 72
| Intervention | z-score (Mean) |
|---|---|
| TDF 12-14 Years | 0.02 |
| TDF 15-17 Years | -0.19 |
| Placebo 12-14 Years | 0.20 |
| Placebo 15-17 Years | 0.06 |
| Total TDF 12-17 Years | -0.16 |
| Total Placebo 12-17 Years | 0.09 |
Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 96
| Intervention | z-score (Mean) |
|---|---|
| TDF 12-14 Years | -0.12 |
| TDF 15-17 Years | -0.19 |
| Placebo 12-14 Years | 0.09 |
| Placebo 15-17 Years | -0.06 |
| Total TDF 12-17 Years | -0.18 |
| Total Placebo 12-17 Years | -0.03 |
Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 144
| Intervention | percentage change (Mean) |
|---|---|
| TDF 12-14 Years | 19.224 |
| TDF 15-17 Years | 5.289 |
| Placebo 12-14 Years | 21.346 |
| Placebo 15-17 Years | 6.144 |
| Total TDF 12-17 Years | 8.133 |
| Total Placebo 12-17 Years | 9.311 |
Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 192
| Intervention | percentage change (Mean) |
|---|---|
| TDF 12-14 Years | 23.933 |
| TDF 15-17 Years | 6.673 |
| Placebo 12-14 Years | 25.036 |
| Placebo 15-17 Years | 6.867 |
| Total TDF 12-17 Years | 10.050 |
| Total Placebo 12-17 Years | 11.212 |
Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 72
| Intervention | percentage change (Mean) |
|---|---|
| TDF 12-14 Years | 11.516 |
| TDF 15-17 Years | 3.589 |
| Placebo 12-14 Years | 14.131 |
| Placebo 15-17 Years | 6.117 |
| Total TDF 12-17 Years | 5.144 |
| Total Placebo 12-17 Years | 8.080 |
Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 96
| Intervention | percentage change (Mean) |
|---|---|
| TDF 12-14 Years | 13.811 |
| TDF 15-17 Years | 4.196 |
| Placebo 12-14 Years | 16.687 |
| Placebo 15-17 Years | 4.272 |
| Total TDF 12-17 Years | 6.119 |
| Total Placebo 12-17 Years | 7.003 |
Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 48
| Intervention | percentage change (Mean) |
|---|---|
| TDF 12-14 Years | 9.234 |
| TDF 15-17 Years | 2.114 |
| Placebo 12-14 Years | 9.038 |
| Placebo 15-17 Years | 4.435 |
| Total TDF 12-17 Years | 3.510 |
| Total Placebo 12-17 Years | 5.562 |
Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 144
| Intervention | percentage change (Mean) |
|---|---|
| TDF 12-14 Years | 10.940 |
| TDF 15-17 Years | 3.529 |
| Placebo 12-14 Years | 12.638 |
| Placebo 15-17 Years | 4.730 |
| Total TDF 12-17 Years | 4.949 |
| Total Placebo 12-17 Years | 6.505 |
Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 192
| Intervention | percentage change (Mean) |
|---|---|
| TDF 12-14 Years | 13.923 |
| TDF 15-17 Years | 4.295 |
| Placebo 12-14 Years | 14.797 |
| Placebo 15-17 Years | 4.549 |
| Total TDF 12-17 Years | 6.086 |
| Total Placebo 12-17 Years | 7.223 |
Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 48
| Intervention | percentage change (Mean) |
|---|---|
| TDF 12-14 Years | 5.123 |
| TDF 15-17 Years | 1.339 |
| Placebo 12-14 Years | 5.470 |
| Placebo 15-17 Years | 3.236 |
| Total TDF 12-17 Years | 2.048 |
| Total Placebo 12-17 Years | 3.817 |
Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 72
| Intervention | percentage change (Mean) |
|---|---|
| TDF 12-14 Years | 7.282 |
| TDF 15-17 Years | 2.141 |
| Placebo 12-14 Years | 8.480 |
| Placebo 15-17 Years | 4.335 |
| Total TDF 12-17 Years | 3.067 |
| Total Placebo 12-17 Years | 5.391 |
Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 96
| Intervention | percentage change (Mean) |
|---|---|
| TDF 12-14 Years | 8.034 |
| TDF 15-17 Years | 3.023 |
| Placebo 12-14 Years | 10.056 |
| Placebo 15-17 Years | 4.291 |
| Total TDF 12-17 Years | 3.943 |
| Total Placebo 12-17 Years | 5.675 |
"Data were summarized by treatment and age group (grouped by baseline age for analysis).~In contrast with what was previously reported in the interim results posting, 1 participant met the primary safety endpoint of at least a 6% decrease from baseline in spine BMD at Week 72, based on the final BMD data analysis. The apparent discrepancy was due to the correction factor applied to the subject-specific BMD calculations performed at the time of the Interim Week 72 clinical study report that could not take into account the actual Week 72 phantom data (ie, calibration test used in longitudinal clinical trials to monitor and adjust for shifts in the dual-energy x-ray absorptiometry (DXA) scanner calibration over time), which were not provided by the site at that time. The correction factor applied to the final analysis has been properly based on all phantom data through the end of Week 72, as well as through the end of Week 192." (NCT00734162)
Timeframe: Baseline to Week 72
| Intervention | percentage of participants (Number) |
|---|---|
| TDF 12-14 Years | 0 |
| TDF 15-17 Years | 2.4 |
| Placebo 12-14 Years | 0 |
| Placebo 15-17 Years | 0 |
| Total TDF 12-17 Years | 1.9 |
| Total Placebo 12-17 Years | 0 |
"The percentage of participants with HBV DNA < 400 copies/mL at Week 72 was summarized by treatment and age group (grouped by baseline age for analysis), using the missing = failure (M = F) analysis with the double-blind efficacy evaluation (DBEE) algorithm.~In the M = F analysis method, all missing data were considered as failure to meet the outcome measure threshold. This method was combined with the DBEE algorithm, which included all available data for the double-blind period, and any data for the open-label period were not included; data generated during treatment-free follow-up from subjects who achieved HBsAg loss and entered treatment-free follow-up during double-blind treatment period were included." (NCT00734162)
Timeframe: Week 72
| Intervention | percentage of participants (Number) |
|---|---|
| TDF 12-14 Years | 90.0 |
| TDF 15-17 Years | 88.1 |
| Placebo 12-14 Years | 0 |
| Placebo 15-17 Years | 0 |
| Total TDF 12-17 Years | 88.5 |
| Total Placebo 12-17 Years | 0 |
The number of participants with changes in drug-resistant mutations during the study was summarized. (NCT00734162)
Timeframe: Baseline through Week 192
| Intervention | participants (Number) | |
|---|---|---|
| New TDF Drug-Resistant Mutations | Enrichment of TDF Drug-Resistant Mutations | |
| Total Placebo 12-17 Years | 0 | 0 |
| Total TDF 12-17 Years | 0 | 0 |
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method. (NCT00734162)
Timeframe: Baseline; Weeks 48, 72, 96, 144, and 192
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 48 | Week 72 | Week 96 | Week 144 | Week 192 | |
| Placebo 12-14 Years | 7.7 | 23.1 | 38.5 | 53.8 | 53.8 |
| Placebo 15-17 Years | 8.6 | 11.4 | 28.6 | 34.3 | 37.1 |
| TDF 12-14 Years | 11.1 | 11.1 | 44.4 | 44.4 | 33.3 |
| TDF 15-17 Years | 17.9 | 23.1 | 30.8 | 38.5 | 43.6 |
| Total Placebo 12-17 Years | 8.3 | 14.6 | 31.3 | 39.6 | 41.7 |
| Total TDF 12-17 Years | 16.7 | 20.8 | 33.3 | 39.6 | 41.7 |
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method. (NCT00734162)
Timeframe: Baseline; Weeks 48, 72, 96, 144, and 192
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 48 | Week 72 | Week 96 | Week 144 | Week 192 | |
| Placebo 12-14 Years | 7.7 | 23.1 | 38.5 | 53.8 | 53.8 |
| Placebo 15-17 Years | 8.6 | 11.4 | 25.7 | 34.3 | 37.1 |
| TDF 12-14 Years | 11.1 | 11.1 | 44.4 | 33.3 | 33.3 |
| TDF 15-17 Years | 15.4 | 23.1 | 30.8 | 38.5 | 38.5 |
| Total Placebo 12-17 Years | 8.3 | 14.6 | 29.2 | 39.6 | 41.7 |
| Total TDF 12-17 Years | 14.6 | 20.8 | 33.3 | 37.5 | 37.5 |
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method. (NCT00734162)
Timeframe: Baseline; Weeks 48, 72, 96, 144, and 192
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 48 | Week 72 | Week 96 | Week 144 | Week 192 | |
| Placebo 12-14 Years | 0 | 0 | 30.8 | 46.2 | 46.2 |
| Placebo 15-17 Years | 0 | 0 | 22.9 | 25.7 | 25.7 |
| TDF 12-14 Years | 11.1 | 11.1 | 44.4 | 22.2 | 33.3 |
| TDF 15-17 Years | 12.8 | 15.4 | 28.2 | 30.8 | 28.2 |
| Total Placebo 12-17 Years | 0 | 0 | 25.0 | 31.3 | 31.3 |
| Total TDF 12-17 Years | 12.5 | 14.6 | 31.3 | 29.2 | 29.2 |
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method. (NCT00734162)
Timeframe: Baseline; Weeks 48, 72, 96, 144, and 192
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 48 | Week 72 | Week 96 | Week 144 | Week 192 | |
| Placebo 12-14 Years | 0 | 0 | 33.3 | 55.6 | 55.6 |
| Placebo 15-17 Years | 0 | 0 | 24.2 | 27.3 | 27.3 |
| TDF 12-14 Years | 16.7 | 16.7 | 50.0 | 33.3 | 50.0 |
| TDF 15-17 Years | 18.5 | 22.2 | 33.3 | 29.6 | 29.6 |
| Total Placebo 12-17 Years | 0 | 0 | 26.2 | 33.3 | 33.3 |
| Total TDF 12-17 Years | 18.2 | 21.2 | 36.4 | 30.3 | 33.3 |
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method. (NCT00734162)
Timeframe: Baseline; Weeks 48, 72, 96, 144, and 192
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 48 | Week 72 | Week 96 | Week 144 | Week 192 | |
| Placebo 12-14 Years | 0 | 0 | 55.6 | 66.7 | 77.8 |
| Placebo 15-17 Years | 0 | 0 | 54.5 | 69.7 | 57.6 |
| TDF 12-14 Years | 85.7 | 85.7 | 85.7 | 57.1 | 85.7 |
| TDF 15-17 Years | 71.4 | 71.4 | 78.6 | 71.4 | 67.9 |
| Total Placebo 12-17 Years | 0 | 0 | 54.8 | 69.0 | 61.9 |
| Total TDF 12-17 Years | 74.3 | 74.3 | 80.0 | 68.6 | 71.4 |
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method. (NCT00734162)
Timeframe: Baseline; Weeks 48, 72, 96, 144, and 192
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 48 | Week 72 | Week 96 | Week 144 | Week 192 | |
| Placebo 12-14 Years | 11.1 | 22.2 | 66.7 | 66.7 | 77.8 |
| Placebo 15-17 Years | 21.2 | 33.3 | 63.6 | 72.7 | 69.7 |
| TDF 12-14 Years | 85.7 | 85.7 | 85.7 | 57.1 | 85.7 |
| TDF 15-17 Years | 71.4 | 71.4 | 78.6 | 71.4 | 75.0 |
| Total Placebo 12-17 Years | 19.0 | 31.0 | 64.3 | 71.4 | 71.4 |
| Total TDF 12-17 Years | 74.3 | 74.3 | 80.0 | 68.6 | 77.1 |
The percentage of participants reported is the cumulative incidence from baseline to the respective time point. Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Weeks 48, 96, 144, and 192
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Week 48 | Week 96 | Week 144 | Week 192 | |
| Placebo 12-14 Years | 0 | 0 | 0 | 0 |
| Placebo 15-17 Years | 0 | 0 | 0 | 4.9 |
| TDF 12-14 Years | 0 | 0 | 0 | 0 |
| TDF 15-17 Years | 0 | 2.4 | 2.4 | 4.8 |
| Total Placebo 12-17 Years | 0 | 0 | 0 | 3.7 |
| Total TDF 12-17 Years | 0 | 1.9 | 1.9 | 3.8 |
The percentage of participants reported is the cumulative incidence from baseline to the respective time point. Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Weeks 48, 72, 96, 144, and 192
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 48 | Week 72 | Week 96 | Week 144 | Week 192 | |
| Placebo 12-14 Years | 0 | 0 | 0 | 0 | 0 |
| Placebo 15-17 Years | 0 | 0 | 0 | 2.4 | 2.4 |
| TDF 12-14 Years | 0 | 0 | 0 | 0 | 0 |
| TDF 15-17 Years | 0 | 0 | 0 | 0 | 0 |
| Total Placebo 12-17 Years | 0 | 0 | 0 | 1.9 | 1.9 |
| Total TDF 12-17 Years | 0 | 0 | 0 | 0 | 0 |
HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. Data were summarized by treatment and age group (grouped by baseline age for analysis), using the M = F. (NCT00734162)
Timeframe: Baseline; Weeks 48, 72, 96, 144, and 192
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 48 | Week 72 | Week 96 | Week 144 | Week 192 | |
| Placebo 12-14 Years | 0 | 0 | 0 | 0 | 0 |
| Placebo 15-17 Years | 0 | 0 | 0 | 0 | 0 |
| TDF 12-14 Years | 0 | 0 | 0 | 0 | 0 |
| TDF 15-17 Years | 0 | 2.4 | 2.4 | 2.4 | 0 |
| Total Placebo 12-17 Years | 0 | 0 | 0 | 0 | 0 |
| Total TDF 12-17 Years | 0 | 1.9 | 1.9 | 1.9 | 0 |
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method. (NCT00734162)
Timeframe: Weeks 48, 72, 96, 144, and 192
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 48 | Week 72 | Week 96 | Week 144 | Week 192 | |
| Placebo 12-14 Years | 0 | 0 | 53.8 | 69.2 | 76.9 |
| Placebo 15-17 Years | 0 | 0 | 63.4 | 82.9 | 73.2 |
| TDF 12-14 Years | 80.0 | 90.0 | 90.0 | 90.0 | 90.0 |
| TDF 15-17 Years | 81.0 | 83.3 | 88.1 | 88.1 | 83.3 |
| Total Placebo 12-17 Years | 0 | 0 | 61.1 | 79.6 | 74.1 |
| Total TDF 12-17 Years | 80.8 | 84.6 | 88.5 | 88.5 | 84.6 |
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method. (NCT00734162)
Timeframe: Weeks 48, 72, 96, 144, and 192
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 48 | Week 72 | Week 96 | Week 144 | Week 192 | |
| Placebo 12-14 Years | 0 | 0 | 46.2 | 53.8 | 69.2 |
| Placebo 15-17 Years | 0 | 0 | 51.2 | 68.3 | 63.4 |
| TDF 12-14 Years | 70.0 | 80.0 | 80.0 | 60.0 | 80.0 |
| TDF 15-17 Years | 69.0 | 69.0 | 73.8 | 69.0 | 64.3 |
| Total Placebo 12-17 Years | 0 | 0 | 50.0 | 64.8 | 64.8 |
| Total TDF 12-17 Years | 69.2 | 71.2 | 75.0 | 67.3 | 67.3 |
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method. (NCT00734162)
Timeframe: Weeks 48, 96, 144, and 192
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Week 48 | Week 96 | Week 144 | Week 192 | |
| Placebo 12-14 Years | 0 | 53.8 | 69.2 | 76.9 |
| Placebo 15-17 Years | 0 | 68.3 | 85.4 | 73.2 |
| TDF 12-14 Years | 90.0 | 90.0 | 100.0 | 90.0 |
| TDF 15-17 Years | 85.7 | 88.1 | 90.5 | 85.7 |
| Total Placebo 12-17 Years | 0 | 64.8 | 81.5 | 74.1 |
| Total TDF 12-17 Years | 86.5 | 88.5 | 92.3 | 86.5 |
Data were summarized by treatment and age group (grouped by baseline age for analysis), using the M = F. (NCT00734162)
Timeframe: Baseline; Weeks 48, 72, 96, 144, and 192
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 48 | Week 72 | Week 96 | Week 144 | Week 192 | |
| Placebo 12-14 Years | 0 | 0 | 0 | 0 | 0 |
| Placebo 15-17 Years | 0 | 0 | 0 | 0 | 0 |
| TDF 12-14 Years | 0 | 0 | 0 | 0 | 0 |
| TDF 15-17 Years | 0 | 2.4 | 2.4 | 2.4 | 2.4 |
| Total Placebo 12-17 Years | 0 | 0 | 0 | 0 | 0 |
| Total TDF 12-17 Years | 0 | 1.9 | 1.9 | 1.9 | 1.9 |
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method. (NCT00734162)
Timeframe: Weeks 48, 72, 96, 144, and 192
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 48 | Week 72 | Week 96 | Week 144 | Week 192 | |
| Placebo 12-14 Years | 30.8 | 30.8 | 69.2 | 69.2 | 84.6 |
| Placebo 15-17 Years | 26.8 | 41.5 | 65.9 | 75.6 | 75.6 |
| TDF 12-14 Years | 70.0 | 80.0 | 80.0 | 60.0 | 80.0 |
| TDF 15-17 Years | 76.2 | 76.2 | 76.2 | 71.4 | 71.4 |
| Total Placebo 12-17 Years | 27.8 | 38.9 | 66.7 | 74.1 | 77.8 |
| Total TDF 12-17 Years | 75.0 | 76.9 | 76.9 | 69.2 | 73.1 |
HBV DNA levels <50 IU/mL=approximately 300 copies/mL. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints. (NCT00410072)
Timeframe: At Week 96
| Intervention | Percentage of participants (Number) |
|---|---|
| ETV 0.5 mg | 76.4 |
| ETV 0.5 mg +TDF 300 mg | 83.2 |
HBV DNA was analyzed by PCR, using the Roche COBAS®TaqMan - HPS assay. Reduction in Log 10 HBV count=reduced viral load. (NCT00410072)
Timeframe: Baseline, Weeks 48 and 96
| Intervention | log10 copies/mL (Mean) | ||
|---|---|---|---|
| Baseline (n=182, 197) | Overall at Week 48 (n=176, 180) | Overall at Week 96 (n=165, 170) | |
| ETV 0.5 mg | 7.48 | 1.88 | 1.68 |
| ETV 0.5 mg +TDF 300 mg | 7.53 | 1.56 | 1.51 |
AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded. (NCT00410072)
Timeframe: From enrollment through Week 100 + 24-week follow-up
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Deaths | SAEs | Adverse events | Discontinuations due to AEs | Related AEs | |
| ETV 0.5 mg | 0 | 12 | 132 | 2 | 39 |
| ETV 0.5 mg +TDF 300 mg | 3 | 14 | 131 | 5 | 49 |
Using the Roche COBAS TaqMan - HPS assay. Lower limit of Quantitation (LOQ) is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Limits of quantitation are matrix-, method-, and analyte-specific. (NCT00410072)
Timeframe: At Weeks 48 and 96
| Intervention | Percentage of participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| < LOQ (29 IU/mL) at Week 48 | LOQ - <50 IU/mL at Week 48 | 50 - <172 IU/mL at Week 48 | 172 - <1720 IU/mL at Week 48 | 1720 - <17,200 IU/mL at Week 48 | 17,200 - <172,000 IU/mL at Week 48 | ≥172,000 IU/mL at Week 48 | Missing at Week 48 | < LOQ (29 IU/mL) at Week 96 | LOQ - <50 IU/mL at Week 96 | 50 - <172 IU/mL at Week 96 | 172 - <1720 IU/mL at Week 96 | 1720 - <17,200 IU/mL at Week 96 | 17,200 - <172,000 IU/mL at Week 96 | ≥172,000 IU/mL at Week 96 | Missing at Week 96 | |
| ETV 0.5 mg | 67.6 | 2.7 | 7.1 | 7.7 | 9.3 | 1.6 | 0.5 | 3.3 | 74.7 | 1.6 | 3.3 | 5.5 | 4.9 | 0.5 | 0 | 9.3 |
| ETV 0.5 mg +TDF 300 mg | 74.6 | 5.6 | 6.6 | 4.1 | 0.5 | 0 | 0 | 8.6 | 81.7 | 1.5 | 1.0 | 1.5 | 0 | 0 | 0.5 | 13.7 |
ETVr=entecavir resistance; TFDr=tenofovir resistance. HBV polymerase using the Trugene® HBV Genotyping Kit. HBV resistance: genotyping of HBV polymerase will be performed on stored viral samples at any timepoint when considered appropriate based on virologic response, including any specimen with detectable HBV DNA. When appropriate, phenotyping will also be used. (NCT00410072)
Timeframe: Week 96
| Intervention | Participants (Number) | |
|---|---|---|
| ETVr | TDFr | |
| ETV 0.5 mg | 0 | 0 |
| ETV 0.5 mg +TDF 300 mg | 0 | 0 |
ETVr=entecavir resistance; TDFr=tenofovir resistance. HBV polymerase using the Trugene® HBV Genotyping Kit. HBV resistance: genotyping of HBV polymerase will be performed on stored viral samples at any timepoint when considered appropriate based on virologic response, including any specimen with detectable HBV DNA. When appropriate, phenotyping will also be used. (NCT00410072)
Timeframe: Week 48
| Intervention | Participants (Number) | |
|---|---|---|
| ETVr | TDFr | |
| ETV 0.5 mg | 0 | 0 |
| ETV 0.5 mg +TDF 300 mg | 0 | 0 |
ETVr=entecavir resistance; TFDr=tenofovir resistance. Virologic breakthrough= confirmed >= 1 log10 increase in HBV DNA from the on-treatment nadir (NCT00410072)
Timeframe: Week 48
| Intervention | Participants (Number) | |
|---|---|---|
| ETVr | TDFr | |
| ETV 0.5 mg | 0 | 0 |
| ETV 0.5 mg +TDF 300 mg | 0 | 0 |
ETVr=entecavir resistance; TFDr=tenofovir resistance. Virologic breakthrough=confirmed >=1 log10 increase in HBV DNA from moving nadir (NCT00410072)
Timeframe: Week 96
| Intervention | Participants (Number) | |
|---|---|---|
| ETVr | TDFr | |
| ETV 0.5 mg | 0 | 0 |
| ETV 0.5 mg +TDF 300 mg | 0 | 0 |
HBV DNA levels <50 IU/mL=approximately 300 copies/mL. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints. (NCT00410072)
Timeframe: At Weeks 48 and 96
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| HBeAg+ at Week 48 (n=126, n=138) | HBeAg- at Week 48 (n=56, n=59) | HBeAg+ at Week 96 (n=126, n=138) | HBeAg- at Week 96 (n=56, n=59) | |
| ETV 0.5 mg | 61.1 | 91.1 | 69.8 | 91.1 |
| ETV 0.5 mg +TDF 300 mg | 74.6 | 93.2 | 80.4 | 89.8 |
LOD=Lower limit of detection. LOD) LOD=10 IU/mL, or approximately 58 copies/mL. LOD is the lowest concentration level that can be determined to be statistically different from a blank (99% confidence). The LOD is typically determined to be in the region where the signal to noise ratio is greater than 5. Limits of detection are matrix-, method-, and analyte-specific.Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints. (NCT00410072)
Timeframe: At Weeks 48 and 96
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Overall at Week 48 | Overall at Week 96 | |
| ETV 0.5 mg | 58.2 | 68.1 |
| ETV 0.5 mg +TDF 300 mg | 66.0 | 76.6 |
LOQ=lower limit of quantitation. LOQ=29 IU/mL, or approximately 169 copies/mL. LOQ is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Limits of quantitation are matrix-, method-, and analyte-specific.Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints. (NCT00410072)
Timeframe: At Weeks 48 and 96
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Overall at Week 48 | Overall at Week 96 | |
| ETV 0.5 mg | 67.6 | 74.7 |
| ETV 0.5 mg +TDF 300 mg | 74.6 | 81.7 |
ALT normalization= ≤1*upper limit of normal (ULN). Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints. (NCT00410072)
Timeframe: At Weeks 48 and 96
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Overall at Week 48 | Overall at Week 96 | |
| ETV 0.5 mg | 83.0 | 81.9 |
| ETV 0.5 mg +TDF 300 mg | 72.6 | 68.0 |
HBeAg seroconversion=HBeAg loss and presence of hepatitis B e antibody (HBeAb). HBeAg is a hepatitis B viral protein and is an indicator of active viral replication. (NCT00410072)
Timeframe: At Weeks 48 and 96
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Week 48 | Week 96 | |
| ETV 0.5 mg | 22.2 | 32.5 |
| ETV 0.5 mg +TDF 300 mg | 18.1 | 21.7 |
HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. (NCT00410072)
Timeframe: At Weeks 48 and 96
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Week 48 | Week 96 | |
| ETV 0.5 mg | 0.8 | 1.6 |
| ETV 0.5 mg +TDF 300 mg | 0.7 | 2.9 |
HBeAg is a hepatitis B viral protein and is an indicator of active viral replication. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints. (NCT00410072)
Timeframe: At Weeks 48 and 96
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Week 48 | Week 96 | |
| ETV 0.5 mg | 25.4 | 3.97 |
| ETV 0.5 mg +TDF 300 mg | 19.6 | 29.7 |
HBsAg = A part of the hepatitis B virus. When found in the blood, HBsAg is an early marker of infection. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints. (NCT00410072)
Timeframe: At Weeks 48 and 96
| Intervention | Percent of participants (Number) | |
|---|---|---|
| Week 48 | Week 96 | |
| ETV 0.5 mg | 3.2 | 4.0 |
| ETV 0.5 mg +TDF 300 mg | 1.4 | 5.1 |
Number of participants whose serum HBV DNA level was <1000 IU/ml at Week 192 (NCT00524173)
Timeframe: At Week 192
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenofovir Only | 12 |
| Tenofovir & Emtricitabine | 12 |
The number of participants whose serum hepatitis B surface antigen was no longer detectable. (NCT00524173)
Timeframe: 192 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenofovir Only | 1 |
| Tenofovir & Emtricitabine | 0 |
Number of participants whose serum ALT levels were measured within normal limits. (NCT00524173)
Timeframe: 192 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenofovir Only | 8 |
| Tenofovir & Emtricitabine | 13 |
Number of subjects whose serum HBV DNA level was <1000 IU/ml at Week 48 (NCT00524173)
Timeframe: At Week 48
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenofovir Only | 11 |
| Tenofovir & Emtricitabine | 13 |
"HBV DNA carries the genetic blueprint of the virus. How many HBV DNA particles or copies are found in the blood indicates how rapidly the virus is reproducing in the liver." (NCT00662545)
Timeframe: week 24
| Intervention | log 10 IU/ml (Median) |
|---|---|
| Entecavir Intensification | 2.4 |
| Standard of Care | 0.8 |
(NCT00662545)
Timeframe: entry, week 12, and week 24
| Intervention | participants (Number) |
|---|---|
| Entecavir Intensification | 5 |
| Standard of Care | 5 |
ALT flare: sudden increase in blood level of alanine transaminase (ALT) (NCT00662545)
Timeframe: every 4 weeks for 24 weeks
| Intervention | participants (Number) |
|---|---|
| Entecavir Intensification | 0 |
| Standard of Care | 0 |
(NCT00662545)
Timeframe: every 4 weeks for 24 weeks
| Intervention | participants (Number) |
|---|---|
| Entecavir Intensification | 0 |
| Standard of Care | 0 |
(NCT00662545)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| Entecavir Intensification | 0 |
| Standard of Care | 0 |
226 reviews available for adenine and Hepatitis B, Chronic
| Article | Year |
|---|---|
Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Hepatitis B, Chronic; Humans; Organophosphonates; | 2022 |
Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data.
Topics: Adenine; Aged; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
The Use of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide for Preventing Vertical Transmission of Hepatitis B.
Topics: Adenine; Antiviral Agents; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Infant; Infectious Dis | 2023 |
Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis.
Topics: Adenine; Alanine; Cholesterol; Cholesterol, LDL; Dyslipidemias; Hepatitis B; Hepatitis B, Chronic; H | 2023 |
Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
Topics: Adenine; Alanine; Antiviral Agents; Bone and Bones; Creatinine; Fumarates; Hepatitis B; Hepatitis B, | 2023 |
[Research progress on the effect of tenofovir disoproxil fumarate on blood lipid profile].
Topics: Adenine; Antiviral Agents; DNA, Viral; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; | 2023 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Fanconi syndrome induced by adefovir dipivoxil: a case report and clinical review.
Topics: Adenine; Antiviral Agents; Fanconi Syndrome; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organo | 2020 |
Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
Topics: Adenine; Antiviral Agents; Controlled Clinical Trials as Topic; Guanine; Hematologic Neoplasms; Hepa | 2017 |
Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Guanine; Hepatitis B v | 2017 |
Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection.
Topics: Adenine; Alanine; Animals; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Hepatitis B e Ant | 2017 |
Tenofovir Alafenamide: A Review in Chronic Hepatitis B.
Topics: Adenine; Adolescent; Adult; Alanine; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, | 2017 |
Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha | 2017 |
Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.
Topics: Adenine; Age Factors; Alanine; Antiviral Agents; Bone Density; Clinical Decision-Making; Female; Glo | 2017 |
Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy.
Topics: Adenine; Alanine; Antiviral Agents; Clinical Trials as Topic; Hepatitis B, Chronic; Humans; Molecula | 2017 |
Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?
Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Dose-Response Relationship, Drug; Hepatitis B, Chr | 2018 |
Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B.
Topics: Adenine; Administration, Oral; Alanine; Antiviral Agents; Drug-Related Side Effects and Adverse Reac | 2018 |
Bayesian Network Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B Drugs.
Topics: Adenine; Antiviral Agents; Bayes Theorem; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Network | 2019 |
Drugs in the Pipeline for HBV.
Topics: Adenine; Antiviral Agents; DNA, Viral; Female; Forecasting; Hepatitis B Surface Antigens; Hepatitis | 2019 |
Update in the management of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Monitoring; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chro | 2013 |
Treatment of delta hepatitis.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Farnesyl-Diphosphate Farnesyltransferase; Hepa | 2013 |
Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.
Topics: Adenine; Administration, Oral; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; He | 2013 |
[Interdisciplinary aspects of and new drugs for chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Comorbidity; Drug Interactions; Drug Therapy, Combination; Female; Gastro | 2013 |
Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Guanine; Hepati | 2013 |
Hepatitis B in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Resistance, Viral; Hepatitis B Vaccine | 2013 |
[Reactivation of chronic hepatitis B].
Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antiviral Agents; Biomarkers | 2013 |
Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Creatinine; DNA, Viral; Drug Therapy, Combination; | 2014 |
Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hep | 2013 |
Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combinati | 2013 |
Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organopho | 2014 |
Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment.
Topics: Acidosis, Lactic; Adenine; Administration, Oral; Antiviral Agents; Arabinofuranosyluracil; Dose-Resp | 2014 |
HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?
Topics: Adenine; Age Factors; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Guanine; Hepatitis B | 2014 |
HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
Topics: Adenine; Age Factors; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Guanine; Hepatitis B | 2014 |
Impact of HBV therapy on the incidence of hepatocellular carcinoma.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Guanine; Hepatitis | 2014 |
New therapeutic perspectives in HBV: when to stop NAs.
Topics: Adenine; Algorithms; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Guanine; H | 2014 |
Clinical utility of entecavir for chronic hepatitis B in Chinese patients.
Topics: Adenine; Antiviral Agents; China; Cost-Benefit Analysis; Drug Resistance, Viral; Hepatitis B, Chroni | 2013 |
Peginterferon alpha versus other antiviral regimes for Chinese HBeAg-positive chronic hepatitis B patients.
Topics: Adenine; Antiviral Agents; China; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepati | 2013 |
Hypophosphatemic osteomalacia due to drug-induced Fanconi's syndrome associated with adefovir dipivoxil treatment for hepatitis B.
Topics: Adenine; Bone Diseases, Metabolic; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Hypophosphatemia; | 2014 |
An update on hepatitis B, D, and E viruses.
Topics: Adenine; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Hepatitis D, Chronic; Hepatitis E | 2014 |
Managing hepatitis B to prevent liver cancer: recent advances.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver N | 2014 |
Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis.
Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B Surface Antigens; H | 2014 |
Management of chronic hepatitis B in children: an unresolved issue.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Carrier State; Child; Databases, Bibliographic | 2014 |
Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments.
Topics: Adenine; Antiviral Agents; Disease Management; DNA, Viral; Drug Delivery Systems; Drug Resistance, V | 2014 |
Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Safety; Tenofo | 2014 |
Molecular diagnosis and treatment of drug-resistant hepatitis B virus.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; | 2014 |
Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B: A meta-analysis.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; H | 2014 |
Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphona | 2014 |
[Treatment of viral hepatitis in children].
Topics: Adenine; Adolescent; Antiviral Agents; Child; Child Welfare; Drug Therapy, Combination; Female; Hepa | 2013 |
Treating Immune-tolerant Hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Therapy; Hepatitis B, Chronic; Humans; Interferons; Nucleotides; Org | 2015 |
Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, | 2015 |
Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, | 2015 |
Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B, Chronic; | 2016 |
Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence.
Topics: Adenine; Antiviral Agents; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Im | 2015 |
Monotherapy for hepatitis B infection: a review of treatment options.
Topics: Adenine; Animals; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans | 2015 |
[Hepatitis B Virus Infection: Current Trends and Issues].
Topics: Adenine; Animals; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chron | 2015 |
HBsAg seroclearance or seroconversion induced by peg-interferon alpha and lamivudine or adefovir combination therapy in chronic hepatitis B treatment: a meta-analysis and systematic review.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B Surface Antigens; Hepatitis B, Chr | 2016 |
Chronic hepatitis B in children: Therapeutic challenges and perspectives.
Topics: Adenine; Alanine Transaminase; Antigens, Viral; Antiviral Agents; Child; Guanine; Hepatitis B virus; | 2017 |
A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepati | 2016 |
Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis.
Topics: Adenine; Creatinine; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney; Kidney Diseas | 2016 |
Management of Antiviral Resistance in Chronic Hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Guanine; Hep | 2017 |
[Treatment recommendations of chronic hepatitis B. Did the world escape us?].
Topics: Adenine; Antiviral Agents; Disease Management; Drug Therapy, Combination; Guanine; Health Planning G | 2008 |
Treatment of chronic hepatitis B infection: an update of Swedish recommendations.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Therapy, Combination; Emtr | 2008 |
[Management of chronic hepatitis B in treatment-naive patients].
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Guanine; Hepatitis B, Chronic; Humans; Interferon | 2008 |
[Management of antiviral-resistant chronic hepatitis B virus infection].
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Drug Resistance, Multiple, Viral; Guanine; Hepati | 2008 |
[Combination therapy in chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; | 2008 |
[Is it possible to stop nucleos(t)ide analogue based therapy in chronic hepatitis B?].
Topics: Adenine; Antiviral Agents; DNA, Viral; Hepatitis B Antigens; Hepatitis B virus; Hepatitis B, Chronic | 2008 |
A review of telbivudine for the management of chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, | 2008 |
LB80380: a promising new drug for the treatment of chronic hepatitis B.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepati | 2008 |
LB80380: a promising new drug for the treatment of chronic hepatitis B.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepati | 2008 |
LB80380: a promising new drug for the treatment of chronic hepatitis B.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepati | 2008 |
LB80380: a promising new drug for the treatment of chronic hepatitis B.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepati | 2008 |
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update.
Topics: Adenine; Antiviral Agents; Case Management; DNA, Viral; Guanine; Hepatitis B, Chronic; Humans; Inter | 2008 |
[Interferon in hepatitis B].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Guanine; H | 2008 |
[Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Viral; Drug The | 2008 |
[Entecavir].
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug T | 2008 |
[Resistance in hepatitis B virus].
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Drug Therapy, C | 2008 |
[Clinical management of patients with chronic hepatitis B virus infection].
Topics: Adenine; Antiviral Agents; Biopsy; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Viral; | 2008 |
Role of combination therapy in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinat | 2009 |
Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success.
Topics: Adenine; Adenine Nucleotides; Alanine Transaminase; Carcinoma, Hepatocellular; DNA, Viral; Drug Admi | 2008 |
Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens | 2008 |
HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B, Chr | 2009 |
Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides.
Topics: Adenine; Administration, Oral; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B vir | 2009 |
On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; DNA, Viral; Drug Resistance, Multiple, Viral; Hepa | 2009 |
[Chronic hepatitis B: current therapy].
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Guanine; Hepatitis B Vacc | 2008 |
Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation.
Topics: Adenine; Adult; Aged; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Interferon-alpha; Male | 2009 |
Tenofovir for the treatment of hepatitis B virus.
Topics: Adenine; Antiviral Agents; Drug Approval; Drug Interactions; Hepatitis B virus; Hepatitis B, Chronic | 2009 |
Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Hepatitis B virus; Hepa | 2009 |
Tenofovir disoproxil fumarate: in chronic hepatitis B.
Topics: Adenine; Administration, Oral; Adult; Hepatitis B, Chronic; Humans; Organophosphonates; Prodrugs; Ra | 2009 |
Lenalidomide-induced acute liver failure.
Topics: Adenine; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Hepatitis B, Chronic; Humans; L | 2009 |
Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion.
Topics: Adenine; Adjuvants, Immunologic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administra | 2010 |
Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B, | 2010 |
Effect of newer oral antiviral agents on future therapy of chronic hepatitis B.
Topics: Adenine; Administration, Oral; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; | 2010 |
[Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab].
Topics: Adenine; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody | 2010 |
Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Hepatit | 2010 |
On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective.
Topics: Adenine; Antiviral Agents; Asia; Biomarkers; DNA, Viral; Drug Monitoring; Drug Resistance, Viral; Gu | 2010 |
Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, | 2010 |
Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Lamivud | 2010 |
Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Clinical Trials, Phase III as Topic; Double-Blind Method; Hepatitis B vir | 2010 |
Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?
Topics: Adenine; Antiviral Agents; Decision Making; Guanine; Hepatitis B, Chronic; Humans; Immunomodulation; | 2011 |
Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection.
Topics: Adenine; Animals; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alp | 2011 |
Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alph | 2011 |
Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; | 2011 |
Hepatitis B virus resistance to antiviral drugs: where are we going?
Topics: Adenine; Antiviral Agents; Capsid; Clinical Protocols; Drug Resistance, Viral; Guanine; Hepatitis B | 2011 |
Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chronic; Human | 2011 |
[Treatment of patients with lamivudine-resistant chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Lamivudine | 2011 |
Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis.
Topics: Adenine; Antiviral Agents; Asia; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Orga | 2011 |
Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: a systematic review.
Topics: Adenine; Antiviral Agents; Controlled Clinical Trials as Topic; Hepatitis B virus; Hepatitis B, Chro | 2011 |
[Interferon-based versus direct antiviral therapy in patients with chronic hepatitis B].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepati | 2011 |
[Progress and perspectives in treatment of chronic hepatitis B].
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Interferons; Lami | 2011 |
Drug safety evaluation of adefovir in HBV infection.
Topics: Adenine; Antiviral Agents; Clinical Trials, Phase III as Topic; Hepatitis B, Chronic; Humans; Organo | 2011 |
Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding.
Topics: Adenine; Antiviral Agents; Breast Feeding; Female; Guanine; Hepatitis B; Hepatitis B virus; Hepatiti | 2011 |
Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B, | 2011 |
Antiviral drugs for viruses other than human immunodeficiency virus.
Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet; | 2011 |
[The past, present and future treatment for chronic hepatitis B].
Topics: Adenine; Adult; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Or | 2011 |
[Lamivudine, adefovir dipivoxil].
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates | 2011 |
[Prevention for the development of hepatitis B virus-related hepatocellular carcinoma by anti-viral treatment].
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Interferons; Lam | 2011 |
Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis B, Chroni | 2011 |
Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?
Topics: Adenine; Antiviral Agents; Biomarkers; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens | 2012 |
Emerging pipeline drugs for hepatitis B infection.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Design; Drugs, Investigational; Guanine; H | 2011 |
Comparative meta-analysis of adefovir dipivoxil monotherapy and combination therapy of adefovir dipivoxil and lamivudine for lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis | 2012 |
Adefovir dipivoxil in chronic hepatitis B: history and current uses.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Nucleic Acid Synthesis Inhibitors; Organoph | 2012 |
Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
Topics: Adenine; Administration, Oral; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combin | 2012 |
New advances in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Coinfection; Disease Progression; Drug Resistance, Viral; Female; Guanine | 2012 |
New perspectives in the therapy of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Monitoring; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; H | 2012 |
[New drugs of treatment of patients with chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Emtricitabine; Hepatitis B, Chroni | 2012 |
First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Guanine; Hepatitis B, Chronic; Humans; Nucleosi | 2012 |
Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
Topics: Adenine; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Organophospho | 2012 |
[Comparison of peg-interferon monotherapy to peg-interferon and nucleoside analogue combination therapy for hepatitis B: a meta-analysis of randomized controlled trials].
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferons; Lam | 2012 |
Long-term therapy with nucleoside/nucleotide analogues for chronic hepatitis B in Asian patients.
Topics: Adenine; Antiviral Agents; Asian People; Carcinoma, Hepatocellular; Disease Progression; Drug Resist | 2013 |
Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs.
Topics: Adenine; Age Factors; Antiviral Agents; Comorbidity; DNA, Viral; Drug Resistance, Viral; Guanine; He | 2012 |
Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple; Guanine; Hepatitis B e Antigens; Hepatitis B v | 2012 |
Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B : a systematic review.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Guanine; Health Care Costs; Hepatitis B, Chronic; | 2013 |
Letter: First-line monotherapies for chronic hepatitis B - indirect comparison between entecavir and tenofovir.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Randomized Con | 2013 |
Update on the management of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Organophosphonates | 2002 |
Advances in therapy for chronic hepatitis B.
Topics: Adenine; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organo | 2002 |
Management of chronic hepatitis B virus infection in remote-dwelling Aboriginals and Torres Strait Islanders: an update for primary healthcare providers.
Topics: Adenine; Adolescent; Adult; Algorithms; Antiviral Agents; Australia; Carcinoma, Hepatocellular; Chil | 2003 |
Treatment of HBeAg-negative chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Endpoint Determination; Hepatitis B e Antigens; Hepatitis B, Chronic; Hum | 2003 |
Adefovir dipivoxil.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Interactions; Hepatitis B, Chronic; Humans | 2003 |
[Antiviral therapy for chronic viral hepatitis B and C].
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon a | 2003 |
Slowing the progression of chronic hepatitis B. Early antiviral therapy can help minimize complications.
Topics: Adenine; Administration, Oral; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Child; Dis | 2003 |
Adefovir dipivoxil: a review of its use in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, | 2003 |
[Hepatitis: associated diseases. Risk groups -- prevention -- treatment].
Topics: Adenine; Adult; Antiviral Agents; Child; DNA, Viral; Female; Hepacivirus; Hepatitis B; Hepatitis B S | 2003 |
Nucleoside analogues and other antivirals for treatment of hepatitis B in the peritransplant period.
Topics: Adenine; Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulins; Lamivud | 2003 |
Current pharmacotherapy for the treatment of chronic hepatitis B.
Topics: 2-Aminopurine; Adenine; Antiviral Agents; Clinical Trials as Topic; Famciclovir; Hepatitis B e Antig | 2003 |
Chronic viral hepatitis: always be current!
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Child; Female; Hepacivirus; Hepatitis B; Hepatitis B v | 2003 |
[Application and efficacy of adefovir dipivoxil in hepatitis B virus-associated chronic liver diseases].
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Liver Diseases; Organophosphonates | 2003 |
Viral hepatitis B.
Topics: Adenine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Genotype; Hepatitis B; Hepatitis | 2003 |
Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy?
Topics: Adenine; Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Hepatitis B virus; | 2004 |
Adefovir (Hepsera) for chronic hepatitis B infection.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Organophosphonates | 2003 |
Adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B: a review of the major clinical studies.
Topics: Adenine; Antiviral Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; He | 2003 |
Combination therapy for chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B Antibodies; Hepatitis B e Antigens | 2003 |
Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others).
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Emtricitabine; Guanine; Hepatitis | 2003 |
Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents | 2003 |
Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection.
Topics: Adenine; Animals; Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Res | 2003 |
Adefovir dipivoxil in the treatment of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Hep | 2004 |
Management of chronic hepatitis B in the HIV-infected patient.
Topics: Adenine; Algorithms; Antiviral Agents; Clinical Trials as Topic; Decision Trees; Drug Therapy, Combi | 2004 |
Editorial comment: HIV and HBV coinfection--a coming-of-age in treatment strategies.
Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Guanin | 2004 |
[Adefovir dipivoxil is a new drug for treatment of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Organophosphonates | 2004 |
[New approaches in the treatment of hepatitis B].
Topics: 2-Aminopurine; Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Contrai | 2004 |
Overview of treatment of hepatitis B: key approaches and clinical challenges.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; | 2004 |
Treatment of patients with chronic hepatitis B with adefovir dipivoxil.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B v | 2004 |
Management of hepatitis B in liver transplantation patients.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Immunization, Passive; Immunoglobulins; Lam | 2004 |
Treatment with interferons (including pegylated interferons) in patients with hepatitis B.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Hepatitis B | 2004 |
New treatment of chronic hepatitis B.
Topics: Adenine; Animals; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Drug Resistance, Viral; E | 2004 |
Antiviral therapy for treatment-naïve hepatitis B virus patients.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha | 2004 |
Treatment of hepatitis B virus infection in patients coinfected with HIV.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudin | 2004 |
Antiviral therapy in patients with chronic hepatitis B and cirrhosis.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Cirrhos | 2004 |
[Treatment of chronic hepatitis B virus infection].
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B, Chronic; | 2004 |
[Hepatitis B (acute and chronic)].
Topics: Acute Disease; Adenine; Adolescent; Adult; Antiviral Agents; Child; Diagnosis, Differential; Drug Th | 2004 |
[Antiviral treatment of chronic hepatitis B with adefovir dipivoxil].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; | 2004 |
[Management of hepatitis B].
Topics: Adenine; Adult; Antiviral Agents; Child; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B | 2004 |
Treatment of chronic hepatitis B: who to treat, what to use, and for how long?
Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis B, Chr | 2004 |
Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Approval; Drug Resistance, Viral; Hepatiti | 2004 |
Current therapies for chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Drug Resistance; Drug Resistance, Viral; Drug Therapy, Combination; Hepat | 2004 |
Adefovir dipivoxil in chronic hepatitis B infection.
Topics: Adenine; Animals; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Hepatitis B e | 2004 |
Adefovir dipivoxil: review of a novel acyclic nucleoside analogue.
Topics: Adenine; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Resistance, Viral; Hepatitis | 2004 |
Emerging treatments in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Viral; Drug | 2004 |
Treatment of chronic viral hepatitis.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; He | 2004 |
The management of chronic viral hepatitis: a Canadian consensus conference 2004.
Topics: Adenine; Adult; Antiviral Agents; Canada; Child; Child, Preschool; Drug Therapy, Combination; Enzyme | 2004 |
[Subjective literature review: adefovir-dipivoxil].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Hepatitis B, Chronic; Humans; Organophosphonate | 2004 |
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.
Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Disease Progression; Drug Monitoring; Emtrici | 2005 |
[Chronic hepatitis B: which patients should be treated and how?].
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamiv | 2005 |
[Management of chronic hepatitis B].
Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; | 2005 |
Adefovir dipivoxil: focus on its use in the treatment of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Monitoring; Hepatitis B, Chronic; Humans; | 2005 |
[Clinical and virologic characteristics and treatment for chronic hepatitis B: relation with HBV genotypes].
Topics: Adenine; Antiviral Agents; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic | 2005 |
[Drug therapy in chronic liver disease].
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Antiviral Agents; Azathioprine; Cholangitis, Scleros | 2005 |
Therapeutic options for chronic hepatitis B: considerations and controversies.
Topics: Adenine; Antiviral Agents; Decision Making; DNA, Viral; Hepatitis B Antigens; Hepatitis B virus; Hep | 2006 |
[New virologic tests and their application in management of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genetic Variation; Genotype; Hepatiti | 2006 |
[Treatment of chronic hepatitis B].
Topics: Adenine; Administration, Oral; Antiviral Agents; Biopsy; DNA, Viral; Drug Resistance, Viral; Drug Th | 2006 |
[Liver transplantation for complications of hepatitis B].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combinati | 2006 |
Medical therapy of patients affected by HBeAg-negative chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon | 2006 |
Personal view: the management of chronic hepatitis B infection.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; H | 2006 |
Current treatment of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Forecasting; Hepatitis B e Antigens; Hepatitis | 2006 |
Management of chronic hepatitis B virus infection: current perspectives for the nurse practitioner.
Topics: Acute Disease; Adenine; Algorithms; Antiviral Agents; Carcinoma, Hepatocellular; Carrier State; Dise | 2006 |
Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression?
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Fibrosis; Genotype; Hepatitis B e Antigens; He | 2006 |
Perspectives on the development of acyclic nucleotide analogs as antiviral drugs.
Topics: Adenine; Animals; Antiviral Agents; Dogs; Drug Design; Hepatitis B virus; Hepatitis B, Chronic; HIV | 2006 |
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Drug Carriers; Drug Therapy, Combination; Health S | 2006 |
New developments in the treatment of chronic hepatitis B.
Topics: Adenine; Animals; Antiviral Agents; Clinical Trials as Topic; DNA, Viral; Drug Resistance, Viral; Dr | 2006 |
Chronic Hepatitis B and C--current treatment and future therapeutic prospects.
Topics: Adenine; Antiviral Agents; DNA-Directed RNA Polymerases; Hepatitis B e Antigens; Hepatitis B, Chroni | 2006 |
[Therapy of hepatitis B].
Topics: Adenine; Administration, Oral; Antiviral Agents; Diagnosis, Differential; Hepatitis B, Chronic; Huma | 2006 |
[Therapy of hepatitis B virus infection].
Topics: Adenine; Antiviral Agents; Drug Antagonism; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Co | 2006 |
[Managing resistance to analogue antiviral drugs in a decompensated cirrhosis patient].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hep | 2006 |
[Treating chronic lamivudine-resistant hepatitis B in HIV co-infected patients].
Topics: Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Drug Resistance, | 2006 |
[Managing lamivudine resistance in liver transplantation for hepatitis B liver disease].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis | 2006 |
Why adefovir is not yet available in Canada.
Topics: Adenine; Antiviral Agents; Canada; Drug Utilization; Hepatitis B, Chronic; Humans; Immunosuppressive | 2006 |
Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients.
Topics: Adenine; Administration, Oral; Algorithms; Antiviral Agents; Clinical Trials, Phase II as Topic; Cli | 2007 |
[Resistance to adefovir in patients with chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; | 2006 |
A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; England; Hepatitis B e Antigens; Hepatitis B, Chro | 2007 |
Improving outcomes for patients with chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B Vaccines; Hepatitis B, Chron | 2007 |
Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B, Chr | 2007 |
Treatment of chronic hepatitis B in HIV-infected patients in 2007.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; | 2007 |
Chronic hepatitis B with advanced fibrosis or cirrhosis: impact of antiviral therapy.
Topics: Adenine; Antiviral Agents; Disease Progression; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatit | 2007 |
Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: a systematic review of economic evidence.
Topics: Adenine; Antiviral Agents; China; Cost-Benefit Analysis; Databases, Factual; Hepatitis B, Chronic; H | 2007 |
[Indications for antiviral therapy for chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Biomarkers; Carrier State; Consensus Development Conferences as Topic; DN | 2007 |
[Therapy for chronic hepatitis B: relationship between HBV genotype and efficacy or resistance of anti-viral therapy].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Genotype; Guanine; Hepatitis B virus; Hepatitis B | 2007 |
Review article: Success and failure of nucleoside and nucleotide analogues in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Lamivudine | 2007 |
[Pharmacological agents for the treatment of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Follow-Up Studies; G | 2008 |
Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Epidemiologic Methods; Guanine; Hepatitis B e Anti | 2008 |
Clinical implications of resistance patterns against HBV-polymerase inhibitors for the treatment of chronic hepatitis B.
Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine | 2007 |
Review article: current antiviral therapy of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Resistance, Viral; Emtrici | 2008 |
[New developments in therapy of chronic hepatitis B. When are nucleoside analogs indicated?].
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Transpl | 2000 |
Current limitations to nucleoside analogue therapy for chronic hepatitis B virus infection in the liver transplant and non-transplant settings.
Topics: 2-Aminopurine; Adenine; Antiviral Agents; DNA, Viral; Famciclovir; Hepatitis B e Antigens; Hepatitis | 2000 |
Nucleoside analogues in the treatment of chronic hepatitis B.
Topics: 2-Aminopurine; Adenine; Antiviral Agents; Deoxycytidine; Emtricitabine; Famciclovir; Hepatitis B e A | 2000 |
Drug therapy for hepatitis B.
Topics: Adenine; Antiviral Agents; Disease Progression; Female; Hepatitis B, Chronic; Humans; Interferons; L | 2001 |
Hepatitis B infection in China.
Topics: 2-Aminopurine; Adenine; Antiviral Agents; China; Deoxycytidine; DNA, Viral; Drug Therapy, Combinatio | 2001 |
[Current knowledge on chronic hepatitis B therapy].
Topics: Adenine; Antiviral Agents; Drug Resistance, Microbial; Hepatitis B, Chronic; Humans; Interferon-alph | 2001 |
Nucleoside analogues for chronic hepatitis B.
Topics: 2-Aminopurine; Adenine; Antiviral Agents; Famciclovir; Ganciclovir; Guanine; Hepatitis B virus; Hepa | 2001 |
How will we use the new antiviral agents for hepatitis B?
Topics: 2-Aminopurine; Adenine; Alanine Transaminase; Antiviral Agents; Drug Resistance; Drug Therapy, Combi | 2002 |
Adefovir dipivoxil. Bis-POM PMEA, GS 0840, GS 840, Piv2PMEA.
Topics: Adenine; Animals; Clinical Trials as Topic; Drug Industry; Hepatitis B, Chronic; HIV Infections; Hum | 2002 |
228 trials available for adenine and Hepatitis B, Chronic
| Article | Year |
|---|---|
Pradefovir Treatment in Patients With Chronic Hepatitis B: Week 24 Results From a Multicenter, Double-Blind, Randomized, Noninferiority, Phase 2 Trial.
Topics: Adenine; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chron | 2022 |
Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients.
Topics: Adenine; Antiviral Agents; Creatinine; DNA, Viral; Fumarates; Hepatitis B e Antigens; Hepatitis B vi | 2022 |
Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study.
Topics: Adenine; Alanine; Antiviral Agents; DNA, Viral; Female; Fumarates; Guanine; Hepatitis B Surface Anti | 2022 |
Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; | 2020 |
Adefovir Dipivoxil plus Chinese Medicine in HBeAg-Positive Chronic Hepatitis B Patients: A Randomized Controlled 48-Week Trial.
Topics: Adenine; Adult; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Drugs, Chinese Her | 2020 |
Mitochondrial toxicity and body shape changes during nucleos(t)ide analogues administration in patients with chronic hepatitis B.
Topics: Adenine; Adiposity; Antiviral Agents; Cross-Sectional Studies; DNA, Mitochondrial; DNA, Viral; Drug | 2020 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Double-Blind Method; Drug | 2020 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Double-Blind Method; Drug | 2020 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Double-Blind Method; Drug | 2020 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Double-Blind Method; Drug | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; | 2020 |
Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; China; Creatinine; DNA, Viral; Drug Therapy, | 2020 |
Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
Topics: Acute-On-Chronic Liver Failure; Adenine; Adult; Alanine; Antiviral Agents; Guanine; Hepatitis B viru | 2021 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B | 2016 |
Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Female; Hepatitis B Antibo | 2017 |
Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Administration Schedule; | 2018 |
Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.
Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens | 2017 |
Effects of the combined administration of entecavir and adefovir dipivoxil to improve hepatic fibrosis in hepatitis B patients with interferon resistance.
Topics: Adenine; Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Creat | 2017 |
Tenofovir
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Dr | 2017 |
Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem | 2018 |
ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Hep | 2018 |
Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Admini | 2018 |
Combined effect of pegylated interferon α with adefovir on renal function in Chinese patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; China; Drug Therapy, Combination; Female; Glomerular Filtration Ra | 2018 |
Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Double-Blind Method; Dru | 2019 |
Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Double-Blind Method; Dru | 2019 |
Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Double-Blind Method; Dru | 2019 |
Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Double-Blind Method; Dru | 2019 |
Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B.
Topics: Adenine; Adult; Aged; Alanine; Antiviral Agents; Female; Guanine; Hepatitis B Surface Antigens; Hepa | 2019 |
Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B.
Topics: Adenine; Adult; Aged; Alanine; Antiviral Agents; Female; Guanine; Hepatitis B Surface Antigens; Hepa | 2019 |
Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B.
Topics: Adenine; Adult; Aged; Alanine; Antiviral Agents; Female; Guanine; Hepatitis B Surface Antigens; Hepa | 2019 |
Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B.
Topics: Adenine; Adult; Aged; Alanine; Antiviral Agents; Female; Guanine; Hepatitis B Surface Antigens; Hepa | 2019 |
Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Double-Blind Method; | 2019 |
Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation.
Topics: Adenine; Adult; Aged; Antiviral Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Fem | 2013 |
Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
Topics: Adenine; Adult; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinati | 2013 |
Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil.
Topics: Adenine; Adult; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e A | 2013 |
Two years efficiency of lamivudine and adefovir dipivoxil combined therapy in chronic hepatitis B patients.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chroni | 2013 |
Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio | 2013 |
Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combinatio | 2013 |
Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
Topics: Adenine; Adult; Aged; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies | 2013 |
Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy | 2013 |
Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Double-Blind Method; Drug Resistance, V | 2013 |
Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: results from the CAPRISA 004 trial.
Topics: Adenine; Adult; Anti-Infective Agents, Local; Antiviral Agents; Carrier State; Female; Hepatitis B v | 2013 |
Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections.
Topics: Adenine; Adult; Aged; Antibodies, Viral; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Com | 2014 |
No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.
Topics: Adenine; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Genotype; Hepati | 2014 |
No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.
Topics: Adenine; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Genotype; Hepati | 2014 |
No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.
Topics: Adenine; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Genotype; Hepati | 2014 |
No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.
Topics: Adenine; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Genotype; Hepati | 2014 |
[Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
Topics: Adenine; Adult; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; H | 2013 |
[Efficacy and safety of peginterferon alfa-2a (40 kd) plus adefovir for 96 weeks in HBeAg-negative chronic hepatitis B patients].
Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatit | 2013 |
Antiviral treatment improves disrupted peripheral B lymphocyte homeostasis in chronic hepatitis B virus-infected patients.
Topics: Adenine; Adult; Antiviral Agents; B-Lymphocytes; Female; Flow Cytometry; Hepatitis B, Chronic; Homeo | 2013 |
De novo combination therapy adefovir plus lamivudine as a treatment for women of child-bearing age with HBeAg-positive chronic hepatitis B before pregnancy.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Disease Transmission, Infectious | 2014 |
Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatit | 2013 |
Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatit | 2013 |
Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatit | 2013 |
Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatit | 2013 |
Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir.
Topics: Adenine; Adult; Antigen-Antibody Complex; Antiviral Agents; Area Under Curve; DNA, Viral; Female; He | 2014 |
Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients.
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; D | 2014 |
Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; | 2014 |
Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Deoxycytidine; DNA, Viral; Double-Blind Method; Drug C | 2014 |
[Therapeutic effect of antiviral regimens for chronic hepatitis B refractory to lamivudine plus adefovir].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B v | 2013 |
The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; China; Dose-Response Relationshi | 2014 |
Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir.
Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administr | 2013 |
Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Deoxycytidine; DNA, | 2014 |
Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings.
Topics: Adenine; Adolescent; Adult; Asian; Creatinine; Drug Resistance, Viral; Female; Hepatitis B, Chronic; | 2014 |
Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice.
Topics: Adenine; Adult; Animals; Antibody Formation; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Ant | 2015 |
Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Egy | 2014 |
Non-interventional study AI463-12 of real-world chronic HBV infection management--baseline characteristics and treatment patterns of Polish patients kohort.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; Europe; Female; Guanine; Hepatitis B, Chronic; Hum | 2013 |
Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.
Topics: Adenine; Adult; Coinfection; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Genotype | 2014 |
[Long-term efficacy and safety of telbivudine as monotherapy and as combination therapy with adefovir dipivoxil in HBeAg-positive chronic hepatitis B patients].
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B e Antig | 2014 |
Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinf | 2014 |
First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Female; Follow | 2014 |
Kinetics and prediction of HBsAg loss during long-term therapy with nucleos(t)ide analogues of different potency in patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chroni | 2014 |
No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinat | 2014 |
Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Double-Blind Method; Female; Gen | 2014 |
Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis | 2015 |
Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B e Antig | 2014 |
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B.
Topics: Adenine; DNA, Viral; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; I | 2015 |
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B.
Topics: Adenine; DNA, Viral; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; I | 2015 |
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B.
Topics: Adenine; DNA, Viral; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; I | 2015 |
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B.
Topics: Adenine; DNA, Viral; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; I | 2015 |
Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Asian People; China; DNA, Viral; Double-Blind Me | 2015 |
Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Asian People; China; DNA, Viral; Double-Blind Me | 2015 |
Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Asian People; China; DNA, Viral; Double-Blind Me | 2015 |
Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Asian People; China; DNA, Viral; Double-Blind Me | 2015 |
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml).
Topics: Adenine; Adult; Asian People; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Native Hawaiian | 2015 |
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml).
Topics: Adenine; Adult; Asian People; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Native Hawaiian | 2015 |
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml).
Topics: Adenine; Adult; Asian People; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Native Hawaiian | 2015 |
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml).
Topics: Adenine; Adult; Asian People; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Native Hawaiian | 2015 |
Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; H | 2015 |
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.
Topics: Adenine; Adult; Alanine; Antiviral Agents; DNA, Viral; Female; Hepatitis B, Chronic; Humans; Male; M | 2015 |
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Resistance, Vi | 2015 |
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Resistance, Vi | 2015 |
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Resistance, Vi | 2015 |
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Resistance, Vi | 2015 |
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Resistance, Vi | 2015 |
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Resistance, Vi | 2015 |
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Resistance, Vi | 2015 |
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Resistance, Vi | 2015 |
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Resistance, Vi | 2015 |
An intrahepatic transcriptional signature of enhanced immune activity predicts response to peginterferon in chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Biopsy; Chi-Square Distribution; Drug Therapy, Combination; Female | 2015 |
Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis B virus e antigen-positive, lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combinatio | 2014 |
Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Femal | 2015 |
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G | 2016 |
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G | 2016 |
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G | 2016 |
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G | 2016 |
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G | 2016 |
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G | 2016 |
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G | 2016 |
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G | 2016 |
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G | 2016 |
Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus.
Topics: Adenine; Adult; DNA, Viral; Female; Follow-Up Studies; Gestational Age; Hepatitis B virus; Hepatitis | 2015 |
Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepati | 2015 |
Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance.
Topics: Adenine; Adult; Antiviral Agents; Cost-Benefit Analysis; Double-Blind Method; Drug Resistance, Viral | 2015 |
[Treatment options in HBeAg-positive chronic hepatitis B patients with a poor response to 24-week interferon monotherapy].
Topics: Adenine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Guanine; Hep | 2015 |
Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
Topics: Adenine; Adult; Amantadine; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Fem | 2016 |
The curative effect of adefovir dipivoxil treating HBeAg negative chronic hepatitis B and treating HBeAg positive chronic hepatitis B combining interferon α-2b.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Combinations; Female; Hepat | 2015 |
[A randomized controlled trial on 240-week monotherapy with entecavir or adefovir in patients with chronic hepatitis B and cirrhosis].
Topics: Adenine; Aged; Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Aspartate Aminotransferas | 2015 |
Cost-effectiveness of Lamivudine, Telbivudine, Adefovir Dipivoxil and Entecavir on decompensated hepatitis B virus-related cirrhosis.
Topics: Adenine; Adult; Antiviral Agents; Cost-Benefit Analysis; Female; Guanine; Hepatitis B virus; Hepatit | 2016 |
[Efficacy Observation of Yiguanjian Decoction Combined Adefovir Dipivoxil Tablet in Treating HBeAg Negative Chronic Viral Hepatitis B Active Compensated Liver Cirrhosis Patients].
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; DNA, Viral; | 2016 |
CONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients: A prospective, randomized study.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Dr | 2016 |
Effect of nucleoside analogues in the treatment of hepatitis B cirrhosis and its effect on Th17 cell.
Topics: Adenine; Adult; Aged; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; L | 2017 |
Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants.
Topics: Adenine; Adolescent; Adult; Cell Line, Tumor; DNA, Viral; Dose-Response Relationship, Drug; Drug Res | 2008 |
Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Dose-Response | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2008 |
Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Guanine; Hep | 2009 |
Complex dynamics of hepatitis B virus resistance to adefovir.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hep | 2009 |
Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and lamivudine.
Topics: Adenine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resi | 2008 |
Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus.
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Biopsy; Double-Blind Method; Female; Hepatitis B e Ant | 2009 |
Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio | 2009 |
[A study on the treatment of chronic hepatitis B with YMDD mutation].
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug The | 2009 |
Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Cell Line; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fema | 2009 |
Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistance, Vir | 2009 |
Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Guanine; Hepatitis B e Antig | 2009 |
Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistanc | 2010 |
[A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period].
Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Collagen; DNA, Viral; Drug Resistance, | 2009 |
Full-length hepatitis B virus sequences from naïve patients with fluctuation of viral load during ADV monotherapy.
Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; China; DNA, Viral; Female; Genome, Viral; | 2010 |
A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; H | 2009 |
[The analyse of effectiveness in HBeAg-positive chronic viral hepatitis B treated by adefovir dipivoxil combined with bicyclol].
Topics: Adenine; Adolescent; Adult; Aged; Biphenyl Compounds; Drug Therapy, Combination; Hepatitis B e Antig | 2009 |
[Comparison of efficacy between adefovir dipivoxil and entecavir in patients with chronic hepatitis B].
Topics: Adenine; Administration, Oral; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Guanine; | 2010 |
Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Female; Follow-Up Studies; Guanine; Hepati | 2010 |
Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e An | 2010 |
Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Femal | 2011 |
Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio | 2010 |
[Comparison of the efficacy of 48 week-Entecavir therapy with that of Adefovir therapy for chronic hepatitis B patients].
Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepati | 2010 |
Overlap/switch to adefovir monotherapy for lamivudine-resistant patients who responded to combination therapy: a pilot controlled study.
Topics: Adenine; Adult; Aged; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; | 2010 |
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Deoxycytidine; DNA, Viral; Doubl | 2010 |
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Deoxycytidine; DNA, Viral; Doubl | 2010 |
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Deoxycytidine; DNA, Viral; Doubl | 2010 |
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Deoxycytidine; DNA, Viral; Doubl | 2010 |
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Deoxycytidine; DNA, Viral; Doubl | 2010 |
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Deoxycytidine; DNA, Viral; Doubl | 2010 |
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Deoxycytidine; DNA, Viral; Doubl | 2010 |
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Deoxycytidine; DNA, Viral; Doubl | 2010 |
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Deoxycytidine; DNA, Viral; Doubl | 2010 |
Question of ALT flare during switch to adefovir from lamivudine: A single center open-label, randomized, safety study (June 17, 2005 to February 5, 2009).
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Drug Substitution; Drug Therapy, Combination; Femal | 2010 |
[Effect of adefovir and lamivudine combination therapy on lamivudine resistance chronic hepatitis B patients for 48 weeks].
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Fem | 2010 |
[Efficacy and durability of generic adefovir dipivoxil in patients with HBeAg positive chronic hepatitis].
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Female; Hepatitis B Antibod | 2009 |
[Add on lamivudine to adefovir monotherapy for the treatment of lamivudine-resistant chronic hepatitis B patients].
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem | 2010 |
Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; DNA, Viral; Drug Resistance | 2010 |
Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Deoxy | 2010 |
[Short-term efficacy of adefovir dipivoxil as an add-on therapy in the pegylated IFNalpha-2a treatment for HBeAg positive chronic hepatitis B patients].
Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatit | 2010 |
Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G | 2010 |
Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.
Topics: Adenine; Adult; Aged; Aged, 80 and over; DNA, Viral; Drug Resistance, Viral; Epidemiologic Methods; | 2011 |
[Efficacy of the 96-week adefovir dipivoxil therapy in patients with chronic hepatitis B].
Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Genotype; | 2010 |
[Observation on effect of peg interferon lphaa-2a treating lamivudine resistant chronic hepatitis B].
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hep | 2010 |
[Efficacy of adefovir treatment in the lamivudine-resistant chronic hepatitis B patients].
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Humans; Lami | 2010 |
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.
Topics: Adenine; Adolescent; Adult; Aged; Creatinine; Deoxycytidine; DNA, Viral; Drug Combinations; Emtricit | 2011 |
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.
Topics: Adenine; Adolescent; Adult; Aged; Creatinine; Deoxycytidine; DNA, Viral; Drug Combinations; Emtricit | 2011 |
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.
Topics: Adenine; Adolescent; Adult; Aged; Creatinine; Deoxycytidine; DNA, Viral; Drug Combinations; Emtricit | 2011 |
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.
Topics: Adenine; Adolescent; Adult; Aged; Creatinine; Deoxycytidine; DNA, Viral; Drug Combinations; Emtricit | 2011 |
[Influence of adefovir dipivoxil on HBV specific CTL in patients with chronic hepatitis B].
Topics: Adenine; Adult; Antiviral Agents; Drug Administration Schedule; Female; Hepatitis B, Chronic; Humans | 2010 |
Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Ch | 2011 |
Evaluation of adefovir & lamivudine in chronic hepatitis B: correlation with HBV viral kinetic, hepatic-necro inflammation & fibrosis.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Drug Resistance, Viral; Female; Hepatitis B | 2011 |
Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents.
Topics: Adenine; Adult; Antiviral Agents; Blood; DNA, Circular; DNA, Viral; Female; Guanine; Hepatitis B vir | 2011 |
No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus.
Topics: Adenine; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Gene Products, pol; Hep G2 Cells; Hep | 2011 |
Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.
Topics: Adenine; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistance, Viral; Fem | 2011 |
Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Biopsy; Chi-Square Distribution; DNA, Circular; DNA, V | 2011 |
[Safety and efficacy of Entecavir combined with Adefovir in patients with chronic hepatitis B who fail to respond to nucleoside analog treatment].
Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic; | 2011 |
Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; China; Drug Resistance, Viral; Drug Therapy, Com | 2011 |
Simple scoring system predicting genotypic resistance during rescue therapy for Lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combin | 2012 |
Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study.
Topics: Adenine; Adult; Aged; Antiviral Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Eur | 2011 |
Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment.
Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; L | 2011 |
[The levels of HBsAg can predict the efficacy of peglated interferon-alpha 2a combined with adefovir dipivoxil, in HBeAg-positive chronic hepatitis B patients].
Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatit | 2011 |
Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis.
Topics: Adenine; Aged; Antiviral Agents; Cohort Studies; Disease Progression; Drug Therapy, Combination; Fem | 2011 |
[Relationship between HBeAg seroconversion with genotypes and HBV specific CTL in patients with chronic hepatitis B treated with Adefovir dipivoxil].
Topics: Adenine; Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Immu | 2011 |
[Efficacy of two nucleoside analogs to treat resistant HBeAg-negative chronic hepatitis B].
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Femal | 2011 |
Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Asian People; DNA, Viral; Drug Resistance, Viral; Fema | 2012 |
[Clinical antiviral effects of Peg-IFNa-2a in patients with chronic hepatitis B].
Topics: Adenine; Adult; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Interferon-alpha; M | 2011 |
Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir.
Topics: Adenine; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Therapy, Combination; Ethnicity; Follow- | 2012 |
[A clinical study on the efficacy of HBeAg-positive chronic hepatitis B patients treated with adefovir dipivoxil for 4 years].
Topics: Adenine; Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Ch | 2011 |
[Polish multicenter study on safety and efficacy of adefovir dipivoxil in the treatment of lamivudine resistant chronic hepatitis B in adults (HEP 2008)].
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Com | 2011 |
Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Guanine; Hepatit | 2012 |
[Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine | 2011 |
Improved efficacy by individualized combination therapy with Peg IFN-a 2a and ADV in HBeAg positive chronic hepatitis B patients.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Chi-Square Distribution; China; | 2012 |
Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatit | 2012 |
[Efficacy of lamivudine and adefovir de novo combination therapy or after mono-therapy in chronic hepatitis B patients].
Topics: Adenine; Adult; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; M | 2012 |
Efficacy and safety of long-term adefovir dipivoxil therapy in children with chronic hepatitis B infection.
Topics: Adenine; Adolescent; Child; Child, Preschool; DNA, Viral; Double-Blind Method; Drug Resistance, Vira | 2012 |
Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B.
Topics: Adenine; Adolescent; Alanine Transaminase; Antiviral Agents; Bone Density; Child; DNA, Viral; Double | 2012 |
[Clinical study on Baihua Xianglian detoxification recipe combined with adefovir dipivoxil in treating HBeAg positive chronic hepatitis].
Topics: Adenine; Adult; Antiviral Agents; Drugs, Chinese Herbal; Female; Hepatitis B e Antigens; Hepatitis B | 2012 |
Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Vir | 2012 |
Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Vir | 2012 |
Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Vir | 2012 |
Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Vir | 2012 |
Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Biomarkers; Chi-Square Dis | 2012 |
Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adolescent; Antiviral Agents; Child; Child, Preschool; DNA, Viral; Drug Resistance, Viral; | 2012 |
[Experimental study on effect of dahuang zhechong wan combined with adefovir dipivoxil in preventing hepatic fibrosis in patients with chronic hepatitis B].
Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; | 2012 |
Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem | 2012 |
Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir.
Topics: Adenine; Adult; Biomarkers; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B e A | 2012 |
[The clinical efficacy and safety of adefovir dipivoxil in combination with bicyclol for the treatment of senior patients with chronic hepatitis B].
Topics: Adenine; Aged; Aged, 80 and over; Antiviral Agents; Biphenyl Compounds; DNA, Viral; Female; Hepatiti | 2011 |
Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genome, | 2013 |
[The therapeutic effect of Anluohuaxian capsule combined with adefovir dipivoxil on patients with chronic hepatitis B and influence on hepatic histology].
Topics: Adenine; Adult; Antiviral Agents; Drugs, Chinese Herbal; Female; Hepatitis B, Chronic; Humans; Liver | 2012 |
Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatit | 2012 |
Comparison of the antiviral effects of entecavir and adefovir dipivoxil in chronic HBV infection: a randomized control trial.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Bilirubin; DNA, Viral; Female; Guanine | 2012 |
Sustained efficacy of adefovir add-on therapy in chronic hepatitis B patient with a poor virological response to peginterferon alfa.
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Drug Administration Schedule; Drug Therapy, Combinatio | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2013 |
Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir.
Topics: Adenine; Adult; Antiviral Agents; B7-H1 Antigen; CD8-Positive T-Lymphocytes; Double-Blind Method; He | 2013 |
[Efficacy of combination therapy of lamivudine and adefovir dipivoxyl for patients with hepatitis B-induced decompensated liver cirrhosis].
Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepati | 2012 |
Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial.
Topics: Adenine; Adult; Analysis of Variance; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; | 2013 |
Antiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic hepatitis B virus infected patients.
Topics: Adenine; Adult; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Killer Cells, Natural; Male; | 2012 |
Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Drug Tolerance; Female; Genotype; Hepatitis B, Chronic | 2012 |
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Dose-Response Relationship, Drug; Drug | 2013 |
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Dose-Response Relationship, Drug; Drug | 2013 |
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Dose-Response Relationship, Drug; Drug | 2013 |
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Dose-Response Relationship, Drug; Drug | 2013 |
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Dose-Response Relationship, Drug; Drug | 2013 |
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Dose-Response Relationship, Drug; Drug | 2013 |
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Dose-Response Relationship, Drug; Drug | 2013 |
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Dose-Response Relationship, Drug; Drug | 2013 |
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Dose-Response Relationship, Drug; Drug | 2013 |
52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Dr | 2013 |
52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Dr | 2013 |
52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Dr | 2013 |
52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Dr | 2013 |
[Efficacy and safety of telbivudine and adefovir dipivoxil for the treatment of chronic hepatitis B patients with high level hepatitis B virus load and hepatitis B e antigen-positivity].
Topics: Adenine; Adult; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Mal | 2012 |
Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks.
Topics: Adenine; Adult; Antiviral Agents; Base Sequence; Carcinoma, Hepatocellular; Conserved Sequence; DNA- | 2002 |
Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hep | 2002 |
Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; H | 2002 |
An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Follow-Up | 2003 |
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2003 |
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2003 |
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2003 |
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2003 |
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2003 |
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2003 |
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2003 |
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2003 |
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M | 2003 |
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Double | 2003 |
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Double | 2003 |
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Double | 2003 |
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Double | 2003 |
Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Base Sequence; Conserve | 2003 |
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.
Topics: Adenine; Adult; Antiviral Agents; Asia; DNA, Viral; Europe; Female; Genotype; Hepatitis B e Antigens | 2003 |
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Amino Acid Motifs; Antiviral Agents; DNA, Viral; Drug Th | 2004 |
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug | 2004 |
Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Hepatitis B Surface Antigens; He | 2004 |
Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Double-Blind Method; Female; Glycosuria; Hematuria; He | 2004 |
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.
Topics: Adenine; Adult; Drug Resistance, Viral; Female; Hepatitis B, Chronic; HIV Infections; Humans; Immuno | 2004 |
Tenofovir in chronic hepatitis B.
Topics: Adenine; Adult; Aged; Hepatitis B, Chronic; Humans; Middle Aged; Organophosphonates; Reverse Transcr | 2005 |
Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Epidemiologic Me | 2005 |
Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Vi | 2005 |
Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hep | 2005 |
Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatic Encephalopathy; Hepa | 2005 |
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Animals; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Adminis | 2005 |
Clinical and virological response to adefovir dipovixil for lamivudine-resistant HBeAg-negative hepatitis B.
Topics: Adenine; Administration, Oral; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resis | 2005 |
Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis | 2005 |
A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; China; DNA, Viral; Double-Blind Method; Female; Follow | 2006 |
Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio | 2006 |
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
Topics: Adenine; Anti-HIV Agents; Chi-Square Distribution; DNA, Viral; Drug Resistance, Viral; Hepatitis B e | 2006 |
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Double-Blind Me | 2006 |
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; | 2006 |
Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, C | 2006 |
[A double-blind, randomized, lamivudine-controlled clinical trial of DAIDING (adefovir dipivoxil) for lamivudine-resistant patients with chronic hepatitis B].
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Resistance, Viral; Fem | 2006 |
[A clinical study of adefovir dipivoxil, made in China, for treatment of hepatitis B e antigen-positive patients with chronic hepatitis B].
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Resistance, Viral; Hep | 2006 |
Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio | 2007 |
Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio | 2007 |
Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio | 2007 |
Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio | 2007 |
Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Drug Th | 2006 |
Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Dose-Response | 2007 |
Hepatitis B virus resistance to adefovir in a nucleotide naive patient with chronic hepatitis B virus infection.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepat | 2007 |
Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antibodies, Viral; Antiviral Agents; Bilirubin; Creatini | 2007 |
Adefovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B.
Topics: Adenine; Adult; Aged; Alanine Transaminase; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combin | 2007 |
[Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients].
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Hepatit | 2007 |
[A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B].
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepa | 2007 |
Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Double-Blind Method; Drug Therapy, Comb | 2007 |
Second tenofovir phase III study for the chronic HBV reaches primary endpoint.
Topics: Adenine; Anti-HIV Agents; Double-Blind Method; Hepatitis B, Chronic; Humans; Organophosphonates; Rev | 2007 |
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combinatio | 2007 |
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combinatio | 2007 |
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combinatio | 2007 |
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combinatio | 2007 |
Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Disease Progressi | 2007 |
[Diammonium glycyrrhizinate does not affect efficacy of adefovir dipivoxil therapy in patients with HBeAg-positive chronic hepatitis B].
Topics: Adenine; Adult; Antiviral Agents; Double-Blind Method; Glycyrrhizic Acid; Hepatitis B e Antigens; He | 2007 |
[Efficacy of adefovir dipivoxil was not related to genotypes B and C of hepatitis B virus: a randomized, double-blind, multicenter clinical study].
Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Genotype; Hep | 2007 |
Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Asian People; Double-Blind Method; Drug Administration Schedule; F | 2007 |
Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity.
Topics: Adenine; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; DNA, Viral; Female; Hepatitis B e Anti | 2008 |
[Adefovir dipivoxil compassionate use program in Spain: efficacy and resistance analysis].
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B viru | 2007 |
Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.
Topics: Adenine; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytid | 2008 |
Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.
Topics: Adenine; Adult; Aged; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Ther | 2008 |
Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.
Topics: Adenine; Adult; Aged; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Ther | 2008 |
Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.
Topics: Adenine; Adult; Aged; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Ther | 2008 |
Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.
Topics: Adenine; Adult; Aged; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Ther | 2008 |
96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, | 2008 |
The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection.
Topics: Adenine; Adolescent; Antiviral Agents; Area Under Curve; Child; Child, Preschool; Dose-Response Rela | 2008 |
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, | 2008 |
Short-term overlap lamivudine treatment with adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Dr | 2008 |
Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B.
Topics: Adenine; Adolescent; Age Factors; Alanine Transaminase; Antiviral Agents; Child; Child, Preschool; D | 2008 |
Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatit | 2008 |
Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy.
Topics: Adenine; Antiviral Agents; DNA, Viral; Half-Life; Hepatitis B Surface Antigens; Hepatitis B virus; H | 1999 |
A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Hep | 1999 |
754 other studies available for adenine and Hepatitis B, Chronic
| Article | Year |
|---|---|
Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide
Topics: Adenine; Alanine; Body Weight; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Male; Middle Aged; | 2022 |
Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study.
Topics: Adenine; Adult; Antiviral Agents; China; Cleft Lip; Cleft Palate; Female; Hepatitis B; Hepatitis B S | 2022 |
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis.
Topics: Adenine; Alanine; Cholesterol; Hepatitis B, Chronic; Humans; Propensity Score; Tenofovir | 2022 |
Effects of Long-Term Tenofovir and Entecavir Treatment on Bone Mineral Density in Patients with Chronic Hepatitis B.
Topics: Adenine; Antiviral Agents; Bone Density; Guanine; Hepatitis B, Chronic; Humans; Prospective Studies; | 2022 |
[Clinical significance and management strategies of low-level viremia during the treatment of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Out | 2021 |
Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Fumarates; Guanine; Hepatitis B Surface Antigens; Hepatitis B, C | 2021 |
Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Hepatitis B Surface Antigens | 2022 |
Renal Outcomes With Tenofovir Alafenamide in Liver Transplant Recipients.
Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Kidney; Liver Transplantation; Ten | 2023 |
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles.
Topics: Adenine; Alanine; Dyslipidemias; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study.
Topics: Adenine; Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Leukemia, Lymphocytic, C | 2022 |
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B.
Topics: Adenine; Alanine; Carcinoma, Hepatocellular; Female; Hepatitis B, Chronic; Humans; Liver Neoplasms; | 2022 |
CKD in a Patient Treated with Adefovir for Chronic Hepatitis B Virus Infection.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Organophosphonates; Renal Insufficiency, Ch | 2021 |
Novel hepatitis B virus reverse transcriptase mutations in patients with sustained viremia despite long-term tenofovir treatment.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chron | 2022 |
Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Female; Hepatitis B; Hepatitis B, Chronic; HIV Infections; | 2022 |
Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
Topics: Adenine; Adult; Alanine; Antiviral Agents; DNA, Viral; Hepatitis B, Chronic; Humans; Renal Insuffici | 2022 |
HERACLIS-TAF: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks.
Topics: Adenine; Adult; Alanine; Hepatitis B, Chronic; HIV Infections; Humans; Phosphates; Prospective Studi | 2022 |
One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study.
Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis | 2022 |
Treatment of chronic hepatitis B: virological and pharmacological aspects
Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Tenofovir Alafenamide use in pregnant women with chronic hepatitis B virus infection: more data needed.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Hu | 2022 |
Plasma and breast milk pharmacokinetics of tenofovir alafenamide of mothers with chronic hepatitis B infection-Authors' reply.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Milk, Human; | 2022 |
Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B, Chronic; HIV Infections; Humans; Milk, Huma | 2022 |
Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis.
Topics: Adenine; Alanine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis B virus; Hepati | 2022 |
Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic hepatitis B patients-author's reply.
Topics: Adenine; Alanine; Bone Density; Fumarates; Hepatitis B, Chronic; Humans; Kidney; Tenofovir | 2022 |
Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B.
Topics: Adenine; Alanine; Bone Density; Fumarates; Hepatitis B, Chronic; Humans; Kidney; Tenofovir | 2022 |
Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Kidney; Long | 2022 |
Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
Topics: Adenine; Alanine; Antiviral Agents; DNA, Viral; Hepatitis B, Chronic; Humans; Recurrence; Retreatmen | 2023 |
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues-treated patients with chronic hepatitis B.
Topics: Adenine; Alanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues-treated patients with chronic hepatitis B - author's reply.
Topics: Adenine; Alanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Switching to Tenofovir Alafenamide Fumarate in Chronic Hepatitis B Patients Who Had Detectable HBV DNA during Treatment with Entecavir.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Fumarates; Hepatitis B, Chronic; H | 2022 |
Effect of nucleos(t)ide analogues on blood lipid profiles in patients with chronic hepatitis B: A cross-sectional survey.
Topics: Adenine; Antiviral Agents; Cross-Sectional Studies; Hepatitis B, Chronic; Humans; Hypercholesterolem | 2022 |
Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.
Topics: Adenine; Alanine; Antiviral Agents; Hepatitis A; Hepatitis B; Hepatitis B virus; Hepatitis B, Chroni | 2023 |
Tenofovir Alafenamide for Multiple Drug-Resistant Chronic Hepatitis B: A 3-Year Clinical Trial.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; HIV Infections; Humans; Tenofovir; Treatment Outcom | 2023 |
Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation.
Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Li | 2023 |
The expression of interleukin-1β in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; DNA, Viral; Drug Therapy, Comb | 2023 |
Tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: A nationwide claims study in South Korea.
Topics: Adenine; Adult; Alanine; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Osteoporotic Fract | 2023 |
Immunomodulatory Mechanism of Acyclic Nucleoside Phosphates in Treatment of Hepatitis B Virus Infection.
Topics: Adenine; Adult; Aged; Antiviral Agents; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hu | 2020 |
In response to identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.
Topics: Adenine; Hepatitis B, Chronic; Humans; Mutation; Organophosphonates; Tenofovir | 2019 |
Reply to: "In response to identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients."
Topics: Adenine; Hepatitis B, Chronic; Humans; Mutation; Organophosphonates; Tenofovir | 2019 |
[Analysis of resistance mutations in patients with persistent low viral load during antiviral therapy with tebivudine alone or in combination with adefovir dipivoxil].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chron | 2019 |
Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
Topics: Adenine; Aged; Alanine; Antibodies, Viral; Antiviral Agents; Female; Fumarates; Genotype; Guanine; H | 2020 |
Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
Topics: Adenine; Aged; Alanine; Antibodies, Viral; Antiviral Agents; Female; Fumarates; Genotype; Guanine; H | 2020 |
Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
Topics: Adenine; Aged; Alanine; Antibodies, Viral; Antiviral Agents; Female; Fumarates; Genotype; Guanine; H | 2020 |
Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
Topics: Adenine; Aged; Alanine; Antibodies, Viral; Antiviral Agents; Female; Fumarates; Genotype; Guanine; H | 2020 |
Effect of nucleos(t)ide analogue on serum HBsAg level in chronic hepatitis B patients: A 3-years study.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B S | 2020 |
Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.
Topics: Adenine; Adult; Alanine; Antiviral Agents; Asian People; Carcinoma, Hepatocellular; Cohort Studies; | 2020 |
Pregnancy outcomes for pregnant women with chronic hepatitis B exposing to entecavir or adefovir dipivoxil therapy before or in early pregnancy.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gu | 2022 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide: perhaps not as simple as we thought.
Topics: Adenine; Alanine; Antiviral Agents; Cholesterol, LDL; Drug Monitoring; Drug Substitution; Glomerular | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report.
Topics: Adenine; Antiviral Agents; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organo | 2020 |
Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; | 2021 |
Hepatitis B virus mutation pattern rtA181S+T184I+M204I may contribute to multidrug resistance in clinical practice: Analysis of a large cohort of Chinese patients.
Topics: Adenine; Adult; Antiviral Agents; Asian People; Beijing; Cohort Studies; DNA, Viral; Drug Resistance | 2020 |
Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?
Topics: Adenine; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Telbivudine; Tenofov | 2020 |
An antiviral drug-resistant mutant of hepatitis B virus with high replication capacity in association with a large in-frame deletion in the preS1 region of viral surface gene.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genes, Viral; Genotype; Hepati | 2020 |
Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study.
Topics: Abnormalities, Drug-Induced; Adenine; Adult; Alanine; Chemoprevention; China; Cohort Studies; DNA, V | 2020 |
HCC risk reduction with oral nucleos(t)ide analogues in patients with chronic hepatitis B: Not perfect, not good enough.
Topics: Adenine; Administration, Oral; Alanine; Carcinoma, Hepatocellular; DNA, Viral; Guanine; Hepatitis B | 2020 |
Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.
Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospe | 2021 |
Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.
Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospe | 2021 |
Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.
Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospe | 2021 |
Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.
Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospe | 2021 |
Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio | 2021 |
Severe hypophosphataemic osteomalacia related to low-dose adefovir dipivoxil therapy in a hepatitis B virus patient.
Topics: Adenine; Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Hypophosphatemia; Organo | 2021 |
Investigation of multidrug-resistance mutations of hepatitis B virus (HBV) in a large cohort of chronic HBV-infected patients with treatment of nucleoside/nucleotide analogs.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Multiple, Viral; Fema | 2021 |
Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; M | 2022 |
Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide.
Topics: Adenine; Aged; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2021 |
Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.
Topics: Adenine; Antiviral Agents; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Drug Therapy | 2017 |
Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.
Topics: Adenine; Alanine; Anti-HIV Agents; Coinfection; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infectio | 2017 |
A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem | 2017 |
HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Stu | 2017 |
Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients.
Topics: Adenine; Adjuvants, Immunologic; Adult; Antigen-Antibody Complex; Combined Modality Therapy; Female; | 2017 |
Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis.
Topics: Acidosis, Lactic; Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Therap | 2017 |
Viral minority variants in the core promoter and precore region identified by deep sequencing are associated with response to peginterferon and adefovir in HBeAg negative chronic hepatitis B patients.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Genetic Variation; | 2017 |
Letter: lipid-lowering effect of tenofovir disoproxil fumarate in chronic hepatitis B-more evidence is needed. Authors' reply.
Topics: Adenine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lipids; Organophosphonates; Tenofovir | 2017 |
Letter: lipid-lowering effect of tenofovir disoproxil fumarate in chronic hepatitis B-more evidence is needed.
Topics: Adenine; Antiviral Agents; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lipids; Organophosp | 2017 |
Successful treatment with tenofovir alafenamide of a HIV/hepatitis B virus coinfected patient with HIV and hepatitis B virus drug resistance, end-stage renal disease on haemodialysis.
Topics: Adenine; Adult; Alanine; Antiviral Agents; Coinfection; Drug Resistance, Viral; Female; Hepatitis B, | 2017 |
Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antig | 2017 |
Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Hepatitis B | 2017 |
Direct Detection of Drug-Resistant Hepatitis B Virus in Serum Using a Dendron-Modified Microarray.
Topics: Adenine; Dendrimers; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Ch | 2018 |
Seroclearance of hepatitis B surface antigen following hepatitis E exacerbation on chronic hepatitis E and B dual infection in a renal transplant recipient: a case report.
Topics: Adenine; Coinfection; Disease Progression; DNA, Viral; Female; Graft Rejection; Hepatitis B Surface | 2018 |
Injectable PLGA Adefovir microspheres; the way for long term therapy of chronic hepatitis-B.
Topics: Adenine; Animals; Antiviral Agents; Drug Delivery Systems; Drug Liberation; Hepatitis B, Chronic; La | 2018 |
Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Guanine; Hep | 2018 |
Chronic hepatitis B virus and liver fibrosis: A mathematical model.
Topics: Adenine; Computer Simulation; Diffusion; Drug Delivery Systems; Hepatic Stellate Cells; Hepatitis B | 2018 |
Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Chin | 2018 |
Combination therapy for chronic hepatitis B: The future and beyond.
Topics: Adenine; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Organophos | 2018 |
Adefovir dipivoxil induced hypophosphatemic osteomalacia in chronic hepatitis B: a comparative study of Chinese and foreign case series.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Female; Hepatitis B, Chroni | 2018 |
Clinical-features analysis on 926 patients with virological breakthrough in chronic hepatitis B receiving nucleos(t)ide analogues.
Topics: Adenine; Adult; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Comb | 2018 |
48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse.
Topics: Adenine; Adult; Antiviral Agents; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepati | 2018 |
[Compare the effect of combined therapy between telbivudine plus adefovir dipivoxil and lamivudine plus adefovir dipivoxil corresponding to renal function in patients with hepatitis B virus infection].
Topics: Adenine; Antiviral Agents; Creatinine; DNA, Viral; Drug Therapy, Combination; Glomerular Filtration | 2018 |
Long-term results of chronic hepatitis B antiviral treatment with nucleos(t)ide analogues: a single center experience.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Guanin | 2019 |
Deep sequencing identifies hepatitis B virus core protein signatures in chronic hepatitis B patients.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antig | 2018 |
[A Case of Fanconi's Syndrome Induced by Adefovir in Hepatitis Type B Patient].
Topics: Adenine; Aged; Antiviral Agents; Fanconi Syndrome; Female; Guanine; Hepatitis B, Chronic; Humans; Or | 2016 |
Hypophosphatemic Osteomalacia Associated with Adefovir-induced Fanconi Syndrome Initially Diagnosed as Diabetic Kidney Disease and Vitamin D Deficiency.
Topics: Adenine; Aged; Antiviral Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diagnostic Error | 2019 |
Management of individuals with chronic hepatitis B virus infection and persistent normal or mildly elevated aminotransferase levels.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; Disease Management; DNA, Viral; Fema | 2019 |
Longitudinal trends in renal function in chronic hepatitis B patients receiving oral antiviral treatment.
Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combinat | 2018 |
Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate.
Topics: Adenine; Adult; Antiviral Agents; Drug Administration Schedule; Female; Glomerular Filtration Rate; | 2019 |
Performance of serum HBcrAg in chronic hepatitis B patients with 8-year nucleos(t)ide analogs therapy.
Topics: Adenine; Adult; Antiviral Agents; Female; Guanine; Hepatitis B Core Antigens; Hepatitis B e Antigens | 2019 |
Telbivudine and adefovir dipivoxil combination therapy improves renal function in patients with chronic hepatitis B: A STROBE-compliant article.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtrati | 2018 |
Cisplatin induces autophagy to enhance hepatitis B virus replication via activation of ROS/JNK and inhibition of the Akt/mTOR pathway.
Topics: Acetylcysteine; Adenine; Animals; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 5; Chl | 2019 |
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Femal | 2019 |
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Femal | 2019 |
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Femal | 2019 |
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Femal | 2019 |
Methylation status of the stimulator of interferon genes promoter in patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; DNA, Viral; Female; Guanine; Hepatitis B, Chronic; Hum | 2018 |
The clinical and pathological features of adefovir dipivoxil-related renal impairment
.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Female; Glycosuria; Hematuria; Hepatitis B, Chronic; H | 2019 |
The different effects of adefovir dipivoxil and telbivudine on the prognosis of hepatitis b virus-related hepatocellular carcinoma patients after curative resection.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Hepatitis B e Antigens; He | 2019 |
Toxic myopathy with multiple deletions in mitochondrial DNA associated with long-term use of oral anti-viral drugs for hepatitis B: A case study.
Topics: Adenine; Administration, Oral; Aged; Antiviral Agents; DNA, Mitochondrial; Female; Gene Deletion; He | 2019 |
[Adefovir Dipivoxil-induced Fanconi's Syndrome and Osteomalacia Following Multiple Bone Fractures in a Patient with Chronic Hepatitis B].
Topics: Adenine; Aged; Carcinoma, Hepatocellular; Fanconi Syndrome; Fractures, Bone; Hepatitis B, Chronic; H | 2019 |
Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice.
Topics: Adenine; Adult; Antiviral Agents; Drug Administration Schedule; Female; Hepatitis B virus; Hepatitis | 2019 |
[Marked improvement in renal tubular markers after switching from adefovir to tenofovir alafenamide in a case of Fanconi syndrome diagnosed through high ALP levels].
Topics: Adenine; Alanine; Alkaline Phosphatase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, V | 2019 |
Brca1 is involved in tolerance to adefovir dipivoxil‑induced DNA damage.
Topics: Adenine; Antiviral Agents; BRCA1 Protein; Cell Line; Chromosome Aberrations; DNA Damage; Gene Deleti | 2019 |
Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Chemical and Drug Induced Liver Injury; Female; Glomerular F | 2020 |
Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hep | 2019 |
Fibrosing Cholestatic Hepatitis-Like Syndrome in an Immunocompetent Patient With an Acute Flare of Chronic Hepatitis B.
Topics: Adenine; Biopsy, Needle; Cholestasis; Disease Progression; Follow-Up Studies; Hepatitis B, Chronic; | 2019 |
Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model.
Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B Surf | 2019 |
Low-dose adefovir dipivoxil-induced hypophosphatemia osteomalacia in five chronic hepatitis B virus-infected patients. Is low-dose adefovir dipivoxil-induced nephrotoxicity completely reversible?
Topics: Adenine; Aged; Dose-Response Relationship, Drug; Fanconi Syndrome; Female; Hepatitis B, Chronic; Hum | 2019 |
A case of entecavir-induced Fanconi syndrome.
Topics: Acidosis; Acute Kidney Injury; Adenine; Aged; Alanine; Antiviral Agents; Fanconi Syndrome; Guanine; | 2019 |
Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis.
Topics: Adenine; Alanine; Hepatitis B, Chronic; HIV Infections; Humans; Liver Transplantation; Tenofovir | 2020 |
In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue.
Topics: Activating Transcription Factor 4; Adenine; Antiviral Agents; Apoptosis; Caspase 12; Cell Line; Cell | 2019 |
[Effects of adefovir dipivoxil on liver pathology in patients with chronic hepatitis B].
Topics: Adenine; Adolescent; Adult; Female; Hepatitis B, Chronic; Humans; Liver; Male; Middle Aged; Organoph | 2012 |
Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine.
Topics: Adenine; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Drug Resistance, Viral; | 2013 |
Combination nucleos(t)ide analogue as initial treatment for chronic hepatitis B: have we put this to rest?
Topics: Adenine; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Male; Phosphorous Acids; Viral Load | 2013 |
Resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Asian People; Creatinine; Dose-Response Relationship, Drug; Female | 2013 |
Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia.
Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Coinfection; Deoxycytidine; DNA, Viral; Drug | 2013 |
A different look at the management of chronic hepatitis B in a resource-constrained country.
Topics: Adenine; Antiviral Agents; China; Drug Therapy, Combination; Health Resources; Hepatitis B virus; He | 2013 |
Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Administrat | 2013 |
[Cost-effectiveness of nucleoside/nucleotide analogues in chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Drug Resistance, Viral; Drug Therapy, Combination; | 2012 |
Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing.
Topics: Adenine; Adolescent; Adult; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Drug | 2013 |
Increased eGFR with telbivudine in combination therapy of chronic hepatitis B infection.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Glomerular Filtration Rate; Guanine; Hepatitis | 2014 |
Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Creatinine; Drug Therapy, Combination; Female; Glomerular Fi | 2014 |
[Three-year efficacy and side effect of adefovir dipivoxil for the treatment of the old patients with chronic hepatitis B virus infection].
Topics: Adenine; Aged; Aged, 80 and over; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Male; Orga | 2012 |
Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Disease | 2014 |
Reversible increase in FGF23 in a hypophosphatemic renal and bone disease linked to antiviral therapy by adefovir.
Topics: Adenine; Aged; Antiviral Agents; Bone Diseases; Female; Fibroblast Growth Factor-23; Fibroblast Grow | 2013 |
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Guanin | 2013 |
Geographic tongue and tenofovir.
Topics: Adenine; Glossitis, Benign Migratory; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophospho | 2013 |
[Genotypes and evolution characteristics of three patients with poor response to initial treatment of Lamivudine and Adefovir dipivoxil for hepatitis].
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Evolution, Molecular; Female; Genetic Drif | 2012 |
Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Stu | 2013 |
Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B viru | 2013 |
Reversal of cirrhosis: an achievable goal of hepatitis B antiviral therapy.
Topics: Adenine; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Reverse | 2013 |
Partial virological response to adefovir add-on lamivudine rescue therapy in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Area Under Curve; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem | 2013 |
Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir.
Topics: Adenine; Adult; Antiviral Agents; Case-Control Studies; DNA, Viral; Drug Resistance, Viral; Drug The | 2013 |
Entecavir plus adefovir rescue therapy for chronic hepatitis B patients after multiple treatment failures in real-life practice.
Topics: Adenine; Adult; Antiviral Agents; Creatine Kinase; Creatinine; DNA, Viral; Female; Guanine; Hepatiti | 2013 |
Prophylaxis in HBV-infected liver transplant patients: end of the HBIG era?
Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transpla | 2013 |
Regression of cirrhosis with long-term tenofovir treatment.
Topics: Adenine; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Reverse | 2013 |
Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment.
Topics: Adenine; Adult; Aged; Antiviral Agents; Asian People; DNA, Viral; Female; Follow-Up Studies; Genotyp | 2013 |
Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection.
Topics: Adenine; Adult; Antiviral Agents; Biopsy; Creatinine; Fanconi Syndrome; Hepatitis B, Chronic; Humans | 2013 |
Chemokine receptor 5 (CCR5) polymorphism in chronic hepatitis B patients treated with three different nucleos(t)ide analogues.
Topics: Adenine; Alanine Transaminase; Genotype; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Homozyg | 2013 |
Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
Topics: Adenine; Adult; Aged; Antiviral Agents; Chemoprevention; Cohort Studies; Deoxycytidine; Drug Therapy | 2013 |
Study of hepatitis B virus quasispecies by ultra-deep pyrosequencing: Resolving the nitty-gritty.
Topics: Adenine; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B viru | 2014 |
Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Antiviral Agents; Coinfection; Female; Glomerular Filtration Rate; Hepatitis B, Chro | 2013 |
Reply: To PMID 23505208.
Topics: Adenine; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B viru | 2014 |
Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine.
Topics: Adenine; Adult; Aged; Asian People; DNA, Viral; Drug Resistance, Multiple; Drug Resistance, Viral; D | 2014 |
[The observation of blood serum creatinine and phosphorus during long-term adefovir dipivoxil treatment in chronic hepatitis].
Topics: Adenine; Adolescent; Adult; Aged; Creatinine; Female; Hepatitis B, Chronic; Humans; Male; Middle Age | 2013 |
[Detection of resistance mutations in chronic hepatitis B patients receiving antiviral therapy for over one year].
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guan | 2013 |
[HBV vaccine escape mutations in a chronic hepatitis B patient treated with nucleos(t)ide analogues].
Topics: Adenine; Biopsy; Drug Resistance, Multiple, Viral; Female; Genes, pol; Guanine; Hepatitis B Vaccines | 2013 |
Long-term efficacy of entecavir plus adefovir combination therapy versus entecavir monotherapy in adefovir refractory chronic hepatitis B patients with prior lamivudine resistance.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem | 2014 |
Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: an Indian perspective.
Topics: Adenine; Adult; Aged; Bilirubin; Creatinine; DNA, Viral; Female; Hepatitis B, Chronic; Humans; India | 2013 |
Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: a pilot study.
Topics: Adenine; Adult; Alanine Transaminase; Analysis of Variance; Aspartate Aminotransferases; Bilirubin; | 2013 |
Real-world application of the roadmap model in chronic hepatitis B patients with telbivudine therapy.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; | 2013 |
Comparison of tenofovir and entecavir in patients with chronic HBV infection.
Topics: Adenine; Adult; Aged; DNA, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; | 2013 |
[Outcome of chronic hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive drugs and anti-TNF agents].
Topics: Adalimumab; Adenine; Adult; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azathioprine; Crohn | 2014 |
Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection.
Topics: Adenine; Adult; Aged; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; | 2013 |
Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients.
Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Administration Schedul | 2013 |
Prevelance of common YMDD motif mutations in long term treated chronic HBV infections in a Turkish population.
Topics: Adenine; Adult; Aged; Amino Acid Motifs; Anti-HIV Agents; Antiviral Agents; Aspartic Acid; Case-Cont | 2013 |
Two rescue therapies in lamivudine-resistant patients with chronic hepatitis B in the central China: adefovir monotherapy and adefovir plus lamivudine.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; China; Drug Resistance, Viral; Female; Hepat | 2014 |
One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepati | 2014 |
Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Europe; Female; Guanine; Hepatitis B virus; Hepatitis | 2014 |
Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis.
Topics: Adenine; Adult; Analysis of Variance; Antiviral Agents; Brazil; Cost-Benefit Analysis; Disease Progr | 2013 |
Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Glomerular Fi | 2014 |
Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Therapy, Co | 2014 |
Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA.
Topics: Adenine; Adult; Antiviral Agents; California; Cohort Studies; DNA, Viral; Female; Guanine; Hepatitis | 2014 |
Rapid detection of hepatitis B virus variants associated with lamivudine and adefovir resistance by multiplex ligation-dependent probe amplification combined with real-time PCR.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; | 2014 |
Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV I | 2014 |
Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure.
Topics: Adenine; Adult; Biomarkers; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; H | 2014 |
Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B, Chr | 2014 |
Interactive medical case: wasting away.
Topics: Adenine; Adult; Bone Density; Electrolytes; Fanconi Syndrome; Female; Hepatitis B, Chronic; Humans; | 2014 |
Dynamic comparison between Daan real-time PCR and Cobas TaqMan for quantification of HBV DNA levels in patients with CHB.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepati | 2014 |
An initial assessment of correlations between host- and virus-related factors affecting analogues antiviral therapy in HBV chronically infected patients.
Topics: Adenine; Adult; Age Factors; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Fe | 2014 |
[The clinical significance of hepatitis B virus large surface protein in the diagnosis and treatment of patients with hepatitis B].
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis | 2013 |
Establishment of real time allele specific locked nucleic acid quantitative PCR for detection of HBV YIDD (ATT) mutation and evaluation of its application.
Topics: Adenine; Adult; Alleles; Antiviral Agents; DNA Primers; DNA, Viral; Drug Resistance, Viral; Early Di | 2014 |
Lamivudine and Adefovir Motif Variants Detected in chronic Hepatıtıs B patients.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chron | 2014 |
Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis | 2015 |
[Detection and analysis of HBV in polymorphonuclear neutrophils of patients with hepatitis B].
Topics: Adenine; Adult; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; | 2014 |
Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Guani | 2014 |
[Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline].
Topics: Adenine; Antiviral Agents; Consensus; Drug Administration Schedule; Drug Therapy, Combination; Evide | 2014 |
[A case of the patient with HBeAg-negative chronic hepatitis B recurrence after retreatment with adefovir occurred HBsAg seroconversion].
Topics: Adenine; Adult; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; | 2013 |
Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare.
Topics: Adenine; Adult; Antiviral Agents; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B vir | 2014 |
Commentary: tenofovir is superior to entecavir in HBeAg-positive chronic hepatitis B patients.
Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Organophosphonates; | 2014 |
Commentary: tenofovir is superior to entecavir in HBeAg-positive chronic hepatitis B patients--authors' reply.
Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Organophosphonates; | 2014 |
Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients.
Topics: Adenine; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Codon; DNA, Viral; Drug Resistance, | 2014 |
A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand.
Topics: Adenine; Adult; Antiviral Agents; Cost-Benefit Analysis; Drugs, Essential; Female; Health Services R | 2014 |
Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Monitoring; Female; Hepatitis B | 2014 |
Hepatitis B virus rtI233V mutation and resistance to adefovir.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; | 2014 |
Effects of entecavir on peripheral blood lymphocyte profiles in chronic hepatitis B patients with suboptimal responses to adefovir.
Topics: Adenine; Antiviral Agents; B-Lymphocytes; Case-Control Studies; CD4-Positive T-Lymphocytes; DNA, Vir | 2014 |
Analysis of reverse transcriptase gene mutations in the hepatitis B virus at a university hospital in Korea.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Hep | 2014 |
Letter: Treatment of HBeAg+ chronic hepatitis B--is tenofovir truly superior to entecavir?
Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Organophosphonates; | 2014 |
Letter: Treatment of HBeAg+ chronic hepatitis B--is tenofovir truly superior to entecavir? Authors' reply.
Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Organophosphonates; | 2014 |
HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels.
Topics: Adenine; Adult; Antiviral Agents; Carnitine; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; | 2014 |
Viral evolutionary changes during tenofovir treatment in a chronic hepatitis B patient with sequential nucleos(t)ide therapy.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Substitution; Hepatitis B virus; Hepatitis B | 2014 |
Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF.
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Gene | 2014 |
Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B Antibodies; Hepatitis B e | 2014 |
Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBeAg loss.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Enzyme-Linked Immunospot Assay; Female; Hepatitis B An | 2014 |
Kinetics of serum HBsAg in Chinese patients with chronic HBV infection with long-term adefovir dipivoxil treatment.
Topics: Adenine; Adult; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans | 2014 |
New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence.
Topics: Adenine; Adult; Cohort Studies; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Guanine; | 2014 |
Higher viral load, higher hepatitis B surface antigen clearance?
Topics: Adenine; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Male; Phosphorous Acids; Viral Load | 2014 |
Telbivudine plus tenofovir in combination therapy in patients with chronic hepatitis B infection--an Indian experience.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Femal | 2013 |
Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
Topics: Adenine; Adult; Antiviral Agents; China; Clone Cells; Drug Resistance, Viral; Female; Gene Expressio | 2015 |
Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio | 2014 |
Effect of prophylactic versus preemptive lamivudine treatment and tenofovir on HBsAg+ kidney transplant recipients.
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Drug Administration Schedule; Female; Graft Survival; | 2015 |
Impact of the rtI187V polymerase substitution of hepatitis B virus on viral replication and antiviral drug susceptibility.
Topics: Adenine; Adolescent; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Child; China; Cohort St | 2014 |
Antiviral therapy of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Gene Products, pol; Gu | 2014 |
Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy.
Topics: Adenine; Antiviral Agents; DNA, Viral; Female; Guanine; Health Personnel; Hepatitis B e Antigens; He | 2014 |
Mechanisms of hepatitis B virus resistance development.
Topics: Adenine; Amino Acid Substitution; Antiviral Agents; Deoxycytidine; Drug Resistance, Multiple, Viral; | 2014 |
Effect of antiretroviral HIV therapy on hepatitis B virus replication and pathogenicity.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Coinfection; Deoxycytidine; Emtrici | 2014 |
Hepatitis B virus drug resistance tools: one sequence, two predictions.
Topics: Adenine; Antiviral Agents; Base Sequence; Drug Resistance, Multiple, Viral; Genotype; Guanine; Hepat | 2014 |
Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.
Topics: Adenine; Amino Acid Substitution; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy | 2014 |
More on hepatitis B virus rtI233V mutation and resistance to adefovir.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; | 2014 |
More on hepatitis B virus rtI233V mutation and resistance to adefovir.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; | 2014 |
The Use of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatit | 2014 |
[A case of chronic hepatitis B managed with continued adefovir despite treatment-related Fanconi syndrome and osteomalacia].
Topics: Adenine; Fanconi Syndrome; Female; Hepatitis B, Chronic; Humans; Middle Aged; Organophosphonates; Os | 2014 |
Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.
Topics: Adenine; Adult; Antiviral Agents; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Hum | 2014 |
The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; | 2015 |
Efficacy and safety of tenofovir in a kidney transplant patient with chronic hepatitis B and nucleos(t)ide multidrug resistance: a case report.
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Follow-Up St | 2014 |
Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains.
Topics: Adenine; Adult; Aged; Antiviral Agents; Base Sequence; Cohort Studies; DNA, Viral; Drug Resistance, | 2014 |
Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?
Topics: Adenine; Adult; Body Mass Index; Bone Density; Cross-Sectional Studies; Female; Hepatitis B virus; H | 2015 |
Safety and efficacy of entecavir in adefovir-experienced patients.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Drug Substitution; Female; Follo | 2015 |
[Efficacy of 48-week tenofovir disoproxil fumarate therapy in patients who were unresponsive to nucleoside-analogue treatments].
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; | 2014 |
Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Greece; Guan | 2015 |
Chronic hepatitis B virus coinfection is associated with renal impairment among Zambian HIV-infected adults.
Topics: Adenine; Adolescent; Adult; Africa; Anti-HIV Agents; Coinfection; Female; Glomerular Filtration Rate | 2014 |
Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling.
Topics: Absorptiometry, Photon; Adenine; Adult; Aged; Antiviral Agents; Asian People; Bone Density; Cross-Se | 2015 |
Efficacy of adefovir dipivoxil combined with a corticosteroid in 38 cases of nephrotic syndrome induced by hepatitis B virus-associated glomerulonephritis.
Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Glomerulonephritis; Glucocortic | 2014 |
The feasibility of discontinuing lamivudine in lamivudine-resistant chronic hepatitis B patients on lamivudine and adefovir combination therapy.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fea | 2014 |
Tenofovir-associated Fanconi syndrome in a patient with chronic hepatitis B.
Topics: Adenine; Aged, 80 and over; Antiviral Agents; Fanconi Syndrome; Fatal Outcome; Hepatitis B, Chronic; | 2014 |
Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA-Directed DNA Polymerase; Drug Resista | 2015 |
Liver biopsy interpretation & the regression of hepatitis B virus related cirrhosis.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Biomarkers; Biopsy; Hepatitis B, Chronic; Humans; I | 2014 |
Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B, Ch | 2014 |
The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Topics: Adenine; Adult; Antiviral Agents; Canada; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B e | 2014 |
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Cohort Studies; DNA | 2014 |
Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Dr | 2014 |
Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Area Under Curve; DNA, Viral; Drug Resistance, Viral; Female; Hepa | 2014 |
Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Humans | 2015 |
Effect of Peg-interferon α-2a combined with Adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antig | 2015 |
Discovering novel direct acting antiviral agents for HBV using in silico screening.
Topics: Adenine; Albumins; Animals; Antiviral Agents; Binding Sites; Cells, Cultured; Chimera; Databases, Pr | 2015 |
Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal.
Topics: Adenine; Antiviral Agents; Fanconi Syndrome; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Human | 2014 |
Efficacy of adefovir dipivoxil therapy in patients with chronic hepatitis B viral infection.
Topics: Adenine; Adult; Antiviral Agents; Bangladesh; Drug Monitoring; Hepatitis B e Antigens; Hepatitis B v | 2014 |
Nucleotide analogue-resistant mutations in hepatitis B viral genomes found in hepatitis B patients.
Topics: Adenine; Amino Acid Substitution; Antiviral Agents; DNA, Viral; Genome, Viral; Genotype; Hepatitis B | 2015 |
Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates.
Topics: Adenine; Adult; Antiviral Agents; Chi-Square Distribution; Cross-Sectional Studies; Diagnostic Imagi | 2014 |
Do we need more nucleos(t)ide analogs for the treatment of chronic hepatitis B?
Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Organophosphonates | 2015 |
[Tenofovir rescue therapy for chronic hepatitis B patients after suboptimal response to treatment with lamivudine plus adefovir dipivoxil].
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepati | 2014 |
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study.
Topics: Adenine; Adult; Aged; Antiviral Agents; Bone Diseases; Drug-Related Side Effects and Adverse Reactio | 2015 |
[Promotion of HBeAg seroconversion/loss in patients with chronic hepatitis B following the switch from nucleoside drugs to telbivudine and adefovir].
Topics: Adenine; Drug Combinations; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Nucleic Acid Synth | 2014 |
[Hypophosphatemic osteomalacia and renal Fanconi syndrome induced by adefovir in a patient with chronic hepatitis B].
Topics: Adenine; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Hypophosphatemia; Organophosphonates; Osteo | 2014 |
Is tenofovir disoproxil fumarate an all-powerful weapon in the treatment of chronic hepatitis B?
Topics: Adenine; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Phosphorou | 2015 |
Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Biomarkers; Creatinine; DNA, Viral; Dr | 2015 |
Response-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective study.
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; China; DNA, Viral; Drug Resistance, Viral; Drug Therap | 2015 |
HBV carrying drug-resistance mutations in chronically infected treatment-naive patients.
Topics: Adenine; Antibodies, Viral; Antiviral Agents; Brazil; DNA, Viral; Drug Resistance, Viral; Gene Produ | 2015 |
Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G | 2015 |
Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures.
Topics: Adenine; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fema | 2015 |
Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B.
Topics: Adenine; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Chi-Square Distribution; Fem | 2015 |
Osteomalacia and Fanconi's syndrome caused by long-term low-dose adefovir dipivoxil.
Topics: Adenine; Antiviral Agents; Calcium; Dose-Response Relationship, Drug; Drug Monitoring; Fanconi Syndr | 2015 |
Tenofovir rescue therapy in pregnant females with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Apgar Score; Biomarkers; Birth Weight; China; DNA, Viral; Drug Res | 2015 |
Clinical course of chronic hepatitis B patients receiving nucleos(t)ide analogues after virological breakthrough during monotherapy with lamivudine.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G | 2015 |
[Pharmacoeconomic evaluation of treatments based on antiretrovirals for HBeAg-negative chronic hepatitis B].
Topics: Adenine; Antiviral Agents; China; Cost-Benefit Analysis; Economics, Pharmaceutical; Guanine; Hepatit | 2015 |
Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Drug S | 2015 |
Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir.
Topics: Adenine; Adult; Aged; Antigens, Surface; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Fe | 2015 |
Low-dose adefovir dipivoxil may induce Fanconi syndrome: clinical characteristics and long-term follow-up for Chinese patients.
Topics: Adenine; Adult; Alkaline Phosphatase; Antiviral Agents; Asian People; Bone Density; Creatinine; Drug | 2015 |
Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lami | 2015 |
[Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures].
Topics: Adenine; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir; Treatment Failure | 2015 |
Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B.
Topics: Acute Kidney Injury; Adenine; Adult; Antiviral Agents; beta 2-Microglobulin; Biomarkers; Case-Contro | 2015 |
Clonal evolution of multidrug resistant hepatitis B virus during entecavir rescue therapy.
Topics: Adenine; Adult; Antiviral Agents; Clonal Evolution; DNA, Viral; Drug Resistance, Viral; Drug Therapy | 2015 |
Impact of nucleos(t)ide analogue combination therapy on the estimated glomerular filtration rate in patients with chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rat | 2015 |
The expression of TLR-9, CD86, and CD95 phenotypes in circulating B cells of patients with chronic viral hepatitis B or C before and after antiviral therapy.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal; Antiviral Agents; B-Lymphocytes; B7-2 Antigen; DNA, Vi | 2015 |
A case of entecavir resistance which is developed after complete viral suppression during entecavir treatment for nucleoside-naive chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; | 2014 |
Response to potent anti-HBV agents in chronic hepatitis B and combined effect of HBV reverse transcriptase mutations.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Mutation; Organ | 2015 |
Entecavir Combined With Adefovir Ameliorates Patients With Chronic Hepatitis B Who Fail to Respond to Nucleotide (Acid) Analog Monotherapy.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; | 2017 |
Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, | 2015 |
Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; H | 2015 |
Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple; Drug Therapy, Combination; | 2015 |
Remission of splenic marginal zone lymphoma in a patient treated for hepatitis B: a case of HBV-associated lymphoma.
Topics: Adenine; Bone Marrow; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunohistochemistry; Lymphom | 2015 |
Prevalence and types of drug-resistant variants in Chinese patients with acute hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral; Female; Genetic Variati | 2015 |
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Elasticity Ima | 2015 |
Initial combination anti-viral therapy with lamivudine and adefovir dipivoxil decreases short-term fatality rate of hepatitis-B-virus-related acute-on-chronic liver failure.
Topics: Acute-On-Chronic Liver Failure; Adenine; Adolescent; Adult; Aged; Antiviral Agents; Female; Hepatiti | 2015 |
Deep sequencing analysis of HBV genotype shift and correlation with antiviral efficiency during adefovir dipivoxil therapy.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B | 2015 |
[Efficacy and safety of telbivudine alone and combined with adefovir for the treatment of nucleos(t)ide-naive chronic hepatitis B in patients with high-level hepatitis B virus load].
Topics: Adenine; Alanine Transaminase; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; | 2015 |
Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Blood; DNA, Viral; Female; Guani | 2016 |
Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Dru | 2016 |
Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance.
Topics: Adenine; Amino Acid Substitution; Antiviral Agents; Arabinofuranosyluracil; Cell Line, Tumor; Drug R | 2015 |
Long-term follow-up of HBsAg-positive patients in Germany.
Topics: Adenine; Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Therapy, | 2016 |
[Adefovir dipivoxil effects on and related factors of blood phosphorus metabolism in patients with chronic hepatitis B].
Topics: Adenine; Aged; Antiviral Agents; Creatinine; Drug Therapy, Combination; Hepatitis B, Chronic; Humans | 2015 |
Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio | 2015 |
Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem | 2015 |
Comprehensive analysis of hospital-based prospective cohort reveals the unique effectiveness and safety for nucleos(t)ide analogues in HBV patients.
Topics: Adenine; Adult; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Hospitalization; Humans; La | 2016 |
Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China.
Topics: Adenine; Adult; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral; Ethnicity; Female; Geno | 2015 |
Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Female; Follow-Up Studies; Guanine; Hepatitis B, Chron | 2015 |
Rhabdomyolysis due to lamivudine re-administration in a patient with HBV-related hepatic failure caused by interruption of lamivudine and adefovir.
Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis B, Chr | 2015 |
[Efficacy of combination antiviral therapy following childbirth in pregnant HBV carriers receiving telbivudine for prevention of mother-to-child transmission].
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Carrier State; DNA, Viral; Drug Therapy, Combinatio | 2015 |
Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Human | 2016 |
In situ analysis of intrahepatic virological events in chronic hepatitis B virus infection.
Topics: Adenine; Case-Control Studies; DNA Probes; DNA, Viral; Hep G2 Cells; Hepatitis B Core Antigens; Hepa | 2016 |
Multidrug resistance protein 4 is a critical protein associated with the antiviral efficacy of nucleos(t)ide analogues.
Topics: Adenine; Adult; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Viral; Female; Guanine; Hepatit | 2016 |
[Drug-resistant mutations in hepatitis B virus found in chronic HBV carriers using PCR sequencing technology].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Guanine; Hepatitis B virus; | 2016 |
Profile of HBV polymerase gene mutations during entecavir treatment in patients with chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Drug Resistance, Viral; Female; | 2016 |
Resistance of ground glass hepatocytes to oral antivirals in chronic hepatitis B patients and implication for the development of hepatocellular carcinoma.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Amino Acid Sequence; Antiviral Agents; Biopsy; Car | 2016 |
Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients.
Topics: Adenine; Adult; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lami | 2016 |
De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine.
Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hep | 2016 |
Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Biopsy; Chemokine CXCL10; DNA, V | 2016 |
Cost-Effectiveness of Peg-Interferon, Interferon and Oral Nucleoside Analogues in the Treatment of Chronic Hepatitis B and D Infections in China.
Topics: Adenine; Adult; Age Factors; Aged; Antiviral Agents; China; Cohort Studies; Cost of Illness; Cost-Be | 2016 |
First case report of renal improvement on tenofovir alafenamide in an HIV/hepatitis B virus-coinfected patient with adefovir-induced Fanconi's syndrome.
Topics: Absorptiometry, Photon; Adenine; Alanine; Coinfection; Dose-Response Relationship, Drug; Fanconi Syn | 2016 |
Pathologic Femoral Neck Fracture Due to Fanconi Syndrome Induced by Adefovir Dipivoxil Therapy for Hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Fanconi Syndrome; Femoral Neck Fractures; Fractures, Spontaneous; | 2016 |
Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Female; Guanine; Hepatitis B, Chronic; Humans; Lam | 2016 |
Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Carcinoma, | 2017 |
Urinary β-2 Microglobulin Levels Sensitively Altered in an Osteomalacia Patient Receiving Add-on Adefovir Dipivoxil Therapy for Hepatitis B Virus Infection.
Topics: Adenine; Aged; Antiviral Agents; beta 2-Microglobulin; Female; Hepatitis B, Chronic; Humans; Japan; | 2016 |
The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio | 2016 |
Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B vi | 2017 |
A five years study of antiviral effect of entecavir in Chinese chronic hepatitis B patients.
Topics: Adenine; Adult; Antiviral Agents; Asian People; China; Drug Resistance, Viral; Drug Therapy, Combina | 2016 |
Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B?
Topics: Adenine; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chron | 2016 |
The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence.
Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug The | 2016 |
Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
Topics: Adenine; Adult; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Female; Guanin | 2016 |
[HBsAg clearance rate in patients with HBeAg-positive chronic hepatitis B: a comparative effect analysis based on the real world].
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis | 2016 |
Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study.
Topics: Adenine; Adult; Aged; Antiviral Agents; Arabinofuranosyluracil; Cohort Studies; Disease Management; | 2017 |
Pre-existing mutations related to tenofovir in chronic hepatitis B patients with long-term nucleos(t)ide analogue drugs treatment by ultra-deep pyrosequencing.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple; Female; Hepatitis B, Chroni | 2016 |
Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Biopsy; DNA, Circular; DNA, Viral; Female; Hepatitis B virus; Hepatitis B | 2017 |
Lamivudine/Adefovir Treatment Increases the Rate of Spontaneous Mutation of Hepatitis B Virus in Patients.
Topics: Adenine; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosupp | 2016 |
No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B v | 2017 |
No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B v | 2017 |
No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B v | 2017 |
No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B v | 2017 |
No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B v | 2017 |
No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B v | 2017 |
No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B v | 2017 |
No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B v | 2017 |
No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B v | 2017 |
Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment.
Topics: Adenine; Adult; Alanine Transaminase; Antibodies, Viral; Antiviral Agents; Disease Progression; DNA, | 2016 |
Identification of a new hepatitis B virus recombinant D2/D3 in the city of São Paulo, Brazil.
Topics: Adenine; Adult; Aged; Antiviral Agents; Brazil; Drug Resistance, Viral; Female; Genotype; Hepatitis | 2017 |
Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asymptomatic Infections; Carcinoma, Hepat | 2018 |
Comparison of Detection Rate and Mutational Pattern of Drug-Resistant Mutations Between a Large Cohort of Genotype B and Genotype C Hepatitis B Virus-Infected Patients in North China.
Topics: Adenine; Adult; Antiviral Agents; China; Cohort Studies; Drug Resistance, Multiple, Viral; Female; G | 2017 |
Treatment outcomes in treatment experienced and treatment naïve patients on Tenofovir disoproxil fumarate for chronic hepatitis B.
Topics: Adenine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2017 |
Comparison of the Efficacies and Safety of Combined Therapy between Telbivudine Plus Adefovir and Lamivudine Plus Adefovir in Patients with Hepatitis B Virus Infection in Real-World Practice.
Topics: Adenine; Adult; Biomarkers; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis | 2016 |
Circulating kidney injury molecule-1 is a novel diagnostic biomarker for renal dysfunction during long-term adefovir therapy in chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Cohort Studies; Female; Hepatitis A Virus Cellular Rec | 2016 |
Relationship between hepatitis B virus reverse transcriptase 181 mutation and S gene mutation in hepatitis B virus chronically infected patients.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Geno | 2016 |
Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy.
Topics: Adenine; Adult; Antiviral Agents; Australia; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B | 2017 |
DNMT1 modulation in chronic hepatitis B patients and hypothetic influence on mitochondrial DNA methylation status during long-term nucleo(t)side analogs therapy.
Topics: Adenine; Aged; Antiviral Agents; Cross-Sectional Studies; Cytosine; DNA (Cytosine-5-)-Methyltransfer | 2017 |
Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Fem | 2016 |
Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Tenofovir | 2016 |
Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study.
Topics: Adenine; Adult; Drug Combinations; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepat | 2016 |
Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug | 2017 |
Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; | 2017 |
[The predictive value of ALT, HBeAg and HBV DNA levels at baseline and the degree of HBV suppression at week 12 adefovir dipivoxil treatment to the efficacy of it at week 52 in patients with HBeAg-positive chronic hepatitis B].
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; | 2008 |
Replication of clinical hepatitis B virus isolate and its application for selecting antiviral agents for chronic hepatitis B patients.
Topics: Adenine; Antiviral Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Vira | 2008 |
[Chronic hepatitis B. Tenofovir--the right choice from the beginning].
Topics: Adenine; Antiviral Agents; Drug Approval; Europe; Hepatitis B, Chronic; Humans; Organophosphonates; | 2008 |
[Drug approval studies of Viread. As effective in HBeAg positive as also in HBeAg negative patients].
Topics: Adenine; Antiviral Agents; Drug Approval; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Mult | 2008 |
[Comparison of antiviral responses to adefovir dipivoxil therapy of genotype B and genotype C HBV infected patients].
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Genotype; Hepatitis B virus; | 2008 |
Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral; Guanine; Hepatitis B | 2008 |
What is the optimum dose of adefovir in the treatment of chronic hepatitis B infection?
Topics: Adenine; Adult; Antiviral Agents; Dose-Response Relationship, Drug; Hepatitis B e Antigens; Hepatiti | 2008 |
Rapid re-emergence of YMDD mutation of hepatitis B virus with hepatic decompensation after lamivudine retreatment.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; | 2008 |
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
Topics: Adenine; Animals; Antigens, Viral; Antiviral Agents; Deoxycytidine; Disease Models, Animal; DNA, Vir | 2008 |
Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Cohort Studies; Drug Resistance; Female; Genotype; Hepat | 2009 |
Does the presence of adefovir-resistant variants lead to failure of tenofovir monotherapy?
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Genetic Variation; Hepatitis B virus; Hepa | 2008 |
[A case of severe hypophosphatemia related to adefovir dipivoxil treatment in a patient with liver cirrhosis related to hepatitis B virus].
Topics: Absorptiometry, Photon; Adenine; Adult; Antiviral Agents; Bone Density; DNA, Viral; Drug Resistance, | 2008 |
[YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].
Topics: Adenine; Amino Acid Motifs; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combi | 2008 |
Are hepatitis B e antigen (HBeAg)-positive chronic hepatitis B and HBeAg-negative chronic hepatitis B distinct diseases?
Topics: Adenine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphonates | 2008 |
Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants.
Topics: Adenine; Adult; Alanine Transaminase; Asian People; DNA Mutational Analysis; DNA, Viral; Female; Hep | 2008 |
Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-alpha-2a.
Topics: Adenine; Adult; Antiviral Agents; Female; Hepatitis B Antigens; Hepatitis B virus; Hepatitis B, Chro | 2009 |
Hepatitis B virus genotype-associated variability in antiviral response to adefovir dipivoxil therapy in Chinese Han population.
Topics: Adenine; Adult; Alanine Transaminase; Antibodies, Viral; Antiviral Agents; Asian People; DNA, Viral; | 2008 |
Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
Topics: Adenine; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Hepatitis B virus; | 2008 |
Two-year data released on Viread for chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Hepatitis B, Chronic; Humans; | 2008 |
[Protocol for the antiviral therapy of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alp | 2008 |
Chronic hepatitis B--new goals, new treatment.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis | 2008 |
[Development of clevudine resistance after switching from lamivudine in a patient with chronic hepatitis B].
Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; Arabinofuranosyluracil; Base Sequence; DN | 2008 |
Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Gene Products, pol; Hepatitis B Surface An | 2009 |
Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study.
Topics: Adenine; Adult; Carcinoma, Hepatocellular; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Stu | 2009 |
[The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; | 2008 |
Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; DNA Mutational Analysis; DNA, Viral; Drug | 2009 |
Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Femal | 2009 |
Adefovir dipivoxil-induced acute tubular necrosis and Fanconi syndrome in a renal transplant patient.
Topics: Acute Kidney Injury; Adenine; Antiviral Agents; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Kidn | 2009 |
On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Follow | 2009 |
Early development of clevudine resistance during clevudine therapy in a patient with chronic hepatitis B who received prior lamivudine therapy.
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Drug Resistance, Viral; Hepatitis B virus; Hepati | 2009 |
Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response.
Topics: Adenine; Antiviral Agents; Biomarkers; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatiti | 2008 |
Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients.
Topics: Acid-Base Equilibrium; Adenine; Aged; Antiviral Agents; Cohort Studies; Dose-Response Relationship, | 2009 |
A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients.
Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Femal | 2009 |
Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil.
Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Resistance, Vira | 2008 |
Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Genotype; Guanine; Hepatitis B e Antigen | 2009 |
Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Nucleosides; Nu | 2009 |
[New molecules in the treatment of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Hepatitis B Vaccines; Hepatitis B, Chronic; Human | 2009 |
[Atazanavir-induced nephrolithiasis].
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cy | 2009 |
Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; | 2009 |
Decision analysis model for hepatitis B prophylaxis one year after liver transplantation.
Topics: Adenine; Administration, Oral; Antiviral Agents; Cost Savings; Cost-Benefit Analysis; Decision Suppo | 2009 |
Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy.
Topics: Adenine; Adult; Antibodies, Monoclonal; Antirheumatic Agents; Antiviral Agents; Drug Therapy, Combin | 2009 |
[Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea].
Topics: Adenine; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatit | 2009 |
[Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, lamivudine-resistant chronic hepatitis B patients].
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e An | 2009 |
Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues.
Topics: Adenine; Antiviral Agents; Cell Line; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug | 2009 |
Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e | 2009 |
Can antiviral therapy for chronic hepatitis B enhance the progression to hepatocellular carcinoma?
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Viral; H | 2009 |
Clinical usefulness of sequential hepatitis B virus DNA measurement (the roadmap concept) during adefovir treatment in lamivudine-resistant patients.
Topics: Adenine; Adult; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B Antibodies; Hepatitis B viru | 2009 |
Current trends in chronic hepatitis B management: results of a questionnaire.
Topics: Adenine; Adult; Antiviral Agents; Biopsy; Clinical Competence; Drug Administration Schedule; Family | 2009 |
[Antiviral efficacy of lamivudine/adefovir combination therapy in chronic hepatitis b patients with resistance to lamivudine and adefovir consecutively].
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem | 2009 |
[Treatment of hepatitis B virus resistant to lamivudine and adefovir].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis | 2009 |
Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; | 2009 |
Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients.
Topics: Adenine; Adult; Antiviral Agents; Asian People; Base Composition; China; Computational Biology; Data | 2009 |
[The clinical study of adding on adefovir dipivoxil to treat for lamivudine resistant patients with chronic hepatitis B].
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Vir | 2009 |
Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil.
Topics: Adenine; Adult; Aged; Antiviral Agents; Cohort Studies; Creatinine; Female; Glomerular Filtration Ra | 2009 |
[Therapy of chronic hepatitis B. Tenofovir--first choice in current EASL guidelines].
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Drug Resistance, Viral; Evidence-Based Medicin | 2009 |
Monitoring of therapy in patients with chronic hepatitis B virus.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA Mutational Analysis; DNA, Viral; Drug Monitoring; | 2010 |
Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.
Topics: Adenine; Administration, Oral; Adult; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; DNA, | 2009 |
Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antiviral Agents; Base | 2009 |
Salvage therapy with tenofovir followed by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hep | 2009 |
Dynamic changes of HBV quasispecies and deletion patterns in a chronic hepatitis B patient.
Topics: Adenine; Antiviral Agents; Cluster Analysis; DNA, Viral; Epitopes, B-Lymphocyte; Epitopes, T-Lymphoc | 2009 |
Different models of HBeAg seroconversion predicated by on-treatment ALT and HBV DNA profiles.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; | 2009 |
Tenofovir: new indication. In chronic hepatitis B: beware bone toxicity.
Topics: Adenine; Antiviral Agents; Bone and Bones; Bone Diseases; Double-Blind Method; Drug Approval; Europe | 2009 |
Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Drug-Related Si | 2010 |
Lamivudine and adefovir resistance in children and young adults with chronic hepatitis B.
Topics: Adenine; Adolescent; Antiviral Agents; Child; Drug Administration Schedule; Drug Resistance, Viral; | 2010 |
Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Gua | 2010 |
Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance.
Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Resistance, | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide | 2009 |
[Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration | 2009 |
Hepatitis B virus in tenofovir-naive Chinese patients with chronic hepatitis B contains no mutation of rtA194T conferring a reduced tenofovir susceptibility.
Topics: Adenine; Adult; Drug Resistance, Viral; Female; Gene Amplification; Genotype; Hepatitis B virus; Hep | 2009 |
Hepatitis B in HIV patients: what is the current treatment and what are the challenges?
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guan | 2009 |
[Telbivudine in the management of HIV/HBV coinfection. Treating hepatitis B without HIV trouble].
Topics: Adenine; AIDS-Related Opportunistic Infections; Algorithms; Anti-HIV Agents; Antiviral Agents; Comor | 2009 |
[Non-standard discontinuation of adefovir dipivoxil causing acute exacerbation of hepatitis].
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Critical Illness; Cytokines; DNA, Viral; Follow-Up Stu | 2009 |
[The efficacy of nucleoside/nucleotide analogue on chronic hepatitis B].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepa | 2009 |
[Dissection of mechanism for the adefovir dipivoxil resistance in chronic hepatitis B patients].
Topics: Adenine; Adult; Alanine Transaminase; Amino Acid Sequence; Antiviral Agents; Base Sequence; DNA Prim | 2009 |
Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral; Evolution, Molecular | 2009 |
Tenofovir disoproxil fumarate for the treatment of hepatitis B infection.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Hepatitis B, Chronic; Humans; Organophosphonate | 2009 |
Decrease in viral load at weeks 12 and 24 in patients with chronic hepatitis B treated with lamivudine or adefovir predicts virological response at week 48.
Topics: Adenine; Adult; Antiviral Agents; Female; Forecasting; Hepatitis B, Chronic; Humans; Lamivudine; Mal | 2009 |
Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy.
Topics: Adenine; Adult; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Vir | 2010 |
Serum levels of surface large envelope proteins: prognostic markers for hepatitis B e antigen-negative patients with adefovir dipivoxil treatment.
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Female; Hepatitis B e Antigens; Hepatitis B Surface An | 2009 |
Hepatitis B viral surface mutations in patients with adefovir resistant chronic hepatitis B with A181T/V polymerase mutations.
Topics: Adenine; Adult; Aged; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Codon, Initiat | 2010 |
Hypophosphatemic osteomalacia after low-dose adefovir dipivoxil therapy for hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Hepatitis B, Chronic; Humans; Hypophosphatemia; Magnetic Resonance | 2010 |
Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.
Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Epitopes, B-Lymph | 2010 |
Establishment of a new quantitative detection approach to adefovir-resistant HBV and its clinical application.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hep | 2010 |
Hepatitis B genotypes and response to adefovir treatment in patients with HBV chronic infection.
Topics: Adenine; Antiviral Agents; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphon | 2010 |
Response to adefovir depends on mutation patterns in precore region, basal core promoter and reverse transcriptase, and on-treatment responses in Lamivudine-resistant chronic hepatitis B patients.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B Core Antig | 2010 |
Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.
Topics: Adenine; Adolescent; Adult; Aged; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem | 2011 |
Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy.
Topics: Adenine; Antiviral Agents; Asia; Cost-Benefit Analysis; Decision Support Techniques; DNA, Viral; Dru | 2010 |
Tenofovir/probenecid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence?
Topics: Adenine; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Organophosphon | 2010 |
Naturally occurring hepatitis B virus (HBV) variants with primary resistance to antiviral therapy and S-mutants with potential primary resistance to adefovir in Argentina.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Argentina; Child; Child, Preschool; Drug Resistance, V | 2010 |
[Serological and sociodemographic differences in HBV-patients with and without migration background].
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Comorbidity; Cross-Sectional Studies; Edu | 2010 |
[Genotype distribution of chronic hepatitis B and hepatitis C patients and investigation of the resistance patterns in hepatitis B cases].
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA Mutational Analysis; DNA-Directed DNA Polyme | 2010 |
Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.
Topics: Adenine; Antiviral Agents; China; Cost-Benefit Analysis; Guanine; Hepatitis B e Antigens; Hepatitis | 2010 |
Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments.
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Female; Guanine; H | 2010 |
rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B.
Topics: Adenine; Amino Acid Substitution; Antiviral Agents; Cell Line; Drug Resistance, Viral; Hepatitis B v | 2010 |
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B viru | 2010 |
Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance - a scholarly case.
Topics: Adenine; Amino Acid Motifs; Amino Acid Sequence; Antiviral Agents; Child; Drug Resistance, Viral; He | 2010 |
Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem | 2010 |
Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Vir | 2010 |
The curative efficiency of tenofovir for patients with chronic hepatitis B after failure of nucleoside/nucleotide analogues.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Nucleosides; Nucleotides; Organophosphonate | 2010 |
[A case of osteomalacia related to adefovir in a patient with chronic hepatitis B].
Topics: Adenine; Aged; Alkaline Phosphatase; Antiviral Agents; Dietary Supplements; DNA, Viral; Hepatitis B, | 2010 |
Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study.
Topics: Adenine; Adult; Antiviral Agents; Female; France; Hepatitis B Antibodies; Hepatitis B Antigens; Hepa | 2010 |
Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
Topics: Adenine; Cost-Benefit Analysis; Guanine; Hepatitis B, Chronic; Humans; Markov Chains; Organophosphon | 2010 |
Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen.
Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Drug Combinations; Female; Guanin | 2010 |
HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.
Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Catheter Ablation; Disease-Free S | 2010 |
[Antiviral treatment of chronic B hepatitis; 2010 - therapeutic recommendations].
Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Guanine; Hepatitis | 2010 |
[Treatment of chronic hepatitis B. High response rate in general practice].
Topics: Adenine; Antiviral Agents; Cross-Sectional Studies; Germany; Guanine; Hepatitis B, Chronic; Humans; | 2010 |
Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery.
Topics: Adenine; Base Sequence; Databases, Genetic; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Vi | 2010 |
Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
Topics: Adenine; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens | 2011 |
Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Female; Guanin | 2011 |
Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Child; Child, Preschool; DNA, Vi | 2010 |
Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies.
Topics: Adenine; Administration, Oral; Adult; Antiviral Agents; Case-Control Studies; Cytokines; DNA, Viral; | 2011 |
Initial virological response and viral mutation with adefovir dipivoxil added to ongoing Lamivudine therapy in Lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio | 2011 |
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resista | 2011 |
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resista | 2011 |
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resista | 2011 |
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resista | 2011 |
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resista | 2011 |
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resista | 2011 |
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resista | 2011 |
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resista | 2011 |
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resista | 2011 |
High rate of adefovir-lamivudine combination therapy in nucleoside-naïve patients with chronic hepatitis B in France: results of a national survey in 1730 patients.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Cross-Sectional Studies; DNA, Vi | 2010 |
Virologic and clinical outcomes in HIV/HBV coinfected patients on tenofovir-containing HAART.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; HIV Infection | 2010 |
Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment.
Topics: Adenine; Adult; Aged; Antiviral Agents; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Mal | 2011 |
Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort | 2010 |
Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'Ivoire; Cr | 2010 |
[Analogs combination therapy in chronic hepatitis B: when and how?].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B, | 2010 |
[Long-term therapy for chronic hepatitis B in HIV co-infected patients].
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Resistance, Vi | 2010 |
[Treatment has a positive impact on the long-term evolution of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Guanine; Hepatitis B | 2010 |
Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil.
Topics: Adenine; Adult; Antiviral Agents; Clinical Trials as Topic; Cytokines; DNA, Viral; Female; Hepatitis | 2010 |
Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience.
Topics: Adenine; Adult; Aged; Antiviral Agents; Base Sequence; Cloning, Molecular; Drug Resistance, Viral; F | 2011 |
Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; China; Cross-Sectional Studie | 2010 |
Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Evolu | 2010 |
Tenofovir for treatment of hepatitis B virus reactivation in patients with chronic GVHD.
Topics: Adenine; Adult; Chronic Disease; Female; Graft vs Host Disease; Hepatitis B virus; Hepatitis B, Chro | 2011 |
Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; | 2011 |
Tenofovir salvage for nucleoside experienced patients: muddy waters?
Topics: Adenine; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Nucleosides; Organophosphonates; Reve | 2011 |
The level of HBV DNA at month 12 is an important predictor of virological breakthrough during adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hep | 2011 |
Hyperlipidemic acute pancreatitis: a possible role of antiretroviral therapy with entecavir.
Topics: Abdominal Pain; Acute Disease; Adenine; Adult; Alcoholism; Antiretroviral Therapy, Highly Active; Cr | 2011 |
Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem | 2011 |
Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Antigens, CD; Case-Control Studies; CD8-Positive T-Lymphocytes; DNA, Viral; Female; | 2011 |
[Efficacy and treatment strategy for drug resistances of nucleos(t)ide analogues for chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Organophos | 2011 |
[Efficacy of entecavir and adefovir combination therapy in patients with chronic hepatitis B refractory to lamivudine and adefovir combination therapy].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepat | 2011 |
HBV core region variability: effect of antiviral treatments on main epitopic regions.
Topics: Adenine; Adult; Amino Acid Sequence; Antigenic Variation; Antiviral Agents; B-Lymphocytes; DNA, Vira | 2011 |
Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Genotype; Guanine; Hepatitis B virus; Hepatitis B | 2011 |
Defining virologic relapse in chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hep | 2011 |
Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
Topics: Adenine; Adult; Albuminuria; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, Chron | 2011 |
Management of chronic hepatitis B patients: efficacy & limitation of nucleos(t)ide analogues.
Topics: Adenine; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organo | 2011 |
Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients.
Topics: Adenine; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Enzymes; | 2011 |
Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Asian People; Cohort Studies; Community Health Services; Drug Resi | 2011 |
[Virological response to adefovir dipivoxil predicts the long-term development of resistance in previously untreated patients with HBeAg-negative chronic hepatitis B].
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepa | 2011 |
Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Deoxycytidine; DNA, Viral; D | 2011 |
Proper antiviral therapy for hepatitis B virus-associated acute-on-chronic liver failure.
Topics: Adenine; Antiviral Agents; End Stage Liver Disease; Guanine; Hepatitis B, Chronic; Humans; Liver Fai | 2011 |
Adefovir-induced Stevens-Johnson syndrome and toxic epidermal necrolysis overlap syndrome.
Topics: Adenine; Antiviral Agents; Biopsy; Epidermis; Follow-Up Studies; Hepatitis B, Chronic; Humans; Immun | 2011 |
Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection.
Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral | 2011 |
On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Biopsy; Disease Progression; Elasticit | 2011 |
Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B | 2011 |
Outcome of patients suffering from a spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure and treated with antivirals.
Topics: Adenine; Antiviral Agents; DNA, Viral; Female; Hepatitis B, Chronic; Humans; Liver Failure, Acute; M | 2011 |
Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, | 2011 |
Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
Topics: Adenine; Adult; Aged; Amino Acid Substitution; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Com | 2011 |
Development of immunity against hepatitis B virus after donor lymphocyte infusion in a peripheral blood stem cell transplantation recipient with chronic hepatitis B.
Topics: Adenine; Adoptive Transfer; Antiviral Agents; DNA, Viral; Drug Combinations; Female; Hepatitis B Ant | 2011 |
Two patterns of alanine aminotransferase increase to predict long-term viral response in chronic hepatitis B patients: virus- or host-induced?
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Guanine; Hepacivir | 2011 |
Effect of antiviral therapy on the immunohistochemical expression of bcl-xL and bax protein in patients with HBeAg-negative chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Biopsy; Fema | 2011 |
Parallel decline of CD8+CD38+ lymphocytes and viremia in treated hepatitis B patients.
Topics: Adenine; ADP-ribosyl Cyclase 1; Adult; CD3 Complex; Female; Hepatitis B, Chronic; Humans; Male; Memb | 2011 |
Hepatitis: PEG-IFN for the treatment of hepatitis D.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis D; Humans; Int | 2011 |
Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy.
Topics: Adenine; Adult; Antiviral Agents; Female; Guanine; Hepatitis B Antigens; Hepatitis B virus; Hepatiti | 2011 |
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Bone Marrow; DNA, Viral; Drug Therapy, Combi | 2011 |
Changes of serum levels of keratin-18 fragments in hepatitis B e antigen-negative chronic hepatitis B patients under oral antiviral therapy.
Topics: Adenine; Administration, Oral; Antiviral Agents; Hepatitis B e Antigens; Hepatitis B, Chronic; Human | 2011 |
Adefovir serum levels do not differ between responders and nonresponders.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Chromatography, High Pressure Liquid; Fem | 2011 |
Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Gene Products, pol; Gu | 2011 |
Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Evolution, Molecular; Female; Guanine; Hepatitis | 2011 |
Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Antiviral Agents; Case-Control Studies; Female; G | 2011 |
Nephrotoxicity, including acquired Fanconi's syndrome, caused by adefovir dipivoxil - is there a safe dose?
Topics: Adenine; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Fanconi Syndrome; Female; Hepatit | 2012 |
Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B S | 2011 |
Antiviral drug resistance testing in patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Data Collection; Decision Making; DNA, Viral; Drug Resistance, Vir | 2012 |
High frequency of CD4+ CXCR5+ TFH cells in patients with immune-active chronic hepatitis B.
Topics: Adaptive Immunity; Adenine; Adult; Alanine Transaminase; Animals; Antiviral Agents; Aspartate Aminot | 2011 |
rtL180M mutation of hepatitis B virus is closely associated with frequent virological resistance to adefovir dipivoxil therapy.
Topics: Adenine; Biomarkers; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Genotype; Hepatiti | 2012 |
Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients.
Topics: Adenine; Adolescent; Adult; Aged; Drug Administration Schedule; Drug Therapy, Combination; Female; G | 2012 |
[Improvement of health-related quality of life in chronic hepatitis B patients treated with entecavir or adefovir].
Topics: Adenine; Adult; Aged; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Or | 2011 |
The efficacy of entecavir therapy in chronic hepatitis B patients with suboptimal response to adevofir.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow- | 2011 |
The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Gene Products, pol; Genotype; Hep G2 Cells; Hepat | 2011 |
High dose lamivudine in HBV-related cirrhotic patients with unsatisfactory response after adefovir add-on.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Huma | 2012 |
Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Follow | 2011 |
Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Fe | 2011 |
Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatit | 2011 |
Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil | 2011 |
Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective study.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; China; Female; Follow-Up Studies | 2011 |
Virological response to adefovir monotherapy and the risk of adefovir resistance.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hep | 2011 |
[A case with poly-bone pain, decrease of bone density and in crease of serum creatinine related to adefovir dipivoxil treatment in a chronic hepatitis B patient].
Topics: Adenine; Adult; Bone Density; Creatinine; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Pa | 2011 |
Adefovir dipivoxil modulates cytokine expression in Th1/Th2 cells in patients with chronic hepatitis B.
Topics: Adenine; Administration, Oral; Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransfe | 2012 |
Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Gua | 2012 |
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study.
Topics: Adenine; Adult; Aged; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combin | 2012 |
[Lamivudine-resistant analysis and management for chronic hepatitis B patients with initial lamivudine therapy].
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Follow-Up Studie | 2011 |
[HBV resistance mutants before and after adefovir dipivoxil treatment and the relationship with HBV genotypes].
Topics: Adenine; Adult; Drug Resistance, Viral; Female; Genes, Viral; Genotype; Hepatitis B virus; Hepatitis | 2011 |
Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change.
Topics: Adenine; Antiviral Agents; Canada; Drug Approval; Guanine; Health Services Accessibility; Hepatitis | 2011 |
Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Canada; Cost-Benefit Analysis; Female; Health Care Cos | 2011 |
Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection.
Topics: Adenine; Adult; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Multiple, Viral; Fatal Outcome; | 2012 |
A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir.
Topics: Adenine; Adult; Antiviral Agents; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Sur | 2012 |
[New drugs of treatment of patients with chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Emtricitabine; Hepatitis B, Chroni | 2011 |
Tenofovir plus entecavir as rescue therapy for multidrug-resistant chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Substitution; Drug Therapy, | 2012 |
Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Fe | 2012 |
[Adefovir dipivoxil-induced Fanconi syndrome and hypophosphatemic osteomalacia associated with muscular weakness in a patient with chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Bone Diseases, Metabolic; Fanconi Syndrome; Hepatitis B, Chronic; Humans; | 2011 |
Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Monitoring; Drug Resistance, Viral; Drug Th | 2012 |
Prevalence, virology and antiviral drugs susceptibility of hepatitis B virus rtN238H polymerase mutation from 1865 Chinese patients with chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Asian People; Child; Ch | 2012 |
De novo combination therapy with lamivudine and adefovir dipivoxil in chronic hepatitis B patients.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hep | 2011 |
Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug The | 2012 |
Peripheral blood lymphocyte dynamics and viral kinetics in patients with chronic active hepatitis B virus infection treated by tenofovir.
Topics: Adenine; ADP-ribosyl Cyclase 1; Adult; Antiviral Agents; Biomarkers; CD28 Antigens; CD8-Positive T-L | 2012 |
Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Therapy, | 2012 |
Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolizat | 2012 |
Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Combinations; Drug Resistance, Vi | 2012 |
Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Cloning, Molecular; Coinfection; DNA, Viral; Drug Resistance, Vira | 2012 |
An improved reverse dot hybridization for simple and rapid detection of adefovir dipivoxil-resistant hepatitis B virus.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Hepatitis B virus; Hepatiti | 2012 |
HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine resistance.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens | 2012 |
High-resolution melting and real-time PCR for quantification and detection of drug-resistant HBV mutants in a single amplicon.
Topics: Adenine; Antiviral Agents; DNA, Complementary; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatiti | 2012 |
Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis B.
Topics: Adenine; Adult; Enzyme-Linked Immunosorbent Assay; Female; Hep G2 Cells; Hepatitis B Surface Antigen | 2012 |
Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hep | 2011 |
Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; Female; Follow-Up Studies; Guanine; Hepatitis B e | 2012 |
Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; Female; Follow-Up Studies; Guanine; Hepatitis B e | 2012 |
Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; Female; Follow-Up Studies; Guanine; Hepatitis B e | 2012 |
Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; Female; Follow-Up Studies; Guanine; Hepatitis B e | 2012 |
Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Follow-Up | 2012 |
Safety of long-term nucleos(t)ide treatment in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Evidence-Based Medicine; Guanine; Hepatitis | 2012 |
Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Femal | 2012 |
[Evaluation of the safety of pregnancy initiated by chronic hepatitis B fathers while taking adefovir].
Topics: Adenine; Adult; Female; Hepatitis B, Chronic; Humans; Infant, Newborn; Male; Organophosphonates; Pat | 2012 |
Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Biomarkers; Creatinine; Female; Glomerular Filtration Rate; | 2012 |
Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Cohort Studies; Creatinine; Female; Glomerular Filtration Ra | 2012 |
Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Cross-Sectional Studies; DNA, Viral; Drug Resist | 2012 |
High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral | 2012 |
Commentary: combination therapy with two nucleos(t)ide analogues in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic | 2012 |
Factors influencing inadequate or suboptimal response to adefovir with or without genotypic resistance.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B | 2012 |
Hepatitis B virus related membranous glomerulonephritis and proteinuria treated with lamivudine and tenofovir.
Topics: Adenine; Glomerulonephritis, Membranous; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosp | 2011 |
[Influence of adefovir dipivoxil or telbivudine monotherapy on renal function of patients with chronic hepatitis B].
Topics: Adenine; Adolescent; Adult; Creatinine; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Hu | 2012 |
Another drug in the armamentarium to combat hepatitis B virus in adolescents.
Topics: Adenine; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Tenofovir | 2012 |
Current practice of chronic hepatitis B treatment in Southern Italy.
Topics: Adenine; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Female; Guanine; Hepatitis B | 2012 |
Long-term hepatitis B virus surface antigen decay in HIV-1/hepatitis B virus-coinfected adults initiating a tenofovir-containing regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HI | 2012 |
Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Cells, Cultured; DNA, Viral; Genotype; Guanine; Hepatitis B e Antigens; H | 2012 |
Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Guanin | 2012 |
Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir.
Topics: Adenine; Anti-HIV Agents; Coinfection; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus | 2012 |
Acute liver failure resulting from discontinuation of nucleoside analogues in chronic hepatitis B patients: a report of two cases.
Topics: Adenine; Adult; Antiviral Agents; Guanine; Hepatitis B, Chronic; Histocytochemistry; Humans; Lamivud | 2013 |
Pathological femoral fractures due to osteomalacia associated with adefovir dipivoxil treatment for hepatitis B: a case report.
Topics: Adenine; Antiviral Agents; Arthroplasty, Replacement, Hip; Fanconi Syndrome; Femoral Neck Fractures; | 2012 |
A case of adefovir-induced membranous nephropathy related to hepatitis B caused by lamivudine-resistant virus after liver transplant due to Byler's disease.
Topics: Adenine; Adolescent; Adult; Child, Preschool; Cholestasis, Intrahepatic; Drug Resistance, Viral; Fem | 2012 |
Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: a 5-year study of patients with hepatitis B with lamivudine resistance.
Topics: Adenine; Adult; Aged; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Hepatitis B e Antigens; | 2012 |
Safety and efficacy of adefovir therapy for lamivudine-resistant hepatitis B virus infection in renal transplant recipients.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; F | 2012 |
Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Dr | 2012 |
Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; China; Drug Resistance, Viral; Drug Therapy, Combination; Female; | 2012 |
Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders.
Topics: Adenine; Adult; Analysis of Variance; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combi | 2012 |
Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy.
Topics: Adenine; Administration, Oral; Amino Acid Substitution; Antiviral Agents; DNA, Viral; Drug Resistanc | 2012 |
Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Blood Chemical Analysis; Drug Therapy, | 2013 |
The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Drug Approval; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chro | 2012 |
Letter: renal tubular dysfunction during nucleotide analogue therapy in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Male; O | 2012 |
Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy.
Topics: Adenine; Adult; Antiviral Agents; Clonal Evolution; DNA, Viral; Drug Resistance, Multiple, Viral; Gu | 2013 |
Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice.
Topics: Adenine; Adult; Animals; Antiviral Agents; Disease Models, Animal; DNA, Viral; Female; Flow Cytometr | 2013 |
Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Child; Ch | 2013 |
[Clinical analysis of hepatitis B virus mutations related to adefovir dipivoxil among patients with chronic hepatitis B virus infection in eastern Zhejiang province].
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral; Femal | 2012 |
The efficacy of adefovir plus entecavir combination therapy in patients with chronic hepatitis B refractory to both lamivudine and adefovir.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis | 2013 |
The short-term efficacy of entecavir in lamivudine-resistant chronic hepatitis B: influence of sequential adefovir-refractoriness.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guan | 2013 |
Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study.
Topics: Adenine; Adult; Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy | 2013 |
Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment.
Topics: Adenine; Adult; Antiviral Agents; Clonal Evolution; Drug Combinations; Drug Resistance, Viral; Drug | 2012 |
Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Femal | 2013 |
Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Femal | 2013 |
Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Femal | 2013 |
Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Femal | 2013 |
[Outcomes of unexpected pregnancy during anti-hepatitis B virus therapy with adefovir dipivoxil: a report on safety and full-term infants].
Topics: Adenine; Adult; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Ma | 2012 |
Scar undone: long-term therapy of hepatitis B.
Topics: Adenine; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Reverse | 2013 |
Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load.
Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease-Free Survival; DNA, Viral; Fema | 2013 |
Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.
Topics: Adenine; Allied Health Personnel; Antibodies, Viral; Antiviral Agents; Canada; Coinfection; Drug Res | 2012 |
Osteomalacia due to Fanconi's syndrome and renal failure caused by long-term low-dose adefovir dipivoxil.
Topics: Adenine; Antiviral Agents; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organo | 2013 |
Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains.
Topics: Adenine; Adult; Antiviral Agents; Arabinofuranosyluracil; Drug Resistance, Viral; Female; Glomerulon | 2012 |
The effect of HLA-DQB1 alleles on virologic breakthroughs during chronic hepatitis B treatment with genetically low barrier drugs.
Topics: Adenine; Adult; Alleles; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepati | 2013 |
Should chronic hepatitis B be treated as early as possible?
Topics: Adenine; Adult; Antiviral Agents; Belgium; Cost-Benefit Analysis; Early Diagnosis; Guanine; Health C | 2013 |
Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.
Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; Deoxycytidine; DNA, Viral; Double-Blind M | 2013 |
[Antiviral therapy for patients with chronic hepatitis B with multi-drug resistance to nucleoside analogues].
Topics: Adenine; Aged; Aged, 80 and over; Antiviral Agents; Drug Resistance, Multiple, Viral; Female; Guanin | 2013 |
Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
Topics: Adenine; Aged; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Female; Genotype; | 2013 |
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; Antiviral Agents; Australia; Coinfectio | 2013 |
Use of ALLGIO probe assays for detection of HBV resistance to adefovir in patients with chronic hepatitis B, Kerman, Iran.
Topics: Adenine; Adult; Aged; Antiviral Agents; Biological Assay; DNA, Viral; Drug Resistance, Viral; Female | 2012 |
Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Human | 2012 |
Outcome of various treatments for posttransplant hepatitis B virus recurrence.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Administrati | 2013 |
Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Cohort Studies; Coinfection; Female; Genotype; Hepatitis B e A | 2013 |
Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B.
Topics: Adenine; Adult; Anti-HIV Agents; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged | 2013 |
FDA notifications. New treatment approved for chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Drug Approval; Hepatitis B, Chronic; Humans; Kidney; Organophospho | 2002 |
From the Food and Drug Administration.
Topics: Adenine; Anastrozole; Antineoplastic Agents, Hormonal; Antiviral Agents; Breast Neoplasms; Chemother | 2002 |
Adefovir (Hepsera) for chronic hepatitis B infection.
Topics: Adenine; Administration, Oral; Controlled Clinical Trials as Topic; Creatinine; Drug Resistance, Vir | 2002 |
Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea.
Topics: Adenine; Adult; Codon; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, C | 2003 |
Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.
Topics: Adenine; Baculoviridae; Carcinoma, Hepatocellular; Drug Resistance, Viral; Hepatitis B Core Antigens | 2003 |
Comparative effects of adefovir and selected nucleoside inhibitors of hepatitis B virus DNA polymerase on mitochondrial DNA in liver and skeletal muscle cells.
Topics: Adenine; Antiviral Agents; DNA, Mitochondrial; Hepatitis B virus; Hepatitis B, Chronic; Hepatoblasto | 2003 |
Suppressing hepatitis B without resistance--so far, so good.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B v | 2003 |
Unsuccessful rescue therapy with adefovir dipivoxil for lamivudine resistant HBV in a patient with liver failure.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Fatal Outcome; Female; Hepatitis B, Chronic; Huma | 2003 |
Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy.
Topics: Adenine; Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, | 2003 |
Adefovir dipivoxil for hepatitis B e antigen-positive chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; L | 2003 |
[The first nucleotide analog permitted. New hepatitis B therapy helps the problem patients, too].
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Drug Resistance; Hepatitis B, Chronic; HIV Infections; H | 2003 |
Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resis | 2003 |
[New option for successful therapy of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Approval; Germany; Hepatitis B, Chronic; H | 2003 |
Use of adefovir in the treatment of the chronic hepatitis B virus infection with resistance to lamivudine.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis | 2003 |
Live-donor liver transplantation for acute-on-chronic hepatitis B liver failure.
Topics: Acute Disease; Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Graft Surviv | 2003 |
Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B viru | 2003 |
Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.
Topics: Adenine; Amino Acid Sequence; Combined Modality Therapy; Drug Resistance, Viral; Hepatitis B virus; | 2003 |
Treatment of pre- and post-liver transplantation HBV infection: Should we aim at combination therapy?
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; | 2003 |
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Child; Drug Resistance, Viral; Female; Genotype; | 2003 |
Resistance of HBV to adefovir dipivoxil: a case for combination antiviral therapy?
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Gene Produ | 2003 |
In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector.
Topics: Adenine; Antiviral Agents; Cell Line; Cloning, Molecular; DNA, Viral; Drug Resistance, Viral; Geneti | 2004 |
Antivirals for the treatment of chronic hepatitis B: current and future options.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Human | 2003 |
Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Forecasting; Hepatitis B, Chronic; HIV; HIV Infections; | 2003 |
[Adefovir].
Topics: Adenine; Antiviral Agents; Drug Monitoring; Drug Prescriptions; Hepatitis B, Chronic; Humans; Organo | 2003 |
[Update in the treatment of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Drug Evaluation; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; O | 2004 |
The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV.
Topics: Adenine; Administration, Oral; Adult; Cohort Studies; Dose-Response Relationship, Drug; Drug Adminis | 2004 |
Efficacy of combined lamivudine and adefovir dipivoxil treatment for severe HBV graft reinfection after living donor liver transplantation.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Immunization, Pa | 2003 |
[New antiviral agent. Hepatitis B therapy with slight resistance risk].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Hepatitis B e Antigens; | 2003 |
Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection.
Topics: Adenine; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Animals; Antigens, Bacterial; Antiviral Age | 2004 |
Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Hep | 2004 |
Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B.
Topics: Adenine; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Sc | 2004 |
Adefovir dipivoxil: new preparation. A third-line option in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Cohort Studies; Drug Approval; Drug Resistance, | 2004 |
[Adefovir dipivoxil--a further step in the control of chronic viral hepatitis B. There is still a long way to go].
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Organophospho | 2004 |
[A case of liver cirrhosis B resistant to lamivudine showing the clinical effect of adefovir dipivoxil].
Topics: Adenine; Amino Acid Motifs; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hep | 2004 |
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.
Topics: Adenine; Antiviral Agents; Biopsy; DNA, Circular; DNA, Viral; Hepatitis B Core Antigens; Hepatitis B | 2004 |
Practical management of chronic hepatitis B infection.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Hepatitis B Surface Antigens; Hepatitis B, Chronic; | 2004 |
Haemolytic anaemia after nucleotide antiretroviral treatment discontinuation in a chronic hepatitis B-virus co-infected AIDS patient.
Topics: Adenine; Adult; Anemia, Hemolytic; Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; HIV | 2004 |
Prevention of hepatitis B virus reinfection after orthotopic liver transplantation.
Topics: Adenine; Adult; Combined Modality Therapy; Female; Hepatitis B Antibodies; Hepatitis B Core Antigens | 2004 |
Lichenoid drug eruption to tenofovir in an HIV/hepatitis B virus co-infected patient.
Topics: Adenine; Anti-HIV Agents; Drug Eruptions; Hepatitis B, Chronic; HIV Infections; Humans; Lichenoid Er | 2004 |
[Active prevention and treatment of superinfection with HBV, HCV and HIV].
Topics: Adenine; Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infe | 2004 |
[An attempt to approach an optional therapeutic regimen for chronic hepatitis B].
Topics: Adenine; Animals; Antiviral Agents; Combined Modality Therapy; Genetic Therapy; Hepatitis B Antigens | 2004 |
Tenofovir therapy for lamivudine resistance following liver transplantation.
Topics: Adenine; Adult; Antiviral Agents; Chronic Disease; Drug Resistance, Viral; Hepatitis B; Hepatitis B, | 2004 |
Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes.
Topics: Adenine; Animals; Antiviral Agents; Disease Models, Animal; DNA, Circular; DNA, Viral; Hepatitis B, | 2005 |
Remofovir mesylate: a prodrug of PMEA with improved liver-targeting and safety in rats and monkeys.
Topics: Adenine; Animals; Antiviral Agents; Autoradiography; Carbon Radioisotopes; Dose-Response Relationshi | 2004 |
Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Drug Resistance, Viral; Female; Gene Products, pol; | 2005 |
Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure.
Topics: Adenine; Adult; DNA, Viral; Drug Therapy, Combination; Hepatitis B Surface Antigens; Hepatitis B, Ch | 2005 |
Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Combinations; Drug Resistance, Viral; Female; Hepatitis | 2005 |
[Therapeutic effect of adefovir dipivoxil on recurrent or de novo infection of hepatitis B virus after liver transplantation: a preliminary report].
Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; L | 2005 |
[Advances in treatment of chronic hepatitis B].
Topics: Adenine; Animals; Antiviral Agents; Drug Therapy, Combination; Genetic Therapy; Hepatitis B, Chronic | 2005 |
Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants.
Topics: Adenine; Adult; Antibodies, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B Surface Ant | 2005 |
Summaries for patients. Antiviral regimens for chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Hepatitis B e Antigen | 2005 |
Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Hepatitis B e Antigen | 2005 |
Assessing the benefits and costs of new therapies for hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Hepatitis B, Chronic; Humans; Organophosphonates | 2005 |
Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis B e | 2005 |
Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Comb | 2005 |
Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection.
Topics: Adenine; Administration, Oral; Animals; Antiviral Agents; Dose-Response Relationship, Drug; Hepatiti | 2005 |
The maze of treatments for hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B e Antigens | 2005 |
[Influence of nucleoside analogues resistance on anti-HBV treatment].
Topics: Adenine; Antiviral Agents; Dideoxynucleosides; Drug Resistance, Viral; Hepatitis B virus; Hepatitis | 2005 |
Chronic hepatitis B--treatment with nucleoside analogues.
Topics: Adenine; Drug Resistance; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Lamivudi | 2005 |
Association of polymorphism of tumor necrosis factor-alpha gene promoter region with outcome of hepatitis B virus infection.
Topics: Adenine; Adult; Case-Control Studies; Cytosine; Female; Genotype; Hepatitis B; Hepatitis B virus; He | 2005 |
[Clinical outcomes after discontinuation of Lamivudine in chronic hepatitis B patients with Lamivudine resistant HBV mutant].
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis | 2005 |
[Adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD mutation].
Topics: Adenine; Adult; Aged; Amino Acid Motifs; Antiviral Agents; DNA-Directed DNA Polymerase; Female; Hepa | 2005 |
Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hep | 2005 |
Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir.
Topics: Adenine; Antiviral Agents; DNA, Viral; Genes, Viral; Genotype; Hepatitis B e Antigens; Hepatitis B, | 2005 |
Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; DNA, V | 2005 |
Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Resistance, Viral; Fem | 2006 |
Cost-effectiveness in hepatitis B.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Hepatitis B, Chronic; Humans; Interferon alpha-2; | 2005 |
Treatment of lamivudine-resistant hepatitis B in HIV-infected persons: is adefovir dipivoxil the answer?
Topics: Adenine; AIDS-Related Opportunistic Infections; Antiviral Agents; DNA, Viral; Drug Resistance, Viral | 2006 |
Heart transplantation in patients with chronic hepatitis B: clinical evolution, molecular analysis, and effect of treatment.
Topics: Adenine; Adult; Alanine Transaminase; DNA, Viral; Drug Resistance, Viral; Female; Heart Diseases; He | 2005 |
Virologic response and resistance to adefovir in patients with chronic hepatitis B.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Genotype; | 2006 |
Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection.
Topics: Adenine; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; | 2005 |
Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Cost-Benefit Analysis; Hepatitis B e Antigens; Hepatitis | 2006 |
[Lamivudine and adefovir resistance in a patient with HBeAg negative chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple, Viral; Hepatitis B e Antigens; Hepatitis B vir | 2006 |
Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil.
Topics: Adenine; Adult; Drug Resistance, Viral; Female; Genotype; Hepatitis B, Chronic; Humans; Lamivudine; | 2006 |
Adefovir dipivoxil-associated thrombocytopenia in a patient with chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Thro | 2006 |
Chronic hepatitis B: a critical appraisal of current approaches to therapy.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Biopsy; Clinical Competence; Disease Progression; D | 2006 |
Combination therapy for chronic hepatitis B: a one-two knockout punch, or a swing and a miss?
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hep | 2006 |
Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.
Topics: Adenine; Adult; DNA, Viral; Drug Resistance, Viral; Follow-Up Studies; Hepatitis B virus; Hepatitis | 2006 |
Replacement of tenofovir with adefovir may result in reactivation of hepatitis B virus replication.
Topics: Adenine; Antiviral Agents; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; | 2006 |
[Chronic hepatitis B: from old braids and new brooms].
Topics: Adenine; Antiviral Agents; Germany; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; | 2005 |
Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir.
Topics: Adenine; Antiviral Agents; Base Sequence; DNA Probes; DNA, Viral; Drug Resistance, Viral; Genes, Vir | 2006 |
First report of genotypic resistance to adefovir in chronic HBV in the Republic of Ireland.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus; Hep | 2006 |
Antiviral options for the treatment of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B v | 2006 |
Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Bilirubin; DNA, Viral; Drug Resistance | 2006 |
Tenofovir for chronic hepatitis B virus infection in HIV-coinfected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Clinical Trials as Topic; Hepatitis B e Antigens; Hepatitis B, Chro | 2006 |
Variant of hepatitis B virus with primary resistance to adefovir.
Topics: Adenine; Amino Acid Sequence; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatiti | 2006 |
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; | 2006 |
Adefovir dipivoxil monotherapy is a sufficiently effective treatment modality for Japanese patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Vir | 2006 |
Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.
Topics: Adenine; Adult; Aged; Antiviral Agents; Base Sequence; Case-Control Studies; DNA, Viral; Dose-Respon | 2006 |
[The change of HBV nucleotide sequence during Adefovir dipivoxil treatment].
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Human | 2006 |
[The use of nucleotide analogues in treating patients with chronic hepatitis B].
Topics: Adenine; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates | 2006 |
[Problems of and strategies in nucleotide analogues therapy for chronic hepatitis B].
Topics: Adenine; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates | 2006 |
Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2).
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Hepatitis B virus; Hepatiti | 2006 |
[To evaluate treatments of chronic hepatitis B].
Topics: Adenine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleos | 2006 |
[Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy in acute exacerbation after viral breakthrough during lamivudine therapy in chronic hepatitis B].
Topics: Acute Disease; Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Female; Hepatitis B vir | 2006 |
Hepatitis B virus with primary resistance to adefovir.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B Antibodies; Hepatitis B e An | 2006 |
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Biopsy; DNA, Circular; DNA, Viral; Drug Carriers; Drug Therapy, Co | 2006 |
Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Chi-Square Distributi | 2006 |
Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antigens, CD; Antiviral Agents; Cytokines; Dendritic Cel | 2006 |
Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.
Topics: Adenine; Adult; Antiviral Agents; Biological Evolution; Cells, Cultured; Drug Resistance, Multiple; | 2006 |
[A case of severe skin eruption caused by lamivudine in a patient with chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Drug Eruptions; Female; Hepatitis B, Chronic; Humans; Ichthyosis; Lamivud | 2006 |
A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient.
Topics: Adenine; Adult; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; | 2006 |
Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; CD4 Lymphocyte Count; Cell Division; Cells, Cultured; Female | 2007 |
Prevalence of hepatitis B virus genotype D in precore mutants among chronic liver disease patients from New Delhi, India.
Topics: Adenine; Adult; DNA Mutational Analysis; DNA, Viral; Female; Genotype; Guanine; Hepatitis B Core Ant | 2007 |
COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma.
Topics: Adenine; Antiviral Agents; Automation; Biopsy; DNA, Viral; Drug Resistance, Viral; Hepatitis B Surfa | 2007 |
[The rate of hepatitis B virus resistance to adefovir dipivoxil (ADV) and the evolution of hepatitis B virus in lamivudine-resistant chronic hepatitis B patients with ADV monotherapy].
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Evolution, Molecular; Female; Hepatitis B | 2007 |
Rescue therapy for lamivudine-resistant chronic hepatitis B: when and how?
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; H | 2007 |
Why do we not yet have combination chemotherapy for chronic hepatitis B?
Topics: Adenine; Antibodies, Viral; Antiviral Agents; DNA, Viral; Drug Combinations; Drug Resistance, Multip | 2007 |
Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; | 2007 |
Treatment of patients with lamivudine-resistant and adefovir dipivoxil-resistant chronic hepatitis B virus infection: is tenofovir the answer?
Topics: Adenine; Adult; Drug Resistance, Multiple, Viral; Hepatitis B, Chronic; Humans; Lamivudine; Male; Mi | 2007 |
In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
Topics: Adenine; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Multiple, Viral; Hepatitis B virus; He | 2007 |
Tailoring antiviral therapy in chronic hepatitis B patients with lamivudine resistance.
Topics: Adenine; Contraindications; Dose-Response Relationship, Drug; Drug Resistance, Viral; Hepatitis B vi | 2007 |
Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Hong K | 2007 |
Decompensated lamivudine-resistant hepatitis B virus-related cirrhosis treated successfully with adefovir dipivoxil allowing surgery for hepatocellular carcinoma.
Topics: Adenine; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Disease Progression; Drug Resis | 2007 |
Characteristics of patients with chronic hepatitis-B virus infection in an urban hospital.
Topics: Adenine; Adolescent; Adult; Black or African American; Contraindications; Female; Hepatitis B, Chron | 2007 |
Optimal duration of therapy in HBV-related cirrhosis.
Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Health Planning Guidelines; Hepatitis B vir | 2007 |
Recommendations for the treatment of chronic hepatitis B infection in children.
Topics: Adenine; Antiviral Agents; Child; Child, Preschool; Female; Hepatitis B e Antigens; Hepatitis B Surf | 2007 |
Reversibility of cirrhosis in HIV/HBV coinfection.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, V | 2007 |
Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Asian People; DNA, Viral; Drug Resistance, Multiple, Vir | 2007 |
Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy.
Topics: Adenine; Adult; Antiviral Agents; Base Sequence; DNA Mutational Analysis; DNA Primers; DNA, Viral; D | 2007 |
[Recent advances in the treatment of the hepatitis HBV-related. Effectiveness and tolerability of adefovir dipivoxil].
Topics: Adenine; Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphonates; Trea | 2007 |
Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Gene D | 2007 |
Does pre-treatment with lamivudine prime for adefovir resistance of hepatitis B virus infection?
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, | 2007 |
[An economic evaluation of different treatments for HBeAg-positive chronic hepatitis B in China].
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Female; Hepatitis B e Antigens; Hepatitis B, Chron | 2007 |
Pre- and post-treatment predictors of the early achievement of HBeAg loss in lamivudine-resistant patients receiving adefovir therapy.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis | 2007 |
Pradefovir, a liver-targeted prodrug of adefovir against HBV infection.
Topics: Adenine; Antiviral Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dr | 2007 |
[A case of chronic hepatitis B with primary adefovir resistance].
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug The | 2007 |
Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiviral Agents; Drug Therapy, Combination; Female; Guideli | 2007 |
Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance; Drug Resistance, Viral; Drug Th | 2007 |
Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy | 2007 |
Adefovir for lamivudine resistant HBV: more than meets the eye.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepat | 2007 |
A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment.
Topics: Adenine; Adult; Arabinofuranosyluracil; Base Sequence; Cell Line, Tumor; Cloning, Molecular; Deoxycy | 2007 |
Chronic hepatitis B: a wider range of therapeutic options.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Interferon | 2007 |
Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues.
Topics: Adenine; Adult; Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Guanine; Hep | 2007 |
[Effect of initial virologic response to adefovir on the development of resistance to adefovir in lamivudine-resistant chronic hepatitis B].
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; | 2007 |
Summaries for patients. Antiviral therapy for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combinatio | 2007 |
Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay.
Topics: Adenine; Amino Acid Substitution; Drug Resistance, Viral; Evolution, Molecular; Gene Products, pol; | 2007 |
[Recent therapies for hepatitis B (discussion)].
Topics: Adenine; Antiviral Agents; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B | 2007 |
The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore.
Topics: Adenine; Antiviral Agents; Asian People; Cost-Benefit Analysis; Drug Costs; Female; Hepatitis B e An | 2007 |
[Adefovir in reactivation of chemotherapy-induced hepatitis B in an anti-Hbc-positive patient].
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bleomycin; Dacarbaz | 2007 |
Hepatitis B: explosion of new knowledge.
Topics: Adenine; Antiviral Agents; Disease Progression; Drug Resistance, Viral; Genotype; Guanine; Hepatitis | 2007 |
Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio | 2008 |
Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir.
Topics: Adenine; Adult; Aged; Antiviral Agents; Clinical Trials, Phase III as Topic; DNA, Viral; Drug Resist | 2007 |
Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Hepa | 2008 |
Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Fe | 2008 |
Potency of tenofovir in chronic hepatitis B: mono or combination therapy?
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guan | 2008 |
[Protocol for the treatment of chronic viral hepatitis].
Topics: Adenine; Algorithms; Antiviral Agents; Clinical Protocols; Hepacivirus; Hepatitis B virus; Hepatitis | 2008 |
Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; | 2008 |
Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; | 2008 |
Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis.
Topics: Adenine; Adult; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B e Antigen | 2008 |
Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Dr | 2008 |
[Anti-viral therapy of type B chronic hepatitis. 3. Future of anti-viral agents].
Topics: Adenine; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Hepatitis B, Chroni | 2008 |
[Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients].
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; DNA, Viral; Dru | 2008 |
Economic evaluation of chronic hepatitis B treatments in Taiwan.
Topics: Adenine; Adult; Antiviral Agents; Cost-Benefit Analysis; Female; Hepatitis B, Chronic; Humans; Lamiv | 2008 |
Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistanc | 2008 |
Europe extends Viread indication for chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Approval; Europe; Hepatitis B, | 2008 |
Comparison of the Cobas Ampliprep/Cobas TaqMan HBV Test versus the Cobas Amplicor HBV monitor for HBV-DNA detection and quantification during antiviral therapy.
Topics: Adenine; Antiviral Agents; Automation; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; | 2008 |
Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance; Female; Hepatitis B virus; Hepatitis | 2000 |
Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma.
Topics: Adenine; Adult; Aged; Carcinoma, Hepatocellular; Case-Control Studies; Cohort Studies; Cytosine; Gua | 2000 |
[Current treatment of hepatitis B].
Topics: 2-Aminopurine; Adenine; Anti-Inflammatory Agents; Antiviral Agents; DNA Replication; Famciclovir; Fo | 2001 |
Adefovir dipivoxil reduces HBV DNA.
Topics: Adenine; Administration, Oral; Antiviral Agents; DNA, Viral; Hepatitis B, Chronic; Humans | 1999 |
Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus.
Topics: Adenine; Antiviral Agents; Drug Resistance, Microbial; Hepatitis B e Antigens; Hepatitis B, Chronic; | 2001 |
Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hep | 2002 |